FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Levack, MM
Madariaga, ML
Kaafarani, HMA
AF Levack, Melissa M.
Madariaga, Maria Lucia
Kaafarani, Haytham M. A.
TI Non-operative successful management of a perforated small bowel
diverticulum
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Jejunal diverticula; Diverticulitis; Small bowel perforation;
Antibiotics; Abscess
AB Jejunoileal diverticula are rare and generally asymptomatic. In the few cases of patients who develop complications such as diverticulitis, perforation, obstruction, and/or hemorrhage, conventional treatment consists of surgical resection. We describe a case of perforated jejunoileal diverticulum with localized abscess and highlight the merits of surgical vs medical management. The patient is a 77-year-old male who presented with sharp, constant abdominal pain just inferior to the umbilicus. Administration of intravenous antibiotics results in complete and long-term resolution of the patient's symptoms. In this report, we establish a framework for safely treating perforated small bowel diverticulum without surgical exploration. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Levack, Melissa M.; Madariaga, Maria Lucia; Kaafarani, Haytham M. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg Surg Crit Care,Div Trauma, Boston, MA 02114 USA.
RP Kaafarani, HMA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg Surg Crit Care,Div Trauma, 165 Cambridge St Suite 810, Boston, MA 02114 USA.
EM hkaafarani@mgh.harvard.edu
NR 6
TC 4
Z9 4
U1 0
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD DEC 28
PY 2014
VL 20
IS 48
BP 18477
EP 18479
DI 10.3748/wjg.v20.i48.18477
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AY3BY
UT WOS:000347460700043
PM 25561819
ER
PT J
AU Ashley, JD
Stefanick, JF
Schroeder, VA
Suckow, MA
Alves, NJ
Suzuki, R
Kikuchi, S
Hideshima, T
Anderson, KC
Kiziltepe, T
Bilgicer, B
AF Ashley, Jonathan D.
Stefanick, Jared F.
Schroeder, Valerie A.
Suckow, Mark A.
Alves, Nathan J.
Suzuki, Rikio
Kikuchi, Shohei
Hideshima, Teru
Anderson, Kenneth C.
Kiziltepe, Tanyel
Bilgicer, Basar
TI Liposomal carfilzomib nanoparticles effectively target multiple myeloma
cells and demonstrate enhanced efficacy in vivo
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Carfilzomib; Nanoparticle; Liposome; Multiple myeloma; Proteasome
inhibitor
ID MEDIATED DRUG-RESISTANCE; PEPTIDE-LINKER LENGTH; IRREVERSIBLE INHIBITOR;
PROTEASOME INHIBITORS; MOLECULAR-MECHANISMS; THERAPEUTIC-EFFICACY;
DELIVERY-SYSTEMS; CELLULAR UPTAKE; CANCER-THERAPY; BREAST-CANCER
AB Carfilzomib, a recently FDA-approved proteasome inhibitor, has remarkable anti-myeloma (MM) activity. However, its effectiveness is limited by associated severe side-effects, short circulation half-life, and limited solubility. Here, we report the engineering of liposomal carfilzomib nanoparticles to overcome these problems and enhance the therapeutic efficacy of carfilzomib by increasing tumoral drug accumulation while decreasing systemic toxicity. In our design, carfilzomib was loaded into the bilayer of liposomes to yield stable and reproducible liposomal nanoparticles. Liposomal carfilzomib nanoparticles were efficiently taken up by MM cells, demonstrated proteasome inhibition, induced apoptosis, and exhibited enhanced cytotoxicity against MM cells. In vivo, liposomal carfilzomib demonstrated significant tumor growth inhibition and dramatically reduced overall systemic toxicity compared to free carfilzomib. Finally, liposomal carfilzomib demonstrated enhanced synergy in combination with doxorubicin. Taken together, this study establishes the successful synthesis of liposomal carfilzomib nanoparticles that demonstrates improved therapeutic index and the potential to improve patient outcome in MM. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Ashley, Jonathan D.; Stefanick, Jared F.; Alves, Nathan J.; Kiziltepe, Tanyel; Bilgicer, Basar] Univ Notre Dame, Dept Chem & Biomol Engn, Notre Dame, IN 46556 USA.
[Schroeder, Valerie A.; Suckow, Mark A.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.
[Schroeder, Valerie A.; Suckow, Mark A.] Univ Notre Dame, Freimann Life Sci Ctr, Notre Dame, IN 46556 USA.
[Suzuki, Rikio; Kikuchi, Shohei; Hideshima, Teru; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Kiziltepe, Tanyel; Bilgicer, Basar] Univ Notre Dame, Notre Dame, IN 46556 USA.
[Kiziltepe, Tanyel; Bilgicer, Basar] Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA.
RP Kiziltepe, T (reprint author), Univ Notre Dame, 171 Fitzpatrick Hall, Notre Dame, IN 46556 USA.
EM bbilgicer@nd.edu; tkiziltepe@nd.edu
RI Suckow, Mark/C-2696-2014;
OI Suckow, Mark/0000-0001-7317-697X
FU Leukemia Research Foundation
FX We thank the Notre Dame Integrated Imaging Facility for confocal
microscopy, the Center for Environmental Science and Technology for the
use of DLS, and the Mass Spectrometry and Proteomics Facility for the
use of MALDI-TOF-MS. We thank Deborah Donahue and the WM Keck Center for
the irradiation of the mice. This work was supported by the Hollis
Brownstein Research Program Grant from Leukemia Research Foundation.
NR 38
TC 7
Z9 8
U1 4
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 28
PY 2014
VL 196
BP 113
EP 121
DI 10.1016/j.jconrel.2014.10.005
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AW2PZ
UT WOS:000346132100013
PM 25312543
ER
PT J
AU Rasmussen, NR
Debebe, Z
Wright, TM
Brooks, SA
Sendor, AB
Brannon, AR
Hakimi, AA
Hsieh, JJ
Choueiri, TK
Tamboli, P
Maranchie, JK
Hinds, P
Wallen, EM
Simpson, C
Norris, JL
Janzen, WP
Rathmell, WK
AF Rasmussen, Neal R.
Debebe, Zufan
Wright, Tricia M.
Brooks, Samira A.
Sendor, Adam B.
Brannon, A. Rose
Hakimi, A. Ari
Hsieh, James J.
Choueiri, Toni K.
Tamboli, Pheroze
Maranchie, Jodi K.
Hinds, Peter
Wallen, Eric M.
Simpson, Catherine
Norris, Jacqueline L.
Janzen, William P.
Rathmell, W. Kimryn
TI Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR TYROSINE KINASE;
BRACHYDACTYLY TYPE-B; TUMOR; METALLOPROTEINASE; OSTEOSARCOMA;
PSEUDOKINASE; MELANOMA; DISEASE; CANCER
AB Ror2 is a Wnt ligand receptor that is overexpressed in a variety of tumors including clear cell renal cell carcinoma (ccRCC). Here we demonstrate that expression of wild type Ror2 results in increased tumorigenic properties in in vitro cell culture and in vivo xenograft models. In addition, Ror2 expression produced positive changes in both cell migration and invasion, which were dependent on matrix metalloprotease 2 (MMP2) activity. Mutations in key regions of the kinase domain of Ror2 resulted in the abrogation of increased tumor growth, cell migration, and cell invasion observed with expression of wild-type Ror2. Finally, we examined Ror2 expression as a prognostic biomarker for ccRCC utilizing the TCGA ccRCC dataset. High expression of Ror2 showed a significant correlation with higher clinical stage, nuclear grade, and tumor stage. Furthermore, high expression of Ror2 in ccRCC patients correlated with significant lower overall survival, cancer specific survival, and recurrence free survival. Together, these findings suggest that Ror2 plays a central role in influencing the ccRCC phenotype, and can be considered as a negative prognostic biomarker and potential therapeutic target in this cancer.
C1 [Rasmussen, Neal R.; Wright, Tricia M.; Brannon, A. Rose] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.
[Rasmussen, Neal R.; Debebe, Zufan; Wright, Tricia M.; Brooks, Samira A.; Sendor, Adam B.; Brannon, A. Rose; Rathmell, W. Kimryn] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Brooks, Samira A.] Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA.
[Brannon, A. Rose; Hakimi, A. Ari; Hsieh, James J.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
[Hakimi, A. Ari; Hsieh, James J.] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10065 USA.
[Choueiri, Toni K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Choueiri, Toni K.] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02215 USA.
[Tamboli, Pheroze] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
[Maranchie, Jodi K.; Hinds, Peter] Univ Pittsburgh, Med Ctr, Dept Urol Oncol, Pittsburgh, PA 15219 USA.
[Wallen, Eric M.] Univ N Carolina, Dept Urol, Chapel Hill, NC 27599 USA.
[Wallen, Eric M.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
[Simpson, Catherine; Norris, Jacqueline L.; Janzen, William P.] Univ N Carolina, Ctr Integrat Chem Biol & Drug Discovery, Chapel Hill, NC 27599 USA.
[Rathmell, W. Kimryn] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
[Rathmell, W. Kimryn] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
RP Rathmell, WK (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
EM Rathmell@med.unc.edu
OI Sendor, Adam/0000-0003-4958-4660; Maranchie, Jodi/0000-0002-8534-9468
FU American Cancer Society Research Scholar [RSG-10-192-01]; National
Heart, Lung, and Blood Institute [T32 HL069768-09]; National Cancer
Institute [5T32CA160001]
FX Funding provided by (www.cancer.org) American Cancer Society Research
Scholar Grant RSG-10-192-01 (WKR), (www.nhlbi.nih.gov) National Heart,
Lung, and Blood Institute T32 HL069768-09 (NR) and (www.cancer.gov)
National Cancer Institute 5T32CA160001 (ARB). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 32
TC 4
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2014
VL 9
IS 12
AR e116101
DI 10.1371/journal.pone.0116101
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX9RO
UT WOS:000347239900141
PM 25542006
ER
PT J
AU Gandhi, RT
Alkasab, TK
Nardi, V
Branda, JA
AF Gandhi, Rajesh T.
Alkasab, Tarik K.
Nardi, Valentina
Branda, John A.
TI Case 40-2014: A 57-Year-Old Man with Inguinal Pain, Lymphadenopathy, and
HIV Infection
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CAT-SCRATCH DISEASE; SYPHILITIC HEPATITIS; INFLAMMATORY PSEUDOTUMOR;
BARTONELLA-HENSELAE; SECONDARY SYPHILIS; UNITED-STATES; CT; PREVALENCE;
SARCOMA; CANCER
C1 [Gandhi, Rajesh T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Alkasab, Tarik K.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Nardi, Valentina; Branda, John A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Gandhi, Rajesh T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Alkasab, Tarik K.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Nardi, Valentina; Branda, John A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Gandhi, RT (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
FU Gilead; Janssen; ViiV; Roche; DiaSorin; Alere; bioMerieux; Immunetics;
AdvanDx
FX Dr. Gandhi reports receiving grant support from Gilead, Janssen, ViiV,
and Roche; and Dr. Branda, receiving grant support from DiaSorin, Alere,
bioMerieux, and Immunetics and fees for serving on an advisory board
from AdvanDx. No other potential conflict of interest relevant to this
article was reported.
NR 25
TC 1
Z9 1
U1 1
U2 8
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 25
PY 2014
VL 371
IS 26
BP 2511
EP 2520
DI 10.1056/NEJMcpc1404518
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX4RZ
UT WOS:000346920300012
PM 25539108
ER
PT J
AU Janesick, AS
Shioda, T
Blumberg, B
AF Janesick, Amanda S.
Shioda, Toshihiro
Blumberg, Bruce
TI Transgenerational inheritance of prenatal obesogen exposure
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Review
DE Obesogen; Endocrine disrupting chemicals; Transgenerational; Obesity;
Adipogenesis; Epigenetics
ID ENDOCRINE-DISRUPTING CHEMICALS; ACTIVATED RECEPTOR-GAMMA; MESENCHYMAL
STEM-CELLS; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; ENVIRONMENTAL
CHEMICALS; ORGANOTIN COMPOUNDS; PERINATAL EXPOSURE; CHILDHOOD OBESITY;
MICROBIAL ECOLOGY
AB Obesity and metabolic syndrome diseases have exploded into an epidemic of global proportions. The generally accepted cause of obesity is overconsumption of calorie-dense food and diminished physical activity (the calories in-calories out model). However, emerging evidence demonstrates that environmental factors can predispose exposed individuals to gain weight, irrespective of diet and exercise. The environmental obesogen model proposes that chemical exposure during critical stages in development can influence subsequent adipogenesis, lipid balance and obesity. Obesogens are chemicals that inappropriately stimulate adipogenesis and fat storage. Numerous obesogens have been identified in recent years and some of these have been shown to act through the peroxisome proliferator activated receptor gamma, the master regulator of adipogenesis. Others act through as yet unidentified pathways. Notably, some of these obesogens elicit transgenerational effects on a variety of health endpoints, including obesity in offspring after exposure of pregnant F0 females. Thus, prenatal exposure to xenobiotic compounds can have lasting, potentially permanent effects on the offspring of exposed animals. Transgenerational effects of chemical exposure raise the stakes in the debate about whether and how endocrine disrupting chemicals should be regulated. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Janesick, Amanda S.; Blumberg, Bruce] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.
[Shioda, Toshihiro] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.
[Blumberg, Bruce] Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA 92697 USA.
RP Blumberg, B (reprint author), Univ Calif Irvine, Dept Dev & Cell Biol, 2011 Biol Sci 3, Irvine, CA 92697 USA.
EM blumberg@uci.edu
OI Janesick, Amanda/0000-0001-7731-2756
FU NIH [1R01E5023316-01]
FX This work was supported by a grant from NIH (B.B, T.S.) 1R01E5023316-01.
NR 90
TC 12
Z9 12
U1 1
U2 30
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD DEC 25
PY 2014
VL 398
IS 1-2
SI SI
BP 31
EP 35
DI 10.1016/j.mce.2014.09.002
PG 5
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA AZ1RJ
UT WOS:000348015300005
PM 25218215
ER
PT J
AU Lamas, D
Rosenbaum, L
AF Lamas, Daniela
Rosenbaum, Lisa
TI Very Complicated Math - Reconfiguring Organ Allocation
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID LIVER-TRANSPLANTATION
C1 [Lamas, Daniela] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Lamas, Daniela] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lamas, Daniela] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Lamas, D (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
NR 5
TC 4
Z9 4
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 25
PY 2014
VL 371
IS 26
BP 2447
EP 2450
DI 10.1056/NEJMp1412764
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX4RZ
UT WOS:000346920300002
PM 25539103
ER
PT J
AU Genovese, G
Kahler, AK
Handsaker, RE
Lindberg, J
Rose, SA
Bakhoum, SF
Chambert, K
Mick, E
Neale, BM
Fromer, M
Purcell, SM
Svantesson, O
Landen, M
Hoglund, M
Lehmann, S
Gabriel, SB
Moran, JL
Lander, ES
Sullivan, PF
Sklar, P
Gronberg, H
Hultman, CM
McCarroll, SA
AF Genovese, Giulio
Kaehler, Anna K.
Handsaker, Robert E.
Lindberg, Johan
Rose, Samuel A.
Bakhoum, Samuel F.
Chambert, Kimberly
Mick, Eran
Neale, Benjamin M.
Fromer, Menachem
Purcell, Shaun M.
Svantesson, Oscar
Landen, Mikael
Hoeglund, Martin
Lehmann, Soeren
Gabriel, Stacey B.
Moran, Jennifer L.
Lander, Eric S.
Sullivan, Patrick F.
Sklar, Pamela
Groenberg, Henrik
Hultman, Christina M.
McCarroll, Steven A.
TI Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA
Sequence
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; STEM-CELLS; MYELODYSPLASTIC SYNDROME; EPIGENETIC
REGULATORS; PPM1D MUTATIONS; MOSAICISM; GENOME; AML; AGE; SCHIZOPHRENIA
AB Background
Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent.
Methods
We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling.
Results
Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones.
Conclusions
Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers.
C1 [Genovese, Giulio; Handsaker, Robert E.; Rose, Samuel A.; Chambert, Kimberly; Neale, Benjamin M.; Moran, Jennifer L.; McCarroll, Steven A.] Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Genovese, Giulio; Handsaker, Robert E.; McCarroll, Steven A.] Program Med & Populat Genet, Cambridge, MA USA.
[Gabriel, Stacey B.; Lander, Eric S.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA USA.
[Genovese, Giulio; Handsaker, Robert E.; McCarroll, Steven A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Mick, Eran] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Neale, Benjamin M.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Neale, Benjamin M.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Kaehler, Anna K.; Lindberg, Johan; Svantesson, Oscar; Sullivan, Patrick F.; Groenberg, Henrik; Hultman, Christina M.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Lindberg, Johan] Karolinska Inst, Sci Life Lab, Stockholm, Sweden.
[Lehmann, Soeren] Karolinska Univ Hosp, Hematol Ctr, Stockholm, Sweden.
[Lehmann, Soeren] Karolinska Univ Hosp, Ctr Hematol & Regenerat Med, Stockholm, Sweden.
[Landen, Mikael] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden.
[Hoeglund, Martin] Univ Hosp, Dept Med Sci, Uppsala, Sweden.
[Hoeglund, Martin] Univ Hosp, Div Hematol, Uppsala, Sweden.
[Bakhoum, Samuel F.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA.
[Fromer, Menachem; Purcell, Shaun M.; Sklar, Pamela] Icahn Sch Med Mt Sinai, Dept Psychiat, Div Psychiat Genom, New York, NY 10029 USA.
[Fromer, Menachem; Purcell, Shaun M.; Sklar, Pamela] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, New York, NY 10029 USA.
[Sullivan, Patrick F.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Sullivan, Patrick F.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA.
RP McCarroll, SA (reprint author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM giulio.genovese@gmail.com; mccarroll@genetics.med.harvard.edu
OI McCarroll, Steven/0000-0002-6954-8184; Bakhoum,
Samuel/0000-0002-4779-8422; Lindberg, Johan/0000-0003-3610-6774; Moran,
Jennifer/0000-0002-5664-4716
FU National Human Genome Research Institute [U54 HG003067, R01 HG006855];
Stanley Center for Psychiatric Research; Alexander and Margaret Stewart
Trust; National Institute of Mental Health [R01 MH077139, RC2 MH089905];
Sylvan C. Herman Foundation
FX Supported by grants from the National Human Genome Research Institute
(U54 HG003067 and R01 HG006855), the Stanley Center for Psychiatric
Research, the Alexander and Margaret Stewart Trust, the National
Institute of Mental Health (R01 MH077139 and RC2 MH089905), and the
Sylvan C. Herman Foundation.
NR 41
TC 314
Z9 322
U1 9
U2 41
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 25
PY 2014
VL 371
IS 26
BP 2477
EP 2487
DI 10.1056/NEJMoa1409405
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX4RZ
UT WOS:000346920300007
PM 25426838
ER
PT J
AU Jaiswal, S
Fontanillas, P
Flannick, J
Manning, A
Grauman, PV
Mar, BG
Lindsley, RC
Mermel, CH
Burtt, N
Chavez, A
Higgins, JM
Moltchanov, V
Kuo, FC
Kluk, MJ
Henderson, B
Kinnunen, L
Koistinen, HA
Ladenvall, C
Getz, G
Correa, A
Banahan, BF
Gabriel, S
Kathiresan, S
Stringham, HM
McCarthy, MI
Boehnke, M
Tuomilehto, J
Haiman, C
Groop, L
Atzmon, G
Wilson, JG
Neuberg, D
Altshuler, D
Ebert, BL
AF Jaiswal, Siddhartha
Fontanillas, Pierre
Flannick, Jason
Manning, Alisa
Grauman, Peter V.
Mar, Brenton G.
Lindsley, R. Coleman
Mermel, Craig H.
Burtt, Noel
Chavez, Alejandro
Higgins, John M.
Moltchanov, Vladislav
Kuo, Frank C.
Kluk, Michael J.
Henderson, Brian
Kinnunen, Leena
Koistinen, Heikki A.
Ladenvall, Claes
Getz, Gad
Correa, Adolfo
Banahan, Benjamin F.
Gabriel, Stacey
Kathiresan, Sekar
Stringham, Heather M.
McCarthy, Mark I.
Boehnke, Michael
Tuomilehto, Jaakko
Haiman, Christopher
Groop, Leif
Atzmon, Gil
Wilson, James G.
Neuberg, Donna
Altshuler, David
Ebert, Benjamin L.
TI Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; B-CELL LYMPHOMA; MYELODYSPLASTIC SYNDROMES;
DISTRIBUTION WIDTH; DNMT3A MUTATIONS; MYELOPROLIFERATIVE DISORDERS;
POINT MUTATIONS; TET2 MUTATIONS; STEM-CELLS; CANCER
AB Background
The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would be detectable in the blood of some persons who are not known to have hematologic disorders.
Methods
We analyzed whole-exome sequencing data from DNA in the peripheral-blood cells of 17,182 persons who were unselected for hematologic phenotypes. We looked for somatic mutations by identifying previously characterized single-nucleotide variants and small insertions or deletions in 160 genes that are recurrently mutated in hematologic cancers. The presence of mutations was analyzed for an association with hematologic phenotypes, survival, and cardiovascular events.
Results
Detectable somatic mutations were rare in persons younger than 40 years of age but rose appreciably in frequency with age. Among persons 70 to 79 years of age, 80 to 89 years of age, and 90 to 108 years of age, these clonal mutations were observed in 9.5% (219 of 2300 persons), 11.7% (37 of 317), and 18.4% (19 of 103), respectively. The majority of the variants occurred in three genes: DNMT3A, TET2, and ASXL1. The presence of a somatic mutation was associated with an increase in the risk of hematologic cancer (hazard ratio, 11.1; 95% confidence interval [CI], 3.9 to 32.6), an increase in all-cause mortality (hazard ratio, 1.4; 95% CI, 1.1 to 1.8), and increases in the risks of incident coronary heart disease (hazard ratio, 2.0; 95% CI, 1.2 to 3.4) and ischemic stroke (hazard ratio, 2.6; 95% CI, 1.4 to 4.8).
Conclusions
Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease.
C1 [Jaiswal, Siddhartha; Grauman, Peter V.; Mar, Brenton G.; Ebert, Benjamin L.] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA.
[Lindsley, R. Coleman] Brigham & Womens Hosp, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA.
[Kuo, Frank C.; Kluk, Michael J.] Brigham & Womens Hosp, Ctr Adv Mol Diagnost, Boston, MA 02115 USA.
[Kuo, Frank C.; Kluk, Michael J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Jaiswal, Siddhartha; Mermel, Craig H.; Chavez, Alejandro; Higgins, John M.; Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Flannick, Jason; Altshuler, David] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Higgins, John M.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Gabriel, Stacey; Altshuler, David] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Altshuler, David] Massachusetts Gen Hosp, Dept Med, Div Endocrinol, Boston, MA 02114 USA.
[Jaiswal, Siddhartha] Brigham & Womens Hosp, Boston Childrens Hosp, Joint Program Transfus Med, Boston, MA 02115 USA.
[Jaiswal, Siddhartha] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mar, Brenton G.] Dept Pediat Oncol, Boston, MA USA.
[Neuberg, Donna] Dept Biostat & Computat Biol, Boston, MA USA.
[Higgins, John M.] Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA.
[Higgins, John M.] Dept Syst Biol, Boston, MA USA.
[Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Altshuler, David] Dept Med, Boston, MA USA.
[Ebert, Benjamin L.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Ebert, Benjamin L.] Harvard Stem Cell Inst, Boston, MA USA.
[Fontanillas, Pierre; Flannick, Jason; Manning, Alisa; Burtt, Noel; Gabriel, Stacey; Kathiresan, Sekar; Altshuler, David] Broad Inst Massachusetts Inst Technol & Harvard, Program Med & Populat Genet, Cambridge, MA USA.
[Altshuler, David] MIT, Dept Biol, Cambridge, MA USA.
[Moltchanov, Vladislav] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
[Moltchanov, Vladislav] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland.
[Koistinen, Heikki A.] Univ Helsinki, Cent Hosp, Minerva Fdn Inst Med Res, Helsinki, Finland.
[Koistinen, Heikki A.] Univ Helsinki, Cent Hosp, Dept Med, Div Endocrinol, Helsinki, Finland.
[Kinnunen, Leena; Koistinen, Heikki A.; Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Diabet Prevent Unit, Helsinki, Finland.
[Henderson, Brian; Haiman, Christopher] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Ladenvall, Claes; Groop, Leif] Lund Univ, Ctr Diabet, Dept Clin Sci, Clin Res Ctr,Skane Univ Hosp, Lund, Sweden.
[Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Oxford, MS USA.
[Wilson, James G.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Oxford, MS USA.
[Banahan, Benjamin F.] Univ Mississippi, Ctr Pharmaceut Mkt & Management, Oxford, MS USA.
[Stringham, Heather M.; Boehnke, Michael] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[McCarthy, Mark I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[McCarthy, Mark I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[McCarthy, Mark I.] Oxford Natl Inst Hlth Res, Biomed Res Ctr, Oxford, England.
[Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria.
[Tuomilehto, Jaakko] King Abdulaziz Univ, Diabet Res Grp, Jeddah 21413, Saudi Arabia.
[Atzmon, Gil] Albert Einstein Coll Med, Dept Med & Genet, New York, NY USA.
RP Ebert, BL (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Hematol, 1 Blackfan Cir,Karp 5-210, Boston, MA 02115 USA.
EM bebert@partners.org
RI kinnunen, leena/B-7059-2012;
OI kinnunen, leena/0000-0001-8739-4812; Lindsley,
Coleman/0000-0001-9822-806X; Koistinen, Heikki/0000-0001-7870-070X; Mar,
Brenton/0000-0002-3857-9324
FU National Institutes of Health (NIH) [R01HL082945]; Gabrielle's Angel
Foundation; Leukemia and Lymphoma Society Scholar and Specialized Center
of Research (SCOR); NIH [5T32HL066987, U01 DK085526, U01 DK085501, U01
DK085524, U01 DK085545, U01 DK085584, DK088389, P01AG021654,
1R01AG042188, P30AG038072]; Medical Research Council [G0601261]; Medical
Research Council (High Throughput Genomics Hub) [G0900747 91070];
Wellcome Trust [090367, 090532, 098381, 083948, 085475]; Paul Glenn
Foundation; National Heart, Lung, and Blood Institute [HSN268201300046C,
HHSN268201300047C, HHSN268201300048C, HHSN268201300049C,
HHSN268201300050C]; National Institute on Minority Health and Health
Disparities; National Human Genome Research Institute (NHGRI) of the NIH
[U54 HG003067]
FX Supported by grants from the National Institutes of Health (NIH)
(R01HL082945) and the Gabrielle's Angel Foundation, by Leukemia and
Lymphoma Society Scholar and Specialized Center of Research (SCOR)
Awards (to Dr. Ebert), and by an NIH Training Grant (5T32HL066987, to
Dr. Jaiswal). The T2D-GENES (Type 2 Diabetes Genetic Exploration by
Next-Generation Sequencing in Multi-Ethnic Samples) consortium was
supported by grants from the NIH (U01s DK085526, DK085501, DK085524,
DK085545, and DK085584). The GoT2D (Genetics of Type 2 Diabetes)
consortium is supported by grants from the Medical Research Council
(G0601261 and High Throughput Genomics Hub grant G0900747 91070), the
Wellcome Trust (090367, 090532, 098381, 083948, 085475), and the NIH
(DK088389). The Longevity Genes Project is supported by grants from the
NIH (P01AG021654, 1R01AG042188, P30AG038072), and by a Paul Glenn
Foundation Grant. The Jackson Heart Study is supported by contracts
(HSN268201300046C, HHSN268201300047C, HHSN268201300048C,
HHSN268201300049C, HHSN268201300050C) from the National Heart, Lung, and
Blood Institute and the National Institute on Minority Health and Health
Disparities. Dr. McCarthy is a Wellcome Trust Senior Investigator and an
NIH Research Senior Investigator. Exome sequencing in the Jackson Heart
Study was funded by an award from the National Human Genome Research
Institute (NHGRI) of the NIH (U54 HG003067, to Dr. Gabriel).
NR 45
TC 351
Z9 362
U1 6
U2 34
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 25
PY 2014
VL 371
IS 26
BP 2488
EP 2498
DI 10.1056/NEJMoa1408617
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX4RZ
UT WOS:000346920300008
PM 25426837
ER
PT J
AU Rustgi, AK
El-Serag, HB
AF Rustgi, Anil K.
El-Serag, Hashem B.
TI Esophageal Carcinoma
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID SQUAMOUS-CELL CARCINOMA; GENOME-WIDE ASSOCIATION; HELICOBACTER-PYLORI
INFECTION; GASTROESOPHAGEAL-REFLUX DISEASE; NUTRITION INTERVENTION
TRIALS; HIGH-RISK POPULATION; BARRETTS-ESOPHAGUS; SUSCEPTIBILITY LOCI;
GASTRIC CARDIA; ORAL BISPHOSPHONATES
C1 [Rustgi, Anil K.] Univ Penn, Dept Med, Div Gastroenterol, Abramson Canc Ctr,Perelman Sch Med, Philadelphia, PA 19104 USA.
[Rustgi, Anil K.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Dept Genet, Philadelphia, PA 19104 USA.
[El-Serag, Hashem B.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
RP El-Serag, HB (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.
EM hasheme@bcm.edu
NR 97
TC 115
Z9 128
U1 7
U2 27
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 25
PY 2014
VL 371
IS 26
BP 2499
EP 2509
DI 10.1056/NEJMra1314530
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX4RZ
UT WOS:000346920300009
PM 25539106
ER
PT J
AU Schwamm, LH
AF Schwamm, Lee H.
TI Progesterone for Traumatic Brain Injury - Resisting the Sirens' Song
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID RANDOMIZED-TRIAL; CLINICAL-TRIAL
C1 [Schwamm, Lee H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,TeleStroke & Acute Stroke Serv, Boston, MA 02163 USA.
[Schwamm, Lee H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Heart Vasc & Stroke Care, Boston, MA USA.
[Schwamm, Lee H.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Schwamm, LH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,TeleStroke & Acute Stroke Serv, Boston, MA 02163 USA.
NR 8
TC 15
Z9 16
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 25
PY 2014
VL 371
IS 26
BP 2522
EP 2523
DI 10.1056/NEJMe1412951
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX4RZ
UT WOS:000346920300013
PM 25493975
ER
PT J
AU Vaina, LM
Rana, KD
Cotos, I
Chen, LY
Huang, MA
Podea, D
AF Vaina, Lucia M.
Rana, Kunjan D.
Cotos, Ionela
Chen Li-Yang
Huang, Melissa A.
Podea, Delia
TI When does Subliminal Affective Image Priming Influence the Ability of
Schizophrenic Patients to Perceive Face Emotions?
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Affective Symptoms; Schizophrenia; Subliminal Stimulation
ID FACIAL-AFFECT RECOGNITION; AFFECTIVE-DISORDERS; RATING-SCALE;
IDENTIFICATION; PERCEPTION; DISCRIMINATION; AWARENESS; TOOLBOX
AB Background: Deficits in face emotion perception are among the most pervasive aspects of schizophrenia impairments which strongly affects interpersonal communication and social skills.
Material/Methods: Schizophrenic patients (PSZ) and healthy control subjects (HCS) performed 2 psychophysical tasks. One, the SAFFIMAP test, was designed to determine the impact of subliminally presented affective or neutral images on the accuracy of face-expression (angry or neutral) perception. In the second test, FEP, subjects saw pictures of face-expression and were asked to rate them as angry, happy, or neutral. The following clinical scales were used to determine the acute symptoms in PSZ: Positive and Negative Syndrome (PANSS), Young Mania Rating (YMRS), Hamilton Depression (HAM-D), and Hamilton Anxiety (HAM-A).
Results: On the SAFFIMAP test, different from the HCS group, the PSZ group tended to categorize the neutral expression of test faces as angry and their response to the test-face expression was not influenced by the affective content of the primes. In PSZ, the PANSS-positive score was significantly correlated with correct perception of angry faces for aggressive or pleasant primes. YMRS scores were strongly correlated with PSZ's tendency to recognize angry face expressions when the prime was a pleasant or a neutral image. The HAM-D score was positively correlated with categorizing the test-faces as neutral, regardless of the affective content of the prime or of the test-face expression (angry or neutral).
Conclusions: Despite its exploratory nature, this study provides the first evidence that conscious perception and categorization of facial emotions (neutral or angry) in PSZ is directly affected by their positive or negative symptoms of the disease as defined by their individual scores on the clinical diagnostic scales.
C1 [Vaina, Lucia M.; Rana, Kunjan D.; Chen Li-Yang; Huang, Melissa A.] Boston Univ, Dept Biomed Engn, Brain & Vis Res Lab, Boston, MA 02215 USA.
[Vaina, Lucia M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Vaina, Lucia M.] Boston Univ, Dept Neurol, Boston, MA 02215 USA.
[Vaina, Lucia M.] Boston Univ, Grad Program Neurosci, Boston, MA 02215 USA.
[Cotos, Ionela; Podea, Delia] Cty Emergency Clin Hosp, Dept Psychiat, Arad, Romania.
RP Vaina, LM (reprint author), Boston Univ, Dept Biomed Engn, Brain & Vis Res Lab, Boston, MA 02215 USA.
EM vaina@bu.edu
FU Brain and Vision research fund
FX This work was supported, in part, by the Brain and Vision research fund
to LMV
NR 35
TC 0
Z9 0
U1 2
U2 11
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD DEC 24
PY 2014
VL 20
BP 2788
EP 2798
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CC3ZM
UT WOS:000350290000001
PM 25537115
ER
PT J
AU van Heesch, S
Simonis, M
van Roosmalen, MJ
Pillalamarri, V
Brand, H
Kuijk, EW
de Luca, KL
Lansu, N
Braat, AK
Menelaou, A
Hao, WS
Korving, J
Snijder, S
van der Veken, LT
Hochstenbach, R
Knegt, AC
Duran, K
Renkens, I
Alekozai, N
Jager, M
Vergult, S
Menten, B
de Bruijn, E
Boymans, S
Ippel, E
van Binsbergen, E
Talkowski, ME
Lichtenbelt, K
Cuppen, E
Kloosterman, WP
AF van Heesch, Sebastiaan
Simonis, Marieke
van Roosmalen, Markus J.
Pillalamarri, Vamsee
Brand, Harrison
Kuijk, Ewart W.
de Luca, Kim L.
Lansu, Nico
Braat, A. Koen
Menelaou, Androniki
Hao, Wensi
Korving, Jeroen
Snijder, Simone
van der Veken, Lars T.
Hochstenbach, Ron
Knegt, Alida C.
Duran, Karen
Renkens, Ivo
Alekozai, Najla
Jager, Myrthe
Vergult, Sarah
Menten, Bjoern
de Bruijn, Ewart
Boymans, Sander
Ippel, Elly
van Binsbergen, Ellen
Talkowski, Michael E.
Lichtenbelt, Klaske
Cuppen, Edwin
Kloosterman, Wigard P.
TI Genomic and Functional Overlap between Somatic and Germline Chromosomal
Rearrangements
SO CELL REPORTS
LA English
DT Article
ID AUTISM SPECTRUM DISORDERS; COPY NUMBER VARIATION; PROSTATE-CANCER;
DE-NOVO; STRUCTURAL VARIATION; GENE FUSIONS; REPAIR; ETV1;
IDENTIFICATION; ABNORMALITIES
AB Genomic rearrangements are a common cause of human congenital abnormalities. However, their origin and consequences are poorly understood. We performed molecular analysis of two patients with congenital disease who carried de novo genomic rearrangements. We found that the rearrangements in both patients hit genes that are recurrently rearranged in cancer (ETV1, FOXP1, and microRNA cluster C19MC) and drive formation of fusion genes similar to those described in cancer. Subsequent analysis of a large set of 552 de novo germline genomic rearrangements underlying congenital disorders revealed enrichment for genes rearranged in cancer and overlap with somatic cancer breakpoints. Breakpoints of common (inherited) germline structural variations also overlap with cancer breakpoints but are depleted for cancer genes. We propose that the same genomic positions are prone to genomic rearrangements in germline and soma but that timing and context of breakage determines whether developmental defects or cancer are promoted.
C1 [van Heesch, Sebastiaan; Simonis, Marieke; Kuijk, Ewart W.; de Luca, Kim L.; Lansu, Nico; Hao, Wensi; Korving, Jeroen; de Bruijn, Ewart; Boymans, Sander; Cuppen, Edwin] Hubrecht Inst KNAW, NL-3584 CT Utrecht, Netherlands.
[van Heesch, Sebastiaan; Simonis, Marieke; Kuijk, Ewart W.; de Luca, Kim L.; Lansu, Nico; Hao, Wensi; Korving, Jeroen; de Bruijn, Ewart; Boymans, Sander; Cuppen, Edwin] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands.
[van Roosmalen, Markus J.; Menelaou, Androniki; van der Veken, Lars T.; Hochstenbach, Ron; Duran, Karen; Renkens, Ivo; Alekozai, Najla; Jager, Myrthe; Ippel, Elly; van Binsbergen, Ellen; Lichtenbelt, Klaske; Cuppen, Edwin; Kloosterman, Wigard P.] Univ Med Ctr Utrecht, Ctr Mol Med, Dept Med Genet, NL-3584 CG Utrecht, Netherlands.
[Pillalamarri, Vamsee; Brand, Harrison; Talkowski, Michael E.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Braat, A. Koen] Univ Med Ctr Utrecht, Ctr Mol Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands.
[Snijder, Simone; Knegt, Alida C.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
[Vergult, Sarah; Menten, Bjoern] Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium.
RP Cuppen, E (reprint author), Hubrecht Inst KNAW, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.
EM e.cuppen@hubrecht.eu; w.kloosterman@umcutrecht.nl
RI Cuppen, Edwin/H-2389-2016
OI Cuppen, Edwin/0000-0002-0400-9542
FU Cancer Genomics Center and Netherlands Center for Systems Biology
programs of the Netherlands Genomics Initiative; Child Health Priority
Program of the University Medical Center Utrecht, an NWO Vici grant
[865.13.004]; Wilhelmina Children's Hospital; NIH [GM061354, HD065286,
MH095867]
FX We would like to thank A. de Graaff and the Hubrecht Imaging Center for
supporting the imaging, M. van Dooren, L. van Zutven, and A. Baas for
providing access to patient data, and A. Marcozzi for help with artwork.
This work was supported by the Cancer Genomics Center and Netherlands
Center for Systems Biology programs of the Netherlands Genomics
Initiative, the Child Health Priority Program of the University Medical
Center Utrecht, an NWO Vici grant (865.13.004) to E.C., a research grant
from the Wilhelmina Children's Hospital to W.P.K., and the NIH
(GM061354, HD065286, and MH095867 to M.E.T.).
NR 44
TC 5
Z9 5
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC 24
PY 2014
VL 9
IS 6
BP 2001
EP 2010
DI 10.1016/j.celrep.2014.11.022
PG 10
WC Cell Biology
SC Cell Biology
GA AX3PX
UT WOS:000346852400003
PM 25497101
ER
PT J
AU Vaduganathan, M
Prasad, V
AF Vaduganathan, Muthiah
Prasad, Vinay
TI Modern Drug Development Which Patients Should Come First?
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID METASTATIC BREAST-CANCER; HEART-FAILURE; TRASTUZUMAB; PERTUZUMAB;
ENALAPRIL; TRIAL
C1 [Vaduganathan, Muthiah] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Prasad, Vinay] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
RP Prasad, V (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, 615 N Wolfe St,Room W1015, Baltimore, MD 21205 USA.
EM vprasad4@jhu.edu
OI Prasad, Vinay/0000-0002-6110-8221
NR 7
TC 3
Z9 3
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 24
PY 2014
VL 312
IS 24
BP 2619
EP 2620
DI 10.1001/jama.2014.15221
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX5KW
UT WOS:000346966100010
PM 25420013
ER
PT J
AU Trinh, NHT
Nadler, DL
Shie, V
Fregni, F
Gilman, SE
Ryan, CM
Schneider, JC
AF Trinh, Nhi-Ha T.
Nadler, Deborah L.
Shie, Vivian
Fregni, Felipe
Gilman, Stephen E.
Ryan, Colleen M.
Schneider, Jeffrey C.
TI Psychological Sequelae of the Station Nightclub Fire: Comparing
Survivors with and without Physical Injuries Using a Mixed-Methods
Analysis
SO PLOS ONE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; BECK DEPRESSION INVENTORY; PSYCHOMETRIC
PROPERTIES; MEDICAL ILLNESS; BURN INJURIES; HEALTH SCALE; PREVALENCE;
DISASTERS
AB Background: Surveying survivors from a large fire provides an opportunity to explore the impact of emotional trauma on psychological outcomes.
Methods: This is a cross-sectional survey of survivors of The Station Fire. Primary outcomes were post-traumatic stress (Impact of Event Scale - Revised) and depressive (Beck Depression Inventory) symptoms. Linear regression was used to examine differences in symptom profiles between those with and without physical injuries. The free-response section of the survey was analyzed qualitatively to compare psychological sequelae of survivors with and without physical injuries.
Results: 104 participants completed the study survey; 47% experienced a burn injury. There was a 42% to 72% response rate range. The mean age of respondents was 32 years, 62% were male, and 47% experienced a physical injury. No significant relationships were found between physical injury and depressive or post-traumatic stress symptom profiles. In the qualitative analysis, the emotional trauma that survivors experienced was a major, common theme regardless of physical injury. Survivors without physical injuries were more likely to experience survivor guilt, helplessness, self-blame, and bitterness. Despite the post-fire challenges described, most survivors wrote about themes of recovery and renewal.
Conclusions: All survivors of this large fire experienced significant psychological sequelae. These findings reinforce the importance of mental health care for all survivors and suggest a need to understand factors influencing positive outcomes.
C1 [Trinh, Nhi-Ha T.] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
[Nadler, Deborah L.; Shie, Vivian; Schneider, Jeffrey C.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA.
[Nadler, Deborah L.; Shie, Vivian; Fregni, Felipe] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Ctr Neuromodulat, Boston, MA USA.
[Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
[Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Gilman, Stephen E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Ryan, Colleen M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sumner Redstone Burn Ctr,Surg Serv, Boston, MA USA.
[Ryan, Colleen M.] Shriners Hosp Children Boston, Boston, MA USA.
RP Trinh, NHT (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
EM ntrinh@partners.org
RI Gilman, Stephen/E-7632-2010
OI Gilman, Stephen/0000-0002-8331-6419
FU International Association of Fire Fighters; Department of Education;
National Institute on Disability and Rehabilitation Research
[H133A120034]
FX This project was supported in part by a pilot grant from the
International Association of Fire Fighters and under a grant from the
Department of Education, National Institute on Disability and
Rehabilitation Research grant number H133A120034. The funders had no
role in the study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 28
TC 1
Z9 1
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 23
PY 2014
VL 9
IS 12
AR e115013
DI 10.1371/journal.pone.0115013
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AZ9UY
UT WOS:000348563300027
PM 25536085
ER
PT J
AU Troisi, R
Ganmaa, D
Silva, ID
Davaalkham, D
Rosenberg, PS
Rich-Edwards, J
Frasier, L
Houghton, L
Janes, C
Stanczyk, F
Hoover, RN
AF Troisi, Rebecca
Ganmaa, Daavasambuu
Silva, Isabel dos Santos
Davaalkham, Dambadarjaa
Rosenberg, Philip S.
Rich-Edwards, Janet
Frasier, Lindsay
Houghton, Lauren
Janes, Craig
Stanczyk, Frank
Hoover, Robert N.
TI The Role of Hormones in the Differences in the Incidence of Breast
Cancer between Mongolia and the United Kingdom
SO PLOS ONE
LA English
DT Article
ID RISK; WOMEN; SUSCEPTIBILITY
AB Background: There are striking differences in breast cancer incidence between Asian and western women. Rates vary substantially within Asia also, with Mongolia's even lower than China's. These profound differences have been speculated to be due in part to diet, mediated by circulating hormone concentrations.
Methods: Sex steroid hormone concentrations were measured in women living in Ulaanbaatar, Mongolia and the United Kingdom (U.K.). Diet was obtained by interview and national survey data. Mean hormone differences were compared by country, and systematic variation by number of days since last menstrual period was modeled and adjusted for age and parity; difference in overall area under the curves was assessed.
Findings: The diet in Mongolia was higher in meat and dairy than in the U.K. Mean testosterone concentrations were 18.5% lower (p<0.0001) while estradiol concentrations were 19.1% higher (p=0.02) in Mongolian than British women, adjusted for age and parity. Progesterone was almost 50% higher in Mongolian women (p=0.04), particularly during the follicular phase and early luteal surge. Hormone concentrations generally were similar in Mongolian women born in Ulaanbaatar compared with those born in rural areas, although there was a decreasing progesterone trend by degree of westernization (rural Mongolia; urban Mongolia; U.K.). Mean hormone differences were similar when restricted to parous women, and with further adjustment for body mass index, height, and smoking status.
Interpretation: These data augment accumulating evidence that circulating estrogens are unlikely to explain reduced breast cancer rates in Asia compared with the west, and suggest casting a wider net with respect to biomarkers. Lower testosterone and higher progesterone in Mongolian women raise the possibility that these hormones may be important to consider. In addition, the almost exclusive dietary reliance of Mongolians on meat and dairy argues against beneficial effects of a low-fat diet on circulating hormones explaining international breast cancer differences.
C1 [Troisi, Rebecca; Rosenberg, Philip S.; Houghton, Lauren; Hoover, Robert N.] NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Rockville, MD 20850 USA.
[Ganmaa, Daavasambuu] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Ganmaa, Daavasambuu] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Ganmaa, Daavasambuu; Davaalkham, Dambadarjaa] Hlth Sci Univ Mongolia, Ulaanbaatar, Mongol Peo Rep.
[Silva, Isabel dos Santos] Univ London London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1E 7HT, England.
[Rich-Edwards, Janet] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Dept Med, Boston, MA 02115 USA.
[Rich-Edwards, Janet] Harvard Univ, Brigham & Womens Hosp, Sch Med, Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02115 USA.
[Frasier, Lindsay] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Janes, Craig] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.
[Stanczyk, Frank] Univ So Calif, Keck Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA.
[Stanczyk, Frank] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
RP Troisi, R (reprint author), NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Rockville, MD 20850 USA.
EM troisir@mail.nih.gov
FU U.S. National Cancer Institute, National Institutes of Health,
Department of Health and Human Services
FX All funding for this study was provided by the U.S. National Cancer
Institute, National Institutes of Health, Department of Health and Human
Services. Drs. Troisi and Hoover represented the NCI and had a role in
the study design, data collection and analysis, decision to publish and
preparation of the ms.
NR 18
TC 4
Z9 4
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 23
PY 2014
VL 9
IS 12
AR e114455
DI 10.1371/journal.pone.0114455
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AZ9UY
UT WOS:000348563300012
PM 25536229
ER
PT J
AU Dodge, HH
Katsumata, Y
Zhu, J
Mattek, N
Bowman, M
Gregor, M
Wild, K
Kaye, JA
AF Dodge, Hiroko H.
Katsumata, Yuriko
Zhu, Jian
Mattek, Nora
Bowman, Molly
Gregor, Mattie
Wild, Katherine
Kaye, Jeffrey A.
TI Characteristics associated with willingness to participate in a
randomized controlled behavioral clinical trial using home-based
personal computers and a webcam
SO TRIALS
LA English
DT Article
DE Sample recruitment selection bias; Volunteer bias; Behavioral randomized
controlled trial; PC; Internet; Webcam; Conversation-based social
interaction; Cognitive function; Mild cognitive impairment
ID OLDER-ADULTS; RECRUITMENT; DEMENTIA; RETENTION; SELECTION; ANXIETY
AB Background: Trials aimed at preventing cognitive decline through cognitive stimulation among those with normal cognition or mild cognitive impairment are of significant importance in delaying the onset of dementia and reducing dementia prevalence. One challenge in these prevention trials is sample recruitment bias. Those willing to volunteer for these trials could be socially active, in relatively good health, and have high educational levels and cognitive function. These participants' characteristics could reduce the generalizability of study results and, more importantly, mask trial effects. We developed a randomized controlled trial to examine whether conversation-based cognitive stimulation delivered through personal computers, a webcam and the internet would have a positive effect on cognitive function among older adults with normal cognition or mild cognitive impairment. To examine the selectivity of samples, we conducted a mass mail-in survey distribution among community-dwelling older adults, assessing factors associated with a willingness to participate in the trial.
Methods: Two thousand mail-in surveys were distributed to retirement communities in order to collect data on demographics, the nature and frequency of social activities, personal computer use and additional health-related variables, and interest in the prevention study. We also asked for their contact information if they were interested in being contacted as potential participants in the trial.
Results: Of 1,102 surveys returned (55.1% response rate), 983 surveys had complete data for all the variables of interest. Among them, 309 showed interest in the study and provided their contact information (operationally defined as the committed with interest group), 74 provided contact information without interest in the study (committed without interest group), 66 showed interest, but provided no contact information (interest only group), and 534 showed no interest and provided no contact information (no interest group). Compared with the no interest group, the committed with interest group were more likely to be personal computer users (odds ratio (OR) = 2.78), physically active (OR = 1.03) and had higher levels of loneliness (OR = 1.16).
Conclusion: Increasing potential participants' familiarity with a personal computer and the internet before trial recruitment could increase participation rates and improve the generalizability of future studies of this type.
C1 [Dodge, Hiroko H.; Mattek, Nora; Bowman, Molly; Gregor, Mattie; Wild, Katherine; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA.
[Dodge, Hiroko H.] Univ Michigan, Dept Neurol, Michigan Alzheimers Dis Ctr, Ann Arbor, MI USA.
[Dodge, Hiroko H.; Mattek, Nora; Bowman, Molly; Wild, Katherine; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA.
[Katsumata, Yuriko] Univ Kentucky, Coll Publ Hlth, Lexington, KY USA.
[Zhu, Jian] Univ Michigan, Grad Sch Publ Hlth, Ann Arbor, MI 48109 USA.
[Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR USA.
RP Dodge, HH (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA.
EM dodgeh@ohsu.edu
FU National Institute on Aging [R01AG033581, P30AG008017, P30AG024978,
R01AG024059]; National Institutes of Health; US Department of Health and
Human Services
FX Funding sources: R01AG033581, P30AG008017, P30AG024978, and R01AG024059
from National Institute on Aging, National Institutes of Health, US
Department of Health and Human Services.
NR 18
TC 3
Z9 3
U1 4
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD DEC 23
PY 2014
VL 15
AR 508
DI 10.1186/1745-6215-15-508
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AY9FA
UT WOS:000347853900002
PM 25539637
ER
PT J
AU Isselbacher, EM
AF Isselbacher, Eric M.
TI Trends in Thoracic Aortic Aneurysms and Dissection Out of the Shadows
and Into the Light
SO CIRCULATION
LA English
DT Editorial Material
DE Editorials; aneurysm; aortic diseases; dissection; thoracic diseases
ID ATHEROSCLEROSIS; REPAIR
C1 [Isselbacher, Eric M.] Massachusetts Gen Hosp, Thorac Aort Ctr, Boston, MA 02144 USA.
[Isselbacher, Eric M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Isselbacher, EM (reprint author), Massachusetts Gen Hosp, 55 Fruit St,YAW 5800, Boston, MA 02144 USA.
EM eisselbacher@partners.org
NR 14
TC 2
Z9 2
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 23
PY 2014
VL 130
IS 25
BP 2267
EP 2268
DI 10.1161/CIRCULATIONAHA.114.013603
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AX1PQ
UT WOS:000346719100008
PM 25394734
ER
PT J
AU Chatterjee, NA
Steiner, J
Lewis, GD
AF Chatterjee, Neal A.
Steiner, Johannes
Lewis, Gregory D.
TI It Is Time to Look at Heart Failure With Preserved Ejection Fraction
From the Right Side
SO CIRCULATION
LA English
DT Editorial Material
DE Editorials; heart failure; heart ventricles; pulmonary; circulation;
ventricular dysfunction, right
ID PULMONARY ARTERIAL-HYPERTENSION; RIGHT-VENTRICULAR FUNCTION;
PHOSPHODIESTERASE-5 INHIBITION; ECHOCARDIOGRAPHIC-ASSESSMENT; EXERCISE
CAPACITY; SYSTOLIC FUNCTION; EUROPEAN-SOCIETY; VENOUS-PRESSURE;
DOUBLE-BLIND; TRIAL
C1 [Chatterjee, Neal A.; Steiner, Johannes; Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, Boston, MA USA.
RP Lewis, GD (reprint author), Massachusetts Gen Hosp, Heart Failure & Cardiac Transplantat Unit, Bigelow 800,Fruit St, Boston, MA 02114 USA.
EM glewis@partners.org
FU NHLBI NIH HHS [5U10HL110337, R01 HL119154, U10 HL110337]
NR 35
TC 7
Z9 7
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 23
PY 2014
VL 130
IS 25
BP 2272
EP 2277
DI 10.1161/CIRCULATIONAHA.114.013536
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AX1PQ
UT WOS:000346719100010
PM 25391521
ER
PT J
AU Waldo, SW
Secemsky, EA
O'Brien, C
Kennedy, KF
Pomerantsev, E
Sundt, TM
McNulty, EJ
Scirica, BM
Yeh, RW
AF Waldo, Stephen W.
Secemsky, Eric A.
O'Brien, Cashel
Kennedy, Kevin F.
Pomerantsev, Eugene
Sundt, Thoralf M., III
McNulty, Edward J.
Scirica, Benjamin M.
Yeh, Robert W.
TI Surgical Ineligibility and Mortality Among Patients With Unprotected
Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous
Coronary Intervention
SO CIRCULATION
LA English
DT Article
DE eligibility determination; percutaneous coronary intervention; risk
adjustment; surgery
ID CARDIOVASCULAR DATA REGISTRY; DRUG-ELUTING STENTS; BYPASS-GRAFTING
SURGERY; RISK PREDICTION; REVASCULARIZATION; SOCIETY; ANGIOPLASTY;
IMPROVEMENT; STRATEGIES; OUTCOMES
AB Background-Decisions to proceed with surgical versus percutaneous revascularization for multivessel coronary artery disease are often based on subtle clinical information that may not be captured in contemporary registries. The present study sought to evaluate the association between surgical ineligibility documented in the medical record and long-term mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention.
Methods and Results-All subjects undergoing nonemergent percutaneous coronary intervention for unprotected left main or multivessel coronary artery disease were identified at 2 academic medical centers from 2009 to 2012. Documentation of surgical ineligibility was assessed through review of electronic medical records. Cox proportional hazard models adjusted for known mortality risk factors were created to assess long-term mortality in patients with and without documentation of surgical ineligibility. Among 1013 subjects with multivessel coronary artery disease, 218 (22%) were deemed ineligible for coronary artery bypass graft surgery. The most common explicitly cited reasons for surgical ineligibility in the medical record were poor surgical targets (24%), advanced age (16%), and renal insufficiency (16%). After adjustment for known risk factors, documentation of surgical ineligibility remained independently associated with an increased risk of in-hospital (odds ratio, 6.26; 95% confidence interval, 2.16-18.15; P<0.001) and long-term mortality (hazard ratio, 2.98; 95% confidence interval, 1.88-4.72, P<0.001) after percutaneous coronary intervention.
Conclusions-Documented surgical ineligibility is common and associated with significantly increased long-term mortality among patients undergoing percutaneous coronary intervention with unprotected left main or multivessel coronary disease, even after adjustment for known risk factors for adverse events during percutaneous revascularization.
C1 [Waldo, Stephen W.; Secemsky, Eric A.; O'Brien, Cashel; Pomerantsev, Eugene; Yeh, Robert W.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Sundt, Thoralf M., III] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA.
[Kennedy, Kevin F.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[McNulty, Edward J.] Kaiser Permanente Med Ctr, Div Cardiol, San Francisco, CA USA.
[Scirica, Benjamin M.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
RP Yeh, RW (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRB 8-843, Boston, MA 02114 USA.
EM ryeh@partners.org
FU National Heart, Lung, and Blood Institute; Hassenfeld Scholars Program
FX Dr Yeh is supported by a career development award from the National
Heart, Lung, and Blood Institute. The study was supported in part by the
Hassenfeld Scholars Program.
NR 25
TC 23
Z9 23
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 23
PY 2014
VL 130
IS 25
BP 2295
EP 2301
DI 10.1161/CIRCULATIONAHA.114.011541
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AX1PQ
UT WOS:000346719100013
PM 25391519
ER
PT J
AU He, B
Lanz, RB
Fiskus, W
Geng, CD
Yi, P
Hartig, SM
Rajapakshe, K
Shou, J
Wei, LP
Shah, SS
Foley, C
Chew, SA
Eedunuri, VK
Bedoya, DJ
Feng, Q
Minami, T
Mitsiades, CS
Frolov, A
Weigel, NL
Hilsenbeck, SG
Rosen, DG
Palzkill, T
Ittmann, MM
Song, YC
Coarfa, C
O'Malley, BW
Mitsiades, N
AF He, Bin
Lanz, Rainer B.
Fiskus, Warren
Geng, Chuandong
Yi, Ping
Hartig, Sean M.
Rajapakshe, Kimal
Shou, John
Wei, Liping
Shah, Shrijal S.
Foley, Christopher
Chew, Sue Anne
Eedunuri, Vijay K.
Bedoya, Diego J.
Feng, Qin
Minami, Takashi
Mitsiades, Constantine S.
Frolov, Anna
Weigel, Nancy L.
Hilsenbeck, Susan G.
Rosen, Daniel G.
Palzkill, Timothy
Ittmann, Michael M.
Song, Yongcheng
Coarfa, Cristian
O'Malley, Bert W.
Mitsiades, Nicholas
TI GATA2 facilitates steroid receptor coactivator recruitment to the
androgen receptor complex
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE prostate cancer; small molecule inhibitor; AR signaling; GATA2; steroid
receptor coactivator
ID RESISTANT PROSTATE-CANCER; TRANSCRIPTION FACTORS; INCREASED SURVIVAL;
GENE-EXPRESSION; GROWTH; ENZALUTAMIDE; ABIRATERONE; ENHANCERS; VARIANTS;
TURNOVER
AB The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC) and frequently even after treatment with second-line hormonal therapies such as abiraterone and enzalutamide. The persistence of AR activity via both ligand-dependent and ligand-independent mechanisms (including constitutively active AR splice variants) highlights the unmet need for alternative approaches to block AR signaling in CRPC. We investigated the transcription factor GATA-binding protein 2 (GATA2) as a regulator of AR signaling and an actionable therapeutic target in PC. We demonstrate that GATA2 directly promotes expression of both full-length and splice-variant AR, resulting in a strong positive correlation between GATA2 and AR expression in both PC cell lines and patient specimens. Conversely, GATA2 expression is repressed by androgen and AR, suggesting a negative feedback regulatory loop that, upon androgen deprivation, derepresses GATA2 to contribute to AR overexpression in CRPC. Simultaneously, GATA2 is necessary for optimal transcriptional activity of both fulllength and splice-variant AR. GATA2 colocalizes with AR and Forkhead box protein A1 on chromatin to enhance recruitment of steroid receptor coactivators and formation of the transcriptional holocomplex. In agreement with these important functions, high GATA2 expression and transcriptional activity predicted worse clinical outcome in PC patients. A GATA2 small molecule inhibitor suppressed the expression and transcriptional function of both full-length and splice-variant AR and exerted potent anticancer activity against PC cell lines. We propose pharmacological inhibition of GATA2 as a firstin-field approach to target AR expression and function and improve outcomes in CRPC.
C1 [He, Bin; Fiskus, Warren; Geng, Chuandong; Shou, John; Shah, Shrijal S.; Foley, Christopher; Chew, Sue Anne; Bedoya, Diego J.; Mitsiades, Nicholas] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[He, Bin; Lanz, Rainer B.; Fiskus, Warren; Yi, Ping; Hartig, Sean M.; Rajapakshe, Kimal; Foley, Christopher; Feng, Qin; Weigel, Nancy L.; Coarfa, Cristian; O'Malley, Bert W.; Mitsiades, Nicholas] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
[Wei, Liping; Palzkill, Timothy; Song, Yongcheng] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.
[Rosen, Daniel G.; Ittmann, Michael M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Frolov, Anna; Hilsenbeck, Susan G.] Baylor Coll Med, Dan L Duncan Canc Ctr Biostat, Houston, TX 77030 USA.
[Rosen, Daniel G.; Ittmann, Michael M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Eedunuri, Vijay K.] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA 70130 USA.
[Minami, Takashi] Univ Tokyo, Res Ctr Adv Sci & Technol, Lab Syst Biol & Med, Tokyo 1538904, Japan.
[Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Coarfa, C (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
EM coarfa@bcm.edu; berto@bcm.edu; mitsiade@bcm.edu
RI EEDUNURI, VIJAY KUMAR /I-8507-2015; Rajapakshe, Kimal/P-1592-2015;
EEDUNURI, VIJAY KUMAR/L-2213-2015
OI EEDUNURI, VIJAY KUMAR /0000-0003-3808-9875;
FU National Cancer Institute (NCI) Cancer Center Support Grant
[P30CA125123]; Prostate Cancer Foundation; Conquer Cancer Foundation of
the American Society of Clinical Oncology Young Investigator and Career
Development Awards; Eunice Kennedy Shriver National Institute of Child
Health and Human Development [8818]; Susan G. Komen for the Cure
Foundation Promise Grant [221410]; National Institutes of Health
[1K01DK096093]; Pilot/Feasibility Program of the Diabetes and
Endocrinology Research Center at BCM [P30-DK079638]; Alkek Foundation
for Molecular Discovery Pilot grant; Center for Drug Discovery at BCM
FX We acknowledge the joint participation by the Adrienne Helis Malvin
Medical Research Foundation through its direct engagement in the
continuous, active conduct of medical research in conjunction with
Baylor College of Medicine (BCM), and the assistance of the Shared
Resources of the Dan L. Duncan Cancer Center [supported by National
Cancer Institute (NCI) Cancer Center Support Grant P30CA125123]. This
work was supported by the Prostate Cancer Foundation (B.W.O. and N.M.);
Conquer Cancer Foundation of the American Society of Clinical Oncology
Young Investigator and Career Development Awards (both to N.M.); Eunice
Kennedy Shriver National Institute of Child Health and Human Development
Grant 8818 (to B.W.O.); Susan G. Komen for the Cure Foundation Promise
Grant 221410 (to B.W.O.); National Institutes of Health Grant
1K01DK096093 (to S.M.H.); pilot grants (to S.M.H. and N.M.) from the
Pilot/Feasibility Program of the Diabetes and Endocrinology Research
Center at BCM (P30-DK079638); and an Alkek Foundation for Molecular
Discovery Pilot grant (to C.C.). N.M. is a Dan L. Duncan Scholar, a
Caroline Wiess Law Scholar, and a member of the Dan L. Duncan Cancer
Center (supported by NCI Cancer Center Support Grant P30CA125123) and
the Center for Drug Discovery at BCM.
NR 35
TC 21
Z9 21
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 23
PY 2014
VL 111
IS 51
BP 18261
EP 18266
DI 10.1073/pnas.1421415111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX2IP
UT WOS:000346767200052
PM 25489091
ER
PT J
AU Whitesell, L
Santagata, S
Mendillo, ML
Lin, NU
Proia, DA
Lindquist, S
AF Whitesell, Luke
Santagata, Sandro
Mendillo, Marc L.
Lin, Nancy U.
Proia, David A.
Lindquist, Susan
TI HSP90 empowers evolution of resistance to hormonal therapy in human
breast cancer models
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE estrogen receptor; antiestrogen; drug resistance; tumor progression;
tamoxifen
ID MOLECULAR CHAPERONE HSP90; HEAT-SHOCK; TARGETED INHIBITION;
ANTITUMOR-ACTIVITY; MORPHOLOGICAL EVOLUTION; TUMOR-CELLS; GANETESPIB;
EXPRESSION; CAPACITOR; PROFILE
AB The efficacy of hormonal therapies for advanced estrogen receptor-positive breast cancers is limited by the nearly inevitable development of acquired resistance. Efforts to block the emergence of resistance have met with limited success, largely because the mechanisms underlying it are so varied and complex. Here, we investigate a new strategy aimed at the very processes by which cancers evolve resistance. From yeast to vertebrates, heat shock protein 90 (HSP90) plays a unique role among molecular chaperones by promoting the evolution of heritable new traits. It does so by regulating the folding of a diverse portfolio of metastable client proteins, many of which mediate adaptive responses that allow organisms to adapt and thrive in the face of diverse challenges, including those posed by drugs. Guided by our previous work in pathogenic fungi, in which very modest HSP90 inhibition impairs resistance to mechanistically diverse antifungals, we examined the effect of similarly modest HSP90 inhibition on the emergence of resistance to antiestrogens in breast cancer models. Even though this degree of inhibition fell below the threshold for proteotoxic activation of the heat-shock response and had no overt anticancer activity on its own, it dramatically impaired the emergence of resistance to hormone antagonists both in cell culture and in mice. Our findings strongly support the clinical testing of combined hormone antagonist-low-level HSP90 inhibitor regimens in the treatment of metastatic estrogen receptor-positive breast cancer. At a broader level, they also provide promising proof of principle for a generalizable strategy to combat the pervasive problem of rapidly emerging resistance to molecularly targeted therapeutics.
C1 [Whitesell, Luke; Santagata, Sandro; Mendillo, Marc L.; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Santagata, Sandro] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Santagata, Sandro] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Lin, Nancy U.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Proia, David A.] Synta Pharmaceut, Lexington, MA 02421 USA.
[Lindquist, Susan] MIT, Dept Biol, Cambridge, MA 02142 USA.
[Lindquist, Susan] MIT, Howard Hughes Med Inst, Cambridge, MA 02142 USA.
RP Whitesell, L (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM whitesell@wi.mit.edu; lindquist_admin@wi.mit.edu
FU NIH [K08NS064168]; National Cancer Institute of the NIH [K99CA175293];
Susan G. Komen Foundation [KG110450]
FX We thank members of the S.L. laboratory for valuable discussions and
comments on the manuscript. We also thank the Genome Technology Center
and George Bell (Whitehead Institute/Bioinformatics and Research
Computing) for help with expression profiling and statistical analysis.
S.L. is a Howard Hughes Medical Institute Investigator. S.S. was
supported by NIH Award K08NS064168. M.L.M. was supported by the National
Cancer Institute of the NIH under Award K99CA175293. Support for this
study was also provided by the Susan G. Komen Foundation [KG110450 (to
L.W. and N.U.L.)].
NR 44
TC 24
Z9 25
U1 4
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 23
PY 2014
VL 111
IS 51
BP 18297
EP 18302
DI 10.1073/pnas.1421323111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX2IP
UT WOS:000346767200058
PM 25489079
ER
PT J
AU Perry, JA
Kiezun, A
Tonzi, P
Van Allen, EM
Carter, SL
Baca, SC
Cowley, GS
Bhatt, AS
Rheinbay, E
Pedamallu, CS
Helman, E
Taylor-Weiner, A
McKenna, A
DeLuca, DS
Lawrence, MS
Ambrogio, L
Sougnez, C
Sivachenko, A
Walensky, LD
Wagle, N
Mora, J
de Torres, C
Lavarino, C
Aguiar, SD
Yunes, JA
Brandalise, SR
Mercado-Celis, GE
Melendez-Zajgla, J
Cardenas-Cardos, R
Velasco-Hidalgo, L
Roberts, CWM
Garraway, LA
Rodriguez-Galindo, C
Gabriel, SB
Lander, ES
Golub, TR
Orkin, SH
Getz, G
Janeway, KA
AF Perry, Jennifer A.
Kiezun, Adam
Tonzi, Peter
Van Allen, Eliezer M.
Carter, Scott L.
Baca, Sylvan C.
Cowley, Glenn S.
Bhatt, Ami S.
Rheinbay, Esther
Pedamallu, Chandra Sekhar
Helman, Elena
Taylor-Weiner, Amaro
McKenna, Aaron
DeLuca, David S.
Lawrence, Michael S.
Ambrogio, Lauren
Sougnez, Carrie
Sivachenko, Andrey
Walensky, Loren D.
Wagle, Nikhil
Mora, Jaume
de Torres, Carmen
Lavarino, Cinzia
Aguiar, Simone Dos Santos
Yunes, Jose Andres
Brandalise, Silvia Regina
Mercado-Celis, Gabriela Elisa
Melendez-Zajgla, Jorge
Cardenas-Cardos, Roco
Velasco-Hidalgo, Liliana
Roberts, Charles W. M.
Garraway, Levi A.
Rodriguez-Galindo, Carlos
Gabriel, Stacey B.
Lander, Eric S.
Golub, Todd R.
Orkin, Stuart H.
Getz, Gad
Janeway, Katherine A.
TI Complementary genomic approaches highlight the PI3K/mTOR pathway as a
common vulnerability in osteosarcoma
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE osteosarcoma; TP53; PI3K; mTOR; genomics
ID RAPAMYCIN INHIBITOR RIDAFOROLIMUS; TUBEROUS SCLEROSIS COMPLEX; MOUSE
OSTEOSARCOMA; MAMMALIAN TARGET; PAGETS-DISEASE; OSTEO-SARCOMA;
CANCER-CELLS; MDM2 GENES; MUTATIONS; AMPLIFICATION
AB Osteosarcoma is the most common primary bone tumor, yet there have been no substantial advances in treatment or survival in three decades. We examined 59 tumor/normal pairs by whole-exome, whole-genome, and RNA-sequencing. Only the TP53 gene was mutated at significant frequency across all samples. The mean nonsilent somatic mutation rate was 1.2 mutations per megabase, and there was a median of 230 somatic rearrangements per tumor. Complex chains of rearrangements and localized hypermutation were detected in almost all cases. Given the intertumor heterogeneity, the extent of genomic instability, and the difficulty in acquiring a large sample size in a rare tumor, we used several methods to identify genomic events contributing to osteosarcoma survival. Pathway analysis, a heuristic analytic algorithm, a comparative oncology approach, and an shRNA screen converged on the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway as a central vulnerability for therapeutic exploitation in osteosarcoma. Osteosarcoma cell lines are responsive to pharmacologic and genetic inhibition of the PI3K/mTOR pathway both in vitro and in vivo.
C1 [Perry, Jennifer A.; Tonzi, Peter; Roberts, Charles W. M.; Rodriguez-Galindo, Carlos; Orkin, Stuart H.; Janeway, Katherine A.] Dana Farber Boston Childrens Canc, Dept Pediat Oncol, Boston, MA 02215 USA.
[Perry, Jennifer A.; Tonzi, Peter; Roberts, Charles W. M.; Rodriguez-Galindo, Carlos; Orkin, Stuart H.; Janeway, Katherine A.] Blood Disorders Ctr, Boston, MA 02215 USA.
[Kiezun, Adam; Van Allen, Eliezer M.; Carter, Scott L.; Baca, Sylvan C.; Cowley, Glenn S.; Bhatt, Ami S.; Rheinbay, Esther; Pedamallu, Chandra Sekhar; Helman, Elena; Taylor-Weiner, Amaro; McKenna, Aaron; DeLuca, David S.; Lawrence, Michael S.; Ambrogio, Lauren; Sougnez, Carrie; Sivachenko, Andrey; Wagle, Nikhil; Garraway, Levi A.; Gabriel, Stacey B.; Lander, Eric S.; Golub, Todd R.; Getz, Gad; Janeway, Katherine A.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Van Allen, Eliezer M.; Baca, Sylvan C.; Bhatt, Ami S.; Pedamallu, Chandra Sekhar; Helman, Elena; Wagle, Nikhil; Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Walensky, Loren D.; Rodriguez-Galindo, Carlos; Golub, Todd R.; Orkin, Stuart H.; Janeway, Katherine A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Wagle, Nikhil; Garraway, Levi A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Lander, Eric S.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Getz, Gad] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Mora, Jaume; de Torres, Carmen; Lavarino, Cinzia] Hosp St Joan Deu, Dept Hematol & Oncol, Barcelona 08950, Spain.
[Aguiar, Simone Dos Santos; Yunes, Jose Andres; Brandalise, Silvia Regina] Ctr Infantil Boldrini, Dept Pediat Oncol, BR-13083210 Campinas, SP, Brazil.
[Aguiar, Simone Dos Santos] Univ Estadual Campinas, Fac Med Sci, Ctr Pediat Res, BR-13083887 Campinas, Brazil.
[Yunes, Jose Andres] Univ Estadual Campinas, Fac Med Sci, Dept Med Genet, BR-13083887 Campinas, Brazil.
[Mercado-Celis, Gabriela Elisa; Melendez-Zajgla, Jorge] Natl Inst Genom Med, Subdirect Basic Res, Mexico City 14610, DF, Mexico.
[Cardenas-Cardos, Roco; Velasco-Hidalgo, Liliana] Natl Inst Pediat, Dept Oncol, Mexico City 04530, DF, Mexico.
[Lander, Eric S.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Golub, Todd R.; Orkin, Stuart H.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Orkin, SH (reprint author), Dana Farber Boston Childrens Canc, Dept Pediat Oncol, Boston, MA 02215 USA.
EM stuart_orkin@dfci.harvard.edu; gadgetz@broadinstitute.org;
kjaneway@partners.org
FU Carlos Slim Health Institute; Foster Foundation; Pedals for Pediatrics;
Brazilian National Counsel of Technological and Scientific Development
(CNPq); CNPq [401991/2010-5]; Alex Lemonade Stand Innovation Award;
National Cancer Institute Grant [U01CA105423]; St. Baldrick's Foundation
Career Development Award; Timothy O'Brien Osteosarcoma Research Fund
FX We thank Ben Hubbell-Engler for technical support. This work was
conducted as part of the Slim Initiative for Genomic Medicine in the
Americas, a project funded by the Carlos Slim Health Institute. This
work was supported in part by the Foster Foundation (J.A.P.), Pedals for
Pediatrics (J.A.P.), a Productivity Fellowship from the Brazilian
National Counsel of Technological and Scientific Development (CNPq,
J.A.Y.), CNPq Grant 401991/2010-5 (to J.A.Y.), an Alex Lemonade Stand
Innovation Award (to S.H.O.), National Cancer Institute Grant
U01CA105423 (to S.H.O.), a St. Baldrick's Foundation Career Development
Award (to K.A.J.), and the Timothy O'Brien Osteosarcoma Research Fund
(K.A.J.).
NR 65
TC 56
Z9 57
U1 3
U2 21
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 23
PY 2014
VL 111
IS 51
BP E5564
EP E5573
DI 10.1073/pnas.1419260111
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX2IP
UT WOS:000346767200013
PM 25512523
ER
PT J
AU Martz, CA
Ottina, KA
Singleton, KR
Jasper, JS
Wardell, SE
Peraza-Penton, A
Anderson, GR
Winter, PS
Wang, T
Alley, HM
Kwong, LN
Cooper, ZA
Tetzlaff, M
Chen, PL
Rathmell, JC
Flaherty, KT
Wargo, JA
McDonnell, DP
Sabatini, DM
Wood, KC
AF Martz, Colin A.
Ottina, Kathleen A.
Singleton, Katherine R.
Jasper, Jeff S.
Wardell, Suzanne E.
Peraza-Penton, Ashley
Anderson, Grace R.
Winter, Peter S.
Wang, Tim
Alley, Holly M.
Kwong, Lawrence N.
Cooper, Zachary A.
Tetzlaff, Michael
Chen, Pei-Ling
Rathmell, Jeffrey C.
Flaherty, Keith T.
Wargo, Jennifer A.
McDonnell, Donald P.
Sabatini, David M.
Wood, Kris C.
TI Systematic identification of signaling pathways with potential to confer
anticancer drug resistance
SO SCIENCE SIGNALING
LA English
DT Article
ID POSITIVE BREAST-CANCER; ESTROGEN-RECEPTOR; METASTATIC MELANOMA; TUMOR
MICROENVIRONMENT; TAMOXIFEN RESISTANCE; KINASE INHIBITORS;
COLORECTAL-CANCER; RAF INHIBITION; LUNG-CANCER; BRAF
AB Cancer cells can activate diverse signaling pathways to evade the cytotoxic action of drugs. Wecreated and screened a library of barcoded pathway-activating mutant complementary DNAs to identify those that enhanced the survival of cancer cells in the presence of 13 clinically relevant, targeted therapies. We found that activation of the RAS-MAPK (mitogen-activated protein kinase), Notch1, PI3K (phosphoinositide 3-kinase)-mTOR (mechanistic target of rapamycin), and ER (estrogen receptor) signaling pathways often conferred resistance to this selection of drugs. Activation of the Notch1 pathway promoted acquired resistance to tamoxifen (an ER-targeted therapy) in serially passaged breast cancer xenografts in mice, and treating mice with a g-secretase inhibitor to inhibit Notch signaling restored tamoxifen sensitivity. Markers of Notch1 activity in tumor tissue correlated with resistance to tamoxifen in breast cancer patients. Similarly, activation of Notch1 signaling promoted acquired resistance toMAPKinhibitors inBRAFV600Emelanoma cells in culture, and the abundance of Notch1 pathway markers was increased in tumors from a subset ofmelanoma patients. Thus, Notch1 signalingmay be a therapeutic target in some drug-resistant breast cancers and melanomas. Additionally, multiple resistance pathways were activated in melanoma cell lines with intrinsic resistance to MAPK inhibitors, and simultaneous inhibition of these pathways synergistically induced drug sensitivity. These data illustrate the potential for systematic identification of the signaling pathways controlling drug resistance that could inform clinical strategies and drug development for multiple types of cancer. This approach may also be used to advance clinical options in other disease contexts.
C1 [Martz, Colin A.; Singleton, Katherine R.; Jasper, Jeff S.; Wardell, Suzanne E.; Peraza-Penton, Ashley; Anderson, Grace R.; Winter, Peter S.; Alley, Holly M.; Rathmell, Jeffrey C.; McDonnell, Donald P.; Wood, Kris C.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
[Ottina, Kathleen A.; Wang, Tim; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Ottina, Kathleen A.; Wang, Tim; Sabatini, David M.] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
[Wang, Tim; Sabatini, David M.] Broad Inst, Cambridge, MA 02142 USA.
[Kwong, Lawrence N.; Cooper, Zachary A.; Tetzlaff, Michael; Chen, Pei-Ling; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Sabatini, DM (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM sabatini@wi.mit.edu; kris.wood@duke.edu
OI Cooper, Zachary/0000-0003-1059-0940
FU Duke University School of Medicine start-up funds; Duke Cancer
Institute; NIH Building Interdisciplinary Research Careers in Women's
Health Program; Harry J. Lloyd Trust Translational Research Award;
Golfers Against Cancer Research Award; Stewart Trust Fellowship; V
Scholar Award from the V Foundation for Cancer Research; NIH [CA103866,
AI07389, R37DK048807]
FX This work was supported by Duke University School of Medicine start-up
funds and by the Duke Cancer Institute (K.C.W.), the NIH Building
Interdisciplinary Research Careers in Women's Health Program (K.C.W.), a
Harry J. Lloyd Trust Translational Research Award (K.C.W.), a Golfers
Against Cancer Research Award (K.C.W.), a Stewart Trust Fellowship
(K.C.W.), a V Scholar Award from the V Foundation for Cancer Research
(K.C.W.), and NIH grants CA103866 (D.M.S.), AI07389 (D.M.S.), and
R37DK048807 (D.P.M.). D.M.S. is an investigator of the Howard Hughes
Medical Institute. All cDNA constructs described here have been
deposited in Addgene.
NR 48
TC 34
Z9 35
U1 1
U2 15
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD DEC 23
PY 2014
VL 7
IS 357
AR ra121
DI 10.1126/scisignal.aaa1877
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AX3GA
UT WOS:000346827000002
PM 25538079
ER
PT J
AU Winter, PS
Sarosiek, KA
Lin, KH
Meggendorfer, M
Schnittger, S
Letai, A
Wood, KC
AF Winter, Peter S.
Sarosiek, Kristopher A.
Lin, Kevin H.
Meggendorfer, Manja
Schnittger, Susanne
Letai, Anthony
Wood, Kris C.
TI RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-
mediated apoptosis
SO SCIENCE SIGNALING
LA English
DT Article
ID MYELOPROLIFERATIVE NEOPLASM CELLS; POLYCYTHEMIA-VERA; KINASE; PROTEIN;
DEATH; PHOSPHORYLATION; BCL-2; BCL-X(L); MUTATION; THERAPY
AB Myeloproliferative neoplasms (MPNs) frequently have an activating mutation in the gene encoding Janus kinase 2 (JAK2). Thus, targeting the pathway mediated by JAK and its downstream substrate, signal transducer and activator of transcription (STAT), may yield clinical benefit for patients with MPNs containing the JAK2V617F mutation. Although JAK inhibitor therapy reduces splenomegaly and improves systemic symptoms in patients, this treatment does not appreciably reduce the number of neoplastic cells. To identify potential mechanisms underlying this inherent resistance phenomenon, we performed pathway- centric, gain- of- function screens in JAK2V617F hematopoietic cells and found that the activation of the guanosine triphosphatase (GTPase) RAS or its effector pathways [ mediated by the kinases AKT and ERK (extracellular signal- regulated kinase)] renders cells insensitive to JAK inhibition. Resistant MPN cells became sensitized to JAK inhibitors when also exposed to inhibitors of the AKT or ERK pathways. Mechanistically, in JAK2V617F cells, a JAK2- mediated inactivating phosphorylation of the proapoptotic protein BAD [ B cell lymphoma 2 (BCL- 2)- associated death promoter] promoted cell survival. In sensitive cells, exposure to a JAK inhibitor resulted in dephosphorylation of BAD, enabling BAD to bind and sequester the prosurvival protein BCL- XL (BCL- 2- like 1), thereby triggering apoptosis. In resistant cells, RAS effector pathways maintained BAD phosphorylation in the presence of JAK inhibitors, yielding a specific dependence on BCL- XL for survival. In patients with MPNs, activating mutations in RAS co- occur with the JAK2V617F mutation in the malignant cells, suggesting that RAS effector pathways likely play an important role in clinically observed resistance.
C1 [Winter, Peter S.; Lin, Kevin H.; Wood, Kris C.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
[Sarosiek, Kristopher A.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Sarosiek, Kristopher A.; Letai, Anthony] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Meggendorfer, Manja; Schnittger, Susanne] Munich Leukemia Lab, D-81377 Munich, Germany.
RP Wood, KC (reprint author), Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
EM kris.wood@duke.edu
FU Duke University start-up funds; NIH Building Interdisciplinary Research
Careers in Women's Health Program; Stewart Trust; Golfers Against
Cancer; Speer Memorial Fellowship; Duke Medical Scientist Training
Program [T32 GM007171]; American Cancer Society Postdoctoral Fellowship
[121360-PF-11-256-01-TBG]; National Cancer Institute [NCI 2R01 CA129974]
FX This work was supported by Duke University start-up funds (K.C.W.), the
NIH Building Interdisciplinary Research Careers in Women's Health
Program (K.C.W.), the Stewart Trust (K.C.W.), Golfers Against Cancer
(K.C.W.), the Speer Memorial Fellowship (P.S.W.), the Duke Medical
Scientist Training Program (T32 GM007171 to K.H.L.), the American Cancer
Society Postdoctoral Fellowship (121360-PF-11-256-01-TBG to K.A.S.), and
the National Cancer Institute (NCI 2R01 CA129974 to A. L.).
NR 47
TC 9
Z9 9
U1 2
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD DEC 23
PY 2014
VL 7
IS 357
AR ra122
DI 10.1126/scisignal.2005301
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AX3GA
UT WOS:000346827000003
PM 25538080
ER
PT J
AU Jia, C
Yu, D
Lamarre, M
Leopold, PL
Teng, YD
Wang, HJ
AF Jia, Chao
Yu, Dou
Lamarre, Marven
Leopold, Philip L.
Teng, Yang D.
Wang, Hongjun
TI Patterned Electrospun Nanofiber Matrices Via Localized Dissolution:
Potential for Guided Tissue Formation
SO ADVANCED MATERIALS
LA English
DT Article
ID STEM-CELLS; IN-VITRO; SCAFFOLDS; FIBERS; GROWTH; DIFFERENTIATION;
MIGRATION; MEDICINE; SURFACES; GUIDANCE
C1 [Jia, Chao; Lamarre, Marven; Leopold, Philip L.; Wang, Hongjun] Stevens Inst Technol, Hoboken, NJ 07030 USA.
[Yu, Dou; Teng, Yang D.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
[Yu, Dou; Teng, Yang D.] Harvard Univ, Div SCI Res, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
RP Wang, HJ (reprint author), Stevens Inst Technol, 1 Castle Point Hudson, Hoboken, NJ 07030 USA.
EM Hongjun.wang@stevens.edu
FU NSF-IIP [1338958, 1346430]; NSF-CBET [1033742]; NIAMS [1R21 AR056416];
VARR D; CIMIT-DoD
FX The authors are grateful for the technical assistance from Mr. Yexin Gu
and Dr. Tsengming Chou in SEM examination. Special thanks are also given
to Dr. Shaohua Li (Rutgers-Robert Wood Johnson, NJ, USA), who provided
GFP transfection to the mouse endothelial cells. Part of the work was
financially supported by NSF-IIP (1338958, 1346430, Wang), NSF-CBET
(1033742, Wang), NIAMS (1R21 AR056416, Wang), VARR& D (Teng) and
CIMIT-DoD (Teng).
NR 36
TC 10
Z9 10
U1 11
U2 67
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD DEC 23
PY 2014
VL 26
IS 48
BP 8192
EP 8197
DI 10.1002/adma.201403509
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA AW7ZR
UT WOS:000346480800017
PM 25352221
ER
PT J
AU Wasfy, JH
Rao, SK
Chittle, MD
Gallen, KM
Isselbacher, EM
Ferris, TG
AF Wasfy, Jason H.
Rao, Sandhya K.
Chittle, Melissa D.
Gallen, Kathleen M.
Isselbacher, Eric M.
Ferris, Timothy G.
TI Initial Results of a Cardiac E-Consult Pilot Program
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Letter
ID COSTS
C1 [Wasfy, Jason H.; Rao, Sandhya K.; Chittle, Melissa D.; Gallen, Kathleen M.; Isselbacher, Eric M.; Ferris, Timothy G.] Massachusetts Gen Hosp, Massachusetts Gen Phys Org, Boston, MA 02114 USA.
RP Wasfy, JH (reprint author), Massachusetts Gen Hosp, Massachusetts Gen Phys Org, BUL 205B 55 Fruit St, Boston, MA 02114 USA.
EM jwasfy@mgh.harvard.edu
NR 4
TC 8
Z9 8
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD DEC 23
PY 2014
VL 64
IS 24
BP 2706
EP 2707
DI 10.1016/j.jacc.2014.09.061
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AW5ZL
UT WOS:000346349300019
PM 25524348
ER
PT J
AU Begg, CB
Seshan, VE
Zabor, EC
Furberg, H
Arora, A
Shen, R
Maranchie, JK
Nielsen, ME
Rathmell, WK
Signoretti, S
Tamboli, P
Karam, JA
Choueiri, TK
Hakimi, AA
Hsieh, JJ
AF Begg, Colin B.
Seshan, Venkatraman E.
Zabor, Emily C.
Furberg, Helena
Arora, Arshi
Shen, Ronglai
Maranchie, Jodi K.
Nielsen, Matthew E.
Rathmell, W. Kimryn
Signoretti, Sabina
Tamboli, Pheroze
Karam, Jose A.
Choueiri, Toni K.
Hakimi, A. Ari
Hsieh, James J.
TI Genomic investigation of etiologic heterogeneity: methodologic
challenges
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE Etiologic heterogeneity; Kidney cancer; Tumor sub-types
ID RENAL-CELL CARCINOMA; HIPPEL-LINDAU GENE; CIGARETTE-SMOKING; CANCER;
TRANSPORTERS; EPIDEMIOLOGY; METAANALYSIS; HYPERTENSION; MUTATIONS;
DISEASE
AB Background: The etiologic heterogeneity of cancer has traditionally been investigated by comparing risk factor frequencies within candidate sub-types, defined for example by histology or by distinct tumor markers of interest. Increasingly tumors are being profiled for molecular features much more extensively. This greatly expands the opportunities for defining distinct sub-types. In this article we describe an exploratory analysis of the etiologic heterogeneity of clear cell kidney cancer. Data are available on the primary known risk factors for kidney cancer, while the tumors are characterized on a genome-wide basis using expression, methylation, copy number and mutational profiles.
Methods: We use a novel clustering strategy to identify sub-types. This is accomplished independently for the expression, methylation and copy number profiles. The goals are to identify tumor sub-types that are etiologically distinct, to identify the risk factors that define specific sub-types, and to endeavor to characterize the key genes that appear to represent the principal features of the distinct sub-types.
Results: The analysis reveals strong evidence that gender represents an important factor that distinguishes disease sub-types. The sub-types defined using expression data and methylation data demonstrate considerable congruence and are also clearly correlated with mutations in important cancer genes. These sub-types are also strongly correlated with survival. The complexity of the data presents many analytical challenges including, prominently, the risk of false discovery.
Conclusions: Genomic profiling of tumors offers the opportunity to identify etiologically distinct sub-types, paving the way for a more refined understanding of cancer etiology.
C1 [Begg, Colin B.; Seshan, Venkatraman E.; Zabor, Emily C.; Furberg, Helena; Arora, Arshi; Shen, Ronglai] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
[Maranchie, Jodi K.] Univ Pittsburgh, Med Ctr, Dept Urol, Pittsburgh, PA USA.
[Nielsen, Matthew E.] Univ N Carolina, Dept Urol, Chapel Hill, NC USA.
[Nielsen, Matthew E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Nielsen, Matthew E.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA.
[Nielsen, Matthew E.] Univ N Carolina, Dept Surg, Chapel Hill, NC USA.
[Rathmell, W. Kimryn] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA.
[Rathmell, W. Kimryn] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA.
[Signoretti, Sabina] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Tamboli, Pheroze] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
[Karam, Jose A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Choueiri, Toni K.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol,Med Sch, Boston, MA 02115 USA.
[Hakimi, A. Ari] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA.
[Hsieh, James J.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
RP Begg, CB (reprint author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
EM beggc@mskcc.org
OI Maranchie, Jodi/0000-0002-8534-9468
FU National Cancer Institute [CA163251, CA101942, CA008748]
FX This research was supported by the National Cancer Institute
(http://www.cancer.gov/), awards CA163251 to CBB and CA101942 to TKC;
CBB, VES and ECZ are supported on CA008748. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 26
TC 3
Z9 3
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD DEC 22
PY 2014
VL 14
AR 138
DI 10.1186/1471-2288-14-138
PG 10
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AZ1IT
UT WOS:000347993800002
PM 25532962
ER
PT J
AU Jain, RK
Netti, PA
AF Jain, Rakesh K.
Netti, Paolo A.
TI Letter to the editor regarding recent article by Wu et al. [J. Theor.
Biol. 355 (2014) pp. 194-207]
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Editorial Material
ID DRUG-DELIVERY; SOLID TUMORS; PRESSURE; EFFICACY; BLOOD; FLOW;
INTERSTITIUM; STRATEGIES; TRANSPORT; COLLAGEN
C1 [Jain, Rakesh K.] Harvard Univ, Edwin L Steele Lab Tumor Biol, Dept Radiat Oncol, Sch Med, Boston, MA 02114 USA.
[Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Netti, Paolo A.] Univ Naples Federico II, Interdisciplinary Res Ctr Biomat, I-80125 Naples, Italy.
RP Jain, RK (reprint author), Harvard Univ, Edwin L Steele Lab Tumor Biol, Dept Radiat Oncol, Sch Med, 100 Blossom St,Cox 7, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
OI NETTI, PAOLO/0000-0002-2435-7181
NR 14
TC 0
Z9 0
U1 1
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
EI 1095-8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD DEC 21
PY 2014
VL 363
BP 453
EP 453
DI 10.1016/j.jtbi.2014.08.052
PG 1
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
Biology
GA AY2SE
UT WOS:000347438600046
PM 25219622
ER
PT J
AU Vodovar, N
Seronde, MF
Laribi, S
Gayat, E
Lassus, J
Boukef, R
Nouira, S
Manivet, P
Samuel, JL
Logeart, D
Ishihara, S
Solal, AC
Januzzi, JL
Richards, AM
Launay, JM
Mebazaa, A
AF Vodovar, Nicolas
Seronde, Marie-France
Laribi, Said
Gayat, Etienne
Lassus, Johan
Boukef, Riadh
Nouira, Semir
Manivet, Philippe
Samuel, Jane-Lise
Logeart, Damien
Ishihara, Shiro
Solal, Alain Cohen
Januzzi, James L., Jr.
Richards, A. Mark
Launay, Jean-Marie
Mebazaa, Alexandre
CA GREAT Network
TI Post-translational modifications enhance NT-proBNP and BNP production in
acute decompensated heart failure
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Acute decompensated heart failure; ProBNP; BNP; NT-proBNP;
Glycosylation; Furin activity
ID BRAIN NATRIURETIC PEPTIDE; B-TYPE; TASK-FORCE; FURIN; CORIN;
GLYCOSYLATION; CONVERTASES; GUIDELINES; PNEUMONIA; OVERLOAD
AB Background Increases in plasma B-type natriuretic peptide (BNP) concentrations in those with acutely decompensated heart failure (ADHF) has been mainly attributed to an increase in NPPB gene transcription. Recently, proBNP glycosylation has emerged as a potential regulatory mechanism in the production of amino-terminal (NT)-proBNP and BNP. The aim of the present study was to investigate proBNP glycosylation, and corin and furin activities in ADHF patients.
Methods and results Plasma levels of proBNP, NT-proBNP, BNP, as well as corin and furin concentration and activity were measured in a large cohort of 683 patients presenting with ADHF (n = 468), non-cardiac dyspnoea (non-ADHF: n = 169) and 46 patients with stable chronic heart failure (CHF); the degree of plasma proBNP glycosylation was assessed in a subset of these patients (ADHF: n = 49, non-ADHF: n = 50, CHF: n = 46). Our results showed a decrease in proBNP glycosylation in ADHF patients that paralleled NT-proBNP overproduction (rho = -0.62, P<0.001) but less so to BNP. In addition, we observed an increase in furin activity that is positively related to the plasma levels of proBNP, NT-proBNP and BNP overproduction (all P< 0.001, all rho>0.88), and negatively related to the degree of proBNP glycosylation (rho = 20.62, P<0.001).
Conclusion These comprehensive results provide a paradigm for the post-translational modification of natriuretic peptides in ADHF: as proBNP glycosylation decreases, furin activity increases. This synergistically amplifies the processing of proBNP into BNP and NT-proBNP.
C1 [Vodovar, Nicolas; Seronde, Marie-France; Laribi, Said; Gayat, Etienne; Manivet, Philippe; Samuel, Jane-Lise; Logeart, Damien; Ishihara, Shiro; Solal, Alain Cohen; Launay, Jean-Marie; Mebazaa, Alexandre] INSERM, UMRS 942, F-75010 Paris, France.
[Vodovar, Nicolas; Logeart, Damien; Solal, Alain Cohen] Univ Hosp Jean Minjoz, DHU FIRE, Besancon, France.
[Seronde, Marie-France] Univ Hosp Jean Minjoz, Dept Cardiol, EA3920, Besancon, France.
[Laribi, Said] Lariboisiere Hosp, Dept Emergency Med, Paris, France.
[Laribi, Said; Gayat, Etienne; Mebazaa, Alexandre] Hop Lariboisiere, DHU Neurovasc, F-75475 Paris 10, France.
[Gayat, Etienne; Samuel, Jane-Lise; Mebazaa, Alexandre] Hop Lariboisiere, Dept Anesthesiol & Intens Care, F-75475 Paris 10, France.
[Lassus, Johan] Helsinki Univ Cent Hosp, Div Cardiol, Heart & Lung Ctr, Helsinki, Finland.
[Boukef, Riadh; Nouira, Semir] Fattouma Bourguiba Univ Hosp, Emergency Dept, Monastir, Tunisia.
[Boukef, Riadh; Nouira, Semir] Fattouma Bourguiba Univ Hosp, Res Unit UR06SP21, Monastir, Tunisia.
[Manivet, Philippe; Launay, Jean-Marie] Hop Lariboisiere, Dept Biochem, F-75475 Paris 10, France.
[Manivet, Philippe; Launay, Jean-Marie] Lariboisiere Hosp, Ctr Biol Resources, Paris, France.
[Logeart, Damien; Solal, Alain Cohen] Lariboisiere Hosp, Dept Cardiol, Paris, France.
[Logeart, Damien; Solal, Alain Cohen; Mebazaa, Alexandre] Paris Diderot Univ, Sorbonne Paris Cite, F-75205 Paris, France.
[Ishihara, Shiro] Nippon Med Sch, Cardiol & Intens Care Unit, Musashi Kosugi Hosp, Kawasaki, Kanagawa, Japan.
[Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Richards, A. Mark] Univ Otago, Christchurch, New Zealand.
[Richards, A. Mark] Natl Univ Hlth Syst, Singapore, Singapore.
RP Launay, JM (reprint author), INSERM, UMRS 942, F-75010 Paris, France.
EM alexandre.mebazaa@lrb.aphp.fr; alexandre.mebazaa@lrb.ap-hp.fr
RI Laribi, said/S-3693-2016;
OI Vodovar, Nicolas/0000-0001-8087-387X; Samuel,
Jane-Lise/0000-0002-7346-2404; Nouira, Semir/0000-0002-0137-5491
NR 26
TC 28
Z9 30
U1 2
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD DEC 21
PY 2014
VL 35
IS 48
BP 3434
EP 3441
DI 10.1093/eurheartj/ehu314
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AX9JW
UT WOS:000347220200014
PM 25157115
ER
PT J
AU Gori, M
Senni, M
Gupta, DK
Charytan, DM
Kraigher-Krainer, E
Pieske, B
Claggett, B
Shah, AM
Santos, ABS
Zile, MR
Voors, AA
McMurray, JJV
Packer, M
Bransford, T
Lefkowitz, M
Solomon, SD
AF Gori, Mauro
Senni, Michele
Gupta, Deepak K.
Charytan, David M.
Kraigher-Krainer, Elisabeth
Pieske, Burkert
Claggett, Brian
Shah, Amil M.
Santos, Angela B. S.
Zile, Michael R.
Voors, Adriaan A.
McMurray, John J. V.
Packer, Milton
Bransford, Toni
Lefkowitz, Martin
Solomon, Scott D.
CA PARAMOUNT Investigators
TI Association between renal function and cardiovascular structure and
function in heart failure with preserved ejection fraction
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Heart failure with preserved ejection fraction; Chronic kidney disease;
Albuminuria; Glomerular filtration rate; Cardiovascular structure and
function
ID LEFT-VENTRICULAR HYPERTROPHY; URINARY ALBUMIN EXCRETION; CHRONIC
KIDNEY-DISEASE; CARDIAC ABNORMALITIES; HYPERTENSIVE PATIENTS;
CYSTATIN-C; PREVALENCE; MORTALITY; DYSFUNCTION; IMPAIRMENT
AB Aim Renal dysfunction is a common comorbidity in patients with heart failure and preserved ejection fraction (HFpEF). We sought to determine whether renal dysfunction was associated with measures of cardiovascular structure/function in patients with HFpEF.
Methods We studied 217 participants from the PARAMOUNT study with HFpEF who had echocardiography and measures of kidney function. We evaluated the relationships between renal dysfunction [estimated glomerular filtration rate (eGFR)>30 and <60 mL/min/1.73 m(2) and/or albuminuria] and cardiovascular structure/function.
Results The mean age of the study population was 71 years, 55% were women, 94% hypertensive, and 40% diabetic. Impairment of at least one parameter of kidney function was present in 62% of patients (16% only albuminuria, 23% only lowe GFR, 23% both). Renal dysfunction was associated with abnormal LV geometry (defined as concentric hypertrophy, or eccentric hypertrophy, or concentric remodelling) (adjusted P = 0.048), lower midwall fractional shortening (MWFS) (P = 0.009), and higherNT-proBNP (P = 0.006). Compared with patients without renal dysfunction, those with lowe GFR and no albuminuria had a higher prevalence of abnormal LV geometry (P = 0.032) and lower MWFS (P< 0.01), as opposed to those with only albuminuria. Conversely, albuminuria alone was associated with greater LV dimensions (P< 0.05). Patients with combined renal impairment had mixed abnormalities (higher LV wall thicknesses, NT-proBNP; lower MWFS).
Conclusion Renal dysfunction, as determined by both eGFR and albuminuria, is highly prevalent in HFpEF, and associated with cardiac remodelling and subtle systolic dysfunction. The observed differences in cardiac structure/function between each type of renal damage suggest that both parameters of kidney function might play a distinct role in HFpEF.
C1 [Gori, Mauro; Gupta, Deepak K.; Claggett, Brian; Shah, Amil M.; Santos, Angela B. S.; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02445 USA.
[Senni, Michele] Azienda Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy.
[Charytan, David M.] Brigham & Womens Hosp, Div Renal, Boston, MA 02445 USA.
[Charytan, David M.] Brigham & Womens Hosp, Boston, MA 02445 USA.
[Kraigher-Krainer, Elisabeth; Pieske, Burkert] Med Univ Graz, Graz, Austria.
[Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Zile, Michael R.] Ralph H Johnson VA Med Ctr, US Dept Vet Affairs, Charleston, SC USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland.
[Packer, Milton] Univ Texas Southwestern, Dallas, TX USA.
[Bransford, Toni; Lefkowitz, Martin] Novartis Pharmaceut, E Hanover, NJ USA.
RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02445 USA.
EM ssolomon@rics.bwh.harvard.edu
OI mcmurray, john/0000-0002-6317-3975
FU NHLBI NIH HHS [K08 HL116792, T32 HL094301]
NR 39
TC 14
Z9 18
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD DEC 21
PY 2014
VL 35
IS 48
BP 3442
EP 3451
DI 10.1093/eurheartj/ehu254
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AX9JW
UT WOS:000347220200015
PM 24980489
ER
PT J
AU Li, TT
Ogino, S
Qian, ZR
AF Li, Ting-Ting
Ogino, Shuji
Qian, Zhi Rong
TI Toll-like receptor signaling in colorectal cancer: carcinogenesis to
cancer therapy
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Toll-like receptor; Colorectal cancer; Carcinogenesis; Prognosis; Cancer
therapy
ID POOR-PROGNOSIS; COLON-CANCER; DNA-REPAIR; EXPRESSION; CELLS;
INFLAMMATION; AGONIST; POLYMORPHISMS; PROTEIN; TUMOR
AB Toll-like receptors (TLRs) are germ line encoded innate immune sensors that recognize conserved microbial structures and host alarmins, and signal expression of major histocompatibility complex proteins, costimulatory molecules, and inflammatory mediators by macrophages, neutrophils, dendritic cells, and other cell types. These protein receptors are characterized by their ability to respond to invading pathogens promptly by recognizing particular TLR ligands, including flagellin and lipopolysaccharide of bacteria, nucleic acids derived from viruses, and zymosan of fungi. There are 2 major TLR pathways; one is mediated by myeloid differentiation factor 88 (MYD88) adaptor proteins, and the other is independent of MYD88. The MYD88-dependent pathway involves early-phase activation of nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NF-kappa B1) and all the TLRs, except TLR3, have been shown to activate this pathway. TLR3 and TLR4 act via MYD88-independent pathways with delayed activation of NF-kappa B signaling. TLRs play a vital role in activating immune responses. TLRs have been shown to mediate inflammatory responses and maintain epithelial barrier homeostasis, and are highly likely to be involved in the activation of a number of pathways following cancer therapy. Colorectal cancer (CRC) is one of the most common cancers, and accounts for almost half a million deaths annually worldwide. Inflammation is considered a risk factor for many common malignancies including cancers of the colorectum. The key molecules involved in inflammation-driven carcinogenesis include TLRs. As sensors of cell death and tissue remodeling, TLRs may have a universal role in cancer; stimulation of TLRs to activate the innate immune system has been a legitimate therapeutic strategy for some years. TLRs 3/4/7/8/9 are all validated targets for cancer therapy, and a number of companies are developing agonists and vaccine adjuvants. On the other hand, antagonists may favor inhibition of signaling responsible for autoimmune responses. In this paper, we review TLR signaling in CRC from carcinogenesis to cancer therapy. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Li, Ting-Ting] Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Gastroenterol, Beijing 100853, Peoples R China.
[Li, Ting-Ting; Ogino, Shuji; Qian, Zhi Rong] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Li, Ting-Ting; Ogino, Shuji; Qian, Zhi Rong] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.
[Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
RP Qian, ZR (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Room M420, Boston, MA 02215 USA.
EM zhirong_qian@dfci.harvard.edu
FU United States National Institute of Health (NIH) [P01 CA87969, UM1
CA167552, P01 CA55075, R01 CA137178, P50 CA127003, R01 CA151993];
Bennett Family Fund for Targeted Therapies Research; Entertainment
Industry Foundation through National Colorectal Cancer Research Alliance
FX Supported by grant from United States National Institute of Health
(NIH), No. P01 CA87969 (to SE Hankinson), No. UM1 CA167552, and No. P01
CA55075 (to WC Willett), No. R01 CA137178 (to AT Chan), No. P50 CA127003
(to CS Fuchs), No. R01 CA151993 (to S Ogino); Bennett Family Fund for
Targeted Therapies Research; and Entertainment Industry Foundation
through National Colorectal Cancer Research Alliance
NR 72
TC 11
Z9 12
U1 4
U2 19
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD DEC 21
PY 2014
VL 20
IS 47
BP 17699
EP 17708
DI 10.3748/wjg.v20.i47.17699
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AX1NE
UT WOS:000346712800002
PM 25548469
ER
PT J
AU Lin, YT
McMahon, SJ
Scarpelli, M
Paganetti, H
Schuemann, J
AF Lin, Yuting
McMahon, Stephen J.
Scarpelli, Matthew
Paganetti, Harald
Schuemann, Jan
TI Comparing gold nano-particle enhanced radiotherapy with protons,
megavoltage photons and kilovoltage photons: a Monte Carlo simulation
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE proton therapy; gold nanoparticles; Monte Carlo simulation;
radiosensitizer; radiation therapy; Geant4-DNA; microscopic dose
enhancement
AB Gold nanoparticles (GNPs) have shown potential to be used as a radiosensitizer for radiation therapy. Despite extensive research activity to study GNP radiosensitization using photon beams, only a few studies have been carried out using proton beams. In this work Monte Carlo simulations were used to assess the dose enhancement of GNPs for proton therapy. The enhancement effect was compared between a clinical proton spectrum, a clinical 6 MV photon spectrum, and a kilovoltage photon source similar to those used in many radiobiology lab settings. We showed that the mechanism by which GNPs can lead to dose enhancements in radiation therapy differs when comparing photon and proton radiation. The GNP dose enhancement using protons can be up to 14 and is independent of proton energy, while the dose enhancement is highly dependent on the photon energy used. For the same amount of energy absorbed in the GNP, interactions with protons, kVp photons and MV photons produce similar doses within several nanometers of the GNP surface, and differences are below 15% for the first 10 nm. However, secondary electrons produced by kilovoltage photons have the longest range in water as compared to protons and MV photons, e. g. they cause a dose enhancement 20 times higher than the one caused by protons 10 mu m away from the GNP surface. We conclude that GNPs have the potential to enhance radiation therapy depending on the type of radiation source. Proton therapy can be enhanced significantly only if the GNPs are in close proximity to the biological target.
C1 [Lin, Yuting; McMahon, Stephen J.; Scarpelli, Matthew; Paganetti, Harald; Schuemann, Jan] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Lin, Yuting; McMahon, Stephen J.; Scarpelli, Matthew; Paganetti, Harald; Schuemann, Jan] Harvard Univ, Sch Med, Boston, MA USA.
[McMahon, Stephen J.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7AE, Antrim, North Ireland.
[Scarpelli, Matthew] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA.
RP Lin, YT (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM ylin20@partners.org
NR 30
TC 28
Z9 29
U1 6
U2 17
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD DEC 21
PY 2014
VL 59
IS 24
BP 7675
EP 7689
DI 10.1088/0031-9155/59/24/7675
PG 15
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA V41QB
UT WOS:000209559600009
PM 25415297
ER
PT J
AU Park, SJ
Jeon, HJ
Kim, JY
Kim, S
Roh, S
AF Park, Se Jin
Jeon, Hong Jin
Kim, Ju Young
Kim, Sohye
Roh, Sungwon
TI Sociodemographic factors associated with the use of mental health
services in depressed adults: results from the Korea National Health and
Nutrition Examination Survey (KNHANES)
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Mental health service; Use; Depressive mood; Sociodemographic factor;
Age; Education
ID COMORBIDITY SURVEY REPLICATION; GENERAL-POPULATION SAMPLE;
UNITED-STATES; SINGLE QUESTION; HELP-SEEKING; DISORDERS; GENDER; STIGMA;
CARE; ANXIETY
AB Background: The aims of this study were to determine the utilization of mental health services (MHSs) by adults with a depressive mood and to identify the influencing sociodemographic factors, using a nationwide representative Korean sample.
Methods: The study included 2735 subjects, aged 19 years or older, who had experienced a depressive mood continuously for over 2 weeks within the previous year, using the data from the KNHANES IV (Fourth Korea National Health and Nutrition Examination Survey), which was performed between 2007 and 2009, and involved a nationally representative sample of the Korean community population who were visited at home. A multivariate logistic regression analysis was used to estimate the adjusted odd ratios (ORs) and 95% confidence intervals (CIs) for the use of MHSs, which was defined as using healthcare institutions, consulting services, and inpatient or outpatient treatments due to mental health problems.
Results: MHSs had been used by 9.6% of the subjects with a depressive mood. The use of the MHSs was significantly associated with age, education level, and employment status, after adjusting for sociodemographic and health-related factors. Specifically, the OR for the nonuse of MHSs by the elderly (>= 65 years) relative to subjects aged 19-34 years was 2.55 (95% CI = 1.13-5.76), subjects with a lower education level were less likely to use MHSs compared to those with a higher education level (7-9 years, OR = 2.35, 95% CI = 1.19-4.64; 10-12 years, OR = 1.66, 95% CI = 1.07-2.56; >= 13 years, reference), and the OR of unemployed relative to employed was 0.47 (95% CI = 0.32-0.67).
Conclusions: Among Korean adults with a depressive mood, the elderly, those with a lower education level, and the employed are less likely to use MHSs. These findings suggest that mental health policies should be made based on the characteristics of the population in order to reduce untreated patients with depression. Greater resources and attention to identifying and treating depression in older, less educated, and employed adults are warranted.
C1 [Park, Se Jin; Roh, Sungwon] Seoul Natl Hosp, Dept Mental Hlth Res, Seoul 143711, South Korea.
[Jeon, Hong Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Depress Ctr,Dept Psychiat, Seoul 135710, South Korea.
[Jeon, Hong Jin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Depress Clin & Res Program,Dept Psychiat, Boston, MA 02114 USA.
[Kim, Ju Young] Seoul Natl Univ, Bundang Hosp, Dept Family Med, Songnam 463707, Gyeonggi Do, South Korea.
[Kim, Sohye] Kyung Hee Univ, Grad Sch East West Med Sci, Dept Med Nutr, Yongin 446701, Gyeonggi Do, South Korea.
[Roh, Sungwon] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Addict Med,Dept Psychiat, Boston, MA 02114 USA.
RP Roh, S (reprint author), Seoul Natl Hosp, Dept Mental Hlth Res, Seoul 143711, South Korea.
EM swroh@korea.kr
FU National Center for Mental Health Research and Education of Seoul
National Hospital, Ministry of Health and Welfare, Korea
FX This study was funded by the National Center for Mental Health Research
and Education of Seoul National Hospital, Ministry of Health and
Welfare, Korea.
NR 37
TC 4
Z9 4
U1 4
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD DEC 20
PY 2014
VL 14
AR 645
DI 10.1186/s12913-014-0645-7
PG 10
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AZ7WU
UT WOS:000348426700001
PM 25527283
ER
PT J
AU Bradner, JE
AF Bradner, James E.
TI From transcriptional regulation to drugging the cancer epigenome
SO GENOME MEDICINE
LA English
DT Letter
AB Jay Bradner discusses the opportunities and challenges for the study and therapeutic targeting of the cancer epigenome, as well as innovative approaches to drug discovery.
C1 [Bradner, James E.] Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Sch Med, Boston, MA 02115 USA.
[Bradner, James E.] Harvard Univ, Dept Med, Sch Med, Boston, MA 02115 USA.
RP Bradner, JE (reprint author), Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Sch Med, Boston, MA 02115 USA.
EM james_bradner@dfci.harvard.edu
NR 1
TC 0
Z9 0
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD DEC 20
PY 2014
VL 6
AR 123
DI 10.1186/s13073-014-0123-1
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA AZ4AJ
UT WOS:000348164500001
PM 25593599
ER
PT J
AU Qi, QB
Kilpelainen, TO
Downer, MK
Tanaka, T
Smith, CE
Sluijs, I
Sonestedtl, E
Chull, AY
Renstrom, F
Lin, XC
Angquist, LH
Huang, JY
Liu, ZH
Li, YP
Ali, MA
Xu, M
Ahluwalia, TS
Boer, JMA
Chen, P
Daimon, M
Eriksson, J
Perola, M
Friedlander, Y
Gao, YT
Heppe, DHM
Holloway, JW
Houston, DK
Kanoni, S
Kim, YM
Laaksonen, MA
Jaaskelainen, T
Lee, NR
Lehtimaki, T
Lemaitre, RN
Lu, W
Luben, RN
Manichaiku, A
Mannisto, S
Marques-Vidal, P
Monda, KL
Ngwa, JS
Perusse, L
van Rooij, FJA
Xiang, YB
Wen, WQ
Wojczynski, MK
Zhu, JW
Borecki, IB
Bouchard, C
Cai, QY
Cooper, C
Dedoussis, GV
Deloukas, P
Ferrucci, L
Forouhi, NG
Hansen, T
Christiansen, L
Hofman, A
Johansson, I
Jorgensen, T
Karasawa, S
Khaw, KT
Kim, MK
Kristiansson, K
Li, HX
Lin, X
Liu, YM
Lohman, KK
Long, JR
Mikkila, V
Mozaffarian, D
North, K
Pedersen, O
Raitakari, O
Rissanen, H
Tuomilehto, J
van der Schouw, YT
Uitterlinden, AG
Zillikens, MC
Franco, OH
Tai, ES
Shu, XO
Siscovick, DS
Toft, U
Verschuren, WMM
Vollenweider, P
Wareham, NJ
Witteman, JCM
Zheng, W
Ridker, PM
Kang, JH
Liang, LM
Jensen, MK
Curhan, GC
Pasquale, LR
Hunter, DJ
Mohlke, KL
Uusitupa, M
Cupples, LA
Rankinen, T
Orho-Melander, M
Wang, T
Chasman, DI
Franks, PW
Sorensen, TIA
Hu, FB
Loos, RJF
Nettleton, JA
Qi, L
AF Qi, Qibin
Kilpelainen, Tuomas O.
Downer, Mary K.
Tanaka, Toshiko
Smith, Caren E.
Sluijs, Ivonne
Sonestedtl, Emily
Chull, Audrey Y.
Renstrom, Frida
Lin, Xiaochen
Angquist, Lars H.
Huang, Jinyan
Liu, Zhonghua
Li, Yanping
Ali, Muhammad Asif
Xu, Min
Ahluwalia, Tarunveer Singh
Boer, Jolanda M. A.
Chen, Peng
Daimon, Makoto
Eriksson, Johan
Perola, Markus
Friedlander, Yechiel
Gao, Yu-Tang
Heppe, Denise H. M.
Holloway, John W.
Houston, Denise K.
Kanoni, Stavroula
Kim, Yu-Mi
Laaksonen, Maarit A.
Jaaskelainen, Tiina
Lee, Nanette R.
Lehtimaki, Terho
Lemaitre, Rozenn N.
Lu, Wei
Luben, Robert N.
Manichaiku, Ani
Mannisto, Satu
Marques-Vidal, Pedro
Monda, Keri L.
Ngwa, Julius S.
Perusse, Louis
van Rooij, Frank J. A.
Xiang, Yong-Bing
Wen, Wanqing
Wojczynski, Mary K.
Zhu, Jingwen
Borecki, Ingrid B.
Bouchard, Claude
Cai, Qiuyin
Cooper, Cyrus
Dedoussis, George V.
Deloukas, Panos
Ferrucci, Luigi
Forouhi, Nita G.
Hansen, Torben
Christiansen, Lene
Hofman, Albert
Johansson, Ingegerd
Jorgensen, Torben
Karasawa, Shigeru
Khaw, Kay-Tee
Kim, Mi-Kyung
Kristiansson, Kati
Li, Huaixing
Lin, Xu
Liu, Yongmei
Lohman, Kurt K.
Long, Jirong
Mikkila, Vera
Mozaffarian, Dariush
North, Kari
Pedersen, Oluf
Raitakari, Olli
Rissanen, Harri
Tuomilehto, Jaakko
van der Schouw, Yvonne T.
Uitterlinden, Andre G.
Zillikens, M. Carola
Franco, Oscar H.
Tai, E. Shyong
Shu, Xiao Ou
Siscovick, David S.
Toft, Ulla
Verschuren, W. M. Monique
Vollenweider, Peter
Wareham, Nicholas J.
Witteman, Jacqueline C. M.
Zheng, Wei
Ridker, Paul M.
Kang, Jae H.
Liang, Liming
Jensen, Majken K.
Curhan, Gary C.
Pasquale, Louis R.
Hunter, David J.
Mohlke, Karen L.
Uusitupa, Matti
Cupples, L. Adrienne
Rankinen, Tuomo
Orho-Melander, Marju
Wang, Tao
Chasman, Daniel I.
Franks, Paul W.
Sorensen, Thorkild I. A.
Hu, Frank B.
Loos, Ruth J. F.
Nettleton, Jennifer A.
Qi, Lu
TI FTO genetic variants, dietary intake and body mass index: insights from
177 330 individuals
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID OBESITY-ASSOCIATED GENE; TIME PHYSICAL-ACTIVITY; FAT MASS;
ENERGY-INTAKE; FOOD-INTAKE; METABOLIC-RATE; ASSOCIATION; CHILDREN;
RS9939609; GENOTYPE
AB FTO is the strongest known genetic susceptibility locus for obesity. Experimental studies in animals suggest the potential roles of FTO in regulating food intake. The interactive relation among FTO variants, dietary intake and body mass index (BMI) is complex and results from previous often small-scale studies in humans are highly inconsistent. We performed large-scale analyses based on data from 177 330 adults (154 439 Whites, 5776 African Americans and 17 115 Asians) from 40 studies to examine: (i) the association between the FTO-rs9939609 variant (or a proxy single-nucleotide polymorphism) and total energy and macronutrient intake and (ii) the interaction between the FTO variant and dietary intake on BM I. The minor allele (A-allele) of the FTO-rs9939609 variant was associated with higher BMI in Whites (effect per allele = 0.34 [0.31, 0.37] kg/m(2), P = 1.9 x 10(-105)), and all participants (0.30 [0.30, 0.35] kg/m(2), P = 3.6 x 10(-107)). The BMI-increasing allele of the FTO variant showed a significant association with higher dietary protein intake (effect per allele = 0.08 [0.06, 0.10] %, P = 2.4 x 10(-16)), and relative weak associations with lower total energy intake (-6.4 [- 10.1, -2.6] kcal/day, P = 0.001) and lower dietary carbohydrate intake (-0.07 [- 0.11, -0.02] %, P = 0.004). The associations with protein (P = 7.5 x 10(-9)) and total energy (P = 0.002) were attenuated but remained significant after adjustment for BMI. We did not find significant interactions between the FTO variant and dietary intake of total energy, protein, carbohydrate or fat on BMI. Our findings suggest a positive association between the BMI-increasing allele of FTO variant and higher dietary protein intake and offer insight into potential link between FTO, dietary protein intake and adiposity.
C1 [Qi, Qibin; Wang, Tao] Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10467 USA.
[Qi, Qibin; Downer, Mary K.; Li, Yanping; Ali, Muhammad Asif; Xu, Min; Mozaffarian, Dariush; Jensen, Majken K.; Hunter, David J.; Franks, Paul W.; Hu, Frank B.; Qi, Lu] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Lin, Xiaochen; Liu, Zhonghua; Mozaffarian, Dariush; Liang, Liming; Jensen, Majken K.; Curhan, Gary C.; Hunter, David J.; Franks, Paul W.; Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Kilpelainen, Tuomas O.; Forouhi, Nita G.; Wareham, Nicholas J.; Loos, Ruth J. F.] Univ Cambridge, Sch Clin Med, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England.
[Kilpelainen, Tuomas O.; Ahluwalia, Tarunveer Singh; Hansen, Torben; Pedersen, Oluf; Sorensen, Thorkild I. A.] Univ Copenhagen, Fac Hlth & Med Sci, Sect Metab Genet, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark.
[Ahluwalia, Tarunveer Singh] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark.
[Tanaka, Toshiko; Ferrucci, Luigi] NIA, Translat Gerontol Branch, Baltimore, MD 21224 USA.
[Smith, Caren E.] Tufts Univ, Jean Mayer USDA HNRCA, Nutr & Genom Lab, Boston, MA 02111 USA.
[Sluijs, Ivonne; van der Schouw, Yvonne T.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
[Sonestedtl, Emily; Renstrom, Frida; Orho-Melander, Marju; Franks, Paul W.] Lund Univ, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden.
[Chull, Audrey Y.; Mozaffarian, Dariush; Kang, Jae H.; Curhan, Gary C.; Pasquale, Louis R.; Hunter, David J.; Hu, Frank B.; Qi, Lu] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Mozaffarian, Dariush; Ridker, Paul M.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
[Chasman, Daniel I.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[Chasman, Daniel I.] Harvard Univ, Sch Med, Boston, MA USA.
[Angquist, Lars H.; Sorensen, Thorkild I. A.] Bispebjerg & Frederiksberg Hosp, Inst Prevent Med, Copenhagen, Denmark.
[Huang, Jinyan] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, State Key Lab Med Genom,Shanghai Inst Hematol, Shanghai 200030, Peoples R China.
[Ahluwalia, Tarunveer Singh] Gentofte Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen, Denmark.
[Boer, Jolanda M. A.; Verschuren, W. M. Monique] Natl Inst Publ Hlth & Environm, Ctr Nutr Prevent & Hlth Serv, NL-3720 BA Bilthoven, Netherlands.
[Chen, Peng; Tai, E. Shyong] Natl Univ Hlth Syst, Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
[Tai, E. Shyong] Natl Univ Hlth Syst, Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.
[Daimon, Makoto] Hirosaki Univ, Grad Sch Med, Dept Endocrinol & Metab, Hirosaki, Aomori, Japan.
[Daimon, Makoto; Karasawa, Shigeru] Yamagata Univ, Fac Med, Dept Neurol Hematol Metab Endocrinol & Diabetol, Yamagata 990, Japan.
[Eriksson, Johan] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland.
[Perola, Markus] Univ Helsinki, Inst Mol Med, Helsinki, Finland.
[Mikkila, Vera] Univ Helsinki, Dept Food & Environm Sci, Helsinki, Finland.
[Perola, Markus; Laaksonen, Maarit A.; Mannisto, Satu; Kristiansson, Kati; Rissanen, Harri; Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Helsinki, Finland.
[Perola, Markus] Univ Tartu, Estonian Genome Ctr, EE-50090 Tartu, Estonia.
[Friedlander, Yechiel] Hebrew Univ Jerusalem, Sch Publ Hlth, Jerusalem, Israel.
[Gao, Yu-Tang; Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Canc Inst, Shanghai 200030, Peoples R China.
[Heppe, Denise H. M.] Erasmus MC, Generat Study Grp R, Rotterdam, Netherlands.
[Heppe, Denise H. M.; van Rooij, Frank J. A.; Hofman, Albert; Uitterlinden, Andre G.; Franco, Oscar H.; Witteman, Jacqueline C. M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Heppe, Denise H. M.] Erasmus MC, Dept Pediat, Rotterdam, Netherlands.
[Uitterlinden, Andre G.; Zillikens, M. Carola] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Holloway, John W.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
[Houston, Denise K.] Wake Forest Sch Med, Dept Internal Med, Sect Gerontol & Geriatr Med, Winston Salem, NC USA.
[Liu, Yongmei] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Epidemiol, Winston Salem, NC USA.
[Lohman, Kurt K.] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA.
[Kanoni, Stavroula; Deloukas, Panos] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England.
[Kim, Yu-Mi] Dong A Univ, Coll Med, Dept Prevent Med, Pusan, South Korea.
[Jaaskelainen, Tiina; Uusitupa, Matti] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland.
[Lee, Nanette R.] Univ San Carlos, U5C Off Populat Studies Fdn Inc, Cebu, Philippines.
[Lehtimaki, Terho] Univ Tampere, Dept Clin Chem, Fimlab Labs, FIN-33101 Tampere, Finland.
[Lehtimaki, Terho] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland.
[Lemaitre, Rozenn N.; Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Lu, Wei] Shanghai Inst Prevent Med, Shanghai, Peoples R China.
[Luben, Robert N.; Khaw, Kay-Tee] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.
[Manichaiku, Ani] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA.
[Manichaiku, Ani] Univ Virginia, Dept Publ Hlth Sci, Div Biostat & Epidemiol, Charlottesville, VA USA.
[Marques-Vidal, Pedro] Inst Social & Prevent Med, CH-1010 Lausanne, Switzerland.
[Marques-Vidal, Pedro; Vollenweider, Peter] CHU Vaudois, Dept Med, CH-1011 Lausanne, Switzerland.
[Monda, Keri L.; North, Kari] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[North, Kari] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA.
[Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Monda, Keri L.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA.
[Ngwa, Julius S.; Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Perusse, Louis] Univ Laval, Dept Kinesiol, Ste Foy, PQ, Canada.
[van Rooij, Frank J. A.; Hofman, Albert; Uitterlinden, Andre G.; Zillikens, M. Carola; Franco, Oscar H.; Witteman, Jacqueline C. M.] NGI NCHA, Leiden, Netherlands.
[Wen, Wanqing; Cai, Qiuyin; Long, Jirong; Shu, Xiao Ou; Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med,Vanderbilt Epidemiol Ctr,Div Epidemiol, Nashville, TN 37212 USA.
[Wojczynski, Mary K.; Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
[Zhu, Jingwen; Li, Huaixing; Lin, Xu] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai, Peoples R China.
[Zhu, Jingwen; Li, Huaixing; Lin, Xu] Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China.
[Bouchard, Claude; Rankinen, Tuomo] Pennington Biomed Res Ctr, Human Genom Lab, Baton Rouge, LA 70808 USA.
[Cooper, Cyrus] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton SO16 6YD, Hants, England.
[Cooper, Cyrus] Univ Southampton, Natl Inst Hlth Res Biomed Res Ctr, Southampton SO16 6YD, Hants, England.
[Cooper, Cyrus] Univ Hosp Southampton NHS Fdn Trust, Southampton SO16 6YD, Hants, England.
[Cooper, Cyrus] Univ Oxford, Natl Inst Hlth Res Musculoskeletal Biomed Res Uni, Oxford OX3 7LE, England.
[Dedoussis, George V.] Harokopio Univ, Dept Dietet Nutr, Athens, Greece.
[Deloukas, Panos] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
[Deloukas, Panos] PACER HD, Jeddah 21589, Saudi Arabia.
[Tuomilehto, Jaakko] King Abdulaziz Univ, Diabet Res Grp, Jeddah 21589, Saudi Arabia.
[Christiansen, Lene] Univ Southern Denmark, Inst Publ Hlth, Danish Twin Registry, Odense, Denmark.
[Johansson, Ingegerd] Umea Univ, Dept Odontol, Umea, Sweden.
[Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Genet Epidemiol & Clin Res Grp, Umea, Sweden.
[Jorgensen, Torben; Toft, Ulla] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark.
[Kim, Mi-Kyung] Hanyang Univ, Coll Med, Dept Prevent Med, Seoul 133791, South Korea.
[Mikkila, Vera; Raitakari, Olli] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland.
[Mozaffarian, Dariush] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
[Raitakari, Olli] Univ Turku, Dept Clin Physiol & Nucl Med, Turku, Finland.
[Raitakari, Olli] Turku Univ Hosp, FIN-20520 Turku, Finland.
[Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, A-3500 Krems, Austria.
[Tuomilehto, Jaakko] Hosp Univ LaPaz IdiPAZ, Inst Invest Sanitaria, Madrid, Spain.
[Tai, E. Shyong] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
[Pasquale, Louis R.] Harvard Univ, Sch Med, Dept Ophthalmol, Mass Eye & Ear Infirm, Boston, MA USA.
[Uusitupa, Matti] Kuopio Univ Hosp, Res Unit, SF-70210 Kuopio, Finland.
[Cupples, L. Adrienne] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
[Loos, Ruth J. F.] Mt Sinai Sch Med, Dept Prevent Med, Mindich Child Hlth & Dev Inst, Genet Obes & Related Metab Traits Program,Charles, New York, NY USA.
[Nettleton, Jennifer A.] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.
RP Qi, L (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM nhlqi@channing.harvard.edu
RI Holloway, John/B-5424-2009; Colaus, PsyColaus/K-6607-2013; Chen,
Peng/E-5546-2015; Lin, Xiaochen/P-6460-2015; Sonestedt,
Emily/I-3814-2016; Bouchard, Claude/A-7637-2009; Deloukas,
Panos/B-2922-2013
OI Forouhi, Nita/0000-0002-5041-248X; Jorgensen,
Torben/0000-0001-9453-2830; Tai, E Shyong/0000-0003-2929-8966; Franks,
Paul/0000-0002-0520-7604; Kristiansson, Kati/0000-0003-4688-107X;
Mannisto, Satu/0000-0002-8668-3046; Holloway, John/0000-0001-9998-0464;
Chen, Peng/0000-0002-1422-4641; Luben, Robert/0000-0002-5088-6343;
Sonestedt, Emily/0000-0002-0747-4562; Deloukas,
Panos/0000-0001-9251-070X
FU Canadian Institutes of Health Research [GR-15187, MOP-77652]; Cancer
Research UK [, 14136]; FIC NIH HHS [TW008288, TW05596]; Medical Research
Council [, G0401527, G0701863, G1000143, MC_U106179471, MC_UP_A100_1003,
MC_UP_A620_1014, MC_UU_12011/1, MC_UU_12015/1, MC_UU_12015/5]; NCATS NIH
HHS [UL1 TR000124, UL1TR000124]; NCI NIH HHS [R01CA148667, CA047988,
CA055075, CA49449, CA87969, P30 CA016086, R01CA064277, R01CA082729,
R01CA092585, R01CA122364, R01CA124558, R01CA82729, R37CA070867,
U54CA155626, UM1 CA173640, UM1 CA182910]; NCRR NIH HHS [RR-024156,
RR20649, UL1RR025005]; NEI NIH HHS [EY015473, R01 EY015473]; NHGRI NIH
HHS [U01 HG004728, U01HG004399, U01HG004402, U01HG004728-02]; NHLBI NIH
HHS [5R01 HL08770003, 5R01 HL08821502, HL-45670, HL043851, HL071981,
HL073168, HL080295, HL080467, HL085144, HL085251, HL087652, HL088521,
HL103612, HL105756, HL120393, HL34594, K08 HL112845, N01-HC-25195,
N01-HC-95159, N01-HC-95169, N01HC55222, N01HC85079, N01HC85080,
N01HC85081, N01HC85082, N01HC85083, N01HC85086, N02-HL-6-4278,
N02‐HL‐6‐4278, R01 HL034594, R01 HL105756, R01 HL120393, R01HL071051,
R01HL071205, R01HL071250, R01HL071251, R01HL071252, R01HL071258,
R01HL071259, R01HL085710, R01HL086694, R01HL087641, R01HL59367]; NIA NIH
HHS [AG023629, N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106,
R01-AG032098]; NIDDK NIH HHS [5P30DK46200, 5R01 DK06833603, 5R01
DK07568102, DK063491, DK078150, DK080140, DK091718, DK46200, DK56350,
DK58845, DK70756, P30 DK046200, R01 DK078150, R01 DK089256, R01
DK091718]; NIEHS NIH HHS [ES10126, P30 ES010126]; NIMHD NIH HHS [263 MD
821336, 263 MD 9164]; PHS HHS [HHSN268200625226C, HHSN268200782096C,
HHSN268200800007C, HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
HHSN268201100010C, HHSN268201100011C, HHSN268201100012C,
HHSN268201200036C]
NR 52
TC 24
Z9 24
U1 3
U2 23
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 20
PY 2014
VL 23
IS 25
BP 6961
EP 6972
DI 10.1093/hmg/ddu411
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AZ0GB
UT WOS:000347923000023
PM 25104851
ER
PT J
AU Riesel, JN
AF Riesel, Johanna N.
TI On seeing Roses
SO LANCET
LA English
DT Editorial Material
C1 [Riesel, Johanna N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Riesel, JN (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
EM jriesel@mgh.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD DEC 20
PY 2014
VL 384
IS 9961
BP 2264
EP 2265
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX0QC
UT WOS:000346655700032
PM 25625400
ER
PT J
AU Sulmasy, D
Moy, B
AF Sulmasy, Daniel
Moy, Beverly
TI Debating the Oncologist's Role in Defining the Value of Cancer Care: Our
Duty Is to Our Patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID TOP 5 LIST; CLINICAL ONCOLOGY; AMERICAN SOCIETY; COST; OPPORTUNITIES;
DISPARITIES
C1 [Sulmasy, Daniel] Univ Chicago, Chicago, IL 60637 USA.
[Moy, Beverly] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Sulmasy, D (reprint author), Univ Chicago, Chicago, IL 60637 USA.
NR 24
TC 8
Z9 8
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 20
PY 2014
VL 32
IS 36
BP 4039
EP U234
DI 10.1200/JCO.2014.57.8716
PG 4
WC Oncology
SC Oncology
GA AW4JO
UT WOS:000346247500007
PM 25366686
ER
PT J
AU Hornbrook, MC
Malin, J
Weeks, JC
Makgoeng, SB
Keating, NL
Potosky, AL
AF Hornbrook, Mark C.
Malin, Jennifer
Weeks, Jane C.
Makgoeng, Solomon B.
Keating, Nancy L.
Potosky, Arnold L.
TI Did Changes in Drug Reimbursement After the Medicare Modernization Act
Affect Chemotherapy Prescribing?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CARE OUTCOMES RESEARCH; CANCER CARE; SURVEILLANCE CONSORTIUM;
LOGISTIC-REGRESSION; COLORECTAL-CANCER; SAMPLE-SIZE; COMORBIDITY;
PROJECTIONS; IMPACT
AB Purpose
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) decreased fee-for-service (FFS) payments for outpatient chemotherapy. We assessed how this policy affected chemotherapy in FFS settings versus in integrated health networks (IHNs).
Patients and Methods
We examined 5,831 chemotherapy regimens for 3,613 patients from 2003 to 2006 with colorectal cancer (CRC) or lung cancers in the Cancer Care Outcomes Research Surveillance Consortium. Patients were from four geographically defined regions, seven large health maintenance organizations, and 15 Veterans Affairs Medical Centers. The outcome of interest was receipt of chemotherapy that included at least one drug for which reimbursement declined after the MMA.
Results
The odds of receiving an MMA-affected drug were lower in the post-MMA era: the odds ratio (OR) was 0.73 (95% CI, 0.59 to 0.89). Important differences across cancers were detected: for CRC, the OR was 0.65 (95% CI, 0.46 to 0.92); for non-small-cell lung cancer (NSCLC), the OR was 1.60 (95% CI, 1.09 to 2.35); and for small-cell lung cancer, the OR was 0.63 (95% CI, 0.34 to 1.16). After the MMA, FFS patients were less likely to receive MMA-affected drugs: OR, 0.73 (95% CI, 0.59 to 0.89). No pre-versus post-MMA difference in the use of MMA-affected drugs was detected among IHN patients: OR, 1.01 (95% CI, 0.66 to 1.56). Patients with CRC were less likely to receive an MMA-affected drug in both FFS and IHN settings in the post-versus pre-MMA era, whereas patients with NSCLC were the opposite: OR, 1.60 (95% CI, 1.09 to 2.35) for FFS and 6.33 (95% CI, 2.09 to 19.11) for IHNs post-versus pre-MMA.
Conclusion
Changes in reimbursement after the passage of MMA appear to have had less of an impact on prescribing patterns in FFS settings than the introduction of new drugs and clinical evidence as well as other factors driving adoption of new practice patterns. (C) 2014 by American Society of Clinical Oncology
C1 [Hornbrook, Mark C.] Kaiser Permanente Northwest, Portland, OR 97227 USA.
[Malin, Jennifer] Univ Calif Los Angeles, Vet Affairs Med Ctr, Los Angeles, CA USA.
[Malin, Jennifer] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Weeks, Jane C.; Keating, Nancy L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Weeks, Jane C.] Dana Farber Canc Inst, Boston, MA USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Makgoeng, Solomon B.; Potosky, Arnold L.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
RP Hornbrook, MC (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA.
EM mark.c.hornbrook@kpchr.org
FU National Cancer Institute (NCI; Harvard University for the CanCORS
Statistical Coordinating Center) [U01 CA093344]; NCI (Primary Data
Collection and Research Centers of the Dana Farber Cancer Institute and
the Cancer Research Network [U01 CA093332]; Harvard Medical School and
Northern California Cancer Center [U01 CA093324]; RAND, University of
California at Los Angeles [U01 CA093348]; University of Alabama at
Birmingham [U01 CA093329]; University of Iowa [U01 CA093339]; University
of North Carolina [U01 CA093326]; Department of Veterans Affairs (Durham
VA Medical Center) [CRS 02-164]; NCI [U19 CA79689, P30 CA051008]; Group
Health Research Institute (Cancer Research Network Across Health Care
Systems)
FX Supported by Grants No. U01 CA093344 from the National Cancer Institute
(NCI; Harvard University for the CanCORS Statistical Coordinating
Center), No. U01 CA093332 from the NCI (Primary Data Collection and
Research Centers of the Dana Farber Cancer Institute and the Cancer
Research Network, No. U01 CA093324 (Harvard Medical School and Northern
California Cancer Center), No. U01 CA093348 (RAND, University of
California at Los Angeles), No. U01 CA093329 (University of Alabama at
Birmingham), No. U01 CA093339 (University of Iowa), No. U01 CA093326
(University of North Carolina), and by Department of Veterans Affairs
Grant No. CRS 02-164 (Durham VA Medical Center). Supported by
Cooperative Agreement No. U19 CA79689 between the NCI and Group Health
Research Institute (Cancer Research Network Across Health Care Systems;
M.C.H.) and Grant No. P30 CA051008 from the NCI (A.L.P.).
NR 24
TC 3
Z9 3
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 20
PY 2014
VL 32
IS 36
BP 4042
EP U247
DI 10.1200/JCO.2013.52.6780
PG 13
WC Oncology
SC Oncology
GA AW4JO
UT WOS:000346247500008
PM 25267762
ER
PT J
AU Polite, BN
Griggs, JJ
Moy, B
Lathan, C
duPont, NC
Villani, G
Wong, SL
Halpern, MT
AF Polite, Blase N.
Griggs, Jennifer J.
Moy, Beverly
Lathan, Christopher
duPont, Nefertiti C.
Villani, Gina
Wong, Sandra L.
Halpern, Michael T.
TI American Society of Clinical Oncology Policy Statement on Medicaid
Reform
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID INSURANCE STATUS; BREAST-CANCER; LYNCH-SYNDROME; PROPHYLACTIC
MASTECTOMY; SURVIVAL DISPARITIES; COST-EFFECTIVENESS; DECISION-ANALYSIS;
HEALTH-INSURANCE; LUNG-CANCER; EARLY-STAGE
C1 [Polite, Blase N.] Univ Chicago, Chicago, IL 60637 USA.
[Griggs, Jennifer J.; Wong, Sandra L.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Moy, Beverly] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lathan, Christopher] Dana Farber Canc Inst, Boston, MA 02115 USA.
[duPont, Nefertiti C.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Villani, Gina] Ralph Lauren Ctr Canc Care & Prevent, New York, NY USA.
[Halpern, Michael T.] RTI Int, Washington, DC USA.
RP Polite, BN (reprint author), Univ Chicago, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.
EM bpolite@medicine.bsd.uchicago.edu
FU NCATS NIH HHS [UL1 TR000430]
NR 47
TC 10
Z9 10
U1 1
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 20
PY 2014
VL 32
IS 36
BP 4162
EP 4167
DI 10.1200/JCO.2014.56.3452
PG 6
WC Oncology
SC Oncology
GA AW4JO
UT WOS:000346247500024
PM 25403206
ER
PT J
AU Plimack, ER
Hoffman-Censits, J
Rosenberg, JE
Wong, YN
Bellmunt, J
Choueiri, TK
AF Plimack, Elizabeth R.
Hoffman-Censits, Jean
Rosenberg, Jonathan E.
Wong, Yu-Ning
Bellmunt, Joaquim
Choueiri, Toni K.
TI Neoadjuvant Phase II Studies of Modified Methotrexate, Vinblastine,
Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Cancer Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
ID CHEMOTHERAPY; SUBTYPES
C1 [Plimack, Elizabeth R.; Wong, Yu-Ning] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Hoffman-Censits, Jean] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA.
[Rosenberg, Jonathan E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Bellmunt, Joaquim; Choueiri, Toni K.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Plimack, ER (reprint author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
NR 15
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 20
PY 2014
VL 32
IS 36
BP 4171
EP U408
DI 10.1200/JCO.2014.58.5281
PG 3
WC Oncology
SC Oncology
GA AW4JO
UT WOS:000346247500028
PM 25385730
ER
PT J
AU Matthay, KK
London, WB
Maris, J
Adamson, PC
Park, JR
AF Matthay, Katherine K.
London, Wendy B.
Maris, John
Adamson, Peter C.
Park, Julie R.
TI When Overall Survival Fails to Confirm Event-Free Survival, Should the
Latter Be Used to Set the Standard of Care? Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
ID HIGH-RISK NEUROBLASTOMA; 13-CIS-RETINOIC ACID; RANDOMIZED-TRIAL;
CHEMOTHERAPY; THERAPY
C1 [Matthay, Katherine K.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94117 USA.
[London, Wendy B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[London, Wendy B.] Boston Childrens Canc & Blood Disorders, Boston, MA USA.
[Maris, John; Adamson, Peter C.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Park, Julie R.] Univ Washington, Sch Med, Seattle, WA USA.
RP Matthay, KK (reprint author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94117 USA.
FU NCI NIH HHS [U10 CA180899, U10 CA180886, U10 CA098413]
NR 8
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 20
PY 2014
VL 32
IS 36
BP 4174
EP U417
DI 10.1200/JCO.2014.58.7006
PG 3
WC Oncology
SC Oncology
GA AW4JO
UT WOS:000346247500031
PM 25403223
ER
PT J
AU Perez-Flores, G
Castillo-Martinez, L
Orea-Tejeda, A
Keirns-Davis, C
Lozano-Cruz, A
Alcala-Davila, E
Kauffman-Ortega, E
Radilla-Davila, F
AF Perez-Flores, Greta
Castillo-Martinez, Lilia
Orea-Tejeda, Arturo
Keirns-Davis, Candace
Lozano-Cruz, Arturo
Alcala-Davila, Efrain
Kauffman-Ortega, Eric
Radilla-Davila, Fernando
TI Frequency and clinical characteristics of acute heart failure patients
at INCMNSZ, Mexico City, Mexico
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Acute heart failure; Emergency department; Clinical characteristics
C1 [Perez-Flores, Greta; Castillo-Martinez, Lilia; Orea-Tejeda, Arturo; Lozano-Cruz, Arturo; Alcala-Davila, Efrain; Kauffman-Ortega, Eric; Radilla-Davila, Fernando] Inst Nacl Ciencias Med Nutr Salvador Zubiran, Mexico City, DF, Mexico.
[Keirns-Davis, Candace] Massachusetts Gen Hosp Interpreter Serv, Boston, MA 02114 USA.
RP Orea-Tejeda, A (reprint author), Providencia 1218-A 402 Col Valle, Mexico City 03100, DF, Mexico.
EM oreatart@gmail.com
RI Castillo-Martinez, Lilia/H-3750-2013
NR 10
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD DEC 20
PY 2014
VL 177
IS 3
BP 1085
EP 1086
DI 10.1016/j.ijcard.2014.10.003
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AU6EX
UT WOS:000345697200104
PM 25456704
ER
PT J
AU Long, SR
Wang, ZQ
Liu, RD
Liu, LN
Li, LG
Jiang, P
Zhang, X
Zhang, ZF
Shi, HN
Cui, J
AF Long, Shao Rong
Wang, Zhong Quan
Liu, Ruo Dan
Liu, Li Na
Li, Ling Ge
Jiang, Peng
Zhang, Xi
Zhang, Zi Fang
Shi, Hai Ning
Cui, Jing
TI Molecular identification of Trichinella spiralis nudix hydrolase and its
induced protective immunity against trichinellosis in BALB/c mice
SO PARASITES & VECTORS
LA English
DT Article
DE Trichinella spiralis; Nudix hydrolases; Protective immunity; Vaccine
ID INTESTINAL EPITHELIAL-CELLS; C9 BINDING DOMAIN; PROTEOMIC ANALYSIS;
INFECTIVE LARVAE; VACCINE CANDIDATE; IN-VITRO; PROTEINS; CLONING; CHINA;
GENE
AB Background: Nudix hydrolases (Nd) is a widespread superfamily, which is found in all classes of organism, hydrolyse a wide range of organic pyrophosphates and has a 'housecleaning' function. The previous study showed that Trichinella spiralis Nd (TsNd) bound to intestinal epithelial cells (IECs), and the vaccination of mice with T7 phage-displayed TsNd polypeptides produced protective immunity. The aim of this study was to clone, express and identify the full-length TsNd and to investigate its immune protection against T. spiralis infection.
Methods: The full-length cDNA sequence of TsNd gene encoding a 46 kDa protein from T. spiralis intestinal infective larvae (IIL) was cloned and identified. The antigenicity of rTsNd was analyzed by Western blot. Transcription and expression of TsNd at T. spiralis different stages were observed by RT-PCR and IFT. The levels of the specific total IgG, IgG1 and IgG2a antibodies to rTsNd were determined by ELISA. The immune protection of rTsNd against T. spiralis infection was investigated.
Results: Sequence and phylogenetic analysis revealed that TsNd had a nudix motif located at 226-244aa, which had high homology and the closest evolutionary status with T. pseudospiralis. The rTsNd was obtained after expression and purification. Western blot analysis showed that anti-rTsNd serum recognized the native TsNd protein in crude antigens of muscle larvae (ML), IIL, adult worms (AW) and newborn larvae (NBL), and ES antigens of ML. Transcription and expression of TsNd gene was observed in all developmental stages of T. spiralis (ML, IIL, AW and NBL), with high level expression in IIL. An immunolocalization analysis identified TsNd in the cuticle, stichocytes and reproductive organs of the parasite. Following immunization, anti-rTsNd IgG levels were increased, and the levels of IgG1 were more significantly higher than that of IgG2a. After a challenge infection with T. spiralis, mice immunized with the rTsNd displayed a 57.7% reduction in adult worms and a 56.9% reduction in muscle larval burden.
Conclusions: TsNd induced a partial protective immunity in mice and could be considered as a novel candidate vaccine antigen against trichinellosis.
C1 [Long, Shao Rong; Wang, Zhong Quan; Liu, Ruo Dan; Liu, Li Na; Li, Ling Ge; Jiang, Peng; Zhang, Xi; Zhang, Zi Fang; Cui, Jing] Zhengzhou Univ, Dept Parasitol, Coll Med, Zhengzhou 450052, Peoples R China.
[Shi, Hai Ning] Massachusetts Gen Hosp, Dept Immunol, Charlestown, MA 02129 USA.
[Shi, Hai Ning] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Wang, ZQ (reprint author), Zhengzhou Univ, Dept Parasitol, Coll Med, Zhengzhou 450052, Peoples R China.
EM wangzq@zzu.edu.cn; cuij@zzu.edu.cn
FU National Natural Science Foundation of China [81371843, 81271860,
81471981]
FX This work was supported by the National Natural Science Foundation of
China (No. 81371843, 81271860, and 81471981).
NR 40
TC 11
Z9 11
U1 0
U2 107
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD DEC 19
PY 2014
VL 7
AR 600
DI 10.1186/s13071-014-0600-9
PG 10
WC Parasitology
SC Parasitology
GA CA5KD
UT WOS:000348946400001
PM 25522912
ER
PT J
AU Crawley, DJ
Holmberg, L
Melvin, JC
Loda, M
Chowdhury, S
Rudman, SM
Van Hemelrijck, M
AF Crawley, Danielle J.
Holmberg, Lars
Melvin, Jennifer C.
Loda, Massimo
Chowdhury, Simon
Rudman, Sarah M.
Van Hemelrijck, Mieke
TI Serum glucose and risk of cancer: a meta-analysis
SO BMC CANCER
LA English
DT Article
DE Glucose; Cancer; Metabolic syndrome; Meta-analysis; Diabetes
ID GROWTH-FACTOR-I; INCIDENT COLORECTAL-CANCER; PROSTATE-CANCER;
INSULIN-RESISTANCE; BREAST-CANCER; METABOLIC SYNDROME; ENDOMETRIAL
CANCER; PANCREATIC-CANCER; DIABETES-MELLITUS; BLOOD-GLUCOSE
AB Background: Raised serum glucose has been linked to increased risk of many solid cancers. We performed a meta-analysis to quantify and summarise the evidence for this link.
Methods: Pubmed and Embase were reviewed, using search terms representing serum glucose and cancer. Inclusion and exclusion criteria focused on epidemiological studies with clear definitions of serum glucose levels, cancer type, as well as well-described statistical methods with sufficient data available. We used 6.1 mmol/L as the cut-off for high glucose, consistent with the WHO definition of metabolic syndrome. Random effects analyses were performed to estimate the pooled relative risk (RR).
Results: Nineteen studies were included in the primary analysis, which showed a pooled RR of 1.32 (95% CI: 1.20 - 1.45). Including only those individuals with fasting glucose measurements did not have a large effect on the pooled RR (1.32 (95% CI: 1.11-1.57). A stratified analysis showed a pooled RR of 1.34 (95% CI: 1.02-1.77) for hormonally driven cancer and 1.21 (95% CI: 1.09-1.36) for cancers thought to be driven by Insulin Growth Factor-1.
Conclusion: A positive association between serum glucose and risk of cancer was found. The underlying biological mechanisms remain to be elucidated but our subgroup analyses suggest that the insulin- IGF-1 axis does not fully explain the association. These findings are of public health importance as measures to reduce serum glucose via lifestyle and dietary changes could be implemented in the context of cancer mortality.
C1 [Crawley, Danielle J.; Holmberg, Lars; Melvin, Jennifer C.; Van Hemelrijck, Mieke] Kings Coll London, Sch Med, Div Canc Studies, Canc Epidemiol Grp, London, England.
[Holmberg, Lars] Univ Uppsala Hosp, Reg Canc Ctr, Uppsala, Sweden.
[Holmberg, Lars] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
[Loda, Massimo] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Loda, Massimo] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Crawley, Danielle J.; Chowdhury, Simon; Rudman, Sarah M.] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London, England.
RP Crawley, DJ (reprint author), Kings Coll London, Sch Med, Div Canc Studies, Canc Epidemiol Grp, London, England.
EM Danielle.crawley@kcl.ac.uk
OI Van Hemelrijck, Mieke/0000-0002-7317-0858; Crawley,
Danielle/0000-0001-7294-5634
FU Experimental Cancer Medicine Centre at King's College London; National
Institute for Health Research (NIHR) Biomedical Research Centre based at
Guy's and St Thomas' NHS Foundation Trust; King's College London
FX This research was supported by the Experimental Cancer Medicine Centre
at King's College London and also by the National Institute for Health
Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas'
NHS Foundation Trust and King's College London. The views expressed are
those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health.
NR 96
TC 3
Z9 3
U1 3
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 19
PY 2014
VL 14
AR 985
DI 10.1186/1471-2407-14-985
PG 11
WC Oncology
SC Oncology
GA AZ0XG
UT WOS:000347964700001
PM 25526881
ER
PT J
AU Jones, A
Kainz, D
Khan, F
Lee, C
Carrithers, MD
AF Jones, Alexis
Kainz, Danielle
Khan, Faatima
Lee, Cara
Carrithers, Michael D.
TI Human Macrophage SCN5A Activates an Innate Immune Signaling Pathway for
Antiviral Host Defense
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Adenylate Cyclase; Double-stranded RNA (dsRNA); Innate Immunity;
Interferon; Sodium Channel
ID SODIUM-CHANNEL NAV1.5; EXPRESSION; PROTEIN; RECOGNITION; INFECTION;
NUCLEAR; BINDING; SYSTEM; CELLS
AB Pattern recognition receptors contain a binding domain for pathogen-associated molecular patterns coupled to a signaling domain that regulates transcription of host immune response genes. Here, a novel mechanism that links pathogen recognition to channel activation and downstream signaling is proposed. We demonstrate that an intracellular sodium channel variant, human macrophage SCN5A, initiates signaling and transcription through a calcium-dependent isoform of adenylate cyclase, ADCY8, and the transcription factor, ATF2. Pharmacological stimulation with a channel agonist or treatment with cytoplasmic poly(I:C), a mimic of viral dsRNA, activates this pathway to regulate expression of SP100-related genes and interferon . Electrophysiological analysis reveals that the SCN5A variant mediates nonselective outward currents and a small, but detectable, inward current. Intracellular poly(I:C) markedly augments an inward voltage-sensitive sodium current and inhibits the outward nonselective current. These results suggest human macrophage SCN5A initiates signaling in an innate immune pathway relevant to antiviral host defense. It is postulated that SCN5A is a novel pathogen sensor and that this pathway represents a channel activation-dependent mechanism of transcriptional regulation.
C1 [Jones, Alexis; Kainz, Danielle; Khan, Faatima; Lee, Cara; Carrithers, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53706 USA.
[Jones, Alexis; Kainz, Danielle; Khan, Faatima; Lee, Cara; Carrithers, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Program Cellular & Mol Pathol, Madison, WI 53706 USA.
[Carrithers, Michael D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Carrithers, MD (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, 1300 Univ Ave,Rm 2679, Madison, WI 53706 USA.
EM carrithers@neurology.wisc.edu
OI Lee, Cara/0000-0003-0614-9060
FU Department of Veterans Affairs; University of Wisconsin at Madison
FX This work was supported by a Merit Award from the Department of Veterans
Affairs and the University of Wisconsin at Madison.
NR 24
TC 1
Z9 1
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 19
PY 2014
VL 289
IS 51
BP 35326
EP 35340
DI 10.1074/jbc.M114.611962
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AX0RT
UT WOS:000346660200024
PM 25368329
ER
PT J
AU Mariappan, MM
Prasad, S
D'Silva, K
Cedillo, E
Sataranatarajan, K
Barnes, JL
Choudhury, GG
Kasinath, BS
AF Mariappan, Meenalakshmi M.
Prasad, Sanjay
D'Silva, Kristin
Cedillo, Esteban
Sataranatarajan, Kavithalakshmi
Barnes, Jeffrey L.
Choudhury, Goutam Ghosh
Kasinath, Balakuntalam S.
TI Activation of Glycogen Synthase Kinase 3 beta Ameliorates
Diabetes-induced Kidney Injury
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Cell Signaling; Eukaryotic Translation Initiation; Extracellular Matrix
Protein; Glycogen Synthase Kinase 3 (GSK-3); Kidney; Mammalian Target of
Rapamycin (mTOR); Type 1 Diabetes; Diabetic Nephropathy; Sodium
Nitroprusside; Kidney Hypertrophy
ID MESSENGER-RNA TRANSLATION; RENAL EPITHELIAL-CELLS; PROTEIN-SYNTHESIS;
HIGH GLUCOSE; HIGH INSULIN; AKT KINASE; PHOSPHORYLATION; NEPHROPATHY;
INITIATION; GROWTH
AB Increase in protein synthesis contributes to kidney hypertrophy and matrix protein accumulation in diabetes. We have previously shown that high glucose-induced matrix protein synthesis is associated with inactivation of glycogen synthase kinase 3 (GSK3) in renal cells and in the kidneys of diabetic mice. We tested whether activation of GSK3 by sodium nitroprusside (SNP) mitigates kidney injury in diabetes. Studies in kidney-proximal tubular epithelial cells showed that SNP abrogated high glucose-induced laminin increment by stimulating GSK3 and inhibiting Akt, mTORC1, and events in mRNA translation regulated by mTORC1 and ERK. NONOate, an NO donor, also activated GSK3, indicating that NO may mediate SNP stimulation of GSK3. SNP administered for 3 weeks to mice with streptozotocin-induced type 1 diabetes ameliorated kidney hypertrophy, accumulation of matrix proteins, and albuminuria without changing blood glucose levels. Signaling studies showed that diabetes caused inactivation of GSK3 by activation of Src, Pyk2, Akt, and ERK; GSK3 inhibition activated mTORC1 and downstream events in mRNA translation in the kidney cortex. These reactions were abrogated by SNP. We conclude that activation of GSK3 by SNP ameliorates kidney injury induced by diabetes.
C1 [Mariappan, Meenalakshmi M.; Prasad, Sanjay; D'Silva, Kristin; Cedillo, Esteban; Sataranatarajan, Kavithalakshmi; Barnes, Jeffrey L.; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78245 USA.
[Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
[Mariappan, Meenalakshmi M.; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] South Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX 78229 USA.
RP Kasinath, BS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM kasinath@uthscsa.edu
FU Veterans Affairs Merit Review Program; National Institutes of Health
[DK077295, RC2AG036613, DK050190]; American Diabetes Association;
Juvenile Diabetes Research Foundation; Veterans Affairs Merit Review
Grant [5I01BX000926]; Veterans Affairs Senior Research Career Scientist
Award
FX This work was supported, in whole or in part, by the Veterans Affairs
Merit Review Program (to B. S. K.), National Institutes of Health Grants
DK077295 (to B. S. K.) and RC2AG036613 (to B. S. K.). This work was also
supported by the American Diabetes Association (to B. S. K.) and the
Juvenile Diabetes Research Foundation (to M. M. M.).; Supported by
National Institutes of Health R01 Grant DK050190 and Veterans Affairs
Merit Review Grant 5I01BX000926; recipient of a Veterans Affairs Senior
Research Career Scientist Award.
NR 51
TC 5
Z9 5
U1 1
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 19
PY 2014
VL 289
IS 51
BP 35363
EP 35375
DI 10.1074/jbc.M114.587840
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AX0RT
UT WOS:000346660200027
PM 25339176
ER
PT J
AU Crystal, AS
Shaw, AT
Sequist, LV
Friboulet, L
Niederst, MJ
Lockerman, EL
Frias, RL
Gainor, JF
Amzallag, A
Greninger, P
Lee, D
Kalsy, A
Gomez-Caraballo, M
Elamine, L
Howe, E
Hur, W
Lifshits, E
Robinson, HE
Katayama, R
Faber, AC
Awad, MM
Ramaswamy, S
Mino-Kenudson, M
Iafrate, AJ
Benes, CH
Engelman, JA
AF Crystal, Adam S.
Shaw, Alice T.
Sequist, Lecia V.
Friboulet, Luc
Niederst, Matthew J.
Lockerman, Elizabeth L.
Frias, Rosa L.
Gainor, Justin F.
Amzallag, Arnaud
Greninger, Patricia
Lee, Dana
Kalsy, Anuj
Gomez-Caraballo, Maria
Elamine, Leila
Howe, Emily
Hur, Wooyoung
Lifshits, Eugene
Robinson, Hayley E.
Katayama, Ryohei
Faber, Anthony C.
Awad, Mark M.
Ramaswamy, Sridhar
Mino-Kenudson, Mari
Iafrate, A. John
Benes, Cyril H.
Engelman, Jeffrey A.
TI Patient-derived models of acquired resistance can identify effective
drug combinations for cancer
SO SCIENCE
LA English
DT Article
ID CELL LUNG-CANCER; KINASE INHIBITION; BYPASS MECHANISMS; ALK; CRIZOTINIB;
MUTATIONS; GEFITINIB; CHEMOTHERAPY; ACTIVATION; CERITINIB
AB Targeted cancer therapies have produced substantial clinical responses, but most tumors develop resistance to these drugs. Here, we describe a pharmacogenomic platform that facilitates rapid discovery of drug combinations that can overcome resistance. We established cell culture models derived from biopsy samples of lung cancer patients whose disease had progressed while on treatment with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors and then subjected these cells to genetic analyses and a pharmacological screen. Multiple effective drug combinations were identified. For example, the combination of ALK and MAPK kinase (MEK) inhibitors was active in an ALK-positive resistant tumor that had developed a MAP2K1 activating mutation, and the combination of EGFR and fibroblast growth factor receptor (FGFR) inhibitors was active in an EGFR mutant resistant cancer with a mutation in FGFR3. Combined ALK and SRC (pp60c-src) inhibition was effective in several ALK-driven patient-derived models, a result not predicted by genetic analysis alone. With further refinements, this strategy could help direct therapeutic choices for individual patients.
C1 [Crystal, Adam S.; Shaw, Alice T.; Sequist, Lecia V.; Friboulet, Luc; Niederst, Matthew J.; Lockerman, Elizabeth L.; Frias, Rosa L.; Gainor, Justin F.; Amzallag, Arnaud; Greninger, Patricia; Lee, Dana; Kalsy, Anuj; Gomez-Caraballo, Maria; Elamine, Leila; Howe, Emily; Lifshits, Eugene; Katayama, Ryohei; Faber, Anthony C.; Awad, Mark M.; Ramaswamy, Sridhar; Benes, Cyril H.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA.
[Crystal, Adam S.; Shaw, Alice T.; Sequist, Lecia V.; Friboulet, Luc; Niederst, Matthew J.; Lockerman, Elizabeth L.; Frias, Rosa L.; Gainor, Justin F.; Amzallag, Arnaud; Greninger, Patricia; Lee, Dana; Kalsy, Anuj; Gomez-Caraballo, Maria; Elamine, Leila; Howe, Emily; Lifshits, Eugene; Robinson, Hayley E.; Katayama, Ryohei; Faber, Anthony C.; Awad, Mark M.; Ramaswamy, Sridhar; Mino-Kenudson, Mari; Iafrate, A. John; Benes, Cyril H.; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Robinson, Hayley E.; Mino-Kenudson, Mari; Iafrate, A. John] Massachusetts Gen Hosp, Ctr Canc, Dept Pathol, Boston, MA 02114 USA.
[Hur, Wooyoung] Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Hur, Wooyoung] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hur, Wooyoung] Korea Inst Sci & Technol, Chem Kin Res Ctr, Seoul 136791, South Korea.
RP Engelman, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA.
EM cbenes@partners.org; jengelman@partners.org
RI friboulet, luc/N-7276-2015
OI Crystal, Adam/0000-0002-2302-2654; friboulet, luc/0000-0002-1129-4978
FU NIH [R01CA137008, R01CA164273, 1U54HG006097-01]; Wellcome Trust [086357,
102696]; National Cancer Institute Lung SPORE [P50CA090578]; Department
of Defense; Conquer Cancer Foundation Young Investigator Award; Uniting
Against Lung Cancer; Free to Breathe; Lungevity; National Foundation for
Cancer Research; Be a Piece of the Solution; Novartis; Sanofi-Aventis;
AstraZeneca; Chugai; Amgen; Genentech; GSK; Merck; Pfizer; Boehringer
Ingelheim; Ariad; Roche; Ignyta
FX We thank L. H. Park for direction, redirection, and support; S. R. Vora
for continual critical discussion and support; W. Michaud for providing
feeder cells and training for the development of patient-derived cell
lines; and N. Gray for providing several kinase inhibitors. This study
was funded by support from the NIH R01CA137008 (J.A.E.), R01CA164273
(A.T.S. and J.A.E.), 1U54HG006097-01 (C.H.B.), the Wellcome Trust
(086357 and 102696, C.H.B.), the National Cancer Institute Lung SPORE
P50CA090578 (A.S.C., A.J.I., and J.A.E.), the Department of Defense
(L.V.S. and J.A.E.), Conquer Cancer Foundation Young Investigator Award
(A.S.C.), Uniting Against Lung Cancer (A.S.C. and A.T.S.), Free to
Breathe (A.S.C.), Lungevity (L.V.S. and J.A.E.), National Foundation for
Cancer Research (A.T.S.), and Be a Piece of the Solution. J.A.E. is a
paid consultant for Novartis, Sanofi-Aventis, AstraZeneca, Chugai,
Amgen, Genentech, GSK, Merck, and Pfizer, and he holds equity in
Gatekeeper Pharmaceuticals, which has a potential equity interest in
T790M inhibitors. J.A.E. also receives research support from Novartis.
J.F.G. is a paid consultant for Boehringer Ingelheim. A.T.S. is a paid
consultant for Pfizer, Novartis, Ariad, Chugai, Genentech, Roche, and
Ignyta. A.J.I. is a Senior Advisory Board member and holds equity in
Enzymatics Inc. For gene expression analyses, the raw data are deposited
in ArrayExpress (accession number is E-MTAB-783). The normalized data
are available at www.cancerrxgene.org/downloads.
NR 27
TC 148
Z9 152
U1 7
U2 66
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 19
PY 2014
VL 346
IS 6216
BP 1480
EP 1486
DI 10.1126/science.1254721
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW8UI
UT WOS:000346536500056
PM 25394791
ER
PT J
AU Nelson, BA
Kaplan, JL
El Saleeby, CM
Lu, MT
Mark, EJ
AF Nelson, Benjamin A.
Kaplan, Jess L.
El Saleeby, Chadi M.
Lu, Michael T.
Mark, Eugene J.
TI Case 39-2014: A 9-Year-Old Girl with Crohn's Disease and Pulmonary
Nodules
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; WEGENERS-GRANULOMATOSIS; LUNG LESIONS;
PATIENT; AZATHIOPRINE; CHILDREN; BIOPSY
C1 [Nelson, Benjamin A.; Kaplan, Jess L.; El Saleeby, Chadi M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Lu, Michael T.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Mark, Eugene J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Nelson, Benjamin A.; Kaplan, Jess L.; El Saleeby, Chadi M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Lu, Michael T.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Mark, Eugene J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Nelson, BA (reprint author), Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
NR 24
TC 3
Z9 3
U1 0
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 18
PY 2014
VL 371
IS 25
BP 2418
EP 2427
DI 10.1056/NEJMcpc1410938
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW7DX
UT WOS:000346425800013
PM 25517709
ER
PT J
AU Lu, EP
McLellan, M
Ding, L
Fulton, R
Mardis, ER
Wilson, RK
Miller, CA
Westervelt, P
DiPersio, JF
Link, DC
Walter, MJ
Ley, TJ
Graubert, TA
AF Lu, Elise Peterson
McLellan, Michael
Ding, Li
Fulton, Robert
Mardis, Elaine R.
Wilson, Richard K.
Miller, Christopher A.
Westervelt, Peter
DiPersio, John F.
Link, Daniel C.
Walter, Matthew J.
Ley, Timothy J.
Graubert, Timothy A.
TI Caspase-9 is required for normal hematopoietic development and
protection from alkylator-induced DNA damage in mice
SO BLOOD
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; NON-HODGKIN-LYMPHOMA; STEM-CELL FUNCTION;
GENE-EXPRESSION; HUMAN CANCER; REPAIR; APOPTOSIS; RISK; DIFFERENTIATION;
SUSCEPTIBILITY
AB Apoptosis and the DNA damage responses have been implicated in hematopoietic development and differentiation, as well as in the pathogenesis of myelodysplastic syndromes (MDS) and leukemia. However, the importance of late-stage mediators of apoptosis in hematopoiesis and leukemogenesis has not been elucidated. Here, we examine the role of caspase-9 (Casp9), the initiator caspase of the intrinsic apoptotic cascade, in murine fetal and adult hematopoiesis. Casp9 deficiency resulted in decreased erythroid and B-cell progenitor abundance and impaired function of hematopoietic stem cells after transplantation. Mouse bone marrow chimeras lacking Casp9 or its cofactor Apaf1 developed low white blood cell counts, decreased B-cell numbers, anemia, and reduced survival. Defects in apoptosis have also been previously implicated in susceptibility to therapy-related leukemia, a disease caused by exposure to DNA-damaging chemotherapy. We found that the burden of DNA damage was increased in Casp9-deficient cells after exposure to the alkylator, N-ethyl-nitrosourea (ENU). Furthermore, exome sequencing revealed that oligoclonal hematopoiesis emerged in Casp9-deficient bone marrow chimeras after alkylator exposure. Taken together, these findings suggest that defects in apoptosis could be a key step in the pathogenesis of alkylator-associated secondary malignancies.
C1 [Lu, Elise Peterson; Westervelt, Peter; DiPersio, John F.; Link, Daniel C.; Walter, Matthew J.; Ley, Timothy J.; Graubert, Timothy A.] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA.
[McLellan, Michael; Ding, Li; Fulton, Robert; Mardis, Elaine R.; Wilson, Richard K.; Miller, Christopher A.; Ley, Timothy J.] Washington Univ, Genome Inst, St Louis, MO USA.
[Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Westervelt, Peter; DiPersio, John F.; Link, Daniel C.; Walter, Matthew J.; Ley, Timothy J.; Graubert, Timothy A.] Washington Univ, Siteman Canc Ctr, St Louis, MO USA.
[Mardis, Elaine R.; Wilson, Richard K.; Walter, Matthew J.; Ley, Timothy J.] Washington Univ, Dept Genet, St Louis, MO 63110 USA.
RP Graubert, TA (reprint author), Massachusetts Gen Hosp, Ctr Canc, 10 North Grove St,Lawrence House 204, Boston, MA 02114 USA.
EM tgraubert@partners.org
OI Graubert, Timothy/0000-0002-7710-1171
FU National Institutes of Health, National Cancer Institute [P01CA101937];
National Institutes of Health, National Heart, Lung, and Blood Institute
[F30HL114316]
FX This work was supported by the National Institutes of Health, National
Cancer Institute grant P01CA101937 and National Heart, Lung, and Blood
Institute grant F30HL114316.
NR 34
TC 4
Z9 5
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 18
PY 2014
VL 124
IS 26
BP 3887
EP 3895
DI 10.1182/blood-2014-06-582551
PG 9
WC Hematology
SC Hematology
GA AY3EU
UT WOS:000347468200011
PM 25349173
ER
PT J
AU Burgess, MR
Hwang, E
Firestone, AJ
Huang, TN
Xu, J
Zuber, J
Bohin, N
Wen, T
Kogan, SC
Haigis, KM
Sampath, D
Lowe, S
Shannon, K
Li, Q
AF Burgess, Michael R.
Hwang, Eugene
Firestone, Ari J.
Huang, Tannie
Xu, Jin
Zuber, Johannes
Bohin, Natacha
Wen, Tiffany
Kogan, Scott C.
Haigis, Kevin M.
Sampath, Deepak
Lowe, Scott
Shannon, Kevin
Li, Qing
TI Preclinical efficacy of MEK inhibition in Nras-mutant AML
SO BLOOD
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; SMALL-MOLECULE INHIBITION; HEMATOPOIETIC STEM;
MYELODYSPLASTIC SYNDROME; HYPERACTIVE RAS; TARGETING RAS; PHASE-I;
MUTATIONS; CANCER; GENE
AB Oncogenic NRAS mutations are highly prevalent in acute myeloid leukemia (AML). Genetic analysis supports the hypothesis that NRAS mutations cooperate with antecedent molecular lesions in leukemogenesis, but have limited independent prognostic significance. Using short hairpin RNA-mediated knockdown in human cell lines and primary mouse leukemias, we show that AML cells with NRAS/Nras mutations are dependent on continued oncogene expression in vitro and in vivo. Using the Mx1-Cre transgene to inactivate a conditional mutant Nras allele, we analyzed hematopoiesis and hematopoietic stem and progenitor cells (HSPCs) under normal and stressed conditions and found that HSPCs lacking Nras expression are functionally equivalent to normal HSPCs in the adult mouse. Treating recipient mice transplanted with primary Nras(G12D) AMLs with 2 potent allosteric mitogen-activated protein kinase kinase (MEK) inhibitors (PD0325901 or trametinib/GlaxoSmithKline 1120212) significantly prolonged survival and reduced proliferation but did not induce apoptosis, promote differentiation, or drive clonal evolution. The phosphatidylinositol 3-kinase inhibitor GDC-0941 was ineffective as a single agent and did not augment the activity of PD0325901. All mice ultimately succumbed to progressive leukemia. Together, these data validate oncogenic N-Ras signaling as a therapeutic target in AML and support testing combination regimens that include MEK inhibitors.
C1 [Burgess, Michael R.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94158 USA.
[Hwang, Eugene; Firestone, Ari J.; Huang, Tannie; Xu, Jin; Shannon, Kevin] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA.
[Zuber, Johannes] Res Inst Mol Pathol, A-1030 Vienna, Austria.
[Bohin, Natacha; Wen, Tiffany; Li, Qing] Univ Michigan, Dept Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
[Kogan, Scott C.; Shannon, Kevin] Univ Calif San Francisco, San Francisco, CA 94158 USA.
[Haigis, Kevin M.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA.
[Haigis, Kevin M.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA.
[Sampath, Deepak] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA.
[Lowe, Scott] Howard Hughes Med Inst, New York, NY USA.
[Lowe, Scott] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Shannon, Kevin] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.
RP Shannon, K (reprint author), Univ Calif San Francisco, Helen Diller Family Canc Res Bldg,1450 3rd St, San Francisco, CA 94158 USA.
EM shannonk@peds.ucsf.edu; lqing@med.umich.edu
FU Rally Foundation for Childhood Cancer Research; Leukemia and Lymphoma
Society of America Specialized Center of Research [LLS 7019-04];
National Institutes of Health, National Cancer Institute [R37 CA72614,
T32 CA108462, K01 CA118425, K08 CA134649]; American Cancer
Society-Hillcrest Committee Postdoctoral Fellowship [PF-14-146-01-LIB];
Damon Runyon Cancer Research Foundation Fellowship [DRG-2149-13]
FX This work was supported by the Rally Foundation for Childhood Cancer
Research and The Truth 365; the Leukemia and Lymphoma Society of America
Specialized Center of Research (LLS 7019-04); the National Institutes of
Health, National Cancer Institute grants R37 CA72614 (K.S.), and T32
CA108462 (M.R.B.), grant K01 CA118425 (K.M.H.), and grant K08 CA134649
(Q.L.); an American Cancer Society-Hillcrest Committee Postdoctoral
Fellowship (PF-14-146-01-LIB) (M.R.B.); and a Damon Runyon Cancer
Research Foundation Fellowship (DRG-2149-13) (A.J.F.) S.L. is an
Investigator of the Howard Hughes Medical Institute, and K.S. is an
American Cancer Society Research Professor.
NR 49
TC 18
Z9 18
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 18
PY 2014
VL 124
IS 26
BP 3947
EP 3955
DI 10.1182/blood-2014-05-574582
PG 9
WC Hematology
SC Hematology
GA AY3EU
UT WOS:000347468200018
PM 25361812
ER
PT J
AU Petersdorf, EW
Gooley, TA
Malkki, M
Bacigalupo, AP
Cesbron, A
Du Toit, E
Ehninger, G
Egeland, T
Fischer, GF
Gervais, T
Haagenson, MD
Horowitz, MM
Hsu, K
Jindra, P
Madrigal, A
Oudshoorn, M
Ringden, O
Schroeder, ML
Spellman, SR
Tiercy, JM
Velardi, A
Witt, CS
O'Huigin, C
Apps, R
Carrington, M
AF Petersdorf, Effie W.
Gooley, Theodore A.
Malkki, Mari
Bacigalupo, Andrea P.
Cesbron, Anne
Du Toit, Ernette
Ehninger, Gerhard
Egeland, Torstein
Fischer, Gottfried F.
Gervais, Thibaut
Haagenson, Michael D.
Horowitz, Mary M.
Hsu, Katharine
Jindra, Pavel
Madrigal, Alejandro
Oudshoorn, Machteld
Ringden, Olle
Schroeder, Marlis L.
Spellman, Stephen R.
Tiercy, Jean-Marie
Velardi, Andrea
Witt, Campbell S.
O'Huigin, Colm
Apps, Richard
Carrington, Mary
CA Int Histocompatibility Working Grp
TI HLA-C expression levels define permissible mismatches in hematopoietic
cell transplantation
SO BLOOD
LA English
DT Article
ID BONE-MARROW TRANSPLANTATION; KIR LIGAND INCOMPATIBILITY;
VERSUS-HOST-DISEASE; CLASS-I MOLECULES; UNRELATED DONOR; HIV CONTROL;
ALLELE; IDENTIFICATION; SUBSTITUTIONS; ENVIRONMENT
AB Life-threatening graft-versus-host disease (GVHD) limits the use of HLA-C-mismatched unrelated donors in transplantation. Clinicians lack criteria for donor selection when HLA-C-mismatched donors are a patient's only option for cure. We examined the role for HLA-Cexpression levels to identify permissible HLA-C mismatches. The median fluorescence intensity, a proxy of HLA-Cexpression, was assigned to each HLA-C allotype in 1975 patients and their HLA-C-mismatched unrelated transplant donors. The association of outcome with the level of expression of patients' and donors' HLA-Callotypes was evaluated in multivariable models. Increasing expression level of the patient's mismatched HLA-C allotype was associated with increased risks of grades III to IV acute GVHD, nonrelapse mortality, and mortality. Increasing expression level among HLA-C mismatches with residue 116 or residue 77/80 mismatching was associated with increased nonrelapse mortality. The immunogenicity of HLA-C mismatches in unrelated donor transplantation is influenced by the expression level of the patient's mismatched HLA-C allotype. HLA-C expression levels provide new information on mismatches that should be avoided and extend understanding of HLA-C-mediated immune responses in human disease.
C1 [Petersdorf, Effie W.; Gooley, Theodore A.; Malkki, Mari] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
[Petersdorf, Effie W.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Bacigalupo, Andrea P.] Azienda Osped Univ San Martino, Ist Ricovero & Cura Carattere Sci, Genoa, Italy.
[Cesbron, Anne] Etab Francais Sang Pays de Loire, Lab Histocompatibilit & Immunogenet, Nantes, France.
[Du Toit, Ernette] Univ Cape Town, Cape Town, South Africa.
[Du Toit, Ernette] South African Bone Marrow Registry, Cape Town, South Africa.
[Ehninger, Gerhard] Univ Klinikum Carl Gustav Carus, Dresden, Germany.
[Egeland, Torstein] Oslo Univ Hosp, Dept Immunol, Oslo, Norway.
[Fischer, Gottfried F.] Med Univ Vienna, Dept Blood Grp Serol & Transfus Med, Vienna, Austria.
[Gervais, Thibaut] Catholic Univ Louvain, Clin St Luc, Brussels, Belgium.
[Haagenson, Michael D.; Spellman, Stephen R.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA.
[Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Hsu, Katharine] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Jindra, Pavel] Univ Hosp, Plzen, Czech Republic.
[Madrigal, Alejandro] Royal Free Hampstead NHS Trust, Anthony Nolan Res Inst, London, England.
[Oudshoorn, Machteld] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Oudshoorn, Machteld] Europdonor Fdn, Leiden, Netherlands.
[Ringden, Olle] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat, Div Therapeut Immunol, Huddinge, Sweden.
[Schroeder, Marlis L.] Univ Manitoba, Canc Care Manitoba, Winnipeg, MB, Canada.
[Tiercy, Jean-Marie] Univ Hosp Geneva, Dept Genet & Lab Med, Natl Reference Lab Histocompatibil, Geneva, Switzerland.
[Velardi, Andrea] European Grp Blood & Marrow Transplantat, Perugia, Italy.
[Velardi, Andrea] Univ Perugia, I-06100 Perugia, Italy.
[Witt, Campbell S.] Royal Perth Hosp, Dept Clin Immunol, Perth, WA 6001, Australia.
[O'Huigin, Colm; Apps, Richard; Carrington, Mary] SAIC Frederick Inc, Frederick Natl Labs Canc Res, Canc & Inflammat Program, Frederick, MD USA.
[Apps, Richard; Carrington, Mary] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA.
[Apps, Richard; Carrington, Mary] Harvard Univ, Boston, MA 02115 USA.
RP Petersdorf, EW (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave North,D4-115,POB 19024, Seattle, WA 98109 USA.
EM epetersd@fhcrc.org
FU National Institute of Allergy and Infectious Diseases (NIAID)
[AI069197]; National Cancer Institute (NCI) [CA18029]; NCI [CA76518,
U24-CA76518, 5U01HL069294]; Health Resources and Services Administration
[HHSH234200637015C]; National Heart, Lung and Blood Institute (NHLBI);
NIAID; Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039];
Associazione Italiana Ricerca sul Cancro (Milano, Italy); European
Regional Development Fund [ED2.1.00/03.0076]; Swedish Cancer Society;
Swedish Research Council; Children's Cancer Foundation; Cancer Society
in Stockholm; Karolinska Institutet (Stockholm, Sweden); Swiss National
Science Foundation [310030-146306/1]; Frederick National Laboratory for
Cancer Research [HHSN261200800001E]; National Institutes of Health,
Frederick National Laboratory, Center for Cancer Research; [T.A. C.R
TA01010342]; [GACRNT/12454-5]
FX E.W.P., T.A.G., M.M., S.R.S., M.D.H., and M.M.H. are supported by
National Institute of Allergy and Infectious Diseases (NIAID) grant
AI069197; E.W.P., T.A.G., and M.M. are supported by National Cancer
Institute (NCI) grant CA18029; M.M.H. is supported by NCI grant CA76518
and Health Resources and Services Administration grant
HHSH234200637015C; S.R.S., M.D.H., and M.M.H. are supported by NCI grant
U24-CA76518, the National Heart, Lung and Blood Institute (NHLBI),
NIAID, NHLBI and NCI grant 5U01HL069294, and Office of Naval Research
grants N00014-12-1-0142 and N00014-13-1-0039; A.P.B. was supported by
The Associazione Italiana Ricerca sul Cancro (Milano, Italy); P.J. was
supported by Project ED2.1.00/03.0076 from the European Regional
Development Fund, T.A. C.R TA01010342, and GACRNT/12454-5, Czech
Republic; O.R. was supported by The Swedish Cancer Society, The Swedish
Research Council, The Children's Cancer Foundation, The Cancer Society
in Stockholm, and Karolinska Institutet (Stockholm, Sweden); J.-M.T. was
supported by Swiss National Science Foundation grant 310030-146306/1;
and M.C. was supported by Frederick National Laboratory for Cancer
Research contract HHSN261200800001E and the Intramural Research Program
of the National Institutes of Health, Frederick National Laboratory,
Center for Cancer Research.
NR 35
TC 27
Z9 27
U1 1
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 18
PY 2014
VL 124
IS 26
BP 3996
EP 4003
DI 10.1182/blood-2014-09-599969
PG 8
WC Hematology
SC Hematology
GA AY3EU
UT WOS:000347468200025
PM 25323824
ER
PT J
AU Meng, FL
Du, Z
Federation, A
Hu, JZ
Wang, Q
Kieffer-Kwon, KR
Meyers, RM
Amor, C
Wasserman, CR
Neuberg, D
Casellas, R
Nussenzweig, MC
Bradner, JE
Liu, XS
Alt, FW
AF Meng, Fei-Long
Du, Zhou
Federation, Alexander
Hu, Jiazhi
Wang, Qiao
Kieffer-Kwon, Kyong-Rim
Meyers, Robin M.
Amor, Corina
Wasserman, Caitlyn R.
Neuberg, Donna
Casellas, Rafael
Nussenzweig, Michel C.
Bradner, James E.
Liu, X. Shirley
Alt, Frederick W.
TI Convergent Transcription at Intragenic Super-Enhancers Targets
AID-Initiated Genomic Instability
SO CELL
LA English
DT Article
ID RNA-POLYMERASE-II; INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH
RECOMBINATION; B-CELL LYMPHOMA; SOMATIC HYPERMUTATION; SEQUENCING
REVEALS; CHROMOSOMAL TRANSLOCATIONS; NONCODING TRANSCRIPTION; IG GENES;
C-MYC
AB Activation-induced cytidine deaminase (AID) initiates both somatic hypermutation (SHM) for antibody affinity maturation and DNA breakage for antibody class switch recombination (CSR) via transcription-dependent cytidine deamination of single-stranded DNA targets. Though largely specific for immunoglobulin genes, AID also acts on a limited set of off-targets, generating oncogenic translocations and mutations that contribute to B cell lymphoma. How AID is recruited to off-targets has been a long-standing mystery. Based on deep GRO-seq studies of mouse and human B lineage cells activated for CSR or SHM, we report that most robust AID off-target translocations occur within highly focal regions of target genes in which sense and antisense transcription converge. Moreover, we found that such AID-targeting "convergent'' transcription arises from antisense transcription that emanates from super-enhancers within sense transcribed gene bodies. Our findings provide an explanation for AID off-targeting to a small subset of mostly lineage-specific genes in activated B cells.
C1 [Meng, Fei-Long; Du, Zhou; Hu, Jiazhi; Meyers, Robin M.; Amor, Corina; Wasserman, Caitlyn R.; Alt, Frederick W.] Harvard Univ, Boston Childrens Hosp, Howard Hughes Med Inst, Program Cellular & Mol Med,Med Sch, Boston, MA 02115 USA.
[Meng, Fei-Long; Du, Zhou; Hu, Jiazhi; Meyers, Robin M.; Amor, Corina; Wasserman, Caitlyn R.; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Du, Zhou] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China.
[Federation, Alexander; Bradner, James E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Federation, Alexander; Bradner, James E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Wang, Qiao; Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10065 USA.
[Kieffer-Kwon, Kyong-Rim; Casellas, Rafael] NCI, NIAMS, NIH, Bethesda, MD 20892 USA.
[Kieffer-Kwon, Kyong-Rim; Casellas, Rafael] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Neuberg, Donna; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Neuberg, Donna; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Bradner, JE (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM james_bradner@dfci.harvard.edu; alt@enders.tch.harvard.edu
FU NIH grants [R01AI077595, P01CA109901]; Leukemia and Lymphoma Society
(LLS) SCOR grant; NIH grant [1R01GM099409]; Leukemia and Lymphoma
Society SCOR; National Science Foundation; NIH [1R01 CA176745-01, P01
CA109901, AI072529, AI037526]; intramural research program of NIAMS,
NIH; Robertson Foundation/Cancer Research Institute Irvington
Fellowship; National Science Foundation of China [NSFC 31329003]
FX F.W.A was supported by NIH grants R01AI077595 and P01CA109901, and a
Leukemia and Lymphoma Society (LLS) SCOR grant, and he is an
investigator of the Howard Hughes Medical Institute. X.S.L was supported
by NIH grant 1R01GM099409. A.F. and J.E.B. were supported by a Leukemia
and Lymphoma Society SCOR, the National Science Foundation, and NIH
grants 1R01 CA176745-01 and P01 CA109901. M.C.N. was supported by NIH
grants AI072529 and AI037526 and is an investigator of the Howard Hughes
Medical Institute. K.K. and R.C. were supported by the intramural
research program of NIAMS, NIH. F.L.M. is a Lymphoma Research Foundation
postdoctoral fellow and was a Cancer Research Institute postdoctoral
fellow. J.Z. is supported by a Robertson Foundation/Cancer Research
Institute Irvington Fellowship. Z.D. was supported by the National
Science Foundation of China grant NSFC 31329003. The authors thank Drs.
Yi Zhang and Li Shen for assistance with DNA sequencing and Dr. David
Schatz (Yale University) for providing primers for GC SHM targets. Dr.
Bradner is a scientific founder of Syros Pharmaceuticals, which is
developing drugs targeting super-enhancers.
NR 53
TC 55
Z9 56
U1 2
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD DEC 18
PY 2014
VL 159
IS 7
BP 1538
EP 1548
DI 10.1016/j.cell.2014.11.014
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AZ0FW
UT WOS:000347922500009
PM 25483776
ER
PT J
AU Woo, JM
Jeon, HJ
Noh, E
Kim, HJ
Lee, SW
Lee, KK
Kim, SH
Hong, JP
AF Woo, Jong-Min
Jeon, Hong Jin
Noh, Eunsun
Kim, Hyo-Jin
Lee, Sun Woo
Lee, Kyung Kyu
Kim, Sung Hwan
Hong, Jin Pyo
TI Importance of remission and residual somatic symptoms in health-related
quality of life among outpatients with major depressive disorder: a
cross-sectional study
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
DE Major depressive disorder; Quality of life; EQ-5D; Q-LES-Q-SF
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PAINFUL PHYSICAL SYMPTOMS;
MENTAL-HEALTH; DSM-IV; OUTCOMES; VALIDATION; SCALE; ASSOCIATION;
POPULATION; IMIPRAMINE
AB Background: Major depressive disorder (MDD) is strongly associated with an impaired quality of life (QoL), which is itself affected by various factors. Symptom-oriented ratings poorly reflect the impact of disease on the QoL and level of functioning of the mental health of subjects. The purpose of this study was to assess health-related QoL (HRQoL) using preference-based measures in outpatients with MDD with regard to their remission achievement and clinical factors affecting the HRQoL.
Methods: This was a cross-sectional observational study. We recruited 811 patients with MDD from 14 psychiatric outpatient clinics in Korea. They were divided into three groups as follows: a new visit group (n = 287), a remitted group (n = 235), and a non-remitted group (n = 289). The 17-item Hamilton Depression Rating Scale was used to assign patients to the remitted or non-remitted group. The general HRQoL was assessed with the EuroQol 5D (EQ-5D), using both the EQ-5D index score and the EuroQol Visual Analog Scale (EQ-VAS). The disease-specific HRQoL was assessed with the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF).
Results: The non-remitted group showed a significant impairment of HRQoL in view of the subscales of EQ-5D index scores, EQ-VAS, and Q-LES-Q-SF. The EQ-5D index score in the remitted group was 0.77 0.10, while it was 0.57 0.23 in the non-remitted group and 0.58 0.24 in the new visit group (p < 0.0001). The EQ-VAS scores for the remitted and non-remitted groups were 72.5 16.6 and 50.9 20.3, respectively (p < 0.0001). Likewise, patients with remission had the Q-LES-Q-SF total score of 46.5 8.8, whereas tho se with non-remission reported 36.7 7.7 (p < 0.0001). The symptom severity measured by the Depression and Somatic Symptoms Scale was significantly correlated with the HRQoL. Furthermore, patients with severe somatic symptoms showed a significantly lower EQ-5D index score (0.54 0.24) than those with mild/moderate somatic symptoms (0.75 0.12; p = 0.002).
Conclusion: Non-remitted MDD patients, especially those with more severe somatic symptoms, show a distinct impairment of HRQoL and more clinical symptoms, suggesting the importance of achieving remission in the treatment of MDD.
C1 [Woo, Jong-Min] Inje Univ, Sch Med, Seoul Paik Hosp, Dept Psychiat, Seoul, South Korea.
[Woo, Jong-Min] Inje Univ, Stress Res Inst, Seoul, South Korea.
[Jeon, Hong Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, Seoul, South Korea.
[Jeon, Hong Jin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA.
[Noh, Eunsun] Vet Affairs Med Ctr, Providence, RI USA.
[Noh, Eunsun] Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, Kingston, RI 02881 USA.
[Kim, Hyo-Jin] Pfizer Pharmaceut Korea Ltd, Hlth & Value Div, OR RWD Team, Seoul, South Korea.
[Lee, Sun Woo] Chungnam Natl Univ, Sch Med, Dept Psychiat, Chungnam, South Korea.
[Lee, Kyung Kyu] Dankook Univ, Sch Med, Dept Psychiat, Cheonan, South Korea.
[Kim, Sung Hwan] Dong A Univ, Sch Med, Dept Psychiat, Pusan, South Korea.
[Hong, Jin Pyo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Psychiat, Seoul 138736, South Korea.
RP Hong, JP (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Psychiat, 388-1 Pungnap 2dong, Seoul 138736, South Korea.
EM jphong@amc.seoul.kr
FU Pfizer Pharmaceuticals Korea Ltd.; Basic Science Research Program
through the National Research Foundation of Korea (NRF) of the Ministry
of Education, Science and Technology [2011-0013064]
FX This study was supported by Pfizer Pharmaceuticals Korea Ltd. and by the
Basic Science Research Program through the National Research Foundation
of Korea (NRF) of the Ministry of Education, Science and Technology (No.
2011-0013064).
NR 43
TC 7
Z9 7
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD DEC 18
PY 2014
VL 12
AR 188
DI 10.1186/s12955-014-0188-y
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AY2NG
UT WOS:000347426300001
PM 25519704
ER
PT J
AU Gaiha, GD
McKim, KJ
Woods, M
Pertel, T
Rohrbach, J
Barteneva, N
Chin, CR
Liu, DF
Soghoian, DZ
Cesa, K
Wilton, S
Waring, MT
Chicoine, A
Doering, T
Wherry, EJ
Kaufmann, DE
Lichterfeld, M
Brass, AL
Walker, BD
AF Gaiha, Gaurav D.
McKim, Kevin J.
Woods, Matthew
Pertel, Thomas
Rohrbach, Janine
Barteneva, Natasha
Chin, Christopher R.
Liu, Dongfang
Soghoian, Damien Z.
Cesa, Kevin
Wilton, Shannon
Waring, Michael T.
Chicoine, Adam
Doering, Travis
Wherry, E. John
Kaufmann, Daniel E.
Lichterfeld, Mathias
Brass, Abraham L.
Walker, Bruce D.
TI Dysfunctional HIV-Specific CD8(+) T Cell Proliferation Is Associated
with Increased Caspase-8 Activity and Mediated by Necroptosis
SO IMMUNITY
LA English
DT Article
ID GENE-EXPRESSION DATA; NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY; PROGRAMMED
NECROSIS; DISEASE PROGRESSION; ACTIVATION; INFECTION; DEATH; EXHAUSTION;
APOPTOSIS
AB Decreased HIV-specific CD8(+) T cell proliferation is a hallmark of chronic infection, but the mechanisms of decline are unclear. We analyzed gene expression profiles from antigen-stimulated HIV-specific CD8(+) T cells from patients with controlled and uncontrolled infection and identified caspase-8 as a correlate of dysfunctional CD8(+) T cell proliferation. Caspase-8 activity was upregulated in HIV-specific CD8(+) T cells from progressors and correlated positively with disease progression and programmed cell death-1 (PD-1) expression, but negatively with proliferation. In addition, progressor cells displayed a decreased ability to upregulate membrane-associated caspase-8 activity and increased necrotic cell death following antigenic stimulation, implicating the programmed cell death pathway necroptosis. In vitro necroptosis blockade rescued HIV-specific CD8(+) T cell proliferation in progressors, as did silencing of necroptosis mediator RIPK3. Thus, chronic stimulation leading to upregulated caspase-8 activity contributes to dysfunctional HIV-specific CD8(+) T cell proliferation through activation of necroptosis and increased cell death.
C1 [Gaiha, Gaurav D.; McKim, Kevin J.; Woods, Matthew; Rohrbach, Janine; Chin, Christopher R.; Soghoian, Damien Z.; Cesa, Kevin; Wilton, Shannon; Waring, Michael T.; Chicoine, Adam; Kaufmann, Daniel E.; Lichterfeld, Mathias; Brass, Abraham L.; Walker, Bruce D.] Ragon Inst MGH, Cambridge, MA 02139 USA.
[Pertel, Thomas] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA.
[Barteneva, Natasha] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Chin, Christopher R.; Brass, Abraham L.] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst MaPS, Worcester, MA 01655 USA.
[Liu, Dongfang] Baylor Coll Med, Texas Childrens Hosp, Ctr Human Immunobiol, Houston, TX 77030 USA.
[Waring, Michael T.; Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Doering, Travis] Hofstra North Shore LIJ Sch Med, Hempstead, NY 11549 USA.
[Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA.
[Kaufmann, Daniel E.] Ctr Hosp Univ Montreal CRCHUM, Ctr Rech, Montreal, PQ H2X 0A9, Canada.
[Lichterfeld, Mathias; Walker, Bruce D.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Walker, BD (reprint author), Ragon Inst MGH, Cambridge, MA 02139 USA.
EM bwalker@partners.org
FU Howard Hughes Medical Institute; Ragon Institute; NIH [AI30914,
AI105343, AI112521, AI082630, AI095608, HHSN266200500030C]; Bill and
Melinda Gates Foundation; NIH-funded Center for AIDS Research grant [P30
AI060354]; NIH Co-Funding and Participating Institute and Center: NIAID;
NIH Co-Funding and Participating Institute and Center: NCI; NIH
Co-Funding and Participating Institute and Center: NICHD; NIH Co-Funding
and Participating Institute and Center: NHLBI; NIH Co-Funding and
Participating Institute and Center: NIDA; NIH Co-Funding and
Participating Institute and Center: NIMH; NIH Co-Funding and
Participating Institute and Center: NIA; NIH Co-Funding and
Participating Institute and Center: FIC; NIH Co-Funding and
Participating Institute and Center: OAR
FX We are grateful to Judy Lieberman and Jennifer Sims for comments on the
manuscript and to Deanna Nguyen for assistance with experiments. This
study was supported by funds from the Howard Hughes Medical Institute,
the Ragon Institute, the NIH (AI30914, AI105343, AI112521, AI082630,
AI095608, HHSN266200500030C), the Bill and Melinda Gates Foundation, and
an NIH-funded Center for AIDS Research grant (P30 AI060354), which is
supported by the following NIH Co-Funding and Participating Institutes
and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR.
NR 61
TC 11
Z9 11
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD DEC 18
PY 2014
VL 41
IS 6
BP 1001
EP 1012
DI 10.1016/j.immuni.2014.12.011
PG 12
WC Immunology
SC Immunology
GA AX0PM
UT WOS:000346654100017
PM 25526311
ER
PT J
AU Tschopp, P
Sherratt, E
Sanger, TJ
Groner, AC
Aspiras, AC
Hu, JK
Pourquie, O
Gros, J
Tabin, CJ
AF Tschopp, Patrick
Sherratt, Emma
Sanger, Thomas J.
Groner, Anna C.
Aspiras, Ariel C.
Hu, Jimmy K.
Pourquie, Olivier
Gros, Jerome
Tabin, Clifford J.
TI A relative shift in cloacal location repositions external genitalia in
amniote evolution
SO NATURE
LA English
DT Article
ID GENE-EXPRESSION; MESENCHYMAL TRANSITION; VERTEBRATE EMBRYOS; HOMOLOGY;
PACKAGE; LIMB; ONTOLOGY; PROGRAM; BIOLOGY; TISSUES
AB The move of vertebrates to a terrestrial lifestyle required major adaptations in their locomotory apparatus and reproductive organs. While the fin-to-limb transition has received considerable attention(1,2), little is known about the developmental and evolutionary origins of external genitalia. Similarities in gene expression have been interpreted as a potential evolutionary link between the limb and genitals(3-6); however, no underlying developmental mechanism has been identified. We re-examined this question using micro-computed tomography, lineage tracing in three amniote clades, and RNA-sequencing-based transcriptional profiling. Here we show that the developmental origin of external genitalia has shifted through evolution, and in some taxa limbs and genitals share a common primordium. In squamates, the genitalia develop directly from the budding hindlimbs, or the remnants thereof, whereas in mice the genital tubercle originates from the ventral and tail bud mesenchyme. The recruitment of different cell populations for genital outgrowth follows a change in the relative position of the cloaca, the genitalia organizing centre. Ectopic grafting of the cloaca demonstrates the conserved ability of different mesenchymal cells to respond to these genitalia-inducing signals. Our results support a limb-like developmental origin of external genitalia as the ancestral condition. Moreover, they suggest that a change in the relative position of the cloacal signalling centre during evolution has led to an altered developmental route for external genitalia in mammals, while preserving parts of the ancestral limb molecular circuitry owing to a common evolutionary origin.
C1 [Tschopp, Patrick; Aspiras, Ariel C.; Hu, Jimmy K.; Pourquie, Olivier; Tabin, Clifford J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Sherratt, Emma; Sanger, Thomas J.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
[Groner, Anna C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Pourquie, Olivier] IGBMC, F-67400 Illkirch Graffenstaden, France.
[Pourquie, Olivier] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Gros, Jerome] Inst Pasteur, Dev & Stem Cell Biol Dept, F-75724 Paris 15, France.
RP Tabin, CJ (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
EM jgros@pasteur.fr; tabin@genetics.med.harvard.edu
RI Sherratt, Emma/A-9931-2011;
OI Sherratt, Emma/0000-0003-2164-7877; Pourquie,
Olivier/0000-0001-5189-1227; Gros, Jerome/0000-0002-2264-2851
FU National Science Foundation [ECS-0335765]; Swiss National Science
Foundation; EMBO; Human Frontiers Science Program; National Institutes
of Health [R37-HD032443]
FX The authors thank D. Duboule, H. Kaessmann, A. Necsulea, B. Okaty, G.
Rey and G. P. Wagner for discussions, M. A. de Bakker for the snake Tbx5
probe and A. M. Herrera and M. J. Cohn for discussing and sharing
unpublished results. mu CT scans were performed at the Center for
Nanoscale Systems, Harvard University (supported by National Science
Foundation award ECS-0335765) and at the Museum of Comparative Zoology.
Next-generation sequencing was performed at the HMS Biopolymers Facility
and computational analyses were run on the Orchestra Cluster, HMS
Research Computing. P.T. was supported by post-doctoral fellowships from
the Swiss National Science Foundation, EMBO and the Human Frontiers
Science Program. A.C.G. was supported by a post-doctoral fellowship from
the Swiss National Science Foundation. This work was supported by
National Institutes of Health grant R37-HD032443 to C.J.T.
NR 48
TC 25
Z9 25
U1 10
U2 41
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 18
PY 2014
VL 516
IS 7531
BP 391
EP +
DI 10.1038/nature13819
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW8BE
UT WOS:000346484800046
PM 25383527
ER
PT J
AU Pellegrino, MW
Nargund, AM
Kirienko, NV
Gillis, R
Fiorese, CJ
Haynes, CM
AF Pellegrino, Mark W.
Nargund, Amrita M.
Kirienko, Natalia V.
Gillis, Reba
Fiorese, Christopher J.
Haynes, Cole M.
TI Mitochondrial UPR-regulated innate immunity provides resistance to
pathogen infection
SO NATURE
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; CAENORHABDITIS-ELEGANS; C. ELEGANS;
TRANSLATIONAL INHIBITION; LIFE-SPAN; GENES; CELLS; DEGRADATION;
ACTIVATION; PATHWAYS
AB Metazoans identify and eliminate bacterial pathogens in microbe-rich environments such as the intestinal lumen; however, the mechanisms are unclear. Host cells could potentially use intracellular surveillance or stress response programs to detect pathogens that target monitored cellular activities and then initiate innate immune responses(1-3). Mitochondrial function is evaluated by monitoring mitochondrial protein import efficiency of the transcription factor ATFS-1, which mediates the mitochondrial unfolded protein response (UPRmt). During mitochondrial stress, mitochondrial import is impaired(4), allowing ATFS-1 to traffic to the nucleus where it mediates a transcriptional response to re-establish mitochondrial homeostasis(5). Here we examined the role of ATFS-1 in Caenorhabditis elegans during pathogen exposure, because during mitochondrial stress ATFS-1 induced not only mitochondrial protective genes but also innate immune genes that included a secreted lysozyme and anti-microbial peptides. Exposure to the pathogen Pseudomonas aeruginosa caused mitochondrial dysfunction and activation of the UPRmt. C. elegans lacking atfs-1 were susceptible to P. aeruginosa, whereas hyper-activation of ATFS-1 and the UPRmt improved clearance of P. aeruginosa from the intestine and prolonged C. elegans survival in a manner mainly independent of known innate immune pathways(6,7). We propose that ATFS-1 import efficiency and the UPRmt is a means to detect pathogens that target mitochondria and initiate a protective innate immune response.
C1 [Pellegrino, Mark W.; Nargund, Amrita M.; Gillis, Reba; Haynes, Cole M.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10065 USA.
[Kirienko, Natalia V.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Kirienko, Natalia V.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Fiorese, Christopher J.; Haynes, Cole M.] Weill Cornell Med Coll, BCMB Allied Program, New York, NY 10065 USA.
RP Haynes, CM (reprint author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10065 USA.
EM haynesc@mskcc.org
FU Ellison Medical Foundation; Lucille Castori Center for Microbes,
Inflammation and Cancer at MSKCC; National Institutes of Health
[R01AG040061, F32AI100501, R01AI085581]
FX We thank E. Troemel, M. Pilon, S. Mitani of the National Bioresource
Project, and the Caenorhabditis Genetics Center for providing C. elegans
strains. We thank D. Kim and J. Xavier for providing P. aeruginosa
strains, and T. Langer and S. Troeder for mammalian reagents. This work
was supported by the Ellison Medical Foundation, the Lucille Castori
Center for Microbes, Inflammation and Cancer at MSKCC and the National
Institutes of Health (R01AG040061) to C.M.H., (F32AI100501) to N.V.K.
and (R01AI085581) to F. Ausubel.
NR 36
TC 44
Z9 45
U1 5
U2 41
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 18
PY 2014
VL 516
IS 7531
BP 414
EP +
DI 10.1038/nature13818
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW8BE
UT WOS:000346484800051
PM 25274306
ER
PT J
AU Kreuels, B
Wichmann, D
Emmerich, P
Schmidt-Chanasit, J
de Heer, G
Kluge, S
Sow, A
Renne, T
Gunther, S
Lohse, AW
Addo, MM
Schmiedel, S
AF Kreuels, Benno
Wichmann, Dominic
Emmerich, Petra
Schmidt-Chanasit, Jonas
de Heer, Geraldine
Kluge, Stefan
Sow, Abdourahmane
Renne, Thomas
Guenther, Stephan
Lohse, Ansgar W.
Addo, Marylyn M.
Schmiedel, Stefan
TI A Case of Severe Ebola Virus Infection Complicated by Gram-Negative
Septicemia
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
AB Ebola virus disease (EVD) developed in a patient who contracted the disease in Sierra Leone and was airlifted to an isolation facility in Hamburg, Germany, for treatment. During the course of the illness, he had numerous complications, including septicemia, respiratory failure, and encephalopathy. Intensive supportive treatment consisting of high-volume fluid resuscitation (approximately 10 liters per day in the first 72 hours), broad-spectrum antibiotic therapy, and ventilatory support resulted in full recovery without the use of experimental therapies. Discharge was delayed owing to the detection of viral RNA in urine (day 30) and sweat (at the last assessment on day 40) by means of polymerase-chain-reaction (PCR) assay, but the last positive culture was identified in plasma on day 14 and in urine on day 26. This case shows the challenges in the management of EVD and suggests that even severe EVD can be treated effectively with routine intensive care.
C1 [Kreuels, Benno; Lohse, Ansgar W.; Addo, Marylyn M.; Schmiedel, Stefan] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Div Trop Med, D-20246 Hamburg, Germany.
[Wichmann, Dominic; de Heer, Geraldine; Kluge, Stefan] Univ Med Ctr Hamburg Eppendorf, Dept Intens Care Med, D-20246 Hamburg, Germany.
[Renne, Thomas] Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem & Lab Med, D-20246 Hamburg, Germany.
[Schmiedel, Stefan] Univ Med Ctr Hamburg Eppendorf, Infect Dis Unit Outpatient Care, D-20246 Hamburg, Germany.
[Kreuels, Benno; Schmidt-Chanasit, Jonas; Guenther, Stephan; Lohse, Ansgar W.; Addo, Marylyn M.; Schmiedel, Stefan] German Ctr Infect Res, Hamburg, Germany.
[Kreuels, Benno] Bernhard Nocht Inst Trop Med, Res Grp Infect Dis Epidemiol, D-20359 Hamburg, Germany.
[Emmerich, Petra; Schmidt-Chanasit, Jonas; Guenther, Stephan] Bernhard Nocht Inst Trop Med, World Hlth Org Collaborating Ctr Arbovirus & Hemo, D-20359 Hamburg, Germany.
[Sow, Abdourahmane] Inst Pasteur, Arboviruses & Hemorrhag Fever Viruses Unit, Dakar, Senegal.
[Sow, Abdourahmane] Cheikh Anta Diop Univ, Publ Hlth & Dev Inst, Dakar, Senegal.
[Sow, Abdourahmane] Bordeaux Univ, INSERM, U897, Bordeaux Publ Hlth Inst, Bordeaux, France.
[Renne, Thomas] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
[Addo, Marylyn M.] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.
RP Addo, MM (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Martinistr 52, D-20246 Hamburg, Germany.
EM m.addo@uke.de; s.schmiedel@uke.de
NR 8
TC 129
Z9 139
U1 4
U2 48
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 18
PY 2014
VL 371
IS 25
BP 2394
EP 2401
DI 10.1056/NEJMoa1411677
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW7DX
UT WOS:000346425800008
PM 25337633
ER
PT J
AU Rigotti, NA
AF Rigotti, Nancy A.
TI Cytisine - A Tobacco Treatment Hiding in Plain Sight
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID SMOKING-CESSATION; METAANALYSIS; TRIAL
C1 [Rigotti, Nancy A.] Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02114 USA.
[Rigotti, Nancy A.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA.
[Rigotti, Nancy A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rigotti, NA (reprint author), Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02114 USA.
NR 11
TC 2
Z9 2
U1 0
U2 9
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 18
PY 2014
VL 371
IS 25
BP 2429
EP 2430
DI 10.1056/NEJMe1412313
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW7DX
UT WOS:000346425800014
PM 25517710
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Increasing obesity and comorbidity in patients undergoing primary total
hip arthroplasty in the US: A 13-year study of time trends
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Total hip replacement; Time trends; Arthroplasty; Joint replacement;
Diagnosis; Obesity; Comorbidity; Osteoarthritis
ID TOTAL KNEE ARTHROPLASTY; TOTAL JOINT ARTHROPLASTY; MODIFYING
ANTIRHEUMATIC DRUGS; RHEUMATOID-ARTHRITIS; UNITED-STATES; PAIN
MEDICATIONS; DEMOGRAPHICS; REPLACEMENT; POPULATION; MORBIDITY
AB Background: Few, if any data are available are available regarding the time-trends in characteristics of patients who have undergone primary THA. Our objective was to examine the time-trends in key demographic and clinical characteristics of patients undergoing primary total hip arthroplasty (THA).
Methods: We used the data from the Mayo Clinic Total Joint Registry from 1993-2005 to examine the time-trends in demographics (age, body mass index (BMI)), medical (Deyo-Charlson index) and psychological comorbidity (anxiety, depression) and underlying diagnosis of patients undergoing primary THA. Chi-square test and analysis for variance were used. Multivariable-adjusted logistic regression (age, sex, comorbidity-adjusted) compared 1993-95 to other study periods. Odds ratio (OR) and 95% confidence interval (CI) are presented.
Results: The primary THA cohort consisted of 6,168 patients with 52% women. In unadjusted analyses, compared to 1993-95, significantly more patients (by > 2-times for most) in 2002-05 had: BMI >= 40, 2.3% vs. 6.3%; depression, 4.1% vs. 9.8%; and anxiety, 3.4% vs. 5.7%; and significantly fewer had an underlying diagnosis of rheumatoid/inflammatory arthritis, 3.7% vs. 1.5% (p <= 0.01 for all). In multivariable-adjusted models, compared to 1993-95, significantly more patients in 2003-05 had (all p-values <= 0.01): BMI >= 40, OR, 2.79 (95% CI: 1.85, 4.22); Deyo-Charlson Index >= 3, 1.32 (1.07, 1.63); depression, 2.25 (1.66, 3.05); and anxiety, 1.71 (1.19, 2.15). Respectively, fewer patients had a diagnosis of RA/inflammatory arthritis: 0.28 (0.17, 0.46; p < 0.01). Over the 13-year study period, Deyo-Charlson index increased by 22% (0.9 to 1.1) and the mean age decreased by 0.7 years (65.0 to 64.3) (p < 0.01 for both).
Conclusions: Obesity, medical and psychological comorbidity increased and the underlying diagnosis of RA/inflammatory arthritis decreased rapidly in primary THA patients over 13-years. Our cohort characteristics are similar to previously described characteristics of national U. S. cohort, suggesting that these trends may be national rather than local trends. This is important information for policy makers to take into account for resource allocation. Studies of THA outcomes and utilization should take these rapidly changing patient characteristics into account.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.
EM Jasvinder.md@gmail.com
FU Mayo Clinic Orthopedic Surgery research funds; Birmingham VA Medical
Center, Alabama, USA; Agency for Health Quality and Research Center for
Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110];
National Institute of Arthritis, Musculoskeletal and Skin Diseases
(NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA)
[U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient
Centered Outcomes Research Institute (PCORI) [CE-1304-6631]
FX This material is the result of work supported Mayo Clinic Orthopedic
Surgery research funds and the resources and use of facilities at the
Birmingham VA Medical Center, Alabama, USA. J.A.S. is also supported by
grants from the Agency for Health Quality and Research Center for
Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110,
National Institute of Arthritis, Musculoskeletal and Skin Diseases
(NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA)
U01 AG018947, and National Cancer Institute (NCI) U10 CA149950, and
research contract CE-1304-6631 from the Patient Centered Outcomes
Research Institute (PCORI).
NR 46
TC 6
Z9 6
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD DEC 17
PY 2014
VL 15
AR 441
DI 10.1186/1471-2474-15-441
PG 9
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA AZ8JI
UT WOS:000348461200001
PM 25519434
ER
PT J
AU Jin, ZC
Wu, C
Zhou, XH
He, J
AF Jin, Zhi-Chao
Wu, Cheng
Zhou, Xiao-Hua
He, Jia
TI A modified regression method to test publication bias in meta-analyses
with binary outcomes
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE Meta-analysis; Observational studies; Publication bias; Smoothed
variance; Weighted regression
ID STATISTICAL TESTS; CLINICAL-RESEARCH; CONTROLLED-TRIALS
AB Background: The tendency towards publication bias is greater for observational studies than for randomized clinical trials. Several statistical methods have been developed to test the publication bias. However, almost all existing methods exhibit rather low power or have inappropriate type I error rates.
Methods: We propose a modified regression method, which used a smoothed variance to estimate the precision of a study, to test for publication bias in meta-analyses of observational studies. A comprehensive simulation study is carried out, and a real-world example is considered.
Results: The simulation results indicate that the performance of tests varies with the number of included studies, level of heterogeneity, event rates, and sample size ratio between two groups. Neither the existing tests nor the newly developed method is particularly powerful in all simulation scenarios. However, our proposed method has a more robust performance across different settings. In the presence of heterogeneity, the arcsine-Thompson test is a suitable alternative, and Peters' test can be considered as a complementary method when mild or no heterogeneity is present.
Conclusions: Several factors should be taken into consideration when employing asymmetry tests for publication bias. Based on our simulation results, we provide a concise table to show the appropriate use of regression methods to test for publication bias based on our simulation results.
C1 [Jin, Zhi-Chao; Wu, Cheng; He, Jia] Second Mil Med Univ, Dept Hlth Stat, Shanghai 200433, Peoples R China.
[Zhou, Xiao-Hua] Vet Affairs Puget Sound Hlth Care Syst, Biostat Unit, HSR&D Ctr Excellence, Seattle, WA 98101 USA.
[Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
RP Zhou, XH (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Biostat Unit, HSR&D Ctr Excellence, Seattle, WA 98101 USA.
EM azhou@u.washington.edu; hejia63@yahoo.com
FU Department of Veterans Affairs, Veterans Health Administration, Health
Service Research and Development [RCS 05-196]; National Natural Science
Foundation, China [81001287]; key discipline construction of
evidence-based public health in Shanghai [12GWZX0602]; Ministry of
Science and Technology of China [2009ZX09312-025, 2008ZX09312-007,
2008ZX10002-018]; China Scholarship Council
FX This work was supported by Department of Veterans Affairs, Veterans
Health Administration, Health Service Research and Development [Research
Career Scientist Award RCS 05-196]; National Natural Science Foundation
[grant number 81001287], China; the key discipline construction of
evidence-based public health in Shanghai [grant number 12GWZX0602]; The
Ministry of Science and Technology of China [grant number
2009ZX09312-025, 2008ZX09312-007, 2008ZX10002-018]. We thank China
Scholarship Council for sponsoring the first author's visiting in
University of Washington.
NR 33
TC 2
Z9 2
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD DEC 17
PY 2014
VL 14
AR 132
DI 10.1186/1471-2288-14-132
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AZ1IM
UT WOS:000347993100001
PM 25516509
ER
PT J
AU Takahashi, Y
Maki, T
Liang, AC
Itoh, K
Lok, J
Osumi, N
Arai, K
AF Takahashi, Yoko
Maki, Takakuni
Liang, Anna C.
Itoh, Kanako
Lok, Josephine
Osumi, Nariko
Arai, Ken
TI p38 MAP kinase mediates transforming-growth factor-beta 1-induced
upregulation of matrix metalloproteinase-9 but not-2 in human brain
pericytes
SO BRAIN RESEARCH
LA English
DT Article
DE Pericyte; MMP-9; p38 MAP kinase; Neurovascular unit
ID GROWTH-FACTOR-BETA-1 INDUCES MATRIX-METALLOPROTEINASE-9; NERVOUS-SYSTEM
DEVELOPMENT; SMOOTH-MUSCLE-CELLS; KAPPA-B PATHWAYS; TGF-BETA; MATRIX
METALLOPROTEINASES; NEUROVASCULAR UNIT; ISCHEMIC-STROKE; IN-VITRO;
EXPRESSION
AB Pericytes are vascular mural cells embedded within the basal lamina of blood microvessels. Within the neurovascular unit, pericytes play important roles in regulating neurovascular homeostasis by secreting soluble factors, such as matrix metalloproteinases (MMPs). However, little is known about the regulatory signaling pathways in brain pericytes. Here we show that transforming growth factor-beta 1 (TGF-beta 1) induces MMP-9 upregulation in pericytes via p38 mitogen-activated protein (MAP) kinase signaling. Cultured human brain vascular pericytes were used in this study. When the brain pericytes were treated with purified human TGF-beta 1 (0.1-10 ng/mL for 24 h), the levels of MMP-2 and MMP-9 in culture media were significantly increased in a concentration dependent manner as measured by gelatin zymography. WST assay confirmed that TGF-beta 1 did not affect cell survival of the brain pericytes. A TGF-beta-receptor inhibitor SB431542 (0.5-5 mu M) decreased the TGF-beta 1-induced upregulation of MMP-2 and MMP-9. To assess the underlying intracellular mechanisms, we focused on p38 MAP kinase signaling, which is one of the major downstream kinases for TGF-beta 1. A well-validated p38 MAP kinase inhibitor SB203580 (0.5-5 mu M) cancelled the effect of TGF-beta 1 in upregulation of MMP-9 but not MMP-2. Western blotting confirmed that TGF-beta 1 treatment increased the level of p38 MAP kinase phosphorylation in pericytes, and again, the TGF-beta-receptor inhibitor SB431542 (0.5-5 mu M) blocked the TGF-beta 1-induced phosphorylation of p38 MAP kinase. Both TGF-beta 1 and MMP-9 are major neurovascular mediators, and therefore, our current finding may suggest a novel mechanism for how pericytes regulate neurovascular homeostasis. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Takahashi, Yoko; Osumi, Nariko] Tohoku Univ, Sch Med, United Ctr Adv Res & Translat Med, Dept Dev Neurosci, Sendai, Miyagi 980, Japan.
[Takahashi, Yoko; Maki, Takakuni; Liang, Anna C.; Itoh, Kanako; Lok, Josephine; Arai, Ken] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA 02129 USA.
[Takahashi, Yoko; Maki, Takakuni; Liang, Anna C.; Itoh, Kanako; Lok, Josephine; Arai, Ken] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.
[Takahashi, Yoko; Maki, Takakuni; Liang, Anna C.; Itoh, Kanako; Lok, Josephine; Arai, Ken] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Arai, K (reprint author), Neuroprotect Res Lab, MGH East 149-2401, Charlestown, MA 02129 USA.
EM karai@partners.org
FU National Institutes of Health [R01 NS065089, P01 NS055104]; Research
Abroad from the Uehara Memorial Foundation
FX Supported in part by National Institutes of Health (Grant nos. R01
NS065089, P01 NS055104) and Research Abroad from the Uehara Memorial
Foundation.
NR 45
TC 8
Z9 8
U1 2
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD DEC 17
PY 2014
VL 1593
BP 1
EP 8
DI 10.1016/j.brainres.2014.10.029
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA AX5FJ
UT WOS:000346951900001
PM 25451097
ER
PT J
AU Yip, S
McCall, K
Aristophanous, M
Chen, AB
Aerts, HJWL
Berbeco, R
AF Yip, Stephen
McCall, Keisha
Aristophanous, Michalis
Chen, Aileen B.
Aerts, Hugo J. W. L.
Berbeco, Ross
TI Comparison of Texture Features Derived from Static and Respiratory-Gated
PET Images in Non-Small Cell Lung Cancer
SO PLOS ONE
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; DUAL TIME-POINT; STANDARDIZED UPTAKE
VALUES; F-18-FDG PET; FDG-PET; UPTAKE HETEROGENEITY; PULMONARY NODULES;
PROGNOSTIC VALUE; CT; CHEMORADIOTHERAPY
AB Background: PET-based texture features have been used to quantify tumor heterogeneity due to their predictive power in treatment outcome. We investigated the sensitivity of texture features to tumor motion by comparing static (3D) and respiratory-gated (4D) PET imaging.
Methods: Twenty-six patients (34 lesions) received 3D and 4D [F-18] FDG-PET scans before the chemo-radiotherapy. The acquired 4D data were retrospectively binned into five breathing phases to create the 4D image sequence. Texture features, including Maximal correlation coefficient (MCC), Long run low gray (LRLG), Coarseness, Contrast, and Busyness, were computed within the physician-defined tumor volume. The relative difference (delta(3D-4D)) in each texture between the 3D-and 4D-PET imaging was calculated. Coefficient of variation (CV) was used to determine the variability in the textures between all 4D-PET phases. Correlations between tumor volume, motion amplitude, and delta(3D-4D) were also assessed.
Results: 4D-PET increased LRLG (=1%-2%, p<0.02), Busyness (=7%-19%, p<0.01), and decreased MCC (=1%-2%, p<7.5x10(-3)), Coarseness (=5%-10%, p<0.05) and Contrast (=4%-6%, p>0.08) compared to 3D-PET. Nearly negligible variability was found between the 4D phase bins with CV<5% for MCC, LRLG, and Coarseness. For Contrast and Busyness, moderate variability was found with CV=9% and 10%, respectively. No strong correlation was found between the tumor volume and delta(3D-4D) for the texture features. Motion amplitude had moderate impact on delta for MCC and Busyness and no impact for LRLG, Coarseness, and Contrast.
Conclusions: Significant differences were found in MCC, LRLG, Coarseness, and Busyness between 3D and 4D PET imaging. The variability between phase bins for MCC, LRLG, and Coarseness was negligible, suggesting that similar quantification can be obtained from all phases. Texture features, blurred out by respiratory motion during 3D-PET acquisition, can be better resolved by 4D-PET imaging. 4D-PET textures may have better prognostic value as they are less susceptible to tumor motion.
C1 [Yip, Stephen; Chen, Aileen B.; Aerts, Hugo J. W. L.; Berbeco, Ross] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yip, Stephen; McCall, Keisha; Chen, Aileen B.; Aerts, Hugo J. W. L.; Berbeco, Ross] Harvard Univ, Sch Med, Boston, MA USA.
[McCall, Keisha] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.
[Aristophanous, Michalis] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Div Radiat Oncol, Houston, TX 77030 USA.
[Aerts, Hugo J. W. L.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
RP Yip, S (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM syip@lroc.harvard.edu
RI Aerts, Hugo/P-6350-2015
OI Aerts, Hugo/0000-0002-2122-2003
NR 51
TC 18
Z9 18
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 17
PY 2014
VL 9
IS 12
AR e115510
DI 10.1371/journal.pone.0115510
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX9IA
UT WOS:000347215600070
PM 25517987
ER
PT J
AU Schwab, JH
Lozano-Calderon, SA
Mankin, HJ
Raskin, KA
Hornicek, FJ
AF Schwab, Joseph H.
Lozano-Calderon, Santiago A.
Mankin, Henry J.
Raskin, Kevin A.
Hornicek, Francis J.
TI What's New in Primary Bone Tumors
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Review
ID SOFT-TISSUE SARCOMAS; CHONDROSARCOMA CELLS; AFFECT SURVIVAL; EWING
SARCOMA; GLUCOSE-METABOLISM; PROGNOSTIC-FACTORS; EXPRESSION;
OSTEOSARCOMA; MANAGEMENT; INHIBITION
C1 [Schwab, Joseph H.; Lozano-Calderon, Santiago A.; Mankin, Henry J.; Raskin, Kevin A.; Hornicek, Francis J.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Schwab, JH (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St, Boston, MA 02114 USA.
EM JHSCHWAB@mgh.harvard.edu
NR 63
TC 2
Z9 2
U1 0
U2 9
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0021-9355
EI 1535-1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD DEC 17
PY 2014
VL 96A
IS 24
BP 2099
EP 2104
DI 10.2106/JBJS.N.01014
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA AW7WI
UT WOS:000346471900015
PM 25520345
ER
PT J
AU Hu, WF
Pomp, O
Ben-Omran, T
Kodani, A
Henke, K
Mochida, GH
Yu, TW
Woodworth, MB
Bonnard, C
Raj, GS
Tan, TT
Hamamy, H
Masri, A
Shboul, M
Al Saffar, M
Partlow, JN
Al-Dosari, M
Alazami, A
Alowain, M
Alkuraya, FS
Reiter, JF
Harris, MP
Reversade, B
Walsh, CA
AF Hu, Wen F.
Pomp, Oz
Ben-Omran, Tawfeg
Kodani, Andrew
Henke, Katrin
Mochida, Ganeshwaran H.
Yu, Timothy W.
Woodworth, Mollie B.
Bonnard, Carine
Raj, Grace Selva
Tan, Thong Teck
Hamamy, Hanan
Masri, Amira
Shboul, Mohammad
Al Saffar, Muna
Partlow, Jennifer N.
Al-Dosari, Mohammed
Alazami, Anas
Alowain, Mohammed
Alkuraya, Fowzan S.
Reiter, Jeremy F.
Harris, Matthew P.
Reversade, Bruno
Walsh, Christopher A.
TI Katanin p80 Regulates Human Cortical Development by Limiting Centriole
and Cilia Number
SO NEURON
LA English
DT Article
ID MICROTUBULE-SEVERING PROTEIN; DE-NOVO FORMATION; SONIC HEDGEHOG;
CENTROSOME DUPLICATION; NEURAL PROGENITORS; NERVOUS-SYSTEM; SPINDLE
LENGTH; CELL-DIVISION; MUTATIONS; CDK5RAP2
AB Katanin is a microtubule-severing complex whose catalytic activities are well characterized, but whose in vivo functions are incompletely understood. Human mutations in KATNB1, which encodes the noncatalytic regulatory p80 subunit of katanin, cause severe microlissencephaly. Loss of Katnb1 in mice confirms essential roles in neurogenesis and cell survival, while loss of zebrafish katnb1 reveals specific roles for katnin p80 in early and late developmental stages. Surprisingly, Katnb1 null mutant mouse embryos display hallmarks of aberrant Sonic hedgehog signaling, including holoprosencephaly. KATNB1-deficient human cells show defective proliferation and spindle structure, while Katnb1 null fibroblasts also demonstrate a remarkable excess of centrioles, with supernumerary cilia but deficient Hedgehog signaling. Our results reveal unexpected functions for KATNB1 in regulating overall centriole, mother centriole, and cilia number, and as an essential gene for normal Hedgehog signaling during neocortical development.
C1 [Hu, Wen F.; Mochida, Ganeshwaran H.; Yu, Timothy W.; Woodworth, Mollie B.; Al Saffar, Muna; Partlow, Jennifer N.; Walsh, Christopher A.] Boston Childrens Hosp, Dept Med, Div Genet & Genom, Boston, MA 02115 USA.
[Hu, Wen F.; Mochida, Ganeshwaran H.; Woodworth, Mollie B.; Al Saffar, Muna; Partlow, Jennifer N.; Walsh, Christopher A.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.
[Hu, Wen F.; Woodworth, Mollie B.; Partlow, Jennifer N.; Walsh, Christopher A.] Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Henke, Katrin; Harris, Matthew P.] Boston Childrens Hosp, Dept Orthoped Res, Boston, MA 02115 USA.
[Hu, Wen F.; Walsh, Christopher A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
[Hu, Wen F.; Walsh, Christopher A.] Harvard Univ, Sch Med, Harvard MD PhD MSTP Program, Boston, MA 02115 USA.
[Mochida, Ganeshwaran H.; Yu, Timothy W.; Woodworth, Mollie B.; Walsh, Christopher A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Walsh, Christopher A.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Henke, Katrin; Harris, Matthew P.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Mochida, Ganeshwaran H.] Massachusetts Gen Hosp, Dept Neurol, Pediat Neurol Unit, Boston, MA 02114 USA.
[Yu, Timothy W.] Broad Inst MIT & Harvard Univ, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Ben-Omran, Tawfeg] Hamad Med Corp, Dept Pediat, Clin & Metab Genet Div, Doha 3050, Qatar.
[Al Saffar, Muna] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Pediat, Al Ain, U Arab Emirates.
[Alazami, Anas; Alkuraya, Fowzan S.] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh 11211, Saudi Arabia.
[Alowain, Mohammed] King Faisal Specialist Hosp & Res Ctr, Dept Med Genet, Riyadh 11211, Saudi Arabia.
[Alowain, Mohammed; Alkuraya, Fowzan S.] Alfaisal Univ, Coll Med, Dept Anat & Cell Biol, Riyadh 11533, Saudi Arabia.
[Al-Dosari, Mohammed] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh 11451, Saudi Arabia.
[Kodani, Andrew; Reiter, Jeremy F.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Biochem & Biophys, San Francisco, CA 94158 USA.
[Pomp, Oz; Bonnard, Carine; Raj, Grace Selva; Tan, Thong Teck; Shboul, Mohammad; Reversade, Bruno] ASTAR, Human Genet & Embryol Lab, Med Biol Inst, Singapore 138648, Singapore.
[Reversade, Bruno] ASTAR, Inst Mol & Cellular Biol, Singapore 138648, Singapore.
[Hamamy, Hanan] Univ Geneva, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland.
[Reversade, Bruno] Natl Univ Singapore, Dept Paediat, Singapore 119260, Singapore.
[Masri, Amira] Univ Jordan, Fac Med, Dept Paediat, Amman 11942, Jordan.
RP Harris, MP (reprint author), Boston Childrens Hosp, Dept Orthoped Res, Boston, MA 02115 USA.
EM harris@genetics.med.harvard.edu; bruno@reversade.com;
christopher.walsh@childrens.harvard.edu
RI ASTAR, IMCB/E-2320-2012;
OI Woodworth, Mollie/0000-0003-2130-2289; Yu, Timothy/0000-0003-2988-7701
FU NIH NINDS [F31NS083111, R01NS035129]; NIH NIGMS [T32GM007753,
R01GM095941]; NIH NHLBI [T32HL007731]; Manton Center for Orphan Disease
Research; F. Hoffman-La Roche Ltd.; Clinical Investigator Training
Program at Harvard-MIT Health Sciences and Technology; BIDMC; Pfizer,
Inc.; Merck Company, Inc; Nancy Lurie Marks Junior Faculty MeRIT
Fellowship; Leonard and Isabelle Goldenson Research Fellowship; KACST
[09-MED941-20]; NIH NIAMS [R01AR054396]; Burroughs Wellcome Fund;
Packard Foundation; Sandler Family Supporting Foundation; Strategic
Positioning Fund for Genetic Orphan Diseases; A*STAR Investigatorship
from the Agency for Science, Technology and Research in Singapore;
A*STAR; EMBO; NIH NIDCR [1U01DE024434-01]; BCH Orthopedic Surgical
Foundation; NIH NIMH [RC2MH089952]; Qatar National Research Fund
National Priorities Research Program
FX We thank the individuals and their families for their participation. We
thank Boston Children's Hospital (BCH) Transgenic Core Laboratory,
Dana-Farber/Harvard Cancer Center Rodent Histopathology Core,
Dana-Farber Cancer Institute Neoplasia Flow Cytometry Core, Beth Israel
Deaconess Medical Center (BIDMC) Histology Core Laboratory, Harvard
Medical School Electron Microscopy Facility, and Genome Institute of
Singapore for use of facilities. We thank Tamara Caspary, Erich Nigg,
Suzie Scales, and James Sillibourne for kind gifts of reagents. This
research was supported by NIH NINDS F31NS083111 and NIGMS T32GM007753
(W.F.H.); NIH NHLBI T32HL007731 (A.K.); Manton Center for Orphan Disease
Research and F. Hoffman-La Roche Ltd. (G.H.M.); Clinical Investigator
Training Program at Harvard-MIT Health Sciences and Technology and BIDMC
in collaboration with Pfizer, Inc. and Merck & Company, Inc, and the
Nancy Lurie Marks Junior Faculty MeRIT Fellowship (T.W.Y.); Leonard and
Isabelle Goldenson Research Fellowship (M.B.W.); KACST grant
09-MED941-20 (F.S.A.); NIH NIAMS R01AR054396, NIGMS R01GM095941,
Burroughs Wellcome Fund, Packard Foundation, and Sandler Family
Supporting Foundation (J.F.R.); Strategic Positioning Fund for Genetic
Orphan Diseases, A*STAR Investigatorship from the Agency for Science,
Technology and Research in Singapore, Branco Weiss Foundation fellow,
and A*STAR and EMBO Young Investigator (B.R.); NIH NIDCR 1U01DE024434-01
and BCH Orthopedic Surgical Foundation (K.H. and M.P.H.); and NIH NINDS
R01NS035129 and NIMH RC2MH089952, the Qatar National Research Fund
National Priorities Research Program, and the Manton Center for Orphan
Disease Research (C.A.W.). C.A.W. is an Investigator of the Howard
Hughes Medical Institute.
NR 78
TC 15
Z9 17
U1 2
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD DEC 17
PY 2014
VL 84
IS 6
BP 1240
EP 1257
DI 10.1016/j.neuron.2014.12.017
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA AW9JY
UT WOS:000346574500016
PM 25521379
ER
PT J
AU Abramson, JS
Chung, RT
AF Abramson, Jeremy S.
Chung, Raymond T.
TI Optimal Antiviral Prophylaxis Against Hepatitis B Reactivation in
Patients Receiving Rituximab-Based Chemotherapy for Lymphoma
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID VIRUS HBV REACTIVATION; CELL LYMPHOMA; CYTOTOXIC CHEMOTHERAPY;
CANCER-PATIENTS; LAMIVUDINE; ENTECAVIR; THERAPY; RISK; METAANALYSIS;
INFECTION
C1 [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA.
[Abramson, Jeremy S.; Chung, Raymond T.] Harvard Univ, Sch Med, Boston, MA USA.
[Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Ctr Liver, Div Gastroenterol, Boston, MA 02114 USA.
RP Abramson, JS (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, 55 Fruit St, Boston, MA 02114 USA.
EM jabramson@mgh.harvard.edu
NR 22
TC 2
Z9 2
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 17
PY 2014
VL 312
IS 23
BP 2505
EP 2507
DI 10.1001/jama.2014.16095
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW5YN
UT WOS:000346346900012
PM 25514300
ER
PT J
AU Bekelman, JE
Sylwestrzak, G
Barron, J
Liu, JA
Epstein, AJ
Freedman, G
Malin, J
Emanuel, EJ
AF Bekelman, Justin E.
Sylwestrzak, Gosia
Barron, John
Liu, Jinan
Epstein, Andrew J.
Freedman, Gary
Malin, Jennifer
Emanuel, Ezekiel J.
TI Uptake and Costs of Hypofractionated vs Conventional Whole Breast
Irradiation After Breast Conserving Surgery in the United States,
2008-2013
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RANDOMIZED-TRIAL; RADIOTHERAPY HYPOFRACTIONATION; UK STANDARDIZATION;
RADIATION-THERAPY; CANCER; FRACTIONATION; WOMEN; MASTECTOMY
AB IMPORTANCE Based on randomized evidence, expert guidelines in 2011 endorsed shorter, hypofractionated whole breast irradiation (WBI) for selected patients with early-stage breast cancer and permitted hypofractionated WBI for other patients.
OBJECTIVES To examine the uptake and costs of hypofractionated WBI among commercially insured patients in the United States.
DESIGN, SETTING, AND PARTICIPANTS Retrospective, observational cohort study, using administrative claims data from 14 commercial health care plans covering 7.4% of US adult women in 2013, we classified patients with incident early-stage breast cancer treated with lumpectomy and WBI from 2008 and 2013 into 2 cohorts: (1) the hypofractionation-endorsed cohort (n = 8924) included patients aged 50 years or older without prior chemotherapy or axillary lymph node involvement and (2) the hypofractionation-permitted cohort (n = 6719) included patients younger than 50 years or those with prior chemotherapy or axillary lymph node involvement.
EXPOSURES Hypofractionated WBI (3-5 weeks of treatment) vs conventional WBI (5-7 weeks of treatment).
MAIN OUTCOMES AND MEASURES Use of hypofractionated and conventional WBI, total and radiotherapy-related health care expenditures, and patient out-of-pocket expenses. Patient and clinical characteristics included year of treatment, age, comorbid disease, prior chemotherapy, axillary lymph node involvement, intensity-modulated radiotherapy, practice setting, and other contextual variables.
RESULTS Hypofractionated WBI increased from 10.6% (95% Cl, 8.8%-12.5%) in 2008 to 34.5% (95% Cl, 32.2%-36.8%) in 2013 in the hypofractionation-endorsed cohort and from 8.1% (95% Cl, 6.0%-10.2%) in 2008 to 21.2% (95% Cl, 18.9%-23.6%) in 2013 in the hypofractionation-permitted cohort. Adjusted mean total health care expenditures in the 1 year after diagnosis were $28 747 for hypofractionated and $31 641 for conventional WBI in the hypofractionation-endorsed cohort (difference, $2894; 95% Cl, $1610-$4234; P < .001) and $64 273 for hypofractionated and $72 860 for conventional WBI in the hypofractionation-permitted cohort (difference, $8587; 95% Cl, $5316-$12 017; P < .001). Adjusted mean total 1-year patient out-of-pocket expenses were not significantly different between hypofractionated vs conventional WBlin either cohort.
CONCLUSIONS AND RELEVANCE Hypofractionated WBI after breast conserving surgery increased among women with early-stage breast cancer in 14 US commercial health care plans between 2008 and 2013. However, only 34.5% of patients with hypofractionation-endorsed and 21.2% with hypofractionation-permitted early-stage breast cancer received hypofractionated WBI in 2013.
C1 [Bekelman, Justin E.; Freedman, Gary] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Bekelman, Justin E.; Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
[Bekelman, Justin E.; Epstein, Andrew J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Sylwestrzak, Gosia; Barron, John; Liu, Jinan] HealthCore, Wilmington, DE USA.
[Epstein, Andrew J.] Univ Penn, Div Gen Internal Med, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Malin, Jennifer] WellPoint Inc, Indianapolis, IN USA.
RP Bekelman, JE (reprint author), Univ Penn, Perelman Ctr Adv Med, Dept Radiat Oncol, Perelman Sch Med, 3400 Civ Ctr Blvd,4 West, Philadelphia, PA 19104 USA.
EM bekelman@uphs.upenn.edu
FU National Cancer Institute [K07-CA163616]; WellPoint
FX Dr Bekelman received support from grant K07-CA163616 from the National
Cancer Institute. WellPoint provided funds to support research at
HealthCore, a wholly-owned WellPoint subsidiary.
NR 27
TC 39
Z9 39
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 17
PY 2014
VL 312
IS 23
BP 2542
EP 2550
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW5YN
UT WOS:000346346900017
PM 25494006
ER
PT J
AU Chen, ZX
Yang, W
Liu, QZ
Yang, JY
Li, J
Yang, MQ
AF Chen, Zhongxue
Yang, William
Liu, Qingzhong
Yang, Jack Y.
Li, Jing
Yang, Mary Qu
TI A new statistical approach to combining p-values using gamma
distribution and its application to genome-wide association study
SO BMC BIOINFORMATICS
LA English
DT Article
ID DIFFERENTIALLY METHYLATED LOCI; WEIGHTED Z-TEST; INDEPENDENT TESTS;
MULTIPLE DISEASES; PROBABILITIES; COMBINATION
AB Background: Combining information from different studies is an important and useful practice in bioinformatics, including genome-wide association study, rare variant data analysis and other set-based analyses. Many statistical methods have been proposed to combine p-values from independent studies. However, it is known that there is no uniformly most powerful test under all conditions; therefore, finding a powerful test in specific situation is important and desirable.
Results: In this paper, we propose a new statistical approach to combining p-values based on gamma distribution, which uses the inverse of the p-value as the shape parameter in the gamma distribution.
Conclusions: Simulation study and real data application demonstrate that the proposed method has good performance under some situations.
C1 [Chen, Zhongxue; Li, Jing] Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN 47405 USA.
[Yang, William] Univ Arkansas, Dept Comp Sci, George W Donaghey Coll Engn & Informat Technol, Little Rock, AR 72204 USA.
[Liu, Qingzhong] Sam Houston State Univ, Dept Comp Sci, Huntsville, TX 77341 USA.
[Yang, Jack Y.] Indiana Univ Sch Med, Ctr Compuat Biol & Bioinformat, Indianapolis, IN 46202 USA.
[Yang, Jack Y.] Massachusetts Gen Hosp, Div Biostat & Biomath, Boston, MA 02114 USA.
[Yang, Jack Y.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Yang, Mary Qu] Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, Dept Informat Sci, MidSouth Bioinformat Ctr, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas, Joint Bioinformat Grad Program, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas Med Sci, Little Rock, AR 72204 USA.
RP Chen, ZX (reprint author), Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 1025 E 7th St,PH C104, Bloomington, IN 47405 USA.
EM zc3@indiana.edu
FU Indiana University Institutional Research Awards; National Institutes of
Health (NIH); Indiana University Bloomington School of Public Health;
NIH/NIGMS [5P20GM10342913]; ASTA [15-B-23]
FX The research was supported by Indiana University Institutional Research
Awards and National Institutes of Health (NIH). ZC would like to thank
the institutional faculty research grant awards from the Indiana
University Bloomington School of Public Health. MQY would like to thank
the support from NIH/NIGMS 5P20GM10342913 and ASTA Award # 15-B-23.
NR 29
TC 3
Z9 3
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 16
PY 2014
VL 15
SU 17
AR S3
DI 10.1186/1471-2105-15-S17-S3
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA CH4AS
UT WOS:000353973500004
PM 25559433
ER
PT J
AU Liu, C
Lu, LL
Kong, Q
Li, Y
Wu, HH
Yang, W
Xu, SD
Yang, XY
Song, XL
Yang, JY
Yang, MQ
Deng, YP
AF Liu, Chang
Lu, Lili
Kong, Quan
Li, Yan
Wu, Haihua
Yang, William
Xu, Shandan
Yang, Xinyu
Song, Xiaolei
Yang, Jack Y.
Yang, Mary Qu
Deng, Youping
TI Developing discriminate model and comparative analysis of differentially
expressed genes and pathways for bloodstream samples of diabetes
mellitus type 2
SO BMC BIOINFORMATICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; IMPAIRED FASTING GLUCOSE; PREVALENCE; PROFILES;
ETIOLOGY; INSIGHTS; RISK
AB Background: Diabetes mellitus of type 2 (T2D), also known as noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes, is a common disease. It is estimated that more than 300 million people worldwide suffer from T2D. In this study, we investigated the T2D, pre-diabetic and healthy human (no diabetes) bloodstream samples using genomic, genealogical, and phonemic information. We identified differentially expressed genes and pathways. The study has provided deeper insights into the development of T2D, and provided useful information for further effective prevention and treatment of the disease.
Results: A total of 142 bloodstream samples were collected, including 47 healthy humans, 22 pre-diabetic and 73 T2D patients. Whole genome scale gene expression profiles were obtained using the Agilent Oligo chips that contain over 20,000 human genes. We identified 79 significantly differentially expressed genes that have fold change >= 2. We mapped those genes and pinpointed locations of those genes on human chromosomes. Amongst them, 3 genes were not mapped well on the human genome, but the rest of 76 differentially expressed genes were well mapped on the human genome. We found that most abundant differentially expressed genes are on chromosome one, which contains 9 of those genes, followed by chromosome two that contains 7 of the 76 differentially expressed genes. We performed gene ontology (GO) functional analysis of those 79 differentially expressed genes and found that genes involve in the regulation of cell proliferation were among most common pathways related to T2D. The expression of the 79 genes was combined with clinical information that includes age, sex, and race to construct an optimal discriminant model. The overall performance of the model reached 95.1% accuracy, with 91.5% accuracy on identifying healthy humans, 100% accuracy on pre-diabetic patients and 95.9% accuract on T2D patients. The higher performance on identifying pre-diabetic patients was resulted from more significant changes of gene expressions among this particular group of humans, which implicated that patients were having profound genetic changes towards disease development.
Conclusion: Differentially expressed genes were distributed across chromosomes, and are more abundant on chromosomes 1 and 2 than the rest of the human genome. We found that regulation of cell proliferation actually plays an important role in the T2D disease development. The predictive model developed in this study has utilized the 79 significant genes in combination with age, sex, and racial information to distinguish pre-diabetic, T2D, and healthy humans. The study not only has provided deeper understanding of the disease molecular mechanisms but also useful information for pathway analysis and effective drug target identification.
C1 [Liu, Chang; Lu, Lili; Kong, Quan; Xu, Shandan; Song, Xiaolei; Deng, Youping] Wuhan Univ Sci & Technol, Wuhan, Peoples R China.
[Li, Yan; Deng, Youping] Rush Univ, Ctr Canc, Chicago, IL 60612 USA.
[Li, Yan; Deng, Youping] Rush Univ, Dept Internal Med, Med Ctr, Chicago, IL 60612 USA.
[Li, Yan; Deng, Youping] Rush Univ, Dept Biochem, Med Ctr, Chicago, IL 60612 USA.
[Wu, Haihua] Guangxi Armed Police Gen Hosp, Nanning, Guangxi Autonom, Peoples R China.
[Yang, William] Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, Dept Comp Sci, Little Rock, AR 72204 USA.
[Yang, Xinyu] Natl 48610 Hosp Armed Police Force, Panjin, Liaoning, Peoples R China.
[Yang, Jack Y.] Massachusetts Gen Hosp, Div Biostat & Biomath, Boston, MA 02114 USA.
[Yang, Jack Y.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Yang, Jack Y.] Indiana Univ Purdue Univ, Indiana Univ, Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
[Yang, Mary Qu] Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, Dept Informat Sci, MidSouth Bioinformat Ctr, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas, Joint Bioinformat Grad Program, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
RP Lu, LL (reprint author), Wuhan Univ Sci & Technol, Wuhan, Peoples R China.
EM lulili@wust.edu.cn; youping_deng@rush.edu
FU Natural Science Foundation Hubei Province of China [2011CDB236,
2012FFB04903]; Open Research Fund Program of the State Key Laboratory of
Virology of China [2012002]; United States National Institutes of Health
(NIH); NIH [5P20GM10342913, R21CA164764]; ASTA [15-B-23]
FX The research and publication of the research were supported by the
Natural Science Foundation Hubei Province of China (2011CDB236 and
2012FFB04903), Open Research Fund Program of the State Key Laboratory of
Virology of China (2012002) and United States National Institutes of
Health (NIH). MQY was supported by NIH 5P20GM10342913 and ASTA Award
#15-B-23, and YD was supported by NIH R21CA164764.
NR 22
TC 1
Z9 1
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 16
PY 2014
VL 15
SU 17
AR S5
DI 10.1186/1471-2105-15-S17-S5
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA CH4AS
UT WOS:000353973500006
PM 25559614
ER
PT J
AU Yang, JY
Dunker, AK
Liu, JS
Qin, X
Arabnia, HR
Yang, W
Niemierko, A
Chen, ZX
Luo, ZJ
Wang, LJ
Liu, YL
Xu, D
Deng, YP
Tong, WD
Yang, MQ
AF Yang, Jack Y.
Dunker, A. Keith
Liu, Jun S.
Qin, Xiang
Arabnia, Hamid R.
Yang, William
Niemierko, Andrzej
Chen, Zhongxue
Luo, Zuojie
Wang, Liangjiang
Liu, Yunlong
Xu, Dong
Deng, Youping
Tong, Weida
Yang, Mary Qu
TI Advances in translational bioinformatics facilitate revealing the
landscape of complex disease mechanisms
SO BMC BIOINFORMATICS
LA English
DT Editorial Material
AB Advances of high-throughput technologies have rapidly produced more and more data from DNAs and RNAs to proteins, especially large volumes of genome-scale data. However, connection of the genomic information to cellular functions and biological behaviours relies on the development of effective approaches at higher systems level. In particular, advances in RNA-Seq technology has helped the studies of transcriptome, RNA expressed from the genome, while systems biology on the other hand provides more comprehensive pictures, from which genes and proteins actively interact to lead to cellular behaviours and physiological phenotypes. As biological interactions mediate many biological processes that are essential for cellular function or disease development, it is important to systematically identify genomic information including genetic mutations from GWAS (genome-wide association study), differentially expressed genes, bidirectional promoters, intrinsic disordered proteins (IDP) and protein interactions to gain deep insights into the underlying mechanisms of gene regulations and networks. Furthermore, bidirectional promoters can co-regulate many biological pathways, where the roles of bidirectional promoters can be studied systematically for identifying co-regulating genes at interactive network level. Combining information from different but related studies can ultimately help revealing the landscape of molecular mechanisms underlying complex diseases such as cancer.
C1 [Yang, Jack Y.] Univ Arkansas, George W Dougherty Coll Engn & Informat Technol, Joint Bioinformat PhD Program, Little Rock, AR 72204 USA.
[Yang, Jack Y.] Univ Arkansas Med Sci, Little Rock, AR 72204 USA.
[Yang, Jack Y.; Niemierko, Andrzej] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Biostat & Biomath, Boston, MA 02114 USA.
[Yang, Jack Y.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Dunker, A. Keith] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
[Liu, Jun S.] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA.
[Qin, Xiang] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Qin, Xiang] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Arabnia, Hamid R.] Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA.
[Yang, William] Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, Dept Comp Sci, Little Rock, AR 72204 USA.
[Chen, Zhongxue] Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN 47405 USA.
[Luo, Zuojie] Guangxi Med Univ, Affiliated Hosp 1, Dept Endocrinol, Nanning 530021, Guangxi, Peoples R China.
[Wang, Liangjiang] Clemson Univ, Dept Biochem & Genet, Clemson, SC 29634 USA.
[Liu, Yunlong; Deng, Youping] Univ Missouri, Dept Comp Sci, Columbia, MO 65211 USA.
[Xu, Dong] Rush Univ, Ctr Canc, Chicago, IL 60612 USA.
[Xu, Dong] Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA.
[Xu, Dong] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA.
[Tong, Weida] US FDA, Div Bioinformat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
[Tong, Weida] US FDA, Div Biostat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
[Yang, Mary Qu] Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, MidSouth Bioinformat Ctr, Dept Informat Sci, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas, Joint Bioinformat Grad Program, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas Med Sci, Little Rock, AR 72204 USA.
RP Arabnia, HR (reprint author), Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA.
EM hra@uga.edu; youping_deng@rush.edu
FU PHS HHS [NIH/NIGMS 5P20GM10342913, NIH/NHGRI 5U54HG003273-11]
NR 6
TC 2
Z9 2
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 16
PY 2014
VL 15
SU 17
AR I1
DI 10.1186/1471-2105-15-S17-I1
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA CH4AS
UT WOS:000353973500001
PM 25559210
ER
PT J
AU Yang, W
Yoshigoe, K
Qin, X
Liu, JS
Yang, JY
Niemierko, A
Deng, YP
Liu, YL
Dunker, AK
Chen, ZX
Wang, LJ
Xu, D
Arabnia, HR
Tong, WD
Yang, MQ
AF Yang, William
Yoshigoe, Kenji
Qin, Xiang
Liu, Jun S.
Yang, Jack Y.
Niemierko, Andrzej
Deng, Youping
Liu, Yunlong
Dunker, A. Keith
Chen, Zhongxue
Wang, Liangjiang
Xu, Dong
Arabnia, Hamid R.
Tong, Weida
Yang, Mary Qu
TI Identification of genes and pathways involved in kidney renal clear cell
carcinoma
SO BMC BIOINFORMATICS
LA English
DT Article
ID HISTONE DEMETHYLASE RBP2; CANCER; NEPHRECTOMY; METASTASIS; ACTIVATION;
INFECTION; DISEASE
AB Background: Kidney Renal Clear Cell Carcinoma (KIRC) is one of fatal genitourinary diseases and accounts for most malignant kidney tumours. KIRC has been shown resistance to radiotherapy and chemotherapy. Like many types of cancers, there is no curative treatment for metastatic KIRC. Using advanced sequencing technologies, The Cancer Genome Atlas (TCGA) project of NIH/NCI-NHGRI has produced large-scale sequencing data, which provide unprecedented opportunities to reveal new molecular mechanisms of cancer. We combined differentially expressed genes, pathways and network analyses to gain new insights into the underlying molecular mechanisms of the disease development.
Results: Followed by the experimental design for obtaining significant genes and pathways, comprehensive analysis of 537 KIRC patients' sequencing data provided by TCGA was performed. Differentially expressed genes were obtained from the RNA-Seq data. Pathway and network analyses were performed. We identified 186 differentially expressed genes with significant p-value and large fold changes (P < 0.01, |log(FC)| > 5). The study not only confirmed a number of identified differentially expressed genes in literature reports, but also provided new findings. We performed hierarchical clustering analysis utilizing the whole genome-wide gene expressions and differentially expressed genes that were identified in this study. We revealed distinct groups of differentially expressed genes that can aid to the identification of subtypes of the cancer. The hierarchical clustering analysis based on gene expression profile and differentially expressed genes suggested four subtypes of the cancer. We found enriched distinct Gene Ontology (GO) terms associated with these groups of genes. Based on these findings, we built a support vector machine based supervised-learning classifier to predict unknown samples, and the classifier achieved high accuracy and robust classification results. In addition, we identified a number of pathways (P < 0.04) that were significantly influenced by the disease. We found that some of the identified pathways have been implicated in cancers from literatures, while others have not been reported in the cancer before. The network analysis leads to the identification of significantly disrupted pathways and associated genes involved in the disease development. Furthermore, this study can provide a viable alternative in identifying effective drug targets.
Conclusions: Our study identified a set of differentially expressed genes and pathways in kidney renal clear cell carcinoma, and represents a comprehensive computational approach to analysis large-scale next-generation sequencing data. The pathway and network analyses suggested that information from distinctly expressed genes can be utilized in the identification of aberrant upstream regulators. Identification of distinctly expressed genes and altered pathways are important in effective biomarker identification for early cancer diagnosis and treatment planning. Combining differentially expressed genes with pathway and network analyses using intelligent computational approaches provide an unprecedented opportunity to identify upstream disease causal genes and effective drug targets.
C1 [Yang, William; Yoshigoe, Kenji] Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, Dept Comp Sci, Little Rock, AR 72204 USA.
[Qin, Xiang] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Qin, Xiang] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Liu, Jun S.] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA.
[Yang, Jack Y.; Niemierko, Andrzej] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Biostat & Biomath, Boston, MA 02114 USA.
[Yang, Jack Y.; Niemierko, Andrzej] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Deng, Youping] Rush Univ, Med Ctr, Ctr Canc, Chicago, IL 60612 USA.
[Deng, Youping] Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA.
[Deng, Youping] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA.
[Yang, Jack Y.; Liu, Yunlong; Dunker, A. Keith] Indiana Univ, Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
[Chen, Zhongxue] Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN 47405 USA.
[Wang, Liangjiang] Clemson Univ, Dept Biochem & Genet, Clemson, SC 29634 USA.
[Xu, Dong] Univ Missouri, Dept Comp Sci, Columbia, MO 65211 USA.
[Arabnia, Hamid R.] Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA.
[Tong, Weida] US FDA, Div Bioinformat & Biostat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
[Yang, Mary Qu] Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, Dept Informat Sci, MidSouth Bioinformat Ctr, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas, Joint Bioinformat Grad Program, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas Med Sci, Little Rock, AR 72204 USA.
RP Yang, MQ (reprint author), Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, Dept Informat Sci, MidSouth Bioinformat Ctr, 2801 S Univ Ave, Little Rock, AR 72204 USA.
EM mqyang@ualr.edu
FU National Institutes of Health (NIH); Arkansas Science and Technology
Authority (ASTA); National Science Foundation (NSF); NIH/NIGMS
[5P20GM10342913]; ASTA [15-B-23]; NIH/NHGRI [5U54HG003273-11]; NSF
[1359323, 1429160]
FX The research was supported by the National Institutes of Health (NIH),
Arkansas Science and Technology Authority (ASTA), and National Science
Foundation (NSF). Specifically, MQY was supported by NIH/NIGMS
5P20GM10342913 and ASTA Award # 15-B-23. XQ was supported by NIH/NHGRI
5U54HG003273-11. KY and WY were supported by NSF Award # 1359323 and NSF
Award # 1429160.
NR 23
TC 14
Z9 14
U1 6
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 16
PY 2014
VL 15
SU 17
AR S2
DI 10.1186/1471-2105-15-S17-S2
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA CH4AS
UT WOS:000353973500003
PM 25559354
ER
PT J
AU Yang, MQ
Yoshigoe, K
Yang, W
Tong, WD
Qin, X
Dunker, AK
Chen, ZX
Arbania, HR
Liu, JS
Niemierko, A
Yang, JY
AF Yang, Mary Qu
Yoshigoe, Kenji
Yang, William
Tong, Weida
Qin, Xiang
Dunker, A. Keith
Chen, Zhongxue
Arbania, Hamid R.
Liu, Jun S.
Niemierko, Andrzej
Yang, Jack Y.
TI The emerging genomics and systems biology research lead to systems
genomics studies
SO BMC GENOMICS
LA English
DT Article
AB Synergistically integrating multi-layer genomic data at systems level not only can lead to deeper insights into the molecular mechanisms related to disease initiation and progression, but also can guide pathway-based biomarker and drug target identification. With the advent of high-throughput next-generation sequencing technologies, sequencing both DNA and RNA has generated multi-layer genomic data that can provide DNA polymorphism, non-coding RNA, messenger RNA, gene expression, isoform and alternative splicing information. Systems biology on the other hand studies complex biological systems, particularly systematic study of complex molecular interactions within specific cells or organisms. Genomics and molecular systems biology can be merged into the study of genomic profiles and implicated biological functions at cellular or organism level. The prospectively emerging field can be referred to as systems genomics or genomic systems biology.
The Mid-South Bioinformatics Centre (MBC) and Joint Bioinformatics Ph.D. Program of University of Arkansas at Little Rock and University of Arkansas for Medical Sciences are particularly interested in promoting education and research advancement in this prospectively emerging field. Based on past investigations and research outcomes, MBC is further utilizing differential gene and isoform/exon expression from RNA-seq and co-regulation from the ChiP-seq specific for different phenotypes in combination with protein-protein interactions, and protein-DNA interactions to construct high-level gene networks for an integrative genome-phoneme investigation at systems biology level.
C1 [Yang, Mary Qu] Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, MidSouth Bioinformat Ctr, Dept Informat Sci, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas, Joint Bioinformat Grad Program, Little Rock, AR 72204 USA.
[Yang, Mary Qu] Univ Arkansas Med Sci, Little Rock, AR 72204 USA.
[Yoshigoe, Kenji; Yang, William] Univ Arkansas, Dept Comp Sci, George W Donaghey Coll Engn & Informat Technol, Little Rock, AR 72204 USA.
[Tong, Weida] US FDA, Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AR 72079 USA.
[Qin, Xiang] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Qin, Xiang] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Dunker, A. Keith; Yang, Jack Y.] Indiana Univ, Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
[Chen, Zhongxue] Indiana Univ, Sch Med, Dept Epidemiol & Biostat, Bloomington, IN 47405 USA.
[Arbania, Hamid R.] Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA.
[Liu, Jun S.; Yang, Jack Y.] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA.
[Niemierko, Andrzej] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Biostat & Biomath, Boston, MA 02114 USA.
[Niemierko, Andrzej] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Yang, MQ (reprint author), Univ Arkansas, George W Donaghey Coll Engn & Informat Technol, MidSouth Bioinformat Ctr, Dept Informat Sci, 2801 S Univ Ave, Little Rock, AR 72204 USA.
EM mqyang@ualr.edu
FU National Institutes of Health (NIH); Arkansas Science and Technology
Authority (ASTA); National Science Foundation (NSF); NIH/NIGMS
[5P20GM10342913]; ASTA [15-B-23]; NIH/NHGRI [5U54HG003273-11]; NSF
[1359323, 1429160]
FX The research at MBC was supported by the National Institutes of Health
(NIH), Arkansas Science and Technology Authority (ASTA), and National
Science Foundation (NSF). MQY was supported by NIH/NIGMS 5P20GM10342913
and ASTA Award # 15-B-23. XQ was supported by NIH/NHGRI 5U54HG003273-11.
KY and WY were supported by NSF Award # 1359323 and NSF Award # 1429160.
NR 4
TC 0
Z9 0
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD DEC 16
PY 2014
VL 15
SU 11
AR I1
DI 10.1186/1471-2164-15-S11-I1
PG 4
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CH4CE
UT WOS:000353978200001
PM 25558922
ER
PT J
AU Cunningham, MA
Wirth, JR
Freeman, LR
Boger, HA
Granholm, AC
Gilkeson, GS
AF Cunningham, Melissa A.
Wirth, Jena R.
Freeman, Linnea R.
Boger, Heather A.
Granholm, Ann-Charlotte
Gilkeson, Gary S.
TI Estrogen receptor alpha deficiency protects against development of
cognitive impairment in murine lupus
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Estrogen receptor alpha (ERa); Neuropsychiatric lupus (NP-SLE);
Microglia
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RADIAL-ARM MAZE; DENDRITIC
CELL-DIFFERENTIATION; MEMORY LOAD INCREASES; MRL-LPR MICE;
NEUROPSYCHIATRIC SYNDROMES; OBJECT-RECOGNITION; WORKING-MEMORY;
GLUTAMATE-RECEPTOR; DNA ANTIBODIES
AB Background: One of the more profound features of systemic lupus erythematosus (SLE) is that females have a 9: 1 prevalence of this disease over males. Up to 80% of SLE patients have cognitive defects or affective disorders. The mechanism of CNS injury responsible for cognitive impairment is unknown. We previously showed that ERa deficiency significantly reduced renal disease and increased survival in lupus-prone mice. We hypothesized that ERa deficiency would be similarly protective in the brain, and that ERa may play a role in modulating blood-brain barrier (BBB) integrity and/or neuroinflammation in lupus-prone mice.
Methods: MRL/lpr ERa+/+ and ERaKO mice (n = 46) were ovariectomized, received 17 beta-estradiol pellets, and underwent radial arm water maze (WRAM) and novel object recognition (NOR) testing starting at eight weeks of age. Mice were sacrificed and brains were hemisected and processed for either immunohistochemistry, or hippocampus and parietal cortex dissection for Western blotting.
Results: MRL/lpr ERaKO mice (n = 21) performed significantly better in WRAM testing than wild-type MRL/lpr mice (n = 25). There was a significant reduction in reference memory errors (P < 0.007), working memory errors (P < 0.05), and start arm errors (P < 0.02) in ERaKO mice. There were significant differences in NOR testing, particularly total exploration time, with ERa deficiency normalizing behavior. No significant differences were seen in markers of tight junction, astrogliosis, or microgliosis in the hippocampus or cortex by Western blot, however, there was a significant reduction in numbers of Iba1+ activated microglia in the hippocampus of ERaKO mice, as evidenced by immunohistochemietry (IHC).
Conclusion: ERa deficiency provides significant protection against cognitive deficits in MRL/lpr mice as early as eight weeks of age. Additionally, the significant reduction in Iba1+ activated microglia in the MRL/lpr ERaKO mice was consistent with reduced inflammation, and may represent a biological mechanism for the cognitive improvement observed.
C1 [Cunningham, Melissa A.] Med Univ S Carolina, Dept Neurosci, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
Med Univ S Carolina, Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29425 USA.
RP Cunningham, MA (reprint author), Med Univ S Carolina, Dept Neurosci, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Suite 814,MSC637, Charleston, SC 29425 USA.
EM cunnima@musc.edu
OI Wirth, Jena/0000-0001-6094-8336; Cunningham, Melissa/0000-0002-9207-1986
FU Office of Research on Women's Health: Specialized Centers of Research on
Sex and Gender Factors Affecting Women's Health (NIH/NIAMS - National
Institutes of Health/National Institute of Arthritis and Musculoskeletal
and Skin diseases) [P50 DA016511]; South Carolina Clinical &
Translational Research Institute, with an academic home at the Medical
University of South Carolina (NIH/NCRR - National Instititutes of
Health/National Center for Research Resources) [UL1 RR029880, UL1
RR029882]; VA Medical Research Service merit award [1I01BX000470-01]
FX The authors wish to thank Ms Claudia Umphlet and Dr Michael Smith for
help with tissue processing. This publication was supported by the
Office of Research on Women's Health: Specialized Centers of Research on
Sex and Gender Factors Affecting Women's Health (NIH/NIAMS - National
Institutes of Health/National Institute of Arthritis and Musculoskeletal
and Skin diseases, grant number: P50 DA016511); The South Carolina
Clinical & Translational Research Institute, with an academic home at
the Medical University of South Carolina (NIH/NCRR - National
Instititutes of Health/National Center for Research Resources, grant
numbers: UL1 RR029880 and UL1 RR029882); and a VA Medical Research
Service merit award (grant number: 1I01BX000470-01). The contents are
solely the responsibility of the authors and do not necessarily
represent the official views of the NIH or NCRR.
NR 76
TC 3
Z9 3
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD DEC 16
PY 2014
VL 11
AR 171
DI 10.1186/s12974-014-0171-x
PG 15
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA CC5ZS
UT WOS:000350444700001
PM 25510908
ER
PT J
AU Guo, AY
Stevens, BW
Wilson, RG
Russell, CN
Cohen, MA
Sturgeon, HC
Thornton, A
Giallourakis, C
Khalili, H
Nguyen, DD
Sauk, J
Yajnik, V
Xavier, RJ
Ananthakrishnan, AN
AF Guo, Abra Y.
Stevens, Betsy W.
Wilson, Robin G.
Russell, Caitlin N.
Cohen, Melissa A.
Sturgeon, Holly C.
Thornton, Anna
Giallourakis, Cosmas
Khalili, Hamed
Nguyen, Deanna D.
Sauk, Jenny
Yajnik, Vijay
Xavier, Ramnik J.
Ananthakrishnan, Ashwin N.
TI Early life environment and natural history of inflammatory bowel
diseases
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Breastfeeding; Early life; Microbiome; Crohn's disease; Surgery
ID CROHNS-DISEASE; ULCERATIVE-COLITIS; RISK-FACTORS; INTESTINAL MICROBIOTA;
CIGARETTE-SMOKING; PASSIVE SMOKING; GUT MICROBIOTA; COHORT; IBD; TOBACCO
AB Background: Early life exposures may modify risk of inflammatory bowel diseases (IBD; Crohn's disease (CD), ulcerative colitis (UC)). However, the relationship between early life exposures and natural history of IBD has not been previously examined.
Methods: This single center study included patients with CD or UC recruited in a prospective IBD registry. Enrolled patients completed a detailed environmental questionnaire that assessed various early life environmental exposures. Our primary outcome was requirement for disease-related surgery in CD and UC. Logistic regression models defined independent effect of early life exposures, adjusting for potential confounders.
Results: Our study included 333 CD and 270 UC patients. Just over half were female with a median age at diagnosis of 25 years. One-third of the cohort had history of bowel surgery (31%) and nearly half had used at least one biologic agent (47%). Among those with CD, being breastfed was associated with reduced risk of CD-related surgery (34% vs. 55%), while childhood cigarette smoke exposure was associated with increased risk. On multivariate analysis, history of being breastfed (odds ratio (OR) 0.21, 95% confidence interval [CI] 0.09-0.46) and cigarette smoke exposure as a child (OR 2.17, 95% CI 1.10-4.29) remained independently associated with surgery. None of the early life variables influenced disease phenotype or outcome in UC.
Conclusion: A history of being breastfed was associated with a decreased risk while childhood cigarette smoke exposure was associated with an increased risk of surgery in patients with CD. Further investigation to examine biological mechanisms is warranted.
C1 [Guo, Abra Y.; Stevens, Betsy W.; Wilson, Robin G.; Russell, Caitlin N.; Cohen, Melissa A.; Sturgeon, Holly C.; Thornton, Anna; Giallourakis, Cosmas; Khalili, Hamed; Nguyen, Deanna D.; Sauk, Jenny; Yajnik, Vijay; Xavier, Ramnik J.; Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Giallourakis, Cosmas; Khalili, Hamed; Nguyen, Deanna D.; Sauk, Jenny; Yajnik, Vijay; Xavier, Ramnik J.] Harvard Univ, Sch Med, Boston, MA USA.
[Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Crohns & Colitis Ctr, Boston, MA 02114 USA.
RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
EM aananthakrishnan@mgh.harvard.edu
FU National Institutes of Health (NIH) [P30 DK043351]; National Institutes
of Health [K23 DK097142]
FX We acknowledge the valuable contributions of the participants and the
research staff of our registry. This work is supported by the National
Institutes of Health (NIH) (P30 DK043351) to the Center for Study of
Inflammatory Bowel Diseases. Ananthakrishnan is supported in part by a
grant from the National Institutes of Health (K23 DK097142).
NR 47
TC 3
Z9 3
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD DEC 16
PY 2014
VL 14
AR 216
DI 10.1186/s12876-014-0216-8
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AZ1EN
UT WOS:000347983100001
PM 25510175
ER
PT J
AU Xia, W
Springer, TA
AF Xia, Wei
Springer, Timothy A.
TI Metal ion and ligand binding of integrin alpha(5)beta(1)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID CRYSTAL-STRUCTURE; STRUCTURAL BASIS; EXTENDED CONFORMATIONS; FIBRONECTIN
RECEPTOR; LEUKOCYTE INTEGRIN; A-DOMAIN; I DOMAIN; SUBUNIT; RECOGNITION;
ACTIVATION
AB Integrin alpha(5)beta(1) binds to an Arg-Gly-Asp (RGD) motif in its ligand fibronectin. We report high-resolution crystal structures of a four-domain alpha(5)beta(1) headpiece fragment, alone or with RGD peptides soaked into crystals, and RGD peptide affinity measurements. The headpiece crystallizes in a closed conformation essentially identical to that seen previously for alpha(5)beta(1) complexed with a Fab that allosterically inhibits ligand binding by stabilizing the closed conformation. Soaking experiments show that binding of cyclic RGD peptide with 20-fold higher affinity than a linear RGD peptide induces conformational change in the beta(1)-subunit beta I domain to a state that is intermediate between closed (low affinity) and open (high affinity). In contrast, binding of a linear RGD peptide induces no shape shifting. However, linear peptide binding induces shape shifting when Ca2+ is depleted during soaking. Ca2+ bound to the adjacent to metal ion-dependent adhesion site (ADMIDAS), at the locus of shape shifting, moves and decreases in occupancy, correlating with an increase in affinity for RGD measured when Ca2+ is depleted. The results directly demonstrate that Ca2+ binding to the ADMIDAS stabilizes integrins in the low-affinity, closed conformation. Comparisons in affinity between four-domain and six-domain headpiece constructs suggest that flexible integrin leg domains contribute to conformational equilibria. High-resolution views of the hybrid domain interface with the plexin-semaphorin-integrin (PSI) domain in different orientations show a ball-and-socket joint with a hybrid domain Arg side chain that rocks in a PSI domain socket lined with carbonyl oxygens.
C1 [Xia, Wei; Springer, Timothy A.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Xia, Wei; Springer, Timothy A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Springer, TA (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
EM timothy.springer@childrens.harvard.edu
FU NIH [HL-108248]
FX We thank beamline 24ID at the Advanced Photon Source and Jianghai Zhu,
Xianchi Dong, and Li-Zhi Mi for help with data collection and
refinement. Supported by NIH Grant HL-108248.
NR 41
TC 16
Z9 16
U1 2
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 16
PY 2014
VL 111
IS 50
BP 17863
EP 17868
DI 10.1073/pnas.1420645111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6GA
UT WOS:000346366500058
PM 25475857
ER
PT J
AU Balasubramanian, R
Choi, JH
Francescatto, L
Willer, J
Horton, ER
Asimacopoulos, EP
Stankovic, KM
Plummer, L
Buck, CL
Quinton, R
Nebesio, TD
Mericq, V
Merino, PM
Meyer, BF
Monies, D
Gusella, JF
Al Tassan, N
Katsanis, N
Crowley, WF
AF Balasubramanian, Ravikumar
Choi, Jin-Ho
Francescatto, Ludmila
Willer, Jason
Horton, Edward R.
Asimacopoulos, Eleni P.
Stankovic, Konstantina M.
Plummer, Lacey
Buck, Cassandra L.
Quinton, Richard
Nebesio, Todd D.
Mericq, Veronica
Merino, Paulina M.
Meyer, Brian F.
Monies, Dorota
Gusella, James F.
Al Tassan, Nada
Katsanis, Nicholas
Crowley, William F., Jr.
TI Functionally compromised CHD7 alleles in patients with isolated GnRH
deficiency
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE CHD7; Kallmann syndrome; idiopathic hypogonadotropic hypogondism; CHARGE
syndrome; missense mutations
ID CHARGE-SYNDROME; KALLMANN-SYNDROME; HYPOGONADOTROPIC HYPOGONADISM; MOUSE
MODEL; MUTATIONS; GENE; IDENTIFICATION; MISSENSE; NEURONS; BIOLOGY
AB Inactivating mutations in chromodomain helicase DNA binding protein 7 (CHD7) cause CHARGE syndrome, a severe multiorgan system disorder of which Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is a minor feature. Recent reports have described predominantly missense CHD7 alleles in IGD patients, but it is unclear if these alleles are relevant to causality or overall genetic burden of Kallmann syndrome (KS) and normosmic form of IGD. To address this question, we sequenced CHD7 in 783 well-phenotyped IGD patients lacking full CHARGE features; we identified nonsynonymous rare sequence variants in 5.2% of the IGD cohort (73% missense and 27% splice variants). Functional analyses in zebrafish using a surrogate otolith assay of a representative set of these CHD7 alleles showed that rare sequence variants observed in controls showed no altered function. In contrast, 75% of the IGD-associated alleles were deleterious and resulted in both KS and normosmic IGD. In two families, pathogenic mutations in CHD7 coexisted with mutations in other known IGD genes. Taken together, our data suggest that rare deleterious CHD7 alleles contribute to the mutational burden of patients with both KS and normosmic forms of IGD in the absence of full CHARGE syndrome. These findings (i) implicate a unique role or preferential sensitivity for CHD7 in the ontogeny of GnRH neurons, (ii) reiterate the emerging genetic complexity of this family of IGD disorders, and (iii) demonstrate how the coordinated use of well-phenotyped cohorts, families, and functional studies can inform genetic architecture and provide insights into the developmental biology of cellular systems.
C1 [Balasubramanian, Ravikumar; Choi, Jin-Ho; Horton, Edward R.; Plummer, Lacey; Buck, Cassandra L.; Crowley, William F., Jr.] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr & Reprod Endocri, Dept Med, Boston, MA 02114 USA.
[Gusella, James F.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Balasubramanian, Ravikumar; Crowley, William F., Jr.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Asimacopoulos, Eleni P.; Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Gusella, James F.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Choi, Jin-Ho] Univ Ulsan, Coll Med, Asan Med Ctr Childrens Hosp, Dept Pediat, Seoul 138736, South Korea.
[Francescatto, Ludmila; Willer, Jason; Katsanis, Nicholas] Duke Univ, Dept Cell Biol & Pediat, Ctr Human Dis Modeling, Durham, NC 27710 USA.
[Asimacopoulos, Eleni P.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Quinton, Richard] Newcastle Univ, Inst Genet Med, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
[Nebesio, Todd D.] Indiana Univ Sch Med, Riley Hosp Children, Dept Pediat, Indianapolis, IN 46202 USA.
[Mericq, Veronica; Merino, Paulina M.] Univ Chile, Inst Maternal & Child Res, Santiago 2263, Chile.
[Meyer, Brian F.; Monies, Dorota; Al Tassan, Nada] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh 11211, Saudi Arabia.
RP Crowley, WF (reprint author), Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr & Reprod Endocri, Dept Med, Boston, MA 02114 USA.
EM wcrowley@partners.org
OI Mericq, Veronica/0000-0003-2287-0181; Katsanis,
Nicholas/0000-0002-2480-0171
FU National Institutes of Health [U54 HD028138, P50 DK096415, K23 HD077043,
K08 DC010419]; Bertarelli Foundation; National Institutes of Health
(Developmental Genome Anatomy Project) [P01 GM061354]
FX This study was supported by the National Institutes of Health Grants U54
HD028138 (to W.F.C.) and P50 DK096415 (to N.K.). R.B. is supported by
the National Institutes of Health Grant K23 HD077043. K.M.S. is
supported by National Institutes of Health Grant K08 DC010419 and the
Bertarelli Foundation. J.F.G. is supported by National Institutes of
Health Grant P01 GM061354 (Developmental Genome Anatomy Project).
NR 34
TC 6
Z9 6
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 16
PY 2014
VL 111
IS 50
BP 17953
EP 17958
DI 10.1073/pnas.1417438111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6GA
UT WOS:000346366500073
PM 25472840
ER
PT J
AU Landman, R
Sharma, J
Sur, M
Desimone, R
AF Landman, Rogier
Sharma, Jitendra
Sur, Mriganka
Desimone, Robert
TI Effect of distracting faces on visual selective attention in the monkey
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE attention; faces; oxytocin; social; vision
ID EMOTIONAL FACIAL EXPRESSIONS; PSYCHOPHYSICS TOOLBOX; PERCEPTUAL LOAD;
RHESUS MACAQUES; EYE TRACKING; OXYTOCIN; AMYGDALA; CAPTURE; THREAT;
STIMULI
AB In primates, visual stimuli with social and emotional content tend to attract attention. Attention might be captured through rapid, automatic, subcortical processing or guided by slower, more voluntary cortical processing. Here we examined whether irrelevant faces with varied emotional expressions interfere with a covert attention task in macaque monkeys. In the task, the monkeys monitored a target grating in the periphery for a subtle color change while ignoring distracters that included faces appearing elsewhere on the screen. The onset time of distracter faces before the target change, as well as their spatial proximity to the target, was varied from trial to trial. The presence of faces, especially faces with emotional expressions interfered with the task, indicating a competition for attentional resources between the task and the face stimuli. However, this interference was significant only when faces were presented for greater than 200 ms. Emotional faces also affected saccade velocity and reduced pupillary reflex. Our results indicate that the attraction of attention by emotional faces in the monkey takes a considerable amount of processing time, possibly involving cortical-subcortical interactions. Intranasal application of the hormone oxytocin ameliorated the interfering effects of faces. Together these results provide evidence for slow modulation of attention by emotional distracters, which likely involves oxytocinergic brain circuits.
C1 [Landman, Rogier; Desimone, Robert] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
[Sharma, Jitendra; Sur, Mriganka] MIT, Picower Inst Learning & Memory, Cambridge, MA 02139 USA.
[Sharma, Jitendra] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Sharma, Jitendra] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Sur, Mriganka] Simons Ctr Social Brain, Cambridge, MA 02139 USA.
RP Landman, R (reprint author), MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
EM landman@mit.edu; desimone@mit.edu
FU Simons Foundation; National Institutes of Health [EY017292]
FX We thank Dr. David Amaral for kindly providing us with the stimuli used,
Dr. David Osher for helpful discussions, and Emma Myers for training the
animals and setting up the training rig. This research was supported in
part by grants from The Simons Foundation (to M.S.) and National
Institutes of Health Grant EY017292 (to R.D.).
NR 64
TC 9
Z9 9
U1 0
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 16
PY 2014
VL 111
IS 50
BP 18037
EP 18042
DI 10.1073/pnas.1420167111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6GA
UT WOS:000346366500079
PM 25472846
ER
PT J
AU Merlo, P
Frost, B
Peng, SY
Yang, YWJ
Park, PJ
Feany, M
AF Merlo, Paola
Frost, Bess
Peng, Shouyong
Yang, Yawei J.
Park, Peter J.
Feany, Mel
TI p53 prevents neurodegeneration by regulating synaptic genes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE p53 transcriptional function; ChIP-chip; neurodegeneration; tauopathy;
synaptic genes
ID ALZHEIMERS-DISEASE; DNA-DAMAGE; NEUROFIBRILLARY TANGLES;
DROSOPHILA-MELANOGASTER; CELL-DEATH; TAUOPATHY; ISOFORMS; MODEL; P73;
DIFFERENTIATION
AB DNA damage has been implicated in neurodegenerative disorders, including Alzheimer's disease and other tauopathies, but the consequences of genotoxic stress to postmitotic neurons are poorly understood. Here we demonstrate that p53, a key mediator of the DNA damage response, plays a neuroprotective role in a Drosophila model of tauopathy. Further, through a whole-genome ChIP-chip analysis, we identify genes controlled by p53 in postmitotic neurons. We genetically validate a specific pathway, synaptic function, in p53-mediated neuroprotection. We then demonstrate that the control of synaptic genes by p53 is conserved in mammals. Collectively, our results implicate synaptic function as a central target in p53-dependent protection from neurodegeneration.
C1 [Merlo, Paola; Frost, Bess; Feany, Mel] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Peng, Shouyong; Park, Peter J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Peng, Shouyong; Park, Peter J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Peng, Shouyong] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Yang, Yawei J.] Childrens Hosp Boston, Div Genet, Boston, MA 02115 USA.
[Yang, Yawei J.] Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.
[Yang, Yawei J.] Broad Inst & Harvard, Cambridge, MA 02142 USA.
[Yang, Yawei J.] Howard Hughes Med Inst, Cambridge, MA 02142 USA.
[Park, Peter J.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
RP Feany, M (reprint author), Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
EM mel_feany@hms.harvard.edu
RI Merlo, Paola/K-5330-2014
OI Merlo, Paola/0000-0003-0105-7044
FU NIH [P40OD018537]; Vienna Drosophila RNAi Center; Transgenic RNAi
Project at Harvard Medical School (NIH/National Institute of General
Medical Sciences) [R01GM084947]; National Institute of Child Health and
Human Development; National Institute on Aging; Ellison Medical
Foundation; American Health Assistance Foundation
FX We thank Art Alekseyenko and C. John Luckey for reagents and helpful
discussions. Drosophila stocks were obtained from the Bloomington
Drosophila Stock Center (NIH Grant P40OD018537), the Vienna Drosophila
RNAi Center, the Transgenic RNAi Project at Harvard Medical School
(NIH/National Institute of General Medical Sciences Grant R01GM084947),
Nancy Bonini, and Thomas Neufeld. Antibodies were from the DSHB,
developed under the auspices of the National Institute of Child Health
and Human Development and maintained by the University of Iowa; and from
the University of California Davis/NIH NeuroMab Facility. This work was
supported by grants from the National Institute on Aging, the Ellison
Medical Foundation, and the American Health Assistance Foundation (to M.
F.).
NR 45
TC 7
Z9 7
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 16
PY 2014
VL 111
IS 50
BP 18055
EP 18060
DI 10.1073/pnas.1419083111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6GA
UT WOS:000346366500082
PM 25453105
ER
PT J
AU Ba, DB
Babadi, B
Purdon, PL
Brown, EN
AF Ba, Demba
Babadi, Behtash
Purdon, Patrick L.
Brown, Emery N.
TI Robust spectrotemporal decomposition by iteratively reweighted least
squares
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE structured sparsity; spectral decomposition; dynamics; recursive
estimation; neural signal processing
ID CONVERGENCE; ALGORITHMS; REGRESSION; SELECTION; NETWORKS; PROPOFOL;
SPECTRUM; MODEL
AB Classical nonparametric spectral analysis uses sliding windows to capture the dynamic nature of most real-world time series. This universally accepted approach fails to exploit the temporal continuity in the data and is not well-suited for signals with highly structured time-frequency representations. For a time series whose time-varying mean is the superposition of a small number of oscillatory components, we formulate nonparametric batch spectral analysis as a Bayesian estimation problem. We introduce prior distributions on the time-frequency plane that yield maximum a posteriori (MAP) spectral estimates that are continuous in time yet sparse in frequency. Our spectral decomposition procedure, termed spectrotemporal pursuit, can be efficiently computed using an iteratively reweighted least-squares algorithm and scales well with typical data lengths. We show that spectrotemporal pursuit works by applying to the time series a set of data-derived filters. Using a link between Gaussian mixture models, l(1) minimization, and the expectation-maximization algorithm, we prove that spectrotemporal pursuit converges to the global MAP estimate. We illustrate our technique on simulated and real human EEG data as well as on human neural spiking activity recorded during loss of consciousness induced by the anesthetic propofol. For the EEG data, our technique yields significantly denoised spectral estimates that have significantly higher time and frequency resolution than multitaper spectral estimates. For the neural spiking data, we obtain a new spectral representation of neuronal firing rates. Spectrotemporal pursuit offers a robust spectral decomposition framework that is a principled alternative to existing methods for decomposing time series into a small number of smooth oscillatory components.
C1 [Ba, Demba; Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Ba, Demba; Purdon, Patrick L.; Brown, Emery N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Babadi, Behtash] Univ Maryland, Dept Elect & Comp Engn, College Pk, MD 20740 USA.
[Purdon, Patrick L.; Brown, Emery N.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Brown, Emery N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
RP Ba, DB (reprint author), MIT, Dept Brain & Cognit Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM demba@mit.edu
FU National Institutes of Health Transformative Research Award [GM 104948];
[DP2-OD006454]; [R01-EB006385]
FX This work was partially supported by National Institutes of Health
Transformative Research Award GM 104948 (to E.N.B.) and by New Innovator
Awards DP2-OD006454 (to P.L.P.) and R01-EB006385 (to E.N.B. and P.L.P.).
NR 39
TC 5
Z9 5
U1 2
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 16
PY 2014
VL 111
IS 50
BP E5336
EP E5345
DI 10.1073/pnas.1320637111
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6GA
UT WOS:000346366500005
PM 25468968
ER
PT J
AU Payne, R
Muenchhoff, M
Mann, J
Roberts, HE
Matthews, P
Adland, E
Hempenstall, A
Huang, KH
Brockman, M
Brumme, Z
Sinclair, M
Miura, T
Frater, J
Essex, M
Shapiro, R
Walker, BD
Ndung'u, T
McLean, AR
Carlson, JM
Goulder, PJR
AF Payne, Rebecca
Muenchhoff, Maximilian
Mann, Jaclyn
Roberts, Hannah E.
Matthews, Philippa
Adland, Emily
Hempenstall, Allison
Huang, Kuan-Hsiang
Brockman, Mark
Brumme, Zabrina
Sinclair, Marc
Miura, Toshiyuki
Frater, John
Essex, Myron
Shapiro, Roger
Walker, Bruce D.
Ndung'u, Thumbi
McLean, Angela R.
Carlson, Jonathan M.
Goulder, Philip J. R.
TI Impact of HLA-driven HIV adaptation on virulence in populations of high
HIV seroprevalence
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE HLA; HIV; adaptation; antiretroviral therapy; virulence
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL LOAD; REPLICATION CAPACITY;
CLASS-I; ESCAPE MUTATIONS; IMMUNE CONTROL; GAG-PROTEASE; CHRONIC
INFECTION; COITAL ACT; SET-POINT
AB It is widely believed that epidemics in new hosts diminish in virulence over time, with natural selection favoring pathogens that cause minimal disease. However, a tradeoff frequently exists between high virulence shortening host survival on the one hand but allowing faster transmission on the other. This is the case in HIV infection, where high viral loads increase transmission risk per coital act but reduce host longevity. We here investigate the impact on HIV virulence of HIV adaptation to HLA molecules that protect against disease progression, such as HLA-B*57 and HLA-B*58:01. We analyzed cohorts in Botswana and South Africa, two countries severely affected by the HIV epidemic. In Botswana, where the epidemic started earlier and adult seroprevalence has been higher, HIV adaptation to HLA including HLA-B*57/58:01 is greater compared with South Africa (P = 7 x 10(-82)), the protective effect of HLA-B*57/58: 01 is absent (P = 0.0002), and population viral replicative capacity is lower (P = 0.03). These data suggest that viral evolution is occurring relatively rapidly, and that adaptation of HIV to the most protective HLA alleles may contribute to a lowering of viral replication capacity at the population level, and a consequent reduction in HIV virulence over time. The potential role in this process played by increasing antiretroviral therapy (ART) access is also explored. Models developed here suggest distinct benefits of ART, in addition to reducing HIV disease and transmission, in driving declines in HIV virulence over the course of the epidemic, thereby accelerating the effects of HLA-mediated viral adaptation.
C1 [Payne, Rebecca; Muenchhoff, Maximilian; Matthews, Philippa; Adland, Emily; Hempenstall, Allison; Sinclair, Marc; Goulder, Philip J. R.] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Durban, South Africa.
[Mann, Jaclyn; Walker, Bruce D.; Ndung'u, Thumbi; Goulder, Philip J. R.] Univ Oxford, Oxford Martin Sch, Inst Emerging Infect, Oxford OX1 3BD, England.
[Roberts, Hannah E.; Huang, Kuan-Hsiang; Frater, John; McLean, Angela R.] Univ Oxford, Nuffield Dept Med, Oxford OX1 3SY, England.
[Roberts, Hannah E.; Huang, Kuan-Hsiang; Frater, John] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.
[Brockman, Mark; Brumme, Zabrina] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.
[Brockman, Mark; Brumme, Zabrina] ViiV Healthcare KK, Shibuya Ku, Tokyo 1518566, Japan.
[Miura, Toshiyuki] Oxford Natl Inst Hlth Res, Biomed Res Ctr, Oxford OX1 3SY, England.
[Frater, John] Botswana Harvard AIDS Inst Partnership, BO-320 Gaborone, Botswana.
[Essex, Myron; Shapiro, Roger] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02215 USA.
[Essex, Myron; Shapiro, Roger] Massachusetts Gen Hosp, MIT, Ragon Inst, Cambridge, MA 02139 USA.
[Walker, Bruce D.; Ndung'u, Thumbi] Harvard Univ, Cambridge, MA 02139 USA.
[Walker, Bruce D.; Ndung'u, Thumbi] Univ Oxford, Dept Zool, Oxford OX1 3PS, England.
[McLean, Angela R.] Microsoft Res, ESci Grp, Los Angeles, CA 90024 USA.
RP Goulder, PJR (reprint author), Univ Oxford, Dept Paediat, Oxford OX1 3SY, England.
EM philip.goulder@paediatrics.ox.ac.uk
OI Matthews, Philippa/0000-0002-4036-4269; Ndung'u,
Thumbi/0000-0003-2962-3992; Brockman, Mark/0000-0001-6432-1426
FU National Institutes of Health [R01AI46995]; Wellcome Trust; Medical
Research Council UK; New Investigator Award (Canadian Institutes of
Health); Michael Smith Foundation for Health Research
FX This work is funded by grants from the National Institutes of Health
[R01AI46995 (to P.J.R.G.)], the Wellcome Trust (to P.J.R.G.), and the
Medical Research Council UK. Z.B. is supported by a New Investigator
Award (Canadian Institutes of Health) and the Michael Smith Foundation
for Health Research. M.B. holds a Canada Research Chair, Tier 2, in
Viral Pathogenesis and Immunity.
NR 52
TC 24
Z9 24
U1 1
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 16
PY 2014
VL 111
IS 50
BP E5393
EP E5400
DI 10.1073/pnas.1413339111
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6GA
UT WOS:000346366500011
PM 25453107
ER
PT J
AU Wojtaszek, JL
Wang, S
Kim, H
Wu, QL
D'Andrea, AD
Zhou, P
AF Wojtaszek, Jessica L.
Wang, Su
Kim, Hyungjin
Wu, Qinglin
D'Andrea, Alan D.
Zhou, Pei
TI Ubiquitin recognition by FAAP20 expands the complex interface beyond the
canonical UBZ domain
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID CROSS-LINK REPAIR; ANEMIA CORE COMPLEX; FANCONI-ANEMIA; BINDING DOMAINS;
ZINC-FINGER; PROTEIN; PATHWAY; RABEX-5
AB FAAP20 is an integral component of the Fanconi anemia core complex that mediates the repair of DNA interstrand crosslinks. The ubiquitin-binding capacity of the FAAP20 UBZ is required for recruitment of the Fanconi anemia complex to interstrand DNA crosslink sites and for interaction with the translesion synthesis machinery. Although the UBZ-ubiquitin interaction is thought to be exclusively encapsulated within the beta beta alpha module of UBZ, we show that the FAAP20-ubiquitin interaction extends beyond such a canonical zinc-finger motif. Instead, ubiquitin binding by FAAP20 is accompanied by transforming a disordered tail C-terminal to the UBZ of FAAP20 into a rigid, extended beta-loop that latches onto the complex interface of the FAAP20 UBZ and ubiquitin, with the invariant C-terminal tryptophan emanating toward I44(Ub) for enhanced binding specificity and affinity. Substitution of the C-terminal tryptophan with alanine in FAAP20 not only abolishes FAAP20-ubiquitin binding in vitro, but also causes profound cellular hypersensitivity to DNA interstrand crosslink lesions in vivo, highlighting the indispensable role of the C-terminal tail of FAAP20, beyond the compact zinc finger module, toward ubiquitin recognition and Fanconi anemia complex-mediated DNA interstrand crosslink repair.
C1 [Wojtaszek, Jessica L.; Wang, Su; Wu, Qinglin; Zhou, Pei] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.
[Kim, Hyungjin; D'Andrea, Alan D.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA.
RP Zhou, P (reprint author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.
EM peizhou@biochem.duke.edu
OI Zhou, Pei/0000-0002-7823-3416
FU National Institutes of Health [NIGMS 51310, R01DK43889, R37HL52725,
2P01HL048546]; Duke Bridge Fund; Leukemia and Lymphoma Society
FX National Institutes of Health [NIGMS 51310 to P.Z.; R01DK43889,
R37HL52725 and 2P01HL048546 to A.D.D.]; Duke Bridge Fund [to P.Z.];
Leukemia and Lymphoma Society [to H.K.]. Funding for open access charge:
National Institutes of Health [NIGMS 51310 to P.Z.; R01DK43889,
R37HL52725 and 2P01HL048546 to A.D.D.]; Duke Bridge Fund [to P.Z.];
Leukemia and Lymphoma Society [to H.K.].
NR 28
TC 2
Z9 2
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC 16
PY 2014
VL 42
IS 22
BP 13997
EP 14005
DI 10.1093/nar/gku1153
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AZ0DQ
UT WOS:000347916900053
PM 25414354
ER
PT J
AU Backus, LI
Belperio, PS
Loomis, TP
Han, SH
Mole, LA
AF Backus, Lisa I.
Belperio, Pamela S.
Loomis, Timothy P.
Han, Steven-Huy
Mole, Larry A.
TI Screening for and Prevalence of Hepatitis B Virus Infection Among
High-Risk Veterans Under the Care of the US Department of Veterans
Affairs: A Case Report
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
ID UNITED-STATES
C1 [Backus, Lisa I.; Belperio, Pamela S.; Loomis, Timothy P.; Mole, Larry A.] Vet Affairs Palo Alto Hlth Care Syst, Off Publ Hlth Populat Hlth, Palo Alto, CA 94304 USA.
[Mole, Larry A.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Hlthcare Syst, Los Angeles, CA 90095 USA.
[Mole, Larry A.] Univ Calif Los Angeles, David Geffen Sch Med, Pfleger Liver Inst, Los Angeles, CA 90095 USA.
RP Backus, LI (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Off Publ Hlth Populat Hlth, Palo Alto, CA 94304 USA.
NR 5
TC 1
Z9 1
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD DEC 16
PY 2014
VL 161
IS 12
BP 926
EP 928
DI 10.7326/L14-5036
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX9UW
UT WOS:000347248400046
PM 25506867
ER
PT J
AU Hentrich, C
Szostak, JW
AF Hentrich, Christian
Szostak, Jack W.
TI Controlled Growth of Filamentous Fatty Acid Vesicles under Flow
SO LANGMUIR
LA English
DT Article
ID MEMBRANE; LIFE; PROLIFERATION; MICROTUBULE; PROTOCELL; MICELLES;
DYNAMICS; BINDING; SURFACE; SYSTEM
AB The earliest forms of cellular life would have required a membrane compartment capable of growth and division. Fatty acid vesicles are an attractive model of protocell membranes, as they can grow into filamentous vesicles that readily divide while retaining their contents. In order to study vesicle growth, we have developed a method for immobilizing multilamellar fatty acid vesicles on modified glass surfaces and inducing filamentous membrane growth under flow. Filament formation strictly depended on the presence of freshly neutralized fatty acid micelles in the flow chamber. Using light microscopy, we observed a strong dependence of initial growth velocity on initial vesicle size, suggesting that new fatty acid molecules were incorporated into the membrane over the entire external surface of the vesicle. We examined the influences of flow rate, fatty acid concentration, and salt concentration on filamentous growth and observed drastic shape changes, including membrane pearling, of preexisting membrane tubules in response to osmotic stress. These results illustrate the versatility of flow studies for exploring the process of fatty acid vesicle growth following exposure to free fatty acids.
C1 [Hentrich, Christian; Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA.
[Hentrich, Christian; Szostak, Jack W.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Hentrich, Christian; Szostak, Jack W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Szostak, Jack W.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
RP Szostak, JW (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, 185 Cambridge St, Boston, MA 02114 USA.
EM szostak@molbio.mgh.harvard.edu
FU NASA Exobiology Program [EXB02-0031-0018]
FX We thank Brian Lee and Lakshminarayanan Mahadevan for helpful
discussions. We also thank Aaron Engelhart, Aaron Larsen, Anders
Bjorkbom, Neha Kamat, Noam Prywes, Tony Z. Jia, and Victor Lelyveld for
critical reading of the manuscript. J.W.S. is an investigator of the
Howard Hughes Medical Institute. This research was supported in part by
Grant EXB02-0031-0018 from the NASA Exobiology Program to J.W.S.
NR 47
TC 4
Z9 4
U1 6
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD DEC 16
PY 2014
VL 30
IS 49
BP 14916
EP 14925
DI 10.1021/la503933x
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
Multidisciplinary
SC Chemistry; Materials Science
GA AX1CE
UT WOS:000346685100025
PM 25402759
ER
PT J
AU Fan, TT
Fang, SC
Cavallari, JM
Barnett, IJ
Wang, ZX
Su, L
Byun, HM
Lin, XH
Baccarelli, AA
Christiani, DC
AF Fan, Tianteng
Fang, Shona C.
Cavallari, Jennifer M.
Barnett, Ian J.
Wang, Zhaoxi
Su, Li
Byun, Hyang-Min
Lin, Xihong
Baccarelli, Andrea A.
Christiani, David C.
TI Heart rate variability and DNA methylation levels are altered after
short-term metal fume exposure among occupational welders: a
repeated-measures panel study
SO BMC PUBLIC HEALTH
LA English
DT Article
ID BOILERMAKER CONSTRUCTION WORKERS; PARTICULATE AIR-POLLUTION; C-REACTIVE
PROTEIN; CARDIOVASCULAR-DISEASE; PROMOTER METHYLATION; PERIPHERAL-BLOOD;
OXIDATIVE STRESS; WELDING FUMES; MATTER; ASSOCIATION
AB Background: In occupational settings, boilermakers are exposed to high levels of metallic fine particulate matter (PM2.5) generated during the welding process. The effect of welding PM2.5 on heart rate variability (HRV) has been described, but the relationship between PM2.5, DNA methylation, and HRV is not known.
Methods: In this repeated-measures panel study, we recorded resting HRV and measured DNA methylation levels in transposable elements Alu and long interspersed nuclear element-1 (LINE-1) in peripheral blood leukocytes under ambient conditions (pre-shift) and right after a welding task (post-shift) among 66 welders. We also monitored personal PM2.5 level in the ambient environment and during the welding procedure.
Results: The concentration of welding PM2.5 was significantly higher than background levels in the union hall (0.43 mg/m(3) vs. 0.11 mg/m(3), p < 0.0001). The natural log of transformed power in the high frequency range (ln HF) had a significantly negative association with PM2.5 exposure (beta = -0.76, p = 0.035). pNN10 and pNN20 also had a negative association with PM2.5 exposure (beta = -0.16%, p = 0.006 and beta = -0.13%, p = 0.030, respectively). PM2.5 was positively associated with LINE-1 methylation [beta = 0.79%, 5-methylcytosince (% mC), p = 0.013]; adjusted for covariates. LINE-1 methylation did not show an independent association with HRV.
Conclusions: Acute decline of HRV was observed following exposure to welding PM2.5 and evidence for an epigenetic response of transposable elements to short-term exposure to high-level metal-rich particulates was reported.
C1 [Fan, Tianteng; Fang, Shona C.; Cavallari, Jennifer M.; Wang, Zhaoxi; Su, Li; Byun, Hyang-Min; Baccarelli, Andrea A.; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Fang, Shona C.; Lin, Xihong] New England Res Inst, Watertown, MA 02172 USA.
[Cavallari, Jennifer M.] Univ Connecticut, Ctr Hlth, Farmington, CT USA.
[Barnett, Ian J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Baccarelli, Andrea A.; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Christiani, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Boston, MA USA.
RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM dchris@hsph.harvard.edu
OI Baccarelli, Andrea/0000-0002-3436-0640; Byun,
Hyang-Min/0000-0002-6278-3165
FU National Institute of Environmental Health Sciences (NIEHS)
[R01ES009860, P50ES000002]
FX This research was supported by the National Institute of Environmental
Health Sciences (NIEHS) grant numbers R01ES009860 and P50ES000002. We
thank the participants and the leadership of Local 29 of the
International Brotherhood of Boilermakers, Iron Ship Builders,
Blacksmiths, Forgers and Helpers in Quincy, MA.
NR 44
TC 6
Z9 6
U1 1
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD DEC 16
PY 2014
VL 14
AR 1279
DI 10.1186/1471-2458-14-1279
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX4AE
UT WOS:000346875800001
PM 25512264
ER
PT J
AU Slow, S
Florkowski, CM
Chambers, ST
Priest, PC
Stewart, AW
Jennings, LC
Livesey, JH
Camargo, CA
Scragg, R
Murdoch, DR
AF Slow, Sandy
Florkowski, Christopher M.
Chambers, Stephen T.
Priest, Patricia C.
Stewart, Alistair W.
Jennings, Lance C.
Livesey, John H.
Camargo, Carlos A., Jr.
Scragg, Robert
Murdoch, David R.
TI CHRISTMAS 2014: GOING TO EXTREMES Effect of monthly vitamin D-3
supplementation in healthy adults on adverse effects of earthquakes:
randomised controlled trial
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Editorial Material
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; DEPRESSION; CHRISTCHURCH;
SYMPTOMS; ANXIETY; IMPACT; AREAS
AB Objective To determine whether supplementation with vitamin D improves resilience to the adverse effects of earthquakes.
Design Opportunistic addition to an established randomised double blind placebo controlled trial.
Setting Christchurch, New Zealand, where a prolonged series of catastrophic earthquakes beginning on 4 September 2010 occurred, which caused widespread destruction, fatalities, and extensive psychological damage.
Participants 322 healthy adults (241 women; 81 men) aged 18-67 who were already participating in the vitamin D and acute respiratory infections study (VIDARIS) between February 2010 and November 2011.
Intervention Participants were randomised to receive an oral dose of either 200 000 IU vitamin D-3 monthly for two months then 100 000 IU monthly (n=161) or placebo (n=161) for a total of 18 months.
Main outcome measure This is a post hoc analysis from the previously published VIDARIS trial. The primary endpoint in the current analysis was the self reported effects and overall adverse impact of the Christchurch earthquakes as assessed by questionnaire four months after the most destructive earthquake on 22 February 2011, which was used as the index event. The secondary end point was the number of "psychological" adverse events that participants reported at their usual monthly appointments as part of the original VIDARIS trial.
Results 308 participants completed the earthquake impact questionnaire (n=152 in the vitamin D group and 156 in the placebo group). There was no significant difference in the number of self reported adverse effects between those receiving vitamin D supplementation and those receiving placebo. There was also no difference in the overall adverse impact score between treatment groups (X-2 P=0.44). The exception was that those in the vitamin D group experienced more adverse effects on family relationships (22% v 13%; X-2 P=0.03). The number of psychological adverse events-such as fatigue, stress, anxiety, and insomnia-that participants reported at their usual monthly appointments was significantly higher after the earthquake (X-2 P=0.007) but did not differ between treatment groups.
Conclusion In this trial, vitamin D supplementation did not reduce the adverse impact of earthquakes in healthy adults. Trial registration Australian New Zealand Clinical
C1 [Slow, Sandy; Florkowski, Christopher M.; Chambers, Stephen T.; Jennings, Lance C.; Murdoch, David R.] Univ Otago, Dept Pathol, Christchurch, New Zealand.
[Florkowski, Christopher M.; Jennings, Lance C.; Livesey, John H.; Murdoch, David R.] Canterbury Hlth Labs, Christchurch, New Zealand.
[Chambers, Stephen T.] Christchurch Hosp, Dept Infect Dis, Christchurch, New Zealand.
[Priest, Patricia C.] Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand.
[Stewart, Alistair W.; Scragg, Robert] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02114 USA.
RP Slow, S (reprint author), Univ Otago, Dept Pathol, POB 4345, Christchurch, New Zealand.
EM sandy.slow@otago.ac.nz
FU Health Research Council of New Zealand
FX The study was funded by the Health Research Council of New Zealand. The
Health Research Council was not involved in the design or conduct of the
study, the collection, management, analysis and interpretation of the
data, or the preparation, review or approval of the manuscript. All
authors were independent from the funders.
NR 26
TC 0
Z9 0
U1 1
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD DEC 16
PY 2014
VL 349
AR g7260
DI 10.1136/bmj.g7260
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX2HK
UT WOS:000346763900006
PM 25516139
ER
PT J
AU Hsu, A
Conell-Price, J
Cenzer, IS
Eng, C
Huang, AJ
Rice-Trumble, K
Lee, SJ
AF Hsu, Amy
Conell-Price, Jessamyn
Cenzer, Irena Stijacic
Eng, Catherine
Huang, Alison J.
Rice-Trumble, Kathy
Lee, Sei J.
TI Predictors of urinary incontinence in communityd-welling frail older
adults with diabetes mellitus in a cross-sectional study
SO BMC GERIATRICS
LA English
DT Article
DE Urinary incontinence; Frail older adults; Diabetes mellitus
ID QUALITY-OF-LIFE; NURSING-HOME RESIDENTS; POSTMENOPAUSAL WOMEN; GERIATRIC
SYNDROMES; OVERACTIVE BLADDER; UNITED-STATES; HEALTH; RISK; PREVALENCE;
CARE
AB Background: Diabetes mellitus is a potent risk factor for urinary incontinence. Previous studies of incontinence in patients with diabetes have focused on younger, healthier patients. Our objective was to characterize risk factors for urinary incontinence among frail older adults with diabetes mellitus in a real-world clinical setting.
Methods: We performed a cross-sectional analysis on enrollees at On Lok (the original Program for All-Inclusive Care of the Elderly) between October 2004 and December 2010. Enrollees were community-dwelling, nursing home-eligible older adults with diabetes mellitus (N = 447). Our outcome was urinary incontinence measures (n = 2602) assessed every 6 months as "never incontinent", "seldom incontinent" (occurring less than once per week), or "often incontinent" (occurring more than once per week). Urinary incontinence was dichotomized ("never" versus "seldom" and "often" incontinent). We performed multivariate mixed effects logistic regression analysis with demographic (age, gender and ethnicity), geriatric (dependence on others for ambulation or transferring; cognitive impairment), diabetes-related factors (hemoglobin A1c level; use of insulin and other glucose-lowering medications; presence of renal, ophthalmologic, neurological and peripheral vascular complications), depressive symptoms and diuretic use.
Results: The majority of participants were 75 years or older (72%), Asian (65%) and female (66%). Demographic factors independently associated with incontinence included older age (OR for age >85, 3.13, 95% CI: 2.15-4.56; Reference: Age <75) and African American or other race (OR 2.12, 95% CI: 1.14-3.93; Reference: Asian). Geriatric factors included: dependence on others for ambulation (OR 1.48, 95% CI: 1.19-1.84) and transferring (OR 2.02, 95% CI: 1.58-2.58) and being cognitively impaired (OR 1.41, 95% CI: 1.15-1.73). Diabetes-related factors associated included use of insulin (OR 2.62, 95% CI: 1.67-4.13) and oral glucose-lowering agents (OR 1.81, 95% CI: 1.33-2.45). Urinary incontinence was not associated with gender, hemoglobin A1c level or depressive symptoms.
Conclusions: Geriatric factors such as the inability to ambulate or transfer independently are important predictors of urinary incontinence among frail older adults with diabetes mellitus. Clinicians should address mobility and cognitive impairment as much as diabetes-related factors in their assessment of urinary incontinence in this population.
C1 [Hsu, Amy; Cenzer, Irena Stijacic; Lee, Sei J.] San Francisco VA Med Ctr, San Francisco, CA 94122 USA.
[Hsu, Amy; Cenzer, Irena Stijacic; Eng, Catherine; Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Conell-Price, Jessamyn] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Eng, Catherine; Rice-Trumble, Kathy] On Lok Lifeways, San Francisco, CA USA.
[Huang, Alison J.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
RP Hsu, A (reprint author), San Francisco VA Med Ctr, 4150 Clement St,181G, San Francisco, CA 94122 USA.
EM Amy.Hsu@ucsf.edu
FU Beeson Career Development Award - National Institution on Aging
[K23AG040779]; American Federation of Aging Research
FX This material is the result of work supported with resources and the use
of facilities at the San Francisco VA Medical Center. Dr. Sei Lee's
effort was supported by the Beeson Career Development Award
(K23AG040779) funded by the National Institution on Aging and the
American Federation of Aging Research.
NR 36
TC 2
Z9 3
U1 3
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2318
J9 BMC GERIATR
JI BMC Geriatr.
PD DEC 16
PY 2014
VL 14
AR 137
DI 10.1186/1471-2318-14-137
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AX2AU
UT WOS:000346746300001
PM 25514968
ER
PT J
AU Rosenson, RS
Davidson, MH
Hirsh, BJ
Kathiresan, S
Gaudet, D
AF Rosenson, Robert S.
Davidson, Michael H.
Hirsh, Benjamin J.
Kathiresan, Sekar
Gaudet, Daniel
TI Genetics and Causality of Triglyceride-Rich Lipoproteins in
Atherosclerotic Cardiovascular Disease
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Review
DE atherosclerosis; cardiovascular disease; genetics; triglyceride;
triglyceride-rich lipoproteins
ID LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; APOLIPOPROTEIN C-III;
ALIPOGENE TIPARVOVEC AAV1-LPLS447X; PAPER GLOBAL RECOMMENDATIONS;
TISSUE-SPECIFIC EXPRESSION; CYTOSOLIC LIPID DROPLETS; GENOME-WIDE
ASSOCIATION; EXTENDED-RELEASE NIACIN; OF-FUNCTION MUTATIONS
AB Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This " omic" approach recently resulted in new targets for reducing CVD events. (C) 2014 by the American College of Cardiology Foundation.
C1 [Rosenson, Robert S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Davidson, Michael H.] Univ Chicago, Pritzker Sch Med, Div Cardiol, Chicago, IL 60637 USA.
[Hirsh, Benjamin J.] Mt Sinai Hosp, New York, NY 10029 USA.
[Kathiresan, Sekar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Gaudet, Daniel] Univ Montreal, Dept Med, ECOGENE 21, Chicoutimi, PQ, Canada.
[Gaudet, Daniel] Univ Montreal, Dept Med, Lipid Clin, Chicoutimi, PQ, Canada.
RP Rosenson, RS (reprint author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl,Box 1030, New York, NY 10029 USA.
EM robert.rosenson@mssm.edu
NR 154
TC 32
Z9 34
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD DEC 16
PY 2014
VL 64
IS 23
BP 2525
EP 2540
DI 10.1016/j.jacc.2014.09.042
PG 16
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AW0EF
UT WOS:000345962400013
PM 25500239
ER
PT J
AU Lamming, DW
AF Lamming, Dudley W.
TI Diminished mTOR signaling: a common mode of action for endocrine
longevity factors
SO SPRINGERPLUS
LA English
DT Review
DE Calorie restriction; Rapamycin; Insulin resistance; Longevity
ID AMES DWARF MICE; GLUCAGON-LIKE PEPTIDE-1; IMPROVES INSULIN SENSITIVITY;
BETA-CELL PROLIFERATION; MAMMALIAN LIFE-SPAN; CALORIC RESTRICTION;
DIETARY RESTRICTION; FAT-METABOLISM; EXTENDS LIFE; ALZHEIMERS-DISEASE
AB Since the initial observation that a calorie-restricted (CR) diet can extend rodent lifespan, many genetic and pharmaceutical interventions that also extend lifespan in mammals have been discovered. The mechanism by which CR and these other interventions extend lifespan is the subject of significant debate and research. One proposed mechanism is that CR promotes longevity by increasing insulin sensitivity, but recent findings that dissociate longevity and insulin sensitivity cast doubt on this hypothesis. These findings can be reconciled if longevity is promoted not via increased insulin sensitivity, but instead via decreased PI3K/Akt/mTOR pathway signaling. This review presents a unifying hypothesis that explains the lifespan-extending effects of a variety of genetic mutations and pharmaceutical interventions and points towards new molecular pathways which may also be leveraged to promote healthy aging.
C1 [Lamming, Dudley W.] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53706 USA.
[Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Lamming, DW (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53706 USA.
EM dlamming@medicine.wisc.edu
OI Lamming, Dudley/0000-0002-0079-4467
FU National Institute of Health [AG041765]; UW-Madison School of Medicine
and Public Health; UW-Madison Department of Medicine; William S.
Middleton Memorial Veterans Hospital
FX This review benefited greatly from the advice of D.E. Cohen, and we also
thank A.K. Linnemann for helpful suggestions about CCK and E.L. Baar for
critical reading of the manuscript. The Lamming lab is supported by a
grant from the National Institute of Health (AG041765) and startup funds
from the UW-Madison School of Medicine and Public Health and the
UW-Madison Department of Medicine. This work was supported using
facilities and resources from the William S. Middleton Memorial Veterans
Hospital. This work does not represent the views of the Department of
Veterans Affairs or the United States Government.
NR 112
TC 13
Z9 15
U1 1
U2 4
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-1801
J9 SPRINGERPLUS
JI SpringerPlus
PD DEC 15
PY 2014
VL 3
AR 735
DI 10.1186/2193-1801-3-735
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO4HY
UT WOS:000359123000002
PM 25674466
ER
PT J
AU Jin, L
Datta, PK
AF Jin, Lin
Datta, Pran K.
TI Oncogenic STRAP functions as a novel negative regulator of E-cadherin
and p21(Cip1) by modulating the transcription factor Sp1
SO CELL CYCLE
LA English
DT Article
DE STRAP; Sp1; transcription factor; cell cycle; ubiquitination; STRAP;
serine threonine kinase receptor-associated protein; Sp1; specificity
protein 1; Sp; KLF; specificity protein; Kruppel-like factor; SWI; SNF;
SWItch; Sucrose nonfermentable; p300; CBP; p300; CREB-binding protein;
TSS; transcription start site; MEF; mouse embryonic fibroblast; HNF4;
hepatocyte nuclear factor 4; TSA; trichostatin A; HDAC1; histone
deacetylase 1; HDAC2; histone deacetylase 2; HDAC3; histone deacetylase
3; NF-YA; nuclear transcription factor Y subunit alpha; TR I; II; TGF-
receptor I; II; RNase; A ribonuclease A; CDK2; cyclin-dependent kinase
2; CDK4; cyclin-dependent kinase 4; PARP; poly (ADP-ribose) polymerase;
RhoA; Ras homolog gene family; member A
ID GENE-TRANSCRIPTION; CANCER-CELLS; LUNG-CANCER; EXPRESSION; PROTEINS;
PROMOTER; BINDING; OVEREXPRESSION; PROGRESSION; INHIBITION
AB We have previously reported the identification of a novel WD-domain protein, STRAP that plays a role in maintenance of mesenchymal morphology by regulating E-cadherin and that enhances tumorigenicity partly by downregulating CDK inhibitor p21(Cip1). However, the functional mechanism of regulation of E-cadherin and p21(Cip1) by STRAP is unknown. Here, we have employed STRAP knock out and knockdown cell models (mouse embryonic fibroblast, human cancer cell lines) to show how STRAP downregulates E-cadherin and p21(Cip1) by abrogating the binding of Sp1 to its consensus binding sites. Moreover, ChIP assays suggest that STRAP recruits HDAC1 to Sp1 binding sites in p21(Cip1) promoter. Interestingly, loss of STRAP can stabilize Sp1 by repressing its ubiquitination in G1 phase, resulting in an enhanced expression of p21(Cip1) by >4.5-fold and cell cycle arrest. Using Bioinformatics and Microarray analyses, we have observed that 87% mouse genes downregulated by STRAP have conserved Sp1 binding sites. In NSCLC, the expression levels of STRAP inversely correlated with that of Sp1 (60%). These results suggest a novel mechanism of regulation of E-cadherin and p21(Cip1) by STRAP by modulating Sp1-dependent transcription, and higher expression of STRAP in lung cancer may contribute to downregulation of E-cadherin and p21(Cip1) and to tumor progression.
C1 [Jin, Lin; Datta, Pran K.] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA.
[Jin, Lin; Datta, Pran K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Datta, PK (reprint author), Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA.
EM prandatta@uabmc.edu
FU Veterans Affairs Merit Review Award; [R01 CA095195]
FX This study was supported by R01 CA095195, and Veterans Affairs Merit
Review Award (to PK Datta).
NR 36
TC 4
Z9 4
U1 1
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD DEC 15
PY 2014
VL 13
IS 24
BP 3909
EP 3920
DI 10.4161/15384101.2014.973310
PG 12
WC Cell Biology
SC Cell Biology
GA AZ6KU
UT WOS:000348329600020
PM 25483064
ER
PT J
AU Wang, ZM
Zhu, B
Zhang, MF
Parikh, H
Jia, JP
Chung, CC
Sampson, JN
Hoskins, JW
Hutchinson, A
Burdette, L
Ibrahim, A
Hautman, C
Raj, PS
Abnet, CC
Adjei, AA
Ahlbom, A
Albanes, D
Allen, NE
Ambrosone, CB
Aldrich, M
Amiano, P
Amos, C
Andersson, U
Andriole, G
Andrulis, IL
Arici, C
Arslan, AA
Austin, MA
Baris, D
Barkauskas, DA
Bassig, BA
Freeman, LEB
Berg, CD
Berndt, SI
Bertazzi, PA
Biritwum, RB
Black, A
Blot, W
Boeing, H
Boffetta, P
Bolton, K
Boutron-Ruault, MC
Bracci, PM
Brennan, P
Brinton, LA
Brotzman, M
Bueno-de-Mesquita, HB
Buring, JE
Butler, MA
Cai, QY
Cancel-Tassin, G
Canzian, F
Cao, GW
Caporaso, NE
Carrato, A
Carreon, T
Carta, A
Chang, GC
Chang, IS
Chang-Claude, J
Che, X
Chen, CJ
Chen, CY
Chen, CH
Chen, C
Chen, KY
Chen, YM
Chokkalingam, AP
Chu, LW
Clavel-Chapelon, F
Colditz, GA
Colt, JS
Conti, D
Cook, MB
Cortessis, VK
Crawford, ED
Cussenot, O
Davis, FG
De Vivo, I
Deng, X
Ding, T
Dinney, CP
Di Stefano, AL
Diver, WR
Duell, EJ
Elena, JW
Fan, JH
Feigelson, HS
Feychting, M
Figueroa, JD
Flanagan, AM
Fraumeni, JF
Freedman, ND
Fridley, BL
Fuchs, CS
Gago-Dominguez, M
Gallinger, S
Gao, YT
Gapstur, SM
Garcia-Closas, M
Garcia-Closas, R
Gastier-Foster, JM
Gaziano, JM
Gerhard, DS
Giffen, CA
Giles, GG
Gillanders, EM
Giovannucci, EL
Goggins, M
Gokgoz, N
Goldstein, AM
Gonzalez, C
Gorlick, R
Greene, MH
Gross, M
Grossman, HB
Grubb, R
Gu, J
Guan, P
Haiman, CA
Hallmans, G
Hankinson, SE
Harris, CC
Hartge, P
Hattinger, C
Hayes, RB
He, QC
Helman, L
Henderson, BE
Henriksson, R
Hoffman-Bolton, J
Hohensee, C
Holly, EA
Hong, YC
Hoover, RN
Hosgood, HD
Hsiao, CF
Hsing, AW
Hsiung, CA
Hu, N
Hu, W
Hu, ZB
Huang, MS
Hunter, DJ
Inskip, PD
Ito, H
Jacobs, EJ
Jacobs, KB
Jenab, M
Ji, BT
Johansen, C
Johansson, M
Johnson, A
Kaaks, R
Kamat, AM
Kamineni, A
Karagas, M
Khanna, C
Khaw, KT
Kim, C
Kim, IS
Kim, JH
Kim, YH
Kim, YC
Kim, YT
Kang, CH
Jung, YJ
Kitahara, CM
Klein, AP
Klein, R
Kogevinas, M
Koh, WP
Kohno, T
Kolonel, LN
Kooperberg, C
Kratz, CP
Krogh, V
Kunitoh, H
Kurtz, RC
Kurucu, N
Lan, Q
Lathrop, M
Lau, CC
Lecanda, F
Lee, KM
Lee, MP
Le Marchand, L
Lerner, SP
Li, DH
Liao, LM
Lim, WY
Lin, DX
Lin, J
Lindstrom, S
Linet, MS
Lissowska, J
Liu, JJ
Ljungberg, B
Lloreta, J
Lu, DR
Ma, J
Malats, N
Mannisto, S
Marina, N
Mastrangelo, G
Matsuo, K
McGlynn, KA
McKean-Cowdin, R
McNeill, LH
McWilliams, RR
Melin, BS
Meltzer, PS
Mensah, JE
Miao, XP
Michaud, DS
Mondul, AM
Moore, LE
Muir, K
Niwa, S
Olson, SH
Orr, N
Panico, S
Park, JY
Patel, AV
Patino-Garcia, A
Pavanello, S
Peeters, PHM
Peplonska, B
Peters, U
Petersen, GM
Picci, P
Pike, MC
Porru, S
Prescott, J
Pu, X
Purdue, MP
Qiao, YL
Rajaraman, P
Riboli, E
Risch, HA
Rodabough, RJ
Rothman, N
Ruder, AM
Ryu, JS
Sanson, M
Schned, A
Schumacher, FR
Schwartz, AG
Schwartz, KL
Schwenn, M
Scotlandi, K
Seow, A
Serra, C
Serra, M
Sesso, HD
Severi, G
Shen, HB
Shen, M
Shete, S
Shiraishi, K
Shu, XO
Siddiq, A
Sierrasesumaga, L
Sierri, S
Sihoe, ADL
Silverman, DT
Simon, M
Southey, MC
Spector, L
Spitz, M
Stampfer, M
Stattin, P
Stern, MC
Stevens, VL
Stolzenberg-Solomon, RZ
Stram, DO
Strom, SS
Su, WC
Sund, M
Sung, SW
Swerdlow, A
Tan, W
Tanaka, H
Tang, W
Tang, ZZ
Tardon, A
Tay, E
Taylor, PR
Tettey, Y
Thomas, DM
Tirabosco, R
Tjonneland, A
Tobias, GS
Toro, JR
Travis, RC
Trichopoulos, D
Troisi, R
Truelove, A
Tsai, YH
Tucker, MA
Tumino, R
Van Den Berg, D
Van Den Eeden, SK
Vermeulen, R
Vineis, P
Visvanathan, K
Vogel, U
Wang, CY
Wang, CF
Wang, JW
Wang, SS
Weiderpass, E
Weinstein, SJ
Wentzensen, N
Wheeler, W
White, E
Wiencke, JK
Wolk, A
Wolpin, BM
Wong, MP
Wrensch, M
Wu, C
Wu, TC
Wu, XF
Wu, YL
Wunder, JS
Xiang, YB
Xu, J
Yang, HP
Yang, PC
Yatabe, Y
Ye, YQ
Yeboah, ED
Yin, ZH
Ying, C
Yu, CJ
Yu, K
Yuan, JM
Zanetti, KA
Zeleniuch-Jacquotte, A
Zheng, W
Zhou, BS
Mirabello, L
Savage, SA
Kraft, P
Chanock, SJ
Yeager, M
Landi, MT
Shi, JX
Chatterjee, N
Amundadottir, LT
AF Wang, Zhaoming
Zhu, Bin
Zhang, Mingfeng
Parikh, Hemang
Jia, Jinping
Chung, Charles C.
Sampson, Joshua N.
Hoskins, Jason W.
Hutchinson, Amy
Burdette, Laurie
Ibrahim, Abdisamad
Hautman, Christopher
Raj, Preethi S.
Abnet, Christian C.
Adjei, Andrew A.
Ahlbom, Anders
Albanes, Demetrius
Allen, Naomi E.
Ambrosone, Christine B.
Aldrich, Melinda
Amiano, Pilar
Amos, Christopher
Andersson, Ulrika
Andriole, Gerald, Jr.
Andrulis, Irene L.
Arici, Cecilia
Arslan, Alan A.
Austin, Melissa A.
Baris, Dalsu
Barkauskas, Donald A.
Bassig, Bryan A.
Freeman, Laura E. Beane
Berg, Christine D.
Berndt, Sonja I.
Bertazzi, Pier Alberto
Biritwum, Richard B.
Black, Amanda
Blot, William
Boeing, Heiner
Boffetta, Paolo
Bolton, Kelly
Boutron-Ruault, Marie-Christine
Bracci, Paige M.
Brennan, Paul
Brinton, Louise A.
Brotzman, Michelle
Bueno-de-Mesquita, H. Bas
Buring, Julie E.
Butler, Mary Ann
Cai, Qiuyin
Cancel-Tassin, Geraldine
Canzian, Federico
Cao, Guangwen
Caporaso, Neil E.
Carrato, Alfredo
Carreon, Tania
Carta, Angela
Chang, Gee-Chen
Chang, I-Shou
Chang-Claude, Jenny
Che, Xu
Chen, Chien-Jen
Chen, Chih-Yi
Chen, Chung-Hsing
Chen, Constance
Chen, Kuan-Yu
Chen, Yuh-Min
Chokkalingam, Anand P.
Chu, Lisa W.
Clavel-Chapelon, Francoise
Colditz, Graham A.
Colt, Joanne S.
Conti, David
Cook, Michael B.
Cortessis, Victoria K.
Crawford, E. David
Cussenot, Olivier
Davis, Faith G.
De Vivo, Immaculata
Deng, Xiang
Ding, Ti
Dinney, Colin P.
Di Stefano, Anna Luisa
Diver, W. Ryan
Duell, Eric J.
Elena, Joanne W.
Fan, Jin-Hu
Feigelson, Heather Spencer
Feychting, Maria
Figueroa, Jonine D.
Flanagan, Adrienne M.
Fraumeni, Joseph F., Jr.
Freedman, Neal D.
Fridley, Brooke L.
Fuchs, Charles S.
Gago-Dominguez, Manuela
Gallinger, Steven
Gao, Yu-Tang
Gapstur, Susan M.
Garcia-Closas, Montserrat
Garcia-Closas, Reina
Gastier-Foster, Julie M.
Gaziano, J. Michael
Gerhard, Daniela S.
Giffen, Carol A.
Giles, Graham G.
Gillanders, Elizabeth M.
Giovannucci, Edward L.
Goggins, Michael
Gokgoz, Nalan
Goldstein, Alisa M.
Gonzalez, Carlos
Gorlick, Richard
Greene, Mark H.
Gross, Myron
Grossman, H. Barton
Grubb, Robert, III
Gu, Jian
Guan, Peng
Haiman, Christopher A.
Hallmans, Goran
Hankinson, Susan E.
Harris, Curtis C.
Hartge, Patricia
Hattinger, Claudia
Hayes, Richard B.
He, Qincheng
Helman, Lee
Henderson, Brian E.
Henriksson, Roger
Hoffman-Bolton, Judith
Hohensee, Chancellor
Holly, Elizabeth A.
Hong, Yun-Chul
Hoover, Robert N.
Hosgood, H. Dean
Hsiao, Chin-Fu
Hsing, Ann W.
Hsiung, Chao Agnes
Hu, Nan
Hu, Wei
Hu, Zhibin
Huang, Ming-Shyan
Hunter, David J.
Inskip, Peter D.
Ito, Hidemi
Jacobs, Eric J.
Jacobs, Kevin B.
Jenab, Mazda
Ji, Bu-Tian
Johansen, Christoffer
Johansson, Mattias
Johnson, Alison
Kaaks, Rudolf
Kamat, Ashish M.
Kamineni, Aruna
Karagas, Margaret
Khanna, Chand
Khaw, Kay-Tee
Kim, Christopher
Kim, In-Sam
Kim, Jin Hee
Kim, Yeul Hong
Kim, Young-Chul
Kim, Young Tae
Kang, Chang Hyun
Jung, Yoo Jin
Kitahara, Cari M.
Klein, Alison P.
Klein, Robert
Kogevinas, Manolis
Koh, Woon-Puay
Kohno, Takashi
Kolonel, Laurence N.
Kooperberg, Charles
Kratz, Christian P.
Krogh, Vittorio
Kunitoh, Hideo
Kurtz, Robert C.
Kurucu, Nilgun
Lan, Qing
Lathrop, Mark
Lau, Ching C.
Lecanda, Fernando
Lee, Kyoung-Mu
Lee, Maxwell P.
Le Marchand, Loic
Lerner, Seth P.
Li, Donghui
Liao, Linda M.
Lim, Wei-Yen
Lin, Dongxin
Lin, Jie
Lindstrom, Sara
Linet, Martha S.
Lissowska, Jolanta
Liu, Jianjun
Ljungberg, Boerje
Lloreta, Josep
Lu, Daru
Ma, Jing
Malats, Nuria
Mannisto, Satu
Marina, Neyssa
Mastrangelo, Giuseppe
Matsuo, Keitaro
McGlynn, Katherine A.
McKean-Cowdin, Roberta
McNeill, Lorna H.
McWilliams, Robert R.
Melin, Beatrice S.
Meltzer, Paul S.
Mensah, James E.
Miao, Xiaoping
Michaud, Dominique S.
Mondul, Alison M.
Moore, Lee E.
Muir, Kenneth
Niwa, Shelley
Olson, Sara H.
Orr, Nick
Panico, Salvatore
Park, Jae Yong
Patel, Alpa V.
Patino-Garcia, Ana
Pavanello, Sofia
Peeters, Petra H. M.
Peplonska, Beata
Peters, Ulrike
Petersen, Gloria M.
Picci, Piero
Pike, Malcolm C.
Porru, Stefano
Prescott, Jennifer
Pu, Xia
Purdue, Mark P.
Qiao, You-Lin
Rajaraman, Preetha
Riboli, Elio
Risch, Harvey A.
Rodabough, Rebecca J.
Rothman, Nathaniel
Ruder, Avima M.
Ryu, Jeong-Seon
Sanson, Marc
Schned, Alan
Schumacher, Fredrick R.
Schwartz, Ann G.
Schwartz, Kendra L.
Schwenn, Molly
Scotlandi, Katia
Seow, Adeline
Serra, Consol
Serra, Massimo
Sesso, Howard D.
Severi, Gianluca
Shen, Hongbing
Shen, Min
Shete, Sanjay
Shiraishi, Kouya
Shu, Xiao-Ou
Siddiq, Afshan
Sierrasesumaga, Luis
Sierri, Sabina
Sihoe, Alan Dart Loon
Silverman, Debra T.
Simon, Matthias
Southey, Melissa C.
Spector, Logan
Spitz, Margaret
Stampfer, Meir
Stattin, Par
Stern, Mariana C.
Stevens, Victoria L.
Stolzenberg-Solomon, Rachael Z.
Stram, Daniel O.
Strom, Sara S.
Su, Wu-Chou
Sund, Malin
Sung, Sook Whan
Swerdlow, Anthony
Tan, Wen
Tanaka, Hideo
Tang, Wei
Tang, Ze-Zhang
Tardon, Adonina
Tay, Evelyn
Taylor, Philip R.
Tettey, Yao
Thomas, David M.
Tirabosco, Roberto
Tjonneland, Anne
Tobias, Geoffrey S.
Toro, Jorge R.
Travis, Ruth C.
Trichopoulos, Dimitrios
Troisi, Rebecca
Truelove, Ann
Tsai, Ying-Huang
Tucker, Margaret A.
Tumino, Rosario
Van Den Berg, David
Van Den Eeden, Stephen K.
Vermeulen, Roel
Vineis, Paolo
Visvanathan, Kala
Vogel, Ulla
Wang, Chaoyu
Wang, Chengfeng
Wang, Junwen
Wang, Sophia S.
Weiderpass, Elisabete
Weinstein, Stephanie J.
Wentzensen, Nicolas
Wheeler, William
White, Emily
Wiencke, John K.
Wolk, Alicja
Wolpin, Brian M.
Wong, Maria Pik
Wrensch, Margaret
Wu, Chen
Wu, Tangchun
Wu, Xifeng
Wu, Yi-Long
Wunder, Jay S.
Xiang, Yong-Bing
Xu, Jun
Yang, Hannah P.
Yang, Pan-Chyr
Yatabe, Yasushi
Ye, Yuanqing
Yeboah, Edward D.
Yin, Zhihua
Ying, Chen
Yu, Chong-Jen
Yu, Kai
Yuan, Jian-Min
Zanetti, Krista A.
Zeleniuch-Jacquotte, Anne
Zheng, Wei
Zhou, Baosen
Mirabello, Lisa
Savage, Sharon A.
Kraft, Peter
Chanock, Stephen J.
Yeager, Meredith
Landi, Maria Terese
Shi, Jianxin
Chatterjee, Nilanjan
Amundadottir, Laufey T.
TI Imputation and subset-based association analysis across different cancer
types identifies multiple independent risk loci in the TERT-CLPTM1L
region on chromosome 5p15.33
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SINGLE-NUCLEOTIDE POLYMORPHISM; POSTMENOPAUSAL
BREAST-CANCER; TERT PROMOTER MUTATIONS; 2 SUSCEPTIBILITY LOCI; TELOMERE
LENGTH; LUNG-CANCER; PROSTATE-CANCER; PANCREATIC-CANCER; DNA METHYLATION
AB Genome-wide association studies (GWAS) have mapped risk alleles for at least 10 distinct cancers to a small region of 63 000 bp on chromosome 5p15.33. This region harbors the TERT and CLPTM1L genes; the former encodes the catalytic subunit of telomerase reverse transcriptase and the latter may play a role in apoptosis. To investigate further the genetic architecture of common susceptibility alleles in this region, we conducted an agnostic subset-based meta-analysis (association analysis based on subsets) across six distinct cancers in 34 248 cases and 45 036 controls. Based on sequential conditional analysis, we identified as many as six independent risk loci marked by common single-nucleotide polymorphisms: five in the TERT gene (Region 1: rs7726159, P = 2.10 x 10(-39); Region 3: rs2853677, P = 3.30 x 10(-36) and P-Conditional = 2.36 x 10(-8); Region 4: rs2736098, P = 3.87 x 10(-12) and P-Conditional = 5.19 x 10(-6), Region 5: rs13172201, P = 0.041 and P-Conditional = 2.04 x 10(-6); and Region 6: rs10069690, P = 7.49 x 10 215 and P-Conditional = 5.35 x 10(-7)) and one in the neighboring CLPTM1L gene(Region 2: rs451360; P = 1.90 x 10(-18) and P-Conditional = 7.06 x 10(-16)). Between three and five cancers mapped to each independent locus with both risk-enhancing and protective effects. Allele-specific effects on DNA methylation were seen for a subset of risk loci, indicating that methylation and subsequent effects on gene expression may contribute to the biology of risk variants on 5p15.33. Our results provide strong support for extensive pleiotropy across this region of 5p15.33, to an extent not previously observed in other cancer susceptibility loci.
C1 [Wang, Zhaoming; Zhu, Bin; Zhang, Mingfeng; Parikh, Hemang; Jia, Jinping; Chung, Charles C.; Sampson, Joshua N.; Hoskins, Jason W.; Hutchinson, Amy; Burdette, Laurie; Ibrahim, Abdisamad; Hautman, Christopher; Raj, Preethi S.; Abnet, Christian C.; Albanes, Demetrius; Baris, Dalsu; Bassig, Bryan A.; Freeman, Laura E. Beane; Berndt, Sonja I.; Black, Amanda; Bolton, Kelly; Brinton, Louise A.; Caporaso, Neil E.; Colt, Joanne S.; Cook, Michael B.; Deng, Xiang; Figueroa, Jonine D.; Fraumeni, Joseph F., Jr.; Freedman, Neal D.; Garcia-Closas, Montserrat; Goldstein, Alisa M.; Greene, Mark H.; Hartge, Patricia; Hayes, Richard B.; Hoover, Robert N.; Hu, Nan; Hu, Wei; Inskip, Peter D.; Ji, Bu-Tian; Kim, Christopher; Kitahara, Cari M.; Kratz, Christian P.; Lan, Qing; Liao, Linda M.; Linet, Martha S.; McGlynn, Katherine A.; Mondul, Alison M.; Moore, Lee E.; Purdue, Mark P.; Rajaraman, Preetha; Rothman, Nathaniel; Shen, Min; Silverman, Debra T.; Stolzenberg-Solomon, Rachael Z.; Tang, Wei; Taylor, Philip R.; Tobias, Geoffrey S.; Toro, Jorge R.; Troisi, Rebecca; Tucker, Margaret A.; Wang, Chaoyu; Wang, Junwen; Weinstein, Stephanie J.; Wentzensen, Nicolas; Yang, Hannah P.; Yu, Kai; Mirabello, Lisa; Savage, Sharon A.; Chanock, Stephen J.; Yeager, Meredith; Landi, Maria Terese; Shi, Jianxin; Chatterjee, Nilanjan; Amundadottir, Laufey T.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Berg, Christine D.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA.
[Helman, Lee; Khanna, Chand; Lee, Maxwell P.; Meltzer, Paul S.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Gerhard, Daniela S.; Jacobs, Kevin B.] NCI, Off Canc Genom, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA.
[Wang, Zhaoming; Chung, Charles C.; Hutchinson, Amy; Burdette, Laurie; Hautman, Christopher; Deng, Xiang; Jacobs, Kevin B.; Wang, Junwen; Chanock, Stephen J.; Yeager, Meredith] NCI, Canc Genom Res Lab, Div Canc Epidemiol & Genet, SAIC Frederick Inc,Frederick Natl Lab Canc Res, Frederick, MD 21701 USA.
[Adjei, Andrew A.; Biritwum, Richard B.; Mensah, James E.; Tay, Evelyn; Tettey, Yao; Yeboah, Edward D.] Korle Bu Teaching Hosp, Accra, Ghana.
[Adjei, Andrew A.; Biritwum, Richard B.; Mensah, James E.; Tay, Evelyn; Tettey, Yao; Yeboah, Edward D.] Univ Ghana, Sch Med, Accra, Ghana.
[Ahlbom, Anders; Feychting, Maria] Karolinska Inst, Epidemiol Unit, Inst Environm Med, Stockholm, Sweden.
[Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Wolk, Alicja] Karolinska Inst, Unit Nutr Epidemiol, Inst Environm Med, Stockholm, Sweden.
[Allen, Naomi E.; Travis, Ruth C.] Univ Oxford, Clin Trial Serv Unit, Oxford, England.
[Allen, Naomi E.; Travis, Ruth C.] Univ Oxford, Epidemiol Studies Unit, Oxford, England.
[Ambrosone, Christine B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
[Aldrich, Melinda; Blot, William; Cai, Qiuyin; Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, Div Epidemiol,Dept Med, Nashville, TN 37212 USA.
[Aldrich, Melinda; Blot, William; Cai, Qiuyin; Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
[Amiano, Pilar] Basque Reg Hlth Dept, Publ Hlth Div Gipuzkoa, San Sebastian, Spain.
[Amiano, Pilar] CIBER Epidemiol & Salud Publ, CIBERESP, Madrid, Spain.
[Amos, Christopher; Karagas, Margaret; Schned, Alan] Geisel Sch Med Dartmouth, Hanover, NH USA.
[Andersson, Ulrika; Henriksson, Roger; Melin, Beatrice S.] Umea Univ, Dept Radiat Sci, Umea, Sweden.
[Hallmans, Goran] Umea Univ, Dept Publ Hlth & Clin Med Nutr Res, Umea, Sweden.
[Johansson, Mattias] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Ljungberg, Boerje; Stattin, Par] Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden.
[Sund, Malin] Umea Univ, Dept Surg & Perioperat Sci Surg, Umea, Sweden.
[Andriole, Gerald, Jr.; Wunder, Jay S.] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA.
[Andrulis, Irene L.; Carta, Angela] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Litwin Ctr Canc Genet, Toronto, ON M5G 1X5, Canada.
[Arici, Cecilia; Porru, Stefano] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, I-25121 Brescia, Italy.
[Arslan, Alan A.] NYU, Dept Obstet & Gynecol, Sch Med, New York, NY 10016 USA.
[Arslan, Alan A.; Zeleniuch-Jacquotte, Anne] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA.
[Arslan, Alan A.; Zeleniuch-Jacquotte, Anne] NYU, Inst Canc, New York, NY USA.
[Austin, Melissa A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Barkauskas, Donald A.; Conti, David; Cortessis, Victoria K.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Div Biostat, Los Angeles, CA 90033 USA.
[Haiman, Christopher A.; Henderson, Brian E.; Pike, Malcolm C.; Schumacher, Fredrick R.; Stern, Mariana C.; Stram, Daniel O.; Van Den Berg, David] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Bassig, Bryan A.] Yale Univ, Sch Publ Hlth, Div Environm Hlth Sci, New Haven, CT USA.
[Bertazzi, Pier Alberto] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
[Bertazzi, Pier Alberto] Fdn IRCCS Ca Granda Policlin Hosp, Dept Prevent Med, Milan, Italy.
[Blot, William] Int Epidemiol Inst, Rockville, MD USA.
[Boeing, Heiner] German Inst Human Nutr, Dept Epidemiol, Potsdam, Germany.
[Boffetta, Paolo] Mt Sinai Hosp, Inst Translat Epidemiol Hematol & Med Oncol, Sch Med, New York, NY 10029 USA.
[Bolton, Kelly] Univ Cambridge, Dept Oncol, Cambridge CB2 2RE, England.
[Boutron-Ruault, Marie-Christine] INSERM, Villejuif, France.
[Boutron-Ruault, Marie-Christine] Inst Gustave Roussy, Villejuif, France.
[Bracci, Paige M.; Holly, Elizabeth A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Brennan, Paul; Jenab, Mazda; Johansson, Mattias] Int Agcy Res Canc IARC WHO, Lyon, France.
[Brotzman, Michelle; Niwa, Shelley; Truelove, Ann] Westat Corp, Rockville, MD USA.
[Bueno-de-Mesquita, H. Bas] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
[Bueno-de-Mesquita, H. Bas] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands.
[Buring, Julie E.; Sesso, Howard D.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Butler, Mary Ann; Carreon, Tania; Ruder, Avima M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Cancel-Tassin, Geraldine; Cussenot, Olivier] CeRePP, Paris, France.
[Cussenot, Olivier] Tenon Hosp, AP HP, Dept Urol, GHU Est, Paris, France.
[Cancel-Tassin, Geraldine; Cussenot, Olivier] Univ Paris 06, GRC 85, ONCOTYPE URO, Paris, France.
[Canzian, Federico; Chang-Claude, Jenny; Kaaks, Rudolf] German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany.
[Cao, Guangwen] Second Mil Med Univ, Dept Epidemiol, Shanghai, Peoples R China.
[Carrato, Alfredo] Hosp Ramon & Cajal, Dept Med Oncol, E-28034 Madrid, Spain.
[Chang, Gee-Chen] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei 112, Taiwan.
[Chang, Gee-Chen] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan.
[Chang, I-Shou; Chen, Chung-Hsing] Natl Inst Canc Res, Zhunan, Taiwan.
[Hsiao, Chin-Fu; Hsiung, Chao Agnes] Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan.
[Hsiao, Chin-Fu] Natl Hlth Res Inst, Taiwan Lung Canc Tissue Specimen Informat Resourc, Zhunan, Taiwan.
[Che, Xu; Wang, Chengfeng] Chinese Acad Med Sci, Dept Abdominal Surg, Beijing 100730, Peoples R China.
[Lin, Dongxin; Tan, Wen; Wu, Chen] Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing 100730, Peoples R China.
[Lin, Dongxin; Tan, Wen; Wu, Chen] Peking Union Med Coll, Beijing 100021, Peoples R China.
[Chen, Chien-Jen] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
[Chen, Chien-Jen] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 10764, Taiwan.
[Chen, Chih-Yi] China Med Univ Hosp, Ctr Canc, Taipei, Taiwan.
[Chen, Constance; De Vivo, Immaculata; Giovannucci, Edward L.; Hunter, David J.; Lindstrom, Sara; Prescott, Jennifer; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Trichopoulos, Dimitrios] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Chen, Kuan-Yu; Huang, Ming-Shyan; Yang, Pan-Chyr; Kraft, Peter] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Chen, Kuan-Yu; Huang, Ming-Shyan; Yang, Pan-Chyr; Kraft, Peter] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
[Chen, Yuh-Min] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore.
[Koh, Woon-Puay; Lim, Wei-Yen; Seow, Adeline; Ying, Chen] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
[Chen, Yuh-Min] Taipei Vet Gen Hosp, Chest Dept, Taipei, Taiwan.
[Chen, Yuh-Min] Taipei Med Univ, Coll Med Sci & Technol, Taipei, Taiwan.
[Chokkalingam, Anand P.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
[Chu, Lisa W.; Hsing, Ann W.] Canc Prevent Inst Calif, Fremont, CA USA.
[Clavel-Chapelon, Francoise] INSERM, Ctr Res Epidemiol & Populat Hlth CESP, Villejuif, France.
[Colditz, Graham A.] Washington Univ, Sch Med, St Louis, MO USA.
[Crawford, E. David] Univ Colorado, Aurora, CO USA.
[Davis, Faith G.] Univ Alberta, Dept Publ Hlth Sci, Sch Publ Hlth, Edmonton, AB T6G 2R3, Canada.
[De Vivo, Immaculata; Hunter, David J.; Ma, Jing; Prescott, Jennifer; Stampfer, Meir] Channing Div Network Med, Dept Med, Boston, MA USA.
[De Vivo, Immaculata; Hunter, David J.; Ma, Jing; Prescott, Jennifer; Stampfer, Meir] Brigham & Womens Hosp, Boston, MA 02115 USA.
[De Vivo, Immaculata; Hunter, David J.; Ma, Jing; Prescott, Jennifer; Stampfer, Meir] Harvard Univ, Sch Med, Boston, MA USA.
[Ding, Ti; Tang, Ze-Zhang] Shanxi Canc Hosp, Taiyuan, Shanxi, Peoples R China.
[Dinney, Colin P.; Grossman, H. Barton; Kamat, Ashish M.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA.
[Gu, Jian; Lin, Jie; McKean-Cowdin, Roberta; Pu, Xia; Wu, Xifeng; Ye, Yuanqing] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
[Li, Donghui] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
[McNeill, Lorna H.] Univ Texas MD Anderson Canc Ctr, Dept Hlth Dispar Res, Div OVP Canc Prevent & Populat Sci, Houston, TX 77030 USA.
[McNeill, Lorna H.] Univ Texas MD Anderson Canc Ctr, Ctr Community Engaged Translat Res, Duncan Family Inst, Houston, TX 77030 USA.
[Strom, Sara S.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA.
[Di Stefano, Anna Luisa; Sanson, Marc] GH Pitie Salpetriere, APHP, Serv Neurol Mazarin, Paris, France.
[Di Stefano, Anna Luisa; Sanson, Marc] UMR 975 INSERM UPMC, CRICM, Paris, France.
[Diver, W. Ryan; Gapstur, Susan M.; Jacobs, Eric J.; Patel, Alpa V.; Stevens, Victoria L.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Duell, Eric J.] Catalan Inst Oncol ICO IDIBELL, Unit Nutr Environm & Canc, Canc Epidemiol Res Program, Bellvitge Biomed Res Inst, Barcelona, Spain.
[Elena, Joanne W.; Zanetti, Krista A.] NCI, Div Canc Control & Populat Sci, Epidemiol & Genom Res Program, Bethesda, MD 20892 USA.
[Fan, Jin-Hu] Shanghai Canc Inst, Shanghai, Peoples R China.
[Feigelson, Heather Spencer] Kaiser Permanente, Inst Hlth Res, Denver, CO USA.
[Flanagan, Adrienne M.] UCL Canc Inst, London WC1E 6BT, England.
[Flanagan, Adrienne M.; Tirabosco, Roberto] Royal Natl Orthopaed Hosp NHS Trust, Stanmore HA7 4LP, Middx, England.
[Fridley, Brooke L.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA.
[Fuchs, Charles S.; Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Fuchs, Charles S.; Hankinson, Susan E.; Wolpin, Brian M.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
[Gaziano, J. Michael] Harvard Univ, Sch Med, Boston, MA USA.
[Gago-Dominguez, Manuela] Complejo Hosp Univ Santiago, Serv Galego Saude SERGAS, Inst Invest Sanitaria Santiago IDIS, Galician Fdn Genom Med,Genom Med Grp, Santiago De Compostela, Spain.
[Gallinger, Steven] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Gokgoz, Nalan] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
[Gao, Yu-Tang; Xiang, Yong-Bing] Shandong Jiaotong Univ, Sch Med, Dept Epidemiol, Shanghai Canc Inst,Renji Hosp, Shanghai, Peoples R China.
[Garcia-Closas, Montserrat; Swerdlow, Anthony] Inst Canc Res, Div Genet & Epidemiol, Sutton, Surrey, England.
[Garcia-Closas, Reina] Hosp Univ Canarias, Unidad Invest, San Cristobal la Laguna, Spain.
[Gastier-Foster, Julie M.] Nationwide Childrens Hosp, Columbus, OH USA.
[Gastier-Foster, Julie M.] Ohio State Univ, Dept Pathol & Pediat, Columbus, OH 43210 USA.
[Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol, Res & Informat Ctr, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
[Giffen, Carol A.; Wheeler, William] Informat Management Serv Inc, Calverton, MD USA.
[Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Canc Epidemiol Ctr, Canc Council Victoria, Melbourne, Vic 3010, Australia.
[Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia.
[Gillanders, Elizabeth M.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Harris, Curtis C.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
[Goggins, Michael; Klein, Alison P.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
[Goggins, Michael; Klein, Alison P.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
[Goggins, Michael; Klein, Alison P.] Johns Hopkins Univ, Sch Med, Dept Med, Sol Goldman Pancreat Res Ctr, Baltimore, MD 21205 USA.
[Gonzalez, Carlos] Catalan Inst Oncol ICO, Unit Nutr Environm & Canc, Canc Epidemiol Res Programme, Barcelona, Spain.
[Gorlick, Richard] Childrens Hosp Montefiore, Albert Einstein Coll Med, Bronx, NY USA.
[Gross, Myron] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Grubb, Robert, III] Washington Univ, Sch Med, Dept Urol, St Louis, MO USA.
[Guan, Peng; He, Qincheng; Yin, Zhihua; Zhou, Baosen] China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang, Peoples R China.
[Hattinger, Claudia; Picci, Piero; Scotlandi, Katia; Serra, Massimo] Orthopaed Rizzoli Inst, Expt Oncol Lab, Bologna, Italy.
[Hayes, Richard B.] NYU, Dept Populat Hlth, Langone Med Ctr, New York, NY USA.
[Hayes, Richard B.] NYU, Dept Environm Med, Langone Med Ctr, Inst Canc, New York, NY 10016 USA.
[Hoffman-Bolton, Judith; Visvanathan, Kala] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Hohensee, Chancellor; Kooperberg, Charles; Peters, Ulrike; Rodabough, Rebecca J.; White, Emily] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Hong, Yun-Chul; Kim, Jin Hee] Seoul Natl Univ, Inst Environm Med, Med Res Ctr, Seoul, South Korea.
[Hong, Yun-Chul; Lee, Kyoung-Mu] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.
[Kim, Young Tae; Kang, Chang Hyun; Jung, Yoo Jin] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.
[Hosgood, H. Dean] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Hsing, Ann W.] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.
[Hu, Zhibin; Shen, Hongbing] Nanjing Med Univ, Ctr Canc, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China.
[Hunter, David J.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Ito, Hidemi; Matsuo, Keitaro; Tanaka, Hideo] Aichi Canc Ctr Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi, Japan.
[Jacobs, Kevin B.] Bioinformed LLC, Gaithersburg, MD USA.
[Johansen, Christoffer] Rigshosp, Dept Oncol, Finsen Ctr, DK-2100 Copenhagen, Denmark.
[Johansen, Christoffer] Danish Canc Soc Res Ctr, Unit Survivorship, Copenhagen, Denmark.
[Johnson, Alison] Vermont Canc Registry, Burlington, VT USA.
[Kamineni, Aruna] Grp Hlth Res Inst, Seattle, WA USA.
[Sung, Sook Whan] Seoul St Marys Hosp, Dept Thorac & Cardiovasc Surg, Seoul, South Korea.
[Khaw, Kay-Tee] Univ Cambridge, Sch Clin Med, Cambridge CB2 1TN, England.
[Kim, In-Sam; Park, Jae Yong] Kyungpook Natl Univ, Dept Biochem, Sch Med, Taegu, South Korea.
[Kim, In-Sam; Park, Jae Yong] Kyungpook Natl Univ, Dept Cell Biol, Sch Med, Taegu, South Korea.
[Kim, Yeul Hong] Korea Univ, Anam Hosp, Genom Res Ctr Lung & Breast Ovarian Canc, Seoul, South Korea.
[Kim, Yeul Hong] Korea Univ, Coll Med, Dept Internal Med, Seoul 136705, South Korea.
[Kim, Yeul Hong] Korea Univ, Coll Med, Div Brain, Seoul 136705, South Korea.
[Kim, Yeul Hong] Korea Univ, Coll Med, Div Oncol Hematol, Dept Internal Med, Seoul 136705, South Korea.
[Kim, Young-Chul] Chonnam Natl Univ, Hwasun Hosp, Lung & Esophageal Canc Clin, Hwasun Eup, South Korea.
[Klein, Alison P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Klein, Robert; Kurtz, Robert C.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Olson, Sara H.; Pike, Malcolm C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
[Kogevinas, Manolis] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.
[Kogevinas, Manolis] IMIM Hosp Mar Med Res Inst, Barcelona, Spain.
[Kogevinas, Manolis; Lloreta, Josep] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain.
[Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, Greece.
[Koh, Woon-Puay] Duke NUS Grad Med Sch, Singapore, Singapore.
[Kohno, Takashi; Kunitoh, Hideo; Shiraishi, Kouya] Natl Canc Ctr, Div Genome Biol, Tokyo, Japan.
[Kolonel, Laurence N.; Le Marchand, Loic] Univ Hawaii, Program Epidemiol, Ctr Canc, Honolulu, HI 96822 USA.
[Krogh, Vittorio] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
[Kunitoh, Hideo] Mitsui Mem Hosp, Dept Resp Med, Tokyo 101, Japan.
[Kurucu, Nilgun] AY Ankara Oncol Training & Res Hosp, Dept Pediat Oncol, Yenimahalle Ankara, Turkey.
[Lathrop, Mark] IG CEA, Ctr Natl Genotypage, Evry, France.
[Lathrop, Mark] CEPH, Paris, France.
[Lau, Ching C.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA.
[Lau, Ching C.] Baylor Coll Med, Hematol Ctr, Houston, TX 77030 USA.
[Lerner, Seth P.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Spitz, Margaret] Baylor Coll Med, Dan L Duncan Ctr, Houston, TX 77030 USA.
[Spitz, Margaret] Baylor Coll Med, Dan L Duncan Ctr, Houston, TX 77030 USA.
[Lecanda, Fernando; Patino-Garcia, Ana; Sierrasesumaga, Luis] Univ Navarra, Univ Navarra Clin, Dept Pediat, E-31080 Pamplona, Spain.
[Lissowska, Jolanta] Maria Sklodowska Curie Canc Ctr, Dept Canc Epidemiol & Prevent, Warsaw, Poland.
[Lissowska, Jolanta] Inst Oncol, Warsaw, Poland.
[Liu, Jianjun] Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
[Liu, Jianjun] Anhui Med Univ, Sch Life Sci, Hefei, Peoples R China.
[Lu, Daru] Fudan Univ, Minist Educ, Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai 200433, Peoples R China.
[Lu, Daru] Fudan Univ, State Key Lab Genet Engn, Sch Life Sci, Shanghai 200433, Peoples R China.
[Malats, Nuria] Ctr Nacl Invest Oncol, E-28029 Madrid, Spain.
[Mannisto, Satu] Natl Inst Hlth & Welf, Helsinki, Finland.
[Marina, Neyssa] Stanford Univ, Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA.
[Mastrangelo, Giuseppe; Pavanello, Sofia; Wu, Tangchun] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
[Matsuo, Keitaro] Kyushu Univ, Dept Prevent Med, Fac Med Sci, Fukuoka 812, Japan.
[McWilliams, Robert R.; Petersen, Gloria M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Miao, Xiaoping] Huazhong Univ Sci & Technol, Key Lab Environm & Hlth, Sch Publ Hlth, Tongji Med Coll, Wuhan 430074, Peoples R China.
[Michaud, Dominique S.] Brown Univ, Div Biol & Med, Dept Epidemiol, Providence, RI 02912 USA.
[Muir, Kenneth] Univ Warwick, Hlth Sci Res Inst, Coventry CV4 7AL, W Midlands, England.
[Orr, Nick] Inst Canc Res, Complex Traits Genet Team, London SW3 6JB, England.
[Swerdlow, Anthony] Inst Canc Res, Div Breast Canc Res, London SW3 6JB, England.
[Panico, Salvatore] Univ Naples Federico II, Dipartimento Med Clin & Chirurgia, Naples, Italy.
[Park, Jae Yong] Kyungpook Natl Univ, Lung Canc Ctr, Med Ctr, Taegu, South Korea.
[Peeters, Petra H. M.] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
[Peeters, Petra H. M.; Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, Sch Publ Hlth, London, England.
[Siddiq, Afshan] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Genom Common Dis, London, England.
[Peplonska, Beata] Nofer Inst Occupat Med, Lodz, Poland.
[Qiao, You-Lin] Chinese Acad Med Sci, Dept Epidemiol, Canc Inst Hosp, Beijing 100730, Peoples R China.
[Risch, Harvey A.] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Ryu, Jeong-Seon] Inha Univ, Coll Med, Dept Internal Med, Inchon, South Korea.
[Schwartz, Ann G.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
[Schwartz, Ann G.] Wayne State Univ, Dept Oncol, Detroit, MI USA.
[Schwartz, Kendra L.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI USA.
[Schwartz, Kendra L.] Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, Detroit, MI USA.
[Schwenn, Molly] Maine Canc Registry, Augusta, ME USA.
[Serra, Consol] Univ Pompeu Fabra, Ctr Res Occupat Hlth, Barcelona, Spain.
[Peeters, Petra H. M.; Riboli, Elio] Univ Texas MD Anderson Canc Ctr, CIBER Epidemiol & Publ Hlth CIBERESP, Houston, TX 77030 USA.
[Siddiq, Afshan] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
[Sierri, Sabina] Fdn IRCCS Ist Nazl Tumori, Nutr Epidemiol Unit, Milan, Italy.
[Sihoe, Alan Dart Loon] Queen Mary Hosp, Dept Surg, Div Cardiothorac Surg, Hong Kong, Hong Kong, Peoples R China.
[Simon, Matthias] Univ Bonn, Med Ctr, Dept Neurosurg, Bonn, Germany.
[Southey, Melissa C.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
[Spector, Logan] Univ Minnesota, Minneapolis, MN USA.
[Su, Wu-Chou; Yu, Chong-Jen] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 70428, Taiwan.
[Su, Wu-Chou; Yu, Chong-Jen] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan.
[Tardon, Adonina] Univ Oviedo, Inst Univ Oncol, Oviedo, Spain.
[Thomas, David M.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, East Melbourne, Vic, Australia.
[Tjonneland, Anne] Danish Canc Soc, Res Ctr, Copenhagen, Denmark.
[Tsai, Ying-Huang] Chang Gung Mem Hosp, Dept Pulm Med, Chiayi, Taiwan.
[Tumino, Rosario] Canc Registry Assoc Iblea Ric Epidemiol, Ragusa, Italy.
[Van Den Eeden, Stephen K.] Kaiser Permanente No Calif, Oakland, CA USA.
[Vermeulen, Roel] Univ Utrecht, Div Environm Epidemiol, Inst Risk Assessment Sci IRAS, Utrecht, Netherlands.
[Vineis, Paolo] Univ London Imperial Coll Sci Technol & Med, London, England.
[Vineis, Paolo] Human Genet Fdn HuGeF, Turin, Italy.
[Vogel, Ulla] Natl Res Ctr Working Environm, Copenhagen, Denmark.
[Vogel, Ulla] Tech Univ Denmark, Natl Food Inst, Soborg, Denmark.
[Wang, Junwen] Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.
[Wang, Junwen] Univ Hong Kong, Ctr Genom Sci, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.
[Wong, Maria Pik] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
[Xu, Jun] Univ Hong Kong, Sch Publ Hlth, Li Ka Shing LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.
[Wang, Sophia S.] City Hope Natl Med Ctr, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA.
[Wang, Sophia S.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.
[Weiderpass, Elisabete] Arct Univ Norway, Dept Community Med, Fac Hlth Sci, Univ Tromso, Tromso, Norway.
[Weiderpass, Elisabete] Canc Registry Norway, Dept Res, Oslo, Norway.
[Weiderpass, Elisabete] Samfundet Folkhalsan, Helsinki, Finland.
[Wiencke, John K.; Wrensch, Margaret] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Wu, Yi-Long] Guangdong Acad Med Sci, Med Res Ctr, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China.
[Wu, Yi-Long] Guangdong Acad Med Sci, Ctr Canc, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China.
[Yatabe, Yasushi] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Pittsburgh, PA USA.
[Yuan, Jian-Min] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Lee, Kyoung-Mu] Korea Natl Open Univ, Dept Environm Hlth, Seoul, South Korea.
RP Amundadottir, LT (reprint author), NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, Adv Technol Ctr, 8717 Grovemont Circle, Bethesda, MD 20892 USA.
EM amundadottirl@mail.nih.gov
RI Serra, Massimo/J-4878-2016; Tobias, Geoffrey/M-4135-2016; Weiderpass,
Elisabete/M-4029-2016; Wang, Junwen/D-3700-2011; Hattinger,
Claudia/Q-1212-2016; Kitahara, Cari/R-8267-2016; Jung,
Yoojin/G-2519-2015; Kogevinas, Manolis/C-3918-2017; Vermeulen,
Roel/F-8037-2011; bertazzi, pietro alberto/D-5039-2017; Vogel,
Ulla/I-5048-2012; Abnet, Christian/C-4111-2015; Malats,
Nuria/H-7041-2015; Chen, Chien-Jen/C-6976-2008; Patino-Garcia,
Ana/I-4299-2012; Tucker, Margaret/B-4297-2015; Simon,
Matthias/F-3046-2014; Cook, Michael/A-5641-2009; Purdue,
Mark/C-9228-2016; Savage, Sharon/B-9747-2015; Tanaka, Hideo/A-8145-2016;
Krogh, Vittorio/K-2628-2016; Panico, Salvatore/K-6506-2016;
Amundadottir, Laufey/L-7656-2016; Gallinger, Steven/E-4575-2013;
Garcia-Closas, Montserrat /F-3871-2015; Chang, I-Shou/D-2084-2010;
Hsiao, Chin-Fu/E-3993-2010; Boutron-Ruault, Marie-Christine/H-3936-2014;
Albanes, Demetrius/B-9749-2015; Beane Freeman, Laura/C-4468-2015;
Brinton, Louise/G-7486-2015; Freedman, Neal/B-9741-2015; miao,
xiaoping/C-4336-2011; Andrulis, Irene/E-7267-2013; Fridley,
Brooke/D-8315-2015; Hsiung, Chao Agnes/E-3994-2010
OI Qiao, You-Lin/0000-0001-6380-0871; Spector, Logan/0000-0003-2516-0222;
Giles, Graham/0000-0003-4946-9099; Zeleniuch-Jacquotte,
Anne/0000-0001-9350-1303; Cancel-Tassin, Geraldine/0000-0002-9583-6382;
Liao, Linda/0000-0002-1923-5294; Mondul, Alison/0000-0002-8843-1416;
Hoskins, Jason/0000-0001-6944-1996; Hayes, Richard/0000-0002-0918-661X;
Serra, Massimo/0000-0003-0742-1177; Tobias,
Geoffrey/0000-0002-2878-8253; Weiderpass, Elisabete/0000-0003-2237-0128;
Wang, Junwen/0000-0002-4432-4707; Hattinger,
Claudia/0000-0002-9316-5095; Vermeulen, Roel/0000-0003-4082-8163;
bertazzi, pietro alberto/0000-0003-3475-2449; Duell, Eric
J/0000-0001-5256-0163; Vogel, Ulla/0000-0001-6807-1524; Abnet,
Christian/0000-0002-3008-7843; Malats, Nuria/0000-0003-2538-3784; Cook,
Michael/0000-0002-0533-7302; Purdue, Mark/0000-0003-1177-3108; Savage,
Sharon/0000-0001-6006-0740; Krogh, Vittorio/0000-0003-0122-8624; Panico,
Salvatore/0000-0002-5498-8312; Amundadottir, Laufey/0000-0003-1859-8971;
Garcia-Closas, Montserrat /0000-0003-1033-2650; Beane Freeman,
Laura/0000-0003-1294-4124; Brinton, Louise/0000-0003-3853-8562;
Freedman, Neal/0000-0003-0074-1098; miao, xiaoping/0000-0002-6818-9722;
Fridley, Brooke/0000-0001-7739-7956;
FU US National Institutes of Health (NIH), National Cancer Institute
[HHSN261200800001E]; Intramural Research Program
FX This work was supported by the Intramural Research Program and by
contract number HHSN261200800001E of the US National Institutes of
Health (NIH), National Cancer Institute. The content of this publication
does not necessarily reflect the views or policies of the Department of
Health and Human Services nor does mention of trade names, commercial
products or organizations imply endorsement by the U.S. Government.
Additional funding acknowledgements are listed in Supplementary
Material. The funders had no role in study design, data collection and
analysis, decision to publish or preparation of the manuscript.
NR 89
TC 25
Z9 25
U1 4
U2 59
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2014
VL 23
IS 24
BP 6616
EP 6633
DI 10.1093/hmg/ddu363
PG 18
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AZ0FP
UT WOS:000347921900017
PM 25027329
ER
PT J
AU Georgieva, L
Rees, E
Moran, JL
Chambert, KD
Milanova, V
Craddock, N
Purcell, S
Sklar, P
McCarroll, S
Holmans, P
O'Donovan, MC
Owen, MJ
Kirov, G
AF Georgieva, Lyudmila
Rees, Elliott
Moran, Jennifer L.
Chambert, Kimberly D.
Milanova, Vihra
Craddock, Nicholas
Purcell, Shaun
Sklar, Pamela
McCarroll, Steven
Holmans, Peter
O'Donovan, Michael C.
Owen, Michael J.
Kirov, George
TI De novo CNVs in bipolar affective disorder and schizophrenia
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COPY-NUMBER VARIANTS; CASE-CONTROL SAMPLE; ASSOCIATION; DUPLICATIONS;
DELETIONS; DEPRESSION; GENETICS; 16P11.2; RISK
AB An increased rate of de novo copy number variants (CNVs) has been found in schizophrenia (SZ), autism and developmental delay. An increased rate has also been reported in bipolar affective disorder (BD). Here, in a larger BD sample, we aimed to replicate these findings and compare de novo CNVs between SZ and BD. We used Illumina microarrays to genotype 368 BD probands, 76 SZ probands and all their parents. Copy number variants were called by PennCNV and filtered for frequency (<1%) and size (>10 kb). Putative de novo CNVs were validated with the z-score algorithm, manual inspection of log R ratios (LRR) and qPCR probes. We found 15 de novo CNVs in BD (4.1% rate) and 6 in SZ (7.9% rate). Combining results with previous studies and using a cut-off of > 100 kb, the rate of de novo CNVs in BD was intermediate between controls and SZ: 1.5% in controls, 2.2% in BD and 4.3% in SZ. Only the differences between SZ and BD and SZ and controls were significant. The median size of de novo CNVs in BD (448 kb) was also intermediate between SZ (613 kb) and controls (338 kb), but only the comparison between SZ and controls was significant. Only one de novo CNV in BD was in a confirmed SZ locus (16p11.2). Sporadic or early onset cases were not more likely to have de novo CNVs. We conclude that de novo CNVs play a smaller role in BD compared with SZ. Patients with a positive family history can also harbour de novo mutations.
C1 [Georgieva, Lyudmila; Rees, Elliott; Craddock, Nicholas; Holmans, Peter; O'Donovan, Michael C.; Owen, Michael J.; Kirov, George] Cardiff Univ, MRC, Ctr Neuropsychiat Genet & Genom, Inst Psychol Med & Clin Neurosci, Cardiff CF24 4HQ, S Glam, Wales.
[Moran, Jennifer L.; Chambert, Kimberly D.; McCarroll, Steven] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Milanova, Vihra] Med Univ, Dept Psychiat, Sofia, Bulgaria.
[Purcell, Shaun; Sklar, Pamela] Mt Sinai Sch Med, Dept Psychiat, Div Psychiat Genom, New York, NY USA.
[Purcell, Shaun; Sklar, Pamela] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
RP Kirov, G (reprint author), Cardiff Univ, MRC, Ctr Neuropsychiat Genet & Genom, Inst Psychol Med & Clin Neurosci, Cardiff CF24 4HQ, S Glam, Wales.
EM kirov@cardiff.ac.uk
RI Holmans, Peter/F-4518-2015;
OI Holmans, Peter/0000-0003-0870-9412; Moran, Jennifer/0000-0002-5664-4716
FU Medical Research Council (MRC) Centre [G0800509, G0801418]; MRC PhD
Studentship; Janssen Research Foundation [045856]; Wellcome Trust
[045856]; Research Councils UK
FX The work at Cardiff University was funded by Medical Research Council
(MRC) Centre (G0800509) and Program Grants (G0801418) and an MRC PhD
Studentship to E.R. Funding for the recruitment of trios in Bulgaria was
provided by the Janssen Research Foundation in 1999-2004, Ref: 045856.
Funding for the recruitment of BD samples in the UK was provided by the
Wellcome Trust as a Training Fellowship to G.K. in 1996-1999, Ref:
045856. The samples were genotyped at the Broad Institute, USA, funded
by a philanthropic gift to the Stanley Center for Psychiatric Research.
Funding to pay the Open Access publication charges for this article was
provided by Research Councils UK.
NR 35
TC 14
Z9 14
U1 2
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2014
VL 23
IS 24
BP 6677
EP 6683
DI 10.1093/hmg/ddu379
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AZ0FP
UT WOS:000347921900022
PM 25055870
ER
PT J
AU Bisio, A
Zamborszky, J
Zaccara, S
Lion, M
Tebaldi, T
Sharma, V
Raimondi, I
Alessandrini, F
Ciribilli, Y
Inga, A
AF Bisio, Alessandra
Zamborszky, Judit
Zaccara, Sara
Lion, Mattia
Tebaldi, Toma
Sharma, Vasundhara
Raimondi, Ivan
Alessandrini, Federica
Ciribilli, Yari
Inga, Alberto
TI Cooperative interactions between p53 and NF kappa B enhance cell
plasticity
SO ONCOTARGET
LA English
DT Article
DE p53; NFkB; chemotherapy; doxorubicin; TNF alpha; EMT; synergy; breast
cancer
ID ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; TRANSCRIPTION FACTORS;
PROMOTES METASTASIS; MICROARRAY DATA; AP-1 ACTIVITY; ACTIVATION; GENES;
IDENTIFICATION; RESPONSES
AB The p53 and NF kappa B sequence-specific transcription factors play crucial roles in cell proliferation and survival with critical, even if typically opposite, effects on cancer progression. To investigate a possible crosstalk between p53 and NF kappa B driven by chemotherapy-induced responses in the context of an inflammatory microenvironment, we performed a proof of concept study using MCF7 cells. Transcriptome analyses upon single or combined treatments with doxorubicin (Doxo, 1.5 mu M) and the NF kappa B inducer TNF-alpha (TNF alpha, 5ng/ml) revealed 432 upregulated (log(2) FC>2), and 390 repressed genes (log(2) FC<-2) for the Doxo+TNF alpha treatment. 239 up-regulated and 161 repressed genes were synergistically regulated by the double treatment. Annotation and pathway analyses of Doxo+TNF alpha selectively up-regulated genes indicated strong enrichment for cell migration terms. A panel of genes was examined by qPCR coupled to p53 activation by Doxo, 5-Fluoruracil and Nutlin-3a, or to p53 or NF kappa B inhibition. Transcriptome data were confirmed for 12 of 15 selected genes and seven (PLK3, LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) were synergistically up-regulated after Doxo+TNF alpha and dependent both on p53 and NF kappa B. Migration assays consistently showed an increase in motility for MCF7 cells upon Doxo+TNF alpha. A signature of 29 Doxo+TNF alpha highly synergistic genes exhibited prognostic value for luminal breast cancer patients, with adverse outcome correlating with higher relative expression. We propose that the crosstalk between p53 and NF kappa B can lead to the activation of specific gene expression programs that may impact on cancer phenotypes and potentially modify the efficacy of cancer therapy.
C1 [Bisio, Alessandra; Zamborszky, Judit; Zaccara, Sara; Lion, Mattia; Sharma, Vasundhara; Raimondi, Ivan; Alessandrini, Federica; Ciribilli, Yari; Inga, Alberto] Univ Trento, Ctr Integrat Biol, Lab Transcript Networks, CIBIO, I-38123 Trento, Italy.
[Tebaldi, Toma] Univ Trento, Ctr Integrat Biol, Lab Translat Genom, CIBIO, I-38123 Trento, Italy.
[Zamborszky, Judit] Res Ctr Nat Sci, Inst Enzymol, Budapest, Hungary.
[Lion, Mattia] Massachusetts Gen Hosp, Dept Genet, Boston, MA 02114 USA.
RP Ciribilli, Y (reprint author), Univ Trento, Ctr Integrat Biol, Lab Transcript Networks, CIBIO, I-38123 Trento, Italy.
EM ciribilli@science.unitn.it; inga@science.unitn.it
FU Italian Association for Cancer Research, AIRC (IG) [12869]; Pezcoller
Foundation
FX We thank Dr. Valentina Adami (CIBIO High-throughput screening facility),
Dr. Isabella Pesce (CIBIO Cell Separation facility), Ms. Sonia
Leonardelli, Mr. Dennis Pedri for technical support. This work was
supported by the Italian Association for Cancer Research, AIRC (IG grant
# 12869 to AI). IR is supported by a Fellowship from the Pezcoller
Foundation.
NR 63
TC 7
Z9 7
U1 3
U2 8
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 15
PY 2014
VL 5
IS 23
BP 12111
EP 12125
PG 15
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AZ2AT
UT WOS:000348037700026
PM 25401416
ER
PT J
AU Baldwin, LA
Hoff, JT
Lefringhouse, J
Zhang, M
Jia, CH
Liu, ZY
Erfani, S
Jin, HY
Xu, M
She, QB
Van Nagell, JR
Wang, C
Chen, L
Plattner, R
Kaetzel, DM
Luo, J
Lu, M
West, D
Liu, CM
Ueland, FR
Drapkin, R
Zhou, BP
Yang, XWH
AF Baldwin, Lauren A.
Hoff, John T.
Lefringhouse, Jason
Zhang, Michael
Jia, Changhe
Liu, Zeyi
Erfani, Sonia
Jin, Hongyan
Xu, Mei
She, Qing-Bai
Van Nagell, John R.
Wang, Chi
Chen, Li
Plattner, Rina
Kaetzel, David M.
Luo, Jia
Lu, Michael
West, Dava
Liu, Chunming
Ueland, Fred R.
Drapkin, Ronny
Zhou, Binhua P.
Yang, Xiuwei H.
TI CD151-alpha 3 beta 1 integrin complexes suppress ovarian tumor growth by
repressing slug-mediated EMT and canonical Wnt signaling
SO ONCOTARGET
LA English
DT Article
DE CD151 integrin EMT tumor growth ovarian cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; TETRASPANIN CD151; CELL-ADHESION;
BREAST-CANCER; SEROUS CARCINOMA; PROSTATE-CANCER; GENE-EXPRESSION;
COLON-CANCER; LOW-GRADE; METASTASIS
AB Human ovarian cancer is diagnosed in the late, metastatic stages but the underlying mechanisms remain poorly understood. We report a surprising functional link between CD151-alpha 3 beta 1 integrin complexes and the malignancy of serous-type ovarian cancer. Analyses of clinical specimens indicate that CD151 expression is significantly reduced or diminished in 90% of metastatic lesions, while it remains detectable in 58% of primary tumors. These observations suggest a putative tumor-suppressing role of CD151 in ovarian cancer. Indeed, our analyses show that knocking down CD151 or alpha 3 integrin enhances tumor cell proliferation, growth and ascites production in nude mice. These changes are accompanied by impaired cell-cell contacts and aberrant expression of E-cadherin, Mucin 5AC and fibronectin, largely reminiscent of an epithelial to mesenchymal transition (EMT)-like change. Importantly, Slug, a master regulator of EMT, is markedly elevated. Knocking down Slug partially restores CD151-alpha 3 beta 1 integrin complex-dependent suppression of cell proliferation. Moreover, disruption of these adhesion protein complexes is accompanied by a concomitant activation of canonical Wnt signaling, including elevated levels of beta-catenin and Axin-2 as well as resistance to the inhibition in beta-catenin-dependent transcriptional complexes. Together, our study demonstrates that CD151-alpha 3 beta 1 integrin complexes regulate ovarian tumor growth by repressing Slug-mediated EMT and Wnt signaling.
C1 [Baldwin, Lauren A.; Hoff, John T.; Lefringhouse, Jason; Zhang, Michael; Jia, Changhe; Liu, Zeyi; Erfani, Sonia; Jin, Hongyan; Xu, Mei; She, Qing-Bai; Wang, Chi; Chen, Li; Plattner, Rina; Luo, Jia; Liu, Chunming; Zhou, Binhua P.; Yang, Xiuwei H.] Univ Kentucky, Dept Mol & Cellular Biochem, Dept Pharmacol & Nutr Sci, Lexington, KY 40506 USA.
[Baldwin, Lauren A.; Hoff, John T.; Lefringhouse, Jason; Zhang, Michael; Jia, Changhe; Liu, Zeyi; Erfani, Sonia; Jin, Hongyan; Xu, Mei; She, Qing-Bai; Van Nagell, John R.; Wang, Chi; Chen, Li; Plattner, Rina; Luo, Jia; West, Dava; Liu, Chunming; Ueland, Fred R.; Zhou, Binhua P.; Yang, Xiuwei H.] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
[Baldwin, Lauren A.; Hoff, John T.; Lefringhouse, Jason; Van Nagell, John R.; West, Dava; Ueland, Fred R.] Univ Kentucky, Coll Med, Dept Pathol & Lab Med, Div Gynecol Oncol,Dept Obstet & Gynecol, Lexington, KY USA.
[Kaetzel, David M.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
[Lu, Michael] Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA.
[Drapkin, Ronny] Dana Farber Canc Inst, Dept Canc Biol & Pathol, Boston, MA 02115 USA.
[Drapkin, Ronny] Harvard Univ, Sch Med, Boston, MA USA.
RP Yang, XWH (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Dept Pharmacol & Nutr Sci, Lexington, KY 40506 USA.
EM xiuwei-yang@uky.edu
RI Drapkin, Ronny/E-9944-2016
OI Drapkin, Ronny/0000-0002-6912-6977
FU DOD Ovarian Cancer Research Program [W81XWH-08-1-0120]; Franchi
Investigator Award/Dana-Farber Cancer Institute; S.G. Komen for the Cure
career catalyst award; NIH COBRE/pilot project fund; American Cancer
Society [IRG85-001-25]
FX This study was supported in part through DOD Ovarian Cancer Research
Program W81XWH-08-1-0120, Franchi Investigator Award/Dana-Farber Cancer
Institute, S.G. Komen for the Cure career catalyst award, NIH
COBRE/pilot project fund and A pilot project grant from American Cancer
Society #IRG85-001-25 to X.H. Yang.
NR 65
TC 17
Z9 20
U1 1
U2 3
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 15
PY 2014
VL 5
IS 23
BP 12203
EP 12217
PG 15
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AZ2AT
UT WOS:000348037700033
PM 25356755
ER
PT J
AU Cho, I
Slight, SP
Nanji, KC
Seger, DL
Maniam, N
Dykes, PC
Bates, DW
AF Cho, Insook
Slight, Sarah P.
Nanji, Karen C.
Seger, Diane L.
Maniam, Nivethietha
Dykes, Patricia C.
Bates, David W.
TI Understanding physicians' behavior toward alerts about nephrotoxic
medications in outpatients: a cross-sectional analysis
SO BMC NEPHROLOGY
LA English
DT Article
DE Medication safety; Clinical decision support system; Renal
insufficiency; Drug prescribing; Chronic kidney disease
ID CHRONIC KIDNEY-DISEASE; DECISION-SUPPORT ALERTS; RENAL-INSUFFICIENCY;
ORDER ENTRY; CARE; QUALITY; SAFETY; SYSTEM; TRIAL
AB Background: Although most outpatients are relatively healthy, many have chronic renal insufficiency, and high override rates for suggestions on renal dosing have been observed. To better understand the override of renal dosing alerts in an outpatient setting, we conducted a study to evaluate which patients were more frequently prescribed contraindicated medications, to assess providers' responses to suggestions, and to examine the drugs involved and the reasons for overrides.
Methods: We obtained data on renal alert overrides and the coded reasons for overrides cited by providers at the time of prescription from outpatient clinics and ambulatory hospital-based practices at a large academic health care center over a period of 3 years, from January 2009 to December 2011. For detailed chart review, a group of 6 trained clinicians developed the appropriateness criteria with excellent inter-rater reliability (kappa = 0.93). We stratified providers by override frequency and then drew samples from the high-and low-frequency groups. We measured the rate of total overrides, rate of appropriate overrides, medications overridden, and the reason(s) for override.
Results: A total of 4120 renal alerts were triggered by 584 prescribers in the study period, among which 78.2% (3,221) were overridden. Almost half of the alerts were triggered by 40 providers and one-third was triggered by high-frequency overriders. The appropriateness rates were fairly similar, at 28.4% and 31.6% for high-and low frequency overriders, respectively. Metformin, glyburide, hydrochlorothiazide, and nitrofurantoin were the most common drugs overridden. Physicians' appropriateness rates were higher than the rates for nurse practitioners (32.9% vs. 22.1%). Physicians with low frequency override rates had higher levels of appropriateness for metformin than the high frequency overriders (P = 0.005).
Conclusion: A small number of providers accounted for a large fraction of overrides, as was the case with a small number of drugs. These data suggest that a focused intervention targeting primarily these providers and medications has the potential to improve medication safety.
C1 [Cho, Insook; Slight, Sarah P.; Dykes, Patricia C.; Bates, David W.] Brigham & Womens Hosp, Ctr Patient Safety Res & Practice, Div Gen Internal Med, Boston, MA 02115 USA.
[Cho, Insook] Inha Univ, Dept Nursing, Inchon, South Korea.
[Cho, Insook; Slight, Sarah P.; Nanji, Karen C.; Dykes, Patricia C.; Bates, David W.] Harvard Univ, Sch Med, Boston, MA USA.
[Seger, Diane L.; Maniam, Nivethietha; Bates, David W.] Partners Healthcare Syst Inc, Wellesley, MA USA.
[Slight, Sarah P.] Univ Nottingham, Div Primary Care, Nottingham, England.
[Nanji, Karen C.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Cho, I (reprint author), Brigham & Womens Hosp, Ctr Patient Safety Res & Practice, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA.
EM insook.cho@inha.ac.kr
FU Centers for Education and Research on Therapeutics (CERT), Agency for
Healthcare Research and Quality, Rockville, MD, USA [U19HS021094]; Korea
Research Foundation - Korean Government (MOEHRD) [KRF-2013R1A1A2006387]
FX This research was sponsored by the Centers for Education and Research on
Therapeutics (CERT Grant # U19HS021094), Agency for Healthcare Research
and Quality, Rockville, MD, USA. I.C. was also supported by a Korea
Research Foundation Grant, which was funded by the Korean Government
(MOEHRD; No. KRF-2013R1A1A2006387).
NR 22
TC 2
Z9 2
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD DEC 15
PY 2014
VL 15
AR 200
DI 10.1186/1471-2369-15-200
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA AY6AC
UT WOS:000347649200002
PM 25511564
ER
PT J
AU Fogelgren, B
Zuo, XF
Buonato, JM
Vasilyev, A
Baek, JI
Choi, SY
Chacon-Heszele, MF
Palmyre, A
Polgar, N
Drummond, I
Park, KM
Lazzara, MJ
Lipschutz, JH
AF Fogelgren, Ben
Zuo, Xiaofeng
Buonato, Janine M.
Vasilyev, Aleksandr
Baek, Jeong-In
Choi, Soo Young
Chacon-Heszele, Maria F.
Palmyre, Aurelien
Polgar, Noemi
Drummond, Iain
Park, Kwon Moo
Lazzara, Matthew J.
Lipschutz, Joshua H.
TI Exocyst Sec10 protects renal tubule cells from injury by EGFR/MAPK
activation and effects on endocytosis
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE AKI; EGFR; exocyst; MAPK
ID GROWTH-FACTOR RECEPTOR; ACUTE KIDNEY INJURY; CRITICALLY-ILL PATIENTS;
EPITHELIAL-CELLS; PRIMARY CILIOGENESIS; EARLY PHASE; IN-VITRO; FAILURE;
RECOVERY; COMPLEX
AB Acute kidney injury is common and has a high mortality rate, and no effective treatment exists other than supportive care. Using cell culture models, we previously demonstrated that exocyst Sec10 overexpression reduced damage to renal tubule cells and speeded recovery and that the protective effect was mediated by higher basal levels of mitogen-activated protein kinase (MAPK) signaling. The exocyst, a highly-conserved eight-protein complex, is known for regulating protein trafficking. Here we show that the exocyst biochemically interacts with the epidermal growth factor receptor (EGFR), which is upstream of MAPK, and Sec10-overexpressing cells express greater levels of phosphorylated (active) ERK, the final step in the MAPK pathway, in response to EGF stimulation. EGFR endocytosis, which has been linked to activation of the MAPK pathway, increases in Sec10-overexpressing cells, and gefitinib, a specific EGFR inhibitor, and Dynasore, a dynamin inhibitor, both reduce EGFR endocytosis. In turn, inhibition of the MAPK pathway reduces ligand-mediated EGFR endocytosis, suggesting a potential feedback of elevated ERK activity on EGFR endocytosis. Gefitinib also decreases MAPK signaling in Sec10-overexpressing cells to levels seen in control cells and, demonstrating a causal role for EGFR, reverses the protective effect of Sec10 overexpression following cell injury in vitro. Finally, using an in vivo zebrafish model of acute kidney injury, morpholino-induced knockdown of sec10 increases renal tubule cell susceptibility to injury. Taken together, these results suggest that the exocyst, acting through EGFR, endocytosis, and the MAPK pathway is a candidate therapeutic target for acute kidney injury.
C1 [Fogelgren, Ben; Polgar, Noemi] Univ Hawaii, Dept Anat, Dept Biochem & Physiol, Honolulu, HI 96822 USA.
[Zuo, Xiaofeng; Baek, Jeong-In; Choi, Soo Young; Lipschutz, Joshua H.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Buonato, Janine M.] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA USA.
[Vasilyev, Aleksandr; Palmyre, Aurelien] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Chacon-Heszele, Maria F.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Drummond, Iain] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Drummond, Iain] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Dept Anat & Plus BK21, Taegu, South Korea.
[Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC USA.
RP Lipschutz, JH (reprint author), Med Univ S Carolina, Clin Sci Bldg 829,96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM Lipschut@musc.edu
OI Polgar, Noemi/0000-0002-8400-162X
FU Veterans Affairs (Merit Award); National Institute of Diabetes and
Digestive and Kidney Diseases [DK-069909, DK-070980, K01-DK-087852,
R0-3DK-100738]
FX This work was supported in part by grants from the Veterans Affairs
(Merit Award to J. H. Lipschutz), National Institute of Diabetes and
Digestive and Kidney Diseases Grants DK-069909 and DK-070980 (to J. H.
Lipschutz) and K01-DK-087852 and R0-3DK-100738 (to B. Fogelgren F.),
Satellite Healthcare (Norman S. Coplon Extramural Research Grant to J.
H. Lipschutz), Hawaii Community Foundation (12ADVC-51347 to B. F.),
March of Dimes (Basil O'Connor No. 5-FY14-56 to B. Fogelgren),
University of Hawaii RCMI-BRIDGES (5G12MD007601, Pilot Award to B.
Fogelgren), Hepato/Renal Fibrocystic Diseases Core Center at the
University of Alabama at Birmingham (5P30-DK-074038, Pilot Award to B.
Fogelgren), National Science Foundation (Graduate Research Fellowship
Award to J. M. Buonato), and the Korean Government (National Research
Foundation Grant NRF-2011-220-E00001 to K. Park).
NR 52
TC 3
Z9 3
U1 1
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD DEC 15
PY 2014
VL 307
IS 12
BP F1334
EP F1341
DI 10.1152/ajprenal.00032.2014
PG 8
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA AW7ZS
UT WOS:000346480900003
PM 25298525
ER
PT J
AU Zheng, P
Wang, YY
Li, HB
AF Zheng, Peng
Wang, Yanyan
Li, Hongbin
TI Reversible Unfolding-Refolding of Rubredoxin: A Single-Molecule Force
Spectroscopy Study
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE force spectroscopy; iron priming; metalloproteins; protein folding;
single-molecule studies
ID FERRIC-THIOLATE BONDS; MECHANICAL STABILITY; PYROCOCCUS-FURIOSUS;
PROTEIN
AB In metalloproteins, metal centers serve as active sites for a range of functional purposes and as important structural elements to facilitate protein folding and assembly. It is challenging to observe the reversible unfolding and refolding of metalloproteins because of a loss or decomposition of the metal center. Here, the reversible unfolding-refolding of the iron-sulfur protein rubredoxin was observed directly using single-molecule force spectroscopy. The results demonstrate that the iron can remain attached to the CXXC motif when rubredoxin is unfolded. Upon relaxation, the unfolded rubredoxin can refold into its native holo state with the reconstituted FeS4 center. The possible loss of iron from the unfolded protein prevents rubredoxin from refolding into its native holo state. These results demonstrated that unfolding of rubredoxin is reversible, as long as the iron remains attached, and provide experimental evidence for the iron-priming mechanism for the folding of rubredoxin.
C1 [Wang, Yanyan; Li, Hongbin] Tianjin Univ, State Key Lab Precis Measurements Technol & Instr, Sch Precis Instrument & Optoelect Engn, Tianjin 300072, Peoples R China.
[Zheng, Peng; Li, Hongbin] Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada.
[Zheng, Peng] Harvard Univ, Sch Med, Program Cellular & Mol Med, Boston Childrens Hosp, Boston, MA USA.
[Zheng, Peng] Harvard Univ, Sch Med, Dept Biol Chem & Mol Med, Boston, MA USA.
RP Li, HB (reprint author), Tianjin Univ, State Key Lab Precis Measurements Technol & Instr, Sch Precis Instrument & Optoelect Engn, Tianjin 300072, Peoples R China.
EM Hongbin@chem.ubc.ca
RI Li, Hongbin/G-2949-2012
OI Li, Hongbin/0000-0001-7813-1332
FU Natural Sciences and Engineering Research Council of Canada; Canada
Foundation for Innovation; Canada Research Chairs program; Tianjin
University
FX We thank Chengzhi He and Ashlee Jollymore for technical assistance. This
work was supported by the Natural Sciences and Engineering Research
Council of Canada, the Canada Foundation for Innovation, the Canada
Research Chairs program, and Tianjin University.
NR 23
TC 6
Z9 6
U1 4
U2 38
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD DEC 15
PY 2014
VL 53
IS 51
BP 14060
EP 14063
DI 10.1002/anie.201408105
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA AW8BA
UT WOS:000346484400015
PM 25314323
ER
PT J
AU Priolo, C
Pyne, S
Rose, J
Regan, ER
Zadra, G
Photopoulos, C
Cacciatore, S
Schultz, D
Scaglia, N
McDunn, J
De Marzo, AM
Loda, M
AF Priolo, Carmen
Pyne, Saumyadipta
Rose, Joshua
Regan, Erzsebet Ravasz
Zadra, Giorgia
Photopoulos, Cornelia
Cacciatore, Stefano
Schultz, Denise
Scaglia, Natalia
McDunn, Jonathan
De Marzo, Angelo M.
Loda, Massimo
TI AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate
Cancer
SO CANCER RESEARCH
LA English
DT Article
ID INTRAEPITHELIAL NEOPLASIA; EXPRESSION; PATHWAYS; GROWTH; CELLS
AB Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or tumor-suppressor pathways that affect their metabolism, or by activating metabolic pathways de novo with targeted mutations in critical metabolic enzymes. It is unknown whether human prostate tumors develop a similar metabolic response to different oncogenic drivers or a particular oncogenic event results in its own metabolic reprogramming. Akt and Myc are arguably the most prevalent driving oncogenes in prostate cancer. Mass spectrometry-based metabolite profiling was performed on immortalized human prostate epithelial cells transformed by AKT1 or MYC, transgenic mice driven by the same oncogenes under the control of a prostatespecific promoter, and human prostate specimens characterized for the expression and activation of these oncoproteins. Integrative analysis of these metabolomic datasets revealed that AKT1 activation was associated with accumulation of aerobic glycolysis metabolites, whereas MYC overexpression was associated with dysregulated lipid metabolism. Selected metabolites that differentially accumulated in the MYC-high versus AKT1-high tumors, or in normal versus tumor prostate tissue by untargeted metabolomics, were validated using absolute quantitation assays. Importantly, the AKT1/MYC status was independent of Gleason grade and pathologic staging. Our findings show how prostate tumors undergo a metabolic reprogramming that reflects their molecular phenotypes, with implications for the development of metabolic diagnostics and targeted therapeutics.
C1 [Priolo, Carmen; Pyne, Saumyadipta; Rose, Joshua; Zadra, Giorgia; Photopoulos, Cornelia; Cacciatore, Stefano; Scaglia, Natalia; Loda, Massimo] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Regan, Erzsebet Ravasz] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.
[Schultz, Denise; De Marzo, Angelo M.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
[McDunn, Jonathan] Metabolon Inc, Durham, NC USA.
[Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Loda, Massimo] Broad Inst, Cambridge, MA USA.
[Loda, Massimo] Kings Coll London, Div Canc Studies, London WC2R 2LS, England.
RP Loda, M (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Dana 1536, Boston, MA 02115 USA.
EM massimo_loda@dfci.harvard.edu
OI Cacciatore, Stefano/0000-0001-7052-7156
FU Nuclea Biomarkers; Lank Center/Dana-Farber Cancer Institute; DBT, India;
MoSPI, India; DST, India [SR/SA/MS: 516/07, 21/04/2008]; Fondazione
Italiana per la Ricerca sul Cancro, Italy; Prostate Cancer Foundation;
Friends of Dana-Farber fund; Patrick C. Walsh Prostate Cancer Research
Fund Award; [R01CA131945]; [P50 CA90381]; Associazione Italiana per la
Ricerca sul Cancro
FX This work was supported by R01CA131945, P50 CA90381, the Prostate Cancer
Foundation, and philanthropic funds from Nuclea Biomarkers (Pittsfield,
MA; M. Loda); the P.A.R.T. Investigatorship in Prostate Cancer Award
from the Lank Center/Dana-Farber Cancer Institute and a Friends of
Dana-Farber fund (C. Priolo); the Ramalingswami Fellowship from DBT,
MoS&PI and DST (CMS Project SR/SA/MS: 516/07; 21/04/2008), India (S.
Pyne); the Patrick C. Walsh Prostate Cancer Research Fund Award (A. M.
De Marzo); and the Fondazione Italiana per la Ricerca sul Cancro, Italy
(S. Cacciatore).
NR 20
TC 14
Z9 14
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7198
EP 7204
DI 10.1158/0008-5472.CAN-14-1490
PG 7
WC Oncology
SC Oncology
GA AW6FC
UT WOS:000346363900007
PM 25322691
ER
PT J
AU Bersani, F
Lee, J
Yu, M
Morris, R
Desai, R
Ramaswamy, S
Toner, M
Haber, DA
Parekkadan, B
AF Bersani, Francesca
Lee, Jungwoo
Yu, Min
Morris, Robert
Desai, Rushil
Ramaswamy, Sridhar
Toner, Mehmet
Haber, Daniel A.
Parekkadan, Biju
TI Bioengineered Implantable Scaffolds as a Tool to Study Stromal-Derived
Factors in Metastatic Cancer Models
SO CANCER RESEARCH
LA English
DT Article
ID INVERTED COLLOIDAL CRYSTALS; TISSUE-ENGINEERED BONE; PROSTATE-CANCER;
BREAST-CANCER; PRIMARY TUMORS; STEM-CELLS; IN-VITRO; PROGRESSION;
EXPRESSION; MICROENVIRONMENTS
AB Modeling the hematogenous spread of cancer cells to distant organs poses one of the greatest challenges in the study of human metastasis. Both tumor cell-intrinsic properties as well as interactions with reactive stromal cells contribute to this process, but identification of relevant stromal signals has been hampered by the lack of models allowing characterization of the metastatic niche. Here, we describe an implantable bioengineered scaffold, amenable to in vivo imaging, ex vivo manipulation, and serial transplantation for the continuous study of human metastasis in mice. Orthotopic or systemic inoculation of tagged human cancer cells into the mouse leads to the release of circulating tumor cells into the vasculature, which seed the scaffold, initiating a metastatic tumor focus. Mouse stromal cells can be readily recovered and profiled, revealing differential expression of cytokines, such as IL1 beta, from tumor-bearing versus unseeded scaffolds. Finally, this platform can be used to test the effect of drugs on suppressing initiation of metastatic lesions. This generalizable model to study cancer metastasis may thus identify key stromal-derived factors with important implications for basic and translational cancer research.
C1 [Bersani, Francesca; Yu, Min; Morris, Robert; Desai, Rushil; Ramaswamy, Sridhar; Haber, Daniel A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
[Bersani, Francesca; Yu, Min; Morris, Robert; Desai, Rushil; Ramaswamy, Sridhar; Haber, Daniel A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Charlestown, MA USA.
[Lee, Jungwoo; Toner, Mehmet; Parekkadan, Biju] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA USA.
[Lee, Jungwoo; Toner, Mehmet; Parekkadan, Biju] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Surg Serv, Boston, MA USA.
[Lee, Jungwoo; Toner, Mehmet; Parekkadan, Biju] Shriners Hosp Children, Boston, MA USA.
[Yu, Min; Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Parekkadan, Biju] Harvard Stem Cell Inst, Boston, MA USA.
RP Haber, DA (reprint author), Massachusetts Gen Hosp, Ctr Canc, 149 13th St, Charlestown, MA 02129 USA.
EM haber@helix.mgh.harvard.edu; biju_parekkadan@hms.harvard.edu
FU NIH [R01EB012521, K01DK087770, K99CA163671, R01CA129933]; Shriners
Hospitals for Children; National Foundation for Cancer Research; Howard
Hughes Medical Institute
FX This work was supported in part by NIH grants R01EB012521 (B.
Parekkadan), K01DK087770 (B. Parekkadan), K99CA163671 (J. Lee),
R01CA129933 (D. A. Haber and F. Bersani), the Shriners Hospitals for
Children (J. Lee and B. Parekkadan), the National Foundation for Cancer
Research (D. A. Haber), and the Howard Hughes Medical Institute (D. A.
Haber).
NR 43
TC 5
Z9 5
U1 1
U2 21
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7229
EP 7238
DI 10.1158/0008-5472.CAN-14-1809
PG 10
WC Oncology
SC Oncology
GA AW6FC
UT WOS:000346363900010
PM 25339351
ER
PT J
AU Samkoe, KS
Tichauer, KM
Gunn, JR
Wells, WA
Hasan, T
Pogue, BW
AF Samkoe, Kimberley S.
Tichauer, Kenneth M.
Gunn, Jason R.
Wells, Wendy A.
Hasan, Tayyaba
Pogue, Brian W.
TI Quantitative In Vivo Immunohistochemistry of Epidermal Growth Factor
Receptor Using a Receptor Concentration Imaging Approach
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; SITU HYBRIDIZATION; DRUG DISCOVERY; QUANTIFICATION;
BINDING; EXPRESSION; THERAPY; PET; UTILITY; MODELS
AB As receptor-targeted therapeutics become increasingly used in clinical oncology, the ability to quantify protein expression and pharmacokinetics in vivo is imperative to ensure successful individualized treatment plans. Current standards for receptor analysis are performed on extracted tissues. These measurements are static and often physiologically irrelevant; therefore, only a partial picture of available receptors for drug targeting in vivo is provided. Until recently, in vivo measurements were limited by the inability to separate delivery, binding, and retention effects, but this can be circumvented by a dual-tracer approach for referencing the detected signal. We hypothesized that in vivo receptor concentration imaging (RCI) would be superior to ex vivo immunohistochemistry (IHC). Using multiple xenograft tumor models with varying EGFR expression, we determined the EGFR concentration in each model using a novel targeted agent (anti-EGFR affibody-IRDye800CW conjugate) along with a simultaneously delivered reference agent (control affibody-IRDye680RD conjugate). The RCI-calculated in vivo receptor concentration was strongly correlated with ex vivo pathologist-scored IHC and computer-quantified ex vivo immunofluorescence. In contrast, no correlation was observed with ex vivo Western blot analysis or in vitro flow-cytometry assays. Overall, our results argue that in vivo RCI provides a robust measure of receptor expression equivalent to ex vivo immunostaining, with implications for use in noninvasive monitoring of therapy or therapeutic guidance during surgery. (C)2014 AACR.
C1 [Samkoe, Kimberley S.; Pogue, Brian W.] Dartmouth Coll, Geisel Sch Med, Dept Surg, Lebanon, NH 03756 USA.
[Samkoe, Kimberley S.; Gunn, Jason R.; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
[Tichauer, Kenneth M.] IIT, Dept Biomed Engn, Chicago, IL 60616 USA.
[Wells, Wendy A.] Dartmouth Coll, Dartmouth Hitchcock Med Ctr, Dept Pathol, Geisel Sch Med, Lebanon, NH 03756 USA.
[Hasan, Tayyaba] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Samkoe, KS (reprint author), Dartmouth Coll, Dartmouth Hitchcock Med Ctr, Dept Surg, Geisel Sch Med, One Med Ctr Dr, Lebanon, NH 03756 USA.
EM Kimberley.S.Samkoe@Dartmouth.edu
FU NIH [R01CA156177, U54CA151662, P01CA84201]
FX This work has been supported by NIH grants R01CA156177 (K.S. Samkoe,
B.W. Pogue, and T. Hasan), U54CA151662 (B.W. Pogue, J.R. Gunn, and K.S.
Samkoe), and P01CA84201 (K.S. Samkoe, J.R. Gunn, and B.W. Pogue)
NR 44
TC 13
Z9 14
U1 1
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7465
EP 7474
DI 10.1158/0008-5472.CAN-14-0141
PG 10
WC Oncology
SC Oncology
GA AW6FC
UT WOS:000346363900030
PM 25344226
ER
PT J
AU Chan, CT
Qi, J
Smith, W
Paranol, R
Mazitschek, R
West, N
Reeves, R
Chiosis, G
Schreiber, SL
Bradner, JE
Paulmurugan, R
Gambhir, SS
AF Chan, C. T.
Qi, J.
Smith, W.
Paranol, R.
Mazitschek, R.
West, N.
Reeves, R.
Chiosis, G.
Schreiber, S. L.
Bradner, J. E.
Paulmurugan, R.
Gambhir, S. S.
TI Syntheses and Discovery of a Novel Class of Cinnamic Hydroxamates as
Histone Deacetylase Inhibitors by Multimodality Molecular Imaging in
Living Subjects
SO CANCER RESEARCH
LA English
DT Article
ID CANCER-THERAPY; HEAT-SHOCK-PROTEIN-90 INHIBITORS; CHAPERONE FUNCTION;
ANTICANCER AGENTS; RECEPTOR; VORINOSTAT; EXPRESSION; CELLS; ACID;
IDENTIFICATION
AB Histone deacetylases (HDAC) that regulate gene expression are being explored as cancer therapeutic targets. In this study, we focused on HDAC6 based on its ability to inhibit cancerous Hsp90 chaperone activities by disrupting Hsp90/p23 interactions. To identify novel HDAC6 inhibitors, we used a dual-luciferase reporter system in cell culture and living mice by bioluminescence imaging (BLI). On the basis of existing knowledge, a library of hydrazone compounds was generated for screening by coupling cinnamic hydroxamates with aldehydes and ketones. Potency and selectivity were determined by in vitro HDAC profiling assays, with further evaluation to inhibit Hsp90(alpha/beta)/p23 interactions by BLI. In this manner, we identified compound 1A12 as a dose-dependent inhibitor of Hsp90(alpha/beta)/p23 interactions, UKE-1 myeloid cell proliferation, p21(waf1) upregulation, and acetylated histone H3 levels. 1A12 was efficacious in tumor xenografts expressing Hsp90(alpha)/p23 reporters relative to carrier control-treated mice as determined by BLI. Small animal F-18-FDG PET/CT imaging on the same cohort showed that 1A12 also inhibited glucose metabolism relative to control subjects. Ex vivo analyses of tumor lysates showed that 1A12 administration upregulated acetylated-H3 by approximately 3.5-fold. Taken together, our results describe the discovery and initial preclinical validation of a novel selective HDAC inhibitor.
C1 [Chan, C. T.; Reeves, R.; Paulmurugan, R.; Gambhir, S. S.] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA.
[Chan, C. T.; Reeves, R.; Paulmurugan, R.; Gambhir, S. S.] Stanford Univ, Sch Med, Mol Imaging Program Stanford, Stanford, CA 94305 USA.
[Chan, C. T.; Reeves, R.; Paulmurugan, R.; Gambhir, S. S.] Stanford Univ, Sch Med, Bio X Program, Stanford, CA 94305 USA.
[Qi, J.; Smith, W.; Paranol, R.; West, N.; Bradner, J. E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mazitschek, R.; Bradner, J. E.] Harvard Univ, Sch Med, Boston, MA USA.
[Mazitschek, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mazitschek, R.; Schreiber, S. L.; Bradner, J. E.] Broad Inst, Cambridge, MA USA.
[Chiosis, G.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Chiosis, G.] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Med Chem, New York, NY 10021 USA.
[Gambhir, S. S.] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA.
[Gambhir, S. S.] Stanford Univ, Sch Med, Div Nucl Med, Stanford, CA 94305 USA.
RP Gambhir, SS (reprint author), Stanford Univ, 318 Campus Dr,Clark Ctr Room E150, Stanford, CA 94305 USA.
EM sgambhir@stanford.edu
FU NIH [NCI RO1 CA082214, NCI ICMIC P50CA114747, P50CA086355]; Susan Komen
Postdoctoral Fellowship
FX This research was supported by the NIH (grant number NCI RO1 CA082214),
NCI ICMIC P50CA114747 at Stanford University (S.S. Gambhir), and the
Susan Komen Postdoctoral Fellowship (C.T. Chan) and NIH P50CA086355 (R.
Mazitschek)
NR 49
TC 4
Z9 4
U1 1
U2 25
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7475
EP 7486
DI 10.1158/0008-5472.CAN-14-0197
PG 12
WC Oncology
SC Oncology
GA AW6FC
UT WOS:000346363900031
PM 25320008
ER
PT J
AU Kawasumi, M
Bradner, JE
Tolliday, N
Thibodeau, R
Sloan, H
Brummond, KM
Nghiem, P
AF Kawasumi, Masaoki
Bradner, James E.
Tolliday, Nicola
Thibodeau, Renee
Sloan, Heather
Brummond, Kay M.
Nghiem, Paul
TI Identification of ATR-Chk1 Pathway Inhibitors That Selectively Target
p53-Deficient Cells without Directly Suppressing ATR Catalytic Activity
SO CANCER RESEARCH
LA English
DT Article
ID DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; CANCER-CELLS;
RADIOSENSITIZING AGENT; CYCLE CHECKPOINTS; PROTEIN-KINASE; G(2) ARREST;
CHK1; P53; ACTIVATION
AB Resistance to DNA-damaging chemotherapy is a barrier to effective treatment that appears to be augmented by p53 functional deficiency in many cancers. In p53-deficient cells in which the G(1)-S checkpoint is compromised, cell viability after DNA damage relies upon intact intra-S and G(2)-M checkpoints mediated by the ATR (ataxia telangiectasia and Rad3 related) and Chk1 kinases. Thus, a logical rationale to sensitize p53-deficient cancers to DNA-damaging chemotherapy is through the use of ATP-competitive inhibitors of ATR or Chk1. To discover small molecules that may act on uncharacterized components of the ATR pathway, we performed a phenotype-based screen of 9,195 compounds for their ability to inhibit hydroxyurea-induced phosphorylation of Ser345 on Chk1, known to be a critical ATR substrate. This effort led to the identification of four small-molecule compounds, three of which were derived from known bioactive library (anthothecol, dihydrocelastryl, and erysolin) and one of which was a novel synthetic compound termed MARPIN. These compounds all inhibited ATR-selective phosphorylation and sensitized p53-deficient cancer cells to DNA-damaging agents in vitro and in vivo. Notably, these compounds did not inhibit ATR catalytic activity in vitro, unlike typical ATP-competitive inhibitors, but acted in a mechanistically distinct manner to disable ATR-Chk1 function. Our results highlight a set of novel molecular probes to further elucidate druggable mechanisms to improve cancer therapeutic responses produced by DNA-damaging drugs. (C)2014 AACR.
C1 [Kawasumi, Masaoki; Thibodeau, Renee; Sloan, Heather; Nghiem, Paul] Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98109 USA.
[Bradner, James E.; Tolliday, Nicola] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Bradner, James E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Brummond, Kay M.] Univ Pittsburgh, Ctr Chem Methodol & Lib Dev, Pittsburgh, PA USA.
[Nghiem, Paul] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
RP Kawasumi, M (reprint author), Univ Washington, Dept Med, Div Dermatol, 850 Republ St,Room 242, Seattle, WA 98109 USA.
EM kawasumi@uw.edu; pnghiem@uw.edu
RI Nghiem, Paul/A-9210-2011
OI Nghiem, Paul/0000-0003-2784-963X
FU NIH [R01-AR049832]; Dermatology Foundation; Michael Piepkorn Endowment
for Dermatology Research at University of Washington
FX This work was supported by the NIH (R01-AR049832; P. Nghiem), a
Dermatology Foundation Career Development Award (M. Kawasumi), and the
Michael Piepkorn Endowment for Dermatology Research at University of
Washington.
NR 50
TC 5
Z9 6
U1 1
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7534
EP 7545
DI 10.1158/0008-5472.CAN-14-2650
PG 12
WC Oncology
SC Oncology
GA AW6FC
UT WOS:000346363900036
PM 25336189
ER
PT J
AU Groeneweg, JW
Hernandez, SF
Byron, VF
DiGloria, CM
Lopez, H
Scialabba, V
Kim, M
Zhang, L
Borger, DR
Tambouret, R
Foster, R
Rueda, BR
Growdon, WB
AF Groeneweg, Jolijn W.
Hernandez, Silvia F.
Byron, Virginia F.
DiGloria, Celeste M.
Lopez, Hector
Scialabba, Vanessa
Kim, Minji
Zhang, Ling
Borger, Darrell R.
Tambouret, Rosemary
Foster, Rosemary
Rueda, Bo R.
Growdon, Whitfield B.
TI Dual HER2 Targeting Impedes Growth of HER2 Gene-Amplified Uterine Serous
Carcinoma Xenografts
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GYNECOLOGIC-ONCOLOGY-GROUP; METASTATIC BREAST-CANCER; PHASE-III TRIAL;
ENDOMETRIAL CARCINOMA; PROGNOSTIC INDICATOR; TRASTUZUMAB; LAPATINIB;
RECEPTOR; AMPLIFICATION; THERAPY
AB Purpose: Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer that commonly harbors HER2 gene amplification. We investigated the effectiveness of HER2 inhibition using lapatinib and trastuzumab in vitro and in xenografts derived from USC cell lines and USC patient-derived xenografts.
Experimental Design: Immunohistochemistry and FISH were performed to assess HER2 expression in 42 primary USC specimens. ARK1, ARK2, and SPEC2 cell lines were treated with trastuzumab or lapatinib. Cohorts of mice harboring xenografts derived from ARK2 and SPEC2 cell lines and EnCa1 and EnCa2 primary human USC samples were treated with either vehicle, trastuzumab, lapatinib, or the combination of trastuzumab and lapatinib. Acute and chronic posttreatment tumor samples were assessed for downstream signaling alterations and examined for apoptosis and proliferation.
Results: HER2 gene amplification (24%) correlated significantly with HER2 protein overexpression (55%). All models were impervious to single-agent trastuzumab treatment. Lapatinib decreased in vitro proliferation of all cell lines and in vivo growth of HER2-amplified xenografts (ARK2, EnCa1). In addition, dual therapy with trastuzumab and lapatinib resulted in significant antitumor activity only in ARK2 and EnCa1 tumors. Dual HER2 therapy induced on target alteration of downstream MAPK and PI3K pathway mediators only in HER2-amplified models, and was associated with increased apoptosis and decreased proliferation.
Conclusions: Although trastuzumab alone did not impact USC growth, dual anti-HER2 therapy with lapatinib led to improved inhibition of tumor growth in HER2-amplified USC and may be a promising avenue for future investigation. (C) 2014 AACR.
C1 [Groeneweg, Jolijn W.; Hernandez, Silvia F.; Byron, Virginia F.; DiGloria, Celeste M.; Kim, Minji; Zhang, Ling; Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Groeneweg, Jolijn W.; Hernandez, Silvia F.; Tambouret, Rosemary; Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Harvard Univ, Sch Med, Boston, MA USA.
[Lopez, Hector; Scialabba, Vanessa; Borger, Darrell R.] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA.
[Tambouret, Rosemary] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02114 USA.
RP Growdon, WB (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, THR901,55 Fruit St, Boston, MA 02114 USA.
EM wgrowdon@partners.org
FU institutional K12 Proton Share NCI Grant [C06 CA059267]; Advanced
Medical Research Foundation; Vincent Department of Obstetrics and
Gynecology Research Funds
FX This research was funded by an institutional K12 Proton Share NCI Grant
C06 CA059267 (to W.B. Growdon), and funding from the Advanced Medical
Research Foundation (to B.R. Rueda) and Vincent Department of Obstetrics
and Gynecology Research Funds (to B.R. Rueda).
NR 50
TC 6
Z9 7
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2014
VL 20
IS 24
BP 6517
EP 6528
DI 10.1158/1078-0432.CCR-14-1647
PG 12
WC Oncology
SC Oncology
GA AW7AZ
UT WOS:000346418100031
PM 25294905
ER
PT J
AU Capelletti, M
Dodge, ME
Ercan, D
Hammerman, PS
Park, SI
Kim, J
Sasaki, H
Jablons, DM
Lipson, D
Young, L
Stephens, PJ
Miller, VA
Lindeman, NI
Munir, KJ
Richards, WG
Janne, PA
AF Capelletti, Marzia
Dodge, Michael E.
Ercan, Dalia
Hammerman, Peter S.
Park, Seung-Il
Kim, Jhingook
Sasaki, Hidefumi
Jablons, David M.
Lipson, Doron
Young, Lauren
Stephens, Phil J.
Miller, Vincent A.
Lindeman, Neal I.
Munir, Kiara J.
Richards, William G.
Jaenne, Pasi A.
TI Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung
Adenocarcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID NEVER SMOKERS; GENE FUSIONS; EGFR MUTATIONS; PHASE-II; CANCER; RET;
ERLOTINIB; FEATURES; ALK; CHEMOTHERAPY
AB Purpose: Targetable oncogenic alterations are detected more commonly in patients with non-small cell lung cancer (NSCLC) who never smoked cigarettes. For such patients, specific kinase inhibitors have emerged as effective clinical treatments. However, the currently known oncogenic alterations do not account for all never smokers who develop NSCLC. We sought to identify additional oncogenic alterations from patients with NSCLC to define additional treatment options.
Experimental Design: We analyzed 576 lung adenocarcinomas from patients of Asian and Caucasian ethnicity. We identified a subset of cancers that did not harbor any known oncogenic alteration. We performed targeted next-generation sequencing (NGS) assay on 24 patients from this set with >75% tumor cell content.
Results: EGFR mutations were the most common oncogenic alteration from both Asian (53%) and Caucasian (41.6%) patients. No known oncogenic alterations were present in 25.7% of Asian and 31% of Caucasian tumor specimens. We identified a FGFR3-TACC3 fusion event in one of 24 patients from this subset using targeted NGS. Two additional patients harboring FGFR3-TACC3 were identified by screening our entire cohort (overall prevalence, 0.5%). Expression of FGFR3-TACC3 led to IL3 independent growth in Ba/F3 cells. These cells were sensitive to pan-fibroblast growth factor receptor (pan-FGFR) inhibitors but not the epidermal growth factor (EGFR) inhibitor gefitinib.
Conclusions: FGFR3-TACC3 rearrangements occur in a subset of patients with lung adenocarcinoma. Such patients should be considered for clinical trials featuring FGFR inhibitors. (C) 2014 AACR.
C1 [Capelletti, Marzia; Dodge, Michael E.; Ercan, Dalia; Hammerman, Peter S.; Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA.
[Park, Seung-Il] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Thorac Surg, Seoul, South Korea.
[Kim, Jhingook] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Thorac Surg, Seoul, South Korea.
[Sasaki, Hidefumi] Nagoya City Univ, Grad Sch Med Sci, Dept Oncol Immunol & Surg, Nagoya, Aichi, Japan.
[Jablons, David M.] Univ Calif San Francisco, Dept Surg, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Lipson, Doron; Young, Lauren; Stephens, Phil J.; Miller, Vincent A.] Fdn Med Inc, Cambridge, MA USA.
[Lindeman, Neal I.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Lindeman, Neal I.] Brigham & Womens Hosp, Ctr Adv Mol Diagnost, Boston, MA 02115 USA.
[Munir, Kiara J.; Richards, William G.] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA.
[Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA.
RP Janne, PA (reprint author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,HIM 223, Boston, MA 02215 USA.
EM pasi_janne@dfci.harvard.edu
FU Cammarata Family Foundation Research Fund; Nirenberg Fellowship at the
Dana-Farber Cancer Institute; V Foundation Scholar Award; Scientific
Research, Japan Society for the Promotion of Science (JSPS) [24592097]
FX This work was supported by the Cammarata Family Foundation Research Fund
(to M. Capelletti and P.A.Janne), the Nirenberg Fellowship at the
Dana-Farber Cancer Institute (to M. Capelletti and P.A.Janne). P.S.
Hammerman is supported by a V Foundation Scholar Award. H. Sasaki is
supported by Grants-in-Aid for Scientific Research, Japan Society for
the Promotion of Science (JSPS; No. 24592097).
NR 41
TC 21
Z9 22
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2014
VL 20
IS 24
BP 6551
EP 6558
DI 10.1158/1078-0432.CCR-14-1337
PG 8
WC Oncology
SC Oncology
GA AW7AZ
UT WOS:000346418100034
PM 25294908
ER
PT J
AU Sucker, A
Zhao, F
Real, B
Heeke, C
Bielefeld, N
Massen, S
Horn, S
Moll, I
Maltaner, R
Horn, PA
Schilling, B
Sabbatino, F
Lennerz, V
Kloor, M
Ferrone, S
Schadendorf, D
Falk, CS
Griewank, K
Paschen, A
AF Sucker, Antje
Zhao, Fang
Real, Birgit
Heeke, Christina
Bielefeld, Nicola
Massen, Stefan
Horn, Susanne
Moll, Iris
Maltaner, Raffaela
Horn, Peter A.
Schilling, Bastian
Sabbatino, Francesco
Lennerz, Volker
Kloor, Matthias
Ferrone, Soldano
Schadendorf, Dirk
Falk, Christine S.
Griewank, Klaus
Paschen, Annette
TI Genetic Evolution of T-cell Resistance in the Course of Melanoma
Progression
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID EMBEDDED TISSUE-SECTIONS; I ANTIGEN-EXPRESSION; METASTATIC MELANOMA;
TUMOR-ANTIGENS; IMMUNE ESCAPE; CANCER; IMMUNOTHERAPY; MUTATIONS;
ANTIBODY; EPITOPE
AB Purpose: CD8(+) T lymphocytes can kill autologous melanoma cells, but their activity is impaired when poorly immunogenic tumor phenotypes evolve in the course of disease progression. Here, we analyzed three consecutive melanoma lesions obtained within one year of developing stage IV disease for their recognition by autologous T cells.
Experimental Design: One skin (Ma-Mel-48a) and two lymph node (Ma-Mel-48b, Ma-Mel-48c) metastases were analyzed for T-cell infiltration. Melanoma cell lines established from the respective lesions were characterized, determining the T-cell-stimulatory capacity, expression of surface molecules involved in T-cell activation, and specific genetic alterations affecting the tumor-T-cell interaction.
Results: Metastases Ma-Mel-48a and Ma-Mel-48b, in contrast with Ma-Mel-48c, were infiltrated by T cells. The T-cell-stimulatory capacity was found to be strong for Ma-Mel-48a, lower for Ma-Mel-48b, and completely abrogated for Ma-Mel-48c cells. The latter proved to be HLA class I-negative due to an inactivating mutation in one allele of the beta-2-microglobulin (B2M) gene and concomitant loss of the other allele by a deletion on chromosome 15q. The same deletion was already present in Ma-Mel-48a and Ma-Mel-48b cells, pointing to an early acquired genetic event predisposing to development of beta 2m deficiency. Notably, the same chronology of genetic alterations was also observed in a second beta 2m-deficient melanoma model.
Conclusion: Our study reveals a progressive loss in melanoma immunogenicity during the course of metastatic disease. The genetic evolvement of T-cell resistance suggests screening tumors for genetic alterations affecting immunogenicity could be clinically relevant in terms of predicting patient responses to T-cell-based immunotherapy. (C) 2014 AACR.
C1 [Sucker, Antje; Zhao, Fang; Real, Birgit; Heeke, Christina; Bielefeld, Nicola; Horn, Susanne; Moll, Iris; Maltaner, Raffaela; Schilling, Bastian; Schadendorf, Dirk; Griewank, Klaus; Paschen, Annette] Univ Duisburg Essen, Univ Hosp Essen, Dept Dermatol, Essen, Germany.
[Sucker, Antje; Zhao, Fang; Real, Birgit; Heeke, Christina; Bielefeld, Nicola; Horn, Susanne; Moll, Iris; Maltaner, Raffaela; Horn, Peter A.; Schilling, Bastian; Schadendorf, Dirk; Griewank, Klaus; Paschen, Annette] German Canc Consortium DKTK, Heidelberg, Germany.
[Massen, Stefan; Falk, Christine S.] Hannover Med Sch, Inst Transplantat Immunol, IFB Tx, Hannover, Germany.
[Horn, Peter A.] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, Essen, Germany.
[Sabbatino, Francesco; Ferrone, Soldano] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Lennerz, Volker] Johannes Gutenberg Univ Mainz, Univ Med Ctr, D-55122 Mainz, Germany.
[Kloor, Matthias] Heidelberg Univ, Inst Pathol, Dept Appl Tumor Biol, Heidelberg, Germany.
RP Paschen, A (reprint author), Univ Hosp Essen, Hufelandstr 55, D-45122 Essen, Germany.
EM annette.paschen@uk-essen.de
RI Sabbatino, Francesco/F-4992-2014; Griewank, Klaus/A-9097-2017
OI Sabbatino, Francesco/0000-0001-6431-8278;
FU Helmholtz Alliance on Cancer Immunotherapy; NRW/EU-Ziel2-Programm
[005-1006-0057]; DFG [TRR77]; Integrated Research and Treatment Centre
Transplantation (IFB-Tx, BMBF) [01EO1302]; National Cancer Institute
[RO1CA138188, RO1CA110249]
FX This study was supported in part by the Helmholtz Alliance on Cancer
Immunotherapy and by the NRW/EU-Ziel2-Programm 2007-2013 (005-1006-0057;
to A. Paschen and D. Schadendorf); the DFG TRR77 and Integrated Research
and Treatment Centre Transplantation (IFB-Tx, BMBF 01EO1302; to C.S.
Falk); and PHS grants RO1CA138188 and RO1CA110249 awarded by the
National Cancer Institute (to S. Ferrone).
NR 47
TC 12
Z9 12
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2014
VL 20
IS 24
BP 6593
EP 6604
DI 10.1158/1078-0432.CCR-14-0567
PG 12
WC Oncology
SC Oncology
GA AW7AZ
UT WOS:000346418100038
PM 25294904
ER
PT J
AU Emmanuel, C
Chiew, YE
George, J
Etemadmoghadam, D
Anglesio, MS
Sharma, R
Russell, P
Kennedy, C
Fereday, S
Hung, JL
Galletta, L
Hogg, R
Wain, GV
Brand, A
Balleine, R
MacConaill, L
Palescandolo, E
Hunter, SM
Campbell, I
Dobrovic, A
Wong, SQ
Do, HD
Clarke, CL
Harnett, PR
Bowtell, DDL
deFazio, A
AF Emmanuel, Catherine
Chiew, Yoke-Eng
George, Joshy
Etemadmoghadam, Dariush
Anglesio, Michael S.
Sharma, Raghwa
Russell, Peter
Kennedy, Catherine
Fereday, Sian
Hung, Jillian
Galletta, Laura
Hogg, Russell
Wain, Gerard V.
Brand, Alison
Balleine, Rosemary
MacConaill, Laura
Palescandolo, Emanuele
Hunter, Sally M.
Campbell, Ian
Dobrovic, Alexander
Wong, Stephen Q.
Do, Hongdo
Clarke, Christine L.
Harnett, Paul R.
Bowtell, David D. L.
deFazio, Anna
CA Australian Ovarian Canc Study AOCS
TI Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline
Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as
an Oncogenic Driver
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HIGH-GRADE CARCINOMAS; BRAF MUTATIONS; OPEN-LABEL; KRAS; EXPRESSION;
PROFILES; ACTIVATION; MELANOMA; SURVIVAL; WOMEN
AB Purpose: Low-grade serous ovarian carcinomas (LGSC) are Ras pathway-mutated, TP53 wild-type, and frequently associated with borderline tumors. Patients with LGSCs respond poorly to platinum-based chemotherapy and may benefit from pathway-targeted agents. High-grade serous carcinomas (HGSC) are TP53-mutated and are thought to be rarely associated with borderline tumors. We sought to determine whether borderline histology associated with grade 2 or 3 carcinoma was an indicator of Ras mutation, and we explored the molecular relationship between coexisting invasive and borderline histologies.
Experimental Design: We reviewed >1,200 patients and identified 102 serous carcinomas with adjacent borderline regions for analyses, including candidate mutation screening, copy number, and gene expression profiling.
Results: We found a similar frequency of low, moderate, and high-grade carcinomas with coexisting borderline histology. BRAF/KRAS alterations were common in LGSC; however, we also found recurrent NRAS mutations. Whereas borderline tumors harbored BRAF/KRAS mutations, NRAS mutations were restricted to carcinomas, representing the first example of a Ras oncogene with an obligatory association with invasive serous cancer. Coexisting borderline and invasive components showed nearly identical genomic profiles. Grade 2 cases with coexisting borderline included tumors with molecular features of LGSC, whereas others were typical of HGSC. However, all grade 3 carcinomas with coexisting borderline histology were molecularly indistinguishable from typical HGSC.
Conclusion: Our findings suggest that NRAS is an oncogenic driver in serous ovarian tumors. We demonstrate that borderline histology is an unreliable predictor of Ras pathway aberration and underscore an important role for molecular classification in identifying patients that may benefit from targeted agents. (C) 2014 AACR.
C1 [Emmanuel, Catherine; Chiew, Yoke-Eng; Kennedy, Catherine; Hung, Jillian; Hogg, Russell; Wain, Gerard V.; Brand, Alison; deFazio, Anna] Univ Sydney, Westmead Hosp, Dept Gynaecol Oncol, Sydney, NSW 2145, Australia.
[Emmanuel, Catherine; Chiew, Yoke-Eng; Kennedy, Catherine; Hung, Jillian; Hogg, Russell; Wain, Gerard V.; Brand, Alison; Harnett, Paul R.; deFazio, Anna] Westmead Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia.
[Emmanuel, Catherine; Sharma, Raghwa; Kennedy, Catherine; Hogg, Russell; Wain, Gerard V.; Brand, Alison; Balleine, Rosemary; Clarke, Christine L.; Harnett, Paul R.; deFazio, Anna] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia.
[Emmanuel, Catherine; Chiew, Yoke-Eng; Kennedy, Catherine; Hung, Jillian; Balleine, Rosemary; Clarke, Christine L.; Harnett, Paul R.; deFazio, Anna] Westmead Hosp, Westmead Inst Canc Res, Westmead Millennium Inst, Sydney, NSW, Australia.
[George, Joshy; Etemadmoghadam, Dariush; Anglesio, Michael S.; Fereday, Sian; Galletta, Laura; Hunter, Sally M.; Campbell, Ian; Dobrovic, Alexander; Wong, Stephen Q.; Do, Hongdo; Bowtell, David D. L.] Peter MacCallum Canc Inst, Canc Genom Program, East Melbourne, Vic, Australia.
[Etemadmoghadam, Dariush; Bowtell, David D. L.] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Oncol, Parkville, Vic 3052, Australia.
[Etemadmoghadam, Dariush; Campbell, Ian; Dobrovic, Alexander; Wong, Stephen Q.; Bowtell, David D. L.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.
[Sharma, Raghwa; Balleine, Rosemary] Pathol West ICPMR Westmead, Sydney, NSW, Australia.
[Sharma, Raghwa] Univ Western Sydney, Westmead Hosp, Westmead, NSW, Australia.
[Russell, Peter] Univ Sydney, Dept Obstet Gynaecol & Neonatal, Camperdown, NSW, Australia.
[Russell, Peter] Douglass Hanly Moir Pathol, Macquarie Pk, NSW, Australia.
[MacConaill, Laura; Palescandolo, Emanuele] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dobrovic, Alexander; Wong, Stephen Q.] La Trobe Univ, Sch Canc Med, Bundoora, Vic, Australia.
[Bowtell, David D. L.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.
[Bowtell, David D. L.] Univ London Imperial Coll Sci Technol & Med, Ovarian Canc Act Res Ctr, Dept Surg & Canc, London, England.
RP deFazio, A (reprint author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Dept Gynaecol Oncol, Westmead, NSW 2145, Australia.
EM anna.defazio@sydney.edu.au
RI deFazio, Anna/D-3939-2013; Bowtell, David/H-1007-2016; Harnett,
Paul/D-4090-2014;
OI deFazio, Anna/0000-0003-0057-4744; Bowtell, David/0000-0001-9089-7525;
Harnett, Paul/0000-0001-7021-0642; Anglesio,
Michael/0000-0003-1639-5003; Dobrovic, Alexander/0000-0003-3414-112X
FU U.S. Army Medical Research and Materiel Command [DAMD17-01-1-0729]
FX The Australian Ovarian Cancer Study was supported by the U.S. Army
Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer
Council Victoria, Queensland Cancer Fund, The Cancer CouncilNew South
Wales, The Cancer Council South Australia, The Cancer Foundation of
Western Australia, The Cancer Council Tasmania, and the National Health
and Medical Research Council of Australia (NHMRC; ID400413, ID400281).
The Gynaecological Oncology Biobank at Westmead is funded by Cancer
Institute NSW and is amember bank of the Australasian Biospecimens
Network-Oncology, funded byNHMRC(ID310670, ID628903). A. de Fazio is
funded by the University of Sydney Cancer Research Fund, and A. de Fazio
and P. R. Harnett are funded by the Cancer Institute NSW through the
Sydney-West Translational Cancer Research Centre. This work was also
supported by a grant from the Cancer Council of New South Wales (CCNSW
RG10-05). This work was also supported by the Victorian Breast Cancer
Research Consortium (VBCRC), the NHMRC (ID 628630), Cancer Australia
(1004673), and theEmer Casey Foundation. H. Do was funded by a
fellowship from the Cancer Council of Victoria, and S. Q. Wong was
supported by the Melbourne Melanoma Project, funded by the Victorian
Cancer Agency Translational Research Program. L. MacConaill and E.
Palescandolo were funded by the Dana-Farber Cancer Institute.
NR 50
TC 16
Z9 16
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2014
VL 20
IS 24
BP 6618
EP 6630
DI 10.1158/1078-0432.CCR-14-1292
PG 13
WC Oncology
SC Oncology
GA AW7AZ
UT WOS:000346418100040
PM 25316818
ER
PT J
AU Knudson, IM
Shera, CA
Melcher, JR
AF Knudson, Inge M.
Shera, Christopher A.
Melcher, Jennifer R.
TI Increased contralateral suppression of otoacoustic emissions indicates a
hyperresponsive medial olivocochlear system in humans with tinnitus and
hyperacusis
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
DE DPOAE; efferent feedback; loudness discomfort level; cochlear efferents;
posteroventral cochlear nucleus; anteroventral cochlear nucleus; dorsal
cochlear nucleus
ID EFFERENT AUDITORY-SYSTEM; VENTRAL COCHLEAR NUCLEUS; ACOUSTIC DISTORTION
PRODUCTS; NORMAL-HEARING SENSITIVITY; NOISE-INDUCED TINNITUS; INFERIOR
COLLICULUS; BRAIN-STEM; PSYCHOMETRIC PROPERTIES; GUINEA-PIG; NEURONS
AB Atypical medial olivocochlear (MOC) feedback from brain stem to cochlea has been proposed to play a role in tinnitus, but even well-constructed tests of this idea have yielded inconsistent results. In the present study, it was hypothesized that low sound tolerance (mild to moderate hyperacusis), which can accompany tinnitus or occur on its own, might contribute to the inconsistency. Sound-level tolerance (SLT) was assessed in subjects (all men) with clinically normal or near-normal thresholds to form threshold-, age-, and sex-matched groups: 1) no tinnitus/high SLT, 2) no tinnitus/low SLT, 3) tinnitus/high SLT, and 4) tinnitus/low SLT. MOC function was measured from the ear canal as the change in magnitude of distortion-product otoacoustic emissions (DPOAE) elicited by broadband noise presented to the contralateral ear. The noise reduced DPOAE magnitude in all groups ("contralateral suppression"), but significantly more reduction occurred in groups with tinnitus and/or low SLT, indicating hyperresponsiveness of the MOC system compared with the group with no tinnitus/high SLT. The results suggest hyperresponsiveness of the interneurons of the MOC system residing in the cochlear nucleus and/or MOC neurons themselves. The present data, combined with previous human and animal data, indicate that neural pathways involving every major division of the cochlear nucleus manifest hyperactivity and/or hyperresponsiveness in tinnitus and/or low SLT. The overactivation may develop in each pathway separately. However, a more parsimonious hypothesis is that top-down neuromodulation is the driving force behind ubiquitous overactivation of the auditory brain stem and may correspond to attentional spotlighting on the auditory domain in tinnitus and hyperacusis.
C1 [Knudson, Inge M.; Shera, Christopher A.; Melcher, Jennifer R.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Knudson, Inge M.; Shera, Christopher A.; Melcher, Jennifer R.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Shera, Christopher A.; Melcher, Jennifer R.] Harvard Div Med Sci, Speech & Hearing Biosci & Technol Program, Boston, MA USA.
RP Knudson, IM (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM inge_knudson@meei.harvard.edu
FU Tinnitus Research Consortium; National Institute of Deafness and Other
Communications Disorders [P30 DC005209]
FX Support for this work was provided by the Tinnitus Research Consortium
and National Institute of Deafness and Other Communications Disorders
Grant P30 DC005209.
NR 70
TC 9
Z9 10
U1 3
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
EI 1522-1598
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD DEC 15
PY 2014
VL 112
IS 12
BP 3197
EP 3208
DI 10.1152/jn.00576.2014
PG 12
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA AW7WB
UT WOS:000346471200016
PM 25231612
ER
PT J
AU Song, DR
Jun, CS
Do Lim, S
Kim, BY
AF Song, Du-Ri
Jun, Chang Su
Do Lim, Sun
Kim, Byoung Yoon
TI Effect of metal coating in all-fiber acousto-optic tunable filter using
torsional wave
SO OPTICS EXPRESS
LA English
DT Article
ID SILICA OPTICAL FIBERS; MODE; BIREFRINGENCE; MODULATION; STRENGTH
AB Torsional mode acousto-optic tunable filter (AOTF) is demonstrated using a metal-coated birefringent optical fiber for an improved robustness. The changes in acoustic and optical properties of a metal-coated birefringent optical fiber induced by the thin metal coating were analyzed experimentally and theoretically. The filter wavelength shift is successfully explained as a result of combined effect of acoustic wavelength change and optical birefringence change. We also demonstrated a small form-factor configuration by coiling the fiber with 6 cm diameter without performance degradation. The center wavelength of the filter can be tuned >35 nm by changing the applied frequency, and the coupling efficiency is higher than 92% with <5 nm 3-dB bandwidth. (C)2014 Optical Society of America
C1 [Song, Du-Ri; Kim, Byoung Yoon] Korea Adv Inst Sci & Technol, Dept Phys, Taejon 305701, South Korea.
[Jun, Chang Su] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Jun, Chang Su] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Do Lim, Sun] Korea Res Inst Stand & Sci, Ctr Photometry & Radiometry, Div Phys Metrol, Taejon 305340, South Korea.
RP Song, DR (reprint author), Korea Adv Inst Sci & Technol, Dept Phys, 373-1 Guseong Dong, Taejon 305701, South Korea.
EM cherry22@kaist.ac.kr
RI Kim, Byoung Yoon/C-2008-2011
FU Basic Science Research Program through the National Research Foundation
of Korea (NRF) - Ministry of Science, ICT & Future Planning
[2013R1A1A2064061]
FX This research was supported by Basic Science Research Program through
the National Research Foundation of Korea (NRF) funded by the Ministry
of Science, ICT & Future Planning (2013R1A1A2064061). The authors thank
Dr. Sejeong Kim (KAIST) for the SEM image.
NR 26
TC 1
Z9 1
U1 1
U2 14
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD DEC 15
PY 2014
VL 22
IS 25
BP 30873
EP 30881
DI 10.1364/OE.22.030873
PG 9
WC Optics
SC Optics
GA AW6GW
UT WOS:000346368800080
PM 25607036
ER
PT J
AU Oh, HJ
Gather, MC
Song, JJ
Yun, SH
AF Oh, Heon Jeong
Gather, Malte C.
Song, Ji-Joon
Yun, Seok Hyun
TI Lasing from fluorescent protein crystals
SO OPTICS EXPRESS
LA English
DT Article
AB We investigated fluorescent protein crystals for potential photonic applications, for the first time to our knowledge. Rod-shaped crystals of enhanced green fluorescent protein (EGFP) were synthesized, with diameters of 0.5-2 mu m and lengths of 100-200 mu m. The crystals exhibit minimal light scattering due to their ordered structure and generate substantially higher fluorescence intensity than EGFP or dye molecules in solutions. The magnitude of concentration quenching in EGFP crystals was measured to be about 7-10 dB. Upon optical pumping at 485 nm, individual EGFP crystals located between dichroic mirrors generated laser emission with a single-mode spectral line at 513 nm. Our results demonstrate the potential of protein crystals as novel optical elements for self-assembled, micro- or nano-lasers and amplifiers in aqueous environment. (C) 2014 Optical Society of America
C1 [Oh, Heon Jeong; Gather, Malte C.; Yun, Seok Hyun] Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Oh, Heon Jeong; Gather, Malte C.; Yun, Seok Hyun] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02139 USA.
[Oh, Heon Jeong; Song, Ji-Joon] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
[Gather, Malte C.] Univ St Andrews, Sch Phys & Astron, SUPA, St Andrews KY16 9SS, Fife, Scotland.
[Song, Ji-Joon; Yun, Seok Hyun] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol WCU, Taejon 305701, South Korea.
RP Yun, SH (reprint author), Wellman Ctr Photomed, 65 Landsdowne St,UP-5, Cambridge, MA 02139 USA.
EM songj@kaist.ac.kr; syun@hms.harvard.edu
RI Song, Ji-Joon/C-1721-2011;
OI Gather, Malte/0000-0002-4857-5562
FU National Science Foundation [ECCS-1101947, EEC-1358296]; Korea National
Research Foundation [R31-2008-000-10071-0]; KAIST-MGH Summer Internship
Program; European Union Marie Curie Career Integration Grant
[PCIG12-GA-2012-334407]
FX We thank Uhn-Soo Cho for discussion about crystal handling and Myunghwan
Choi for taking two-photon fluorescence images of the crystals. This
work was funded by the National Science Foundation (ECCS-1101947,
EEC-1358296), the Korea National Research Foundation
(R31-2008-000-10071-0), the KAIST-MGH Summer Internship Program, and the
European Union Marie Curie Career Integration Grant
(PCIG12-GA-2012-334407).
NR 13
TC 3
Z9 3
U1 3
U2 31
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD DEC 15
PY 2014
VL 22
IS 25
BP 31411
EP 31416
DI 10.1364/OE.22.031411
PG 6
WC Optics
SC Optics
GA AW6GW
UT WOS:000346368800134
PM 25607090
ER
PT J
AU Iftimia, N
Maguluri, G
Chang, EW
Chang, S
Magill, J
Brugge, W
AF Iftimia, Nicusor
Maguluri, Gopi
Chang, Ernest W.
Chang, Shing
Magill, John
Brugge, William
TI Hand scanning optical coherence tomography imaging using encoder
feedback
SO OPTICS LETTERS
LA English
DT Article
ID TRACKING; BIOPSY
AB We present a new method for generating micron-scale OCT images of interstitial tissue with a hand scanning probe and a linear optical encoder that senses probe movement relative to a fixed reference point, i.e., tissue surface. Based on this approach, we demonstrate high resolution optical imaging of biological tissues through a very long biopsy needle. Minor artifacts caused by tissue noncompliance are corrected using a software algorithm which detects the simple repetition of the adjacent A-scans. This hand-scanning OCT imaging approach offers the physician the freedom to access imaging sites of interest repeatedly. (C) 2014 Optical Society of America
C1 [Iftimia, Nicusor; Maguluri, Gopi; Chang, Ernest W.; Chang, Shing; Magill, John] Phys Sci Inc, Andover, MA 01810 USA.
[Brugge, William] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA.
RP Iftimia, N (reprint author), Phys Sci Inc, 20 New England Business Ctr, Andover, MA 01810 USA.
EM iftimia@psicorp.com
FU NCI [5R44CA117218]
FX This work was supported by the NCI Grant 5R44CA117218.
NR 16
TC 2
Z9 2
U1 0
U2 4
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
EI 1539-4794
J9 OPT LETT
JI Opt. Lett.
PD DEC 15
PY 2014
VL 39
IS 24
BP 6807
EP 6810
DI 10.1364/OL.39.006807
PG 4
WC Optics
SC Optics
GA AW5YX
UT WOS:000346347900011
PM 25503002
ER
PT J
AU Fung, TT
Kashambwa, R
Sato, K
Chiuve, SE
Fuchs, CS
Wu, KN
Giovannucci, E
Ogino, S
Hu, FB
Meyerhardt, JA
AF Fung, Teresa T.
Kashambwa, Rutendo
Sato, Kaori
Chiuve, Stephanie E.
Fuchs, Charles S.
Wu, Kana
Giovannucci, Edward
Ogino, Shuji
Hu, Frank B.
Meyerhardt, Jeffrey A.
TI Post Diagnosis Diet Quality and Colorectal Cancer Survival in Women
SO PLOS ONE
LA English
DT Article
ID SYSTEMIC INFLAMMATORY RESPONSE; FOOD-FREQUENCY QUESTIONNAIRE;
CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; III COLON-CANCER;
MEDITERRANEAN DIET; PROSPECTIVE COHORT; ALL-CAUSE; RISK; MORTALITY
AB Background: Dietary factors are known to influence colorectal cancer (CRC) risk, however, their association with CRC survival is unclear. Therefore, we prospectively examined the association between diet quality scores, dietary patterns and colorectal cancer (CRC) survival.
Methods: 1201 women diagnosed with stage I-III CRC between 1986 and 2008, were followed through 2010. Diet was assessed via a food frequency questionnaire administered at least 6 months after diagnosis. We computed the Alternate Healthy Eating Index-2010 (AHEI-2010), alternate Mediterranean Diet score (aMED) and Dietary Approaches to Stop Hypertension score (DASH) and derived two dietary patterns, Western (unhealthy) and prudent (healthy), by principal component analysis for each woman.
Results: During follow-up, we documented 435 deaths, including 162 from CRC. After adjusting for potential confounders, only a higher AHEI-2010 score was significantly associated with lower overall mortality (HR comparing extreme quintiles=0.71, 95% CI 0.52-0.98, p trend=0.01) as well as borderline significantly with lower risk of CRC mortality by the trend test (HR Q5 vs Q1=0.72, 95% CI=0.43-1.21, p trend=0.07). When AHEI-2010 components were examined separately, inverse associations for overall mortality were primarily accounted for by moderate alcohol intake (HR comparing abstainers vs 5-15 g/d=1.30, 95% CI=1.05-1.61) and lower intake of sugar sweetened beverages and fruit juices combined (HR for each additional serving=1.11, 95% CI=1.01-1.23). No other diet quality score or dietary pattern was associated with overall or CRC-specific mortality.
Conclusion: Higher AHEI-2010 score may be associated with lower overall mortality, moderate alcohol consumption and lower consumption of sugar sweetened beverages and juices combined appeared to account for most of the observed associations.
C1 [Fung, Teresa T.] Simmons Coll, Dept Nutr, Boston, MA 02115 USA.
[Kashambwa, Rutendo] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Chiuve, Stephanie E.; Wu, Kana; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Ogino, Shuji] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Surg, Boston, MA 02115 USA.
[Fuchs, Charles S.; Hu, Frank B.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Fuchs, Charles S.; Ogino, Shuji; Meyerhardt, Jeffrey A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Fung, TT (reprint author), Simmons Coll, Dept Nutr, Boston, MA 02115 USA.
EM fung@simmons.edu
FU National Institute of Health [CA87969, CA127003, CA149222, CA95589,
CA151993, CA169141, CA 118553, UM1CA167552, U54CA155626, UM1 CA167552]
FX This work is funded by the National Institute of Health research grants
CA87969, CA127003, CA149222, CA95589, CA151993, CA169141, CA 118553,
UM1CA167552, U54CA155626, UM1 CA167552. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 39
TC 9
Z9 9
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 15
PY 2014
VL 9
IS 12
AR e115377
DI 10.1371/journal.pone.0115377
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW9WY
UT WOS:000346607100072
PM 25506700
ER
PT J
AU Paweletz, CP
Janne, PA
AF Paweletz, Cloud P.
Jaenne, Pasi A.
TI Monitoring Cancer Through the Blood
SO CANCER
LA English
DT Editorial Material
ID PLASMA DNA; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; MUTATIONS; THERAPY
AB Tumor biopsies remain the gold standard for the evaluation of genetic changes in tumors either at diagnosis or after treatment with targeted therapies. However, this is not always feasible and can seldom be performed more than once. Noninvasive techniques that measure the allelic burden in blood have the potential to realize genotype-directed cancer therapy. These technologies can potentially be used for noninvasive tumor genotyping and also provide an opportunity for disease monitoring. Several non-invasive genotyping technologies are currently under development and being evaluated in patients treated with targeted therapies.
C1 [Paweletz, Cloud P.; Jaenne, Pasi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Paweletz, Cloud P.; Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA.
[Jaenne, Pasi A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Janne, PA (reprint author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,HIM223, Boston, MA 02215 USA.
EM pasi_janne@dfci.harvard.edu
FU NCI NIH HHS [R01 CA135257, R01-CA135257]
NR 14
TC 0
Z9 0
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 15
PY 2014
VL 120
IS 24
BP 3859
EP 3861
DI 10.1002/cncr.28967
PG 3
WC Oncology
SC Oncology
GA AW1TX
UT WOS:000346074300006
PM 25103496
ER
PT J
AU Viswanathan, AN
Lee, LJ
Eswara, JR
Horowitz, NS
Konstantinopoulos, PA
Mirabeau-Beale, KL
Rose, BS
von Keudell, AG
Wo, JY
AF Viswanathan, Akila N.
Lee, Larissa J.
Eswara, Jairam R.
Horowitz, Neil S.
Konstantinopoulos, Panagiotis A.
Mirabeau-Beale, Kristina L.
Rose, Brent S.
von Keudell, Arvind G.
Wo, Jennifer Y.
TI Complications of Pelvic Radiation in Patients Treated for Gynecologic
Malignancies
SO CANCER
LA English
DT Review
DE radiation; morbidity; toxicity; gynecologic cancer
ID ADVANCED CERVICAL-CANCER; DOSE-RATE BRACHYTHERAPY; QUALITY-OF-LIFE;
PHASE-III TRIAL; RANDOMIZED-CONTROLLED-TRIAL; ACUTE HEMATOLOGIC
TOXICITY; HYPERBARIC-OXYGEN THERAPY; RISK ENDOMETRIAL CANCER; TERM
FOLLOW-UP; INSUFFICIENCY FRACTURES
AB Radiation therapy is a critical treatment modality in the management of patients with gynecologic tumors. New highly conformal external-beam and brachytherapy techniques have led to important reductions in recurrence and patient morbidity and mortality. However, patients who receive pelvic radiation for gynecologic malignancies may experience a unique constellation of toxicity because of the anatomic locations, combination with concurrent chemotherapy and/or surgery, as well as potential surgical interventions. Although side effects are often categorized into acute versus late toxicities, several late toxicities represent continuation and evolution of the same pathologic process. Comorbidities and radiation dose can significantly increase the risk of morbidity. Current understanding of the incidence of various morbidities in patients treated with current radiation techniques for gynecologic malignancies, the impact of chemotherapy and surgery, treatment options for those effects, and future areas of research are highlighted. Cancer 2014;120:3870-3883. (c) 2014 American Cancer Society.
Modern radiotherapy techniques, including highly conformal radiation and image-guided conformal brachytherapy, may reduce the risk of radiation-related side effects. The management of side effects, including surgical and chemotherapeutic implications, is discussed.
C1 [Viswanathan, Akila N.; Lee, Larissa J.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Viswanathan, Akila N.; Lee, Larissa J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Eswara, Jairam R.] Washington Univ, Sch Med, Div Urol, St Louis, MO USA.
[Horowitz, Neil S.] Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA 02115 USA.
[Konstantinopoulos, Panagiotis A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Mirabeau-Beale, Kristina L.; Rose, Brent S.] Harvard Radiat Oncol Residency Program, Boston, MA USA.
[von Keudell, Arvind G.] Harvard Orthoped Combined Residency Program, Boston, MA USA.
[Wo, Jennifer Y.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Viswanathan, AN (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St,ASB 1,L2, Boston, MA 02115 USA.
EM aviswanathan@lroc.harvard.edu
FU National Institutes of Health [R21 CA 167800]
FX Dr. Viswanathan receives funding from the National Institutes of Health
(grant R21 CA 167800).
NR 115
TC 10
Z9 10
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 15
PY 2014
VL 120
IS 24
BP 3870
EP 3883
DI 10.1002/cncr.28849
PG 14
WC Oncology
SC Oncology
GA AW1TX
UT WOS:000346074300009
PM 25056522
ER
PT J
AU Garrido, MM
Harrington, ST
Prigerson, HG
AF Garrido, Melissa M.
Harrington, Shannon T.
Prigerson, Holly G.
TI End-of-Life Treatment Preferences: A Key to Reducing Ethnic/Racial
Disparities in Advance Care Planning?
SO CANCER
LA English
DT Article
DE health care disparities; end-of-life care; do-not-resuscitate orders;
cardiopulmonary resuscitation; advance care planning
ID ADVANCED CANCER; RACIAL-DIFFERENCES; HOSPICE CARE; OLDER-ADULTS;
NEAR-DEATH; DIRECTIVES; RACE/ETHNICITY; RESUSCITATION; VALIDATION;
PREDICTORS
AB BACKGROUNDThe objective of this study was to identify targets for interventions to reduce end-of-life care disparities among patients with advanced cancer. To do this, the authors evaluated the degree to which end-of-life care values and preferences are associated with advance care planning within racial/ethnic minority groups.
METHODSThe Coping with Cancer study recruited patients with advanced cancer from outpatient clinics in 5 states from 2002 to 2008. Then, the rates of 1 type of advance care planningdo-not-resuscitate (DNR) ordersreported at baseline interviews by 606 patients were investigated. Bivariate tests determined associations among DNR order completion, religious values, and treatment preferences within racial/ethnic groups.
RESULTSNon-Latino white patients were significantly more likely to have a DNR order (45%) than black (25%) and Latino (20%) patients (P<.001). A preference against specific life-prolonging treatment (eg, chemotherapy, ventilation) was the only factor significantly associated with higher DNR order likelihood in each group, with non-Latino white patients more likely than Latino or black patients to express preferences against life-prolonging care (eg, 26% of non-Latino white patients, 46% of black patients, and 41% of Latino patients wanted a feeding tube if it would extend life for 1 more day; P<.001).
CONCLUSIONSPreferences against life-prolonging care differ dramatically by race/ethnicity, but they have a uniform significant association with DNR order completion rates across racial/ethnic groups of patients with advanced cancer. Advance care planning interventions that target preferences associated with DNR orders across racial/ethnic groups may reach a broad patient population and reduce end-of-life care disparities. Cancer 2014;120:3981-3986. (c) 2014 American Cancer Society.
Patient interview data are used to demonstrate that, although patient preferences against life-prolonging care differ dramatically by race/ethnicity, they are uniformly significantly associated with do-not-resuscitate order completion rates across racial/ethnic groups of patients with advanced cancer.
C1 [Garrido, Melissa M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, New York, NY USA.
[Garrido, Melissa M.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Harrington, Shannon T.] Dana Farber Canc Inst, Phillis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA 02115 USA.
[Harrington, Shannon T.] Univ Massachusetts, Boston, MA 02125 USA.
[Prigerson, Holly G.] Weill Cornell Med Coll, Ctr Res End Life Care, New York, NY 10065 USA.
RP Prigerson, HG (reprint author), Weill Cornell Med Coll, Ctr Res End Life Care, 525 East 68th St,Box 39, New York, NY 10065 USA.
EM hgp2001@med.cornell.edu
FU National Institute of Mental Health [MH63892]; National Cancer Institute
[CA106370, CA156732]; Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Health Services
Research and Development Service [CDA 11-201/CDP 12-255]
FX This research was supported in part by the following grants to Dr.
Prigerson: grant MH63892 from the National Institute of Mental Health,
grants CA106370 and CA156732 from the National Cancer Institute. Dr.
Garrido is supported by grant CDA 11-201/CDP 12-255 from the Department
of Veterans Affairs, Veterans Health Administration, Office of Research
and Development, Health Services Research and Development Service.
NR 31
TC 14
Z9 14
U1 4
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 15
PY 2014
VL 120
IS 24
BP 3981
EP 3986
DI 10.1002/cncr.28970
PG 6
WC Oncology
SC Oncology
GA AW1TX
UT WOS:000346074300021
PM 25145489
ER
PT J
AU George, S
Muto, MG
AF George, Suzanne
Muto, Michael G.
TI Reply to In-Bag Morcellation for Presumed Myoma Retrieval at Laparoscopy
SO CANCER
LA English
DT Letter
C1 [George, Suzanne] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA.
[Muto, Michael G.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gynecol Oncol,Dept Obstet & Gynecol, Boston, MA 02115 USA.
RP George, S (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, 44 Binney St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 15
PY 2014
VL 120
IS 24
BP 4005
EP 4005
DI 10.1002/cncr.28957
PG 1
WC Oncology
SC Oncology
GA AW1TX
UT WOS:000346074300027
PM 25102828
ER
PT J
AU Koo, S
Thomas, HR
Daniels, SD
Lynch, RC
Fortier, SM
Shea, MM
Rearden, P
Comolli, JC
Baden, LR
Marty, FM
AF Koo, Sophia
Thomas, Horatio R.
Daniels, S. David
Lynch, Robert C.
Fortier, Sean M.
Shea, Margaret M.
Rearden, Preshious
Comolli, James C.
Baden, Lindsey R.
Marty, Francisco M.
TI A Breath Fungal Secondary Metabolite Signature to Diagnose Invasive
Aspergillosis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE aspergillosis; diagnostics; volatile organic compounds; breath; fungal
infection
ID VOLATILE ORGANIC-COMPOUNDS; SURVEILLANCE NETWORK TRANSNET; CELL
TRANSPLANT RECIPIENTS; INFECTIOUS-DISEASES; FUMIGATUS; METAANALYSIS;
BERGAMOTENE; PROGRESS
AB Background. Invasive aspergillosis (IA) remains a leading cause of mortality in immunocompromised patients, in part due to the difficulty of diagnosing this infection.
Methods. Using thermal desorption-gas chromatography/mass spectrometry, we characterized the in vitro volatile metabolite profile of Aspergillus fumigatus, the most common cause of IA, and other pathogenic aspergilli. We prospectively collected breath samples from patients with suspected invasive fungal pneumonia from 2011 to 2013, and assessed whether we could discriminate patients with proven or probable IA from patients without aspergillosis, as determined by European Organization for Research and Treatment of Cancer/Mycoses Study Group consensus definitions, by direct detection of fungal volatile metabolites in these breath samples.
Results. The monoterpenes camphene, alpha- and beta-pinene, and limonene, and the sesquiterpene compounds alpha- and beta-trans-bergamotene were distinctive volatile metabolites of A. fumigatus in vitro, distinguishing it from other pathogenic aspergilli. Of 64 patients with suspected invasive fungal pneumonia based on host risk factors, clinical symptoms, and radiologic findings, 34 were diagnosed with IA, whereas 30 were ultimately diagnosed with other causes of pneumonia, including other invasive mycoses. Detection of alpha-trans-bergamotene, beta-trans-bergamotene, a beta-vatirenene-like sesquiterpene, or trans-geranylacetone identified IA patients with 94% sensitivity (95% confidence interval [CI], 81%-98%) and 93% specificity (95% CI, 79%-98%).
Conclusions. In patients with suspected fungal pneumonia, an Aspergillus secondary metabolite signature in breath can identify individuals with IA. These results provide proof-of-concept that direct detection of exogenous fungal metabolites in breath can be used as a novel, noninvasive, pathogen-specific approach to identifying the precise microbial cause of pneumonia.
C1 [Koo, Sophia; Thomas, Horatio R.; Daniels, S. David; Lynch, Robert C.; Fortier, Sean M.; Shea, Margaret M.; Baden, Lindsey R.; Marty, Francisco M.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Koo, Sophia; Baden, Lindsey R.; Marty, Francisco M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Koo, Sophia; Thomas, Horatio R.; Baden, Lindsey R.; Marty, Francisco M.] Harvard Univ, Sch Med, Boston, MA USA.
[Rearden, Preshious; Comolli, James C.] Draper Lab, Cambridge, MA USA.
RP Koo, S (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St,PBB A4, Boston, MA 02115 USA.
EM skoo@partners.org
OI Koo, Sophia/0000-0002-4973-7439
FU Harvard Catalyst Pilot Grant Program [UL1 RR 025758]; National Institute
of Allergy and Infectious Diseases at the National Institutes of Health
[K23 AI097225, R21 AI085454]
FX This work was supported by the Harvard Catalyst Pilot Grant Program
(grant number UL1 RR 025758) and the National Institute of Allergy and
Infectious Diseases at the National Institutes of Health (grant numbers
K23 AI097225 to S. K. and R21 AI085454).
NR 40
TC 14
Z9 15
U1 2
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 15
PY 2014
VL 59
IS 12
BP 1733
EP 1740
DI 10.1093/cid/ciu725
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AU9KM
UT WOS:000345911500018
PM 25342502
ER
PT J
AU Cherayil, BJ
AF Cherayil, Bobby J.
TI Response to Comment on "Intestinal Inflammation Modulates Expression of
the Iron-Regulating Hormone Hepcidin Depending on Erythropoietic
Activity and the Commensal Microbiota"
SO JOURNAL OF IMMUNOLOGY
LA English
DT Letter
C1 [Cherayil, Bobby J.] Massachusetts Gen Hosp, Dept Pediat, Mucosal Immunol & Biol Res Ctr, Boston, MA 02129 USA.
[Cherayil, Bobby J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Cherayil, BJ (reprint author), Massachusetts Gen Hosp, Room 3600,MGH East,Bldg 114,16th St, Boston, MA 02129 USA.
EM cherayil@helix.mgh.harvard.edu
FU NIDDK NIH HHS [P30 DK040561]
NR 1
TC 0
Z9 0
U1 1
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2014
VL 193
IS 12
BP 5763
EP 5763
DI 10.4049/jimmunol.1402567
PG 1
WC Immunology
SC Immunology
GA AW1XQ
UT WOS:000346082400002
PM 25480954
ER
PT J
AU Playa, H
Lewis, TA
Ting, A
Suh, BC
Munoz, B
Matuza, R
Passer, BJ
Schreiber, SL
Buolamwini, JK
AF Playa, Hilaire
Lewis, Timothy A.
Ting, Amal
Suh, Byung-Chul
Munoz, Benito
Matuza, Robert
Passer, Brent J.
Schreiber, Stuart L.
Buolamwini, John K.
TI Dilazep analogues for the study of equilibrative nucleoside transporters
1 and 2 (ENT1 and ENT2)
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Equilibrative nucleoside transporters (ENTs); hENT1; hENT2; rENT2;
Dilazep
ID PROTEINS; FAMILY; VIRUS
AB As ENT inhibitors including dilazep have shown efficacy improving oHSV1 targeted oncolytic cancer therapy, a series of dilazep analogues was synthesized and biologically evaluated to examine both ENT1 and ENT2 inhibition. The central diamine core, alkyl chains, ester linkage and substituents on the phenyl ring were all varied. Compounds were screened against ENT1 and ENT2 using a radio-ligand cell-based assay. Dilazep and analogues with minor structural changes are potent and selective ENT1 inhibitors. No selective ENT2 inhibitors were found, although some analogues were more potent against ENT2 than the parent dilazep. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Playa, Hilaire; Buolamwini, John K.] Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA.
[Lewis, Timothy A.; Ting, Amal; Suh, Byung-Chul; Munoz, Benito; Schreiber, Stuart L.] Broad Inst MIT & Harvard, Ctr Sci Therapeut, Cambridge, MA 02142 USA.
[Matuza, Robert; Passer, Brent J.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP Buolamwini, JK (reprint author), Rosalind Franklin Univ Med & Sci, Coll Pharm, Dept Pharmaceut Sci, 3333 Green Bay Rd, N Chicago, IL 60064 USA.
EM john.buolamwini@rosalindfranklin.edu
FU NIH-MLPCN program [1 U54 HG005032-1]; NIH [RO1GM10405, RO1CA102139]
FX This work was funded in part by the NIH-MLPCN program (1 U54 HG005032-1
awarded to S.L.S.) as well as NIH RO1GM10405 (J.K.B.) and Grant
RO1CA102139 (R.L.M.).
NR 15
TC 2
Z9 2
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD DEC 15
PY 2014
VL 24
IS 24
BP 5801
EP 5804
DI 10.1016/j.bmcl.2014.10.026
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA AU4LA
UT WOS:000345581300053
PM 25454272
ER
PT J
AU Lapidus, KAB
Levitch, CF
Perez, AM
Brallier, JW
Parides, MK
Soleimani, L
Feder, A
Iosifescu, DV
Charney, DS
Murrough, JW
AF Lapidus, Kyle A. B.
Levitch, Cara F.
Perez, Andrew M.
Brallier, Jess W.
Parides, Michael K.
Soleimani, Laili
Feder, Adriana
Iosifescu, Dan V.
Charney, Dennis S.
Murrough, James W.
TI A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive
Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Antidepressant; depression; glutamate; intranasal; ketamine; treatment
resistant
ID TREATMENT-RESISTANT DEPRESSION; D-ASPARTATE ANTAGONIST;
MAGNETIC-RESONANCE-SPECTROSCOPY; RAPID ANTIDEPRESSANT RESPONSE; ADD-ON
TRIAL; UNIPOLAR DEPRESSION; BIPOLAR DEPRESSION; GLUTAMATE; EFFICACY;
PREMEDICATION
AB Background: The N-methyl-D-aspartate glutamate receptor antagonist ketamine, delivered via an intravenous route, has shown rapid antidepressant effects in patients with treatment-resistant depression. The current study was designed to test the safety, tolerability, and efficacy of intranasal ketamine in patients with depression who had failed at least one prior antidepressant trial.
Methods: In a randomized, double-blind, crossover study, 20 patients with major depression were randomly assigned, and 18 completed 2 treatment days with intranasal ketamine hydrochloride (50 mg) or saline solution. The primary efficacy outcome measure was change in depression severity 24 hours after ketamine or placebo, measured using the Montgomery-Asberg Depression Rating Scale. Secondary outcomes included persistence of benefit, changes in self-reports of depression, changes in anxiety, and proportion of responders. Potential psychotomimetic, dissociative, hemodynamic, and general adverse effects associated with ketamine were also measured.
Results: Patients showed significant improvement in depressive symptoms at 24 hours after ketamine compared to placebo (t = 4.39, p < .001; estimated mean Montgomery-Asberg Depression Rating Scale score difference of 7.6 +/- 3.7; 95% confidence interval, 3.9-11.3). Response criteria were met by 8 of 18 patients (44%) 24 hours after ketamine administration compared with 1 of 18 (6%) after placebo (p = .033). Intranasal ketamine was well tolerated with minimal psychotomimetic or dissociative effects and was not associated with clinically significant changes in hemodynamic parameters.
Conclusions: This study provides the first controlled evidence for the rapid antidepressant effects of intranasal ketamine. Treatment was associated with minimal adverse effects. If replicated, these findings may lead to novel approaches to the pharmacologic treatment of patients with major depression.
C1 [Lapidus, Kyle A. B.; Levitch, Cara F.; Soleimani, Laili; Iosifescu, Dan V.; Charney, Dennis S.; Murrough, James W.] Icahn Sch Med Mt Sinai, Dept Psychiat, Mood & Anxiety Disorders Program, New York, NY 10029 USA.
[Lapidus, Kyle A. B.; Iosifescu, Dan V.; Charney, Dennis S.; Murrough, James W.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA.
[Perez, Andrew M.; Brallier, Jess W.] Icahn Sch Med Mt Sinai, Dept Anesthesiol, New York, NY 10029 USA.
[Parides, Michael K.] Icahn Sch Med Mt Sinai, Dept Hlth Evidence & Policy, New York, NY 10029 USA.
[Charney, Dennis S.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
[Iosifescu, Dan V.; Murrough, James W.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
[Soleimani, Laili] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Murrough, JW (reprint author), 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.
EM james.murrough@mssm.edu
RI Murrough, James/J-7129-2013
OI Murrough, James/0000-0001-6286-1242
FU National Institutes of Health [UL1TR000067, K23MH094707]; National
Alliance for Research on Schizophrenia and Depression Young Investigator
Award from the Brain and Behavior Research Foundation; National
Institutes of Health; National Institute of Mental Health; Department of
Veterans Affairs; Doris Duke Charitable Foundation; American Foundation
for Suicide Prevention; Brain and Behavior Research Foundation; Janssen
Research and Development; Avanir Pharmaceuticals; American Psychiatric
Institute for Research and Education Janssen Resident Psychiatric
Research Scholars; Le Foundation; LCN Consulting; Icahn School of
Medicine at Mount Sinai from AstraZeneca; Brainsway; Euthymics
Bioscience; NeoSync; Roche; Shire; CNS Response; Otsuka Pharmaceutical
Co, Ltd; Servier Laboratories; Sunovion Pharmaceuticals, Inc.; United
States Department of Defense; National Alliance for Research on
Schizophrenia and Depression; United States Army Medical Research
Acquisition Activity; CNS Spectrums
FX This work was supported by National Institutes of Health Grant Nos.
UL1TR000067 (Mount Sinai Clinical and Translational Science Award) and
K23MH094707 (JWM) and a National Alliance for Research on Schizophrenia
and Depression Young Investigator Award from the Brain and Behavior
Research Foundation (KABL). A portion of the data from the current study
was previously presented at the 52nd annual meeting of the American
College of Neuropsychopharmacology.; The content of this article is
solely the responsibility of the authors and does not represent the
official views of the National Institutes of Health or other sponsoring
entity. In the past 2 years, JWM has received research support from the
National Institutes of Health, the National Institute of Mental Health,
the Department of Veterans Affairs, the Doris Duke Charitable
Foundation, the American Foundation for Suicide Prevention, the Brain
and Behavior Research Foundation, Janssen Research and Development, and
Avanir Pharmaceuticals; he has served on advisory boards for Janssen
Research and Development and Genentech and has provided consultation
services for ProPhase, LLC, and Impel NeuroPharma. KABL has received
research support from the Brain and Behavior Research Foundation,
American Psychiatric Institute for Research and Education Janssen
Resident Psychiatric Research Scholars, and the Le Foundation; he has
received consulting fees from LCN Consulting and serves on the advisory
board for Halo Neuro Inc. DVI has received research funding through
Icahn School of Medicine at Mount Sinai from AstraZeneca, Brainsway,
Euthymics Bioscience, NeoSync, Roche, and Shire; he has received
consulting fees for Avanir Pharmaceuticals, CNS Response, Otsuka
Pharmaceutical Co, Ltd, Servier Laboratories, and Sunovion
Pharmaceuticals, Inc. DSC has received consulting fees or research
support from the United States Department of Defense, National
Institutes of Health, National Institute of Mental Health, National
Alliance for Research on Schizophrenia and Depression, United States
Army Medical Research Acquisition Activity, and CNS Spectrums; he a
member of the Advisory and Editorial Boards of the Institute of Medicine
Committee on Department of Homeland Security Workforce Resilience. DSC
(Dean of Icahn School of Medicine at Mount Sinai and coinvestigator on
this study) and Icahn School of Medicine at Mount Sinai have been named
on a use patent on ketamine for the treatment of depression. The Icahn
School of Medicine has entered into a licensing agreement for the use of
ketamine as therapy for treatment-resistant depression. DSC and Icahn
School of Medicine at Mount Sinai could potentially benefit from the
results of this study. DSC and AF (a coinvestigator on this study) are
named coinventors on a use patent application filed by Mount Sinai for
the use of ketamine as a treatment for posttraumatic stress disorder. If
ketamine were shown to be effective in the treatment of posttraumatic
stress disorder and received approval from the U.S. Food and Drug
Administration for this indication, DSC, AF, and the Icahn School of
Medicine at Mount Sinai could benefit financially. All other authors
report no biomedical financial interests or potential conflicts of
interest.
NR 38
TC 69
Z9 71
U1 9
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD DEC 15
PY 2014
VL 76
IS 12
BP 970
EP 976
DI 10.1016/j.biopsych.2014.03.026
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AU2DY
UT WOS:000345427500009
PM 24821196
ER
PT J
AU Gros, DF
AF Gros, Daniel F.
TI Development and initial evaluation of Transdiagnostic Behavior Therapy
(TBT) for veterans with affective disorders
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Transdiagnostic Behavior Therapy TBT; Anxiety disorders; Depression;
Posttraumatic stress disorder
ID POSTTRAUMATIC-STRESS-DISORDER; COMORBIDITY SURVEY REPLICATION;
RANDOMIZED CONTROLLED-TRIAL; MENTAL-HEALTH PROBLEMS; PRIMARY-CARE
CLINICS; DSM-IV DISORDERS; EMOTIONAL DISORDERS; ANXIETY DISORDER;
UNIFIED PROTOCOL; PANIC DISORDER
AB Considerable attention has focused on the growing need for evidence-based psychotherapy for veterans with affective disorders within the Department of Veteran Affairs. Despite, and possibly due to, the large number of evidence-based protocols available, several obstacles remain in their widespread delivery within Veterans Affairs Medical Centers. In part as an effort to address these concerns, newer transdiagnostic approaches to psychotherapy have been developed to provide a single treatment that is capable of addressing several, related disorders. The goal of the present investigation was to develop and evaluate a transdiagnostic psychotherapy, Transdiagnostic Behavior Therapy (TBT), in veterans with affective disorders. Study 1 provided initial support for transdiagnostic presentation of evidence-based psychotherapy components in veterans with principal diagnoses of affective disorders (n=15). These findings were used to inform the development of the TBT protocol. In Study 2, an initial evaluation of TBT was completed in a second sample of veterans with principal diagnoses of affective disorders (n=29). The findings of Study 2 demonstrated significant improvements in symptoms of depression, anxiety, stress, posttraumatic stress, and related impairment across participants with various principal diagnoses. Together, the investigation provided preliminary support for effectiveness of TBT in veterans with affective disorders. Published by Elsevier Ireland Ltd.
C1 [Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA.
[Gros, Daniel F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
FU CSRD VA [IK2 CX000845]
NR 42
TC 9
Z9 9
U1 3
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD DEC 15
PY 2014
VL 220
IS 1-2
BP 275
EP 282
DI 10.1016/j.psychres.2014.08.018
PG 8
WC Psychiatry
SC Psychiatry
GA AT6OJ
UT WOS:000345058400044
PM 25193379
ER
PT J
AU Park, JM
Lewin, AB
Storch, EA
AF Park, Jennifer M.
Lewin, Adam B.
Storch, Eric A.
TI Adult offspring perspectives on parental hoarding behaviors
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Hoarding; Family; Parent-offspring relationships; Parental
psychopathology; Path analysis
ID OBSESSIVE-COMPULSIVE DISORDER; FAMILY ASSESSMENT DEVICE; SOCIAL SUPPORT;
FIT INDEXES; ACCOMMODATION; CHILDREN; BURDEN; HEALTH; SCALE; VALIDATION
AB Hoarding disorder (HD) is characterized by difficulty discarding unneeded items and the accumulation of items within living spaces and is associated with significant functional impairment and distress. Along with the negative impact of hoarding on the individual, HD is substantially impairing for family members, and linked to disruptions in family functioning. The present study utilized a path model analysis to examine the associations between an array of hoarding variables hypothesized to impact family functioning and parent-offspring relationships in 150 adult-aged children of hoarders who responded to online requests to participate in a research study. It was hypothesized that increased hoarding severity, decreased insight, and increased family accommodation (i.e., act of family members facilitating or assisting in hoarding behaviors) would be associated with decreased family functioning, decreased quality of parent-offspring relationships, and increased offspring impairment. Results from the path model revealed that family functioning mediated the relationship between hoarding severity and parent-offspring relationship. Diminished insight in the hoarding parent (as reported by the offspring) was associated with increased familial conflict and family functioning partially mediated the relationship between insight and quality of parent-offspring relationship. Increased family accommodation was significantly associated with increased impairment (work, social, and family domains) in offspring of hoarders. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Park, Jennifer M.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp,Child CBT Program, Boston, MA 02114 USA.
[Lewin, Adam B.; Storch, Eric A.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
[Lewin, Adam B.; Storch, Eric A.] Univ S Florida, Dept Pediat, Tampa, FL 33620 USA.
[Lewin, Adam B.; Storch, Eric A.] Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA.
[Lewin, Adam B.; Storch, Eric A.] Univ S Florida, Dept Behav Neurosci, Tampa, FL 33620 USA.
RP Park, JM (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp,Child CBT Program, 151 Merrimac St,3rd Floor, Boston, MA 02114 USA.
EM jpark12@partners.org
NR 57
TC 3
Z9 3
U1 7
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD DEC 15
PY 2014
VL 220
IS 1-2
BP 328
EP 334
DI 10.1016/j.psychres.2014.07.061
PG 7
WC Psychiatry
SC Psychiatry
GA AT6OJ
UT WOS:000345058400052
PM 25129564
ER
PT J
AU Kasckow, J
Morse, J
Begley, A
Anderson, S
Bensasi, S
Thomas, S
Quinn, SC
Reynolds, CF
AF Kasckow, John
Morse, Jennifer
Begley, Amy
Anderson, Stewart
Bensasi, Salem
Thomas, Stephen
Quinn, Sandra C.
Reynolds, Charles F., III
TI Treatment of post traumatic stress disorder symptoms in emotionally
distressed individuals
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Post traumatic stress disorder; Dietary education; Problem solving
therapy
ID RANDOMIZED CONTROLLED-TRIAL; PROBLEM-SOLVING THERAPY; PRIMARY-CARE
PATIENTS; SUBSYNDROMAL DEPRESSION; MAJOR DEPRESSION; RATING-SCALE;
PREVENTION; VETERANS; PTSD; INTERVENTION
AB Older individuals with emotional distress and a history of psychologic trauma are at risk for post traumatic stress disorder (PTSD) and major depression. This study was an exploratory, secondary analysis of data from the study "Prevention of Depression in Older African Americans". It examined whether Problem Solving Therapy-Primary Care (PST-PC) would lead to improvement in PTSD symptoms in patients with subsyndromal depression and a history of psychologic trauma. The control condition was dietary education (DIET). Participants (n=60) were age 50 or older with scores on the Center for Epidemiologic Studies -Depression scale of 11 or greater and history of psychologic trauma. Exclusions stipulated no major depression and substance dependence within a year. Participants were randomized to 6-8 sessions of either PST-PC or DIET and followed 2 years with booster sessions every 6 months; 29 participants were in the PST-PC group and 31 were in the DIET group. Mixed effects models showed that improvement of PTSD Check List scores was significantly greater in the DIET group over two years than in the PST-PC group (based on a group time interaction). We observed no intervention*time interactions in Beck Depression Inventory or Brief Symptom Inventory-Anxiety subscale scores. Published by Elsevier Ireland Ltd.
C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth, Pittsburgh, PA 15240 USA.
[Kasckow, John; Morse, Jennifer; Begley, Amy; Bensasi, Salem; Reynolds, Charles F., III] UPMC Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
[Anderson, Stewart] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Thomas, Stephen; Quinn, Sandra C.] Univ Maryland, Ctr Hlth Equ, College Pk, MD 20742 USA.
[Thomas, Stephen] Univ Maryland, Dept Hlth Serv Adm, Sch Publ Hlth, College Pk, MD 20742 USA.
[Quinn, Sandra C.] Univ Maryland, Dept Family Sci, Sch Publ Hlth, College Pk, MD 20742 USA.
RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth, Univ Dr C, Pittsburgh, PA 15240 USA.
EM kasckowjw@upmc.edu
OI Anderson, Stewart/0000-0001-8948-0650
FU NCATS NIH HHS [UL1 TR000005]; NIMH NIH HHS [P30 MH090333, P30MH090333];
NIMHD NIH HHS [P20 MD006737, P60 MD000207, P60MD000207]
NR 36
TC 1
Z9 1
U1 1
U2 28
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD DEC 15
PY 2014
VL 220
IS 1-2
BP 370
EP 375
DI 10.1016/j.psychres.2014.06.043
PG 6
WC Psychiatry
SC Psychiatry
GA AT6OJ
UT WOS:000345058400058
PM 25107318
ER
PT J
AU Brack, AS
AF Brack, Andrew S.
TI Pax7 is back
SO SKELETAL MUSCLE
LA English
DT Editorial Material
DE Pax7; Satellite cell; Skeletal muscle; Regeneration; Lineage tracing;
Cre
ID MYOGENIC SATELLITE CELLS; ADULT SKELETAL-MUSCLE; STEM-CELLS;
SPECIFICATION; PROGENITORS; RESIDENT; FIBERS
AB Two recent studies have reinvigorated the conversation regarding the role of Pax7 in adult satellite. Studies by Gunther et al (Cell Stem Cell 13: 590 601, 2013) and Von Maltzhen et al (Proc Natl Acad Sci U S A 110: 16474 16479) show that Pax7 is critical for adult satellite cell function and their contribution to muscle repair. Previously, Lepper et al (Nature 460: 627 631, 2009) demonstrated that Pax7 was dispensable for adult muscle repair. In this commentary I have summarized the results from these studies, focusing on the differences in experimental paradigms that led the authors to different conclusions. I also take this opportunity to discuss the potential limitations and hurdles of Cre-lox technology that are responsible for the discrepant results.
C1 [Brack, Andrew S.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Brack, Andrew S.] HSCI, Boston, MA 02114 USA.
[Brack, Andrew S.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Brack, AS (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
EM brack.andrew@mgh.harvard.edu
FU NIAMS NIH HHS [R01 AR060868, R01 AR061002]
NR 18
TC 2
Z9 2
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2044-5040
J9 SKELET MUSCLE
JI Skeletal Muscle
PD DEC 14
PY 2014
VL 4
AR 24
DI 10.1186/s13395-014-0024-4
PG 5
WC Cell Biology
SC Cell Biology
GA CL9YL
UT WOS:000357334900001
PM 25546147
ER
PT J
AU McLaughlin, HM
Ceyhan-Birsoy, O
Christensen, KD
Kohane, IS
Krier, J
Lane, WJ
Lautenbach, D
Lebo, MS
Machini, K
MacRae, CA
Azzariti, DR
Murray, MF
Seidman, CE
Vassy, JL
Green, RC
Rehm, HL
AF McLaughlin, Heather M.
Ceyhan-Birsoy, Ozge
Christensen, Kurt D.
Kohane, Isaac S.
Krier, Joel
Lane, William J.
Lautenbach, Denise
Lebo, Matthew S.
Machini, Kalotina
MacRae, Calum A.
Azzariti, Danielle R.
Murray, Michael F.
Seidman, Christine E.
Vassy, Jason L.
Green, Robert C.
Rehm, Heidi L.
CA MedSeq Project
TI A systematic approach to the reporting of medically relevant findings
from whole genome sequencing
SO BMC MEDICAL GENETICS
LA English
DT Review
DE Clinical genome sequencing; Incidental findings; MedSeq Project;
Clinical report formatting
ID GENETIC-VARIANTS; ACMG RECOMMENDATIONS; CLINICAL EXOME; PRIMARY-CARE;
KNOWLEDGE; RISK; PHYSICIANS; MEDICINE; CARRIERS; CANCER
AB Background: The MedSeq Project is a randomized clinical trial developing approaches to assess the impact of integrating genome sequencing into clinical medicine. To facilitate the return of results of potential medical relevance to physicians and patients participating in the MedSeq Project, we sought to develop a reporting approach for the effective communication of such findings.
Methods: Genome sequencing was performed on the Illumina HiSeq platform. Variants were filtered, interpreted, and validated according to methods developed by the Laboratory for Molecular Medicine and consistent with current professional guidelines. The GeneInsight software suite, which is integrated with the Partners HealthCare electronic health record, was used for variant curation, report drafting, and delivery.
Results: We developed a concise 5-6 page Genome Report (GR) featuring a single-page summary of results of potential medical relevance with additional pages containing structured variant, gene, and disease information along with supporting evidence for reported variants and brief descriptions of associated diseases and clinical implications. The GR is formatted to provide a succinct summary of genomic findings, enabling physicians to take appropriate steps for disease diagnosis, prevention, and management in their patients.
Conclusions: Our experience highlights important considerations for the reporting of results of potential medical relevance and provides a framework for interpretation and reporting practices in clinical genome sequencing.
C1 [McLaughlin, Heather M.; Ceyhan-Birsoy, Ozge; Christensen, Kurt D.; Kohane, Isaac S.; Krier, Joel; Lane, William J.; Lebo, Matthew S.; MacRae, Calum A.; Seidman, Christine E.; Vassy, Jason L.; Green, Robert C.; Rehm, Heidi L.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[McLaughlin, Heather M.; Ceyhan-Birsoy, Ozge; Lebo, Matthew S.; Machini, Kalotina; Azzariti, Danielle R.; Rehm, Heidi L.] Partners HealthCare Personalized Med, Mol Med Lab, Cambridge, MA USA.
[McLaughlin, Heather M.; Lane, William J.; Lebo, Matthew S.; Rehm, Heidi L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Christensen, Kurt D.; Krier, Joel; Lautenbach, Denise; MacRae, Calum A.; Green, Robert C.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[MacRae, Calum A.; Seidman, Christine E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Seidman, Christine E.] Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Kohane, Isaac S.] Boston Childrens Hosp, Dept Pediat, Boston, MA USA.
[Murray, Michael F.] Geisinger Hlth Syst, Danville, PA USA.
[MacRae, Calum A.; Seidman, Christine E.; Green, Robert C.; Rehm, Heidi L.] Broad Inst, Cambridge, MA USA.
[Vassy, Jason L.] VA Boston HealthCare Syst, Sect Gen Internal Med, Boston, MA USA.
[Vassy, Jason L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA.
RP Rehm, HL (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM hrehm@partners.org
OI Christensen, Kurt/0000-0003-4068-776X; Lebo, Matthew/0000-0002-9733-5207
FU [U01 HG006500]; [U19 HD077671]; [U41 HG006834-01A1]; [L30 DK089597];
[F32 HG006993]
FX We would like to thank MedSeq Project patients and physicians for their
participation in this study. We would like to acknowledge Elizabeth
Duffy Hynes, Lisa Mahanta, and Laura Hutchinson for their work on
laboratory process improvement, Siva Gowrisankar and Rimma Shakhbatyan
for their bioinformatics contributions, and Bob Hurley, Matt Varugheese,
Mike Oates, and Tom Venman for their work on developing the GeneInsight
report templates. This work was supported by U01 HG006500, U19 HD077671,
U41 HG006834-01A1, L30 DK089597, and F32 HG006993. Members of the MedSeq
Project are as follows: David W Bates, Alexis D Carere, Allison Cirino,
Lauren Connor, Kurt D Christensen, Jake Duggan, Robert C Green, Carolyn
Y Ho, Joel B Krier, William J Lane, Denise M Lautenbach, Lisa Lehmann,
Christina Liu, Calum A MacRae, Rachel Miller, Cynthia C Morton,
Christine E Seidman, Shamil Sunyaev, Jason L Vassy, Sandy Aronson, Ozge
Ceyhan-Birsoy, Siva Gowrisankar, Matthew S Lebo, Ignat Leschiner,
Kalotina Machini, Heather M McLaughlin, Danielle R Metterville, Heidi L
Rehm, Jennifer Blumenthal-Barby, Lindsay Zausmer Feuerman, Amy L
McGuire, Sarita Panchang, Jill Oliver Robinson, Melody J Slashinski,
Stewart C Alexander, Kelly Davis, Peter A Ubel, Peter Kraft, J Scott
Roberts, Judy E Garber, Tina Hambuch, Michael F Murray, Isaac Kohane,
Sek Won Kong.
NR 35
TC 19
Z9 19
U1 6
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD DEC 14
PY 2014
VL 15
AR 134
DI 10.1186/s12881-014-0134-1
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA CB0UV
UT WOS:000349343900001
PM 25714468
ER
PT J
AU Breithardt, G
Baumgartner, H
Berkowitz, SD
Hellkamp, AS
Piccini, JP
Stevens, SR
Lokhnygina, Y
Patel, MR
Halperin, JL
Singer, DE
Hankey, GJ
Hacke, W
Becker, RC
Nessel, CC
Mahaffey, KW
Fox, KAA
Califf, RM
AF Breithardt, Gunter
Baumgartner, Helmut
Berkowitz, Scott D.
Hellkamp, Anne S.
Piccini, Jonathan P.
Stevens, Susanna R.
Lokhnygina, Yuliya
Patel, Manesh R.
Halperin, Jonathan L.
Singer, Daniel E.
Hankey, Graeme J.
Hacke, Werner
Becker, Richard C.
Nessel, Christopher C.
Mahaffey, Kenneth W.
Fox, Keith A. A.
Califf, Robert M.
CA Rocket AF Steering Comm Investigat
TI Clinical characteristics and outcomes with rivaroxaban vs. warfarin in
patients with non-valvular atrial fibrillation but underlying native
mitral and aortic valve disease participating in the ROCKET AF trial
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Fibrillation; Anticoagulants; Heart diseases; Regurgitation; Stenosis
ID MANAGEMENT; RATIONALE; DESIGN; STROKE; REGISTRY; PREVENTION; APIXABAN;
EVENTS; RISK; GUIDELINES
AB We investigated clinical characteristics and outcomes of patients with significant valvular disease (SVD) in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial.
ROCKET AF excluded patients with mitral stenosis or artificial valve prostheses. We used Cox regression to adjust comparisons for potential confounders. Among 14 171 patients, 2003 (14.1%) had SVD; they were older and had more comorbidities than patients without SVD. The rate of stroke or systemic embolism with rivaroxaban vs. warfarin was consistent among patients with SVD [2.01 vs. 2.43%; hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.55-1.27] and without SVD (1.96 vs. 2.22%; HR 0.89, 95% CI 0.75-1.07; interaction P = 0.76). However, rates of major and non-major clinically relevant bleeding with rivaroxaban vs. warfarin were higher in patients with SVD (19.8% rivaroxaban vs. 16.8% warfarin; HR 1.25, 95% CI 1.05-1.49) vs. those without (14.2% rivaroxaban vs. 14.1% warfarin; HR 1.01, 95% CI 0.94-1.10; interaction P = 0.034), even when controlling for risk factors and potential confounders. In intracranial haemorrhage, there was no interaction between patients with and without SVD where the overall rate was lower among those randomized to rivaroxaban.
Many patients with 'non-valvular atrial fibrillation' have significant valve lesions. Their risk of stroke is similar to that of patients without SVD after controlling for stroke risk factors. Efficacy of rivaroxaban vs. warfarin was similar in patients with and without SVD; however, the observed risk of bleeding was higher with rivaroxaban in patients with SVD but was the same among those without SVD. Atrial fibrillation patients with and without SVD experience the same stroke-preventive benefit of oral anticoagulants.
C1 [Breithardt, Gunter] Univ Hosp Munster, Dept Cardiovasc Med, Div Electrophysiol, D-48149 Munster, Germany.
[Baumgartner, Helmut] Univ Hosp Munster, Dept Cardiovasc Med, Div Adult Congenital & Valvular Heart Dis, D-48149 Munster, Germany.
[Berkowitz, Scott D.] Bayer Healthcare Pharmaceut LP, Whippany, NJ USA.
[Hellkamp, Anne S.; Piccini, Jonathan P.; Stevens, Susanna R.; Lokhnygina, Yuliya; Patel, Manesh R.; Becker, Richard C.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Piccini, Jonathan P.] Mt Sinai Med Ctr, Ctr Cardiovasc, New York, NY 10029 USA.
[Singer, Daniel E.] Massachusetts Gen Hosp, Clin Epidemiol Unit, Div Gen Med, Boston, MA 02114 USA.
[Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
[Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.
[Hacke, Werner] Heidelberg Univ, Heidelberg, Germany.
[Nessel, Christopher C.] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
[Mahaffey, Kenneth W.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Fox, Keith A. A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
[Fox, Keith A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
[Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA.
RP Breithardt, G (reprint author), Univ Hosp Munster, Dept Cardiovasc Med, Div Electrophysiol, Von Esmarch Str 117, D-48149 Munster, Germany.
EM g.breithardt@uni-muenster.de
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
NR 25
TC 37
Z9 38
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD DEC 14
PY 2014
VL 35
IS 47
BP 3377
EP 3385
DI 10.1093/eurheartj/ehu305
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AW6WS
UT WOS:000346406800016
PM 25148838
ER
PT J
AU Hayano, K
Fujishiro, T
Sahani, DV
Satoh, A
Aoyagi, T
Ohira, G
Tochigi, T
Matsubara, H
Shuto, K
AF Hayano, Koichi
Fujishiro, Takeshi
Sahani, Dushyant V.
Satoh, Asami
Aoyagi, Tomoyoshi
Ohira, Gaku
Tochigi, Toru
Matsubara, Hisahiro
Shuto, Kiyohiko
TI Computed tomography perfusion imaging as a potential imaging biomarker
of colorectal cancer
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE Colorectal cancer; Angiogenesis; Computed tomography perfusion;
Antiangiogenic therapy; Chemoradiation therapy
ID TUMOR BLOOD-FLOW; INTERSTITIAL FLUID PRESSURE; INDIVIDUAL PATIENT DATA;
18 RANDOMIZED-TRIALS; RECTAL-CANCER; CT PERFUSION; POSTOPERATIVE
CHEMORADIOTHERAPY; HEPATIC METASTASES; PROGNOSTIC-FACTORS;
RADIATION-THERAPY
AB Neovascularization was reported to arise early in the adenoma- carcinoma sequence in colorectal cancer (CRC), and the importance of angiogenesis in cancer progression has been established. Computed tomography (CT) perfusion (CTP) based on high temporal resolution CT images enables evaluation of hemodynamics of tissue in vivo by modeling tracer kinetics. CTP has been reported to characterize tumor angiogenesis, and to be a sensitive marker for predicting recurrence or survival in CRC. In this review, we will discuss the biomarker value of CTP in the management of CRC patients. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Hayano, Koichi; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA.
[Fujishiro, Takeshi; Satoh, Asami; Aoyagi, Tomoyoshi; Ohira, Gaku; Tochigi, Toru; Matsubara, Hisahiro] Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chiba 2608677, Japan.
[Shuto, Kiyohiko] Teikyo Univ, Med Ctr, Dept Surg, Ichihara, Chiba 2990111, Japan.
RP Hayano, K (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, 55 Fruit St,White 270, Boston, MA 02114 USA.
EM khayano@partners.org
NR 49
TC 3
Z9 3
U1 2
U2 3
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD DEC 14
PY 2014
VL 20
IS 46
BP 17345
EP 17351
DI 10.3748/wjg.v20.i46.17345
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AW6NN
UT WOS:000346386300009
PM 25516645
ER
PT J
AU Wong, JC
Fernandes, KA
Amin, S
Lwin, Z
Krzyzanowska, MK
AF Wong, Janice C.
Fernandes, Kimberly A.
Amin, Shubarna
Lwin, Zarnie
Krzyzanowska, Monika K.
TI Involvement of low- and middle-income countries in randomized controlled
trial publications in oncology
SO GLOBALIZATION AND HEALTH
LA English
DT Article
DE Randomized controlled trials; Publications; Cancer; Low and middle
income countries; Authorship; Sponsorship
ID BREAST HEALTH-CARE; GUIDELINE IMPLEMENTATION; CLINICAL-TRIALS;
RESOURCE-ALLOCATION; CANCER; BURDEN; DISEASE; AFRICA; WORLD
AB Background: We describe trends in participation by investigators from low- and middle-income countries (LMCs) in publications describing oncology randomized control trials (RCTs) over a decade.
Methods: We used Medline to identify RCTs published in English from 1998 to 2008 evaluating treatment in lung, breast, colorectal, stomach and liver cancers. Data on author affiliations, authorship roles, trial characteristics, funding and interventions were extracted from each article. Countries were stratified as low-, middle-or high-income using World Bank data. Interventions were categorized as requiring basic, limited, enhanced or maximal resources as per the Breast Health Global Initiative classification. Logistic regression was used to identify factors associated with authorship by investigators from LMCs.
Results: 454 publications were identified. Proportion of articles with at least one LMC author increased over time from 20% in 1998 to 29% in 2008 (p = 0.01), but almost all LMC authors were from middle-income countries. Proportion of articles with at least one LMC author was higher among articles that explicitly reported recruitment in at least one LMC vs those that did not (76% vs 13%). Among 87 articles (19%) that involved authors from LMCs, 17% had LMC authors as first or corresponding authors, and 67% evaluated interventions requiring enhanced or maximal resources. Factors associated with LMC authorship included industry funding (OR = 3.54, p = 0.0001), placebo comparator arm (OR = 2.57, p = 0.02) and palliative intent treatment (OR = 4.00, p = 0.0003).
Conclusion: An increasing number of publications describing oncology RCTs involve authors from LMC countries but primarily in non-leadership roles in industry-funded trials.
C1 [Wong, Janice C.] Brigham & Womens Hosp, Dept Neurol, Boston, MA USA.
[Wong, Janice C.] Harvard Univ, Dept Neurol, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Fernandes, Kimberly A.; Krzyzanowska, Monika K.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada.
[Amin, Shubarna; Krzyzanowska, Monika K.] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada.
[Lwin, Zarnie] Univ Queensland, Royal Brisbane & Womens Hosp, Sch Med, Dept Med Oncol, Brisbane, Qld 4029, Australia.
[Krzyzanowska, Monika K.] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada.
RP Krzyzanowska, MK (reprint author), Inst Clin Evaluat Sci, G1 44,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM monika.krzyzanowska@uhn.ca
NR 29
TC 0
Z9 0
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1744-8603
J9 GLOBALIZATION HEALTH
JI Global. Health
PD DEC 13
PY 2014
VL 10
AR 83
DI 10.1186/s12992-014-0083-7
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AY7EI
UT WOS:000347723700001
PM 25498958
ER
PT J
AU Steckling, N
Bose-O'Reilly, S
Pinheiro, P
Plass, D
Shoko, D
Drasch, G
Bernaudat, L
Siebert, U
Hornberg, C
AF Steckling, Nadine
Bose-O'Reilly, Stephan
Pinheiro, Paulo
Plass, Dietrich
Shoko, Dennis
Drasch, Gustav
Bernaudat, Ludovic
Siebert, Uwe
Hornberg, Claudia
TI The burden of chronic mercury intoxication in artisanal small-scale gold
mining in Zimbabwe: data availability and preliminary estimates
SO ENVIRONMENTAL HEALTH
LA English
DT Article
DE Environmental burden of disease; Disability-adjusted life years;
Artisanal small-scale gold mining; Mercury; Occupational health;
Zimbabwe
ID HUMAN BIOMONITORING COMMISSION; ADJUSTED LIFE YEARS; ELEMENTAL MERCURY;
GLOBAL BURDEN; OCCUPATIONAL-EXPOSURE; ENVIRONMENTAL-HEALTH; CHLORALKALI
WORKERS; SYSTEMATIC ANALYSIS; 21 REGIONS; MINERS
AB Background: Artisanal small-scale gold mining (ASGM) is a poverty-driven activity practiced in over 70 countries worldwide. Zimbabwe is amongst the top ten countries using large quantities of mercury to extract gold from ore. This analysis was performed to check data availability and derive a preliminary estimate of disability-adjusted life years (DALYs) due to mercury use in ASGM in Zimbabwe.
Methods: Cases of chronic mercury intoxication were identified following an algorithm using mercury-related health effects and mercury in human specimens. The sample prevalence amongst miners and controls (surveyed by the United Nations Industrial Development Organization in 2004 and the University of Munich in 2006) was determined and extrapolated to the entire population of Zimbabwe. Further epidemiological and demographic data were taken from the literature and missing data modeled with DisMod II to quantify DALYs using the methods from the Global Burden of Disease (GBD) 2004 update published by the World Health Organization (WHO). While there was no disability weight (DW) available indicating the relative disease severity of chronic mercury intoxication, the DW of a comparable disease was assigned by following the criteria 1) chronic condition, 2) triggered by a substance, and 3) causing similar health symptoms.
Results: Miners showed a sample prevalence of 72% while controls showed no cases of chronic mercury intoxication. Data availability is very limited why it was necessary to model data and make assumptions about the number of exposed population, the definition of chronic mercury intoxication, DW, and epidemiology. If these assumptions hold, the extrapolation would result in around 95,400 DALYs in Zimbabwe's total population in 2004.
Conclusions: This analysis provides a preliminary quantification of the mercury-related health burden from ASGM based on the limited data available. If the determined assumptions hold, chronic mercury intoxication is likely to have been one of the top 20 hazards for population health in Zimbabwe in 2004 when comparing with more than 130 categories of diseases and injuries quantified in the WHO's GBD 2004 update. Improving data quality would allow more accurate estimates. However, the results highlight the need to reduce a burden which could be entirely avoided.
C1 [Steckling, Nadine; Hornberg, Claudia] Univ Bielefeld, Sch Publ Hlth, Dept Environm & Hlth, D-33615 Bielefeld, Germany.
[Steckling, Nadine; Bose-O'Reilly, Stephan] Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, WHO Collaborating Ctr Occupat Hlth, Workgrp Paediat Environm Epidemiol, D-80336 Munich, Germany.
[Steckling, Nadine; Bose-O'Reilly, Stephan; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, Inst Publ Hlth Med Decis Making & Hlth Technol As, Eduard Wallnoefer Ctr 1, A-6060 Hall In Tirol, Austria.
[Pinheiro, Paulo] Univ Bielefeld, Fac Educ Sci, D-33615 Bielefeld, Germany.
[Plass, Dietrich] Fed Environm Agcy, Sect Exposure Assessment & Environm Hlth Indicato, D-14195 Berlin, Germany.
[Shoko, Dennis] Tailjet Consultancy Serv, Harare, Zimbabwe.
[Drasch, Gustav] Univ Munich LMU, Dept Forens Toxicol, Inst Forens Med, D-80336 Munich, Germany.
[Bernaudat, Ludovic] UN Ind Dev Org, Vienna Int Ctr, A-1400 Vienna, Austria.
[Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA.
[Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
[Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
RP Steckling, N (reprint author), Univ Bielefeld, Sch Publ Hlth, Dept Environm & Hlth, Univ Str 25, D-33615 Bielefeld, Germany.
EM nadine.steckling@uni-bielefeld.de
FU GEF (Global Environment Facility); LMU; Deutsche Forschungsgemeinschaft;
Bielefeld University
FX Thanks are due to all the volunteers and colleagues who were involved in
the UNIDO Global Mercury Project and the LMU project. Data were taken
from a 2004 project organized by UNIDO as part of the Global Mercury
Project, with funds from the GEF (Global Environment Facility) and a
2006 project funded by the LMU. Special thanks are due to Beate
Lettmeier for assisting with data collection. Thanks are also due to
Debbie Johnson and Saskia Untiet- Kepp for English language editing.
This analysis received no funding. We acknowledge support of the
publication fee by the Deutsche Forschungsgemeinschaft and the Open
Access Publication Funds of Bielefeld University.
NR 124
TC 7
Z9 8
U1 7
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD DEC 13
PY 2014
VL 13
AR 111
DI 10.1186/1476-069X-13-111
PG 20
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AY3MP
UT WOS:000347488100001
PM 25495641
ER
PT J
AU Zhang, LY
Li, K
Sun, R
Zhang, Y
Ji, JF
Huang, PG
Yang, HY
Tian, Y
AF Zhang, Liyuan
Li, Kun
Sun, Rui
Zhang, Yuan
Ji, JianFeng
Huang, Peigeng
Yang, Hongying
Tian, Ye
TI Minocycline ameliorates cognitive impairment induced by whole-brain
irradiation: an animal study
SO RADIATION ONCOLOGY
LA English
DT Article
DE Whole-brain irradiation; Cognitive deficit; Minocycline; Newborn neuron;
Apoptosis; Neurogenesis
ID MORRIS WATER MAZE; NEURAL STEM-CELLS; HIPPOCAMPAL NEUROGENESIS; DENTATE
GYRUS; CRANIAL IRRADIATION; ADULT NEUROGENESIS; X-IRRADIATION; MICE;
RAT; LITHIUM
AB Background: It has been long recognized that cranial irradiation used for the treatment of primary and metastatic brain tumor often causes neurological side-effects such as intellectual impairment, memory loss and dementia, especially in children patients. Our previous study has demonstrated that whole-brain irradiation (WBI) can cause cognitive decline in rats. Minocycline is an antibiotic that has shown neuroprotective properties in a variety of experimental models of neurological diseases. However, whether minocycline can ameliorate cognitive impairment induced by ionizing radiation (IR) has not been tested. Thus this study aimed to demonstrate the potential implication of minocycline in the treatment of WBI-induced cognitive deficits by using a rat model.
Methods: Sprague Dawley rats were cranial irradiated with electron beams delivered by a linear accelerator with a single dose of 20 Gy. Minocycline was administered via oral gavages directly into the stomach before and after irradiation. The open field test was used to assess the anxiety level of rats. The Morris water maze (MWM) was used to assess the spatial learning and memory of rats. The level of apoptosis in hippocampal neurons was measured using immunohistochemistry for caspase-3 and relative markers for mature neurons (NeuN) or for newborn neurons (Doublecortin (DCX)). Neurogenesis was determined by BrdU incorporation method.
Results: Neither WBI nor minocycline affected the locomotor activity and anxiety level of rats. However, compared with the sham-irradiated controls, WBI caused a significant loss of learning and memory manifest as longer latency to reach the hidden platform in the MWM task. Minocycline intervention significantly improved the memory retention of irradiated rats. Although minocycline did not rescue neurogenesis deficit caused by WBI 2 months post-IR, it did significantly decreased WBI-induced apoptosis in the DCX positive neurons, thereby resulting in less newborn neuron depletion 12 h after irradiation.
Conclusions: Minocycline significantly inhibits WBI-induced neuron apoptosis, leading to less newborn neurons loss shortly after irradiation. In the long run, minocycline improves the cognitive performance of rats post WBI. The results indicate a potential clinical implication of minocycline as an effective adjunct in radiotherapy for brain tumor patients.
C1 [Zhang, Liyuan; Li, Kun; Sun, Rui; Zhang, Yuan; Ji, JianFeng; Tian, Ye] Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, Suzhou 215004, Jiangsu, Peoples R China.
[Zhang, Liyuan; Li, Kun; Sun, Rui; Zhang, Yuan; Ji, JianFeng; Tian, Ye] Soochow Univ, Affiliated Hosp 2, Jiangsu Key Lab Translat Res & Therapy Neuropsych, Suzhou 215004, Jiangsu, Peoples R China.
[Zhang, Liyuan; Yang, Hongying; Tian, Ye] Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou 215123, Jiangsu, Peoples R China.
[Li, Kun] Taishan Med Univ, Affiliated Hosp, Dept Med Oncol, Tai An 271000, Shandong, Peoples R China.
[Huang, Peigeng] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.
[Yang, Hongying] Soochow Univ, Sch Radiat Med & Protect, Coll Med, Sch Radiol & Interdisciplinary Sci RAD X, Suzhou 215123, Jiangsu, Peoples R China.
RP Yang, HY (reprint author), Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou 215123, Jiangsu, Peoples R China.
EM yanghongying@suda.edu.cn; dryetian@hotmail.com
FU National Natural Science Foundation of China [81172128, 81102077,
81372411, 81472804]; Jiangsu Provincial Special Program of Clinical
Medical Science [BL2014040]; Jiangsu Province's Key Medical Department;
Priority Academic Program Development of Jiangsu Higher Education
Institutions (PARD)
FX This research was supported by the National Natural Science Foundation
of China grants (81172128, 81102077, 81372411, 81472804), Jiangsu
Provincial Special Program of Clinical Medical Science (BL2014040),
Jiangsu Province's Key Medical Department in 2011 and A Project Funded
by the Priority Academic Program Development of Jiangsu Higher Education
Institutions (PARD).
NR 36
TC 8
Z9 8
U1 2
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-717X
J9 RADIAT ONCOL
JI Radiat. Oncol.
PD DEC 12
PY 2014
VL 9
AR 281
DI 10.1186/s13014-014-0281-8
PG 10
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CA9XZ
UT WOS:000349280100001
PM 25498371
ER
PT J
AU Dempsey, PP
Businger, AC
Whaley, LE
Gagne, JJ
Linder, JA
AF Dempsey, Patrick P.
Businger, Alexandra C.
Whaley, Lauren E.
Gagne, Joshua J.
Linder, Jeffrey A.
TI Primary care clinicians? perceptions about antibiotic prescribing for
acute bronchitis: a qualitative study
SO BMC FAMILY PRACTICE
LA English
DT Article
DE Bronchitis; Respiratory tract infections; Anti-bacterial agents; Primary
health care; Qualitative research
ID RESPIRATORY-TRACT INFECTIONS; PATIENT SATISFACTION;
PHYSICAL-EXAMINATION; PRACTICE GUIDELINES; EXPECTATIONS; ADULTS; TRIAL;
PRINCIPLES
AB Background: Clinicians prescribe antibiotics to over 65% of adults with acute bronchitis despite guidelines stating that antibiotics are not indicated.
Methods: To identify and understand primary care clinician perceptions about antibiotic prescribing for acute bronchitis, we conducted semi-structured interviews with 13 primary care clinicians in Boston, Massachusetts and used thematic content analysis.
Results: All the participants agreed with guidelines that antibiotics are not indicated for acute bronchitis and felt that clinicians other than themselves were responsible for overprescribing. Barriers to guideline adherence included 6 themes: (1) perceived patient demand, which was the main barrier, although some clinicians perceived a recent decrease; (2) lack of accountability for antibiotic prescribing; (3) saving time and money; (4) other clinicians? misconceptions about acute bronchitis; (5) diagnostic uncertainty; and (6) clinician dissatisfaction in failing to meet patient expectations. Strategies to decrease inappropriate antibiotic prescribing included 5 themes: (1) patient educational materials; (2) quality reporting; (3) clinical decision support; (4) use of an over-the-counter prescription pad; and (5) pre-visit triage and education by nurses to prevent visits.
Conclusions: Clinicians continued to cite patient demand as the main reason for antibiotic prescribing for acute bronchitis, though some clinicians perceived a recent decrease. Clinicians felt that other clinicians were responsible for inappropriate antibiotic prescribing and that better pre-visit triage by nurses could prevent visits and change patients? expectations.
C1 [Dempsey, Patrick P.; Businger, Alexandra C.; Linder, Jeffrey A.] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA.
[Whaley, Lauren E.] Massachusetts Dept Publ Hlth, Bur Infect Dis, Boston, MA USA.
[Gagne, Joshua J.] Dana Farber Canc Inst, Survey & Data Management Core, Boston, MA 02115 USA.
[Linder, Jeffrey A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Linder, JA (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA.
EM jlinder@partners.org
FU Agency for Healthcare Research and Quality [R18 HS018419]
FX This project was funded by the Agency for Healthcare Research and
Quality (R18 HS018419).
NR 44
TC 8
Z9 8
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2296
J9 BMC FAM PRACT
JI BMC Fam. Pract.
PD DEC 12
PY 2014
VL 15
AR UNSP 194
DI 10.1186/s12875-014-0194-5
PG 10
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AZ3DZ
UT WOS:000348109200001
PM 25495918
ER
PT J
AU Veena, MS
Wilken, R
Zheng, JY
Gholkar, A
Venkatesan, N
Vira, D
Ahmed, S
Basak, SK
Dalgard, CL
Ravichandran, S
Batra, RK
Kasahara, N
Elashoff, D
Fishbein, MC
Whitelegge, JP
Torres, JZ
Wang, MB
Srivatsan, ES
AF Veena, Mysore S.
Wilken, Reason
Zheng, Jun-Ying
Gholkar, Ankur
Venkatesan, Natarajan
Vira, Darshni
Ahmed, Sameer
Basak, Saroj K.
Dalgard, Clifton L.
Ravichandran, Sandhiya
Batra, Raj K.
Kasahara, Noriyuki
Elashoff, David
Fishbein, Michael C.
Whitelegge, Julian P.
Torres, Jorge Z.
Wang, Marilene B.
Srivatsan, Eri S.
TI p16 Protein and Gigaxonin Are Associated with the Ubiquitination of NF
kappa B in Cisplatin-induced Senescence of Cancer Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Cancer Stem Cells; Cellular Senescence; Chemoresistance; Head and Neck
Cancer; Ubiquitination; Cisplatin; Gigaxonin; NFB; p16 Suppressor Gene
ID CURCUMIN SUPPRESSES GROWTH; RANDOMIZED PHASE-II; TRANSCRIPTION FACTOR;
NECK-CANCER; OROPHARYNGEAL CANCER; HUMAN-PAPILLOMAVIRUS; INDUCTION
CHEMOTHERAPY; INDEPENDENT PATHWAY; HUMAN HEAD; IN-VITRO
AB Background: Molecular mechanism of p16-mediated cellular senescence in cisplatin-treated cells is not known. Results: Cisplatin treatment leads to p16 nuclear transport and association with gigaxonin for the ubiquitination of NFB. Conclusion: A protein associated with neural diseases is involved in cisplatin-mediated cellular senescence. Significance: Nuclear expression of p16 and gigaxonin is a useful marker of cancer cell chemosensitivity.
The molecular mechanism of p16-mediated senescence in cisplatin-treated cancer cells is not fully understood. Here we show that cisplatin treatment of head and neck cancer cells results in nuclear transport of p16 leading to a molecular modification of NFB. Chromatin immunoprecipitation assays show that this modification is associated with the inhibition of NFB interacting with its DNA binding sequences, leading to decreased expression of NFB-transcribed proteins. LCMS proteomic analysis of LAP-TAP-purified proteins from HeLa cells containing a tetracycline-inducible GFP-S peptide-NFB expression system identified gigaxonin, an ubiquitin E3 ligase adaptor, as an NFB-interacting protein. Immunoblotting and siRNA studies confirmed the NFB-gigaxonin interaction and the dependence of this binding on p16-NFB binding. Using gel shift assays, we have confirmed p16-NFB and gigaxonin-NFB interactions. Furthermore, we have observed increased NFB ubiquitination with cisplatin treatment that is abolished in the absence of p16 and gigaxonin expression. Analysis of 103 primary tumors has shown that increased nuclear p16 expression correlates with enhanced survival of head and neck cancer patients (p < 0.0000542), indicating the importance of nuclear p16 expression in prognosis. Finally, p16 expression is associated with reduced cytokine expression and the presence of human papilloma virus in chemoradiation-sensitive basaloid tumors. However, the absence of p16 expression is associated with enhanced cytokine expression and the absence of human papilloma virus in aggressive tumors. These results clearly demonstrate that nuclear p16 and gigaxonin play an important role in chemosensitivity of head and neck cancers through ubiquitination of NF kappa B.
C1 [Veena, Mysore S.; Wilken, Reason; Zheng, Jun-Ying; Venkatesan, Natarajan; Vira, Darshni; Basak, Saroj K.; Ravichandran, Sandhiya; Wang, Marilene B.; Srivatsan, Eri S.] UCLA, David Geffen Sch Med, VAGLAHS, Dept Surg, Los Angeles, CA 90073 USA.
[Gholkar, Ankur; Torres, Jorge Z.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.
[Vira, Darshni; Ahmed, Sameer; Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.
[Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Dept Anat, Bethesda, MD 20814 USA.
[Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Dept Physiol, Bethesda, MD 20814 USA.
[Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Dept Genet, Bethesda, MD 20814 USA.
[Batra, Raj K.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90073 USA.
[Batra, Raj K.; Kasahara, Noriyuki; Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Fishbein, Michael C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Whitelegge, Julian P.] UCLA, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Batra, Raj K.; Torres, Jorge Z.; Wang, Marilene B.; Srivatsan, Eri S.] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
RP Srivatsan, ES (reprint author), UCLA, David Geffen Sch Med, VAGLAHS, Dept Surg, Bldg 304,Rm E2-218,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM esrivats@ucla.edu
FU National Institutes of Health [R21 CA116826-01]; Veterans Affairs,
Washington, D. C.; Veterans Affairs Greater Los Angeles Healthcare
System; West Los Angeles Surgical Education Research Center; UCLA
Academic Senate grant
FX This work was supported, in whole or in part, by National Institutes of
Health Grant R21 CA116826-01 (to M. W.). This work was also supported by
a merit grant from Veterans Affairs, Washington, D. C. (to E. S. S.), by
funds from Veterans Affairs Greater Los Angeles Healthcare System, West
Los Angeles Surgical Education Research Center, and by a UCLA Academic
Senate grant (to M. W.).
NR 59
TC 6
Z9 7
U1 0
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 12
PY 2014
VL 289
IS 50
BP 34921
EP 34937
DI 10.1074/jbc.M114.568543
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AW4OP
UT WOS:000346260800042
PM 25331947
ER
PT J
AU Haggerty, TJ
Dunn, IS
Rose, LB
Newton, EE
Pandolfi, F
Kurnick, JT
AF Haggerty, Timothy J.
Dunn, Ian S.
Rose, Lenora B.
Newton, Estelle E.
Pandolfi, Franco
Kurnick, James T.
TI Heat Shock Protein-90 Inhibitors Enhance Antigen Expression on Melanomas
and Increase T Cell Recognition of Tumor Cells
SO PLOS ONE
LA English
DT Article
ID PHASE-II TRIAL; HSP90 INHIBITORS; METASTATIC MELANOMA;
ANTITUMOR-ACTIVITY; PANCREATIC-CANCER; BRAF INHIBITION; DOWN-MODULATION;
B-RAF; IMMUNOTHERAPY; CHAPERONE
AB In an effort to enhance antigen-specific T cell recognition of cancer cells, we have examined numerous modulators of antigen-expression. In this report we demonstrate that twelve different Hsp90 inhibitors (iHsp90) share the ability to increase the expression of differentiation antigens and MHC Class I antigens. These iHsp90 are active in several molecular and cellular assays on a series of tumor cell lines, including eleven human melanomas, a murine B16 melanoma, and two human glioma-derived cell lines. Intra-cytoplasmic antibody staining showed that all of the tested iHsp90 increased expression of the melanocyte differentiation antigens Melan-A/MART-1, gp100, and TRP-2, as well as MHC Class I. The gliomas showed enhanced gp100 and MHC staining. Quantitative analysis of mRNA levels showed a parallel increase in message transcription, and a reporter assay shows induction of promoter activity for Melan-A/MART-1 gene. In addition, iHsp90 increased recognition of tumor cells by T cells specific for Melan-A/MART-1. In contrast to direct Hsp90 client proteins, the increased levels of full-length differentiation antigens that result from iHsp90 treatment are most likely the result of transcriptional activation of their encoding genes. In combination, these results suggest that iHsp90 improve recognition of tumor cells by T cells specific for a melanoma-associated antigen as a result of increasing the expressed intracellular antigen pool available for processing and presentation by MHC Class I, along with increased levels of MHC Class I itself. As these Hsp90 inhibitors do not interfere with T cell function, they could have potential for use in immunotherapy of cancer.
C1 [Haggerty, Timothy J.; Dunn, Ian S.; Rose, Lenora B.; Newton, Estelle E.; Kurnick, James T.] CytoCure LLC, Beverly, MA USA.
[Haggerty, Timothy J.; Kurnick, James T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA.
[Pandolfi, Franco] Catholic Univ, Dept Internal Med, Rome, Italy.
RP Pandolfi, F (reprint author), Catholic Univ, Dept Internal Med, Rome, Italy.
EM pandolfi@rm.unicatt.it
FU National Institutes of Health [CA-165553]; International Cancer Research
Scholarship
FX The studies were supported in part by a grant from the National
Institutes of Health, CA-165553 (TJH, ISD, EEN, LBR, JTK), and by an
International Cancer Research Scholarship to JTK. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 59
TC 4
Z9 4
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2014
VL 9
IS 12
AR e114506
DI 10.1371/journal.pone.0114506
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6JI
UT WOS:000346375400032
PM 25503774
ER
PT J
AU King, LY
Johnson, KB
Zheng, H
Wei, L
Gudewicz, T
Hoshida, Y
Corey, KE
Ajayi, T
Ufere, N
Baumert, TF
Chan, AT
Tanabe, KK
Fuchs, BC
Chung, RT
AF King, Lindsay Y.
Johnson, Kara B.
Zheng, Hui
Wei, Lan
Gudewicz, Thomas
Hoshida, Yujin
Corey, Kathleen E.
Ajayi, Tokunbo
Ufere, Nneka
Baumert, Thomas F.
Chan, Andrew T.
Tanabe, Kenneth K.
Fuchs, Bryan C.
Chung, Raymond T.
TI Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis
SO PLOS ONE
LA English
DT Article
ID CHRONIC HEPATITIS-C; THAN-G POLYMORPHISM; GROWTH-FACTOR GENE;
HEPATOCELLULAR-CARCINOMA; FUNCTIONAL POLYMORPHISM; RISK; VIRUS; ENTRY;
PROGRESSION; EXPRESSION
AB Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown. We genotyped SNPs in EGF, PNPLA3, and IL28B from liver tissue from 169 patients with biopsy-proven HCV cirrhosis. We estimated risk of clinical deterioration, defined as development of ascites, encephalopathy, variceal hemorrhage, HCC, or liver-related death using Cox proportional hazards modeling. During a median follow-up of 6.6 years, 66 of 169 patients experienced clinical deterioration. EGF non-AA, PNPLA3 non-CC, and IL28B non-CC genotypes were each associated with increased risk of clinical deterioration in age, sex, and race-adjusted analysis. Only EGF non-AA genotype was independently associated with increased risk of clinical deterioration (hazard ratio [HR] 2.87; 95% confidence interval [CI] 1.31-6.25) after additionally adjusting for bilirubin, albumin, and platelets. Compared to subjects who had 0-1 unfavorable genotypes, the HR for clinical deterioration was 1.79 (95% CI 0.96-3.35) for 2 unfavorable genotypes and 4.03 (95% CI 2.13-7.62) for unfavorable genotypes for all three loci (P-trend<0.0001). In conclusion, among HCV cirrhotics, EGF non-AA genotype is independently associated with increased risk for clinical deterioration. Specific PNPLA3 and IL28B genotypes also appear to be associated with clinical deterioration. These SNPs have potential to identify patients with HCV-related cirrhosis who require more intensive monitoring for decompensation or future therapies preventing disease progression.
C1 [King, Lindsay Y.; Johnson, Kara B.; Corey, Kathleen E.; Chan, Andrew T.; Chung, Raymond T.] Massachusetts Gen Hosp, Ctr Liver, Gastrointestinal Div, Boston, MA 02114 USA.
[King, Lindsay Y.; Johnson, Kara B.; Corey, Kathleen E.; Ufere, Nneka; Chan, Andrew T.; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Wei, Lan; Tanabe, Kenneth K.; Fuchs, Bryan C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Gudewicz, Thomas] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[King, Lindsay Y.; Johnson, Kara B.; Zheng, Hui; Wei, Lan; Gudewicz, Thomas; Corey, Kathleen E.; Ufere, Nneka; Baumert, Thomas F.; Chan, Andrew T.; Tanabe, Kenneth K.; Fuchs, Bryan C.; Chung, Raymond T.] Harvard Univ, Sch Med, Boston, MA USA.
[Hoshida, Yujin] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
[Ajayi, Tokunbo] North Shore Med Ctr, Dept Med, Salem, MA USA.
[Baumert, Thomas F.] Univ Strasbourg, INSERM, U1110, Strasbourg, France.
RP Chung, RT (reprint author), Massachusetts Gen Hosp, Ctr Liver, Gastrointestinal Div, Boston, MA 02114 USA.
EM rtchung@partners.org
FU National Institutes of Health [DK078772, T32DK007191, DK098311];
National Cancer Institute [CA140861]
FX This study was funded by the National Institutes of Health DK078772
(RC), National Cancer Institute CA140861 (BF), National Institutes of
Health T32DK007191 (LK and KJ), National Institutes of Health DK098311
(AC). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 28
TC 4
Z9 4
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2014
VL 9
IS 12
AR e114747
DI 10.1371/journal.pone.0114747
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6JI
UT WOS:000346375400049
PM 25504078
ER
PT J
AU Martinez, KG
Franco-Chaves, JA
Milad, MR
Quirk, GJ
AF Martinez, Karen G.
Franco-Chaves, Jose A.
Milad, Mohammed R.
Quirk, Gregory J.
TI Ethnic Differences in Physiological Responses to Fear Conditioned
Stimuli
SO PLOS ONE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; ANXIETY DISORDERS; EXTINCTION; CONTEXT;
RECOMMENDATIONS; METAANALYSIS; MECHANISMS; CULTURE; HUMANS; SEX
AB The idea that emotional expression varies with ethnicity is based largely on questionnaires and behavioral observations rather than physiological measures. We therefore compared the skin conductance responses (SCR) of Hispanic (Puerto Rican) and White non-Hispanic subjects in a fear conditioning and fear extinction task. Subjects were recruited from two sites: San Juan, Puerto Rico (PR), and Boston, Massachusetts (MA), using identical methods. A total of 78 healthy subjects (39 from PR, 39 from MA) were divided by sex and matched for age and educational level. Females from the two sites did not differ in their SCRs during any experimental phase of fear conditioning (habituation, conditioning, or extinction). In contrast, PR males responded significantly to the conditioned stimulus than MA males or PR females. Subtracting ethnic differences observed during the habituation phase (prior to conditioning) eliminated differences from subsequent phases, suggesting that PR males are elevated in their response to novelty rather than fear learning. Our findings suggest that, in addition to sex differences, there are ethnic differences in physiological responses to novel stimuli at least in males, which could be relevant for the assessment and treatment of anxiety disorders.
C1 [Martinez, Karen G.; Franco-Chaves, Jose A.; Quirk, Gregory J.] Univ Puerto Rico, Sch Med, Dept Psychiat, San Juan, PR 00936 USA.
[Quirk, Gregory J.] Univ Puerto Rico, Sch Med, Dept Anat & Neurobiol, San Juan, PR 00936 USA.
[Milad, Mohammed R.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
[Milad, Mohammed R.] Harvard Univ, Sch Med, Charlestown, MA USA.
RP Martinez, KG (reprint author), Univ Puerto Rico, Sch Med, Dept Psychiat, San Juan, PR 00936 USA.
EM Karen.martinez4@upr.edu
FU National Center for Research Resources [U54 RR026139]; National
Institute on Minority Health and Health Disparities [8U54MD 007587-03];
HISPANICS-IN-RESEARCH CAPABILITY: SoHP & SoM PARTNERSHIP (HiREC)
[S21MD001830]
FX The project described was supported by award number U54 RR026139 from
the National Center for Research Resources, award number 8U54MD
007587-03 from the National Institute on Minority Health and Health
Disparities and the HISPANICS-IN-RESEARCH CAPABILITY: SoHP & SoM
PARTNERSHIP (HiREC) Endowment Program award number: S21MD001830 (kgm).
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health. The funders had no role in the study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 27
TC 2
Z9 2
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2014
VL 9
IS 12
AR e114977
DI 10.1371/journal.pone.0114977
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6JI
UT WOS:000346375400064
PM 25501365
ER
PT J
AU Gutchess, A
AF Gutchess, Angela
TI Recognizing the risks of brain stimulation Response
SO SCIENCE
LA English
DT Letter
ID TRANSCRANIAL MAGNETIC STIMULATION; SAFETY
C1 [Gutchess, Angela] Brandeis Univ, Ctr Complex Syst, Dept Psychol & Volen Natl, Waltham, MA 02453 USA.
[Gutchess, Angela] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
RP Gutchess, A (reprint author), Brandeis Univ, Ctr Complex Syst, Dept Psychol & Volen Natl, Waltham, MA 02453 USA.
EM gutchess@brandeis.edu
NR 8
TC 0
Z9 0
U1 2
U2 6
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 12
PY 2014
VL 346
IS 6215
BP 1307
EP 1307
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW3MA
UT WOS:000346189600031
PM 25504708
ER
PT J
AU Mansour, MR
Abraham, BJ
Anders, L
Berezovskaya, A
Gutierrez, A
Durbin, AD
Etchin, J
Lawton, L
Sallan, SE
Silverman, LB
Loh, ML
Hunger, SP
Sanda, T
Young, RA
Look, AT
AF Mansour, Marc R.
Abraham, Brian J.
Anders, Lars
Berezovskaya, Alla
Gutierrez, Alejandro
Durbin, Adam D.
Etchin, Julia
Lawton, Lee
Sallan, Stephen E.
Silverman, Lewis B.
Loh, Mignon L.
Hunger, Stephen P.
Sanda, Takaomi
Young, Richard A.
Look, A. Thomas
TI An oncogenic super-enhancer formed through somatic mutation of a
noncoding intergenic element
SO SCIENCE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; MONOALLELIC EXPRESSION; TRANSCRIPTION
FACTORS; SELECTIVE-INHIBITION; CELL IDENTITY; TAL1 COMPLEX; GENES;
DISRUPTION; DISEASE; LINEAGE
AB In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell's transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase-binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells.
C1 [Mansour, Marc R.; Berezovskaya, Alla; Gutierrez, Alejandro; Durbin, Adam D.; Etchin, Julia; Sallan, Stephen E.; Silverman, Lewis B.; Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Mansour, Marc R.] UCL, UCL Canc Inst, Dept Haematol, London WC1E 6BT, England.
[Abraham, Brian J.; Anders, Lars; Lawton, Lee; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Gutierrez, Alejandro; Sallan, Stephen E.; Silverman, Lewis B.; Look, A. Thomas] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Loh, Mignon L.] Univ Calif San Francisco, Benioff Childrens Hosp, Dept Pediat, San Francisco, CA 94143 USA.
[Hunger, Stephen P.] Univ Colorado, Sch Med, Aurora, CO 80045 USA.
[Hunger, Stephen P.] Childrens Hosp Colorado, Aurora, CO 80045 USA.
[Sanda, Takaomi] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore.
[Sanda, Takaomi] Yong Loo Lin Sch Med, Dept Med, Singapore 117599, Singapore.
[Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02142 USA.
RP Look, AT (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
EM young@wi.mit.edu; thomas_look@dfci.harvard.edu
RI Young, Richard/F-6495-2012
OI Young, Richard/0000-0001-8855-8647
FU Claudia Adams Barr Innovative Basic Science Research Program; Kay
Kendall Leukaemia Trust; Leukaemia and Lymphoma Research, UK; National
Cancer Institute, NIH [CA167124]; Department of Defense [CA120215];
William Lawrence and Blanche Hughes Foundation; National Research
Foundation (NRF), Prime Minister's Office, Singapore under its NRF
Fellowship Program [NRF-NRFF2013-02]; NIH [1R01CA176746-01,
5P01CA109901-08, 5P01CA68484, CA98543, CA114766, CA98413, CA30969,
CA29139]
FX We thank J. Gilbert for helpful editorial comments on the manuscript, J.
Reddy for sharing data, and F. Alt and F. Meng for helpful advice on the
design of the CRISPR experiments. We would like to dedicate this paper
to the memory of Michael Fayngersh. We gratefully acknowledge the
children with T-ALL and their families for the samples analyzed in these
studies. M.R.M. was supported by the Claudia Adams Barr Innovative Basic
Science Research Program, the Kay Kendall Leukaemia Trust, and a Bennett
Fellowship from Leukaemia and Lymphoma Research, UK. A.G. is a Research
Fellow of the Gabrielle's Angel Foundation for Cancer Research, a
Clinical Investigator of the Damon Runyon Cancer Research Foundation,
and is supported by grants National Cancer Institute, NIH, CA167124,
Department of Defense, CA120215 and an award from the William Lawrence
and Blanche Hughes Foundation. T.S. is supported by a grant from the
National Research Foundation (NRF), Prime Minister's Office, Singapore
under its NRF Fellowship Program (award no. NRF-NRFF2013-02). This work
was funded by NIH grants 1R01CA176746-01 and 5P01CA109901-08 (A.T.L.),
and 5P01CA68484 (S.E.S. and A.T.L.). Children's Oncology Group cell
banking and sample distribution were supported by grants CA98543,
CA114766, CA98413, CA30969, and CA29139 from the NIH. S.P.H. is the
Ergen Family Chair in Pediatric Cancer. R.A.Y. is a founder and member
of the Board of Directors of Syros Pharmaceuticals, a company developing
therapies that target gene regulatory elements including
super-enhancers.
NR 24
TC 120
Z9 123
U1 5
U2 25
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 12
PY 2014
VL 346
IS 6215
BP 1373
EP 1377
DI 10.1126/science.1259037
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW3MA
UT WOS:000346189600053
PM 25394790
ER
PT J
AU Craft, D
Bangert, M
Long, T
Papp, D
Unkelbach, J
AF Craft, David
Bangert, Mark
Long, Troy
Papp, David
Unkelbach, Jan
TI Shared data for intensity modulated radiation therapy (IMRT)
optimization research: the CORT dataset
SO GIGASCIENCE
LA English
DT Article
DE IMRT; Optimization; Radiation therapy; Beam angle optimization; VMAT;
Treatment plan optimization
ID DIRECT APERTURE OPTIMIZATION; BEAM ANGLE; ARC THERAPY; PENCIL BEAM;
GENERATION; RADIOTHERAPY; NUMBER; PLANS
AB Background: We provide common datasets (which we call the CORT dataset: common optimization for radiation therapy) that researchers can use when developing and contrasting radiation treatment planning optimization algorithms. The datasets allow researchers to make one-to-one comparisons of algorithms in order to solve various instances of the radiation therapy treatment planning problem in intensity modulated radiation therapy (IMRT), including beam angle optimization, volumetric modulated arc therapy and direct aperture optimization.
Results: We provide datasets for a prostate case, a liver case, a head and neck case, and a standard IMRT phantom. We provide the dose-influence matrix from a variety of beam/couch angle pairs for each dataset. The dose-influence matrix is the main entity needed to perform optimizations: it contains the dose to each patient voxel from each pencil beam. In addition, the original Digital Imaging and Communications in Medicine (DICOM) computed tomography (CT) scan, as well as the DICOM structure file, are provided for each case.
Conclusions: Here we present an open dataset - the first of its kind - to the radiation oncology community, which will allow researchers to compare methods for optimizing radiation dose delivery.
C1 [Craft, David; Papp, David; Unkelbach, Jan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Bangert, Mark] German Canc Res Ctr, D-69120 Heidelberg, Germany.
[Long, Troy] Univ Michigan, Ann Arbor, MI 48109 USA.
RP Craft, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
EM dcraft@mgh.harvard.edu
NR 31
TC 7
Z9 7
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
EI 2047-217X
J9 GIGASCIENCE
JI GigaScience
PD DEC 12
PY 2014
VL 3
AR 37
DI 10.1186/2047-217X-3-37
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CX4HI
UT WOS:000365659600001
PM 25678961
ER
PT J
AU Korn, LL
Hubbeling, HG
Porrett, PM
Yang, Q
Barnett, LG
Laufer, TM
AF Korn, Lisa L.
Hubbeling, Harper G.
Porrett, Paige M.
Yang, Qi
Barnett, Lisa G.
Laufer, Terri M.
TI Regulatory T Cells Occupy an Isolated Niche in the Intestine that Is
Antigen Independent
SO CELL REPORTS
LA English
DT Article
ID THYMIC EMIGRANTS; ULCERATIVE-COLITIS; COMMENSAL BACTERIA;
COLONIC-MUCOSA; GENERATION; IL-2; INDUCTION; METABOLITES; EXPRESSION;
EPITHELIUM
AB Regulatory T cells (Tregs) are CD4(+) T cells that maintain immune homeostasis and prevent autoimmunity. Like all CD4(+) T cells, Tregs require antigenspecific signals via T cell receptor-major histocompatibility complex class II (TCR-MHCII) interactions for their development. However, the requirement for MHCII in Treg homeostasis in tissues such as intestinal lamina propria (LP) is unknown. We examined LP Treg homeostasis in a transgenic mouse model that lacks peripheral TCR-MHCII interactions and generation of extrathymic Tregs (iTregs). Thymically generated Tregs entered the LP of weanlings and proliferated independently of MHCII to fill the compartment. The adult LP was a closed niche; new thymic Tregs were excluded, and Tregs in parabiotic pairs were LP resident. The isolated LP niche was interleukin-2 (IL-2) independent but dependent on commensal bacteria. Thus, an LP Treg niche can be filled, isolated, and maintained independently of antigen signals and iTregs. This niche may represent a tissue-specific mechanism for maintaining immune tolerance.
C1 [Korn, Lisa L.; Hubbeling, Harper G.; Barnett, Lisa G.; Laufer, Terri M.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Porrett, Paige M.] Univ Penn, Perelman Sch Med, Dept Surg, Philadelphia, PA 19104 USA.
[Yang, Qi] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Laufer, TM (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
EM tlaufer@mail.med.upenn.edu
FU Penn-CHOP Joint Center for Digestive, Liver and Pancreatic Medicine
[P30DK050306]; Training Program in Rheumatic Disease [5T32AR007442-25]
FX The authors would like to thank Yasmine Belkaid, Nicolas Bouladoux, Tim
Hand, and Sean Spencer for helpful discussions, Amy Wagers for technical
advice, and Chris Hunter and Helen Simkins for critical reading of the
manuscript. This work was initiated with support from pilot grant from
the Penn-CHOP Joint Center for Digestive, Liver and Pancreatic Medicine
(P30DK050306). L. L. K. was supported by the Training Program in
Rheumatic Disease (5T32AR007442-25).
NR 35
TC 3
Z9 3
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC 11
PY 2014
VL 9
IS 5
BP 1567
EP 1573
DI 10.1016/j.celrep.2014.11.006
PG 7
WC Cell Biology
SC Cell Biology
GA AX3PR
UT WOS:000346851900001
PM 25482559
ER
PT J
AU Cai, CM
He, HH
Gao, S
Chen, S
Yu, ZY
Gao, YF
Chen, SY
Chen, MW
Zhang, J
Ahmed, M
Wang, Y
Metzger, E
Schule, R
Liu, XS
Brown, M
Balk, SP
AF Cai, Changmeng
He, Housheng Hansen
Gao, Shuai
Chen, Sen
Yu, Ziyang
Gao, Yanfei
Chen, Shaoyong
Chen, Mei Wei
Zhang, Jesse
Ahmed, Musaddeque
Wang, Yang
Metzger, Eric
Schuele, Roland
Liu, X. Shirley
Brown, Myles
Balk, Steven P.
TI Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of
Androgen Receptor Transcriptional Activity
SO CELL REPORTS
LA English
DT Article
ID METASTATIC PROSTATE-CANCER; INCREASED SURVIVAL; GENE-EXPRESSION; LSD1;
METHYLATION; ENHANCERS; CHROMATIN; FOXA1; PHOSPHORYLATION; CHEMOTHERAPY
AB Lysine-Specific Demethylase 1 (LSD1, KDM1A) functions as a transcriptional corepressor through demethylation of histone 3 lysine 4 (H3K4) but has a coactivator function on some genes through mechanisms that are unclear. We show that LSD1, interacting with CoREST, associates with and coactivates androgen receptor (AR) on a large fraction of androgen-stimulated genes. A subset of these AR/LSD1-associated enhancer sites have histone 3 threonine 6 phosphorylation (H3T6ph), and these sites are further enriched for androgen-stimulated genes. Significantly, despite its coactivator activity, LSD1 still mediates H3K4me2 demethylation at these androgen-stimulated enhancers. FOXA1 is also associated with LSD1 at AR-regulated enhancer sites, and a FOXA1 interaction with LSD1 enhances binding of both proteins at these sites. These findings show that LSD1 functions broadly as a regulator of AR function, that it maintains a transcriptional repression function at AR-regulated enhancers through H3K4 demethylation, and that it has a distinct AR-linked coactivator function mediated by demethylation of other substrates.
C1 [Cai, Changmeng; Gao, Shuai; Chen, Sen; Yu, Ziyang; Gao, Yanfei; Chen, Shaoyong; Balk, Steven P.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA.
[Cai, Changmeng; He, Housheng Hansen; Gao, Shuai; Chen, Sen; Yu, Ziyang; Gao, Yanfei; Chen, Shaoyong; Chen, Mei Wei; Zhang, Jesse; Brown, Myles; Balk, Steven P.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[He, Housheng Hansen; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[He, Housheng Hansen; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[He, Housheng Hansen; Chen, Mei Wei; Zhang, Jesse; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[He, Housheng Hansen; Ahmed, Musaddeque] Princess Margaret Canc Ctr, Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 1L7, Canada.
[He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.
[Wang, Yang] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin 300070, Peoples R China.
[Metzger, Eric; Schuele, Roland] Univ Freiburg, Klinikum Univ Freiburg, Urolog Klin & Zentrale Klin Forsch, D-79106 Freiburg, Germany.
[Wang, Yang; Metzger, Eric; Schuele, Roland] DKTK, D-79106 Freiburg, Germany.
[Liu, X. Shirley; Brown, Myles] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
RP Cai, CM (reprint author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA.
EM ccai1@bidmc.harvard.edu; hansenhe@uhnresearch.ca
OI Brown, Myles/0000-0002-8213-1658; Cai, Changmeng/0000-0002-8701-2586
FU NIH [K99 CA166507, K99 CA172948-01, R01 GM099409, P01 CA163227]; SPORE
in Prostate Cancer [P50 CA090381]; DOD [W81XWH-11-1-0295,
W81XWH-131-0266, W81XWH-10-1-0557, W81XWH-13-PCRP-PTA,
W81XWH-12-PCRP-PTA, W81XWH-13-PCRP-EHDA]; DF/HCC Mazzone Impact Award;
Prostate Cancer Foundation
FX Supported by grants from NIH (K99 CA166507 to C.C., K99 CA172948-01 to
H.H.H., R01 GM099409 to X.S.L., P01 CA163227, and SPORE in Prostate
Cancer P50 CA090381), and DOD (W81XWH-11-1-0295 and W81XWH-131-0266 to
S.P.B., W81XWH-10-1-0557 to H.H.H., W81XWH-13-PCRP-PTA to Y.G.,
W81XWH-12-PCRP-PTA and W81XWH-13-PCRP-EHDA to Z.Y.), a DF/HCC Mazzone
Impact Award, and by Awards from the Prostate Cancer Foundation.
NR 33
TC 23
Z9 23
U1 0
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC 11
PY 2014
VL 9
IS 5
BP 1618
EP 1627
DI 10.1016/j.celrep.2014.11.008
PG 10
WC Cell Biology
SC Cell Biology
GA AX3PR
UT WOS:000346851900007
PM 25482560
ER
PT J
AU Chow, NA
Jasenosky, LD
Goldfeld, AE
AF Chow, Nancy A.
Jasenosky, Luke D.
Goldfeld, Anne E.
TI A Distal Locus Element Mediates IFN-gamma Priming of Lipopolysaccharide-
Stimulated TNF Gene Expression
SO CELL REPORTS
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; CREB-BINDING-PROTEIN; FACTOR-ALPHA;
INTERFERON-GAMMA; TRANSCRIPTION FACTORS; MONOCYTIC CELLS; IRF FAMILY;
CHROMATIN; PROMOTER; ACTIVATION
AB Interferon gamma (IFN-gamma) priming sensitizes monocytes and macrophages to lipopolysaccharide (LPS) stimulation, resulting in augmented expression of a set of genes including TNF. Here, we demonstrate that IFN-gamma priming of LPS-stimulated TNF transcription requires a distal TNF/LT locus element 8 kb upstream of the TNF transcription start site (hHS-8). IFN-gamma stimulation leads to increased DNase I accessibility of hHS-8 and its recruitment of interferon regulatory factor 1 (IRF1), and subsequent LPS stimulation enhances H3K27 acetylation and induces enhancer RNA synthesis at hHS-8. Ablation of IRF1 or targeting the hHS-8 IRF1 binding site in vivo with Cas9 linked to the KRAB repressive domain abolishes IFN-gamma priming, but does not affect LPS induction of the gene. Thus, IFN-gamma poises a distal enhancer in the TNF/LT locus by chromatin remodeling and IRF1 recruitment, which then drives enhanced TNF gene expression in response to a secondary toll-like receptor (TLR) stimulus.
C1 [Chow, Nancy A.; Jasenosky, Luke D.; Goldfeld, Anne E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA 02115 USA.
RP Goldfeld, AE (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Program Cellular & Mol Med, 200 Longwood Ave, Boston, MA 02115 USA.
EM anne.goldfeld@childrens.harvard.edu
FU GlaxoSmithKline; NIH/NIGMS [GM076685]
FX We are indebted to Laurens Kruidenier and David Tough for stimulating
discussions and experimental suggestions. We thank Alla Tsytsykova and
Shahin Ranjbar for critical experimental advice and discussions. We also
thank James Falvo for helpful discussions. This work was supported by
grants from GlaxoSmithKline and the NIH/NIGMS (GM076685) to A.E.G.
NR 41
TC 5
Z9 5
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC 11
PY 2014
VL 9
IS 5
BP 1718
EP 1728
DI 10.1016/j.celrep.2014.11.011
PG 11
WC Cell Biology
SC Cell Biology
GA AX3PR
UT WOS:000346851900017
PM 25482561
ER
PT J
AU Sung, VMH
Tsai, CL
AF Sung, Vicky M-H
Tsai, Chia-Lun
TI ADP-Ribosylargininyl reaction of cholix toxin is mediated through
diffusible intermediates
SO BMC BIOCHEMISTRY
LA English
DT Article
DE Cholix toxin; ADP-ribosylation; Auto-ADP-ribosylation; Arginine
ID NICOTINAMIDE ADENINE-DINUCLEOTIDE; PSEUDOMONAS-AERUGINOSA EXOS;
SITE-DIRECTED MUTAGENESIS; DIPHTHERIA-TOXIN; CRYSTAL-STRUCTURE;
VIBRIO-CHOLERAE; POLY(ADP-RIBOSE) POLYMERASE; RIBOSYLTRANSFERASE
ACTIVITY; RIBOSYLATING TOXINS; ESCHERICHIA-COLI
AB Background: Cholix toxin is an ADP-ribosyltransferase found in non-O1/non-O139 strains of Vibrio cholera. The catalytic fragment of cholix toxin was characterized as a diphthamide dependent ADP-ribosyltransferase.
Results: Our studies on the enzymatic activity of cholix toxin catalytic fragment show that the transfer of ADP-ribose to toxin takes place by a predominantly intramolecular mechanism and results in the preferential alkylation of arginine residues proximal to the NAD(+) binding pocket. Multiple arginine residues, located near the catalytic site and at distal sites, can be the ADP-ribose acceptor in the auto-reaction. Kinetic studies of a model enzyme, M8, showed that a diffusible intermediate preferentially reacted with arginine residues in proximity to the NAD(+) binding pocket. ADP-ribosylarginine activity of cholix toxin catalytic fragment could also modify exogenous substrates. Auto-ADP-ribosylation of cholix toxin appears to have negatively regulatory effect on ADP-ribosylation of exogenous substrate. However, at the presence of both endogenous and exogenous substrates, ADP-ribosylation of exogenous substrates occurred more efficiently than that of endogenous substrates.
Conclusions: We discovered an ADP-ribosylargininyl activity of cholix toxin catalytic fragment from our studies in auto-ADP-ribosylation, which is mediated through diffusible intermediates. The lifetime of the hypothetical intermediate exceeds recorded and predicted lifetimes for the cognate oxocarbenium ion. Therefore, a diffusible strained form of NAD(+) intermediate was proposed to react with arginine residues in a proximity dependent manner.
C1 [Sung, Vicky M-H; Tsai, Chia-Lun] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Sung, Vicky M-H] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Sung, VMH (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
EM mvsung@gmail.com
FU Massachusetts General Hospital
FX We thank Drs. Chi-Wang Lin and Jesse Chen for assistance with circular
dichroism spectra analysis; Dr. Stephen H. Leppla (NIH) for providing
diphthamide synthesis deficient CHO cell lines; Naifang Lu for providing
the catalytic fragment of cholix toxin; Drs. Mikako Tsuchiya and Harumi
Osago for mass spectrometry analysis for orn peptide detection; Dr.
Brian Seed for critical review, suggestions and language editing this
manuscript. This research is supported by Massachusetts General
Hospital.
NR 49
TC 2
Z9 2
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2091
J9 BMC BIOCHEM
JI BMC Boichem.
PD DEC 11
PY 2014
VL 15
AR 26
DI 10.1186/s12858-014-0026-1
PG 22
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AW7LQ
UT WOS:000346446000002
PM 25494717
ER
PT J
AU Koven, S
AF Koven, Suzanne
TI The Disease of the Little Paper
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Koven, Suzanne] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Koven, Suzanne] Harvard Univ, Sch Med, Boston, MA USA.
RP Koven, S (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 5
TC 0
Z9 0
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 11
PY 2014
VL 371
IS 24
BP 2251
EP 2253
DI 10.1056/NEJMp1411685
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW1KQ
UT WOS:000346048800005
PM 25494267
ER
PT J
AU Trivedi, AN
Nsa, W
Hausmann, LRM
Lee, JS
Ma, A
Bratzler, DW
Mor, MK
Baus, K
Larbi, F
Fine, MJ
AF Trivedi, Amal N.
Nsa, Wato
Hausmann, Leslie R. M.
Lee, Jonathan S.
Ma, Allen
Bratzler, Dale W.
Mor, Maria K.
Baus, Kristie
Larbi, Fiona
Fine, Michael J.
TI Quality and Equity of Care in US Hospitals
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID TO-BALLOON TIME; ACUTE MYOCARDIAL-INFARCTION; HEALTH-CARE; OF-CARE;
ETHNIC DISPARITIES; RACIAL DISPARITIES; BLACK PATIENTS; PERFORMANCE;
RACE; VACCINATION
AB BACKGROUND
Nearly every U.S. hospital publicly reports its performance on quality measures for patients who are hospitalized for acute myocardial infarction, heart failure, or pneumonia. Because performance rates are not reported according to race or ethnic group, it is unclear whether improvements in equity of care have accompanied aggregate improvements in health care quality over time.
METHODS
We assessed performance rates for quality measures covering three conditions (six measures for acute myocardial infarction, four for heart failure, and seven for pneumonia). These rates, adjusted for patient-and hospital-level covariates, were compared among non-Hispanic white, non-Hispanic black, and Hispanic patients who received care between 2005 and 2010 in acute care hospitals throughout the United States.
RESULTS
Adjusted performance rates for the 17 quality measures improved by 3.4 to 57.6 percentage points between 2005 and 2010 for white, black, and Hispanic adults (P<0.001 for all comparisons). In 2005, as compared with adjusted performance rates for white patients, adjusted performance rates were more than 5 percentage points lower for black patients on 3 measures (range of differences, 12.3 to 14.2) and for Hispanic patients on 6 measures (5.6 to 14.5). Gaps decreased significantly on all 9 of these measures between 2005 and 2010, with adjusted changes for differences between white patients and black patients ranging from -8.5 to -11.8 percentage points and from -6.2 to -15.1 percentage points for differences between white patients and Hispanic patients. Decreasing differences according to race or ethnic group were attributable to more equitable care for white patients and minority patients treated in the same hospital, as well as to greater performance improvements among hospitals that disproportionately serve minority patients.
CONCLUSIONS
Improved performance on quality measures for white, black, and Hispanic adults hospitalized for acute myocardial infarction, heart failure, or pneumonia was accompanied by increased racial and ethnic equity in performance rates both within and among U.S. hospitals.
C1 [Trivedi, Amal N.] Brown Univ, Sch Publ Hlth, Providence Vet Affairs VA Med Ctr, Providence, RI 02903 USA.
[Trivedi, Amal N.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02903 USA.
[Nsa, Wato; Ma, Allen] Oklahoma Fdn Med Qual, Oklahoma City, OK USA.
[Bratzler, Dale W.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Oklahoma City, OK 73190 USA.
[Bratzler, Dale W.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK 73190 USA.
[Hausmann, Leslie R. M.; Mor, Maria K.; Fine, Michael J.] VA Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hausmann, Leslie R. M.; Lee, Jonathan S.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Baus, Kristie; Larbi, Fiona] Ctr Medicare & Medicaid Serv, Baltimore, MD USA.
RP Trivedi, AN (reprint author), Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, 121 S Main St,6th Fl, Providence, RI 02903 USA.
EM amal_trivedi@brown.edu
FU Centers for Medicare and Medicaid Services; Veterans Affairs Health
Services Research and Development Career Development Program
FX Funded by the Centers for Medicare and Medicaid Services and the
Veterans Affairs Health Services Research and Development Career
Development Program.
NR 39
TC 11
Z9 11
U1 0
U2 7
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 11
PY 2014
VL 371
IS 24
BP 2298
EP 2308
DI 10.1056/NEJMoa1405003
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW1KQ
UT WOS:000346048800010
PM 25494269
ER
PT J
AU Kraut, JA
Madias, NE
AF Kraut, Jeffrey A.
Madias, Nicolaos E.
TI DISORDERS OF FLUIDS AND ELECTROLYTES Lactic Acidosis
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID CRITICALLY-ILL PATIENTS; VENOUS OXYGEN-SATURATION; SEPTIC SHOCK;
METABOLIC-ACIDOSIS; LACTATE CLEARANCE; MICROCIRCULATORY ALTERATIONS;
SEVERE SEPSIS; ANION GAP; HOSPITAL MORTALITY; CONTROLLED-TRIAL
C1 [Kraut, Jeffrey A.] Univ Calif Los Angeles, Med Serv, Membrane Biol Lab, Los Angeles, CA USA.
[Kraut, Jeffrey A.] Univ Calif Los Angeles, Res Serv, Membrane Biol Lab, Los Angeles, CA USA.
[Kraut, Jeffrey A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Nephrol, Los Angeles, CA 90095 USA.
[Kraut, Jeffrey A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Madias, Nicolaos E.] St Elizabeths Med Ctr, Dept Med, Div Nephrol, Boston, MA USA.
[Madias, Nicolaos E.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.
RP Kraut, JA (reprint author), VHAGLA Healthcare Syst, Div Nephrol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jkraut@ucla.edu; nicolaos.madias@steward.org
NR 61
TC 61
Z9 62
U1 9
U2 34
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 11
PY 2014
VL 371
IS 24
BP 2309
EP 2319
DI 10.1056/NEJMra1309483
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW1KQ
UT WOS:000346048800011
PM 25494270
ER
PT J
AU Iyasere, CA
Simmons, LH
Fintelmann, FJ
Dighe, AS
AF Iyasere, Christiana A.
Simmons, Leigh H.
Fintelmann, Florian J.
Dighe, Anand S.
TI Case 38-2014: An 87-Year-Old Man with Sore Throat, Hoarseness, Fatigue,
and Dyspnea
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CREATINE-KINASE LEVELS; VENA-CAVA SYNDROME; SUBCLINICAL HYPOTHYROIDISM;
THYROXINE; MYOPATHY; OVERT
C1 [Iyasere, Christiana A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Simmons, Leigh H.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Fintelmann, Florian J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Dighe, Anand S.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Iyasere, Christiana A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Simmons, Leigh H.] Harvard Univ, Sch Med, Dept Internal Med, Boston, MA USA.
[Fintelmann, Florian J.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Dighe, Anand S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Iyasere, CA (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
NR 16
TC 4
Z9 4
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 11
PY 2014
VL 371
IS 24
BP 2321
EP 2327
DI 10.1056/NEJMcpc1410935
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW1KQ
UT WOS:000346048800013
PM 25494272
ER
PT J
AU Cisterna, BA
Cardozo, C
Saez, JC
AF Cisterna, Bruno A.
Cardozo, Christopher
Saez, Juan C.
TI Neuronal involvement in muscular atrophy
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE acetylcholine; hemichannels; connexins; trophic factors; electrical
activity
ID SPINAL-CORD-INJURY; CILIARY NEUROTROPHIC FACTOR; RAT SKELETAL-MUSCLE;
FUNCTIONAL ELECTRICAL-STIMULATION; CHOLINERGIC SYNAPTIC VESICLES;
RECEPTOR GENE-EXPRESSION; CONNEXIN-43 HEMICHANNELS MEDIATE; PHOSPHATE
ADENINE-NUCLEOTIDES; MYOGENIC REGULATORY FACTORS; IN-SITU HYBRIDIZATION
AB The innervation of skeletal myofibers exerts a crucial influence on the maintenance of muscle tone and normal operation. Consequently, denervated myofibers manifest atrophy, which is preceded by an increase in sarcolemma permeability. Recently, de novo expression of hemichannels (HCs) formed by connexins (Cxs) and other none selective channels, including P2X(7) receptors (P2X(7)Rs), and transient receptor potential, sub family V, member 2 (TRPV2) channels was demonstrated in denervated fast skeletal muscles. The denervation-induced atrophy was drastically reduced in denervated muscles deficient in Cxs 43 and 45. Nonetheless, the transduction mechanism by which the nerve represses the expression of the above mentioned non selective channels remains unknown. The paracrine action of extracellular signaling molecules including ATR neurotrophic factors (i.e., brain-derived neurotrophic factor (BDNF)), agrin/LDL receptor-related protein 4 (Lrp4)/muscle-specific receptor kinase (MuSK) and acetylcholine (Ach) are among the possible signals for repression for connexin expression. This review discusses the possible role of relevant factors in maintaining the normal functioning of fast skeletal muscles and suppression of connexin hemichannel expression.
C1 [Cisterna, Bruno A.; Saez, Juan C.] Pontificia Univ Catolica Chile, Dept Fisiol, Santiago 8331150, Chile.
[Cardozo, Christopher] James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY USA.
[Cardozo, Christopher] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
[Cardozo, Christopher] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA.
[Saez, Juan C.] Univ Valparaiso, Ctr Interdisciplinario Neurociencias Valparaiso, Valparaiso, Chile.
RP Cisterna, BA (reprint author), Pontificia Univ Catolica Chile, Dept Fisiol, Alameda 340, Santiago 8331150, Chile.
EM bcisterna@uc.cl
FU FONDECYT [1111033]; millennium institute; CONICYT; Department of
Veterans Affairs Rehabilitation Research and Development Service
[B9212C]; James J. Peters VA Medical Center
FX This work was partially funded by FONDECYT grants 1111033 (to Juan C.
Saez), millennium institute (to Juan C. Saez), and Bruno A. Cisterna
acknowledge the support of a CONICYT fellowship, and the Department of
Veterans Affairs Rehabilitation Research and Development Service
(B9212C) and the James J. Peters VA Medical Center.
NR 182
TC 6
Z9 6
U1 1
U2 18
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD DEC 10
PY 2014
VL 8
AR 405
DI 10.3389/fncel.2014.00405
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA AX9QE
UT WOS:000347236200001
PM 25540609
ER
PT J
AU Hayes, J
Jackson, JL
McNutt, GM
Hertz, BJ
Ryan, JJ
Pawlikowski, SA
AF Hayes, John
Jackson, Jeffrey L.
McNutt, Gail M.
Hertz, Brian J.
Ryan, Jeffrey J.
Pawlikowski, Scott A.
TI Association Between Physician Time-Unlimited vs Time-Limited Internal
Medicine Board Certification and Ambulatory Patient Care Quality
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; OF-CARE; HEALTH-CARE; PREVENTION;
METAANALYSIS; MAINTENANCE; OUTCOMES; DISEASE; SCORES
AB IMPORTANCE American Board of Internal Medicine (ABIM) initiatives encourage internists with time-unlimited certificates to recertify. However, there are limited data evaluating differences in performance between internists with time-limited or time-unlimited board certification.
OBJECTIVE To determine whether there are differences in primary care quality between physicians holding time-limited or time-unlimited certification.
DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of performance data from 1 year (2012-2013) at 4 Veterans Affairs (VA) medical centers. Participants were internists with time-limited (n = 71) or time-unlimited (n = 34) ABIM certification providing primary care to 68 213 patients. Median physician panel size was 610 patients (range, 19-1316), with no differences between groups (P = .90).
MAIN OUTCOMES AND MEASURES Ten primary care performance measures: colorectal screening rates; diabetes with glycated hemoglobin (HbA(1c) level) less than 9.0%; diabetes with blood pressure less than 140/90 mmHg; diabetes with low-density lipoprotein cholesterol (LDL-C) level less than 100 mg/dL; hypertension with blood pressure less than 140/90 mmHg; thiazide diuretics used in multidrug hypertensive regimen; atherosclerotic coronary artery disease and LDL-C level less than 100 mg/dL; post-myocardial infarction use of aspirin; post-myocardial infarction use of beta-blockers; congestive heart failure (CHF) with use of angiotensin-converting enzyme (ACE) inhibitor.
RESULTS After adjustment for practice site, panel size, years since certification, and clustering by physician, there were no differences in outcomes for patients cared for by internists with time-limited or time-unlimited certification for any performance measure: colorectal screening (odds ratio [OR], 0.95 [95% CI, 0.89-1.01]); diabetes with HbA1c level less than 9.0% (OR, 0.96 [95% CI, 0.74-1.2]); blood pressure control (OR, 0.99 [95% CI, 0.69-1.4]); LDL-C level less than 100 mg/dL (OR, 1.1 [95% CI, 0.79-1.5]); hypertension with blood pressure less than 140/90 mmHg (OR, 1.0 [95% CI, 0.92-1.2]); thiazide use (OR, 1.0 [95% CI, 0.8-1.3]); atherosclerotic coronary artery disease with LDL-C level less than 100 mg/dL (OR, 1.1 [95% CI, 0.75-1.7]); post-myocardial infarction use of aspirin (OR, 0.98 [95% CI, 0.58-1.68]) or beta-blockers (OR, 1.0 [95% CI, 0.57-1.9]); CHF with use of ACE inhibitor (OR, 0.98 [95% CI, 0.61-1.6]).
CONCLUSIONS AND RELEVANCE Among internists providing primary care at 4 VA medical centers, there were no significant differences between those with time-limited ABIM certification and those with time-unlimited ABIM certification on 10 primary care performance measures. Additional research to examine the difference in patient outcomes among holders of time-limited and time-unlimited certificates in non-VA and nonacademic settings and the association with other ABIM goals may help clarify the potential benefit of Maintenance of Certification participation. Copyright 2014 American Medical Association. All rights reserved.
C1 [Hayes, John] Clement J Zablocki VA Med Ctr, Milwaukee, WI 53295 USA.
[Jackson, Jeffrey L.] Clement J Zablocki VA Med Ctr, GIM Sect, Milwaukee, WI 53295 USA.
[McNutt, Gail M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Hertz, Brian J.; Pawlikowski, Scott A.] Hines VA Med Ctr, Chicago, IL USA.
[Ryan, Jeffrey J.] Jesse Brown VA Med Ctr, Chicago, IL USA.
RP Hayes, J (reprint author), Clement J Zablocki VA Med Ctr, 5000 W Natl Ave, Milwaukee, WI 53295 USA.
EM john.hayes3@va.gov
NR 28
TC 13
Z9 13
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 10
PY 2014
VL 312
IS 22
BP 2358
EP 2363
DI 10.1001/jama.2014.13992
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW5YB
UT WOS:000346345700010
PM 25490326
ER
PT J
AU Patel, MS
Volpp, KG
Small, DS
Hill, AS
Even-Shoshan, O
Rosenbaum, L
Ross, RN
Bellini, L
Zhu, JS
Silber, JH
AF Patel, Mitesh S.
Volpp, Kevin G.
Small, Dylan S.
Hill, Alexander S.
Even-Shoshan, Orit
Rosenbaum, Lisa
Ross, Richard N.
Bellini, Lisa
Zhu, Jingsan
Silber, Jeffrey H.
TI Association of the 2011 ACGME Resident Duty Hour Reforms With Mortality
and Readmissions Among Hospitalized Medicare Patients
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; ADMINISTRATIVE DATA;
COMORBIDITY MEASURES; INTERNAL-MEDICINE; BENEFICIARIES; ICD-9-CM;
CONSEQUENCES; INFORMATION; EDUCATION
AB IMPORTANCE Patient outcomes associated with the 2011 Accreditation Council for Graduate Medical Education (ACGME) duty hour reforms have not been evaluated at a national level.
OBJECTIVE To evaluate the association of the 2011 ACGME duty hour reforms with mortality and readmissions.
DESIGN, SETTING, AND PARTICIPANTS Observational study of Medicare patient admissions (6 384 273 admissions from 2 790 356 patients) to short-term, acute care, nonfederal hospitals (n = 3104) with principal medical diagnoses of acute myocardial infarction, stroke, gastrointestinal bleeding, or congestive heart failure or a Diagnosis Related Group classification of general, orthopedic, or vascular surgery. Of the hospitals, 96 (3.1%) were very major teaching, 138 (4.4%) major teaching, 442 (14.2%) minor teaching, 443 (14.3%) very minor teaching, and 1985 (64.0%) nonteaching.
EXPOSURE Resident-to-bed ratio as a continuous measure of hospital teaching intensity.
MAIN OUTCOMES AND MEASURES Change in 30-day all-location mortality and 30-day all-cause readmission, comparing patients in more intensive relative to less intensive teaching hospitals before (July 1, 2009-June 30, 2011) and after (July 1, 2011-June 30, 2012) duty hour reforms, adjusting for patient comorbidities, time trends, and hospital site.
RESULTS In the 2 years before duty hour reforms, there were 4 325 854 admissions with 288 422 deaths and 602 380 readmissions. In the first year after the reforms, accounting for teaching hospital intensity, there were 2 058 419 admissions with 133 547 deaths and 272 938 readmissions. There were no significant postreform differences in mortality accounting for teaching hospital intensity for combined medical conditions (odds ratio [OR], 1.00; 95% CI, 0.96-1.03), combined surgical categories (OR, 0.99; 95% CI, 0.94-1.04), or any of the individual medical conditions or surgical categories. There were no significant postreform differences in readmissions for combined medical conditions (OR, 1.00; 95% CI, 0.97-1.02) or combined surgical categories (OR, 1.00; 95% CI, 0.98-1.03). For the medical condition of stroke, there were higher odds of readmissions in the postreform period (OR, 1.06; 95% CI, 1.001-1.13). However, this finding was not supported by sensitivity analyses and there were no significant postreform differences for readmissions for any other individual medical condition or surgical category.
CONCLUSIONS AND RELEVANCE Among Medicare beneficiaries, there were no significant differences in the change in 30-day mortality rates or 30-day all-cause readmission rates for those hospitalized in more intensive relative to less intensive teaching hospitals in the year after implementation of the 2011 ACGME duty hour reforms compared with those hospitalized in the 2 years before implementation. Copyright 2014 American Medical Association. All rights reserved.
C1 [Patel, Mitesh S.; Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Patel, Mitesh S.; Volpp, Kevin G.; Bellini, Lisa; Zhu, Jingsan] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Patel, Mitesh S.; Volpp, Kevin G.; Silber, Jeffrey H.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Patel, Mitesh S.; Volpp, Kevin G.; Small, Dylan S.; Zhu, Jingsan] Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
[Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA.
[Hill, Alexander S.; Even-Shoshan, Orit; Ross, Richard N.; Silber, Jeffrey H.] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA.
[Even-Shoshan, Orit; Silber, Jeffrey H.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Rosenbaum, Lisa] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Silber, Jeffrey H.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
RP Patel, MS (reprint author), Univ Penn, 423 Guardian Dr,12th Floor,Blockley Hall, Philadelphia, PA 19104 USA.
EM mpatel@upenn.edu
FU National Heart, Lung, and Blood Institute [RO1-HLO94593]; Department of
Veteran Affairs; Robert Wood Johnson Foundation
FX This project was funded in part through National Heart, Lung, and Blood
Institute grant RO1-HLO94593. Dr Patel was supported by the Department
of Veteran Affairs and the Robert Wood Johnson Foundation.
NR 46
TC 29
Z9 29
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 10
PY 2014
VL 312
IS 22
BP 2364
EP 2373
DI 10.1001/jama.2014.15273
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW5YB
UT WOS:000346345700011
PM 25490327
ER
PT J
AU Rajaram, R
Chung, JW
Jones, AT
Cohen, ME
Dahlke, AR
Ko, CY
Tarpley, JL
Lewis, FR
Hoyt, DB
Bilimoria, KY
AF Rajaram, Ravi
Chung, Jeanette W.
Jones, Andrew T.
Cohen, Mark E.
Dahlke, Allison R.
Ko, Clifford Y.
Tarpley, John L.
Lewis, Frank R.
Hoyt, David B.
Bilimoria, Karl Y.
TI Association of the 2011 ACGME Resident Duty Hour Reform With General
Surgery Patient Outcomes and With Resident Examination Performance
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID SURGICAL QUALITY; WORK HOURS; RESTRICTIONS; MORTALITY; EDUCATION;
INTERNS; CARE; REGULATIONS; MEDICINE; FAILURES
AB IMPORTANCE In 2011, the Accreditation Council for Graduate Medical Education (ACGME) restricted resident duty hour requirements beyond those established in 2003, leading to concerns about the effects on patient care and resident training.
OBJECTIVE To determine if the 2011 ACGME duty hour reform was associated with a change in general surgery patient outcomes or in resident examination performance.
DESIGN, SETTING, AND PARTICIPANTS Quasi-experimental study of general surgery patient outcomes 2 years before (academic years 2009-2010) and after (academic years 2012-2013) the 2011 duty hour reform. Teaching and nonteaching hospitals were compared using a difference-in-differences approach adjusted for procedural mix, patient comorbidities, and time trends. Teaching hospitals were defined based on the proportion of cases at which residents were present intraoperatively. Patients were those undergoing surgery at hospitals participating in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). General surgery resident performance on the annual in-training, written board, and oral board examinations was assessed for this same period.
EXPOSURES National implementation of revised resident duty hour requirements on July 1, 2011, in all ACGME accredited residency programs.
MAIN OUTCOMES AND MEASURES Primary outcome was a composite of death or serious morbidity; secondary outcomes were other postoperative complications and resident examination performance.
RESULTS In the main analysis, 204 641 patients were identified from 23 teaching (n = 102 525) and 31 nonteaching (n = 102 116) hospitals. The unadjusted rate of death or serious morbidity improved during the study period in both teaching (11.6%[95% CI, 11.3%-12.0%] to 9.4%[95% CI, 9.1%-9.8%], P < .001) and nonteaching hospitals (8.7%[95% CI, 8.3%-9.0%] to 7.1% [95% CI, 6.8%-7.5%], P < .001). In adjusted analyses, the 2011 ACGME duty hour reform was not associated with a significant change in death or serious morbidity in either postreform year 1 (OR, 1.12; 95% CI, 0.98-1.28) or postreform year 2 (OR, 1.00; 95% CI, 0.86-1.17) or when both postreform years were combined (OR, 1.06; 95% CI, 0.93-1.20). There was no association between duty hour reform and any other postoperative adverse outcome. Mean (SD) in-training examination scores did not significantly change from 2010 to 2013 for first-year residents (499.7 [85.2] to 500.5 [84.2], P = .99), for residents from other postgraduate years, or for first-time examinees taking the written or oral board examinations during this period.
CONCLUSIONS AND RELEVANCE Implementation of the 2011 ACGME duty hour reform was not associated with a change in general surgery patient outcomes or differences in resident examination performance. The implications of these findings should be considered when evaluating the merit of the 2011 ACGME duty hour reform and revising related policies in the future. Copyright 2014 American Medical Association. All rights reserved.
C1 [Rajaram, Ravi; Cohen, Mark E.; Ko, Clifford Y.; Hoyt, David B.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Rajaram, Ravi; Chung, Jeanette W.; Dahlke, Allison R.; Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, SOQIC, Chicago, IL 60611 USA.
[Rajaram, Ravi; Chung, Jeanette W.; Dahlke, Allison R.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, Chicago, IL 60611 USA.
[Jones, Andrew T.; Lewis, Frank R.] Amer Board Surg, Philadelphia, PA USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Tarpley, John L.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN USA.
RP Bilimoria, KY (reprint author), Northwestern Univ, Dept Surg, SOQIC, 633 N St Clair St,20th Floor, Chicago, IL 60611 USA.
EM k-bilimoria@northwestern.edu
FU Agency for Healthcare Research and Quality [T32HS000078]; American
College of Surgeons Clinical Scholars in Residence Program; Merck
FX Dr Rajaramis supported by grant T32HS000078 from the Agency for
Healthcare Research and Quality, the American College of Surgeons
Clinical Scholars in Residence Program, and an unrestricted educational
grant from Merck.
NR 38
TC 40
Z9 40
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 10
PY 2014
VL 312
IS 22
BP 2374
EP 2384
DI 10.1001/jama.2014.15277
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW5YB
UT WOS:000346345700012
PM 25490328
ER
PT J
AU Wayne, PM
Gow, BJ
Costa, MD
Peng, CK
Lipsitz, LA
Hausdorff, JM
Davis, RB
Walsh, JN
Lough, M
Novak, V
Yeh, GY
Ahn, AC
Macklin, EA
Manor, B
AF Wayne, Peter M.
Gow, Brian J.
Costa, Madalena D.
Peng, C. -K.
Lipsitz, Lewis A.
Hausdorff, Jeffrey M.
Davis, Roger B.
Walsh, Jacquelyn N.
Lough, Matthew
Novak, Vera
Yeh, Gloria Y.
Ahn, Andrew C.
Macklin, Eric A.
Manor, Brad
TI Complexity-Based Measures Inform Effects of Tai Chi Training on Standing
Postural Control: Cross-Sectional and Randomized Trial Studies
SO PLOS ONE
LA English
DT Article
ID OLDER-ADULTS; BALANCE CONTROL; PHYSIOLOGICAL COMPLEXITY; CEREBRAL
CONCUSSION; CHALLENGES INHERENT; MULTISCALE ENTROPY; STABILITY LIMITS;
OPEN-LOOP; FALLS; EXERCISE
AB Background: Diminished control of standing balance, traditionally indicated by greater postural sway magnitude and speed, is associated with falls in older adults. Tai Chi (TC) is a multisystem intervention that reduces fall risk, yet its impact on sway measures vary considerably. We hypothesized that TC improves the integrated function of multiple control systems influencing balance, quantifiable by the multi-scale "complexity'' of postural sway fluctuations.
Objectives: To evaluate both traditional and complexity-based measures of sway to characterize the short- and potential long-term effects of TC training on postural control and the relationships between sway measures and physical function in healthy older adults.
Methods: A cross-sectional comparison of standing postural sway in healthy TC-nalve and TC-expert (24.5 +/- 12 yrs experience) adults. TC-nalve participants then completed a 6-month, two-arm, wait-list randomized clinical trial of TC training.Postural sway was assessed before and after the training during standing on a force-plate with eyes-open (EO) and eyes-closed (EC). Anterior-posterior (AP) and medio-lateral (ML) sway speed, magnitude, and complexity (quantified by multiscale entropy) were calculated. Single- legged standing time and Timed-Up-and- Go tests characterized physical function.
Results: At baseline, compared to TC-nalve adults (n=60, age 64.5 +/- 7.5 yrs), TC-experts (n=27, age 62.8 +/- 7.5 yrs) exhibited greater complexity of sway in the AP EC (P=0.023), ML EO (P, 0.001), and ML EC (P, 0.001) conditions. Traditional measures of sway speed and magnitude were not significantly lower among TC-experts. Intention-to-treat analyses indicated no significant effects of short-term TC training; however, increases in AP EC and ML EC complexity amongst those randomized to TC were positively correlated with practice hours (P=0.044, P=0.018). Long- and short-term TC training were positively associated with physical function.
Conclusion: Multiscale entropy offers a complementary approach to traditional COP measures for characterizing sway during quiet standing, and may be more sensitive to the effects of TC in healthy adults.
C1 [Wayne, Peter M.; Gow, Brian J.; Walsh, Jacquelyn N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Osher Ctr Integrat Med, Boston, MA 02115 USA.
[Costa, Madalena D.; Peng, C. -K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Interdisciplinary Med & Biotechnol, Boston, MA 02115 USA.
[Costa, Madalena D.; Peng, C. -K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Margret & HA Rey Inst Nonlinear Dynam Med, Boston, MA 02115 USA.
[Peng, C. -K.] Natl Cent Univ, Ctr Dynam Biomarkers & Translat Med, Chungli 32054, Taiwan.
[Lipsitz, Lewis A.; Novak, Vera; Manor, Brad] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gerontol, Boston, MA 02115 USA.
[Lipsitz, Lewis A.; Lough, Matthew] Hebrew SeniorLife, Inst Aging Res, Roslindale, MA USA.
[Hausdorff, Jeffrey M.] Tel Aviv Med Ctr & Sch Med, Dept Neurol, Movement Disorders Unit, Tel Aviv, Israel.
[Hausdorff, Jeffrey M.] Tel Aviv Univ, Dept Phys Therapy, IL-69978 Tel Aviv, Israel.
[Hausdorff, Jeffrey M.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.
[Davis, Roger B.; Yeh, Gloria Y.; Ahn, Andrew C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gen Med & Primary Care, Boston, MA 02115 USA.
[Novak, Vera] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Ahn, Andrew C.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Macklin, Eric A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Biostat, Boston, MA 02115 USA.
RP Wayne, PM (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Osher Ctr Integrat Med, Boston, MA 02115 USA.
EM pwayne@partners.org
FU National Center for Complementary and Alternative Medicine (NCCAM) at
the National Institutes of Health (NIH) [R21 AT005501-01A1]; Harvard
Clinical and Translational Science Center, from the National Center for
Research Resourses (NCRR) [UL1 RR025758]; National Institute on Aging
(NIA) [R37-AG25037]; NIH-National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) [5R21-DK-084463-02]; National Institutes of
Health (NIH)-National Institute on Aging (NIA) [1R01-AG-0287601-A2];
Harvard Catalyst \ The Harvard Clinical and Translational Science Center
(National Center for Research Resources); Harvard Catalyst \ The Harvard
Clinical and Translational Science Center (National Center for Advancing
Translational Sciences); Harvard Catalyst \ The Harvard Clinical and
Translational Science Center (National Institutes of Health Award)
[8UL1TR000170-05]; Harvard Catalyst \ The Harvard Clinical and
Translational Science Center (Harvard University); Irving and Edyth S.
Usen and Family Chair in Geriatric Medicine at Hebrew SeniorLife
FX This publication was made possible by grant number R21 AT005501-01A1
from the National Center for Complementary and Alternative Medicine
(NCCAM: http://nccam.nih.gov/) at the National Institutes of Health
(NIH: http://www.nih.gov/), and from grant number UL1 RR025758
supporting the Harvard Clinical and Translational Science Center, from
the National Center for Research Resourses (NCRR:
http://www.nih.gov/about/almanac/organization/NCRR.htm). Its contents
are solely the responsibility of the authors and do not necessarily
represent the official views of the NCCAM, NCRR, or the NIH. Dr. Lipsitz
was supported by grant R37-AG25037 from the National Institute on Aging
(NIA: http://www.nia. nih.gov/) and the Irving and Edyth S. Usen and
Family Chair in Geriatric Medicine at Hebrew SeniorLife. Dr. Novak has
received grants from the NIH-National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK: http://www.niddk.nih. gov/)
(5R21-DK-084463-02) and the National Institutes of Health (NIH)-National
Institute on Aging (NIA: http://www.nia.nih.gov/) (1R01-AG-0287601-A2)
unrelated to this study. The work in the SAFE lab was conducted with
support from Harvard Catalyst (http://catalyst.harvard.edu/) vertical
bar The Harvard Clinical and Translational Science Center (National
Center for Research Resources and the National Center for Advancing
Translational Sciences, National Institutes of Health Award
8UL1TR000170-05 and financial contributions from Harvard University and
its affiliated academic health care centers). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of Harvard Catalyst, Harvard University and its
affiliated academic health care centers, or the National Institutes of
Health. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 72
TC 10
Z9 10
U1 3
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 10
PY 2014
VL 9
IS 12
AR e114731
DI 10.1371/journal.pone.0114731
PG 28
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW9YP
UT WOS:000346611400072
PM 25494333
ER
PT J
AU Liu, Y
Asnani, A
Zou, L
Bentley, VL
Yu, M
Wang, Y
Dellaire, G
Sarkar, KS
Dai, M
Chen, HH
Sosnovik, DE
Shin, JT
Haber, DA
Berman, JN
Chao, W
Peterson, RT
AF Liu, Yan
Asnani, Aarti
Zou, Lin
Bentley, Victoria L.
Yu, Min
Wang, You
Dellaire, Graham
Sarkar, Kumar S.
Dai, Matthew
Chen, Howard H.
Sosnovik, David E.
Shin, Jordan T.
Haber, Daniel A.
Berman, Jason N.
Chao, Wei
Peterson, Randall T.
TI Visnagin protects against doxorubicin-induced cardiomyopathy through
modulation of mitochondrial malate dehydrogenase
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID IN-VIVO; ZEBRAFISH; CANCER; CARDIOTOXICITY; CELLS; DEXRAZOXANE;
CARDIOPROTECTION; INHIBITION; HEART; CONTRACTILITY
AB Doxorubicin is a highly effective anticancer chemotherapy agent, but its use is limited by its cardiotoxicity. To develop a drug that prevents this toxicity, we established a doxorubicin-induced cardiomyopathy model in zebrafish that recapitulates the cardiomyocyte apoptosis and contractility decline observed in patients. Using this model, we screened 3000 compounds and found that visnagin (VIS) and diphenylurea (DPU) rescue the cardiac performance and circulatory defects caused by doxorubicin in zebrafish. VIS and DPU reduced doxorubicin-induced apoptosis in cultured cardiomyocytes and in vivo in zebrafish and mouse hearts. VIS treatment improved cardiac contractility in doxorubicin-treated mice. Further, VIS and DPU did not reduce the chemotherapeutic efficacy of doxorubicin in several cultured tumor lines or in zebrafish and mouse xenograft models. Using affinity chromatography, we found that VIS binds to mitochondrial malate dehydrogenase (MDH2), a key enzyme in the tricarboxylic acid cycle. As with VIS, treatment with the MDH2 inhibitors mebendazole, thyroxine, and iodine prevented doxorubicin cardiotoxicity, as did treatment with malate itself, suggesting that modulation of MDH2 activity is responsible for VIS' cardioprotective effects. Thus, VIS and DPU are potent cardioprotective compounds, and MDH2 is a previously undescribed, druggable target for doxorubicin-induced cardiomyopathy.
C1 [Liu, Yan; Asnani, Aarti; Wang, You; Sarkar, Kumar S.; Dai, Matthew; Chen, Howard H.; Sosnovik, David E.; Shin, Jordan T.; Peterson, Randall T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
[Liu, Yan; Asnani, Aarti; Zou, Lin; Yu, Min; Wang, You; Sarkar, Kumar S.; Dai, Matthew; Chen, Howard H.; Sosnovik, David E.; Shin, Jordan T.; Haber, Daniel A.; Chao, Wei; Peterson, Randall T.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Liu, Yan; Asnani, Aarti; Wang, You; Sarkar, Kumar S.; Peterson, Randall T.] Broad Inst, Cambridge, MA 02142 USA.
[Zou, Lin; Chao, Wei] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA.
[Bentley, Victoria L.; Dellaire, Graham] Dalhousie Univ, Dept Pathol, Halifax, NS B3H 4R2, Canada.
[Yu, Min; Haber, Daniel A.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
[Dellaire, Graham] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4R2, Canada.
[Chen, Howard H.; Sosnovik, David E.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Haber, Daniel A.] Dalhousie Univ, Howard Hughes Med Inst, Halifax, NS B3H 4R2, Canada.
[Berman, Jason N.] Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4R2, Canada.
[Berman, Jason N.] Izaak Walton Killam Hlth Ctr, Dept Pediat, Halifax, NS B3K 6R8, Canada.
RP Peterson, RT (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
EM rtpeterson@mgh.harvard.edu
OI Dellaire, Graham/0000-0002-3466-6316
FU National Heart, Lung, and Blood Institute [T32HL007208]; John S. LaDue
Memorial Fellowship; American Heart Association [IRG14600006]; Charles
and Ann Sanders MGH Research Scholar Award; Howard Hughes Medical
Institute; Beatrice Hunter Cancer Research Institute; Canadian Imperial
Bank of Commerce; Nova Scotia Health Research Foundation; Natural
Sciences and Engineering Research Council Collaborative Health Research
Project; CIHR; Cancer Care Nova Scotia, The Terry Fox Strategic Health
Research Training Program in Cancer Research at Canadian Institutes of
Health Research (CIHR)
FX Y.L. and A.A. are supported by training grant T32HL007208 from the
National Heart, Lung, and Blood Institute. A.A. is supported by a John
S. LaDue Memorial Fellowship. This work was supported by an Innovative
Research Grant from the American Heart Association (IRG14600006 to
R.T.P.) and by the Charles and Ann Sanders MGH Research Scholar Award
(to R.T.P.). D.A.H. and M.Y. are supported by the Howard Hughes Medical
Institute. V.L.B. is supported by a trainee award from the Beatrice
Hunter Cancer Research Institute, with funds provided by the Canadian
Imperial Bank of Commerce and Cancer Care Nova Scotia as part of The
Terry Fox Strategic Health Research Training Program in Cancer Research
at Canadian Institutes of Health Research (CIHR), and a trainee award
from the Nova Scotia Health Research Foundation. Zebrafish xenograft
studies were funded by a CIHR and Natural Sciences and Engineering
Research Council Collaborative Health Research Project awarded to G.D.
and J.N.B.
NR 43
TC 11
Z9 11
U1 0
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD DEC 10
PY 2014
VL 6
IS 266
AR 266ra170
DI 10.1126/scitranslmed.3010189
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA AW3NJ
UT WOS:000346193300002
PM 25504881
ER
PT J
AU Greenfield, E
Griner, E
AF Greenfield, Edward
Griner, Erin
CA Reproducibility Project Canc Biol
TI Registered report: Widespread potential for growth factor-driven
resistance to anticancer kinase inhibitors
SO ELIFE
LA English
DT Article
ID LUNG-CANCER; M14 MELANOMA; CELL-LINES; MDA-MB-435; EGFR; RAF; MET
AB The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of 50 papers in the field of cancer biology published between 2010 and 2012. This Registered Report describes the proposed replication plan of key experiments from 'Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors' by Wilson and colleagues, published in Nature in 2012 (Wilson et al., 2012). The experiments that will be replicated are those reported in Figure 2B and C. In these experiments, Wilson and colleagues show that sensitivity to receptor tyrosine kinase (RTK) inhibitors can be bypassed by various ligands through reactivation of downstream signaling pathways (Figure 2A; Wilson et al., 2012), and that blocking the receptors for these bypassing ligands abrogates their ability to block sensitivity to the original RTK inhibitor (Figure 2C; Wilson et al., 2012). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by eLife.
C1 [Greenfield, Edward] Dana Farber Canc Inst, Monoclonal Antibody Core Facil, Boston, MA 02115 USA.
[Griner, Erin] Univ Virginia, Charlottesville, VA USA.
RP Greenfield, E (reprint author), Dana Farber Canc Inst, Monoclonal Antibody Core Facil, Boston, MA 02115 USA.
OI Errington, Timothy/0000-0002-4959-5143
FU Laura and John Arnold Foundation; American Type Culture Collection
(ATCC)
FX Laura and John Arnold Foundation Reproducibility Project: Cancer
Biology; American Type Culture Collection (ATCC) Reproducibility
Project: Cancer Biology; The Reproducibility Project: Cancer Biology is
funded by the Laura and John Arnold Foundation, provided to the Center
for Open Science in collaboration with Science Exchange. The funders had
no role in study design or the decision to submit the work for
publication.
NR 23
TC 0
Z9 0
U1 1
U2 3
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD DEC 10
PY 2014
VL 3
AR e04037
DI 10.7554/eLife.04037
PG 17
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA AW3FD
UT WOS:000346170600005
ER
PT J
AU Beerman, I
Rossi, DJ
AF Beerman, Isabel
Rossi, Derrick J.
TI Epigenetic regulation of hematopoietic stem cell aging
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Review
DE Aging; HSC; Hematopoietic stem cells; Epigenetics; Methylation; miRNA
ID ACUTE MYELOID-LEUKEMIA; SELF-RENEWAL CAPACITY; DNA METHYLATION DYNAMICS;
LONG NONCODING RNAS; MYELODYSPLASTIC SYNDROMES; TUMOR-SUPPRESSOR;
PROGENITOR CELLS; HISTONE MODIFICATIONS; IN-VIVO; DIFFERENTIATION
AB Aging is invariably associated with alterations of the hematopoietic stem cell (HSC) compartment, including loss of functional capacity, altered clonal composition, and changes in lineage contribution. Although accumulation of DNA damage occurs during HSC aging, it is unlikely such consistent aging phenotypes could be solely attributed to changes in DNA integrity. Another mechanism by which heritable traits could contribute to the changes in the functional potential of aged HSCs is through alterations in the epigenetic landscape of adult stem cells. Indeed, recent studies on hematopoietic stem cells have suggested that altered epigenetic profiles are associated with HSC aging and play a key role in modulating the functional potential of HSCs at different stages during ontogeny. Even small changes of the epigenetic landscape can lead to robustly altered expression patterns, either directly by loss of regulatory control or through indirect, additive effects, ultimately leading to transcriptional changes of the stem cells. Potential drivers of such changes in the epigenetic landscape of aged HSCs include proliferative history, DNA damage, and deregulation of key epigenetic enzymes and complexes. This review will focus largely on the two most characterized epigenetic marks - DNA methylation and histone modifications - but will also discuss the potential role of non-coding RNAs in regulating HSC function during aging. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Beerman, Isabel; Rossi, Derrick J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Beerman, Isabel; Rossi, Derrick J.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Beerman, Isabel; Rossi, Derrick J.] Boston Childrens Hosp, Div Hematol Oncol, Program Cellular & Mol Med, Boston, MA 02116 USA.
RP Beerman, I (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM isabel.beerman@childrens.harvard.edu
FU National Institutes of Health [RO1HL107630, R00AG029760,
UO1DK072473-01]; Leona M. and Harry B. Helmsley Charitable Trust
[2012PG-T1D007]; New York Stem Cell Foundation [RI04]; Harvard Stem Cell
Institute [DP-0132-13-01]; Joint Program in Transfusion Medicine
fellowship [5T32HL066987-12]
FX Special thanks to Morag Stewart, Paula Gutierrez-Martinez, Wataru Ebina,
and Brian Garrison for their thoughtful comments and conversation about
this manuscript. Our research is supported by grants from the National
Institutes of Health (RO1HL107630, R00AG029760, and UO1DK072473-01) as
well as grants from The Leona M. and Harry B. Helmsley Charitable Trust
(2012PG-T1D007), The New York Stem Cell Foundation (RI04), and The
Harvard Stem Cell Institute (DP-0132-13-01). IB also received funding
from a Joint Program in Transfusion Medicine fellowship
(5T32HL066987-12). DJR is New York Stem Cell Foundation, Robertson
Investigator.
NR 117
TC 11
Z9 11
U1 1
U2 31
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD DEC 10
PY 2014
VL 329
IS 2
BP 192
EP 199
DI 10.1016/j.yexcr.2014.09.013
PG 8
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AW2JH
UT WOS:000346113400002
PM 25261778
ER
PT J
AU Blayney, DW
McNiff, K
Eisenberg, PD
Gilmore, T
Jacobsen, PB
Jacobson, JO
Kadlubek, PJ
Neuss, MN
Simone, J
AF Blayney, Douglas W.
McNiff, Kristen
Eisenberg, Peter D.
Gilmore, Terry
Jacobsen, Paul B.
Jacobson, Joseph O.
Kadlubek, Pamela J.
Neuss, Michael N.
Simone, Joseph
TI Development and Future of the American Society of Clinical Oncology's
Quality Oncology Practice Initiative
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID TOP 5 LIST; CANCER CARE; UNITED-STATES; IMPROVEMENT
C1 [Blayney, Douglas W.] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
[McNiff, Kristen; Gilmore, Terry; Kadlubek, Pamela J.] Amer Soc Clin Oncol, Alexandria, VA USA.
[Eisenberg, Peter D.] Marin Specialty Care, Greenbrae, CA USA.
[Jacobsen, Paul B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Jacobson, Joseph O.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Simone, Joseph] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN 37235 USA.
Simone Consulting, Dunwoody, GA USA.
RP Blayney, DW (reprint author), Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
NR 31
TC 5
Z9 5
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 10
PY 2014
VL 32
IS 35
BP 3907
EP 3913
DI 10.1200/JCO.2014.56.8899
PG 7
WC Oncology
SC Oncology
GA AU9IK
UT WOS:000345905100002
PM 25225418
ER
PT J
AU Tevaarwerk, AJ
Wang, ML
Zhao, FM
Fetting, JH
Cella, D
Wagner, LI
Martino, S
Ingle, JN
Sparano, JA
Solin, LJ
Wood, WC
Robert, NJ
AF Tevaarwerk, Amye J.
Wang, Molin
Zhao, Fengmin
Fetting, John H.
Cella, David
Wagner, Lynne I.
Martino, Silvana
Ingle, James N.
Sparano, Joseph A.
Solin, Lawrence J.
Wood, William C.
Robert, Nicholas J.
TI Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function
Suppression in Premenopausal Women With Node-Negative, Hormone
Receptor-Positive Breast Cancer (E-3193, INT-0142): A Trial of the
Eastern Cooperative Oncology Group
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; RANDOMIZED-TRIAL; ADJUVANT TREATMENT;
RESEARCH-ASSOCIATION; LEUPRORELIN ACETATE; CMF CHEMOTHERAPY; ZOLEDRONIC
ACID; FOLLOW-UP; GOSERELIN; CYCLOPHOSPHAMIDE
AB Purpose
The effects of ovarian function suppression (OFS) on survival and patient-reported outcomes were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen with or without OFS.
Patients and Methods
Premenopausal women with axillary node-negative, hormone receptor-positive breast cancer tumors measuring <= 3 cm were randomly assigned to tamoxifen alone versus tamoxifen plus OFS; adjuvant chemotherapy was not permitted. Primary end points were disease-free survival (DFS) and overall survival (OS). Secondary end points included toxicity and patient-reported outcomes. Patient-reported outcome data included health-related quality of life, menopausal symptoms, and sexual function. These were evaluated at baseline, 6 months, 12 months, and then annually for up to 5 years after registration.
Results
In all, 345 premenopausal women were enrolled: 171 on tamoxifen alone and 174 on tamoxifen plus OFS. With a median follow-up of 9.9 years, there was no significant difference between arms for DFS (5-year rate: 87.9% v 89.7%; log-rank P = .62) or OS (5-year rate: 95.2% v 97.6%; log-rank P = .67). Grade 3 or higher toxicity was more common in the tamoxifen plus OFS arm (22.4% v 12.3%; P = .004). Patients treated with tamoxifen plus OFS had more menopausal symptoms, lower sexual activity, and inferior health-related quality of life at 3-year follow-up (P < .01 for all). Differences diminished with further follow-up.
Conclusion
When added to tamoxifen, OFS results in more menopausal symptoms and sexual dysfunction, which contributes to inferior self-reported health-related quality of life. Because of early closure, this study is underpowered for drawing conclusions about the impact on survival when adding OFS to tamoxifen. (C) 2014 by American Society of Clinical Oncology
C1 [Tevaarwerk, Amye J.] Univ Wisconsin, Madison, WI 53705 USA.
[Wang, Molin] Harvard Univ, Cambridge, MA 02138 USA.
[Zhao, Fengmin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fetting, John H.] Johns Hopkins Univ, Baltimore, MD USA.
[Cella, David; Wagner, Lynne I.] Northwestern Univ, Chicago, IL 60611 USA.
[Martino, Silvana] Angeles Clin & Res Inst, Santa Monica, CA USA.
[Ingle, James N.] Mayo Clin, Rochester, MN USA.
[Sparano, Joseph A.] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Solin, Lawrence J.] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA.
[Wood, William C.] Emory Univ, Atlanta, GA 30322 USA.
[Robert, Nicholas J.] Virginia Canc Specialists, Fairfax, VA USA.
RP Tevaarwerk, AJ (reprint author), Univ Wisconsin, 1111 Highland Ave,WIMR 6037, Madison, WI 53705 USA.
EM at4@medicine.wisc.edu
FU National Cancer Institute, National Institutes of Health (NIH),
Department of Health and Human Services [CA23318, CA66636, CA21115,
CA21076, CA16116, CA17145, CA14958, CA32102, CA25224]; Clinical and
Translational Science Award program through the NIH National Center for
Advancing Translational Sciences [UL1TR000427]
FX Supported in part by Public Health Service Grants No. CA23318, CA66636,
CA21115, CA21076, CA16116, CA17145, CA14958, CA32102, and CA25224 from
the National Cancer Institute, National Institutes of Health (NIH),
Department of Health and Human Services, and by Grant No. UL1TR000427
from the Clinical and Translational Science Award program through the
NIH National Center for Advancing Translational Sciences (A.J.T.).
NR 40
TC 31
Z9 34
U1 1
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 10
PY 2014
VL 32
IS 35
BP 3948
EP U237
DI 10.1200/JCO.2014.55.6993
PG 15
WC Oncology
SC Oncology
GA AU9IK
UT WOS:000345905100010
PM 25349302
ER
PT J
AU Burstein, HJ
Cirrincione, CT
Barry, WT
Chew, HK
Tolaney, SM
Lake, DE
Ma, C
Blackwell, KL
Winer, EP
Hudis, CA
AF Burstein, Harold J.
Cirrincione, Constance T.
Barry, William T.
Chew, Helen K.
Tolaney, Sara M.
Lake, Diana E.
Ma, Cynthia
Blackwell, Kimberly L.
Winer, Eric P.
Hudis, Clifford A.
TI Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor
Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized,
Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or
Without Lapatinib for Postmenopausal Women With Hormone
Receptor-Positive Advanced Breast Cancer-CALGB 40302 (Alliance)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ESTROGEN-RECEPTOR; TYROSINE KINASES; MCF-7 CELLS; TAMOXIFEN; RESISTANCE;
ANASTROZOLE; PATHWAYS; REGIMENS; GW572016; SAFETY
AB Purpose
CALGB 40302 sought to determine whether lapatinib would improve progression-free survival (PFS) among women with hormone receptor-positive metastatic breast cancer treated with fulvestrant.
Patients and Methods
Eligible women had estrogen receptor-positive and/or progesterone receptor-positive tumors, regardless of human epidermal growth factor receptor 2 (HER2) status, and prior aromatase inhibitor treatment. Patients received fulvestrant 500 mg intramuscularly on day 1, followed by 250 mg on days 15 and 28 and every 4 weeks thereafter, and either lapatinib 1,500 mg or placebo daily. The study planned to accrue 324 patients and was powered for a 50% improvement in PFS with lapatinib from 5 to 7.5 months.
Results
At the third planned interim analysis, the futility boundary was crossed, and the data and safety monitoring board recommend study closure, having accrued 295 patients. At the final analysis, there was no difference in PFS (hazard ratio [HR] of placebo to lapatinib, 1.04; 95% CI, 0.82 to 1.33; P = .37); median PFS was 4.7 months for fulvestrant plus lapatinib versus 3.8 months for fulvestrant plus placebo. There was no difference in overall survival (OS) (HR, 0.91; 95% CI, 0.68 to 1.21; P = .25). For HER2-normal tumors, median PFS did not differ by treatment arm (4.1 v 3.8 months). For HER2-positive tumors, lapatinib was associated with longer median PFS (5.9 v 3.3 months), but the differential treatment effect by HER2 status was not significant (P = .53). The most frequent toxicities were diarrhea, fatigue, and rash associated with lapatinib.
Conclusion
Adding lapatinib to fulvestrant does not improve PFS or OS in advanced ER-positive breast cancer and is more toxic. (C) 2014 by American Society of Clinical Oncology
C1 [Burstein, Harold J.; Barry, William T.; Tolaney, Sara M.; Winer, Eric P.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Cirrincione, Constance T.] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA.
[Blackwell, Kimberly L.] Duke Univ, Med Ctr, Durham, NC USA.
[Chew, Helen K.] Univ Calif Davis, Davis, CA 95616 USA.
[Lake, Diana E.; Hudis, Clifford A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Ma, Cynthia] Washington Univ, Sch Med, St Louis, MO USA.
RP Burstein, HJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM hburstein@partners.org
FU National Cancer Institute [CA31946, CA33601, CA32102, CA46441]
FX Supported in part by National Cancer Institute Grants No. CA31946 to the
Alliance for Clinical Trials in Oncology, No. CA33601 to the Alliance
Statistics and Data Center, and No. CA32102 and CA46441 to the Southwest
Oncology Group.
NR 32
TC 17
Z9 17
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 10
PY 2014
VL 32
IS 35
BP 3959
EP U247
DI 10.1200/JCO.2014.56.7941
PG 10
WC Oncology
SC Oncology
GA AU9IK
UT WOS:000345905100011
PM 25348000
ER
PT J
AU Hagedorn, EJ
Durand, EM
Fast, EM
Zon, LI
AF Hagedorn, Elliott J.
Durand, Ellen M.
Fast, Eva M.
Zon, Leonard I.
TI Getting more for your marrow: Boosting hematopoietic stem cell numbers
with PGE(2)
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Review
DE Hematopoietic stem cells; Ex Vivo expansion; Umbilical cord blood
transplantation; Self-renewal; Engraftment; Prostaglandin E-2
ID PROGENITOR CELLS; CORD-BLOOD; PROSTAGLANDIN E-2; EP4 RECEPTOR;
EXPANSION; TRANSPLANTATION; PROLIFERATION; EXPRESSION; BIOLOGY;
RECONSTITUTION
AB Throughout the lifetime of an individual, hematopoietic stem cells (HSCs) self-renew and differentiate into lineages that include erythrocytes, platelets and all immune cells. HSC transplantation offers a potentially curative treatment for a number of hematopoietic and non-hematopoietic malignancies as well as immune and genetic disorders. Limited availability of immune-matched donors reduces the viable options for many patients in need of HSC transplantation, particularly those of diverse racial and ethnic backgrounds. Due to rapid availability and less stringent immune-matching requirements, umbilical cord blood (UCB) has emerged as a valuable source of transplantable HSCs. A single UCB unit contains a suboptimal number of HSCs for treating larger children or adults and there has thus been great clinical interest in expanding UCB HSCs ex vivo for use in transplantation. In this review we discuss the latest research and future avenues for the therapeutic use of small lipid mediator dmPGE(2) to expand HSC numbers for transplantation. Originally identified in a chemical screen in zebrafish, dmPGE2 has now advanced to a phase II clinical trial as a therapy for patients with leukemia and lymphoma who are undergoing UCB transplantation. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Zon, Leonard I.] Boston Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA.
Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Howard Hughes Med Inst, Harvard Stem Cell Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Zon, LI (reprint author), Boston Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA.
EM zon@enders.tch.harvard.edu
FU NIH [R01 HL04880, 5P30 DK49216, R24 DK092760, 5U01 HL10001-05]
FX This work was supported by NIH Grants R01 HL04880, 5P30 DK49216, R24
DK092760 and 5U01 HL10001-05. In addition, L.I.Z. is a Howard Hughes
Medical Institute Investigator. E.J.H. is a Howard Hughes Medical
Institute Fellow of The Helen Hay Whitney Foundation.
NR 39
TC 14
Z9 14
U1 1
U2 9
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD DEC 10
PY 2014
VL 329
IS 2
BP 220
EP 226
DI 10.1016/j.yexcr.2014.07.030
PG 7
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AW2JH
UT WOS:000346113400006
PM 25094063
ER
PT J
AU Jones, CN
Moore, M
Dimisko, L
Alexander, A
Ibrahim, A
Hassell, BA
Warren, HS
Tompkins, RG
Fagan, SP
Irimia, D
AF Jones, Caroline N.
Moore, Molly
Dimisko, Laurie
Alexander, Andrew
Ibrahim, Amir
Hassell, Bryan A.
Warren, H. Shaw
Tompkins, Ronald G.
Fagan, Shawn P.
Irimia, Daniel
TI Spontaneous Neutrophil Migration Patterns during Sepsis after Major
Burns
SO PLOS ONE
LA English
DT Article
ID CLINICAL MICROBIOLOGY; MICROFLUIDIC CHANNELS; CHEMICAL GRADIENTS; SEPTIC
PATIENTS; INJURY; CHEMOTAXIS; INTERLEUKIN-6; EXPRESSION; PROCALCITONIN;
INFLAMMATION
AB Finely tuned to respond quickly to infections, neutrophils have amazing abilities to migrate fast and efficiently towards sites of infection and inflammation. Although neutrophils ability to migrate is perturbed in patients after major burns, no correlations have yet been demonstrated between altered migration and higher rate of infections and sepsis in these patients when compared to healthy individuals. To probe if such correlations exist, we designed microfluidic devices to quantify the neutrophil migration phenotype with high precision. Inside these devices, moving neutrophils are confined in channels smaller than the neutrophils and forced to make directional decisions at bifurcations and around posts. We employed these devices to quantify neutrophil migration across 18 independent parameters in 74 blood samples from 13 patients with major burns and 3 healthy subjects. Blinded, retrospective analysis of clinical data and neutrophil migration parameters revealed that neutrophils isolated from blood samples collected during sepsis migrate spontaneously inside the microfluidic channels. The spontaneous neutrophil migration is a unique phenotype, typical for patients with major burns during sepsis and often observed one or two days before the diagnosis of sepsis is confirmed. The spontaneous neutrophil migration phenotype is rare in patients with major burns in the absence of sepsis, and is not encountered in healthy individuals. Our findings warrant further studies of neutrophils and their utility for early diagnosing and monitoring sepsis in patients after major burns.
C1 [Jones, Caroline N.; Moore, Molly; Dimisko, Laurie; Alexander, Andrew; Ibrahim, Amir; Tompkins, Ronald G.; Fagan, Shawn P.; Irimia, Daniel] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Jones, Caroline N.; Moore, Molly; Dimisko, Laurie; Alexander, Andrew; Ibrahim, Amir; Warren, H. Shaw; Tompkins, Ronald G.; Fagan, Shawn P.; Irimia, Daniel] Harvard Univ, Sch Med, Boston, MA USA.
[Jones, Caroline N.; Dimisko, Laurie; Hassell, Bryan A.; Irimia, Daniel] BioMEMS Resource Ctr, Ctr Engn Med & Surg Serv, Boston, MA USA.
[Jones, Caroline N.; Ibrahim, Amir; Warren, H. Shaw; Irimia, Daniel] Shriners Hosp Children, Boston, MA USA.
[Warren, H. Shaw] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Warren, H. Shaw] Massachusetts Gen Hosp, Dept Med, Infect Dis Unit, Boston, MA 02114 USA.
RP Irimia, D (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
EM dirimia@mgh.harvard.edu
OI Irimia, Daniel/0000-0001-7347-2082
FU Kidder Burn Critical Care Fellowship; National Institutes of Health
[GM007035, GM092804, EB002503]
FX MM was the recipient of the Kidder Burn Critical Care Fellowship. CNJ
has been supported by an institutional training grant from the National
Institutes of Health: GM007035. This research has been supported through
research grants from the National Institutes of Health GM092804 and
EB002503. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 52
TC 10
Z9 10
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2014
VL 9
IS 12
AR e114509
DI 10.1371/journal.pone.0114509
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AY3YM
UT WOS:000347515300044
PM 25489947
ER
PT J
AU Dong, F
Irshad, H
Oh, EY
Lerwill, MF
Brachtel, EF
Jones, NC
Knoblauch, NW
Montaser-Kouhsari, L
Johnson, NB
Rao, LKF
Faulkner-Jones, B
Wilbur, DC
Schnitt, SJ
Beck, AH
AF Dong, Fei
Irshad, Humayun
Oh, Eun-Yeong
Lerwill, Melinda F.
Brachtel, Elena F.
Jones, Nicholas C.
Knoblauch, Nicholas W.
Montaser-Kouhsari, Laleh
Johnson, Nicole B.
Rao, Luigi K. F.
Faulkner-Jones, Beverly
Wilbur, David C.
Schnitt, Stuart J.
Beck, Andrew H.
TI Computational Pathology to Discriminate Benign from Malignant
Intraductal Proliferations of the Breast
SO PLOS ONE
LA English
DT Article
ID CARCINOMA IN-SITU; NUCLEAR MORPHOMETRIC FEATURES; WHOLE-SLIDE IMAGES;
DUCTAL HYPERPLASIA; PROGNOSTIC VALUE; CANCER; EXPRESSION; LESIONS;
TISSUE; INTEROBSERVER
AB The categorization of intraductal proliferative lesions of the breast based on routine light microscopic examination of histopathologic sections is in many cases challenging, even for experienced pathologists. The development of computational tools to aid pathologists in the characterization of these lesions would have great diagnostic and clinical value. As a first step to address this issue, we evaluated the ability of computational image analysis to accurately classify DCIS and UDH and to stratify nuclear grade within DCIS. Using 116 breast biopsies diagnosed as DCIS or UDH from the Massachusetts General Hospital (MGH), we developed a computational method to extract 392 features corresponding to the mean and standard deviation in nuclear size and shape, intensity, and texture across 8 color channels. We used L1-regularized logistic regression to build classification models to discriminate DCIS from UDH. The top-performing model contained 22 active features and achieved an AUC of 0.95 in cross-validation on the MGH data-set. We applied this model to an external validation set of 51 breast biopsies diagnosed as DCIS or UDH from the Beth Israel Deaconess Medical Center, and the model achieved an AUC of 0.86. The top-performing model contained active features from all color-spaces and from the three classes of features (morphology, intensity, and texture), suggesting the value of each for prediction. We built models to stratify grade within DCIS and obtained strong performance for stratifying low nuclear grade vs. high nuclear grade DCIS (AUC=0.98 in cross-validation) with only moderate performance for discriminating low nuclear grade vs. intermediate nuclear grade and intermediate nuclear grade vs. high nuclear grade DCIS (AUC=0.83 and 0.69, respectively). These data show that computational pathology models can robustly discriminate benign from malignant intraductal proliferative lesions of the breast and may aid pathologists in the diagnosis and classification of these lesions.
C1 [Dong, Fei; Lerwill, Melinda F.; Brachtel, Elena F.; Jones, Nicholas C.; Rao, Luigi K. F.; Wilbur, David C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Dong, Fei] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Irshad, Humayun; Oh, Eun-Yeong; Knoblauch, Nicholas W.; Montaser-Kouhsari, Laleh; Johnson, Nicole B.; Faulkner-Jones, Beverly; Schnitt, Stuart J.; Beck, Andrew H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
RP Beck, AH (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
EM abeck2@bidmc.harvard.edu
FU National Library of Medicine of the National Institutes of Health
[K22LM011931]
FX The research reported in this publication was supported in part by the
National Library of Medicine of the National Institutes of Health under
Award Number K22LM011931. No additional external funding was received
for this study. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 43
TC 4
Z9 4
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2014
VL 9
IS 12
AR UNSP e114885
DI 10.1371/journal.pone.0114885
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AY3YM
UT WOS:000347515300091
PM 25490766
ER
PT J
AU Litvinova, L
Atochin, D
Vasilenko, M
Fattakhov, N
Zatolokin, P
Vaysbeyn, I
Kirienkova, E
AF Litvinova, Larisa
Atochin, Dmitriy
Vasilenko, Mariia
Fattakhov, Nikolai
Zatolokin, Pavel
Vaysbeyn, Igor
Kirienkova, Elena
TI Role of adiponectin and proinflammatory gene expression in adipose
tissue chronic inflammation in women with metabolic syndrome
SO DIABETOLOGY & METABOLIC SYNDROME
LA English
DT Article
DE Metabolic syndrome; Adipose tissue; Inflammation; Obesity; Adipokine;
Gene expression
ID C-REACTIVE PROTEIN; ENDOTHELIAL GROWTH-FACTOR; INTIMA-MEDIA THICKNESS;
NF-KAPPA-B; INSULIN-RESISTANCE; OBESE SUBJECTS; FAT THICKNESS;
WEIGHT-LOSS; ADIPOKINES; ASSOCIATION
AB Background: The purpose of this research was to study the gene expression of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), nuclear factor kappa B (NF-kappa B), vascular endothelial growth factor A (VEGF-A) and adiponectin (AdipoQ) genes in the visceral (omental, mesenteric) and subcutaneous adipose tissue depots in metabolic syndrome (MS). We studied 23 women with MS, with a mean age of 50.7 +/- 4.5 years and mean body mass index (BMI) of 45.6 +/- 9.8 kg/m(2). The control group included 10 women, with a mean age of 40.6 +/- 8.7 years and normal BMI (22.3 +/- 3.7 kg/m(2)). The gene expression levels in the omental (OAT), mesenteric (MAT) and subcutaneous (SAT) adipose tissues were assessed by quantitative real-time PCR.
Findings: Increased gene expression levels of IL-6 and TNF-alpha were detected in MAT in patients with MS, compared with the control group (p < 0.05 and p < 0.005, respectively). Significant positive correlations were observed between IL-6 mRNA expression levels in OAT and the content of CD14 + cells in the peripheral blood (r = 0.55, p < 0.05), as well as between NF-kappa B and VEGF-A mRNA levels in OAT (r = 0.43, p < 0.05) in patients with MS. The AdipoQ gene expression levels in OAT were significantly decreased in women with MS compared with the control group (p < 0.05). In addition, there were inverse correlations between AdipoQ gene levels in MAT and serum CRP levels (r = -0.63, p < 0.05), as well as between AdipoQ gene levels in MAT and serum IL-6 levels (r = -0.46, p < 0.05).
Conclusion: These data demonstrate that proinflammatory gene expression of MAT in women with MS was increased compared with the control group. The AdipoQ gene expression levels in OAT were significantly decreased in women with MS compared with the control group.
C1 [Litvinova, Larisa; Atochin, Dmitriy; Vasilenko, Mariia; Fattakhov, Nikolai; Kirienkova, Elena] Immanuel Kant Balt Fed Univ, Kaliningrad, Russia.
[Atochin, Dmitriy] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
[Zatolokin, Pavel] Kaliningrad Reg Hosp, Dept Reconstruct & Endoscop Surg, Kaliningrad, Russia.
[Vaysbeyn, Igor] Kaliningrad Reg Hosp, Dept Gen Surg, Kaliningrad, Russia.
RP Litvinova, L (reprint author), Immanuel Kant Balt Fed Univ, Innovat Pk,Bldg 3,Botkina St, Kaliningrad, Russia.
EM larisalitvinova@yandex.ru; atochin@cvrc.mgh.harvard.edu
RI Atochin, Dmitriy/Q-3150-2016; Василенко, Мария/E-4926-2017
OI Василенко, Мария/0000-0002-4989-045X
FU Federal Targeted Program Scientific and Pedagogical Personnel of
Innovative Russia; President of Russian Federation for young scientists
and postgraduates [SP-454.2013]; [14.A18.21.1518]
FX This study was supported by the Federal Targeted Program Scientific and
Pedagogical Personnel of Innovative Russia in 2009-2013, the State
contract 14.A18.21.1518 and a Scholarship of the President of Russian
Federation for young scientists and postgraduates, number SP-454.2013.
NR 59
TC 7
Z9 8
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-5996
J9 DIABETOL METAB SYNDR
JI Diabetol. Metab. Syndr.
PD DEC 9
PY 2014
VL 6
AR 137
DI 10.1186/1758-5996-6-137
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AX3ZO
UT WOS:000346874300001
PM 25516772
ER
PT J
AU Jarzabek, MA
Amberger-Murphy, V
Callanan, JJ
Gao, C
Zagozdzon, AM
Shiels, L
Wang, J
Ligon, KL
Rich, BE
Dicker, P
Gallagher, WM
Prehn, JHM
Byrne, AT
AF Jarzabek, M. A.
Amberger-Murphy, V.
Callanan, J. J.
Gao, C.
Zagozdzon, A. M.
Shiels, L.
Wang, J.
Ligon, K. L.
Rich, B. E.
Dicker, P.
Gallagher, W. M.
Prehn, J. H. M.
Byrne, A. T.
TI Interrogation of gossypol therapy in glioblastoma implementing cell line
and patient-derived tumour models
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE GBM; gossypol; TMZ; angiogenesis; apoptosis; invasion
ID CENTRAL-NERVOUS-SYSTEM; HUMAN PROSTATE-CANCER; GLIOMA STEM-CELLS;
IN-VIVO; LACTATE-DEHYDROGENASE; MALIGNANT GLIOMA; BRAIN-TUMORS;
SENSITIZES GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; BCL-2 OVEREXPRESSION
AB Background: Glioblastoma (GBM), being a highly vascularised and locally invasive tumour, is an attractive target for antiangiogenic and anti-invasive therapies. The GBM/endothelial cell response to gossypol/temozolomide (TMZ) treatment was investigated with a particular aim to assess treatment effects on cancer hallmarks.
Methods: Cell viability, endothelial tube formation and GBM tumour cell invasion were variously assessed following combined treatment in vitro. The U87MG-luc2 subcutaneous xenograft model was used to investigate therapeutic response in vivo. Viable tumour response to treatment was interrogated using immunohistochemistry. Combined treatment protocols were also tested in primary GBM patient-derived cultures.
Results: An endothelial/GBM cell viability inhibitory effect, as well as an anti-angiogenic and anti-invasive response, to combined treatment have been demonstrated in vitro. A significantly greater anti-proliferative (P = 0.020, P = 0.030), anti-angiogenic (P = 0.040, P<0.0001) and pro-apoptotic (P = 0.0083, P = 0.0149) response was observed when combined treatment was compared with single gossypol/TMZ treatment response, respectively. GBM cell line and patient-specific response to gossypol/TMZ treatment was observed.
Conclusions: Our results indicate that response to a combined gossypol/TMZ treatment is related to inhibition of tumour-associated angiogenesis, invasion and proliferation and warrants further investigation as a novel targeted GBM treatment strategy.
C1 [Jarzabek, M. A.; Shiels, L.; Prehn, J. H. M.; Byrne, A. T.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland.
[Jarzabek, M. A.; Shiels, L.; Prehn, J. H. M.; Byrne, A. T.] Royal Coll Surgeons Ireland, Ctr Syst Med, Dublin 2, Ireland.
[Amberger-Murphy, V.] Dublin City Univ, Mol Therapeut Canc Ireland, Dublin 9, Ireland.
[Amberger-Murphy, V.] All Ireland Cooperat Oncol Res Grp, Dublin 2, Ireland.
[Callanan, J. J.] Univ Coll Dublin, UCD Sch Vet Med, Dublin 4, Ireland.
[Callanan, J. J.] Ross Sch Vet Med, Basseterre, St Kitts & Nevi.
[Gao, C.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Zagozdzon, A. M.; Gallagher, W. M.; Byrne, A. T.] Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.
[Wang, J.] Univ Bergen, Dept Biomed, Bergen, Norway.
[Ligon, K. L.; Rich, B. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Dicker, P.] Royal Coll Surgeons Ireland, PHS Dept Epidemiol & Publ Hlth Med, Dublin 2, Ireland.
RP Byrne, AT (reprint author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland.
EM annettebyrne@rcsi.ie
RI Prehn, Jochen/A-3928-2010
OI Prehn, Jochen/0000-0003-3479-7794
FU Higher Education Authority Program in Research in Third Level
Institution Cycle 4 (National Biophotonics Imaging Platform Ireland);
FP7 AngioTox Industry Academic Pathways and Partnerships initiative;
Science Foundation Ireland in the context of the Molecular Therapeutics
for Cancer Ireland Strategic Research Cluster; [08/IN.1/B1949];
[13/IA/1881]
FX We kindly acknowledge Professor Rolf Bjerkvig for providing GBM
patient-derived spheroids. Funding is acknowledged from the Higher
Education Authority Program in Research in Third Level Institution Cycle
4 (National Biophotonics Imaging Platform Ireland), FP7 AngioTox
Industry Academic Pathways and Partnerships initiative (www. angiotox.
com) and Science Foundation Ireland in the context of the Molecular
Therapeutics for Cancer Ireland Strategic Research Cluster to ATB and
WMG and Investigator Awards 08/IN.1/B1949 and 13/IA/1881 to JHMP.
NR 69
TC 3
Z9 3
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD DEC 9
PY 2014
VL 111
IS 12
BP 2275
EP 2286
DI 10.1038/bjc.2014.529
PG 12
WC Oncology
SC Oncology
GA AW4JJ
UT WOS:000346247000012
PM 25375271
ER
PT J
AU Wheeler, SE
Clark, AM
Taylor, DP
Young, CL
Pillai, VC
Stolz, DB
Venkataramanan, R
Lauffenburger, D
Griffith, L
Wells, A
AF Wheeler, S. E.
Clark, A. M.
Taylor, D. P.
Young, C. L.
Pillai, V. C.
Stolz, D. B.
Venkataramanan, R.
Lauffenburger, D.
Griffith, L.
Wells, A.
TI Spontaneous dormancy of metastatic breast cancer cells in an all human
liver microphysiologic system
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE bioreactor; 3D culture systems; mammary carcinoma; liver; hepatocytes
ID EPITHELIAL-MESENCHYMAL TRANSITION; BALANCED PROLIFERATION; CULTURE
MODELS; TUMOR DORMANCY; E-CADHERIN; PROGRESSION; THERAPY; TISSUE;
MORPHOGENESIS; CHEMOTHERAPY
AB Background: Metastatic outgrowth in breast cancer can occur years after a seeming cure. Existing model systems of dormancy are limited as they do not recapitulate human metastatic dormancy without exogenous manipulations and are unable to query early events of micrometastases.
Methods: Here, we describe a human ex vivo hepatic microphysiologic system. The system is established with fresh human hepatocytes and non-parenchymal cells (NPCs) creating a microenvironment into which breast cancer cells (MCF7 and MDA-MB-231) are added.
Results: The hepatic tissue maintains function through 15 days as verified by liver-specific protein production and drug metabolism assays. The NPCs form an integral part of the hepatic niche, demonstrated within the system through their participation in differential signalling cascades and cancer cell outcomes. Breast cancer cells intercalate into the hepatic niche without interfering with hepatocyte function. Examination of cancer cells demonstrated that a significant subset enter a quiescent state of dormancy as shown by lack of cell cycling (EdU(-) or Ki67(-)). The presence of NPCs altered the cancer cell fraction entering quiescence, and lead to differential cytokine profiles in the microenvironment effluent.
Conclusions: These findings establish the liver microphysiologic system as a relevant model for the study of breast cancer metastases and entry into dormancy.
C1 [Wheeler, S. E.; Clark, A. M.; Taylor, D. P.; Stolz, D. B.; Venkataramanan, R.; Wells, A.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA.
[Taylor, D. P.; Wells, A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
[Young, C. L.; Lauffenburger, D.; Griffith, L.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Pillai, V. C.; Venkataramanan, R.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA.
[Stolz, D. B.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA.
[Stolz, D. B.; Wells, A.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA.
[Stolz, D. B.; Wells, A.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Wells, A.] VA Pittsburgh Healthcare Syst, Pittsburgh VA Med Ctr, Pittsburgh, PA USA.
RP Wells, A (reprint author), Univ Pittsburgh, Dept Pathol, S711 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15260 USA.
EM wellsa@upmc.edu
OI Clark, Amanda/0000-0003-1590-2560; Wells, Alan/0000-0002-1637-8150
FU NIH [1UH2TR000496-01]; VA Merit Award; DARPA [BAA-11-73,
W911NF-12-2-0039]
FX The authors thank other members of their laboratories for thoughtful
discussions. The work described herein is being funded by grants from
the NIH (1UH2TR000496-01), a VA Merit Award, and DARPA (BAA-11-73
Microphysiological Systems: W911NF-12-2-0039).
NR 45
TC 11
Z9 11
U1 1
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD DEC 9
PY 2014
VL 111
IS 12
BP 2342
EP 2350
DI 10.1038/bjc.2014.533
PG 9
WC Oncology
SC Oncology
GA AW4JJ
UT WOS:000346247000018
PM 25314052
ER
PT J
AU Amato, AA
Sivakumar, K
Goyal, N
David, WS
Salajegheh, M
Praestgaard, J
Lach-Trifilieff, E
Trendelenburg, AU
Laurent, D
Glass, DJ
Roubenoff, R
Tseng, BS
Greenberg, SA
AF Amato, Anthony A.
Sivakumar, Kumaraswamy
Goyal, Namita
David, William S.
Salajegheh, Mohammad
Praestgaard, Jens
Lach-Trifilieff, Estelle
Trendelenburg, Anne-Ulrike
Laurent, Didier
Glass, David J.
Roubenoff, Ronenn
Tseng, Brian S.
Greenberg, Steven A.
TI Treatment of sporadic inclusion body myositis with bimagrumab
SO NEUROLOGY
LA English
DT Article
ID CYTOSOLIC 5'-NUCLEOTIDASE 1A; RANDOMIZED PILOT TRIAL; DOUBLE-BLIND;
MUSCLE; HYPERTROPHY; PLACEBO; PATHWAY; DIFFERENTIATION; MYOSTATIN;
THERAPY
AB Objective:To study activin signaling and its blockade in sporadic inclusion body myositis (sIBM) through translational studies and a randomized controlled trial.Methods:We measured transforming growth factor signaling by SMAD2/3 phosphorylation in muscle biopsies of 50 patients with neuromuscular disease (17 with sIBM). We tested inhibition of activin receptors IIA and IIB (ActRII) in 14 patients with sIBM using one dose of bimagrumab (n = 11) or placebo (n = 3). The primary outcome was the change in right thigh muscle volume by MRI at 8 weeks. Lean body mass, strength, and function were secondary outcomes. Twelve of the patients (10 bimagrumab, 2 placebo) participated in a subsequent 16-week observation phase.Results:Muscle SMAD2/3 phosphorylation was higher in sIBM than in other muscle diseases studied (p = 0.003). Eight weeks after dosing, the bimagrumab-treated patients increased thigh muscle volume (right leg +6.5% compared with placebo, p = 0.024; left leg +7.6%, p = 0.009) and lean body mass (+5.7% compared with placebo, p = 0.014). Subsequently, bimagrumab-treated patients had improved 6-minute walking distance, which peaked at 16 weeks (+14.6%, p = 0.008) compared with placebo. There were no serious adverse events; the main adverse events with bimagrumab were mild acne and transient involuntary muscle contractions.Conclusions:Transforming growth factor superfamily signaling, at least through ActRII, is implicated in the pathophysiology of sIBM. Inhibition of ActRII increased muscle mass and function in this pilot trial, offering a potential novel treatment of sIBM.Classification of evidence:This study provides Class I evidence that for patients with inclusion body myositis, bimagrumab increases thigh muscle volume at 8 weeks.
C1 [Amato, Anthony A.; Salajegheh, Mohammad; Greenberg, Steven A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Amato, Anthony A.; Salajegheh, Mohammad; Greenberg, Steven A.] Harvard Univ, Sch Med, Boston, MA USA.
[Greenberg, Steven A.] Boston Childrens Hosp, Boston, MA USA.
[Greenberg, Steven A.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Sivakumar, Kumaraswamy] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
[Goyal, Namita; David, William S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lach-Trifilieff, Estelle; Trendelenburg, Anne-Ulrike; Laurent, Didier; Glass, David J.; Roubenoff, Ronenn; Tseng, Brian S.] Novartis Inst Biomed Res, Cambridge, MA USA.
[Lach-Trifilieff, Estelle; Trendelenburg, Anne-Ulrike; Laurent, Didier; Glass, David J.; Roubenoff, Ronenn; Tseng, Brian S.] Novartis Inst Biomed Res, Basel, Switzerland.
[Praestgaard, Jens] Novartis Pharmaceut, E Hanover, NJ USA.
RP Greenberg, SA (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM brian.tseng@novartis.com; sagreenberg@partners.org
FU Novartis Institutes for Biomedical Research; Boston Children's Hospital;
Brigham and Women's Hospital, Harvard Medical School; Novartis
FX Supported by Novartis Institutes for Biomedical Research, Boston
Children's Hospital, and Brigham and Women's Hospital, Harvard Medical
School. Role of the funding source: The study was designed and the data
were analyzed by the sponsor, Novartis, in collaboration with the
principal investigator (S.A.G.). Novartis participated in the
interpretation of data, review, and approval of the report. An initial
draft of the report was prepared by R.R. and S.A.G. All authors
participated in interpretation of the data, contributed substantially to
report drafts, and agreed to submit the report for publication. All
authors had full access to the data and vouch for accuracy and
completeness of the data and analyses.
NR 24
TC 36
Z9 36
U1 1
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD DEC 9
PY 2014
VL 83
IS 24
BP 2239
EP 2246
DI 10.1212/WNL.0000000000001070
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA AW1SK
UT WOS:000346070000013
PM 25381300
ER
PT J
AU Bonaca, MP
Scirica, BM
Braunwald, E
Wiviott, SD
O'Donoghue, ML
Murphy, SA
Morrow, DA
AF Bonaca, Marc P.
Scirica, Benjamin M.
Braunwald, Eugene
Wiviott, Stephen D.
O'Donoghue, Michelle L.
Murphy, Sabina A.
Morrow, David A.
TI Coronary Stent Thrombosis With Vorapaxar Versus Placebo Results From the
TRA 2 degrees P-TIMI 50 Trial
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE antiplatelet therapy; atherothrombosis; DES; PAR-1; stent;
thienopyridine
ID DRUG-ELUTING STENTS; DUAL-ANTIPLATELET THERAPY; RANDOMIZED
CLINICAL-TRIALS; SECONDARY PREVENTION; EVENTS; INTERVENTION;
IMPLANTATION; METAANALYSIS; MULTICENTER; PREDICTORS
AB BACKGROUND Vorapaxar, a novel thrombin receptor antagonist, reduces cardiovascular death and recurrent thrombotic events when added to standard antiplatelet therapy in patients with stable atherosclerotic vascular disease.
OBJECTIVES The goal of this study was to test the hypothesis that treatment with vorapaxar reduces the rate of coronary stent thrombosis (ST) in stable patients with a history of coronary stenting.
METHODS TRA2 degrees P-TIMI 50 (Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50) was a multinational, randomized, double-blind, placebocontrolled trial of vorapaxar in stable patients with prior myocardial infarction, peripheral arterial disease, or stroke. We evaluated the rates of definite ST as adjudicated by a central events committee using Academic Research Consortium (ARC) criteria.
RESULTS A total of 26,449 patients were randomized, with 14,042 (53%) having a history of a coronary stent implantation before randomization, and an additional 449 patients receiving a coronary stent during the trial (total 14,491). During follow-up (median 2.5 years), there were 152 definite ST events, with the majority (92%) occurring late or very late. Vorapaxar reduced ARC definite ST (1.1% vs. 1.4%, hazard ratio [HR]: 0.71, 95% confidence interval [CI]: 0.51 to 0.98; p = 0.037). The reduction was consistent, regardless of time from percutaneous coronary intervention, history of diabetes, use of drug-eluting stents, and use of dual antiplatelet therapy (DAPT) at randomization. Vorapaxar increased GUSTO moderate/severe bleeding (HR: 1.57, 95% CI: 1.26 to 1.94; p < 0.001).
CONCLUSIONS The rate of ARC definite ST in stable patients, the majority of whom were receiving DAPT, was approximately 1.4% at 3 years. In stable patients with coronary stenting receiving standard antiplatelet therapy, vorapaxar administered for long-term secondary prevention significantly reduced ARC definite ST, including very late ST.
C1 Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Bonaca, MP (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
EM mbonaca@partners.org
FU Merck Co.
FX This study was supported by a grant from Merck & Co. The TIMI Study
Group has received significant research grant support from Accumetrics,
Amgen, AstraZeneca, Beckman Coulter, Bristol-Myers Squibb, CV
Therapeutics, Daiichi-Sankyo Co. Ltd., Eli Lilly and Company,
GlaxoSmithKline, Integrated Therapeutics, Merck & Co., Nanosphere,
Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical Diagnostics, Pfizer,
Roche Diagnostics, Sanofi, Sanofi-Synthelabo, Siemens Medical Solutions,
and Singulex. Dr. Bonaca has received consulting fees from Roche
Diagnostics, Merck & Co., AstraZeneca, and Bayer. Dr. Scirica has
received research grants via the TIMI Study and Brigham and Women's
Hospital from AstraZeneca, BristolMyers Squibb, Daiichi-Sankyo,
GlaxoSmithKline, Johnson & Johnson, Bayer Healthcare, Gilead, Eisai, and
Merck & Co.; and consulting fees from AstraZeneca, GE Healthcare,
Gilead, Lexicon, Arena, Eisai, St. Jude's Medical, Forest
Pharmaceuticals, Bristol-Myers Squibb, Boston ClinicalResearch
Institute, Covance, University of Calgary, and Elsevier PracticeUpdate
Cardiology. Dr. Braunwald has received research grants (institutional)
from Daiichi- Sankyo, Duke University, AstraZeneca, Merck & Co., and
GlaxoSmithKline; has received fees for lectures from Daiichi- Sankyo,
Menarini International, and Medscape; has received fees as a consultant
for The Medicines Company and Sanofi; and has been an unpaid consultant
and has given unpaid lectures for Merck & Co. Dr. Wiviott has received
research grants from Merck & Co., AstraZeneca, and Eisai; and has been a
consultant for Eli Lilly and Company, AstraZeneca, Johnson & Johnson,
St. Jude Medical, ICON, and Bristol-Myers Squibb. Dr. O'Donoghue has
received research grants from GlaxoSmithKline, AstraZeneca, and Eisai;
and has been a consultant with Aegerion. Dr. Morrow has received
research grant support from Abbott, Amgen, AstraZeneca, Beckman Coulter,
BG Medicine, BRAHMS, Bristol-Myers Squibb, Critical Diagnostics, CV
Therapeutics, Daiichi- Sankyo Co. Ltd., Eli Lilly and Company,
GlaxoSmithKline, Johnson & Johnson, Merck and Co., Novartis
Pharmaceuticals, Roche Diagnostics, Sanofi, and Singulex; and has
received consulting fees from Abbott Laboratories, BG Medicine, Daiichi-
Sankyo, Eli Lilly and Company, Gilead, Instrumentation Laboratory,
Johnson & Johnson, Konica Minolta, Merck & Co., Novartis, Roche
Diagnostics, and Servier. Ms. Murphy has reported that she has no
relationships relevant to the contents of this paper to disclose.
NR 18
TC 18
Z9 18
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD DEC 9
PY 2014
VL 64
IS 22
BP 2309
EP 2317
DI 10.1016/j.jacc.2014.09.037
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AW0ED
UT WOS:000345962200002
PM 25465416
ER
PT J
AU Bonaca, MP
Scirica, BM
Braunwald, E
Wiviott, SD
Goto, S
Nilsen, DW
Bonarjee, V
Murphy, SA
Morrow, DA
AF Bonaca, Marc P.
Scirica, Benjamin M.
Braunwald, Eugene
Wiviott, Stephen D.
Goto, Shinya
Nilsen, Dennis W.
Bonarjee, Vernon
Murphy, Sabina A.
Morrow, David A.
TI New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo Results
From the TRA 2 degrees P-TIMI 50 Trial
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE antiplatelet therapy; intracranial hemorrhage; PAR-1; platelet
aggregation inhibitors; secondary prevention; thrombin receptor
ID RECENT LACUNAR STROKE; SECONDARY PREVENTION; CLOPIDOGREL; ASPIRIN;
DISEASE; ATTACK; EVENTS; RISK; ASSOCIATION; UPDATE
AB BACKGROUND Vorapaxar, a novel antiplatelet therapy, reduces thrombotic events in patients with a history of myocardial infarction (MI) or peripheral artery disease (PAD); however, because of an increased risk of intracranial hemorrhage, it is contraindicated in patients with a history of stroke.
OBJECTIVES The aim of this study was to investigate the incidence of new ischemic stroke and subsequent death or intracerebral hemorrhage in patients with MI or PAD and no cerebrovascular disease (CVD) treated with vorapaxar.
METHODS The TRA 2 degrees P-TIMI 50 (Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50) was a randomized, double-blind, place-bocontrolled trial of vorapaxar 2.5 mg daily in 26,449 patients with atherosclerosis, stratified by qualifying disease (MI, PAD, or CVD). A total of 20,170 patients with MI/ PAD, but no CVD, were enrolled.
RESULTS In patients with MI/ PAD and no prior stroke or transient ischemic attack, vorapaxar reduced first ischemic stroke (hazard ratio [ HR]: 0.57, 95% confidence interval [ CI]: 0.43 to 0.75; p < 0.001). The risk of hemorrhagic conversion after stroke (HR: 1.19, 95% CI: 0.49 to 2.91; p = 0.70) or death (HR: 1.09, 95% CI: 0.57 to 2.07; p = 0.79) during follow-up was not significantly increased with vorapaxar in patients who had a new ischemic stroke (n = 204). Although hemorrhagic stroke was increased (HR: 2.79, 95% CI: 1.00 to 7.73; p = 0.049), overall stroke was significantly reduced (HR: 0.67, 95% CI: 0.52 to 0.87; p = 0.002).
CONCLUSIONS Vorapaxar reduces ischemic stroke in patients with MI or PAD and no known CVD. There does not appear to be a significant increase in the risk of hemorrhagic conversion or death in patients who experienced a first ischemic stroke on vorapaxar. Although primary hemorrhagic stroke is increased, vorapaxar reduces the total incidence of stroke.
C1 [Bonaca, Marc P.; Scirica, Benjamin M.; Braunwald, Eugene; Wiviott, Stephen D.; Murphy, Sabina A.; Morrow, David A.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Bonaca, Marc P.; Scirica, Benjamin M.; Braunwald, Eugene; Wiviott, Stephen D.; Murphy, Sabina A.; Morrow, David A.] Harvard Univ, Sch Med, Boston, MA USA.
[Goto, Shinya] Tokai Univ, Sch Med, Inst Med Sci, Dept Med Cardiol, Isehara, Kanagawa 25911, Japan.
[Nilsen, Dennis W.; Bonarjee, Vernon] Stavanger Univ Hosp, Dept Cardiol, Stavanger, Norway.
[Nilsen, Dennis W.; Bonarjee, Vernon] Univ Bergen, Fac Med & Dent, Dept Clin Sci, Bergen, Norway.
RP Bonaca, MP (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
EM mbonaca@partners.org
FU Merck Co.
FX This study was supported by a grant from Merck & Co. The TIMI Study
Group has received significant research grant support from Accumetrics,
Amgen, AstraZeneca, Beckman Coulter, Bristol-Myers Squibb, CV
Therapeutics, Daiichi-Sankyo Co. Ltd., Eli Lilly and Company,
GlaxoSmithKline, Integrated Therapeutics, Merck & Co., Nanosphere,
Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical Diagnostics, Pfizer,
Roche Diagnostics, Sanofi, Sanofi-Synthelabo, Siemens Medical Solutions,
and Singulex. Dr. Bonaca was supported by a Research Career Development
Award (K12 HL083786) from the National Heart, Lung, and Blood Institute;
and has received consulting fees from Roche Diagnostics, Merck & Co.,
AstraZeneca, and Bayer. Dr. Scirica has received research grants via the
TIMI Study and Brigham and Women's Hospital from AstraZeneca,
Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Johnson &
Johnson, Bayer Healthcare, Gilead, Eisai, and Merck & Co.; and
consulting fees from AstraZeneca, GE Healthcare, Gilead, Lexicon, Arena,
Eisai, St. Jude's Medical, Forest Pharmaceuticals, Bristol-Myers Squibb,
Boston Clinical Research Institute, Covance, University of Calgary, and
Elsevier Practice Update Cardiology. Dr. Braunwald has received research
grants (institutional) from Daiichi-Sankyo, Duke University,
AstraZeneca, Merck & Co., and GlaxoSmithKline; has received fees for
lectures from Daiichi-Sankyo, Menarini International, and Medscape; has
received fees as a consultant for The Medicines Company and Sanofi; and
has been an unpaid consultant and has given unpaid lectures for Merck &
Co. Dr. Wiviott has received research grants from Merck & Co.,
AstraZeneca, and Eisai; and has been a consultant for Eli Lilly and
Company, AstraZeneca, Johnson & Johnson, Arena, St. Jude Medical, Icon
Medical Imaging, and Bristol-Myers Squibb. Dr. Goto has received
honoraria from Eisai, Sanofi, Otsuka, Bayer, Novartis, AstraZeneca,
Asteras, Pfizer, Medtronics-Japan, Tanabe-Mitsubishi, Takeda,
DaiichiSankyo, Mochida, and MSD; and has received research grants from
Sanofi, Boehringer Ingelheim, Otsuka, and Daiichi-Sankyo. Dr. Morrow has
received research grant support from Abbott, Amgen, AstraZeneca, Beckman
Coulter, BG Medicine, BRAHMS, Bristol-Myers Squibb, Critical
Diagnostics, CV Therapeutics, Daiichi-Sankyo Co. Ltd., Eli Lilly and
Company, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis
Pharmaceuticals, Roche Diagnostics, Sanofi, and Singulex; and has
received consulting fees from Abbott Laboratories, BG Medicine,
Daiichi-Sankyo, Eli Lilly and Company, Gilead, Instrumentation
Laboratory, Johnson & Johnson, Konica Minolta, Merck & Co., Novartis,
Roche Diagnostics, and Servier. All other authors have reported that
they have no relationships relevant to the contents of this paper to
disclose.
NR 21
TC 17
Z9 18
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD DEC 9
PY 2014
VL 64
IS 22
BP 2318
EP 2326
DI 10.1016/j.jacc.2014.07.997
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AW0ED
UT WOS:000345962200003
PM 25465417
ER
PT J
AU Lopez-Pelaez, M
Lamont, DJ
Peggie, M
Shpiro, N
Gray, NS
Cohen, P
AF Lopez-Pelaez, Marta
Lamont, Douglas J.
Peggie, Mark
Shpiro, Natalia
Gray, Nathanael S.
Cohen, Philip
TI Protein kinase IKK beta-catalyzed phosphorylation of IRF5 at Ser462
induces its dimerization and nuclear translocation in myeloid cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE IKK beta; interferon beta; IRF5; plasmacytoid dendritic cell; TLR7
ID INTERFERON REGULATORY FACTOR; PLASMACYTOID DENDRITIC CELLS;
VIRAL-INFECTION; IN-VIVO; INHIBITORS; INDUCTION; ACTIVATION; GENE;
TOLL-LIKE-RECEPTOR-7; LOCALIZATION
AB The siRNA knockdown of IFN Regulatory Factor 5 (IRF5) in the human plasmacytoid dendritic cell line Gen2.2 prevented IFN alpha production induced by compound CL097, a ligand for Toll-like receptor 7 (TLR7). CL097 also stimulated the phosphorylation of IRF5 at Ser462 and stimulated the nuclear translocation of wild-type IRF5, but not the IRF5[Ser462Ala] mutant. The CL097-stimulated phosphorylation of IRF5 at Ser462 and its nuclear translocation was prevented by the pharmacological inhibition of protein kinase IKK beta or the siRNA knockdown of IKK beta or its "upstream" activator, the protein kinase TAK1. Similar results were obtained in a murine macrophage cell line stimulated with the TLR7 agonist compound R848 or the nucleotide oligomerization domain 1 (NOD1) agonist KF-1B. IKK beta phosphorylated IRF5 at Ser462 in vitro and induced the dimerization of wild-type IRF5 but not the IRF5[S462A] mutant. These findings demonstrate that IKK beta activates two "master" transcription factors of the innate immune system, IRF5 and NF-kappa B.
C1 [Lopez-Pelaez, Marta; Peggie, Mark; Shpiro, Natalia; Cohen, Philip] Univ Dundee, Prot Phosphorylat & Ubiquitylat Unit, MRC, Dundee DD1 5EH, Scotland.
[Lamont, Douglas J.] Univ Dundee, Coll Life Sci, Dundee DD1 5EH, Scotland.
[Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Cohen, P (reprint author), Univ Dundee, Prot Phosphorylat & Ubiquitylat Unit, MRC, Dundee DD1 5EH, Scotland.
EM p.cohen@dundee.ac.uk
FU Wellcome Trust [WT100294]; UK Medical Research Council; AstraZeneca;
Boehringer Ingelheim; GlaxoSmithKline; Janssen Pharmaceutica;
Merck-Serono; Pfizer
FX The Gen2.2 cells were generously provided by Joel Plumas and Laurence
Chaperot (French Blood Bank). The research was supported by the Wellcome
Trust (WT100294), the UK Medical Research Council, AstraZeneca,
Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceutica,
Merck-Serono, and Pfizer.
NR 35
TC 15
Z9 15
U1 2
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 9
PY 2014
VL 111
IS 49
BP 17432
EP 17437
DI 10.1073/pnas.1418399111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU9NR
UT WOS:000345921500031
PM 25326418
ER
PT J
AU Sok, D
van Gils, MJ
Pauthner, M
Julien, JP
Saye-Francisco, KL
Hsueh, J
Briney, B
Lee, JH
Le, KM
Lee, PS
Hua, YZ
Seaman, MS
Moore, JP
Ward, AB
Wilson, IA
Sanders, RW
Burton, DR
AF Sok, Devin
van Gils, Marit J.
Pauthner, Matthias
Julien, Jean-Philippe
Saye-Francisco, Karen L.
Hsueh, Jessica
Briney, Bryan
Lee, Jeong Hyun
Le, Khoa M.
Lee, Peter S.
Hua, Yuanzi
Seaman, Michael S.
Moore, John P.
Ward, Andrew B.
Wilson, Ian A.
Sanders, Rogier W.
Burton, Dennis R.
TI Recombinant HIV envelope trimer selects for quaternary-dependent
antibodies targeting the trimer apex
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE HIV; broadly neutralizing antibodies; BG505 SOSIP; B cell; vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; BROADLY
NEUTRALIZING ANTIBODIES; N-GLYCAN RECOGNITION; CONFORMATIONAL EPITOPE;
BINDING-SITE; ENV TRIMERS; CD4 BINDING; B-CELLS; TYPE-1
AB Broadly neutralizing antibodies (bnAbs) targeting the trimer apex of HIV envelope are favored candidates for vaccine design and immunotherapy because of their great neutralization breadth and potency. However, methods of isolating bnAbs against this site have been limited by the quaternary nature of the epitope region. Here we report the use of a recombinant HIV envelope trimer, BG505 SOSIP.664 gp140, as an affinity reagent to isolate quaternary-dependent bnAbs from the peripheral blood mononuclear cells of a chronically infected donor. The newly isolated bnAbs, named "PGDM1400-1412," show a wide range of neutralization breadth and potency. One of these variants, PGDM1400, is exceptionally broad and potent with cross-clade neutralization coverage of 83% at a median IC50 of 0.003 mu g/mL. Overall, our results highlight the utility of BG505 SOSIP. 664 gp140 as a tool for the isolation of quaternary-dependent antibodies and reveal a mosaic of antibody responses against the trimer apex within a clonal family.
C1 [Sok, Devin; Pauthner, Matthias; Saye-Francisco, Karen L.; Hsueh, Jessica; Briney, Bryan; Le, Khoa M.; Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[Sok, Devin; Pauthner, Matthias; Julien, Jean-Philippe; Saye-Francisco, Karen L.; Hsueh, Jessica; Briney, Bryan; Lee, Jeong Hyun; Le, Khoa M.; Hua, Yuanzi; Ward, Andrew B.; Wilson, Ian A.; Burton, Dennis R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, La Jolla, CA 92037 USA.
[Sok, Devin; Pauthner, Matthias; Julien, Jean-Philippe; Saye-Francisco, Karen L.; Hsueh, Jessica; Briney, Bryan; Lee, Jeong Hyun; Le, Khoa M.; Hua, Yuanzi; Ward, Andrew B.; Wilson, Ian A.; Burton, Dennis R.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA.
[Julien, Jean-Philippe; Lee, Jeong Hyun; Lee, Peter S.; Hua, Yuanzi; Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
[Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
[Sok, Devin] Int AIDS Vaccine Initiat, New York, NY 10038 USA.
[van Gils, Marit J.; Sanders, Rogier W.] Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam, Lab Expt Virol,Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands.
[Julien, Jean-Philippe] Univ Toronto, Hosp Sick Children, Res Inst, Program Mol Struct & Funct, Toronto, ON M5G 0A4, Canada.
[Julien, Jean-Philippe] Univ Toronto, Dept Biochem, Toronto, ON M5G 0A4, Canada.
[Julien, Jean-Philippe] Univ Toronto, Dept Immunol, Toronto, ON M5G 0A4, Canada.
[Seaman, Michael S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Moore, John P.; Sanders, Rogier W.] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
[Burton, Dennis R.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02142 USA.
[Burton, Dennis R.] Harvard Univ, Boston, MA 02142 USA.
RP Sanders, RW (reprint author), Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam, Lab Expt Virol,Dept Med Microbiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM rws2002@med.cornell.edu; burton@scripps.edu
RI Ward, Andrew/F-9203-2014;
OI Ward, Andrew/0000-0001-7153-3769; Hsueh, Jessica/0000-0002-4070-5270
FU International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody
Consortium [SFP1849]; National Institutes of Health (NIH) [R01 AI033292,
R01 AI84817, R37 AI36082]; Center for HIV/AIDS Vaccine Immunology and
Immunogen Discovery Grant [UM1AI100663]; HIV Vaccine Research and Design
Program [P01 AI82362]; NIH Interdisciplinary Training Program in
Immunology [5T32AI007606-10]; Dutch Aids Fonds [2012041, 2009012,
2011032]; European Molecular Biology Organization Application Short-Term
Fellowship [260-2013]; Netherlands Organization for Scientific Research;
European Research Council [ERC-StG-2011-280829-SHEV]; Canadian
Institutes of Health Research fellowship; Bill and Melinda Gates
Foundation [38619]; Ministry of Foreign Affairs of Denmark; Irish Aid;
Ministry of Finance of Japan; Ministry of Foreign Affairs of the
Netherlands; Norwegian Agency for Development Cooperation; United
Kingdom Department for International Development; US Agency for
International Development (USAID); American people through USAID; Bill
and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery
FX This work was supported by the International AIDS Vaccine Initiative
(IAVI) Neutralizing Antibody Consortium SFP1849 (D.R.B.); National
Institutes of Health (NIH) Grants R01 AI033292 (to D.R.B.), R01 AI84817
(to I.A.W.), and R37 AI36082 (to J.P.M.); Center for HIV/AIDS Vaccine
Immunology and Immunogen Discovery Grant UM1AI100663 (to D.R.B., I.A.W.,
and A.B.W.); and HIV Vaccine Research and Design Program Grant P01
AI82362 (to J.P.M., I.A.W., and A.B.W.). Funding also was provided by
the NIH Interdisciplinary Training Program in Immunology 5T32AI007606-10
(D.S.); Dutch Aids Fonds Grant 2012041 and a European Molecular Biology
Organization Application Short-Term Fellowship 260-2013 (to M.J.v.G.);
Dutch Aids Fonds Grants 2009012 and 2011032 (to R.W.S.); a Vidi grant
from the Netherlands Organization for Scientific Research (to R.W.S.);
Starting Investigator Grant ERC-StG-2011-280829-SHEV from the European
Research Council (to R.W.S.); and a Canadian Institutes of Health
Research fellowship (to J.-P.J.). A portion of the neutralization
experiments was done by the M.S. group (Beth Israel Deaconess Medical
Center, Harvard Medical School), and that work was funded by Bill and
Melinda Gates Foundation Grant 38619. The work of the IAVI is made
possible by generous support from many donors, including the Bill and
Melinda Gates Foundation; the Ministry of Foreign Affairs of Denmark;
Irish Aid; the Ministry of Finance of Japan; the Ministry of Foreign
Affairs of the Netherlands; the Norwegian Agency for Development
Cooperation; the United Kingdom Department for International
Development, and the US Agency for International Development (USAID).
The full list of IAVI donors is available at www.iavi.org. This study
was made possible by the generous support of the Bill and Melinda Gates
Foundation Collaboration for AIDS Vaccine Discovery and the American
people through USAID.
NR 45
TC 72
Z9 72
U1 1
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 9
PY 2014
VL 111
IS 49
BP 17624
EP 17629
DI 10.1073/pnas.1415789111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU9NR
UT WOS:000345921500063
PM 25422458
ER
PT J
AU Olsen, LR
Campos, B
Winther, O
Sgroi, DC
Karger, BL
Brusic, V
AF Olsen, Lars Ronn
Campos, Benito
Winther, Ole
Sgroi, Dennis C.
Karger, Barry L.
Brusic, Vladimir
TI Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas
SO BMC MEDICAL GENOMICS
LA English
DT Article
ID HUMAN BREAST-CANCER; EPITHELIAL OVARIAN-CANCER; SET ENRICHMENT ANALYSIS;
PHOSPHOGLYCERATE KINASE; EXPRESSION PROFILES; IMMUNE SURVEILLANCE;
SUPPRESSOR-CELLS; CLINICAL-TRIALS; TESTIS ANTIGEN; BETA-CATENIN
AB Background: The majority of genetic biomarkers for human cancers are defined by statistical screening of high-throughput genomics data. While a large number of genetic biomarkers have been proposed for diagnostic and prognostic applications, only a small number have been applied in the clinic. Similarly, the use of proteomics methods for the discovery of cancer biomarkers is increasing. The emerging field of proteogenomics seeks to enrich the value of genomics and proteomics approaches by studying the intersection of genomics and proteomics data. This task is challenging due to the complex nature of transcriptional and translation regulatory mechanisms and the disparities between genomic and proteomic data from the same samples. In this study, we have examined tumor antigens as potential biomarkers for breast cancer using genomics and proteomics data from previously reported laser capture microdissected ER+ tumor samples.
Results: We applied proteogenomic analyses to study the genetic aberrations of 32 tumor antigens determined in the proteomic data. We found that tumor antigens that are aberrantly expressed at the genetic level and expressed at the protein level, are likely involved in perturbing pathways directly linked to the hallmarks of cancer. The results found by proteogenomic analysis of the 32 tumor antigens studied here, capture largely the same pathway irregularities as those elucidated from large-scale screening of genomics analyses, where several thousands of genes are often found to be perturbed.
Conclusion: Tumor antigens are a group of proteins recognized by the cells of the immune system. Specifically, they are recognized in tumor cells where they are present in larger than usual amounts, or are physiochemically altered to a degree at which they no longer resemble native human proteins. This proteogenomic analysis of 32 tumor antigens suggests that tumor antigens have the potential to be highly specific biomarkers for different cancers.
C1 [Olsen, Lars Ronn; Winther, Ole] Univ Copenhagen, Dept Biol, Bioinformat Ctr, Copenhagen, Denmark.
[Olsen, Lars Ronn] Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark.
[Olsen, Lars Ronn; Brusic, Vladimir] Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Campos, Benito] Univ Heidelberg Hosp, Dept Neurosurg, Div Expt Neurosurg, Heidelberg, Germany.
[Winther, Ole] Tech Univ Denmark, Cognit Syst, DTU Compute, DK-2800 Lyngby, Denmark.
[Sgroi, Dennis C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Karger, Barry L.] Northeastern Univ, Barnett Inst, Boston, MA 02115 USA.
[Brusic, Vladimir] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Brusic, Vladimir] Boston Univ, Dept Comp Sci, Metropolitan Coll, Boston, MA 02215 USA.
[Brusic, Vladimir] Nazarbayev Univ, Sch Sci & Technol, Astana, Kazakhstan.
RP Brusic, V (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, 44 Binney St, Boston, MA 02115 USA.
EM vladimir.brusic@nu.edu.kz
OI Olsen, Lars Ronn/0000-0002-6725-7850
FU Novo Nordisk Foundation; Susan G. Komen Breast Cancer Foundation; NIH
[RO1GM15847, R01CA112021]; NCI; Avon Foundation
FX This work was supported by the Novo Nordisk Foundation (LRO and OW), the
Susan G. Komen Breast Cancer Foundation (BLK and DCS), NIH grant
RO1GM15847 (BLK), NIH grant R01CA112021 (DCS), the NCI SPORE in breast
cancer at Massachusetts General Hospital (DCS) and the Avon Foundation
(DCS). Publication charges for this work was funded by a Novo Nordisk
Foundation grant to OW.
NR 117
TC 4
Z9 4
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD DEC 8
PY 2014
VL 7
SU 3
AR S2
DI 10.1186/1755-8794-7-S3-S2
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA CH4DF
UT WOS:000353981300002
PM 25521819
ER
PT J
AU Lee, SJ
Ritchie, CS
Yaffe, K
Cenzer, IS
Barnes, DE
AF Lee, Sei J.
Ritchie, Christine S.
Yaffe, Kristine
Cenzer, Irena Stijacic
Barnes, Deborah E.
TI A Clinical Index to Predict Progression from Mild Cognitive Impairment
to Dementia Due to Alzheimer's Disease
SO PLOS ONE
LA English
DT Article
ID OLDER-ADULTS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL
INSTITUTE; RISK; RECOMMENDATIONS; CLASSIFICATION; VALIDATION;
BIOMARKERS; CONVERSION
AB Background: Mild cognitive impairment is often a precursor to dementia due to Alzheimer's disease, but many patients with mild cognitive impairment never develop dementia. New diagnostic criteria may lead to more patients receiving a diagnosis of mild cognitive impairment.
Objective: To develop a prediction index for the 3-year risk of progression from mild cognitive impairment to dementia relying only on information that can be readily obtained in most clinical settings.
Design and Participants: 382 participants diagnosed with amnestic mild cognitive impairment enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI), a multi-site, longitudinal, observational study.
Main Predictors Measures: Demographics, comorbid conditions, caregiver report of participant symptoms and function, and participant performance on individual items from basic neuropsychological scales.
Main Outcome Measure: Progression to probable Alzheimer's disease.
Key Results: Subjects had a mean (SD) age of 75 (7) years and 43% progressed to probable Alzheimer's disease within 3 years. Important independent predictors of progression included being female, resisting help, becoming upset when separated from caregiver, difficulty shopping alone, forgetting appointments, number of words recalled from a 10-word list, orientation and difficulty drawing a clock. The final point score could range from 0 to 16 (mean [SD]: 4.2 [2.9]). The optimism-corrected Harrell's c-statistic was 0.71(95% CI: 0.68-0.75). Fourteen percent of subjects with low risk scores (0-2 points, n=124) converted to probable Alzheimer's disease over 3 years, compared to 51% of those with moderate risk scores (3-8 points, n=223) and 91% of those with high risk scores (9-16 points, n=35).
Conclusions: An index using factors that can be obtained in most clinical settings can predict progression from amnestic mild cognitive impairment to probable Alzheimer's disease and may help clinicians differentiate between mild cognitive impairment patients at low vs. high risk of progression.
C1 [Lee, Sei J.; Ritchie, Christine S.; Cenzer, Irena Stijacic] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Lee, Sei J.; Ritchie, Christine S.; Yaffe, Kristine; Cenzer, Irena Stijacic; Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ritchie, Christine S.] Jewish Home San Francisco, San Francisco, CA USA.
[Yaffe, Kristine; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, Kristine; Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Lee, SJ (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
EM sei.lee@ucsf.edu
FU S.D. Bechtel, Jr. Foundation; National Institutes of Health
[K24-AG031155, R01-DK69406, R01-AG26720]; Veterans Health Administration
FX SJL was supported by the S.D. Bechtel, Jr. Foundation
(http://sdbjrfoundation.org/). KY was supported for this study by the
National Institutes of Health (K24-AG031155, R01-DK69406 and
R01-AG26720) and the Veterans Health Administration. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 40
TC 4
Z9 4
U1 3
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 8
PY 2014
VL 9
IS 12
AR e113535
DI 10.1371/journal.pone.0113535
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX4MX
UT WOS:000346907600021
PM 25486250
ER
PT J
AU Umeh, CC
Peerez, A
Augustine, EF
Dhall, R
Dewey, RB
Mari, Z
Simon, DK
Wills, AMA
Christine, CW
Schneider, JS
Suchowersky, O
AF Umeh, Chizoba C.
Perez, Adriana
Augustine, Erika F.
Dhall, Rohit
Dewey, Richard B., Jr.
Mari, Zoltan
Simon, David K.
Wills, Anne-Marie A.
Christine, Chadwick W.
Schneider, Jay S.
Suchowersky, Oksana
TI No Sex Differences in Use of Dopaminergic Medication in Early Parkinson
Disease in the US and Canada - Baseline Findings of a Multicenter Trial
SO PLOS ONE
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; GENDER-DIFFERENCES;
LEVODOPA; DISPARITIES; DYSKINESIA; STROKE
AB Background: Sex differences in Parkinson disease clinical features have been reported, but few studies have examined sex influences on use of dopaminergic medication in early Parkinson disease. The objective of this study was to test if there are differences in the type of dopaminergic medication used and levodopa equivalent daily dose between men and women with early Parkinson disease enrolled in a large multicenter study of Creatine as a potential disease modifying therapy - the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease Long-Term Study-1.
Methods: Baseline data of 1,741 participants from 45 participating sites were analyzed. Participants from the United States and Canada were enrolled within five years of Parkinson Disease diagnosis. Two outcome variables were studied: type of dopaminergic medication used and levodopa equivalent daily dose at baseline in the Long-Term Study-1. Chi-square statistic and linear regression models were used for statistical analysis.
Results: There were no statistically significant differences in the frequency of use of different types of dopaminergic medications at baseline between men and women with Parkinson Disease. A small but statistically significant difference was observed in the median unadjusted levodopa equivalent daily dose at baseline between women (300 mg) and men (325 mg), but this was not observed after controlling for disease duration (years since Parkinson disease diagnosis), disease severity (Unified Parkinson's Disease Rating Scale Motor and Activities of Daily Living Scores), and body weight.
Conclusions: In this large multicenter study, we did not observe sex differences in the type and dose of dopaminergic medications used in early Parkinson Disease. Further research is needed to evaluate the influence of male or female sex on use of dopaminergic medication in mid-and late-stage Parkinson Disease.
C1 [Umeh, Chizoba C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Perez, Adriana] Univ Texas Austin, Sch Publ Hlth, Dept Biostat, Austin, TX 78712 USA.
[Augustine, Erika F.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
[Dhall, Rohit] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA.
[Dewey, Richard B., Jr.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA.
[Mari, Zoltan] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
[Simon, David K.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
[Simon, David K.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Wills, Anne-Marie A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Christine, Chadwick W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Schneider, Jay S.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.
[Suchowersky, Oksana] Univ Alberta, Dept Med Neurol, Edmonton, AB, Canada.
[Suchowersky, Oksana] Univ Alberta, Dept Med Genet, Edmonton, AB, Canada.
[Suchowersky, Oksana] Univ Alberta, Dept Pediat, Edmonton, AB, Canada.
RP Umeh, CC (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.
EM cumeh@partners.org
FU NIH [U01NS043128]
FX Dr. Adriana Perez received financial support from NIH grant U01NS043128.
NIH had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
NR 21
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 8
PY 2014
VL 9
IS 12
AR e112287
DI 10.1371/journal.pone.0112287
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX4MX
UT WOS:000346907600009
PM 25486269
ER
PT J
AU Sun, J
Zhang, GL
Li, SY
Ivanov, AR
Fenyo, D
Lisacek, F
Murthy, SK
Karger, BL
Brusic, V
AF Sun, Jing
Zhang, Guang Lan
Li, Siyang
Ivanov, Alexander R.
Fenyo, David
Lisacek, Frederique
Murthy, Shashi K.
Karger, Barry L.
Brusic, Vladimir
TI Pathway analysis and transcriptomics improve protein identification by
shotgun proteomics from samples comprising small number of cells - a
benchmarking study
SO BMC GENOMICS
LA English
DT Article
ID CIRCULATING TUMOR-CELLS; MASS-SPECTROMETRY; CANCER-CELLS; RESOURCE
UNIPROT; SINGLE-CELL; DATABASE; SPECTRA; LINE
AB Background: Proteomics research is enabled with the high-throughput technologies, but our ability to identify expressed proteome is limited in small samples. The coverage and consistency of proteome expression are critical problems in proteomics. Here, we propose pathway analysis and combination of microproteomics and transcriptomics analyses to improve mass-spectrometry protein identification from small size samples.
Results: Multiple proteomics runs using MCF-7 cell line detected 4,957 expressed proteins. About 80% of expressed proteins were present in MCF-7 transcripts data; highly expressed transcripts are more likely to have expressed proteins. Approximately 1,000 proteins were detected in each run of the small sample proteomics. These proteins were mapped to gene symbols and compared with gene sets representing canonical pathways, more than 4,000 genes were extracted from the enriched gene sets. The identified canonical pathways were largely overlapping between individual runs. Of identified pathways 182 were shared between three individual small sample runs.
Conclusions: Current technologies enable us to directly 10% of expressed proteomes from small sample comprising as few as 50 cells. We used knowledge-based approaches to elucidate the missing proteome that can be verified by targeted proteomics. This knowledge-based approach includes pathway analysis and combination of gene expression and protein expression data for target prioritization. Genes present in both the enriched gene sets (canonical pathways collection) and in small sample proteomics data correspond to approximately 50% of expressed proteomes in larger sample proteomics data. In addition, 90% of targets from canonical pathways were estimated to be expressed. The comparison of proteomics and transcriptomics data, suggests that highly expressed transcripts have high probability of protein expression. However, approximately 10% of expressed proteins could not be matched with the expressed transcripts.
C1 [Sun, Jing; Zhang, Guang Lan; Brusic, Vladimir] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Zhang, Guang Lan; Brusic, Vladimir] Boston Univ, Dept Comp Sci, Metropolitan Coll, Boston, MA 02215 USA.
[Li, Siyang; Ivanov, Alexander R.; Karger, Barry L.] Northeastern Univ, Barnett Inst, Boston, MA 02115 USA.
[Fenyo, David] NYU, Med Ctr, Ctr Hlth Informat & Bioinformat, Lab Computat Prote, New York, NY 10016 USA.
[Lisacek, Frederique] CMU, Swiss Inst Bioinformat, Proteome Informat Grp, Geneva, Switzerland.
[Murthy, Shashi K.] Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA.
[Brusic, Vladimir] Nazarbayev Univ, Sch Sci & Technol, Astana, Kazakhstan.
RP Brusic, V (reprint author), Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
EM Vladimir.brusic@nu.edu.kz
OI LISACEK, Frederique/0000-0002-0948-4537; Fenyo,
David/0000-0001-5049-3825
FU Vladimir Brusic
FX The cost of this publication was funded by Vladimir Brusic.
NR 43
TC 1
Z9 1
U1 4
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD DEC 8
PY 2014
VL 15
SU 9
AR S1
DI 10.1186/1471-2164-15-S9-S1
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AW3DQ
UT WOS:000346166300002
ER
PT J
AU Kaelin, WG
AF Kaelin, William G., Jr.
TI DisABLing Kidney Cancers Caused by Fumarate Hydratase Mutations
SO CANCER CELL
LA English
DT Editorial Material
ID RENAL-CELL CARCINOMA; PHENOTYPE
AB Reprogramming of cellular metabolism by oncogenic mutations probably creates specific vulnerabilities that could be exploited therapeutically. In this issue of Cancer Cell, Sourbier and colleagues show that kidney cancers lacking fumarate hydratase display increased sensitivity to agents that interfere with their ability to cope with reactive oxygen species.
C1 [Kaelin, William G., Jr.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Kaelin, William G., Jr.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Kaelin, William G., Jr.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA.
RP Kaelin, WG (reprint author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
EM william_kaelin@dfci.harvard.edu
NR 10
TC 1
Z9 1
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD DEC 8
PY 2014
VL 26
IS 6
BP 779
EP 780
DI 10.1016/j.ccell.2014.11.022
PG 2
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AW2JN
UT WOS:000346114000005
PM 25490441
ER
PT J
AU Landau, DA
Clement, K
Ziller, MJ
Boyle, P
Fan, J
Gu, HC
Stevenson, K
Sougnez, C
Wang, L
Li, SQ
Kotliar, D
Zhang, W
Ghandi, M
Garraway, L
Fernandes, SM
Livak, KJ
Gabriel, S
Gnirke, A
Lander, ES
Brown, JR
Neuberg, D
Kharchenko, PV
Hacohen, N
Getz, G
Meissner, A
Wu, CJ
AF Landau, Dan A.
Clement, Kendell
Ziller, Michael J.
Boyle, Patrick
Fan, Jean
Gu, Hongcang
Stevenson, Kristen
Sougnez, Carrie
Wang, Lili
Li, Shuqang
Kotliar, Dylan
Zhang, Wandi
Ghandi, Mahmoud
Garraway, Levi
Fernandes, Stacey M.
Livak, Kenneth J.
Gabriel, Stacey
Gnirke, Andreas
Lander, Eric S.
Brown, Jennifer R.
Neuberg, Donna
Kharchenko, Peter V.
Hacohen, Nir
Getz, Gad
Meissner, Alexander
Wu, Catherine J.
TI Locally Disordered Methylation Forms the Basis of Intratumor Methylome
Variation in Chronic Lymphocytic Leukemia
SO CANCER CELL
LA English
DT Article
ID DNA METHYLATION; GENE-EXPRESSION; EPIGENETIC MEMORY; STEM-CELLS;
RNA-SEQ; CANCER; GENOME; HYPOMETHYLATION; PROFILE; IDENTIFICATION
AB Intratumoral heterogeneity plays a critical role in tumor evolution. To define the contribution of DNA methylation to heterogeneity within tumors, we performed genome-scale bisulfite sequencing of 104 primary chronic lymphocytic leukemias (CLLs). Compared with 26 normal B cell samples, CLLs consistently displayed higher intrasample variability of DNA methylation patterns across the genome, which appears to arise from stochastically disordered methylation in malignant cells. Transcriptome analysis of bulk and single CLL cells revealed that methylation disorder was linked to low-level expression. Disordered methylation was further associated with adverse clinical outcome. We therefore propose that disordered methylation plays a similar role to that of genetic instability, enhancing the ability of cancer cells to search for superior evolutionary trajectories.
C1 [Landau, Dan A.; Wang, Lili; Garraway, Levi; Fernandes, Stacey M.; Brown, Jennifer R.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Landau, Dan A.; Clement, Kendell; Ziller, Michael J.; Boyle, Patrick; Gu, Hongcang; Sougnez, Carrie; Ghandi, Mahmoud; Garraway, Levi; Gabriel, Stacey; Gnirke, Andreas; Lander, Eric S.; Hacohen, Nir; Getz, Gad; Meissner, Alexander] Broad Inst, Cambridge, MA 02139 USA.
[Clement, Kendell; Ziller, Michael J.; Meissner, Alexander] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Clement, Kendell; Ziller, Michael J.; Meissner, Alexander] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Fan, Jean; Kharchenko, Peter V.] Harvard Univ, Sch Med, Ctr Informat Biol, Boston, MA 02115 USA.
[Stevenson, Kristen; Neuberg, Donna] Dana Farber Canc Inst, Deptt Biostatist & Computat Biol, Boston, MA 02115 USA.
[Li, Shuqang; Livak, Kenneth J.] Fluidigm, San Francisco, CA 94080 USA.
[Brown, Jennifer R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Kharchenko, Peter V.; Wu, Catherine J.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Getz, Gad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Meissner, A (reprint author), Broad Inst, Cambridge, MA 02139 USA.
EM alexander_meissner@harvard.edu; cwu@partners.org
OI Fan, Jean/0000-0002-0212-5451; Ghandi, Mahmoud/0000-0003-1897-2265
FU American Cancer Society (ACS); NIH Big Data to Knowledge initiative
[BD2K, 1K01ES025431-01]; National Science Foundation [DGE1144152]; NIH
[U01ES017155, R01DA036898]; Blavatnik Family Foundation; American
Association for Cancer Research; National Heart, Lung, and Blood
Institute [1R01HL103532-01]; National Cancer Institute
[1R01CA15501001A1]
FX We thank all members of the Broad Institute's Biological Samples,
Genetic Analysis, and Genome Sequencing Platforms, who made this work
possible (NHGRI-U54HG003067). We thank Rahul Satija, Angela Brooks,
Scott Carter and Brad Bernstein for their Valuable input and insights.
We thank John Daley, Suzan Lazo-Kallanian, Jonna Grimsby, and Niall
Lennon for their assistance in the single-cell RNA-seq. We thank Adam
Kiezun for his guidance regarding germline SNP detection and Michael
Lawrence for the replication time data. D.A.L. is supported by a
Postdoctoral Fellowship from the American Cancer Society (ACS) and by
the NIH Big Data to Knowledge initiative (BD2K, 1K01ES025431-01). K.C.
is supported by the National Science Foundation Graduate Research
Fellowship under Grant No. 112237. L.W. is supported by a Lymphoma
Research Foundation Postdoctoral Fellowship. J.F. is supported by the
National Science Foundation Graduate Research Fellowship (DGE1144152).
J.R.B. is a Scholar in Clinical Research of the Leukemia & Lymphoma
Society (LLS) and is supported by a LLS Translational Research Program
award as well as an ACS Research Scholar Grant and the Melton and
Rosenbach Funds. A.M. is a New York Stem Cell Foundation Robertson
Investigator and received support from NIH grants U01ES017155 and
1R01DA036898. C.J.W. is a Scholar of LLS and the recipient of a Quest
for Cures Award from LLS. She acknowledges support from the Blavatnik
Family Foundation, the American Association for Cancer Research (Stand
Up to Cancer Innovative Research Grant), the National Heart, Lung, and
Blood Institute (1R01HL103532-01), and the National Cancer Institute
(1R01CA15501001A1). K.J.L. and S.L. are employees of Fluidigm
Corporation.
NR 52
TC 57
Z9 58
U1 1
U2 22
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD DEC 8
PY 2014
VL 26
IS 6
BP 813
EP 825
DI 10.1016/j.ccell.2014.10.012
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AW2JN
UT WOS:000346114000011
PM 25490447
ER
PT J
AU Deshpande, AJ
Deshpande, A
Sinha, AU
Chen, L
Chang, J
Cihan, A
Fazio, M
Chen, CW
Zhu, N
Koche, R
Dzhekieva, L
Ibanez, G
Dias, S
Banka, D
Krivtsov, A
Luo, M
Roeder, RG
Bradner, JE
Bernt, KM
Armstrong, SA
AF Deshpande, Aniruddha J.
Deshpande, Anagha
Sinha, Amit U.
Chen, Liying
Chang, Jenny
Cihan, Ali
Fazio, Maurizio
Chen, Chun-wei
Zhu, Nan
Koche, Richard
Dzhekieva, Liuda
Ibanez, Gloria
Dias, Stuart
Banka, Deepti
Krivtsov, Andrei
Luo, Minkui
Roeder, Robert G.
Bradner, James E.
Bernt, Kathrin M.
Armstrong, Scott A.
TI AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in
Diverse AML Subtypes
SO CANCER CELL
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; METHYLTRANSFERASE ACTIVITY; CHROMATIN
MODIFICATIONS; STEM-CELLS; ADULT AML; DOT1L; EZH2; FUSION; INHIBITION;
PROTEIN
AB Homeotic (HOX) genes are dysregulated in multiple malignancies, including several AML subtypes. We demonstrate that H3K79 dimethylation (H3K79me2) is converted to monomethylation (H3K79me1) at HOX loci as hematopoietic cells mature, thus coinciding with a decrease in HOX gene expression. We show that H3K79 methyltransferase activity as well as H3K79me1-to-H3K79me2 conversion is regulated by the DOT1L cofactor AF10. AF10 inactivation reverses leukemia-associated epigenetic profiles, precludes abnormal HOXA gene expression, and impairs the transforming ability of MLL-AF9, MLL-AF6, and NUP98-NSD1 fusions-mechanistically distinct HOX-activating oncogenes. Furthermore, NUP98-NSD1-transformed cells are sensitive to small-molecule inhibition of DOT1L. Our findings demonstrate that pharmacological inhibition of the DOT1L/JAF10 complex may provide therapeutic benefits in an array of malignancies with abnormal HOXA gene expression.
C1 [Deshpande, Aniruddha J.; Chen, Liying; Dias, Stuart; Banka, Deepti; Armstrong, Scott A.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Dzhekieva, Liuda; Luo, Minkui] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10065 USA.
[Bradner, James E.] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bernt, Kathrin M.] Univ Colorado, Dept Pediat, Aurora, CO 80045 USA.
[Cihan, Ali; Roeder, Robert G.] Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10065 USA.
[Deshpande, Aniruddha J.; Deshpande, Anagha; Sinha, Amit U.; Chang, Jenny; Fazio, Maurizio; Chen, Chun-wei; Zhu, Nan; Koche, Richard; Krivtsov, Andrei; Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA.
[Deshpande, Aniruddha J.; Deshpande, Anagha; Sinha, Amit U.; Chang, Jenny; Fazio, Maurizio; Chen, Chun-wei; Zhu, Nan; Koche, Richard; Krivtsov, Andrei; Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
RP Armstrong, SA (reprint author), Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
EM armstros@mskcc.org
RI Bernt, Kathrin/L-1826-2016;
OI Bernt, Kathrin/0000-0002-5400-0482; Krivtsov, Andrei/0000-0002-5511-1686
FU American Cancer Society; Leukemia and Lymphoma Society; Gabrielle's
Angel Foundation; NCI [CA105423, CA140575, CA176745]
FX We acknowledge Ronald Hendrickson, Yuko Fujiwara, and Stuart Orkin for
valuable assistance with MS analysis and knockout mouse generation. This
work was supported by the American Cancer Society; by the Leukemia and
Lymphoma Society; by Gabrielle's Angel Foundation and by NCI Grants
CA105423, CA140575, and CA176745 (to S.A.A.); and by the NCI K99 Award
(to A.J.D.). S.A.A. is a consultant for Epizyme Inc. The protein complex
purification work and the MS studies were supported by LLS SCOR Grant
7132-08 (to R.G.R.) and by NCI Cancer Center Support Grant P30 CA08748
(to M.S.K.C.C.).
NR 39
TC 29
Z9 30
U1 0
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD DEC 8
PY 2014
VL 26
IS 6
BP 896
EP 908
DI 10.1016/j.ccell.2014.10.009
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AW2JN
UT WOS:000346114000017
PM 25464900
ER
PT J
AU Christensen, CL
Kwiatkowski, N
Abrahanm, BJ
Carretero, J
Al-Shahrour, F
Zhang, TH
Chipumuro, E
Herter-Sprie, GS
Akbay, EA
Altabef, A
Zhang, JM
Shimamura, T
Capelletti, M
Reibel, JB
Cavanaugh, JD
Gao, P
Liu, Y
Michaelsen, SR
Poulsen, HS
Aref, AR
Barbie, DA
Bradner, JE
George, RE
Gray, NS
Young, RA
Won, KK
AF Christensen, Camilla L.
Kwiatkowski, Nicholas
Abrahanm, Brian J.
Carretero, Julian
Al-Shahrour, Fatima
Zhang, Tinghu
Chipumuro, Edmond
Herter-Sprie, Grit S.
Akbay, Esra A.
Altabef, Abigail
Zhang, Jianming
Shimamura, Takeshi
Capelletti, Marzia
Reibel, Jakob B.
Cavanaugh, Jillian D.
Gao, Peng
Liu, Yan
Michaelsen, Signe R.
Poulsen, Hans S.
Aref, Amir R.
Barbie, David A.
Bradner, James E.
George, Rani E.
Gray, Nathanael S.
Young, Richard A.
Won, Kwok-Kin
TI Targeting Transcriptional Addictions in Small Cell Lung Cancer with a
Covalent CDK7 Inhibitor
SO CANCER CELL
LA English
DT Article
ID CONDITIONAL MOUSE MODEL; NEUROENDOCRINE DIFFERENTIATION;
SUPER-ENHANCERS; GENE-EXPRESSION; SELECTIVE-INHIBITION; TUMOR-CELLS;
AMPLIFICATION; MYC; CARCINOMA; GENOME
AB Small cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective pharmacological strategies to target SCLC biology represents an urgent need. Using a high-throughput cellular screen of a diverse chemical library, we observe that SCLC is sensitive to transcription-targeting drugs, in particular to THZ1, a recently identified covalent inhibitor of cyclin-dependent kinase 7. We find that expression of super-enhancer-associated transcription factor genes, including MYC family proto-oncogenes and neuroendocrine lineage-specific factors, is highly vulnerability to THZ1 treatment. We propose that downregulation of these transcription factors contributes, in part, to SCLC sensitivity to transcriptional inhibitors and that THZ1 represents a prototype drug for tailored SCLC therapy.
C1 [Christensen, Camilla L.; Herter-Sprie, Grit S.; Akbay, Esra A.; Altabef, Abigail; Capelletti, Marzia; Reibel, Jakob B.; Cavanaugh, Jillian D.; Gao, Peng; Liu, Yan; Aref, Amir R.; Barbie, David A.; Bradner, James E.; Won, Kwok-Kin] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kwiatkowski, Nicholas; Abrahanm, Brian J.; Young, Richard A.] MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Carretero, Julian] Univ Valencia, Fac Farm, Dept Fisiol, E-46010 Valencia, Spain.
[Al-Shahrour, Fatima] Spanish Natl Canc Res Ctr, Translat Bioinformat Unit, Clin Res Programme, Madrid 28029, Spain.
[Zhang, Tinghu; Zhang, Jianming; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Chipumuro, Edmond; George, Rani E.] Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA.
[Chipumuro, Edmond; George, Rani E.] Childrens Hosp, Boston, MA 02115 USA.
[Shimamura, Takeshi] Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Oncol Res Inst, Stritch Sch Med, Maywood, IL 60153 USA.
[Michaelsen, Signe R.; Poulsen, Hans S.] Univ Copenhagen Hosp, Dept Radiat Biol, Finsen Ctr, DK-2100 Copenhagen, Denmark.
[Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Gray, Nathanael S.; Won, Kwok-Kin] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.
RP Young, RA (reprint author), MIT, Whitehead Inst Biomed Res, 77 Massachusetts Ave, Cambridge, MA 02142 USA.
EM young@wi.mit.edu; kwong1@partners.org
RI Carretero, Julian/N-5214-2014; Young, Richard/F-6495-2012
OI Carretero, Julian/0000-0001-7269-8506; Young,
Richard/0000-0001-8855-8647
FU Danish Cancer Society [R56-A3106-12-S2]; Deutsche Forschungsgemeinschaft
[HE6897/1-1]; National Institutes of Health [CA122794, CA140594,
CA163896, CA166480, CA154303, CA120964, R01 CA179483-01A1]; Thoracic
Foundation; Susan Spooner Foundation; MIT-DFCI Bridge grant
FX This work was supported by a Post-Doctoral Fellowship (R56-A3106-12-S2)
from the Danish Cancer Society (C.L.C.), Deutsche Forschungsgemeinschaft
(HE6897/1-1) (G.S.H.-S.), National Institutes of Health grants CA122794,
CA140594, CA163896, CA166480, CA154303, and CA120964 (K.-K.W.), grant
R01 CA179483-01A1 (N.S.G.), the Thoracic Foundation (K.-K.W.), the Susan
Spooner Foundation (K.-K.W.), and an MIT-DFCI Bridge grant (K.-K.W.,
N.S.G., and RAY.). R.A.Y., N.S.G., and J.E.B. are founders and equity
holders in Syros, which has licensed the CDK7 intellectual property from
the DanaFarber Cancer Institute. N.K., T.Z., and N.S.G. are inventors on
a patent application covering THZ1.
NR 42
TC 43
Z9 43
U1 8
U2 28
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD DEC 8
PY 2014
VL 26
IS 6
BP 909
EP 922
DI 10.1016/j.ccell.2014.10.019
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AW2JN
UT WOS:000346114000018
PM 25490451
ER
PT J
AU Tardif, JC
Ballantyne, CM
Barter, P
Dasseux, JL
Fayad, ZA
Guertin, MC
Kastelein, JJP
Keyserling, C
Klepp, H
Koenig, W
L'Allier, PL
Lesperance, J
Luscher, TF
Paolini, JF
Tawakol, A
Waters, DD
AF Tardif, Jean-Claude
Ballantyne, Christie M.
Barter, Philip
Dasseux, Jean-Louis
Fayad, Zahi A.
Guertin, Marie-Claude
Kastelein, John J. P.
Keyserling, Constance
Klepp, Heather
Koenig, Wolfgang
L'Allier, Philippe L.
Lesperance, Jacques
Luescher, Thomas F.
Paolini, John F.
Tawakol, Ahmed
Waters, David D.
CA Can Hdl Infusions Significantly
TI Effects of the high-density lipoprotein mimetic agent CER-001 on
coronary atherosclerosis in patients with acute coronary syndromes: a
randomized trial
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Atherosclerosis; Coronary disease; High-density lipoproteins; Clinical
trial
ID ARTERY-DISEASE; INTRAVASCULAR ULTRASOUND; INTERVENTION TRIAL; STATIN
THERAPY; HIGH-RISK; CHOLESTEROL; PROGRESSION; PROBUCOL; ANGIOPLASTY;
INHIBITOR
AB Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo.
Objective To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA).
Design and setting A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2-5) weeks after the last study infusion.
Patients Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively.
Intervention Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001.
Main outcome measures The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints.
Results The nominal change in the total atheroma volume (adjusted means) was -2.71, -3.13, -1.50, and -3.05 mm(3) with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, -0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was -0.022, -0.036, -0.022, and -0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was -0.51, 2.65, 0.71, and -0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups.
Conclusion CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await further study. Name of the trial registry: Clinicaltrials.gov; Registry's URL:http://clinicaltrials.gov/ct2/show/NCT01201837?term=cer-001 & rank=2; Trial registration number: NCT01201837.
C1 [Tardif, Jean-Claude; Guertin, Marie-Claude; L'Allier, Philippe L.; Lesperance, Jacques] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Tardif, Jean-Claude; Guertin, Marie-Claude; L'Allier, Philippe L.; Lesperance, Jacques] Univ Montreal, MHICC, Montreal, PQ H1T 1C8, Canada.
[Ballantyne, Christie M.] Baylor Coll Med, Houston, TX 77030 USA.
[Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA.
[Barter, Philip] Univ New S Wales, Ctr Vasc Res, Sydney, NSW, Australia.
[Dasseux, Jean-Louis; Keyserling, Constance; Klepp, Heather; Paolini, John F.] Cerenis Therapeut Holding, Labege, France.
[Fayad, Zahi A.] Icahn Sch Med Mt Sinai, Translat & Mol Imaging Inst, New York, NY 10029 USA.
[Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands.
[Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, D-89069 Ulm, Germany.
[Luescher, Thomas F.] Univ Zurich Hosp, Univ Heart Ctr, CH-8091 Zurich, Switzerland.
[Tawakol, Ahmed] Harvard Univ, Sch Med, Boston, MA USA.
[Tawakol, Ahmed] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Waters, David D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Tardif, JC (reprint author), Montreal Heart Inst, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada.
EM jean-claude.tardif@icm-mhi.org
OI Brilakis, Emmanouil/0000-0001-9416-9701
NR 25
TC 64
Z9 65
U1 1
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD DEC 7
PY 2014
VL 35
IS 46
BP 3277
EP 3286
DI 10.1093/eurheartj/ehu171
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AW6WN
UT WOS:000346406300016
PM 24780501
ER
PT J
AU Verburg, JM
Seco, J
AF Verburg, Joost M.
Seco, Joao
TI Proton range verification through prompt gamma-ray spectroscopy
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE proton therapy; range verification; prompt gamma-ray detection
ID CROSS-SECTIONS; TREATMENT SITE; THERAPY; EMISSION; DISTRIBUTIONS;
NUCLEI; CARBON; PET; RADIOTHERAPY; BOMBARDMENT
AB We present an experimental study of a novel method to verify the range of proton therapy beams. Differential cross sections were measured for 15 prompt gamma-ray lines from proton-nuclear interactions with C-12 and O-16 at proton energies up to 150 MeV. These cross sections were used to model discrete prompt gamma-ray emissions along proton pencil-beams. By fitting detected prompt gamma-ray counts to these models, we simultaneously determined the beam range and the oxygen and carbon concentration of the irradiated matter. The performance of the method was assessed in two phantoms with different elemental concentrations, using a small scale prototype detector. Based on five pencil-beams with different ranges delivering 5 x 108 protons and without prior knowledge of the elemental composition at the measurement point, the absolute range was determined with a standard deviation of 1.0-1.4 mm. Relative range shifts at the same dose level were detected with a standard deviation of 0.3-0.5 mm. The determined oxygen and carbon concentrations also agreed well with the actual values. These results show that quantitative prompt gamma-ray measurements enable knowledge of nuclear reaction cross sections to be used for precise proton range verification in the presence of tissue with an unknown composition.
C1 [Verburg, Joost M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Verburg, Joost M.; Seco, Joao] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Verburg, Joost M.] Eindhoven Univ Technol, Sch Med Phys & Engn, NL-5600 MB Eindhoven, Netherlands.
RP Verburg, JM (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.
EM jverburg@fas.harvard.edu
FU Federal Share of program [C06-CA059267]
FX The authors would like to thank M Testa PhD, for the helpful discussions
and for his assistance with the experiments. We would like to thank E
Cascio for designing the electronic circuit for beam monitoring and T
Ruggieri for machining parts for the experimental setup. Also, thanks to
B Clasie PhD, B Brett and J Flanz PhD, for their help with the cyclotron
operations. This work was supported by the Federal Share of program
income earned by Massachusetts General Hospital on C06-CA059267, Proton
Therapy Research and Treatment Center.
NR 30
TC 33
Z9 33
U1 1
U2 3
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD DEC 7
PY 2014
VL 59
IS 23
BP 7089
EP 7106
DI 10.1088/0031-9155/59/23/7089
PG 18
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA AT9NN
UT WOS:000345254000004
PM 25365362
ER
PT J
AU Edmund, JM
Kjer, HM
Van Leemput, K
Hansen, RH
Andersen, JAL
Andreasen, D
AF Edmund, Jens M.
Kjer, Hans M.
Van Leemput, Koen
Hansen, Rasmus H.
Andersen, Jon A. L.
Andreasen, Daniel
TI A voxel-based investigation for MRI-only radiotherapy of the brain using
ultra short echo times
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE radiotherapy; MRI; imaging; MRI-only; pseudo CT; radiation therapy;
substitute CT
ID MAGNETIC-RESONANCE; ATTENUATION-CORRECTION; COMPUTED-TOMOGRAPHY; IMAGE
REGISTRATION; RADIATION-THERAPY; QUALITY-ASSURANCE; ION RADIOTHERAPY;
CT; PROSTATE; SEQUENCES
AB Radiotherapy (RT) based on magnetic resonance imaging (MRI) as the only modality, so-called MRI-only RT, would remove the systematic registration error between MR and computed tomography (CT), and provide co-registered MRI for assessment of treatment response and adaptive RT. Electron densities, however, need to be assigned to the MRI images for dose calculation and patient setup based on digitally reconstructed radiographs (DRRs). Here, we investigate the geometric and dosimetric performance for a number of popular voxel-based methods to generate a so-called pseudo CT (pCT).
Five patients receiving cranial irradiation, each containing a co-registered MRI and CT scan, were included. An ultra short echo time MRI sequence for bone visualization was used. Six methods were investigated for three popular types of voxel-based approaches; (1) threshold-based segmentation, (2) Bayesian segmentation and (3) statistical regression. Each approach contained two methods. Approach 1 used bulk density assignment of MRI voxels into air, soft tissue and bone based on logical masks and the transverse relaxation time T-2 of the bone. Approach 2 used similar bulk density assignments with Bayesian statistics including or excluding additional spatial information. Approach 3 used a statistical regression correlating MRI voxels with their corresponding CT voxels. A similar photon and proton treatment plan was generated for a target positioned between the nasal cavity and the brainstem for all patients. The CT agreement with the pCT of each method was quantified and compared with the other methods geometrically and dosimetrically using both a number of reported metrics and introducing some novel metrics.
The best geometrical agreement with CT was obtained with the statistical regression methods which performed significantly better than the threshold and Bayesian segmentation methods (excluding spatial information). All methods agreed significantly better with CT than a reference water MRI comparison. The mean dosimetric deviation for photons and protons compared to the CT was about 2% and highest in the gradient dose region of the brainstem. Both the threshold based method and the statistical regression methods showed the highest dosimetrical agreement.
Generation of pCTs using statistical regression seems to be the most promising candidate for MRI-only RT of the brain. Further, the total amount of different tissues needs to be taken into account for dosimetric considerations regardless of their correct geometrical position.
C1 [Edmund, Jens M.; Andersen, Jon A. L.; Andreasen, Daniel] Copenhagen Univ Hosp, Dept Oncol, Radiotherapy Res Unit, Herlev, Denmark.
[Kjer, Hans M.; Van Leemput, Koen; Andreasen, Daniel] Tech Univ Denmark, Dept Appl Math & Comp Sci, DK-2800 Lyngby, Denmark.
[Van Leemput, Koen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
[Hansen, Rasmus H.] Copenhagen Univ Hosp, Dept Radiol, Herlev, Denmark.
RP Edmund, JM (reprint author), Copenhagen Univ Hosp, Dept Oncol, Radiotherapy Res Unit, Herlev, Denmark.
EM jens.edmund@regionh.dk
RI Van Leemput, Koen/A-9197-2009;
OI Van Leemput, Koen/0000-0001-6466-5309; Edmund, Jens
Morgenthaler/0000-0001-5831-6209
FU Varian Medical Systems, Inc.
FX This work was supported by a research grant from Varian Medical Systems,
Inc.
NR 54
TC 14
Z9 14
U1 0
U2 7
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD DEC 7
PY 2014
VL 59
IS 23
BP 7501
EP 7519
DI 10.1088/0031-9155/59/23/7501
PG 19
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA AT9NN
UT WOS:000345254000026
PM 25393873
ER
PT J
AU Advani, AS
Stein, AS
Kantarjian, HM
Shustov, AR
DeAngelo, DJ
Ananthakrishnan, R
Liau, K
Vandendries, E
Stock, W
AF Advani, Anjali S.
Stein, Anthony S.
Kantarjian, Hagop M.
Shustov, Andrei R.
DeAngelo, Daniel J.
Ananthakrishnan, Revathi
Liau, Katherine
Vandendries, Erik
Stock, Wendy
TI A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients
with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later
Salvage
SO BLOOD
LA English
DT Meeting Abstract
C1 [Advani, Anjali S.] Cleveland Clin, Cleveland, OH 44106 USA.
[Stein, Anthony S.] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Shustov, Andrei R.] Univ Washington, Seattle, WA 98195 USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ananthakrishnan, Revathi; Liau, Katherine; Vandendries, Erik] Pfizer Inc, Cambridge, MA USA.
[Stock, Wendy] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707062
ER
PT J
AU Aftab, BT
Anderson, DJ
Le Moigne, R
Djakovic, S
Dhimolea, E
Murnane, M
King, E
Rice, J
Wong, S
Kumar, B
Valle, E
Menon, MK
von Soly, SK
Wang, JH
Yao, B
Soriano, F
Kampmann, M
Alcost-Alvear, D
Chesi, M
Bergsagel, L
Yakes, FM
Zhou, HJ
Wustrow, D
Martin, TG
Wolf, JL
Mitsiades, CS
Rolfe, M
AF Aftab, Blake T.
Anderson, Daniel J.
Le Moigne, Ronan
Djakovic, Stevan
Dhimolea, Eugen
Murnane, Megan
King, Emily
Rice, Julie
Wong, Steve
Kumar, Brajesh
Valle, Eduardo
Menon, Mary-Kamala
von Soly, Szerenke Kiss
Wang, Jinhai
Yao, Bing
Soriano, Ferdie
Kampmann, Martin
Alcost-Alvear, Diego
Chesi, Marta
Bergsagel, Leif
Yakes, F. Michael
Zhou, Han-Jie
Wustrow, David
Martin, Thomas G.
Wolf, Jeffrey L.
Mitsiades, Constantine S.
Rolfe, Mark
TI Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor,
CB-5083, in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Aftab, Blake T.; Murnane, Megan; Kampmann, Martin; Alcost-Alvear, Diego; Martin, Thomas G.; Wolf, Jeffrey L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Anderson, Daniel J.; Le Moigne, Ronan; Djakovic, Stevan; Rice, Julie; Wong, Steve; Kumar, Brajesh; Valle, Eduardo; Menon, Mary-Kamala; von Soly, Szerenke Kiss; Wang, Jinhai; Yao, Bing; Soriano, Ferdie; Yakes, F. Michael; Zhou, Han-Jie; Wustrow, David; Rolfe, Mark] Cleave Biosci, Burlingame, CA USA.
[Dhimolea, Eugen; King, Emily; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chesi, Marta; Bergsagel, Leif] Mayo Clin Scottsdale, Scottsdale, AZ USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700049
ER
PT J
AU An, G
Jiang, H
Acharya, C
Zhong, MY
Cai, T
Yang, G
Song, ZL
Theilhaber, J
Adrian, F
Tai, YT
Anderson, KC
AF An, Gang
Jiang, Hua
Acharya, Chirag
Zhong, Mike Y.
Cai, Ti
Yang, Guang
Song, Zhili
Theilhaber, Joachim
Adrian, Francisco
Tai, Yu-Tzu
Anderson, Kenneth C.
TI SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks
CD38-CD31 Interaction in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
C1 [An, Gang; Jiang, Hua; Acharya, Chirag; Zhong, Mike Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cai, Ti; Yang, Guang; Song, Zhili; Theilhaber, Joachim; Adrian, Francisco] Sanofi Oncol, Cambridge, MA USA.
[Tai, Yu-Tzu] Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA.
[Tai, Yu-Tzu] LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704074
ER
PT J
AU Barnes, JA
Redd, RA
Jacobsen, ED
Fisher, DC
Freedman, AS
Hochberg, EP
Takvorian, T
Neuberg, D
Abramson, JS
AF Barnes, Jeffrey A.
Redd, Robert Allyn
Jacobsen, Eric D.
Fisher, David C.
Freedman, Arnold S.
Hochberg, Ephraim P.
Takvorian, Tak
Neuberg, Donna
Abramson, Jeremy S.
TI Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse
Large B-Cell Lymphoma: Results of a Phase II Study
SO BLOOD
LA English
DT Meeting Abstract
C1 [Barnes, Jeffrey A.; Hochberg, Ephraim P.; Takvorian, Tak; Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Redd, Robert Allyn; Jacobsen, Eric D.; Fisher, David C.; Freedman, Arnold S.; Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 2
Z9 2
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706020
ER
PT J
AU Beltran, BE
Castro, D
Chavez, JC
Sotomayor, EM
Castillo, JJ
AF Beltran, Brady E.
Castro, Denisse
Chavez, Julio C.
Sotomayor, Eduardo M.
Castillo, Jorge J.
TI The Prognostic Value of the Neutrophil to Lymphocyte Ratio in 209
Patients with Peripheral T-Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Beltran, Brady E.; Castro, Denisse] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru.
[Chavez, Julio C.; Sotomayor, Eduardo M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Castillo, Jorge J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708181
ER
PT J
AU Castillo, JJ
Olszewski, AJ
Kanan, S
Meid, K
Hunter, Z
Treon, SP
AF Castillo, Jorge J.
Olszewski, Adam J.
Kanan, Sandra
Meid, Kirsten
Hunter, Zachary
Treon, Steven P.
TI Incidence and Survival Outcomes of Secondary Malignancies Among
Survivors of Waldenstrom Macroglobulinemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Castillo, Jorge J.; Kanan, Sandra; Meid, Kirsten; Hunter, Zachary; Treon, Steven P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Olszewski, Adam J.] Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704066
ER
PT J
AU Chapuy, B
Roemer, MGM
Tan, YX
Stewart, C
Zhang, LY
Dunford, AJ
Jordanova, ES
Feuerhake, F
Illerhaus, G
Gusenleitner, D
Linden, E
Sun, HH
Aono, M
Freeman, GJ
Golub, TR
Getz, G
Rodig, SJ
de Jong, D
Monti, S
Shipp, MA
AF Chapuy, Bjoern
Roemer, Margaretha G. M.
Tan, Yuxiang
Stewart, Chip
Zhang, Liye
Dunford, Andrew J.
Jordanova, Ekaterina S.
Feuerhake, Friedrich
Illerhaus, Gerald
Gusenleitner, Daniel
Linden, Erica
Sun, Heather H.
Aono, Miyuki
Freeman, Gordon J.
Golub, Todd R.
Getz, Gad
Rodig, Scott J.
de Jong, Daphne
Monti, Stefano
Shipp, Margaret A.
TI Actionable Genetic Features of Primary Testicular and Primary Central
Nervous System Lymphomas
SO BLOOD
LA English
DT Meeting Abstract
C1 [Chapuy, Bjoern; Roemer, Margaretha G. M.; Aono, Miyuki; Freeman, Gordon J.; Golub, Todd R.; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Roemer, Margaretha G. M.; Jordanova, Ekaterina S.; de Jong, Daphne] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
[Tan, Yuxiang; Zhang, Liye; Gusenleitner, Daniel; Monti, Stefano] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Stewart, Chip; Dunford, Andrew J.; Golub, Todd R.] Broad Inst, Cambridge, MA USA.
[Feuerhake, Friedrich] Hannover Med Sch, Hannover, Germany.
[Illerhaus, Gerald] Univ Hosp Freiburg, Freiburg, Germany.
[Linden, Erica] MGH North Shore Canc Ctr, Danvers, MA USA.
[Sun, Heather H.; Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Getz, Gad] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Getz, Gad] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704021
ER
PT J
AU Chen, YB
Shuli, L
Andrew, LA
Connolly, C
Del Rio, C
Valles, B
Curtis, M
Ballen, KK
Cutler, CS
Dey, BR
El-Jawahri, A
Fathi, AT
Ho, VT
Joyce, A
McAfee, SL
Rudek, MA
Rajkhowa, T
Verselis, S
Antin, JH
Spitzer, TR
Levis, M
Soiffer, RJ
AF Chen, Yi-Bin
Shuli, Li
Andrew, Lane A.
Connolly, Christine
Del Rio, Candice
Valles, Betsy
Curtis, Morgan
Ballen, Karen K.
Cutler, Corey S.
Dey, Bimalangshu R.
El-Jawahri, Areej
Fathi, Amir T.
Ho, Vincent T.
Joyce, Amy
McAfee, Steven L.
Rudek, Michelle A.
Rajkhowa, Trivikram
Verselis, Sigitas
Antin, Joseph H.
Spitzer, Thomas R.
Levis, Mark
Soiffer, Robert J.
TI Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic
Stem Cell Transplantation for Patients with FLT3-ITD AML
SO BLOOD
LA English
DT Meeting Abstract
C1 [Chen, Yi-Bin; Ballen, Karen K.; Dey, Bimalangshu R.; McAfee, Steven L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Shuli, Li; Andrew, Lane A.; Cutler, Corey S.; Ho, Vincent T.; Joyce, Amy; Verselis, Sigitas; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Connolly, Christine; Del Rio, Candice; Valles, Betsy; Curtis, Morgan; Fathi, Amir T.; Spitzer, Thomas R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[El-Jawahri, Areej] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Rudek, Michelle A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Rajkhowa, Trivikram] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Levis, Mark] Johns Hopkins Univ, Kimmel Canc Ctr, Baltimore, MD USA.
[Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700218
ER
PT J
AU Ciurea, SO
Zhang, MJ
Bacigalupo, A
Bashey, A
Appelbaum, FR
Antin, JH
Chen, JF
Devine, SM
Fowler, DH
Nakamura, R
Perales, MA
Pingali, SR
Porter, DL
Ringden, O
Rocha, V
Vij, R
Weisdorf, DJ
Champlin, RE
Fuchs, EJ
Eapen, M
AF Ciurea, Stefan O.
Zhang, Mei-Jie
Bacigalupo, Andrea
Bashey, Asad
Appelbaum, Frederick R.
Antin, Joseph H.
Chen, Junfang
Devine, Steven M.
Fowler, Daniel H.
Nakamura, Ryotaro
Perales, Miguel-Angel
Pingali, Sai Ravi
Porter, David L.
Ringden, Olle
Rocha, Vanderson
Vij, Ravi
Weisdorf, Daniel J.
Champlin, Richard E.
Fuchs, Ephraim J.
Eapen, Mary
TI Survival after T-Cell Replete Haplo-Identical Related Donor Transplant
Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated
Donor Transplant for Acute Myeloid Leukemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Ciurea, Stefan O.; Pingali, Sai Ravi; Champlin, Richard E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Zhang, Mei-Jie; Chen, Junfang; Eapen, Mary] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Bacigalupo, Andrea] IRCCS AOU San Martino IST, Genoa, Italy.
[Bashey, Asad] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA.
[Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Devine, Steven M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Fowler, Daniel H.] NCI, Bethesda, MD 20892 USA.
[Nakamura, Ryotaro] City Hope Natl Med Ctr, Duarte, CA USA.
[Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Porter, David L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Ringden, Olle] Karolinska Univ Hosp Huddinge, Stockholm, Sweden.
[Rocha, Vanderson] Churchill Hosp, Oxford OX3 7LJ, England.
[Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA.
[Weisdorf, Daniel J.] Univ Minnesota, Minneapolis, MN USA.
[Fuchs, Ephraim J.] Johns Hopkins Univ, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708145
ER
PT J
AU Cleynen, A
Szalat, R
Samur, MK
Rashid, N
Parmigiani, G
Munshi, NC
Avet-Loiseau, H
AF Cleynen, Alice
Szalat, Raphael
Samur, Mehmet Kemal
Rashid, Naim
Parmigiani, Giovanni
Munshi, Nikhil C.
Avet-Loiseau, Herve
TI Frequent Igh Fusion Transcripts with Clinical Impact in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Cleynen, Alice; Parmigiani, Giovanni] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cleynen, Alice; Parmigiani, Giovanni] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Szalat, Raphael] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Szalat, Raphael] Hop St Louis, Paris, France.
[Samur, Mehmet Kemal; Rashid, Naim] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
[Avet-Loiseau, Herve] Univ Hosp Toulouse, Toulouse, France.
[Avet-Loiseau, Herve] CHU Rangueil, F-31054 Toulouse, France.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242705057
ER
PT J
AU Corbacioglu, S
Carreras, E
Mohty, M
Pagliuca, A
Ballabio, M
Hume, RL
Bandiera, V
Finetto, G
Richardson, PG
AF Corbacioglu, Selim
Carreras, Enric
Mohty, Mohamad
Pagliuca, Antonio
Ballabio, Maria
Hume, Robin L.
Bandiera, Valeria
Finetto, Giorgia
Richardson, Paul G.
TI Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An
Update from the International Compassionate Use Program in 710 Patients
SO BLOOD
LA English
DT Meeting Abstract
C1 [Corbacioglu, Selim] Univ Regensburg, Childrens Hosp Regensburg, D-93053 Regensburg, Germany.
[Carreras, Enric] Hosp Clin Barcelona, Barcelona, Spain.
[Mohty, Mohamad] Hosp St Antoine, Paris, France.
[Pagliuca, Antonio] Kings Coll Hosp NHS Fdn Trust, London, England.
[Ballabio, Maria; Bandiera, Valeria; Finetto, Giorgia] Gentium SpA, Villa Guardia, Italy.
[Hume, Robin L.] Jazz Pharmaceut Inc, Palo Alto, CA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700214
ER
PT J
AU Cottini, F
Hideshima, T
Suzuki, R
Richardson, PG
Anderson, KC
Tonon, G
AF Cottini, Francesca
Hideshima, Teru
Suzuki, Rikio
Richardson, Paul G.
Anderson, Kenneth C.
Tonon, Giovanni
TI Synthetic Lethal Approaches to Exploit Replicative Stress in Aggressive
Myeloma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Cottini, Francesca; Hideshima, Teru; Suzuki, Rikio; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Tonon, Giovanni] Ist Sci San Raffaele, I-20132 Milan, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706184
ER
PT J
AU Danis, E
Yamauchi, T
Echanique, K
Haladyna, J
Xie, HF
Zhu, N
Riedel, S
Bernt, KM
Orkin, SH
Armstrong, SA
Neff, T
AF Danis, Etienne
Yamauchi, Taylor
Echanique, Kristen
Haladyna, Jessica
Xie, Huafeng
Zhu, Nan
Riedel, Simone
Bernt, Kathrin M.
Orkin, Stuart H.
Armstrong, Scott A.
Neff, Tobias
TI Context Dependent Role of Polycomb Repressive Complex 2 in Acute
Leukemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Danis, Etienne; Yamauchi, Taylor; Echanique, Kristen; Haladyna, Jessica; Riedel, Simone; Bernt, Kathrin M.; Neff, Tobias] Childrens Hosp Colorado, Aurora, CO USA.
[Xie, Huafeng; Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Zhu, Nan; Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242705024
ER
PT J
AU Das, DS
Tian, Z
Ray, A
Ravillah, D
Song, Y
Richardson, PG
Oronsky, B
Scicinski, J
Chauhan, D
Anderson, KC
AF Das, Deepika Sharma
Tian, Ze
Ray, Arghya
Ravillah, Durgadevi
Song, Yan
Richardson, Paul G.
Oronsky, Bryan
Scicinski, Jan
Chauhan, Dharminder
Anderson, Kenneth C.
TI Anti-Myeloma Activity of a Novel Free Radical Inducer Rrx-001
SO BLOOD
LA English
DT Meeting Abstract
C1 [Das, Deepika Sharma; Tian, Ze; Ray, Arghya; Ravillah, Durgadevi; Song, Yan; Richardson, Paul G.; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Das, Deepika Sharma; Tian, Ze; Ray, Arghya; Ravillah, Durgadevi; Song, Yan; Richardson, Paul G.; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Oronsky, Bryan; Scicinski, Jan] RadioRx Inc, Mountain View, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706148
ER
PT J
AU Davids, MS
Kim, HT
Costello, CL
Avigan, D
Chen, YB
Armand, P
Alyea, EP
Hedlund, J
McSweeney, PA
Liguori, R
Ritz, J
Ball, ED
Bashey, A
Soiffer, RJ
AF Davids, Matthew S.
Kim, Haesook T.
Costello, Caitlin L.
Avigan, David
Chen, Yi-Bin
Armand, Philippe
Alyea, Edwin P.
Hedlund, Jacquelyn
McSweeney, Peter A.
Liguori, Rebecca
Ritz, Jerome
Ball, Edward D.
Bashey, Asad
Soiffer, Robert J.
TI A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for
Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell
Transplantation
SO BLOOD
LA English
DT Meeting Abstract
C1 [Davids, Matthew S.; Kim, Haesook T.; Armand, Philippe; Alyea, Edwin P.; Liguori, Rebecca; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Costello, Caitlin L.; Ball, Edward D.] Moores UCSD Canc Ctr, La Jolla, CA USA.
[Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Chen, Yi-Bin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Hedlund, Jacquelyn] New England Canc Specialisits, Scarborough, ME USA.
[McSweeney, Peter A.] Rocky Mt Canc Ctr, Denver, CO USA.
[Bashey, Asad] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA.
[Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707213
ER
PT J
AU Davids, MS
Deng, J
Ryan, J
Fernandes, SM
Brown, JR
Letai, AG
AF Davids, Matthew S.
Deng, Jing
Ryan, Jeremy
Fernandes, Stacey M.
Brown, Jennifer R.
Letai, Anthony G.
TI Mitochondrial Apoptotic Priming Is Associated with Clinical Response to
the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Davids, Matthew S.; Deng, Jing; Ryan, Jeremy; Fernandes, Stacey M.; Brown, Jennifer R.; Letai, Anthony G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701094
ER
PT J
AU Deveau, A
Forrester, AM
Coombs, AJ
Wagner, GS
Grabher, C
Chute, I
Leger, D
Lewis, S
Mingay, M
Hirst, M
Look, AT
Berman, JN
AF Deveau, Adam
Forrester, Alexander Michael
Coombs, Andrew J.
Wagner, Gretchen S.
Grabher, Clemens
Chute, Ian
Leger, Daniel
Lewis, Stephen
Mingay, Matthew
Hirst, Martin
Look, A. Thomas
Berman, Jason N.
TI Preclinical Determination of the Efficacy of Epigenetic Therapy in High
Risk Myeloid Disease Using the Zebrafish Model
SO BLOOD
LA English
DT Meeting Abstract
C1 [Deveau, Adam; Coombs, Andrew J.; Wagner, Gretchen S.] Dalhousie Univ, Halifax, NS, Canada.
[Forrester, Alexander Michael] McMaster Univ, Hamilton, ON, Canada.
[Grabher, Clemens] Karlsruhe Inst Technol, D-76021 Karlsruhe, Germany.
[Chute, Ian; Leger, Daniel] Atlantic Canc Res Inst, Moncton, NB, Canada.
[Lewis, Stephen] Univ Moncton, Moncton, NB E1A 3E9, Canada.
[Mingay, Matthew; Hirst, Martin] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Hirst, Martin] BC Canc Agcy, Vancouver, BC, Canada.
[Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Berman, Jason N.] Dalhousie Univ, IWK Hlth Ctr, Halifax, NS, Canada.
RI Hirst, Martin/B-7684-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700006
ER
PT J
AU Dhimolea, E
King, E
Sheffer, M
Hu, YG
Sarkar, S
Murnane, M
Bariteau, MA
Aftab, BT
Mitsiades, CS
AF Dhimolea, Eugen
King, Emily
Sheffer, Michal
Hu, Yiguo
Sarkar, Subhashis
Murnane, Megan
Bariteau, Megan A.
Aftab, Blake T.
Mitsiades, Constantine S.
TI Functional Mapping of Multiple Myeloma Kinome Using a Small Molecule
Inhibitor Library
SO BLOOD
LA English
DT Meeting Abstract
C1 [Dhimolea, Eugen; King, Emily; Sheffer, Michal; Hu, Yiguo; Sarkar, Subhashis; Bariteau, Megan A.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Murnane, Megan; Aftab, Blake T.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702035
ER
PT J
AU Dohner, H
Seymour, JF
Butrym, A
Wierzbowska, A
Selleslag, D
Lang, JH
Cavenagh, JD
Kumar, R
Schuh, AC
Candoni, A
Recher, C
Sandhu, I
del Castillo, TB
Al-Ali, HK
Martinelli, G
Falantes, J
Stone, RM
Minden, MD
McIntyre, H
Songer, S
Lucy, LM
Beach, CL
Dombret, H
AF Doehner, Hartmut
Seymour, John F.
Butrym, Aleksandra
Wierzbowska, Agnieszka
Selleslag, Dominik
Lang, Jun Ho
Cavenagh, James D.
Kumar, Rajat
Schuh, Andre C.
Candoni, Anna
Recher, Christian
Sandhu, Irwindeep
Bernal del Castillo, Teresa
Al-Ali, Haifa Kathrin
Martinelli, Giovanni
Falantes, Jose
Stone, Richard M.
Minden, Mark D.
McIntyre, Heidi
Songer, Stephen
Lucy, Lela M.
Beach, C. L.
Dombret, Herve
TI Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid
Leukemia (AML) with > 30% Bone Marrow Blasts Treated with Azacitidine By
Cytogenetic Risk Status: Results of the AZA-AML-001 Study
SO BLOOD
LA English
DT Meeting Abstract
C1 [Doehner, Hartmut] Univ Ulm Klinikum, Ulm, Germany.
[Seymour, John F.] Peter MacCallum Canc Ctr, East Melbourne, Australia.
[Butrym, Aleksandra] Wroclaw Med Univ, Wroclaw, Poland.
[Wierzbowska, Agnieszka] Med Univ Lodz, Lodz, Poland.
[Selleslag, Dominik] AZ Sint Jan Brugge Oostende, Brugge, Belgium.
[Lang, Jun Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Cavenagh, James D.] St Bartholomews Hosp, London, England.
[Kumar, Rajat] CancerCare Manitoba, Winnipeg, MB, Canada.
[Schuh, Andre C.; Minden, Mark D.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Candoni, Anna] Azienda Osped Univ S Maria della Misericordia Udi, Udine, Italy.
[Recher, Christian] Inst Univ Canc Toulouse Oncopole, Toulouse, France.
[Sandhu, Irwindeep] Univ Alberta, Edmonton, AB, Canada.
[Bernal del Castillo, Teresa] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain.
[Al-Ali, Haifa Kathrin] Univ Hosp Leipzig, Leipzig, Germany.
[Martinelli, Giovanni] Inst Hematol & Med Oncol L&A Seragnoli, Bologna, Italy.
[Falantes, Jose] Hosp Univ Virgen del Rocio, Inst BioMed Sevilla, Seville, Spain.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McIntyre, Heidi; Songer, Stephen; Lucy, Lela M.; Beach, C. L.] Gelgene Corp, Summit, NJ USA.
[Dombret, Herve] Hop St Louis, Paris 10, France.
RI Wierzbowska, Agnieszka/S-9449-2016
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242705065
ER
PT J
AU Donato, J
Campigotto, F
Coletti, E
Neuberg, D
Weber, G
Zwicker, JI
AF Donato, Jessica
Campigotto, Federico
Coletti, Erika
Neuberg, Donna
Weber, Griffin
Zwicker, Jeffrey I.
TI Risk of Intracranial Hemorrhage Associated with Enoxaparin
Administration in Patients with Brain Metastasis
SO BLOOD
LA English
DT Meeting Abstract
C1 [Donato, Jessica; Coletti, Erika; Weber, Griffin; Zwicker, Jeffrey I.] Harvard Univ, Sch Med, Boston, MA USA.
[Campigotto, Federico] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700180
ER
PT J
AU Dunleavy, K
Fanale, M
LaCasce, A
Noy, A
Caimi, P
Parekh, S
Hayslip, JW
Jagadeesh, D
Lord, RS
Lechowicz, MJ
Gaur, R
Lucas, A
Staudt, LM
Steinberg, SM
Kahl, B
Friedberg, JW
Little, RF
Bartlett, NL
Wilson, WH
AF Dunleavy, Kieron
Fanale, Michelle
LaCasce, Ann
Noy, Ariela
Caimi, Paolo
Parekh, Samir
Hayslip, John W.
Jagadeesh, Deepa
Lord, Raymond S.
Lechowicz, Mary J.
Gaur, Rakesh
Lucas, Andrea
Staudt, Louis M.
Steinberg, Seth M.
Kahl, Brad
Friedberg, Jonathan W.
Little, Richard F.
Bartlett, Nancy L.
Wilson, Wyndham H.
TI Preliminary Report of a Multicenter Prospective Phase II Study of
DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Dunleavy, Kieron; Lucas, Andrea; Staudt, Louis M.; Steinberg, Seth M.; Little, Richard F.; Wilson, Wyndham H.] NCI, Bethesda, MD 20892 USA.
[Fanale, Michelle] Univ Texas, Houston, TX USA.
[LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Noy, Ariela] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Caimi, Paolo] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Parekh, Samir] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Hayslip, John W.] Univ Kentucky, Lexington, KY USA.
[Jagadeesh, Deepa] Cleveland Clin, Cleveland, OH 44106 USA.
[Lord, Raymond S.] West Michigan Canc Ctr, Kalamazoo, MI USA.
[Lechowicz, Mary J.] Emory Univ, Sch Med, Atlanta, GA USA.
[Gaur, Rakesh] Kansas City CCOP, Kansas City, KS USA.
[Kahl, Brad] UW Carbone Canc Ctr, Madison, WI USA.
[Friedberg, Jonathan W.] Univ Rochester, Rochester, NY USA.
[Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 3
U2 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707201
ER
PT J
AU Fathi, AT
Chen, R
Trippett, TM
O'Brien, MM
DeAngelo, DJ
Shah, BD
Cooper, TM
Foran, JM
Hale, GA
Pressey, J
Silverman, LB
Tibes, R
Kim, S
Albertson, TM
Sandalic, L
Zhao, BT
Borate, U
AF Fathi, Amir T.
Chen, Robert
Trippett, Tanya M.
O'Brien, Maureen M.
DeAngelo, Daniel J.
Shah, Bijal D.
Cooper, Todd M.
Foran, James M.
Hale, Gregory A.
Pressey, Joseph
Silverman, Lewis B.
Tibes, Raoul
Kim, Stella
Albertson, Tina M.
Sandalic, Larissa
Zhao, Baiteng
Borate, Uma
TI Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate
SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly
Aggressive Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Chen, Robert] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Trippett, Tanya M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[O'Brien, Maureen M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shah, Bijal D.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Cooper, Todd M.] Childrens Healthcare Atlanta Egleston, Atlanta, GA USA.
[Foran, James M.] Mayo Clin, Jacksonville, FL 32224 USA.
[Hale, Gregory A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA.
[Pressey, Joseph] Univ Alabama Birmingham, Childrens Hosp Alabama, Birmingham, AL USA.
[Silverman, Lewis B.] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Tibes, Raoul] Mayo Clin Arizona, Scottsdale, AZ USA.
[Kim, Stella] Cizik Eye Clin, Houston, TX USA.
[Albertson, Tina M.; Sandalic, Larissa; Zhao, Baiteng] Seattle Genet Inc, Bothell, WA USA.
[Borate, Uma] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700139
ER
PT J
AU Freytes, CO
Callander, NS
Goodman, SA
Luo, SH
Toro, JJ
Carson, KR
AF Freytes, Cesar O.
Callander, Natalie S.
Goodman, Stacey A.
Luo, Suhong
Toro, Juan J.
Carson, Kenneth R.
TI The Veterans Health Administration Provides Equal Access to Autologous
Hematopoietic Stem Cell Transplantation for Patients with Multiple
Myeloma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Freytes, Cesar O.; Toro, Juan J.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
[Freytes, Cesar O.; Toro, Juan J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Callander, Natalie S.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Callander, Natalie S.] Univ Wisconsin, Madison, WI USA.
[Goodman, Stacey A.] Nashville VA Med Ctr, Nashville, TN USA.
[Goodman, Stacey A.] Vanderbilt Univ, Nashville, TN 37235 USA.
[Luo, Suhong; Carson, Kenneth R.] St Louis VA Med Ctr, Res Serv, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706152
ER
PT J
AU Fulciniti, M
Bhasin, M
Samur, MK
Bandi, RL
Rashid, N
Jaime, R
Lin, C
Anderson, KC
Parmigiani, G
Bradner, JE
Munshi, NC
AF Fulciniti, Mariateresa
Bhasin, Manoj
Samur, Mehmet Kemal
Bandi, Rajya Lakshmi
Rashid, Naim
Jaime, Reyes
Lin, Charles
Anderson, Kenneth C.
Parmigiani, Giovanni
Bradner, James E.
Munshi, Nikhil C.
TI Functional and Clinical Relevance of Splicing Factor SRSF1 in Multiple
Myeloma (MM)
SO BLOOD
LA English
DT Meeting Abstract
C1 [Fulciniti, Mariateresa] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bhasin, Manoj] Beth Israel, Boston, MA USA.
[Samur, Mehmet Kemal; Bandi, Rajya Lakshmi; Jaime, Reyes; Lin, Charles; Parmigiani, Giovanni; Bradner, James E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rashid, Naim] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
[Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708006
ER
PT J
AU Fulciniti, M
Bandi, RL
Amodio, N
Cagnetta, A
Senapedis, W
Baloglu, E
Anderson, KC
Munshi, NC
AF Fulciniti, Mariateresa
Bandi, Rajya Lakshmi
Amodio, Nicola
Cagnetta, Antonia
Senapedis, William
Baloglu, Erkan
Anderson, Kenneth C.
Munshi, Nikhil C.
TI Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of
Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric
Modulators (PAMs)
SO BLOOD
LA English
DT Meeting Abstract
C1 [Fulciniti, Mariateresa] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bandi, Rajya Lakshmi] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Amodio, Nicola] Magna Graecia Univ Catanzaro, Catanzaro, Italy.
[Cagnetta, Antonia; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Cagnetta, Antonia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Senapedis, William] Karyopharm Therapeut, Boston, MA USA.
[Baloglu, Erkan] Karyopharm Therapeut Inc, Newton, MA USA.
[Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700017
ER
PT J
AU Garbati, MR
Rathbun, RK
Yates, JE
Yang, WJ
Bagby, GC
AF Garbati, Michael R.
Rathbun, R. K.
Yates, Jane E.
Yang, Wenjin
Bagby, Grover C.
TI ALDH1A1 Dysfunction in FA-Deficient Macrophages Contributes to Aberrant
Activation of the Innate Immune Response
SO BLOOD
LA English
DT Meeting Abstract
C1 [Garbati, Michael R.; Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA.
[Rathbun, R. K.; Yates, Jane E.; Bagby, Grover C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Yang, Wenjin] Aldea Pharmaceut, Redwood City, CA USA.
[Bagby, Grover C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707171
ER
PT J
AU Garcia-Manero, G
Fenaux, P
Al-Kali, A
Baer, MR
Sekeres, MA
Roboz, GJ
Gaidano, G
Scott, BL
Greenberg, PL
Platzbecker, U
Steensma, DP
Kambhampati, S
Kreuzer, KA
Godley, LA
Collins, R
Atallah, E
Wilhelm, F
Wilhelm, IE
Azarnia, N
Maniar, M
Silverman, LR
AF Garcia-Manero, Guillermo
Fenaux, Pierre
Al-Kali, Aref
Baer, Maria R.
Sekeres, Mikkael A.
Roboz, Gail J.
Gaidano, Gianluca
Scott, Bart L.
Greenberg, Peter L.
Platzbecker, Uwe
Steensma, David P.
Kambhampati, Suman
Kreuzer, Karl-Anton
Godley, Lucy A.
Collins, Robert
Atallah, Ehab
Wilhelm, Francois
Wilhelm, Isabelle E.
Azarnia, Nozar
Maniar, Manoj
Silverman, Lewis R.
TI Overall Survival and Subgroup Analysis from a Randomized Phase III Study
of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients
(pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure
of Hypomethylating Agents (HMAs)
SO BLOOD
LA English
DT Meeting Abstract
C1 [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Fenaux, Pierre] Univ Paris 07, Hop St Louis, Paris, France.
[Al-Kali, Aref] Mayo Clin, Rochester, MN USA.
[Baer, Maria R.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Roboz, Gail J.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Gaidano, Gianluca] Amedeo Avogadro Univ Eastern Piedmont, Novara, Italy.
[Scott, Bart L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Greenberg, Peter L.] Stanford Univ, Stanford, CA 94305 USA.
[Platzbecker, Uwe] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany.
[Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kambhampati, Suman] Univ Kansas, Ctr Canc, Kansas City, KS USA.
[Kreuzer, Karl-Anton] Univ Cologne, D-50931 Cologne, Germany.
[Godley, Lucy A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Collins, Robert] Univ Texas Southwestern, Dallas, TX USA.
[Atallah, Ehab] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Wilhelm, Francois; Wilhelm, Isabelle E.; Azarnia, Nozar; Maniar, Manoj] Onconova Therapeut Inc, Newtown, PA USA.
[Silverman, Lewis R.] Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700138
ER
PT J
AU Gardie, B
Couve, S
Ladroue, C
Laine, E
Mahtouk, K
Guegan, J
Gad, S
Le Jeune, H
Lecomte, B
Pages, JC
Benusiglio, P
Bressac-de Paillerets, B
Feunteun, J
Dessen, P
Hermouet, S
Tchertanov, L
Mole, DR
Kaelin, WG
Ratcliffe, PJ
Richard, S
AF Gardie, Betty
Couve, Sophie
Ladroue, Charline
Laine, Elodie
Mahtouk, Karene
Guegan, Justine
Gad, Sophie
Le Jeune, Helene
Lecomte, Bernard
Pages, Jean-Christophe
Benusiglio, Patrick
Bressac-de Paillerets, Brigitte
Feunteun, Jean
Dessen, Philippe
Hermouet, Sylvie
Tchertanov, Luba
Mole, David R.
Kaelin, William G.
Ratcliffe, Peter J.
Richard, Stephane
TI A Comprehensive Study of the VHL-R200W Chuvash Polycythemia Mutation
Reveals a Gradual Dysregulation of the Hypoxia Pathway in Oncogenesis
SO BLOOD
LA English
DT Meeting Abstract
C1 [Gardie, Betty; Couve, Sophie; Ladroue, Charline; Mahtouk, Karene; Gad, Sophie; Le Jeune, Helene; Richard, Stephane] Ecole Prat Hautes Etud, Villejuif, France.
[Gardie, Betty; Hermouet, Sylvie] CRCNA, UMR INSERM U892, CNRS 6299, Nantes, France.
[Gardie, Betty; Couve, Sophie; Ladroue, Charline; Mahtouk, Karene; Gad, Sophie; Le Jeune, Helene; Richard, Stephane] Gustave Roussy Canc Campus, INSERM U753, Villejuif, France.
[Laine, Elodie; Tchertanov, Luba] LBPA, Cachan, France.
[Guegan, Justine; Dessen, Philippe] Gustave Roussy Canc Campus, Plate Forme Genom, Villejuif, France.
[Pages, Jean-Christophe] Univ Tours, Tours, France.
[Benusiglio, Patrick] Gustave Roussy Canc Campus, Dept Med Oncol, Villejuif, France.
[Benusiglio, Patrick; Richard, Stephane] Ctr Expert Natl Canc Rares INCa PREDIR, Le Kremlin Bicetre, France.
[Benusiglio, Patrick; Richard, Stephane] Reseau Natl INCa Malad VHL & Predisposit Canc Rei, Le Kremlin Bicetre, France.
[Bressac-de Paillerets, Brigitte] Gustave Roussy Canc Campus, Serv Genet, Villejuif, France.
[Feunteun, Jean] Gustave Roussy Canc Campus, Lab Stabil Genet & Oncogenese, Villejuif, France.
[Tchertanov, Luba] CNRS ENS Cachan, Cachan, France.
[Mole, David R.] Univ Oxford, Oxford, England.
[Kaelin, William G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ratcliffe, Peter J.] Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242705020
ER
PT J
AU Gavillet, M
Martinod, K
Wagner, DD
Williams, DA
AF Gavillet, Mathilde
Martinod, Kimberly
Wagner, Denisa D.
Williams, David A.
TI The Role of Rac and Pak in Neutrophil Histone Hypercitrullination and
Neutrophil Extracellular Traps Formation
SO BLOOD
LA English
DT Meeting Abstract
C1 [Gavillet, Mathilde; Wagner, Denisa D.; Williams, David A.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Martinod, Kimberly] Harvard Univ, Sch Med, Div Med Sci, Grad Program Immunol, Boston, MA USA.
[Martinod, Kimberly; Wagner, Denisa D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Wagner, Denisa D.; Williams, David A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706174
ER
PT J
AU Ghamari, A
Jaensch, E
Giadone, R
Akie, TE
Xu, J
Bauer, D
Orkin, SH
Cantor, AB
AF Ghamari, Alireza
Jaensch, Elizabeth
Giadone, Richard
Akie, Thomas E.
Xu, Jian
Bauer, Daniel
Orkin, Stuart H.
Cantor, Alan B.
TI An SCF-FBXW7 Ubiquitin Ligase Mediated Feedback Loop Facilitates GATA
Factor Switching and Reinforces Commitment to Terminal Erythroid
Maturation
SO BLOOD
LA English
DT Meeting Abstract
C1 [Ghamari, Alireza; Jaensch, Elizabeth; Giadone, Richard; Akie, Thomas E.; Xu, Jian; Bauer, Daniel; Orkin, Stuart H.; Cantor, Alan B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707107
ER
PT J
AU Ghobrial, IM
AF Ghobrial, Irene M.
TI Molecular Modification of the Microenvironment by the Tumor Clone
SO BLOOD
LA English
DT Meeting Abstract
C1 [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707012
ER
PT J
AU Ghobrial, IM
Laubach, JP
Shain, KH
Baz, R
Boswell, EN
Henrick, PM
Azab, AK
Hanlon, C
Chuma, S
Leblebjian, H
Noonan, K
MacNabb, MH
Warren, D
Armand, P
Paba-Prada, CE
Munshi, NC
Schlossman, RL
Anderson, KC
Richardson, PG
AF Ghobrial, Irene M.
Laubach, Jacob P.
Shain, Kenneth H.
Baz, Rachid
Boswell, Erica N.
Henrick, Patrick M.
Azab, Abdel Kareem
Hanlon, Courtney
Chuma, Stacey
Leblebjian, Houry
Noonan, Kimberly
MacNabb, Megan H.
Warren, Diane
Armand, Philippe
Paba-Prada, Claudia E.
Munshi, Nikhil C.
Schlossman, Robert L.
Anderson, Kenneth C.
Richardson, Paul G.
TI Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization
Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Ghobrial, Irene M.; Laubach, Jacob P.; Henrick, Patrick M.; Azab, Abdel Kareem; Hanlon, Courtney; Chuma, Stacey; Noonan, Kimberly; MacNabb, Megan H.; Warren, Diane; Paba-Prada, Claudia E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shain, Kenneth H.; Baz, Rachid] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Boswell, Erica N.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Leblebjian, Houry; Armand, Philippe; Schlossman, Robert L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700051
ER
PT J
AU Gkotzamanidou, M
Shammas, M
Sanchez, JM
Ding, L
Minvielle, S
Magrangeas, F
Avet-Loiseau, H
Anderson, KC
Munshi, NC
AF Gkotzamanidou, Maria
Shammas, Masood
Martin Sanchez, Jesus
Ding, Lai
Minvielle, Stephane
Magrangeas, Florence
Avet-Loiseau, Herve
Anderson, Kenneth C.
Munshi, Nikhil C.
TI HDAC8 Mediates Homologous Recombination and Cytoskeleton Integrity in
Myeloma with Potential Impact on Cell Growth and Survival
SO BLOOD
LA English
DT Meeting Abstract
C1 [Gkotzamanidou, Maria; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Gkotzamanidou, Maria; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Shammas, Masood; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Shammas, Masood] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Martin Sanchez, Jesus] Hosp Univ Virgen del Rocio, Seville, Spain.
[Ding, Lai] Harvard Neurodiscovery Ctr, Boston, MA USA.
[Minvielle, Stephane; Magrangeas, Florence] CNRS 6299, Ctr Rech Cancerol Nantes Angers UMR Inserm 892, Nantes, France.
[Avet-Loiseau, Herve] Univ Hosp Toulouse, Toulouse, France.
RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702163
ER
PT J
AU Glavey, S
Naba, A
Manier, S
Gambella, M
Rocci, A
Sacco, A
Asara, JM
Moschetta, M
Reagan, MR
Mishima, Y
Kawano, Y
Roccaro, AM
Palumbo, A
Hynes, RO
Ghobrial, IM
AF Glavey, Siobhan
Naba, Alexandra
Manier, Salomon
Gambella, Manuela
Rocci, Alberto
Sacco, Antonio
Asara, John M.
Moschetta, Michele
Reagan, Michaela R.
Mishima, Yuji
Kawano, Yawara
Roccaro, Aldo M.
Palumbo, Antonio
Hynes, Richard O.
Ghobrial, Irene M.
TI Proteomic Characterization of the Multiple Myeloma Bone Marrow
Extracellular Matrix
SO BLOOD
LA English
DT Meeting Abstract
C1 [Glavey, Siobhan; Manier, Salomon; Sacco, Antonio; Moschetta, Michele; Reagan, Michaela R.; Mishima, Yuji; Kawano, Yawara; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Naba, Alexandra; Hynes, Richard O.] MIT, Howard Hughes Med Inst, Koch Inst, Cambridge, MA USA.
[Gambella, Manuela] Univ Turin, Turin, Italy.
[Rocci, Alberto] Dept Haematol, Manchester, Lancs, England.
[Asara, John M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Palumbo, Antonio] Univ Turin, Div Hematol, Myeloma Unit, Turin, Italy.
RI Reagan, Michaela/E-3549-2017
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704012
ER
PT J
AU Godbersen, C
Paiva, C
Berger, AJ
Brown, JR
Danilov, AV
AF Godbersen, Claire
Paiva, Cody
Berger, Allison J.
Brown, Jennifer R.
Danilov, Alexey V.
TI Targeting Nedd8 Activating Enzyme Induces DNA Damage and Cell Cycle
Arrest and Sensitizes Chronic Lymphocytic Leukemia (CLL) B-Cells to
Alkylating Agents
SO BLOOD
LA English
DT Meeting Abstract
C1 [Godbersen, Claire; Danilov, Alexey V.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Paiva, Cody] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Berger, Allison J.] Takeda Pharmaceut Co Ltd, Cambridge, MA USA.
[Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707028
ER
PT J
AU Graw, JA
Rosales, IA
Liu, YM
Sabbisetti, VS
Riley, FE
Rechester, O
Bloch, KD
Warren, HS
Bonventre, JV
Zapol, WM
AF Graw, Jan A.
Rosales, Ivy A.
Liu, Yumin
Sabbisetti, Venkata S.
Riley, Frank E.
Rechester, Osher
Bloch, Kenneth D.
Warren, H. Shaw
Bonventre, Joseph V.
Zapol, Warren M.
TI Haptoglobin Therapy Prevents Kidney Injury in Stored Blood Resuscitation
of Murine Hemorrhagic Shock
SO BLOOD
LA English
DT Meeting Abstract
C1 [Graw, Jan A.; Rosales, Ivy A.; Riley, Frank E.; Rechester, Osher; Bloch, Kenneth D.; Warren, H. Shaw; Zapol, Warren M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Graw, Jan A.; Rosales, Ivy A.; Riley, Frank E.; Rechester, Osher; Bloch, Kenneth D.; Warren, H. Shaw; Zapol, Warren M.] Harvard Univ, Sch Med, Boston, MA USA.
[Liu, Yumin; Sabbisetti, Venkata S.; Bonventre, Joseph V.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708091
ER
PT J
AU Jain, S
Alam, M
Rajabi, H
Stroopinsky, D
Yin, L
Rosenblatt, J
Palmer, KA
Douglas, M
Pyzer, AR
Luptakova, K
Arnason, J
Joyce, R
Bar-Natan, M
Somaiya, P
Clark, RA
Kupper, TS
Kufe, D
Avigan, D
AF Jain, Salvia
Alam, Maroof
Rajabi, Hasan
Stroopinsky, Dina
Yin, Li
Rosenblatt, Jacalyn
Palmer, Kristen A.
Douglas, Maxwell
Pyzer, Athalia Rachel
Luptakova, Katarina
Arnason, Jon
Joyce, Robin
Bar-Natan, Michal
Somaiya, Poorvi
Clark, Rachael A.
Kupper, Thomas S.
Kufe, Donald
Avigan, David
TI MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Jain, Salvia; Stroopinsky, Dina; Rosenblatt, Jacalyn; Palmer, Kristen A.; Douglas, Maxwell; Pyzer, Athalia Rachel; Luptakova, Katarina; Arnason, Jon; Bar-Natan, Michal; Somaiya, Poorvi; Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Alam, Maroof; Rajabi, Hasan; Yin, Li; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Joyce, Robin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Clark, Rachael A.; Kupper, Thomas S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707211
ER
PT J
AU Joshi, I
Jena, N
Yoshida, T
Paraskevopoulou, L
Zhang, ZH
Liu, ZY
Korber, S
Krause, DS
Shapiro, IM
Weaver, DT
Pachter, JA
Paietta, EM
Van Etten, RA
Georgopoulos, K
AF Joshi, Ila
Jena, Nilamani
Yoshida, Toshimi
Paraskevopoulou, Leto
Zhang, Zhihong
Liu, Zhong-Ying
Korber, Shane
Krause, Daniela S.
Shapiro, Irina M.
Weaver, David T.
Pachter, Jonathan A.
Paietta, Elisabeth M.
Van Etten, Richard A.
Georgopoulos, Katia
TI Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype
of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1
Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy
of High-Risk B-ALL
SO BLOOD
LA English
DT Meeting Abstract
C1 [Joshi, Ila; Yoshida, Toshimi; Paraskevopoulou, Leto; Zhang, Zhihong; Georgopoulos, Katia] Massachusetts Gen Hosp, Charlestown, MA USA.
[Jena, Nilamani; Liu, Zhong-Ying; Korber, Shane; Van Etten, Richard A.] Univ Calif Irvine, Irvine, CA USA.
[Krause, Daniela S.] Georg Speyer Haus, Frankfurt, Germany.
[Shapiro, Irina M.; Weaver, David T.; Pachter, Jonathan A.] Verastem Inc, Cambridge, MA USA.
[Paietta, Elisabeth M.] Montefiore Med Ctr, Bronx, NY 10467 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707081
ER
PT J
AU Joung, JK
AF Joung, J. Keith
TI Genome and Epigenome Editing: A Revolution in Science and Medicine
SO BLOOD
LA English
DT Meeting Abstract
C1 [Joung, J. Keith] Massachusetts Gen Hosp, Charlestown, MA USA.
[Joung, J. Keith] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700078
ER
PT J
AU Kanan, S
Meid, K
Treon, SP
Castillo, JJ
AF Kanan, Sandra
Meid, Kirsten
Treon, Steven P.
Castillo, Jorge J.
TI Clinical Characteristics of Rituximab Intolerance in Patients with
Waldenstrom's Macroglobulinemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Kanan, Sandra; Meid, Kirsten; Treon, Steven P.; Castillo, Jorge J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700035
ER
PT J
AU Kassim, AA
Payne, AB
Rodeghier, M
Macklin, EA
Strunk, RC
DeBaun, MR
AF Kassim, Adetola A.
Payne, Amanda B.
Rodeghier, Mark
Macklin, Eric A.
Strunk, Robert C.
DeBaun, Michael R.
TI Forced Expiratory Volume in 1 Second Is Associated with Earlier Death in
Sickle Cell Anemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Kassim, Adetola A.; DeBaun, Michael R.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Payne, Amanda B.] Ctr Dis Control & Prevent, Nashville, TN USA.
[Rodeghier, Mark] Rodeghier Consultants, Chicago, IL USA.
[Macklin, Eric A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Strunk, Robert C.] Washington Univ, Sch Med, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702032
ER
PT J
AU Kekre, N
Mak, K
Binder, M
Branvall, E
Ishii, K
Stopsack, K
Cutler, CS
AF Kekre, Natasha
Mak, Kimberley
Binder, Moritz
Branvall, Elsa
Ishii, Kazusa
Stopsack, Konrad
Cutler, Corey S.
TI Meta-Analysis of HLA-Mismatched Compared to HLA-Matched Hematopoietic
Stem Cell Transplantation
SO BLOOD
LA English
DT Meeting Abstract
C1 [Kekre, Natasha; Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mak, Kimberley] Harvard Radiat Oncol Program, Boston, MA USA.
[Binder, Moritz; Stopsack, Konrad] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Branvall, Elsa] Karolinska Univ Hosp, Stockholm, Sweden.
[Ishii, Kazusa] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708130
ER
PT J
AU Kelly, KM
Ladas, EJ
Cole, P
Silverman, LB
Stevenson, KE
Orjuela, M
AF Kelly, Kara M.
Ladas, Elena J.
Cole, Peter
Silverman, Lewis B.
Stevenson, Kristen E.
Orjuela, Manuela
TI Dietary Intake of Zinc and Severity of Infection during
Prophase/Induction in Children with Acute Lymphoblastic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Kelly, Kara M.; Ladas, Elena J.; Orjuela, Manuela] Columbia Univ, Med Ctr, New York, NY USA.
[Cole, Peter] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Silverman, Lewis B.] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Stevenson, Kristen E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 10
Z9 10
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707024
ER
PT J
AU Kelly, KR
Chanan-Khan, A
Heffner, LT
Somlo, G
Siegel, DS
Zimmerman, T
Karnad, A
Munshi, NC
Jagannath, S
Greenberg, AL
Lonial, S
Roy, V
Ailawadhi, S
Barmaki-Rad, F
Chavan, S
Patel, P
Wartenberg-Demand, A
Thomas, H
Anderson, KC
AF Kelly, Kevin R.
Chanan-Khan, Asher
Heffner, Leonard T.
Somlo, George
Siegel, David S.
Zimmerman, Todd
Karnad, Anand
Munshi, Nikhil C.
Jagannath, Sundar
Greenberg, Allen L.
Lonial, Sagar
Roy, Vivek
Ailawadhi, Sikander
Barmaki-Rad, Farima
Chavan, Shailesh
Patel, Pankaj
Wartenberg-Demand, Andrea
Haeder, Thomas
Anderson, Kenneth C.
TI Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and
Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory
Multiple Myeloma: Clinical Activity in Patients Already Exposed to
Lenalidomide and Bortezomib
SO BLOOD
LA English
DT Meeting Abstract
C1 [Kelly, Kevin R.] Univ So Calif, Los Angeles, CA USA.
[Chanan-Khan, Asher; Roy, Vivek; Ailawadhi, Sikander] Mayo Clin, Jacksonville, FL 32224 USA.
[Heffner, Leonard T.; Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Somlo, George] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Siegel, David S.] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[Zimmerman, Todd] Univ Chicago Med, Chicago, IL USA.
[Karnad, Anand] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Jagannath, Sundar] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
[Greenberg, Allen L.] Mem Canc Inst, Pembroke Pines, FL USA.
[Barmaki-Rad, Farima; Wartenberg-Demand, Andrea; Haeder, Thomas] Biotest AG, Dreieich, Germany.
[Chavan, Shailesh; Patel, Pankaj] Biotest Pharmaceut Corp, Boca Raton, FL USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704099
ER
PT J
AU Komrokji, RS
Garcia-Manero, G
Ades, L
Laadem, A
Vo, B
Prebet, T
Stamatoullas, A
Boyd, T
Delaunay, J
Steensma, DP
Sekeres, MA
Beyne-Rauzy, O
Zou, J
Attie, K
Sherman, ML
Fenaux, P
List, AF
AF Komrokji, Rami S.
Garcia-Manero, Guillermo
Ades, Lionel
Laadem, Abderrahmane
Vo, Bond
Prebet, Thomas
Stamatoullas, Aspasia
Boyd, Thomas
Delaunay, Jacques
Steensma, David P.
Sekeres, Mikkael A.
Beyne-Rauzy, Odile
Zou, Jun
Attie, Kenneth
Sherman, Matthew L.
Fenaux, Pierre
List, Alan F.
TI An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in
Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic
Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia
(CMML) and Anemia Requiring Transfusion
SO BLOOD
LA English
DT Meeting Abstract
C1 [Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Ades, Lionel] Hop St Louis, Paris, France.
[Laadem, Abderrahmane; Vo, Bond; Zou, Jun] Celgene Corp, Summit, NJ USA.
[Prebet, Thomas] Inst J Paoli I Calmettes, F-13009 Marseille, France.
[Stamatoullas, Aspasia] Ctr Henri Becquerel, F-76038 Rouen, France.
[Boyd, Thomas] North Star Lodge Canc Ctr, Yakima, WA USA.
[Delaunay, Jacques] Hop Hotel Dieu, CHU Nantes, Nantes, France.
[Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Beyne-Rauzy, Odile] CHU Purpan, Toulouse, France.
[Attie, Kenneth; Sherman, Matthew L.] Acceleron Pharma, Cambridge, MA USA.
[Fenaux, Pierre] Univ Paris 07, Hop St Louis, Paris, France.
[List, Alan F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700134
ER
PT J
AU Konantz, M
Grzywna, S
Pereboom, TC
Carroll, KJ
Esain, V
Kanz, L
North, TE
Lengerke, C
AF Konantz, Martina
Grzywna, Sarah
Pereboom, Tamara C.
Carroll, Kelli J.
Esain, Virginie
Kanz, Lothar
North, Trista E.
Lengerke, Claudia
TI Multiple Roles for the Zebrafish Homologue of the Murine Evi1 Gene
during Primitive Myelopoiesis and HSC Development
SO BLOOD
LA English
DT Meeting Abstract
C1 [Konantz, Martina; Pereboom, Tamara C.; Lengerke, Claudia] Univ Basel Hosp, CH-4031 Basel, Switzerland.
[Grzywna, Sarah; Kanz, Lothar; Lengerke, Claudia] Univ Tubingen Hosp, Tubingen, Germany.
[Carroll, Kelli J.; Esain, Virginie; North, Trista E.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700185
ER
PT J
AU Kopolovic, I
Ostro, J
Cserti, C
Dzik, WS
Tsubota, H
Keir, A
Messner, HA
denHollander, N
Lin, YL
Callum, J
AF Kopolovic, Ilana
Ostro, Jackie
Cserti, Christine
Dzik, Walter Sunny
Tsubota, Hidacki
Keir, Amy
Messner, Hans A.
denHollander, Neal
Lin, Yulia
Callum, Jeannie
TI Product Attributes and Donor Factors in Reported Cases of
Transfusion-Associated Graft Versus Host Disease: A Systematic Review
SO BLOOD
LA English
DT Meeting Abstract
C1 [Kopolovic, Ilana; Ostro, Jackie] Univ Toronto, Toronto, ON, Canada.
[Ostro, Jackie; Tsubota, Hidacki; Lin, Yulia; Callum, Jeannie] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
[Cserti, Christine; denHollander, Neal] Univ Hlth Network, Toronto, ON, Canada.
[Dzik, Walter Sunny] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Keir, Amy] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Messner, Hans A.] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada.
[denHollander, Neal] Canadian Blood Serv, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702144
ER
PT J
AU Koreth, J
Kim, HT
Jones, KT
Reynolds, CG
Chammas, MJ
Dusenbury, K
Whangbo, J
Nikiforow, S
Alyea, EP
Armand, P
Cutler, CS
Ho, VT
Chen, YB
Avigan, D
Antin, JH
Ritz, J
Soiffer, RJ
AF Koreth, John
Kim, Haesook T.
Jones, Kyle T.
Reynolds, Carol G.
Chammas, Marie J.
Dusenbury, Katherine
Whangbo, Jennifer
Nikiforow, Sarah
Alyea, Edwin P.
Armand, Philippe
Cutler, Corey S.
Ho, Vincent T.
Chen, Yi-Bin
Avigan, David
Antin, Joseph H.
Ritz, Jerome
Soiffer, Robert J.
TI Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host
Disease: Phase 2 and Long Term Efficacy, Safety and Immune Correlates
SO BLOOD
LA English
DT Meeting Abstract
C1 [Koreth, John; Reynolds, Carol G.; Chammas, Marie J.; Ho, Vincent T.; Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kim, Haesook T.; Jones, Kyle T.; Dusenbury, Katherine; Nikiforow, Sarah; Alyea, Edwin P.; Armand, Philippe; Cutler, Corey S.; Antin, Joseph H.; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Whangbo, Jennifer] Dana Farber Childrens Hosp Canc Ctr, Boston, MA USA.
[Chen, Yi-Bin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707108
ER
PT J
AU Kumar, S
Gkotzamanidou, M
Pal, J
Lu, RQ
Nanjappa, P
Shi, JL
Shammas, M
Munshi, NC
AF Kumar, Subodh
Gkotzamanidou, Maria
Pal, Jagannath
Lu, Renquan
Nanjappa, Puru
Shi, Jialan
Shammas, Masood
Munshi, Nikhil C.
TI Elevated APE1 Mediates Dysregulation of Homologous Recombination in
Myeloma: Mechanisms and Translational Significance
SO BLOOD
LA English
DT Meeting Abstract
C1 [Kumar, Subodh; Pal, Jagannath; Lu, Renquan; Nanjappa, Puru; Shammas, Masood; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Kumar, Subodh; Pal, Jagannath; Lu, Renquan; Nanjappa, Puru; Shammas, Masood; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Shi, Jialan; Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708168
ER
PT J
AU LaCasce, A
Bociek, RG
Matous, J
Sawas, A
Caimi, P
Ansell, SM
Islas-Ohlmayer, M
Cheung, E
Agura, E
Behler, C
Crosswell, H
Vose, JM
Josephson, N
Advani, R
AF LaCasce, Ann
Bociek, R. Gregory
Matous, Jeffrey
Sawas, Ahmed
Caimi, Paolo
Ansell, Stephen M.
Islas-Ohlmayer, Miguel
Cheung, Eric
Agura, Edward
Behler, Caroline
Crosswell, Howland
Vose, Julie M.
Josephson, Neil
Advani, Ranjana
TI Brentuximab Vedotin in Combination with Bendamustine for Patients with
Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy
SO BLOOD
LA English
DT Meeting Abstract
C1 [LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bociek, R. Gregory; Vose, Julie M.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Matous, Jeffrey] Colorado Blood Canc Inst, Denver, CO USA.
[Sawas, Ahmed] Columbia Univ, Med Ctr, New York, NY USA.
[Caimi, Paolo] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Ansell, Stephen M.] Mayo Clin, Rochester, MN USA.
[Islas-Ohlmayer, Miguel] Jewish Hosp Mercy Hlth, Cincinnati, OH USA.
[Cheung, Eric] Oncol Inst Hope & Innovat, Whittier, CA USA.
[Agura, Edward] Charles A Sammons Canc Ctr, Dallas, TX USA.
[Behler, Caroline] Pacific Hematol Oncol Associates, San Francisco, CA USA.
[Crosswell, Howland] St Francis Hosp, Greenville, SC USA.
[Josephson, Neil] Seattle Genet Inc, Bothell, WA USA.
[Advani, Ranjana] Stanford Canc Ctr, Stanford, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708087
ER
PT J
AU Lai, HY
Morse, SJ
Luty, SB
Garbati, MR
Edmiston, JB
Bagby, GC
Druker, BJ
Fleischman, AG
AF Lai, Hew Yeng
Morse, Sarah J.
Luty, Samuel B.
Garbati, Michael R.
Edmiston, J. Blair
Bagby, Grover C.
Druker, Brian J.
Fleischman, Angela G.
TI Exaggerated Response to Toll-like Receptor Agonist Contributes to
Excessive TNF Production in Myeloproliferative Neoplasm
SO BLOOD
LA English
DT Meeting Abstract
C1 [Lai, Hew Yeng; Morse, Sarah J.; Fleischman, Angela G.] Univ Calif Irvine, Irvine, CA USA.
[Luty, Samuel B.; Edmiston, J. Blair; Bagby, Grover C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Garbati, Michael R.] Portland VA Med Ctr, Portland, OR USA.
[Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702116
ER
PT J
AU Lesokhin, AM
Ansell, SM
Armand, P
Scott, EC
Halwani, A
Gutierrez, M
Millenson, MM
Cohen, AD
Schuster, SJ
Lebovic, D
Dhodapkar, MV
Avigan, D
Chapuy, B
Ligon, AH
Rodig, SJ
Cattry, D
Zhu, LL
Grosso, JF
Kim, SY
Shipp, MA
Borrello, I
Timmerman, J
AF Lesokhin, Alexander M.
Ansell, Stephen M.
Armand, Philippe
Scott, Emma C.
Halwani, Ahmad
Gutierrez, Martin
Millenson, Michael M.
Cohen, Adam D.
Schuster, Stephen J.
Lebovic, Daniel
Dhodapkar, Madhav V.
Avigan, David
Chapuy, Bjoern
Ligon, Azra H.
Rodig, Scott J.
Cattry, Deepika
Zhu, Lili
Grosso, Joseph F.
Kim, Su Young
Shipp, Margaret A.
Borrello, Ivan
Timmerman, John
TI Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in
Patients with Relapsed or Refractory Lymphoid Malignancies
SO BLOOD
LA English
DT Meeting Abstract
C1 [Lesokhin, Alexander M.; Cattry, Deepika] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Ansell, Stephen M.] Mayo Clin, Rochester, MN USA.
[Armand, Philippe; Chapuy, Bjoern; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Scott, Emma C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Halwani, Ahmad] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Gutierrez, Martin] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[Millenson, Michael M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Cohen, Adam D.; Schuster, Stephen J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Lebovic, Daniel] Univ Michigan, Ann Arbor, MI 48109 USA.
[Dhodapkar, Madhav V.] Yale Canc Ctr, New Haven, CT USA.
[Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Ligon, Azra H.; Rodig, Scott J.] Brigham & Womens Hosp, Clin Cytogenet Lab, Boston, MA 02115 USA.
[Zhu, Lili; Grosso, Joseph F.; Kim, Su Young] Bristol Myers Squibb Co, Princeton, NJ USA.
[Borrello, Ivan] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Borrello, Ivan] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Timmerman, John] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 2
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706112
ER
PT J
AU Levine, JE
Braun, TM
Harris, AC
Holler, E
Taylor, A
Miller, HK
Magenau, JM
Weisdorf, DJ
Ho, VT
Bolanos-Meade, J
Alousi, AM
Ferrara, JLM
AF Levine, John E.
Braun, Thomas M.
Harris, Andrew C.
Holler, Ernst
Taylor, Austin
Miller, Holly K.
Magenau, John M.
Weisdorf, Daniel J.
Ho, Vincent T.
Bolanos-Meade, Javier
Alousi, Amin M.
Ferrara, James L. M.
TI A Biomarker Algorithm Defines Onset Grades of Acute Graft-Vs-Host
Disease with Distinct Non-Relapse Mortality
SO BLOOD
LA English
DT Meeting Abstract
C1 [Levine, John E.; Braun, Thomas M.; Harris, Andrew C.; Taylor, Austin; Miller, Holly K.; Magenau, John M.; Ferrara, James L. M.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Holler, Ernst] Univ Hosp Regensburg, Regensburg, Germany.
[Weisdorf, Daniel J.] Univ Minnesota, Minneapolis, MN USA.
[Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bolanos-Meade, Javier] Johns Hopkins Univ, Baltimore, MD USA.
[Alousi, Amin M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700090
ER
PT J
AU Li, LS
Wu, SC
Kopp, N
Montero, J
Ryan, J
Chapuy, B
Van der Zwet, JC
Layer, J
Weigert, O
Christie, AL
Christodoulou, AN
Liu, HY
Yoda, A
Hofmann, F
Baffert, F
Vangrevelinghe, E
Gaul, C
Radimerski, T
Letai, AG
Weinstock, DM
AF Li, Loretta S.
Wu, Shuo-Chieh
Kopp, Nadja
Montero, Joan
Ryan, Jeremy
Chapuy, Bjoern
Van der Zwet, Jordy C.
Layer, Jacob
Weigert, Oliver
Christie, Amanda L.
Christodoulou, Alexandra N.
Liu, Huiyun
Yoda, Akinori
Hofmann, Francesco
Baffert, Fabienne
Vangrevelinghe, Eric
Gaul, Christoph
Radimerski, Thomas
Letai, Anthony G.
Weinstock, David M.
TI Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against
JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)
SO BLOOD
LA English
DT Meeting Abstract
C1 [Li, Loretta S.; Wu, Shuo-Chieh; Kopp, Nadja; Montero, Joan; Ryan, Jeremy; Chapuy, Bjoern; Van der Zwet, Jordy C.; Layer, Jacob; Christie, Amanda L.; Christodoulou, Alexandra N.; Liu, Huiyun; Yoda, Akinori; Letai, Anthony G.; Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Weigert, Oliver] Helmholtz Ctr, Munich, Germany.
[Weigert, Oliver] LMU, Univ Hosp Munich, Munich, Germany.
[Hofmann, Francesco; Baffert, Fabienne; Vangrevelinghe, Eric; Gaul, Christoph; Radimerski, Thomas] Novartis Inst Biomed Res, Basel, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701083
ER
PT J
AU Li, Y
Esain, V
Teng, L
Xu, J
Frost, I
Kwan, W
Yzaguirre, AD
Maijenberg, MW
Orkin, SH
Tan, K
North, TE
Speck, NA
AF Li, Yan
Esain, Virginie
Teng, Li
Xu, Jian
Frost, Isaura
Kwan, Wanda
Yzaguirre, Amanda D.
Maijenberg, Marijke W.
Orkin, Stuart H.
Tan, Kai
North, Trista E.
Speck, Nancy A.
TI Inflammatory Signaling Regulates Embryonic Hematopoietic Stem and
Lymphoid Progenitor Cell Formation
SO BLOOD
LA English
DT Meeting Abstract
C1 [Li, Yan; Yzaguirre, Amanda D.; Maijenberg, Marijke W.; Speck, Nancy A.] Univ Penn, Philadelphia, PA 19104 USA.
[Esain, Virginie; Frost, Isaura; Kwan, Wanda; North, Trista E.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
[Teng, Li; Tan, Kai] Univ Iowa, Iowa City, IA USA.
[Xu, Jian] Boston Childrens Hosp, Boston, MA USA.
[Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242705058
ER
PT J
AU Luskin, MR
Lee, JW
Fernandez, HF
Lazarus, HM
Rowe, JM
Tallman, MS
Paietta, EM
Litzow, M
Abdel-Wahab, O
Patel, JP
Levine, RL
Sun, ZX
Luger, SM
AF Luskin, Marlise R.
Lee, Ju-Whei
Fernandez, Hugo F.
Lazarus, Hillard M.
Rowe, Jacob M.
Tallman, Martin S.
Paietta, Elisabeth M.
Litzow, Mark
Abdel-Wahab, Omar
Patel, Jay P.
Levine, Ross L.
Sun, Zhuoxin
Luger, Selina M.
TI Results of the ECOG E1900 Trial in Younger Adults with AML Using an
Event Free Survival Endpoint Are Concordant with Results Based on
Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid
Approval of Therapies in AML
SO BLOOD
LA English
DT Meeting Abstract
C1 [Luskin, Marlise R.; Luger, Selina M.] Univ Penn, Philadelphia, PA 19104 USA.
[Lee, Ju-Whei; Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fernandez, Hugo F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Lazarus, Hillard M.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
[Rowe, Jacob M.] Shaare Zedek Med Ctr, Jerusalem, Israel.
[Tallman, Martin S.; Abdel-Wahab, Omar; Patel, Jay P.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Paietta, Elisabeth M.] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Litzow, Mark] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706175
ER
PT J
AU MacMillan, ML
Robin, M
Harris, AC
Defor, TE
Martin, PJ
Alousi, A
Ho, VT
Bolanos-Meade, J
Ferrara, JLM
Jones, RJ
Arora, M
Blazar, BR
Holtan, SG
Jacobsohn, D
Pasquini, MC
Socie, G
Antin, JH
Levine, JE
Weisdorf, DJ
AF MacMillan, Margaret L.
Robin, Marie
Harris, Andrew C.
Defor, Todd E.
Martin, Paul J.
Alousi, Amin
Ho, Vincent T.
Bolanos-Meade, Javier
Ferrara, James L. M.
Jones, Richard J.
Arora, Mukta
Blazar, Bruce R.
Holtan, Shernan G.
Jacobsohn, David
Pasquini, Marcelo C.
Socie, Gerard
Antin, Joseph H.
Levine, John E.
Weisdorf, Daniel J.
TI A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That
Predicts Response to Initial Therapy, Survival and Transplant-Related
Mortality
SO BLOOD
LA English
DT Meeting Abstract
C1 [MacMillan, Margaret L.; Defor, Todd E.; Arora, Mukta; Blazar, Bruce R.; Holtan, Shernan G.; Weisdorf, Daniel J.] Univ Minnesota, Minneapolis, MN USA.
[Robin, Marie] St Louis Hosp, Paris, France.
[Harris, Andrew C.; Ferrara, James L. M.; Levine, John E.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Martin, Paul J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Alousi, Amin] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Alousi, Amin; Ho, Vincent T.; Bolanos-Meade, Javier; Ferrara, James L. M.; Jones, Richard J.; Jacobsohn, David; Pasquini, Marcelo C.; Antin, Joseph H.; Levine, John E.; Weisdorf, Daniel J.] BMT CTN GVHD Study Comm, Milwaukee, WI USA.
[Ho, Vincent T.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bolanos-Meade, Javier] Johns Hopkins Univ, Baltimore, MD USA.
[Jones, Richard J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Jacobsohn, David] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Pasquini, Marcelo C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Socie, Gerard] Hop St Louis, Paris, France.
[Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707010
ER
PT J
AU Majerus, EM
Ataga, KI
Vichinsky, E
Eaton, CA
Mazanet, R
Nathan, DG
Field, JJ
AF Majerus, Elaine M.
Ataga, Kenneth I.
Vichinsky, Elliott
Eaton, Cheryl A.
Mazanet, Rosemary
Nathan, David G.
Field, Joshua J.
TI NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable
Adult Sickle Cell Patients in a Phase 1 Trial
SO BLOOD
LA English
DT Meeting Abstract
C1 [Majerus, Elaine M.] Washington Univ, St Louis, MO USA.
[Ataga, Kenneth I.] Univ N Carolina, Chapel Hill, NC USA.
[Vichinsky, Elliott] UCSF Benioff Childrens Hosp Oakland, Oakland, CA USA.
[Eaton, Cheryl A.; Mazanet, Rosemary] NKT Therapeut, Waltham, MA USA.
[Nathan, David G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Field, Joshua J.] BloodCtr Wisconsin, Milwaukee, WI USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242703113
ER
PT J
AU Marshall, AL
Li, A
Drucker, A
Dzik, WS
AF Marshall, Ariela L.
Li, Ang
Drucker, Adrienne
Dzik, Walter Sunny
TI Aminocaproic Acid Use in Patients with Hematologic Malignancy: A Case
Series
SO BLOOD
LA English
DT Meeting Abstract
C1 [Marshall, Ariela L.; Li, Ang; Drucker, Adrienne; Dzik, Walter Sunny] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Marshall, Ariela L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707042
ER
PT J
AU Meister, M
Spencer, JA
Wu, J
Zhao, C
Stefania, L
Ferraro, F
Lo Celso, C
Scadden, DT
Van Etten, RA
Lin, C
Krause, DS
AF Meister, Melanie
Spencer, Joel A.
Wu, Juwell
Zhao, Cher
Stefania, Lymperi
Ferraro, Francesca
Lo Celso, Cristina
Scadden, David T.
Van Etten, Richard A.
Lin, Charles
Krause, Daniela S.
TI The Microanatomy of the Leukemic Stem Cell Niche in Murine Chronic
Myelogenous Leukemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Meister, Melanie; Krause, Daniela S.] Georg Speyer Haus, Frankfurt, Germany.
[Spencer, Joel A.; Wu, Juwell; Zhao, Cher; Stefania, Lymperi; Ferraro, Francesca; Lin, Charles] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lo Celso, Cristina] Univ London Imperial Coll Sci Technol & Med, London, England.
[Scadden, David T.] Harvard Stem Cell Inst, Boston, MA USA.
[Van Etten, Richard A.] Univ Calif Irvine, Irvine, CA USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700186
ER
PT J
AU Montillo, M
O'Brien, S
Tedeschi, A
Hillmen, P
Dearden, C
Gill, D
Brown, JR
Barrientos, JC
Mulligan, S
Furman, RR
Cymbalista, F
Plascencia, C
Chang, S
Hsu, E
James, DF
Byrd, JC
AF Montillo, Marco
O'Brien, Susan
Tedeschi, Alessandra
Hillmen, Peter
Dearden, Claire
Gill, Devinder
Brown, Jennifer R.
Barrientos, Jaqueline C.
Mulligan, Stephen
Furman, Richard R.
Cymbalista, Florence
Plascencia, Clara
Chang, Stephen
Hsu, Emily
James, Danelle F.
Byrd, John C.
TI Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the
Phase III RESONATE (TM) Study of Ibrutinib Vs Ofatumumab in
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma, Including a Case Report
SO BLOOD
LA English
DT Meeting Abstract
C1 [Montillo, Marco; Tedeschi, Alessandra] Osped Niguarda Ca Granda, Milan, Italy.
[O'Brien, Susan] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Hillmen, Peter] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
[Dearden, Claire] Royal Marsden Hosp, London SW3 6JJ, England.
[Gill, Devinder] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
[Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Barrientos, Jaqueline C.] North Shore LIJ Canc Inst, Lake Success, NY USA.
[Mulligan, Stephen] Royal N Shore Hosp, Sydney, NSW, Australia.
[Furman, Richard R.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Cymbalista, Florence] Hop Avicenne, Paris, France.
[Plascencia, Clara; Chang, Stephen; Hsu, Emily; James, Danelle F.] Pharmacyclics Inc, Sunnyvale, CA USA.
[Byrd, John C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242705173
ER
PT J
AU Munshi, NC
Minvielle, S
Tai, YT
Fulciniti, M
Richardson, PG
Attal, M
Moreau, P
Magrangeas, F
Anderson, KC
Faham, M
Avet-Loiseau, H
AF Munshi, Nikhil C.
Minvielle, Stephane
Tai, Yu-Tzu
Fulciniti, Mariateresa
Richardson, Paul G.
Attal, Michel
Moreau, Philippe
Magrangeas, Florence
Anderson, Kenneth C.
Faham, Malek
Avet-Loiseau, Herve
TI Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in
Multiple Myeloma Patients over the Course of Treatment
SO BLOOD
LA English
DT Meeting Abstract
C1 [Munshi, Nikhil C.; Tai, Yu-Tzu; Fulciniti, Mariateresa; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Boston Vet Adm Healthcare Syst, Roxbury, MA USA.
[Minvielle, Stephane; Moreau, Philippe; Magrangeas, Florence] Ctr Rech Cancerol Nantes Angers UMR Inserm 892CNR, F-44007 Nantes, France.
[Minvielle, Stephane; Moreau, Philippe; Magrangeas, Florence] IRT UN, F-44007 Nantes, France.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Attal, Michel; Avet-Loiseau, Herve] CHU Rangueil, Unite Genom Myelome, F-31054 Toulouse, France.
[Faham, Malek] Sequenta Inc, San Francisco, CA USA.
RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015;
richard, chrystelle/K-8595-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706124
ER
PT J
AU Murphy, EJ
Neuberg, D
Rai, KR
Rassenti, L
Emson, C
Li, K
Kay, NE
Wierda, WG
Hayes, GM
Brown, JR
Byrd, JC
McConnel, C
Barrientos, JC
Redd, RA
Turner, S
Busch, R
Greaves, A
Hellerstein, M
Chiorazzi, N
Kipps, TJ
AF Murphy, Elizabeth J.
Neuberg, Donna
Rai, Kanti R.
Rassenti, Laura
Emson, Claire
Li, Kelvin
Kay, Neil E.
Wierda, William G.
Hayes, Gregory M.
Brown, Jennifer R.
Byrd, John C.
McConnel, Coline
Barrientos, Jacqueline C.
Redd, Robert Allyn
Turner, Scott
Busch, Robert
Greaves, Andrew
Hellerstein, Marc
Chiorazzi, Nicholas
Kipps, Thomas J.
TI Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium
Labeling Predicts Time to Initial Treatment of Patients with Chronic
Lymphocytic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
C1 [Murphy, Elizabeth J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Neuberg, Donna; Brown, Jennifer R.; Redd, Robert Allyn] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rai, Kanti R.] Hofstra North Shore Long Isl Jewish Sch Med, Hempstead, NY USA.
[Rassenti, Laura; Greaves, Andrew; Kipps, Thomas J.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Emson, Claire; Li, Kelvin; McConnel, Coline; Turner, Scott; Hellerstein, Marc] KineMed Inc, Emeryville, CA USA.
[Kay, Neil E.] Mayo Clin, Rochester, MN USA.
[Wierda, William G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Hayes, Gregory M.] Igenica Inc, Burlingame, CA USA.
[Byrd, John C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Barrientos, Jacqueline C.] North Shore LIJ Canc Inst, Lake Success, NY USA.
[Busch, Robert] Univ Roehampton, London, England.
[Chiorazzi, Nicholas] North Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706126
ER
PT J
AU Nand, S
Diaz, MO
Marinier, DE
Walshauser, MA
Rosenfeld, AB
Michaelis, LC
Stiff, PJ
Gai, XW
AF Nand, Sucha
Diaz, Manuel O.
Marinier, David E.
Walshauser, Mark A.
Rosenfeld, Amy B.
Michaelis, Laura C.
Stiff, Patrick J.
Gai, Xiaowu
TI Germ-Line and Somatic Mutations in Familial Myeloproliferative Neoplasms
(MPNs). a Pilot Study
SO BLOOD
LA English
DT Meeting Abstract
C1 [Nand, Sucha; Rosenfeld, Amy B.; Stiff, Patrick J.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
[Diaz, Manuel O.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA.
[Marinier, David E.] Gundersen Hlth, La Crosse, WI USA.
[Walshauser, Mark A.] Canc Care Specialists Illinois, Swansea, IL USA.
[Michaelis, Laura C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Gai, Xiaowu] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704100
ER
PT J
AU Newell, LF
Rathbun, RK
Garbati, MR
Dao, KHT
Holtan, SG
Cook, RJ
Meyers, G
Bagby, GC
AF Newell, Laura F.
Rathbun, R. K.
Garbati, Michael R.
Dao, Kim-Hien T.
Holtan, Shernan G.
Cook, Rachel J.
Meyers, Gabrielle
Bagby, Grover C.
TI The Contribution of Toll-like Receptor (TLR) Pathway Hyper-Reactivity to
Clonal Selection in Secondary MDS and AML
SO BLOOD
LA English
DT Meeting Abstract
C1 [Newell, Laura F.; Rathbun, R. K.; Cook, Rachel J.; Meyers, Gabrielle; Bagby, Grover C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Garbati, Michael R.; Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA.
[Dao, Kim-Hien T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Holtan, Shernan G.] Univ Minnesota, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708115
ER
PT J
AU Obeng, EA
McConkey, ME
Campagna, D
Schneider, RK
Chen, MC
Schmidt, PJ
Mullally, A
Fleming, MD
Ebert, BL
AF Obeng, Esther A.
McConkey, Marie E.
Campagna, Dean
Schneider, Rebekka K.
Chen, Michelle C.
Schmidt, Paul J.
Mullally, Ann
Fleming, Mark D.
Ebert, Benjamin L.
TI Mutant Splicing Factor 3b Subunit 1 (SF3B1) Causes Dysregulated
Erythropoiesis and a Stem Cell Disadvantage
SO BLOOD
LA English
DT Meeting Abstract
C1 [Obeng, Esther A.; McConkey, Marie E.; Schneider, Rebekka K.; Chen, Michelle C.; Mullally, Ann; Ebert, Benjamin L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Obeng, Esther A.; Ebert, Benjamin L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Obeng, Esther A.; Campagna, Dean; Schmidt, Paul J.; Fleming, Mark D.] Boston Childrens Hosp, Boston, MA USA.
[Mullally, Ann] Broad Inst, Cambridge, MA USA.
[Mullally, Ann] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 3
Z9 3
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708125
ER
PT J
AU Parnes, A
Mitchell, C
Rachel, W
Campigotto, F
Lashley, L
Brunswick, C
Neuberg, D
Lin, JC
AF Parnes, Aric
Mitchell, Christine
Rachel, Wentz
Campigotto, Federico
Lashley, Latoya
Brunswick, Cathee
Neuberg, Donna
Lin, Judith C.
TI The Effects of Hemophilia on Socialization
SO BLOOD
LA English
DT Meeting Abstract
C1 [Parnes, Aric; Mitchell, Christine; Rachel, Wentz; Lashley, Latoya; Brunswick, Cathee; Lin, Judith C.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Campigotto, Federico] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707087
ER
PT J
AU Plesner, T
Arkenau, HT
Lokhorst, HM
Gimsing, P
Krejcik, J
Lemech, C
Minnema, MC
Lassen, U
Laubach, JP
Ahmadi, T
Yeh, H
Guckert, ME
Feng, HB
Brun, NC
Lisby, S
Basse, L
Palumbo, A
Richardson, PG
AF Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary E.
Feng, Huaibao
Brun, Nikolai Constantin
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
TI Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone
in Relapsed or Relapsed, Refractory Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Plesner, Torben; Krejcik, Jakub] Vejle Hosp, Velje, Denmark.
[Arkenau, Hendrik-Tobias] Sarah Cannon Res Insitute, London, England.
[Lokhorst, Henk M.; Minnema, Monique C.] UMC Utrecht, Utrecht, Netherlands.
[Gimsing, Peter] Univ Copenhagen, Copenhagen, Denmark.
[Lemech, Charlotte] Sarah Cannon Res Inst, London, England.
[Lassen, Ulrik] Rigshosp, DK-2100 Copenhagen, Denmark.
[Laubach, Jacob P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ahmadi, Tahamtan; Guckert, Mary E.] Janssen, Spring House, PA USA.
[Yeh, Howard; Feng, Huaibao] Janssen Res & Dev, Raritan, NJ USA.
[Brun, Nikolai Constantin; Basse, Linda] Genmab AS, Copenhagen, Denmark.
[Lisby, Steen] Genmab, Copenhagen, Denmark.
[Palumbo, Antonio] Univ Turin, Myeloma Unit, Div Hematol, Turin, Italy.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 5
Z9 5
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706117
ER
PT J
AU Politikos, I
Kim, HT
Nikiforow, S
Li, LQ
Ballen, KK
Antin, JH
Ritz, J
Cutler, CS
Boussiotis, VA
AF Politikos, Ioannis
Kim, Haesook T.
Nikiforow, Sarah
Li, Lequn
Ballen, Karen K.
Antin, Joseph H.
Ritz, Jerome
Cutler, Corey S.
Boussiotis, Vassiliki A.
TI Prognostic Value of TREC, IL-7 and SCF Levels on Clinical Outcomes after
Double Umbilical Cord Blood Transplantation in Adults
SO BLOOD
LA English
DT Meeting Abstract
C1 [Politikos, Ioannis; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Kim, Haesook T.; Antin, Joseph H.; Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Nikiforow, Sarah; Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ballen, Karen K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242700131
ER
PT J
AU Prabhu, VV
Ishizawa, J
Zhao, D
Allen, JE
Batchelor, TT
Chi, AS
Andreeff, M
El-Deiry, WS
AF Prabhu, Varun Vijay
Ishizawa, Jo
Zhao, Dan
Allen, Joshua E.
Batchelor, Tracy T.
Chi, Andrew S.
Andreeff, Michael
El-Deiry, Wafik S.
TI ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples
SO BLOOD
LA English
DT Meeting Abstract
C1 [Prabhu, Varun Vijay; El-Deiry, Wafik S.] Penn State Hershey Canc Inst, Hershey, PA USA.
[Ishizawa, Jo; Andreeff, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Zhao, Dan; Batchelor, Tracy T.; Chi, Andrew S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
[Allen, Joshua E.] Oncoceutics Inc, Hummelstown, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704169
ER
PT J
AU Rand, KA
Song, C
Hwang, AE
Huff, CA
Bernal-Mizrachi, L
Tomasson, MH
Ailawadhi, S
Van Den Berg, DJ
Sheng, X
Graff, JJ
Conti, DV
Zimmerman, T
Peters, E
Singhal, S
Bock, CH
Pawlish, K
Colditz, GA
Sheng, X
Stram, A
Strom, SS
Rybicki, B
Kittles, R
Terebelo, H
Stanford, J
Goodman, PJ
Berndt, SI
Carpten, J
Hennis, AJ
Chu, LS
Casey, G
Driver, WR
Klein, EA
Leske, MC
John, E
Murphy, AB
Neslund-Dudas, C
Stevens, VL
Pettaway, C
Zheng, W
Wu, SY
Witte, J
Zheng, SL
Xu, JF
Munshi, NC
Hsing, A
Ingles, S
Mehta, J
Signorello, LB
Chanock, SJ
Nemesure, B
Mohrbacher, AM
Janakiraman, N
Blot, WJ
Henderson, BE
Kolonel, LN
Anderson, KC
Chiu, BCH
Zonder, J
Orlowski, RZ
Lonial, S
Stram, DO
Haiman, C
Cozen, W
AF Rand, Kristin A.
Song, Chi
Hwang, Amie E.
Huff, Carol A.
Bernal-Mizrachi, Leon
Tomasson, Michael H.
Ailawadhi, Sikander
Van Den Berg, David J.
Sheng, Xin
Graff, John J.
Conti, David V.
Zimmerman, Todd
Peters, Edward
Singhal, Seema
Bock, Cathryn H.
Pawlish, Karen
Colditz, Graham A.
Sheng, Xin
Stram, Alexander
Strom, Sara S.
Rybicki, Benjamin
Kittles, Rick
Terebelo, Howard
Stanford, Janet
Goodman, Phyllis J.
Berndt, Sonja I.
Carpten, John
Hennis, Anselm Jm
Chu, Lisa
Casey, Graham
Driver, W. R.
Klein, Eric A.
Leske, M. Christina
John, Esther
Murphy, Adam Bryant
Neslund-Dudas, Christine
Stevens, Victoria L.
Pettaway, Curtis
Zheng, Wei
Wu, Suh-Yuh
Witte, John
Zheng, Siqun Lilly
Xu, Jianfeng
Munshi, Nikhil C.
Hsing, Ann
Ingles, Sue
Mehta, Jayesh
Signorello, Lisa B.
Chanock, Stephen Jacob
Nemesure, Barbara
Mohrbacher, Ann M.
Janakiraman, Nalini
Blot, William J.
Henderson, Brian E.
Kolonel, Laurence N.
Anderson, Kenneth C.
Chiu, Brian C-H
Zonder, Jeffrey
Orlowski, Robert Z.
Lonial, Sagar
Stram, Daniel O.
Haiman, Christopher
Cozen, Wendy
TI Genetic Susceptibility Markers of Multiple Myeloma in African-Americans
SO BLOOD
LA English
DT Meeting Abstract
C1 [Rand, Kristin A.; Hwang, Amie E.; Conti, David V.; Mohrbacher, Ann M.; Henderson, Brian E.; Haiman, Christopher] Univ So Calif, USC Keck Sch Med, Los Angeles, CA USA.
[Song, Chi; Sheng, Xin; Sheng, Xin; Ingles, Sue; Stram, Daniel O.; Cozen, Wendy] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Hwang, Amie E.; Van Den Berg, David J.] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA.
[Huff, Carol A.] Johns Hopkins Univ, Baltimore, MD USA.
[Bernal-Mizrachi, Leon] Emory Univ, Sch Med, Atlanta, GA USA.
[Tomasson, Michael H.; Colditz, Graham A.] Washington Univ, Sch Med, St Louis, MO USA.
[Ailawadhi, Sikander] Mayo Clin, Jacksonville, FL 32224 USA.
[Graff, John J.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA.
[Zimmerman, Todd] Univ Chicago Med, Chicago, IL USA.
[Peters, Edward] Louisiana State Univ, Sch Publ Hlth, New Orleans, LA USA.
[Singhal, Seema] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Bock, Cathryn H.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI USA.
[Pawlish, Karen] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA.
[Stram, Alexander; Casey, Graham; Witte, John] Univ So Calif, Keck Sch Med, Norris Comprehens Ctr, Los Angeles, CA 90033 USA.
[Pettaway, Curtis; Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Rybicki, Benjamin; Murphy, Adam Bryant; Janakiraman, Nalini] Henry Ford Hosp, Detroit, MI 48202 USA.
[Kittles, Rick] Univ Arizona, Tucson, AZ USA.
[Terebelo, Howard] Providence Canc Inst, Southfield, MI USA.
[Stanford, Janet; Goodman, Phyllis J.] Univ Washington, Seattle, WA 98195 USA.
[Berndt, Sonja I.] NCI, NIH, Bethesda, MD 20892 USA.
[Carpten, John] Translat Genom Res Inst, Phoenix, AZ USA.
[Hennis, Anselm Jm] Univ W Indies, Bridgetown, Barbados.
[Chu, Lisa; John, Esther; Hsing, Ann] Canc Prevent Inst Calif, Fremont, CA USA.
[Driver, W. R.; Stevens, Victoria L.] Amer Canc Soc, Atlanta, GA 30329 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
[Leske, M. Christina] SUNY Stony Brook, Med Ctr, Stony Brook, NY 11794 USA.
[Murphy, Adam Bryant; Mehta, Jayesh] Northwestern Univ, Chicago, IL 60611 USA.
[Neslund-Dudas, Christine] Henry Ford Hlth Syst, Detroit, MI USA.
[Zheng, Wei] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
[Wu, Suh-Yuh; Nemesure, Barbara] SUNY Stony Brook, Stony Brook, NY 11794 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Zheng, Siqun Lilly] Wake Forest Sch Med, Winston Salem, NC USA.
[Xu, Jianfeng] Wake Forest Sch Med, Salem Winston, NC USA.
[Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Signorello, Lisa B.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Chanock, Stephen Jacob] NCI, NIH, US Dept Human Hlth Serv, Rockville, MD USA.
[Blot, William J.] Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, Nashville, TN 37212 USA.
[Kolonel, Laurence N.] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
[Chiu, Brian C-H] Univ Chicago, Chicago, IL 60637 USA.
[Zonder, Jeffrey] Karmanos Canc Inst, Detroit, MI USA.
[Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702025
ER
PT J
AU Rashid, N
Minvielle, S
Magrangeas, F
Samur, MK
Clynen, A
Sperling, A
Tai, YT
Fulciniti, M
Richardson, PG
Attal, M
Moreau, P
Anderson, KC
Parmigiani, G
Avet-Loiseau, H
Munshi, NC
AF Rashid, Naim
Minvielle, Stephane
Magrangeas, Florence
Samur, Mehmet Kemal
Clynen, Alice
Sperling, Adam
Tai, Yu-Tzu
Fulciniti, Mariateresa
Richardson, Paul G.
Attal, Michel
Moreau, Philippe
Anderson, Kenneth C.
Parmigiani, Giovanni
Avet-Loiseau, Herve
Munshi, Nikhil C.
TI Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in
Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma
Patients
SO BLOOD
LA English
DT Meeting Abstract
C1 [Rashid, Naim; Samur, Mehmet Kemal; Clynen, Alice; Parmigiani, Giovanni] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Minvielle, Stephane; Magrangeas, Florence] CNRS 6299, UMR 892, INSERM, Ctr Rech Cancerol Nantes Angers, Nantes, France.
[Sperling, Adam; Tai, Yu-Tzu; Fulciniti, Mariateresa; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Richardson, Paul G.; Munshi, Nikhil C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Attal, Michel] CHU Purpan, Toulouse, France.
[Moreau, Philippe] CHU Nantes, F-44035 Nantes 01, France.
[Avet-Loiseau, Herve] CHU Rangueil, F-31054 Toulouse, France.
RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015;
richard, chrystelle/K-8595-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704211
ER
PT J
AU Rhee, C
Manzo, V
Shea, T
Desjardins, C
van der Auwera, G
Young, S
Riley, AM
DeAngelo, DJ
Baden, LR
Gee, J
Meyerson, M
Klompas, M
Yokoe, D
Weiser, L
Pedamallu, CS
Bhatt, AS
AF Rhee, Chanu
Manzo, Veronica
Shea, Terrance
Desjardins, Christopher
van der Auwera, Geraldine
Young, Sarah
Riley, Ann Marie
DeAngelo, Daniel J.
Baden, Lindsey R.
Gee, Jay
Meyerson, Matthew
Klompas, Michael
Yokoe, Deborah
Weiser, Linda
Pedamallu, Chandra Sekhar
Bhatt, Ami S.
TI Bacillus Cereus: A Leukemia-Specific, Neuroinvasive Pathogen?
SO BLOOD
LA English
DT Meeting Abstract
C1 [Rhee, Chanu] Harvard Univ, Sch Med, Boston, MA USA.
[Manzo, Veronica; Bhatt, Ami S.] Stanford Univ, Stanford, CA 94305 USA.
[Shea, Terrance; Desjardins, Christopher; van der Auwera, Geraldine; Young, Sarah; Pedamallu, Chandra Sekhar] Broad Inst, Cambridge, MA USA.
[Riley, Ann Marie] Boston Childrens Hosp, Boston, MA USA.
[DeAngelo, Daniel J.; Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Baden, Lindsey R.; Klompas, Michael; Yokoe, Deborah; Weiser, Linda] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Gee, Jay] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707200
ER
PT J
AU Rosenblat, T
Heaney, ML
Jurcic, JG
Raza, A
Mears, JG
Santos, R
Carrillo, D
Shum, D
Gonzales, J
Zikaras, K
Santos, M
Zhang, R
Ibanezs, G
Hogdal, L
Crombie, J
Djaballah, H
Scandura, JM
Letai, AG
Frattini, MG
AF Rosenblat, Todd
Heaney, Mark L.
Jurcic, Joseph G.
Raza, Azra
Mears, John G.
Santos, Ruth
Carrillo, Diana
Shum, David
Gonzales, Jacquelyn
Zikaras, Kevin
Santos, Martin
Zhang, Rong
Ibanezs, Glorymar
Hogdal, Leah
Crombie, Jennifer
Djaballah, Hakim
Scandura, Joseph M.
Letai, Anthony G.
Frattini, Mark G.
TI A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and
Thioguanine Combination in Patients with Advanced Myeloid Malignancies
SO BLOOD
LA English
DT Meeting Abstract
C1 [Rosenblat, Todd; Heaney, Mark L.; Jurcic, Joseph G.; Raza, Azra; Mears, John G.; Santos, Ruth; Carrillo, Diana; Gonzales, Jacquelyn; Zikaras, Kevin; Santos, Martin; Zhang, Rong; Frattini, Mark G.] Columbia Univ, Med Ctr, New York, NY USA.
[Shum, David; Ibanezs, Glorymar; Djaballah, Hakim] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Hogdal, Leah] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Crombie, Jennifer] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Scandura, Joseph M.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Letai, Anthony G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708105
ER
PT J
AU Roti, G
Qi, J
Su, A
Varca, A
Aster, JC
Bradner, JE
Stegmaier, K
AF Roti, Giovanni
Qi, Jun
Su, Angela
Varca, Antony
Aster, Jon C.
Bradner, James E.
Stegmaier, Kimberly
TI Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin
Derivative
SO BLOOD
LA English
DT Meeting Abstract
C1 [Roti, Giovanni; Qi, Jun; Su, Angela; Varca, Antony; Bradner, James E.; Stegmaier, Kimberly] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Aster, Jon C.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bradner, James E.; Stegmaier, Kimberly] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Stegmaier, Kimberly] Boston Childrens Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706021
ER
PT J
AU Schram, AM
Mullally, A
Fogerty, AE
Massarotti, E
Berliner, N
AF Schram, Alison M.
Mullally, Ann
Fogerty, Annemarie E.
Massarotti, Elena
Berliner, Nancy
TI Hemophagocytic Lymphohistiocytosis: The Partners Healthcare Experience
over the Past 8 Years
SO BLOOD
LA English
DT Meeting Abstract
C1 [Schram, Alison M.; Massarotti, Elena; Berliner, Nancy] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Mullally, Ann; Berliner, Nancy] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mullally, Ann] Broad Inst, Cambridge, MA USA.
[Mullally, Ann] Harvard Univ, Sch Med, Boston, MA USA.
[Fogerty, Annemarie E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242708063
ER
PT J
AU Schram, AM
Mullally, A
Campigotto, F
Fogerty, AE
Massarotti, E
Neuberg, DS
Berliner, N
AF Schram, Alison M.
Mullally, Ann
Campigotto, Federico
Fogerty, Annemarie E.
Massarotti, Elena
Neuberg, Donna S.
Berliner, Nancy
TI Marked Hyperferritinemia Does Not Predict for Hemophagocytic
Lymphohistiocytosis (HLH) in the Adult Population
SO BLOOD
LA English
DT Meeting Abstract
C1 [Schram, Alison M.; Massarotti, Elena; Berliner, Nancy] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Mullally, Ann; Campigotto, Federico; Neuberg, Donna S.; Berliner, Nancy] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mullally, Ann] Broad Inst, Cambridge, MA USA.
[Mullally, Ann] Harvard Univ, Sch Med, Boston, MA USA.
[Fogerty, Annemarie E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704033
ER
PT J
AU Sekeres, MA
Othus, M
List, AF
Odenike, O
Stone, RM
Gore, SD
Litzow, MR
Buckstein, R
Velasco, MR
Gaur, R
Atallah, E
Attar, E
Appelbaum, FR
Erba, HP
AF Sekeres, Mikkael A.
Othus, Megan
List, Alan F.
Odenike, Olatoyosi
Stone, Richard M.
Gore, Steven D.
Litzow, Mark R.
Buckstein, Rena
Velasco, Mario R.
Gaur, Rakesh
Atallah, Ehab
Attar, Eyal
Appelbaum, Frederick R.
Erba, Harry P.
TI A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or
with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk
Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia
(CMML): North American Intergroup Study SWOG S1117
SO BLOOD
LA English
DT Meeting Abstract
C1 [Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Othus, Megan] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[List, Alan F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Odenike, Olatoyosi] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gore, Steven D.] Yale Univ, Sch Med, New Haven, CT USA.
[Gore, Steven D.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Litzow, Mark R.] Mayo Clin, Rochester, MN USA.
[Buckstein, Rena] Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada.
[Velasco, Mario R.] Cent Illinois CCOP, Decatur, IL USA.
[Gaur, Rakesh] Kansas City CCOP, Kansas City, KS USA.
[Atallah, Ehab] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Attar, Eyal] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Appelbaum, Frederick R.] Univ Washington, Seattle, WA 98195 USA.
[Erba, Harry P.] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707005
ER
PT J
AU Shammas, M
Kumar, S
Pal, J
Nanjappa, P
Samur, M
Gkotzamanidou, M
Shi, JL
Munshi, NC
AF Shammas, Masood
Kumar, Subodh
Pal, Jagannath
Nanjappa, Puru
Samur, Mehmat
Gkotzamanidou, Maria
Shi, Jialan
Munshi, Nikhil C.
TI Dysregulation of SHFM1, a Novel Target for Prevention of Genomic
Instability in Myeloma, Is Associated with Epigenetic Changes at
Specific CpG Sites
SO BLOOD
LA English
DT Meeting Abstract
C1 [Shammas, Masood; Kumar, Subodh; Pal, Jagannath; Nanjappa, Puru; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Shammas, Masood; Kumar, Subodh; Pal, Jagannath; Nanjappa, Puru; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Samur, Mehmat] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gkotzamanidou, Maria] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Shi, Jialan; Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242705035
ER
PT J
AU Shi, JL
Lu, XG
Thatte, HS
AF Shi, Jialan
Lu, Xiu-Gui
Thatte, Hemant S.
TI Extended Storage of Platelets in a Novel Organ Preservation Solution,
Somah
SO BLOOD
LA English
DT Meeting Abstract
C1 [Shi, Jialan] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, West Roxbury, MA USA.
[Lu, Xiu-Gui; Thatte, Hemant S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, West Roxbury, MA USA.
[Lu, Xiu-Gui; Thatte, Hemant S.] VA Boston Healthcare Syst, West Roxbury, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242703010
ER
PT J
AU Shinde, A
Rhieu, BH
Berhane, H
Guinan, EC
Parmar, K
Wang, H
Franicola, D
Zhang, XC
Li, S
Dixon, TM
Greenberger, JS
AF Shinde, Ashwin
Rhieu, Byung Han
Berhane, Hebist
Guinan, Eva C.
Parmar, Kalindi
Wang, Hong
Franicola, Darcy
Zhang, Xichen
Li, Song
Dixon, Tracy M.
Greenberger, Joel S.
TI Intraoral Mitochondrial-Targeted GS Nitroxide JP4-039 Ameliorates
Radiation-Induced Mucositis in Orthotopic Tumor-Bearing Fanconi Anemia
(FA) (Fancd2-/-) Mice
SO BLOOD
LA English
DT Meeting Abstract
C1 [Shinde, Ashwin; Rhieu, Byung Han; Zhang, Xichen; Li, Song] Univ Pittsburgh, Pittsburgh, PA USA.
[Berhane, Hebist; Wang, Hong; Franicola, Darcy; Dixon, Tracy M.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Guinan, Eva C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Parmar, Kalindi] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Greenberger, Joel S.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707153
ER
PT J
AU Shirai, CL
Ley, JN
White, BS
Tibbitts, J
Shao, J
Ndonwi, M
Kim, S
Wadugu, B
Okeyo-Owuor, T
Graubert, TA
Walter, MJ
AF Shirai, Cara Lunn
Ley, James N.
White, Brian S.
Tibbitts, Justin
Shao, Jin
Ndonwi, Matthew
Kim, Sanghyun
Wadugu, Brian
Okeyo-Owuor, Theresa
Graubert, Timothy A.
Walter, Matthew J.
TI Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing in
Transgenic Mice
SO BLOOD
LA English
DT Meeting Abstract
C1 [Shirai, Cara Lunn; Ley, James N.; Tibbitts, Justin; Shao, Jin; Ndonwi, Matthew; Kim, Sanghyun; Wadugu, Brian; Walter, Matthew J.] Washington Univ, Sch Med, St Louis, MO USA.
[White, Brian S.; Okeyo-Owuor, Theresa] Washington Univ, St Louis, MO USA.
[Graubert, Timothy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706054
ER
PT J
AU Silverman, LR
Fenaux, P
Al-Kali, A
Baer, MR
Sekeres, MA
Roboz, GJ
Gaidano, G
Scott, BL
Greenberg, PL
Platzbecker, U
Steensma, DP
Kambhampati, S
Kreuzer, KA
Godley, LA
Collins, R
Atallah, E
Navada, SC
Wilhelm, F
Azarnia, N
Garcia-Manero, G
AF Silverman, Lewis R.
Fenaux, Pierre
Al-Kali, Aref
Baer, Maria R.
Sekeres, Mikkael A.
Roboz, Gail J.
Gaidano, Gianluca
Scott, Bart L.
Greenberg, Peter L.
Platzbecker, Uwe
Steensma, David P.
Kambhampati, Suman
Kreuzer, Karl-Anton
Godley, Lucy A.
Collins, Robert
Atallah, Ehab
Navada, Shyamala C.
Wilhelm, Francois
Azarnia, Nozar
Garcia-Manero, Guillermo
TI Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival
(OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)
SO BLOOD
LA English
DT Meeting Abstract
C1 [Silverman, Lewis R.; Navada, Shyamala C.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Fenaux, Pierre] Univ Paris 07, Hop St Louis, Paris, France.
[Al-Kali, Aref] Mayo Clin, Rochester, MN USA.
[Baer, Maria R.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Roboz, Gail J.] Weill Cornell Med Coll, New York, NY USA.
[Gaidano, Gianluca] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy.
[Scott, Bart L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Greenberg, Peter L.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Platzbecker, Uwe] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany.
[Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kambhampati, Suman] Univ Kansas, Ctr Canc, Kansas City, KS USA.
[Kreuzer, Karl-Anton] Univ Cologne, D-50931 Cologne, Germany.
[Godley, Lucy A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Collins, Robert] Univ Texas Southwestern, Dallas, TX USA.
[Atallah, Ehab] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Wilhelm, Francois; Azarnia, Nozar] Onconova Therapeut Inc, Newtown, PA USA.
[Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242703148
ER
PT J
AU Sivina, M
Werner, L
Rassenti, L
Wierda, WG
Keating, MJ
O'Brien, S
Neuberg, D
Kipps, TJ
Burger, JA
AF Sivina, Mariela
Werner, Lillian
Rassenti, Laura
Wierda, William G.
Keating, Michael J.
O'Brien, Susan
Neuberg, Donna
Kipps, Thomas J.
Burger, Jan A.
TI Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients
with Chronic Lymhocytic Leukemia (CLL) Managed with Observation
SO BLOOD
LA English
DT Meeting Abstract
C1 [Sivina, Mariela; Wierda, William G.; Keating, Michael J.; O'Brien, Susan; Burger, Jan A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Werner, Lillian; Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rassenti, Laura; Kipps, Thomas J.] Univ Calif San Diego, La Jolla, CA 92093 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701003
ER
PT J
AU Song, Y
Das, DS
Ray, A
Ravillah, D
Munshi, NC
Chauhan, D
Anderson, KC
AF Song, Yan
Das, Deepika Sharma
Ray, Arghya
Ravillah, Durgadevi
Munshi, Nikhil C.
Chauhan, Dharminder
Anderson, Kenneth C.
TI Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
C1 [Song, Yan; Das, Deepika Sharma; Ray, Arghya; Ravillah, Durgadevi; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Song, Yan; Das, Deepika Sharma; Ray, Arghya; Ravillah, Durgadevi; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242706230
ER
PT J
AU Spitzer, B
Guryanova, OA
Abdel-Wahab, O
Kucine, N
Adli, M
Berman, JN
Meshinchi, S
Bernstein, B
Pelossof, R
Leslie, C
Levine, RL
AF Spitzer, Barbara
Guryanova, Olga A.
Abdel-Wahab, Omar
Kucine, Nicole
Adli, Mazhar
Berman, Jason N.
Meshinchi, Soheil
Bernstein, Bradley
Pelossof, Raphael
Leslie, Christina
Levine, Ross L.
TI Characterizing Transcriptional and Epigenetic Signatures Induced By
FLT3-ITD Activation
SO BLOOD
LA English
DT Meeting Abstract
C1 [Spitzer, Barbara; Guryanova, Olga A.; Abdel-Wahab, Omar; Pelossof, Raphael; Leslie, Christina; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kucine, Nicole] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
[Adli, Mazhar] Massachusetts Gen Hosp, Dept Pathol, Broad Inst Harvard & MIT, Howard Hughes Med Inst, Boston, MA 02114 USA.
[Adli, Mazhar] Harvard Univ, Sch Med, Boston, MA USA.
[Berman, Jason N.] Dalhousie Univ, IWK Hlth Ctr, Halifax, NS, Canada.
[Meshinchi, Soheil] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Bernstein, Bradley] Massachusetts Gen Hosp, Broad Inst, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242705224
ER
PT J
AU Szalat, R
Dreze, M
Samur, MK
Calkins, AS
Parmigiani, G
Avet-Loiseau, H
Anderson, KC
Fermand, JP
Lazaro, JB
Munshi, NC
AF Szalat, Raphael
Dreze, Matija
Samur, Mehmet Kemal
Calkins, Anne S.
Parmigiani, Giovanni
Avet-Loiseau, Herve
Anderson, Kenneth C.
Fermand, Jean-Paul
Lazaro, Jean-Bernard
Munshi, Nikhil C.
TI Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects
Outcome in Multiple Myeloma (MM)
SO BLOOD
LA English
DT Meeting Abstract
C1 [Szalat, Raphael; Samur, Mehmet Kemal; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dreze, Matija; Calkins, Anne S.; Parmigiani, Giovanni; Lazaro, Jean-Bernard] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Avet-Loiseau, Herve] Univ Hosp, Unit Genom Myeloma, Toulouse, France.
[Fermand, Jean-Paul] Hop St Louis, Paris, France.
[Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702201
ER
PT J
AU Tai, YT
Acharya, C
An, G
Zhong, MY
Cea, M
Cagnetta, A
Jiang, H
van Eenennaam, H
van Elsas, A
Munshi, NC
Anderson, KC
AF Tai, Yu-Tzu
Acharya, Chirag
An, Gang
Zhong, Mike Y.
Cea, Michele
Cagnetta, Antonia
Jiang, Hua
van Eenennaam, Hans
van Elsas, Andrea
Munshi, Nikhil C.
Anderson, Kenneth C.
TI A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal
Antibody Targets Multiple Myeloma Cells in the Bone Marrow
Microenvironment
SO BLOOD
LA English
DT Meeting Abstract
C1 [Tai, Yu-Tzu] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Acharya, Chirag; Zhong, Mike Y.; Cea, Michele; Cagnetta, Antonia; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Acharya, Chirag; Zhong, Mike Y.; Cea, Michele; Cagnetta, Antonia; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[An, Gang; Jiang, Hua] Dana Farber Canc Inst, Boston, MA 02115 USA.
[van Eenennaam, Hans; van Elsas, Andrea] BioNovion, Oss, Netherlands.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242704020
ER
PT J
AU Tatetsu, H
Wang, F
Gao, C
Ueno, S
Tian, X
Armant, M
Federation, A
Qi, J
Bradner, JE
Tenen, DG
Chai, L
AF Tatetsu, Hiro
Wang, Fei
Gao, Chong
Ueno, Shikiko
Tian, Xi
Armant, Myriam
Federation, Alex
Qi, Jun
Bradner, James E.
Tenen, Daniel G.
Chai, Li
TI SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of
Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+Cells
SO BLOOD
LA English
DT Meeting Abstract
C1 [Tatetsu, Hiro; Wang, Fei; Gao, Chong; Tian, Xi; Chai, Li] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Ueno, Shikiko] Kumamoto Univ, Sch Med, Kumamoto 860, Japan.
[Armant, Myriam] Ctr Human Cell Therapy, Boston, MA USA.
[Federation, Alex; Qi, Jun; Bradner, James E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tenen, Daniel G.] Harvard Univ, Sch Med, Boston, MA USA.
[Tenen, Daniel G.] Natl Univ Singapore, Singapore 117548, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702082
ER
PT J
AU Touzeau, C
Ryan, J
Moreau, P
Chonghaile, TN
Le Gouill, S
Richardson, PG
Anderson, KC
Amiot, M
Letai, AG
AF Touzeau, Cyrille
Ryan, Jeremy
Moreau, Philippe
Chonghaile, Triona Ni
Le Gouill, Steven
Richardson, Paul G.
Anderson, Kenneth C.
Amiot, Martine
Letai, Anthony G.
TI BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and
Predicts Sensitivity to BH3 Mimetics
SO BLOOD
LA English
DT Meeting Abstract
C1 [Touzeau, Cyrille; Ryan, Jeremy; Chonghaile, Triona Ni; Letai, Anthony G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Moreau, Philippe] Univ Hosp Nantes, Nantes, France.
[Le Gouill, Steven] CHU Nantes, F-44035 Nantes 01, France.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Amiot, Martine] CNRS 6299, Inserm 892, CRCNA, Nantes, France.
RI Ni Chonghaile, Triona/L-9418-2015; richard, chrystelle/K-8595-2015
OI Ni Chonghaile, Triona/0000-0002-3041-4031;
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701161
ER
PT J
AU Vaughn, JE
Storer, BE
Armand, P
Raimondi, R
Gibson, CJ
Rambaldi, A
Ciceri, F
Oneto, R
Bruno, B
Martin, PJ
Sandmaier, BM
Storb, RF
Sorror, ML
AF Vaughn, Jennifer E
Storer, Barry E
Armand, Philippe P
Raimondi, Roberto R
Gibson, Christopher J
Rambaldi, Alessandro A
Ciceri, Fabio C
Oneto, Rosi R
Bruno, Benedetto B
Martin, Paul J
Sandmaier, Brenda M
Storb, Rainer F
Sorror, Mohamed L
TI Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic
Information to Comorbidities for Allogeneic Hematopoietic Cell
Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation
Study
SO BLOOD
LA English
DT Meeting Abstract
C1 [Vaughn, Jennifer E; Storer, Barry E; Martin, Paul J; Sandmaier, Brenda M; Storb, Rainer F; Sorror, Mohamed L] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Vaughn, Jennifer E; Martin, Paul J; Sandmaier, Brenda M; Sorror, Mohamed L] Univ Washington, Seattle, WA 98195 USA.
[Storer, Barry E] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Armand, Philippe P; Gibson, Christopher J] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Raimondi, Roberto R] Osped San Bortolo, Vicenza, Italy.
[Rambaldi, Alessandro A] Osped Riuniti Bergamo, I-24100 Bergamo, Italy.
[Ciceri, Fabio C] Ist Sci San Raffaele, I-20132 Milan, Italy.
[Oneto, Rosi R] Osped San Martino Genova, Genoa, Italy.
[Bruno, Benedetto B] Univ Turin, AOU San Giovanni Battista, Turin, Italy.
[Storb, Rainer F] Univ Washington, Sch Med, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701142
ER
PT J
AU Verstovsek, S
Talpaz, M
Ritchie, EK
Wadleigh, M
Odenike, O
Jamieson, C
Stein, BL
Tomonori, U
Mesa, R
AF Verstovsek, Srdan
Talpaz, Moshe
Ritchie, Ellen K.
Wadleigh, Martha
Odenike, Olatoyosi
Jamieson, Catriona
Stein, Brady L.
Tomonori, Uno
Mesa, Ruben
TI A Phase 1/2, Open-Label, Dose-Escalation, Multi-Center Study to Assess
the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of
Orally Administered NS-018 in Patients with Primary Myelofibrosis (PMF),
Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential
Thrombocythemia Myelofibrosis (postET MF)
SO BLOOD
LA English
DT Meeting Abstract
C1 [Verstovsek, Srdan] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Talpaz, Moshe] Univ Michigan, Ann Arbor, MI 48109 USA.
[Ritchie, Ellen K.] Cornell Univ, New York, NY 10021 USA.
[Wadleigh, Martha] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Odenike, Olatoyosi] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Jamieson, Catriona] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Stein, Brady L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Tomonori, Uno] NS Phrama Inc, Paramus, NJ USA.
[Mesa, Ruben] Mayo Clin, Scottsdale, AZ USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701160
ER
PT J
AU Wang, M
Nooka, AK
Yee, AJ
Thomas, SK
O'Donnell, E
Shah, J
Weber, DM
Kaufman, JL
Lonial, S
Avigan, D
Raje, N
AF Wang, Michael (Luhua)
Nooka, Ajay K.
Yee, Andrew J.
Thomas, Sheeba K.
O'Donnell, Elizabeth
Shah, Jatin
Weber, Donna M.
Kaufman, Jonathan L.
Lonial, Sagar
Avigan, David
Raje, Noopur
TI Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410
Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple
Myeloma (SMM)
SO BLOOD
LA English
DT Meeting Abstract
C1 [Wang, Michael (Luhua); Thomas, Sheeba K.; Shah, Jatin; Weber, Donna M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Nooka, Ajay K.; Kaufman, Jonathan L.; Lonial, Sagar] Emory Univ, Atlanta, GA 30322 USA.
[Yee, Andrew J.; O'Donnell, Elizabeth] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242707017
ER
PT J
AU Xie, HF
Peng, C
Qi, J
Cheloni, G
Das, P
Huang, JL
Nguyen, M
Li, SG
Bradner, JE
Orkin, SH
AF Xie, Huafeng
Peng, Cong
Qi, Jun
Cheloni, Giullia
Das, Partha
Huang, Jialiang
Minh Nguyen
Li, Shaoguang
Bradner, James E.
Orkin, Stuart H.
TI Eradication of Chronic Myelogenous Leukemia By Inactivation of the
Polycomb Group Protein EZH2
SO BLOOD
LA English
DT Meeting Abstract
C1 [Xie, Huafeng; Huang, Jialiang] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Peng, Cong] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA.
[Qi, Jun] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cheloni, Giullia; Li, Shaoguang] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Das, Partha] Boston Childrens Hosp, Boston, MA USA.
[Bradner, James E.; Orkin, Stuart H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701007
ER
PT J
AU Xu, J
Shao, Z
Li, D
Xie, HF
Kim, W
Huang, JL
Pinello, L
Glass, K
Yuan, GC
Orkin, SH
AF Xu, Jian
Shao, Zhen
Li, Dan
Xie, Huafeng
Kim, Woojin
Huang, Jialiang
Pinello, Luca
Glass, Kimberly
Yuan, Guo-Cheng
Orkin, Stuart H.
TI Developmental Control of Polycomb Subunit Composition Mediates a Switch
to Non-Canonical Functions during Hematopoiesis
SO BLOOD
LA English
DT Meeting Abstract
C1 [Xu, Jian; Shao, Zhen; Xie, Huafeng; Kim, Woojin; Huang, Jialiang; Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Xu, Jian] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Shao, Zhen] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai, Peoples R China.
[Li, Dan] Harvard Univ, Boston, MA USA.
[Pinello, Luca; Glass, Kimberly; Yuan, Guo-Cheng] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701076
ER
PT J
AU Yeh, AC
Spitzer, TR
Chen, YB
McAfee, S
Ballen, KK
Attar, EC
Fathi, AT
Dey, BR
AF Yeh, Albert C.
Spitzer, Thomas R.
Chen, Yi-Bin
McAfee, Steven
Ballen, Karen K.
Attar, Eyal C.
Fathi, Amir T.
Dey, Bimalangshu R.
TI Serum Uric Acid Levels during Allogeneic Hematopoeitic Cell
Transplantation and Subsequent Graft Versus Host Disease
SO BLOOD
LA English
DT Meeting Abstract
C1 [Yeh, Albert C.; Spitzer, Thomas R.; McAfee, Steven; Attar, Eyal C.; Dey, Bimalangshu R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chen, Yi-Bin; Ballen, Karen K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242703118
ER
PT J
AU Yi, JS
Federation, A
Qi, J
Dhe-Paganon, S
Hadler, M
Xu, X
Varca, A
St Pierre, R
Armstrong, SA
Bradner, JE
AF Yi, Joanna S.
Federation, Alex
Qi, Jun
Dhe-Paganon, Sirano
Hadler, Michael
Xu, Xiang
Varca, Anthony
St Pierre, Roodolph
Armstrong, Scott A.
Bradner, James E.
TI Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a
Novel, Label Free Assay Platform
SO BLOOD
LA English
DT Meeting Abstract
C1 [Yi, Joanna S.] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA.
[Federation, Alex; Qi, Jun; Bradner, James E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dhe-Paganon, Sirano; Varca, Anthony; St Pierre, Roodolph] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hadler, Michael; Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Xu, Xiang] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701202
ER
PT J
AU Yoda, A
Adelmant, G
Tamburini, J
Chapuy, B
Shindoh, N
Yoda, Y
Weigert, O
Kopp, N
Wu, SC
Kim, SS
Liu, HY
Tivey, T
Christie, AL
Elpek, KG
Card, J
Gritsman, K
Gotlib, J
Deininger, MW
Makishima, H
Turley, S
Javidi-Sharifi, N
Maciejewski, JP
Rodig, SJ
Tyner, JW
Marto, JA
Weinstock, DM
Lane, AA
AF Yoda, Akinori
Adelmant, Guillaume
Tamburini, Jerome
Chapuy, Bjoern
Shindoh, Nobuaki
Yoda, Yuka
Weigert, Oliver
Kopp, Nadja
Wu, Shuo-Chieh
Kim, Sunhee S.
Liu, Huiyun
Tivey, Trevor
Christie, Amanda L.
Elpek, Kutlu G.
Card, Joseph
Gritsman, Kira
Gotlib, Jason
Deininger, Michael W.
Makishima, Hideki
Turley, Shannon
Javidi-Sharifi, Nathalie
Maciejewski, Jaroslaw P.
Rodig, Scott J.
Tyner, Jeffrey W.
Marto, Jarrod A.
Weinstock, David M.
Lane, Andrew A.
TI GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms
Targetable By Combined PI3K/mTOR Inhibition
SO BLOOD
LA English
DT Meeting Abstract
C1 [Yoda, Akinori; Adelmant, Guillaume; Chapuy, Bjoern; Shindoh, Nobuaki; Yoda, Yuka; Weigert, Oliver; Kopp, Nadja; Wu, Shuo-Chieh; Kim, Sunhee S.; Liu, Huiyun; Tivey, Trevor; Christie, Amanda L.; Elpek, Kutlu G.; Card, Joseph; Turley, Shannon; Marto, Jarrod A.; Weinstock, David M.; Lane, Andrew A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tamburini, Jerome] Univ Paris 05, Paris, France.
[Shindoh, Nobuaki] Astellas Pharma Inc, Tsukuba, Ibaraki, Japan.
[Weigert, Oliver] Univ Hosp, Dept Internal Med 3, Munich, Germany.
[Gritsman, Kira] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gotlib, Jason] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Deininger, Michael W.] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA.
[Makishima, Hideki; Maciejewski, Jaroslaw P.] Cleveland Clin, Cleveland, OH 44106 USA.
[Javidi-Sharifi, Nathalie] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702149
ER
PT J
AU Zhang, Y
Zhang, Y
Mishima, Y
Moschetta, M
Zhang, WJ
Maiso, P
Sacco, A
Aljawai, Y
Sahin, I
Reagan, MR
Ring, JE
Tam, WF
Xu, QL
Pachte, JA
Roccaro, AM
Ghobrial, IM
AF Zhang, Yu
Zhang, Yong
Mishima, Yuji
Moschetta, Michele
Zhang, Wenjing
Maiso, Patricia
Sacco, Antonio
Aljawai, Yosra
Sahin, Ilyas
Reagan, Michaela R.
Ring, Jennifer E.
Tam, Winnie F.
Xu, Qunli
Pachte, Jonathan A.
Roccaro, Aldo M.
Ghobrial, Irene M.
TI Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in
Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM
SO BLOOD
LA English
DT Meeting Abstract
C1 [Zhang, Yu; Mishima, Yuji; Moschetta, Michele; Zhang, Wenjing; Maiso, Patricia; Sacco, Antonio; Aljawai, Yosra; Sahin, Ilyas; Reagan, Michaela R.; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zhang, Yong] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ring, Jennifer E.; Tam, Winnie F.; Xu, Qunli; Pachte, Jonathan A.] Verastem Inc, Cambridge, MA USA.
RI Reagan, Michaela/E-3549-2017
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242702113
ER
PT J
AU Zhou, L
Wang, WH
Zimmerman, G
Myers, J
Huang, YS
Yu, VWC
Huang, D
Yu, SL
Wang, YW
Huang, XR
Shim, J
Yan, MH
Lowe, J
Xin, W
Stanley, P
Scadden, DT
Huang, AY
Siebel, CW
AF Zhou, Lan
Wang, Weihuan
Zimmerman, Grant
Myers, Jay
Huang, Yuanshuai
Yu, Vionnie W. C.
Huang, Dan
Yu, Shuiliang
Wang, Yiwei
Huang, Xiaoran
Shim, Jeongsup
Yan, Minhong
Lowe, John
Xin, Wei
Stanley, Pamela
Scadden, David T.
Huang, Alex Y.
Siebel, Christian W.
TI Loss of Notch Receptor-Ligand Engagement Leads to Increased
Hematopoietic Stem and Progenitor Cell Egress and Mobilization
SO BLOOD
LA English
DT Meeting Abstract
C1 [Zhou, Lan; Wang, Weihuan; Zimmerman, Grant; Myers, Jay; Huang, Yuanshuai; Huang, Dan; Yu, Shuiliang; Wang, Yiwei; Huang, Xiaoran; Xin, Wei; Huang, Alex Y.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Yu, Vionnie W. C.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Yu, Vionnie W. C.] Harvard Stem Cell Inst, Boston, MA USA.
[Shim, Jeongsup; Yan, Minhong; Lowe, John; Siebel, Christian W.] Genentech Inc, San Francisco, CA 94080 USA.
[Stanley, Pamela] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Scadden, David T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KQ
UT WOS:000349242701041
ER
PT J
AU Abel, GA
Efficace, F
Buckstein, R
Tinsley, S
Jurcic, JG
Martins, Y
Steensma, DP
Watts, CD
Raza, A
List, AF
Klaassen, RJ
AF Abel, Gregory A.
Efficace, Fabio
Buckstein, Rena
Tinsley, Sara
Jurcic, Joseph G.
Martins, Yolanda
Steensma, David P.
Watts, Corey D.
Raza, Azra
List, Alan F.
Klaassen, Robert J.
TI Preliminary International Validation of the Quality of Life in
Myelodysplasia Scale (QUALMS)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Abel, Gregory A.; Martins, Yolanda; Steensma, David P.; Watts, Corey D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Efficace, Fabio] GIMEMA Fdn, Italian Grp Adult Hematol Dis GIMEMA, Rome, Italy.
[Buckstein, Rena] Odette Canc Ctr, Toronto, ON, Canada.
[Tinsley, Sara; List, Alan F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Jurcic, Joseph G.; Raza, Azra] Columbia Univ, Med Ctr, New York, NY USA.
[Klaassen, Robert J.] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233801103
ER
PT J
AU Abramson, JS
Jacobsen, ED
Redd, RA
Takvorian, T
Fisher, DC
Brown, JR
Schwartz, JH
Weitzman, J
Neuberg, D
Barnes, JA
Hochberg, EP
AF Abramson, Jeremy S.
Jacobsen, Eric D.
Redd, Robert Allyn
Takvorian, Tak
Fisher, David C.
Brown, Jennifer R.
Schwartz, Joel H.
Weitzman, James
Neuberg, Donna
Barnes, Jeffrey A.
Hochberg, Ephraim P.
TI Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final
Results from a Phase 1-2 Trial
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Abramson, Jeremy S.; Takvorian, Tak; Barnes, Jeffrey A.; Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Jacobsen, Eric D.; Redd, Robert Allyn; Fisher, David C.; Brown, Jennifer R.; Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schwartz, Joel H.; Weitzman, James] MGH North Shore Canc Ctr, Danvers, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808119
ER
PT J
AU Acharya, C
An, G
Zhong, MY
Cea, M
Cagnetta, A
Jiang, H
Tai, YT
Anderson, KC
AF Acharya, Chirag
An, Gang
Zhong, Mike Y.
Cea, Michele
Cagnetta, Antonia
Jiang, Hua
Tai, Yu-Tzu
Anderson, Kenneth C.
TI NF kappa B Signaling and Mcl-1 Are Critical in B Cell Maturation
Antigen-Promoted Multiple Myeloma Cell Growth and Survival
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Acharya, Chirag; Zhong, Mike Y.; Cea, Michele; Cagnetta, Antonia; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Acharya, Chirag; Zhong, Mike Y.; Cea, Michele; Cagnetta, Antonia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[An, Gang; Jiang, Hua] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tai, Yu-Tzu] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805015
ER
PT J
AU Adamia, S
Toniolo, P
Fathi, AT
Galinsky, I
Liu, SY
Yen, K
Kim, HK
Zhu, DW
Kim, S
Wadleigh, M
Steensma, DP
Dagogo-Jack, I
DeAngelo, DJ
Griffin, JD
Stone, RM
AF Adamia, Sophia
Toniolo, Patricia
Fathi, Amir T.
Galinsky, Ilene
Liu, Suiyang
Yen, Katharine
Kim, Hyeryun Kim
Zhu, Dongwei
Kim, Straley
Wadleigh, Martha
Steensma, David P.
Dagogo-Jack, Ibiayi
DeAngelo, Daniel J.
Griffin, James D.
Stone, Richard M.
TI IDH1 Splicing Alterations in Patients with AML and Their Relationship to
Blood 2HG Levels
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Adamia, Sophia; Toniolo, Patricia; Galinsky, Ilene; Liu, Suiyang; Wadleigh, Martha; Steensma, David P.; Dagogo-Jack, Ibiayi; DeAngelo, Daniel J.; Griffin, James D.; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Adamia, Sophia] HMS, Boston, MA USA.
[Fathi, Amir T.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Yen, Katharine; Kim, Hyeryun Kim; Zhu, Dongwei; Kim, Straley] Agios Pharmaceut, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502069
ER
PT J
AU Alho, AC
Haesook, KT
Reynolds, CG
Chammas, MJ
McDonough, S
Lazo-Kallanian, S
Daley, J
Nikiforow, S
Cutler, CS
Koreth, J
Ho, VT
Armand, P
Soiffer, RJ
Antin, JH
Ritz, J
AF Alho, Ana Cristina
Haesook, Kim T.
Reynolds, Carol G.
Chammas, Marie J.
McDonough, Sean
Lazo-Kallanian, Suzan
Daley, John
Nikiforow, Sarah
Cutler, Corey S.
Koreth, John
Ho, Vincent T.
Armand, Philippe
Soiffer, Robert J.
Antin, Joseph H.
Ritz, Jerome
TI Homeostatic Reconstitution of CD4+Regulatory and Conventional T Cell
Subsets in Adult Patients after Allogeneic Hematopoietic Stem Cell
Transplantation (HSCT)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Alho, Ana Cristina; Reynolds, Carol G.; Chammas, Marie J.; McDonough, Sean; Lazo-Kallanian, Suzan; Daley, John; Nikiforow, Sarah; Koreth, John; Ho, Vincent T.; Armand, Philippe; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Alho, Ana Cristina] Univ Lisbon, Fac Med, P-1699 Lisbon, Portugal.
[Haesook, Kim T.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Haesook, Kim T.; Cutler, Corey S.; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504024
ER
PT J
AU Amrein, PC
Kai, X
Iuchi, Y
Arnason, J
Brown, JR
Ballen, KK
Attar, EC
Fathi, AT
Hochberg, EP
Hwang, H
Pillai, S
AF Amrein, Philip C.
Kai, Xin
Iuchi, Yasuyuki
Arnason, Jon
Brown, Jennifer R.
Ballen, Karen K.
Attar, Eyal C.
Fathi, Amir T.
Hochberg, Ephraim P.
Hwang, HyukJoo
Pillai, Shiv
TI Inhibition of Phosphorylation of ERK in CLL Cells Pre-Treatment
Correlates Best with Response to Dasatinib, Fludarabine, and Rituximab
for Patients with Relapsed CLL
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Amrein, Philip C.; Kai, Xin; Iuchi, Yasuyuki; Hwang, HyukJoo; Pillai, Shiv] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Arnason, Jon] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ballen, Karen K.; Attar, Eyal C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
[Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504199
ER
PT J
AU Anagnostou, T
Arvanitis, M
Ziakas, PD
Zacharioudakis, I
Zervou, F
Caliendo, A
Mylonakis, EE
AF Anagnostou, Theodora
Arvanitis, Marios
Ziakas, Panayiotis D.
Zacharioudakis, Ioannis
Zervou, Fainareti
Caliendo, Angela
Mylonakis, Eleftherios E.
TI Polymerase Chain Reaction in the Diagnosis of Invasive Aspergillosis in
Hematopoietic Stem Cell Transplant Recipients: A Meta-Analysis of
Diagnostic Performance
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Anagnostou, Theodora] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
[Anagnostou, Theodora] Harvard Univ, Sch Med, Mt Auburn Hosp, Boston, MA USA.
[Arvanitis, Marios] Boston Med Ctr, Boston, MA USA.
[Ziakas, Panayiotis D.; Zacharioudakis, Ioannis] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA.
[Zervou, Fainareti; Caliendo, Angela; Mylonakis, Eleftherios E.] Brown Univ, Rhode Isl Hosp, Providence, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503002
ER
PT J
AU Appelmann, I
Scuoppo, C
Thapar, V
Ledezma, D
Lujambio, A
Lowe, SW
Chicas, A
AF Appelmann, Iris
Scuoppo, Claudio
Thapar, Vishal
Ledezma, Daniela
Lujambio, Amaia
Lowe, Scott W.
Chicas, Agustin
TI Suppression of EZH2 Accelerates MYC-Driven Lymphomagenesis By Inhibition
of Apoptosis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Appelmann, Iris; Lujambio, Amaia; Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Scuoppo, Claudio] Columbia Univ, New York, NY USA.
[Thapar, Vishal] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ledezma, Daniela] Univ Nacl Autonoma Mexico, Cuernavaca 62191, Morelos, Mexico.
[Chicas, Agustin] H3 Biomed, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500165
ER
PT J
AU Armand, P
Ansell, SM
Lesokhin, AM
Halwani, A
Millenson, MM
Schuster, SJ
Timmerman, J
Borrello, I
Gutierrez, M
Scott, EC
Cattry, D
Chapuy, B
Ligon, AH
Rodig, SJ
Zhu, LL
Grosso, JF
Kim, SY
Shipp, MA
AF Armand, Philippe
Ansell, Stephen M.
Lesokhin, Alexander M.
Halwani, Ahmad
Millenson, Michael M.
Schuster, Stephen J.
Timmerman, John
Borrello, Ivan
Gutierrez, Martin
Scott, Emma C.
Cattry, Deepika
Chapuy, Bjoern
Ligon, Azra H.
Rodig, Scott J.
Zhu, Lili
Grosso, Joseph F.
Kim, Su Young
Shipp, Margaret A.
TI Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma -
Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Armand, Philippe; Chapuy, Bjoern; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ansell, Stephen M.] Mayo Clin, Rochester, MN USA.
[Lesokhin, Alexander M.; Cattry, Deepika] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Halwani, Ahmad] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Millenson, Michael M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Schuster, Stephen J.] Perelman Ctr Adv Med, Philadelphia, PA USA.
[Timmerman, John] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Borrello, Ivan] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Borrello, Ivan] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Gutierrez, Martin] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[Scott, Emma C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Ligon, Azra H.; Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Zhu, Lili; Grosso, Joseph F.; Kim, Su Young] Bristol Myers Squibb Co, Princeton, NJ USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805057
ER
PT J
AU Asano, T
Kim, HT
Koreth, J
Soiffer, RJ
Meguri, Y
Yoshioka, T
Yagita, H
Tanimoto, M
Ritz, J
Matsuoka, K
AF Asano, Takeru
Kim, Haesook T.
Koreth, John
Soiffer, Robert J.
Meguri, Yusuke
Yoshioka, Takanori
Yagita, Hideo
Tanimoto, Mitsune
Ritz, Jerome
Matsuoka, Ken-ichi
TI Enhanced Expression of PD-1 Modulates CD4+Foxp3+Regulatory T Cell
Homeostasis during Low-Dose IL-2 Therapy in Patients with Chronic
Graft-Versus-Host Disease
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Asano, Takeru; Meguri, Yusuke; Yoshioka, Takanori; Tanimoto, Mitsune; Matsuoka, Ken-ichi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008530, Japan.
[Kim, Haesook T.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Koreth, John; Soiffer, Robert J.; Ritz, Jerome; Matsuoka, Ken-ichi] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yagita, Hideo] Juntendo Univ, Grad Sch Med, Tokyo, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502068
ER
PT J
AU Avet-Loiseau, H
Corre, J
Maheo, S
Zheng, JB
Faham, M
Richardson, PG
Anderson, KC
Attal, M
Munshi, N
AF Avet-Loiseau, Herve
Corre, Jill
Maheo, Sabrina
Zheng, Jianbiao
Faham, Malek
Richardson, Paul G.
Anderson, Kenneth C.
Attal, Michel
Munshi, Nikhil
TI Identification Rate of Myeloma-Specific Clonotypes in Multiple
Diagnostic Sample Types from Patients with Multiple Myeloma Using
Next-Generation Sequencing Method
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Avet-Loiseau, Herve; Corre, Jill; Maheo, Sabrina; Attal, Michel] Univ Hosp Toulouse, Toulouse, France.
[Zheng, Jianbiao; Faham, Malek] Sequenta Inc, San Francisco, CA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Anderson, Kenneth C.; Munshi, Nikhil] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI corre, jill/Q-2460-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504210
ER
PT J
AU Bagby, GC
AF Bagby, Grover C.
TI The Role of Innate Immune Dysfunction in Inherited Bone Marrow Failure
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA.
NR 1
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233802005
ER
PT J
AU Baljevic, M
Dumitriu, B
Lee, JW
Paietta, E
Racevskis, J
Chen, C
Stein, EM
Gallagher, RE
Rowe, JM
Appelbaum, FR
Powell, BL
Larson, RA
Young, NS
Tallman, MS
AF Baljevic, Muhamed
Dumitriu, Bogdan
Lee, Ju-Whei
Paietta, Elisabeth
Racevskis, Janis
Chen, Christina
Stein, Eytan M.
Gallagher, Robert E.
Rowe, Jacob M.
Appelbaum, Frederick R.
Powell, Bayard L.
Larson, Richard A.
Young, Neal S.
Tallman, Martin S.
TI Telomere Length Recovery Strongly Predicts Overall Survival in Acute
Promyelocytic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Baljevic, Muhamed] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Dumitriu, Bogdan; Chen, Christina; Young, Neal S.] NIH, Bethesda, MD 20892 USA.
[Lee, Ju-Whei] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Paietta, Elisabeth] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA.
[Racevskis, Janis] 4Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA.
[Stein, Eytan M.; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Gallagher, Robert E.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Rowe, Jacob M.] Shaare Zedek Med Ctr, Jerusalem, Israel.
[Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA.
[Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804117
ER
PT J
AU Ballen, KK
Li, SL
Cutler, CS
Chen, YB
McAfee, SL
Dey, BR
Le, MT
Winkfield, KM
Avigan, D
Rosenblatt, J
Joyce, R
Boussiotis, VA
Ho, VT
Armand, P
Alyea, EP
Koreth, J
Soiffer, RJ
Spitzer, TR
Antin, JH
Makar, R
Kuter, DJ
AF Ballen, Karen K.
Li, Shuli
Cutler, Corey S.
Chen, Yi-Bin
McAfee, Steven L.
Dey, Bimalangshu R.
Le, Maria Theresa
Winkfield, Karen M.
Avigan, David
Rosenblatt, Jacalyn
Joyce, Robin
Boussiotis, Vassiliki A.
Ho, Vincent T.
Armand, Philippe
Alyea, Edwin P.
Koreth, John
Soiffer, Robert J.
Spitzer, Thomas R.
Antin, Joseph H.
Makar, Robert
Kuter, David J.
TI Delayed Platelet Engraftment after Umbilical Cord Blood Transplant:
Relationship to Circulating Levels of Thrombopoietin
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ballen, Karen K.; Chen, Yi-Bin; McAfee, Steven L.; Dey, Bimalangshu R.; Winkfield, Karen M.; Spitzer, Thomas R.; Makar, Robert; Kuter, David J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Li, Shuli; Cutler, Corey S.; Ho, Vincent T.; Armand, Philippe; Alyea, Edwin P.; Soiffer, Robert J.; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Le, Maria Theresa] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Rosenblatt, Jacalyn; Joyce, Robin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Boussiotis, Vassiliki A.] Beth Israel Deaconess Med Ctr, Harvard Inst Med, Boston, MA 02215 USA.
[Koreth, John] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501126
ER
PT J
AU Bar-Natan, M
Luptakova, K
Douglas, M
Stroopinsky, D
Rajabi, H
Pyzer, AR
Palmer, KA
Reagan, MR
Somaiya, P
Jain, S
Arnason, J
Ghobrial, IM
Rosenblatt, J
Anderson, KC
Kufe, D
Avigan, D
AF Bar-Natan, Michal
Luptakova, Katarina
Douglas, Maxwell
Stroopinsky, Dina
Rajabi, Hasan
Pyzer, Athalia Rachel
Palmer, Kristen A.
Reagan, Michaela R.
Somaiya, Poorvi
Jain, Salvia
Arnason, Jon
Ghobrial, Irene M.
Rosenblatt, Jacalyn
Anderson, Kenneth C.
Kufe, Donald
Avigan, David
TI Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via
Induction of the Oncoprotein MUC1
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Bar-Natan, Michal; Luptakova, Katarina; Douglas, Maxwell; Stroopinsky, Dina; Pyzer, Athalia Rachel; Palmer, Kristen A.; Somaiya, Poorvi; Jain, Salvia; Arnason, Jon; Rosenblatt, Jacalyn; Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Rajabi, Hasan; Reagan, Michaela R.; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ghobrial, Irene M.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
RI Reagan, Michaela/E-3549-2017
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808067
ER
PT J
AU Bararia, D
Heide, M
Romashova, T
Alessandro, P
Wilson, BG
Roberts, CWM
Hiddemann, W
Weinstock, DM
Weigert, O
AF Bararia, Deepak
Heide, Michael
Romashova, Tatiana
Alessandro, Pastore
Wilson, Boris G.
Roberts, Charles W. M.
Hiddemann, Wolfgang
Weinstock, David M.
Weigert, Oliver
TI ARID1A Is Recurrently and Significantly Mutated in Follicular Lymphoma
(FL) and Impairs DNA Repair Efficiency
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Bararia, Deepak; Heide, Michael; Romashova, Tatiana; Alessandro, Pastore; Hiddemann, Wolfgang; Weigert, Oliver] Univ Hosp Munich, LMU, Munich, Germany.
[Wilson, Boris G.] GlaxoSmithKline, Collegeville, PA USA.
[Roberts, Charles W. M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500070
ER
PT J
AU Barrientos, JC
O'Brien, S
Brown, JR
Kay, NE
Reddy, NM
Coutre, S
Tam, C
Mulligan, S
Jaeger, U
Devereux, S
Pocock, C
Robak, T
Schuster, SJ
Schuh, A
Gill, D
Bloor, A
Dearden, C
Moreno, C
Cull, G
Hamblin, M
Jones, JA
Kierschniak, T
Eckert, K
Suzuki, S
Hsu, E
James, DF
Byrd, JC
Hillmen, P
AF Barrientos, Jacqueline C.
O'Brien, Susan
Brown, Jennifer R.
Kay, Neil E.
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine
Mulligan, Stephen
Jaeger, Ulrich
Devereux, Steve
Pocock, Christopher
Robak, Tadeusz
Schuster, Stephen J.
Schuh, Anna
Gill, Devinder
Bloor, Adrian
Dearden, Claire
Moreno, Carol
Cull, Gavin
Hamblin, Michael
Jones, Jeffrey A.
Kierschniak, Tanja
Eckert, Karl
Suzuki, Samuel
Hsu, Emily
James, Danelle F.
Byrd, John C.
Hillmen, Peter
TI Hematologic and Immunologic Function and Patient Well-Being for the
Phase III RESONATE (TM) Study of Ibrutinib Vs Ofatumumab in
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Barrientos, Jacqueline C.] North Shore LIJ Canc Inst, Lake Success, NY USA.
[O'Brien, Susan] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kay, Neil E.] Mayo Clin, Rochester, MN USA.
[Reddy, Nishitha M.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Coutre, Steven] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Tam, Constantine] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Tam, Constantine] St Vincents Hosp, Melbourne, Vic, Australia.
[Mulligan, Stephen] Royal N Shore Hosp, Sydney, NSW, Australia.
[Jaeger, Ulrich] Med Univ Vienna, Vienna, Austria.
[Devereux, Steve] Kings Coll Hosp London, NHS Fdn Trust, London, England.
[Pocock, Christopher] East Kent Hosp, Canterbury, Kent, England.
[Robak, Tadeusz] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland.
[Schuster, Stephen J.] Perelman Ctr Adv Med, Philadelphia, PA USA.
[Schuh, Anna] Univ Oxford, Oxford Natl Inst Hlth Res Biomed Res Ctr, Oxford, England.
[Gill, Devinder] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
[Bloor, Adrian] Christie Clin, Manchester, Lancs, England.
[Dearden, Claire] Royal Marsden Hosp, London SW3 6JJ, England.
[Moreno, Carol] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
[Cull, Gavin] Sir Charles Gairdner Hosp, Perth, WA, Australia.
[Hamblin, Michael] Colchester Gen Hosp, Colchester, Essex, England.
[Jones, Jeffrey A.; Byrd, John C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Kierschniak, Tanja; Eckert, Karl; Suzuki, Samuel; Hsu, Emily; James, Danelle F.] Pharmacyclics Inc, Sunnyvale, CA USA.
[Hillmen, Peter] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
NR 0
TC 2
Z9 2
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505160
ER
PT J
AU Bejar, R
Papaemmanuil, E
Haferlach, T
Garcia-Manero, G
Maciejewski, JP
Sekeres, MA
Walter, MJ
Graubert, TA
Cazzola, M
Malcovati, L
Campbell, PJ
Ogawa, S
Boultwood, J
Bowen, D
Tauro, S
Groves, MJ
Fontenay, M
Shih, LY
Tuchler, H
Stevenson, KE
Neuberg, D
Greenberg, PL
Ebert, BL
AF Bejar, Rafael
Papaemmanuil, Elli
Haferlach, Torsten
Garcia-Manero, Guillermo
Maciejewski, Jaroslaw P.
Sekeres, Mikkael A.
Walter, Matthew J.
Graubert, Timothy A.
Cazzola, Mario
Malcovati, Luca
Campbell, Peter J.
Ogawa, Seishi
Boultwood, Jacqueline
Bowen, David
Tauro, Sudhir
Groves, Michael J.
Fontenay, Michaela
Shih, Lee-Yung
Tuechler, Heinz
Stevenson, Kristen E.
Neuberg, Donna
Greenberg, Peter L.
Ebert, Benjamin L.
TI TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into
Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the
International Working Group for MDS-Molecular Prognosis Committee
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Bejar, Rafael] UCSD Moores Canc Ctr, La Jolla, CA USA.
[Papaemmanuil, Elli; Campbell, Peter J.] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
[Haferlach, Torsten] MLL Munich Leukemia Lab, Munich, Germany.
[Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Maciejewski, Jaroslaw P.; Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Walter, Matthew J.] Washington Univ, Sch Med, St Louis, MO USA.
[Graubert, Timothy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Cazzola, Mario; Malcovati, Luca] Fdn IRCCS Policlin San Matteo, Pavia, Italy.
[Cazzola, Mario; Malcovati, Luca] Univ Pavia, I-27100 Pavia, Italy.
[Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Kyoto, Japan.
[Boultwood, Jacqueline] John Radcliffe Hosp, NDCLS, LRF Mol Haematol Unit, Oxford OX3 9DU, England.
[Bowen, David] Leeds Teaching Hosp, Leeds, W Yorkshire, England.
[Tauro, Sudhir; Groves, Michael J.] Ninewells Hosp, Dundee DD1 9SY, Scotland.
[Fontenay, Michaela] AP HP, Paris, France.
[Shih, Lee-Yung] Chang Gung Mem Hosp, Taipei 10591, Taiwan.
[Tuechler, Heinz] Ludwig Boltzmann Inst Leukemia Res, Vienna, Austria.
[Stevenson, Kristen E.; Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Greenberg, Peter L.] Stanford Univ, Stanford, CA 94305 USA.
[Ebert, Benjamin L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803090
ER
PT J
AU Beltran, BE
Chavez, JC
Sotomayor, EM
Castillo, JJ
AF Beltran, Brady E.
Chavez, Julio C.
Sotomayor, Eduardo M.
Castillo, Jorge J.
TI Lymphopenia Is an Adverse Prognostic Factor in EBV-Positive Diffuse
Large B-Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Beltran, Brady E.] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru.
[Chavez, Julio C.; Sotomayor, Eduardo M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Castillo, Jorge J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233802016
ER
PT J
AU Bendapudi, PK
Li, A
Hamdan, A
Fry, AM
Uhl, L
Marques, M
Kaufman, R
Stowell, CP
Sunny, W
Makar, RS
AF Bendapudi, Pavan K.
Li, Ang
Hamdan, Ayad
Fry, Ashley Michelle
Uhl, Lynne
Marques, Marisa
Kaufman, Richard
Stowell, Christopher P.
Sunny, Walter
Makar, Robert S.
TI Derivation and Prospective Validation of a Predictive Score for the
Rapid Diagnosis of Thrombotic Thrombocytopenic Purpura: The Plasmic
Score
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Bendapudi, Pavan K.; Li, Ang; Stowell, Christopher P.; Sunny, Walter; Makar, Robert S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hamdan, Ayad] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Fry, Ashley Michelle] Univ Alabama Hosp & Clin, Birmingham, AL USA.
[Uhl, Lynne] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Marques, Marisa] Univ Alabama Birmingham, Birmingham, AL USA.
[Kaufman, Richard] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502064
ER
PT J
AU Blaser, BW
Li, B
Tamplin, OJ
Binder, V
Prober, D
Schier, A
Vidal, M
Zon, LI
AF Blaser, Bradley Wayne
Li, Brian
Tamplin, Owen J.
Binder, Vera
Prober, David
Schier, Alexander
Vidal, Marc
Zon, Leonard I.
TI Identification of Secreted Factors with a Role in Hematopoietic Stem and
Progenitor Cell Engraftment in the Developing Zebrafish
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Blaser, Bradley Wayne; Vidal, Marc] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Li, Brian; Binder, Vera] Boston Childrens Hosp, Boston, MA USA.
[Tamplin, Owen J.] Childrens Hosp Boston, Howard Hughes Med Inst, Boston, MA USA.
[Prober, David] CALTECH, Pasadena, CA 91125 USA.
[Schier, Alexander] Harvard Univ, Cambridge, MA 02138 USA.
[Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
RI Binder, Vera/N-2078-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806009
ER
PT J
AU Bolli, N
Bignell, GR
Ganly, P
Papaemmanuil, E
Avet-Loiseau, H
Sperling, A
Minvielle, S
Campbell, PJ
Munshi, NC
AF Bolli, Niccolo
Bignell, Graham R.
Ganly, Peter
Papaemmanuil, Elli
Avet-Loiseau, Herve
Sperling, Adam
Minvielle, Stephane
Campbell, Peter J.
Munshi, Nikhil C.
TI A Next Generation Sequencing-Based Approach to Detect Gene Mutations,
Copy Number Changes and IGH Translocations in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Bolli, Niccolo] Univ Cambridge, Cambridge, England.
[Bignell, Graham R.; Papaemmanuil, Elli; Campbell, Peter J.] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
[Ganly, Peter] Christchurch Hosp, Christchurch, New Zealand.
[Avet-Loiseau, Herve] Univ Hosp, Unit Genom Myeloma, Toulouse, France.
[Avet-Loiseau, Herve] Univ Hosp Toulouse, Toulouse, France.
[Sperling, Adam] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Minvielle, Stephane] Ctr Rech Cancerol Nantes Angers UMR Inserm 892 CN, Nantes, France.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
RI Minvielle, Stephane/K-8251-2015
NR 0
TC 0
Z9 0
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804201
ER
PT J
AU Brendel, C
Guda, S
Renella, R
Du, P
Bauer, DE
Canver, MC
Kamran, SC
Thornton, J
de Boer, H
Milsom, MD
Orkin, SH
Gregory, R
Williams, DA
AF Brendel, Christian
Guda, Swaroopa
Renella, Raffaele
Du, Peng
Bauer, Daniel E.
Canver, Matthew C.
Kamran, Sophia C.
Thornton, James
de Boer, Helen
Milsom, Michael D.
Orkin, Stuart H.
Gregory, Richard
Williams, David A.
TI Optimization of Bcl11a Knockdown By miRNA Scaffold Embedded Shrnas
Leading to Enhanced Induction of Fetal Hemoglobin in Erythroid Cells for
the Treatment of Beta-Hemoglobinopathies
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Brendel, Christian; Guda, Swaroopa; Renella, Raffaele; Bauer, Daniel E.; Canver, Matthew C.; Gregory, Richard] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA.
[Du, Peng; Thornton, James; de Boer, Helen; Williams, David A.] Boston Childrens Hosp, Boston, MA USA.
[Kamran, Sophia C.] Harvard Univ, Sch Med, Boston, MA USA.
[Milsom, Michael D.] German Canc Res Ctr, Heidelberg, Germany.
[Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502179
ER
PT J
AU Brissot, E
Ito, S
Lu, K
Cantilena, C
Smith, BD
Prince, G
Sadrzadeh, H
Fathi, AT
Strickland, SA
Hensel, NF
Chinian, F
Keyvanfar, K
Battiwalla, M
Muranski, P
Hourigan, CS
Barrett, J
AF Brissot, Eolia
Ito, Sawa
Lu, Kit
Cantilena, Carly
Smith, B. Douglas
Prince, Gabrielle
Sadrzadeh, Hossein
Fathi, Amir T.
Strickland, Stephen A.
Hensel, Nancy F.
Chinian, Fariba
Keyvanfar, Keyvan
Battiwalla, Minoo
Muranski, Pawel
Hourigan, Christopher S.
Barrett, John
TI T Cell Exhaustion and Downregulation of Cytotoxic NK Cells - an Immune
Escape Mechanism in Adult Acute Lymphoblastic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Brissot, Eolia] NHLBI, NIH, Bethesda, MD 20892 USA.
[Ito, Sawa; Lu, Kit; Keyvanfar, Keyvan; Battiwalla, Minoo; Muranski, Pawel; Hourigan, Christopher S.; Barrett, John] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
[Cantilena, Carly] NHLBI, Hematol Branch, Bethesda, MD 20892 USA.
[Smith, B. Douglas; Prince, Gabrielle] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Sadrzadeh, Hossein; Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
[Strickland, Stephen A.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Hensel, Nancy F.; Chinian, Fariba] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243507203
ER
PT J
AU Brown, JR
Fernandes, SM
Kasar, S
Hoang, K
Moorhead, M
Carlton, V
Faham, M
Miklos, DB
Logan, AC
AF Brown, Jennifer R.
Fernandes, Stacey M.
Kasar, Siddha
Hoang, Kevin
Moorhead, Martin
Carlton, Victoria
Faham, Malek
Miklos, David B.
Logan, Aaron C.
TI Next-Generation Sequencing Reveals Clonal Evolution at the
Immunoglobulin Loci in Chronic Lymphocytic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Brown, Jennifer R.; Fernandes, Stacey M.; Kasar, Siddha; Hoang, Kevin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Moorhead, Martin; Carlton, Victoria; Faham, Malek] Sequenta Inc, San Francisco, CA USA.
[Miklos, David B.] Stanford Univ, Stanford, CA 94305 USA.
[Logan, Aaron C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501218
ER
PT J
AU Brown, JR
Hillmen, P
O'Brien, S
Barrientos, JC
Reddy, N
Coutre, S
Tam, C
Mulligan, S
Jaeger, U
Barr, PM
Furman, RR
Kipps, TJ
Cymbalista, F
Thornton, P
Caligaris-Cappio, F
Delgado, J
Montillo, M
Devos, S
Moreno, C
Pagel, J
Burger, JA
Chung, D
Lin, J
Gau, L
Chang, B
McGreivy, J
James, DF
Byrd, JC
AF Brown, Jennifer R.
Hillmen, Peter
O'Brien, Susan
Barrientos, Jaqueline C.
Reddy, Nishitha
Coutre, Steven
Tam, Constantine
Mulligan, Stephen
Jaeger, Ulrich
Barr, Paul M.
Furman, Richard R.
Kipps, Thomas J.
Cymbalista, Florence
Thornton, Patrick
Caligaris-Cappio, Federico
Delgado, Julio
Montillo, Marco
Devos, Sven
Moreno, Carol
Pagel, John
Burger, Jan A.
Chung, Devon
Lin, Jennifer
Gau, Linda
Chang, Betty
McGreivy, Jesse
James, Danelle F.
Byrd, John C.
TI Updated Efficacy Including Genetic and Clinical Subgroup Analysis and
Overall Safety in the Phase 3 RESONATE (TM) Trial of Ibrutinib Versus
Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hillmen, Peter] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
[O'Brien, Susan; Burger, Jan A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Barrientos, Jaqueline C.] North Shore LIJ Sch Med, New Hyde Pk, NY USA.
[Reddy, Nishitha] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Coutre, Steven] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Tam, Constantine] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Tam, Constantine] St Vincents Hosp, Melbourne, Vic, Australia.
[Mulligan, Stephen] Royal N Shore Hosp, Sydney, NSW, Australia.
[Jaeger, Ulrich] Med Univ Vienna, Vienna, Austria.
[Barr, Paul M.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Furman, Richard R.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Kipps, Thomas J.] UCSD Moores Canc Ctr, San Diego, CA USA.
[Cymbalista, Florence] Hop Avicenne, Paris, France.
[Thornton, Patrick] Beaumont Hosp, Dublin 9, Ireland.
[Caligaris-Cappio, Federico] Univ Vita Salute San Raffaele, Milan, Italy.
[Delgado, Julio] Hosp Clin Barcelona, Barcelona, Spain.
[Montillo, Marco] Osped Niguarda Ca Granda, Milan, Italy.
[Devos, Sven] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Moreno, Carol] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
[Pagel, John] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Chung, Devon; Lin, Jennifer; Gau, Linda; Chang, Betty; McGreivy, Jesse; James, Danelle F.] Pharmacyclics Inc, Sunnyvale, CA USA.
[Byrd, John C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
RI Delgado, Julio/D-4891-2013
OI Delgado, Julio/0000-0002-5157-4376
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806080
ER
PT J
AU Brown, JR
Klinger, M
Hervold, K
Fernandes, SM
Hoang, K
Faham, M
Oki, Y
Wolf, JL
Martinez-Lopez, J
AF Brown, Jennifer R.
Klinger, Mark
Hervold, Kieran
Fernandes, Stacey M.
Hoang, Kevin
Faham, Malek
Oki, Yasuhiro
Wolf, Jeffrey L.
Martinez-Lopez, Joaquin
TI Chronic Lymphocytic Leukemia Patients Harbor Very Low Frequency
Stereotypic Immunoglobulin CDR3 Sequences
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Brown, Jennifer R.; Fernandes, Stacey M.; Hoang, Kevin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Klinger, Mark; Hervold, Kieran; Faham, Malek] Sequenta Inc, San Francisco, CA USA.
[Oki, Yasuhiro] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Wolf, Jeffrey L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Martinez-Lopez, Joaquin] Hosp 12 Octubre, E-28041 Madrid, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806012
ER
PT J
AU Brunner, AM
Wander, SA
Neuberg, D
Sadrzadeh, H
Ballen, KK
Amrein, PC
Attar, EC
Chen, YB
Perry, AM
Burke, M
Silver, R
Adamia, S
Yen, K
Yang, H
Straley, K
Agresta, S
Borger, DR
Iafrate, AJ
Stone, RM
Fathi, AT
AF Brunner, Andrew M.
Wander, Seth A.
Neuberg, Donna
Sadrzadeh, Hossein
Ballen, Karen K.
Amrein, Philip C.
Attar, Eyal C.
Chen, Yi-Bin
Perry, Ashley M.
Burke, Meghan
Silver, Regina
Adamia, Sophia
Yen, Katharine
Yang, Hua
Straley, Kimberly
Agresta, Sam
Borger, Darrell R.
Iafrate, Anthony J.
Stone, Richard M.
Fathi, Amir T.
TI Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute
Myeloid Leukemia (AML) Patients with and without Isocitrate
Dehydrogenase (IDH) Mutations
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Brunner, Andrew M.; Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA USA.
[Wander, Seth A.; Ballen, Karen K.; Amrein, Philip C.; Attar, Eyal C.; Chen, Yi-Bin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Neuberg, Donna; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sadrzadeh, Hossein] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
[Perry, Ashley M.; Burke, Meghan; Silver, Regina; Borger, Darrell R.; Iafrate, Anthony J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Adamia, Sophia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yen, Katharine; Yang, Hua; Straley, Kimberly; Agresta, Sam] Agios Pharmaceut, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803155
ER
PT J
AU Buonamici, S
Perino, S
Lim, KH
Feala, J
Obeng, EA
Aicher, M
Aird, D
Bailey, S
Berkenblit, A
Chan, B
Erik, C
Corson, L
Darman, R
Fekkes, P
Furman, RR
Keaney, GF
Kumar, P
Kunii, K
Lee, L
Mackenzie, C
Park, E
Puyang, XL
Selvaraj, A
Thomas, M
Wang, J
Warmuth, M
Yu, LH
Zhu, P
Mizui, Y
Ebert, BL
Smith, PG
AF Buonamici, Silvia
Perino, Samantha
Lim, Kian Huat
Feala, Jacob
Obeng, Esther A.
Aicher, Michelle
Aird, Daniel
Bailey, Suzanna
Berkenblit, Anna
Chan, Betty
Erik, Corcoran
Corson, Laura
Darman, Rachel
Fekkes, Peter
Furman, Richard R.
Keaney, Gregg F.
Kumar, Pavan
Kunii, Kaiko
Lee, Linda
Mackenzie, Crystal
Park, Eunice
Puyang, Xiaoling
Selvaraj, Anand
Thomas, Michael
Wang, John
Warmuth, Markus
Yu, Lihua
Zhu, Ping
Mizui, Yoshiharu
Ebert, Benjamin L.
Smith, Peter G.
TI Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing
Activity and Block Erythroid Differentiation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Buonamici, Silvia; Perino, Samantha; Lim, Kian Huat; Feala, Jacob; Aicher, Michelle; Aird, Daniel; Bailey, Suzanna; Berkenblit, Anna; Chan, Betty; Erik, Corcoran; Corson, Laura; Darman, Rachel; Fekkes, Peter; Keaney, Gregg F.; Kunii, Kaiko; Lee, Linda; Park, Eunice; Puyang, Xiaoling; Selvaraj, Anand; Thomas, Michael; Wang, John; Warmuth, Markus; Yu, Lihua; Zhu, Ping; Mizui, Yoshiharu; Smith, Peter G.] H3 Biomed, Cambridge, MA USA.
[Obeng, Esther A.] Boston Childrens Hosp, Boston, MA USA.
[Obeng, Esther A.; Ebert, Benjamin L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Obeng, Esther A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Furman, Richard R.] Weill Cornell Med Coll, New York, NY USA.
[Kumar, Pavan; Mackenzie, Crystal] Eisai, Andover, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804015
ER
PT J
AU Burgess, MR
Hwang, E
Firestone, AJ
Huang, TN
Xu, J
Zuber, J
Bohin, N
Wen, T
Kogan, SC
Haigis, KM
Lowe, SW
Shannon, K
Li, Q
AF Burgess, Michael R.
Hwang, Eugene
Firestone, Ari J.
Huang, Tannie
Xu, Jin
Zuber, Johannes
Bohin, Natacha
Wen, Tiffany
Kogan, Scott C.
Haigis, Kevin M.
Lowe, Scott W.
Shannon, Kevin
Li, Qing
TI Preclinical Efficacy of MEK Inhibition in Nras Mutant Acute Myeloid
Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Burgess, Michael R.; Hwang, Eugene; Huang, Tannie; Xu, Jin; Kogan, Scott C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Firestone, Ari J.; Shannon, Kevin] UCSF, San Francisco, CA USA.
[Zuber, Johannes] Res Inst Mol Pathol IMP, Vienna, Austria.
[Bohin, Natacha; Wen, Tiffany; Li, Qing] Univ Michigan, Ann Arbor, MI 48109 USA.
[Haigis, Kevin M.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502046
ER
PT J
AU Calimeri, T
Caracciolo, D
Amodio, N
Samur, MK
Leotta, M
Fulciniti, M
Rossi, M
Minvielle, S
Avet-Loiseau, H
Tagliaferri, P
Shammas, M
Anderson, KC
Tassone, P
Munshi, NC
AF Calimeri, Teresa
Caracciolo, Daniele
Amodio, Nicola
Samur, Mehmet Kemal
Leotta, Marzia
Fulciniti, Mariateresa
Rossi, Marco
Minvielle, Stephane
Avet-Loiseau, Herve
Tagliaferri, Pierosandro
Shammas, Masood
Anderson, Kenneth C.
Tassone, Pierfrancesco
Munshi, Nikhil C.
TI Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role
of the Classical and Alternative Pathways in Genomic Instability
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Calimeri, Teresa; Caracciolo, Daniele; Amodio, Nicola; Leotta, Marzia; Rossi, Marco; Tagliaferri, Pierosandro] Magna Graecia Univ Catanzaro, Catanzaro, Italy.
[Calimeri, Teresa] Tommaso Campanella Canc Ctr, Catanzaro, Italy.
[Calimeri, Teresa; Fulciniti, Mariateresa; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Calimeri, Teresa; Fulciniti, Mariateresa; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Samur, Mehmet Kemal] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Leotta, Marzia; Rossi, Marco; Tagliaferri, Pierosandro] T Campanella Canc Ctr, Catanzaro, Italy.
[Minvielle, Stephane] Ctr Rech Cancerol Nantes Angers UMR Inserm 892 CN, Nantes, France.
[Avet-Loiseau, Herve] Univ Hosp, Unit Genom Myeloma, Toulouse, France.
[Shammas, Masood; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Shammas, Masood] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Tassone, Pierfrancesco] Univ Catanzaro, Catanzaro, Italy.
[Tassone, Pierfrancesco] Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.
RI Minvielle, Stephane/K-8251-2015
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807115
ER
PT J
AU Cameron, DR
Lonial, S
Mazumder, A
Mortimer, J
Bowser, AD
Obholz, KL
Anderson, KC
AF Cameron, Davecia R.
Lonial, Sagar
Mazumder, Amitabha
Mortimer, Jim
Bowser, Andrew D.
Obholz, Kevin L.
Anderson, Kenneth C.
TI Clinical Impact of an Internet-Based Tool to Provide Expert Guidance for
Multiple Myeloma ( MM) from 2012 to 2014
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Cameron, Davecia R.] Clin Care Opt, Miami, FL USA.
[Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Mazumder, Amitabha] NYU, Ctr Canc, New York, NY USA.
[Mortimer, Jim; Bowser, Andrew D.; Obholz, Kevin L.] Clin Care Opt LLC, Reston, VA USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501027
ER
PT J
AU Carey, A
Edwards, D
Eide, CA
Traer, E
Tyner, JW
Bagby, GC
Druker, BJ
Agarwal, A
AF Carey, Alyssa
Edwards, David
Eide, Christopher A.
Traer, Elie
Tyner, Jeffrey W.
Bagby, Grover C.
Druker, Brian J.
Agarwal, Anupriya
TI Targeted Suppression of Interleukin-1 Signaling Attenuates Leukemic
Cellular Growth and Disease Progression in Primary Human Cells and
Murine Models of Acute Myeloid leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Carey, Alyssa; Edwards, David; Eide, Christopher A.; Traer, Elie; Tyner, Jeffrey W.; Bagby, Grover C.; Druker, Brian J.; Agarwal, Anupriya] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Eide, Christopher A.; Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA.
[Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503028
ER
PT J
AU Cassaday, RD
Stevenson, PA
Gooley, TA
Chauncey, T
Pagel, J
Till, BG
Philip, M
Orozco, JJ
Bensinger, WI
Holmberg, L
Shustov, AR
Green, DJ
Smith, SD
Libby, EN
Maloney, DG
Soma, LA
Press, OW
Gopal, AK
AF Cassaday, Ryan D.
Stevenson, Philip A.
Gooley, Theodore A.
Chauncey, Thomas
Pagel, John
Till, Brian G.
Philip, Mary
Orozco, Johnnie J.
Bensinger, William I.
Holmberg, Leona
Shustov, Andrei R.
Green, Damian J.
Smith, Stephen D.
Libby, Edward N.
Maloney, David G.
Soma, Lorinda A.
Press, Oliver W.
Gopal, Ajay K.
TI Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based
Autologous Transplantation for Patients with Mantle Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Cassaday, Ryan D.; Gooley, Theodore A.; Pagel, John; Till, Brian G.; Bensinger, William I.; Green, Damian J.; Smith, Stephen D.; Maloney, David G.; Press, Oliver W.; Gopal, Ajay K.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Cassaday, Ryan D.; Stevenson, Philip A.; Gooley, Theodore A.; Chauncey, Thomas; Pagel, John; Till, Brian G.; Philip, Mary; Orozco, Johnnie J.; Bensinger, William I.; Shustov, Andrei R.; Green, Damian J.; Smith, Stephen D.; Libby, Edward N.; Soma, Lorinda A.; Press, Oliver W.; Gopal, Ajay K.] Univ Washington, Seattle, WA 98195 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Holmberg, Leona] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Maloney, David G.] Univ Washington, Sch Med, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808151
ER
PT J
AU Chaudhury, S
HiJiya, N
Hu, ZH
Sparapani, R
Kalaycio, ME
Alyea, EP
Popat, UR
Saber, W
AF Chaudhury, Sonali
HiJiya, Nobuko
Hu, Zhenhuan
Sparapani, Rodney
Kalaycio, Matt E.
Alyea, Edwin P.
Popat, Uday R.
Saber, Wael
TI Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in
Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort
Analysis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Chaudhury, Sonali; HiJiya, Nobuko] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp, Chicago, IL 60611 USA.
[Hu, Zhenhuan; Sparapani, Rodney; Saber, Wael] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Kalaycio, Matt E.] Cleveland Clin, Cleveland, OH 44106 USA.
[Alyea, Edwin P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Popat, Uday R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805104
ER
PT J
AU Chung, J
Bauer, DE
Ghamari, A
Nizzi, CP
Deck, KM
Kingsley, PD
Yien, YY
Huston, NC
Chen, CY
Wittig, JG
Palis, J
Orkin, SH
Lodish, HF
Eisenstein, RS
Cantor, AB
Paw, BH
AF Chung, Jacky
Bauer, Daniel E.
Ghamari, Alireza
Nizzi, Christopher P.
Deck, Kathryn M.
Kingsley, Paul D.
Yien, Yvette Y.
Huston, Nicholas C.
Chen, Caiyong
Wittig, Johannes G.
Palis, James
Orkin, Stuart H.
Lodish, Harvey F.
Eisenstein, Richard S.
Cantor, Alan B.
Paw, Barry H.
TI Erythroid Cells Adapt to L-Leucine Scarcity By Reducing Hemoglobin
Production Via the mTORC1/4E-BP Pathway
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Chung, Jacky; Yien, Yvette Y.; Huston, Nicholas C.; Chen, Caiyong; Wittig, Johannes G.; Paw, Barry H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA.
[Bauer, Daniel E.; Ghamari, Alireza; Orkin, Stuart H.; Cantor, Alan B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Nizzi, Christopher P.; Deck, Kathryn M.; Eisenstein, Richard S.] Univ Wisconsin, Madison, WI USA.
[Kingsley, Paul D.; Palis, James] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Lodish, Harvey F.] MIT, Whitehead Inst, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804102
ER
PT J
AU Cole, P
Neuberg, DS
Silverman, LB
Stevenson, KE
Vijayanathan, V
Finkelstein, Y
Sallan, SE
Waber, D
AF Cole, Peter
Neuberg, Donna S.
Silverman, Lewis B.
Stevenson, Kristen E.
Vijayanathan, Veena
Finkelstein, Yaron
Sallan, Stephen E.
Waber, Deborah
TI Polymorphisms in Genes Related to Oxidative Stress Are Associated with
Inferior Cognitive Function after Therapy for Childhood ALL
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Cole, Peter; Vijayanathan, Veena] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Neuberg, Donna S.; Silverman, Lewis B.; Stevenson, Kristen E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Finkelstein, Yaron] Dept Clin Pharmacol & Emergency Med, Toronto, ON, Canada.
[Sallan, Stephen E.] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Waber, Deborah] Boston Childrens Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233801192
ER
PT J
AU Cortes, JE
Kim, DW
Pinilla-Ibarz, J
Le Coutre, P
Paquette, R
Chuah, C
Nicolini, FE
Apperley, JF
Khoury, HJ
Talpaz, M
DiPersio, JF
DeAngelo, DJ
Abruzzese, E
Rea, D
Baccarani, M
Muller, MC
Gambacorti-Passerini, C
Lustgarten, S
Rivera, VM
Clackson, T
Turner, CD
Haluska, FG
Guilhot, F
Deininger, MW
Hochhaus, A
Hughes, TP
Shah, NP
Kantarjian, HM
AF Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Le Coutre, Philipp
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Kantarjian, Hagop M.
TI Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE
Trial
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Cortes, Jorge E.; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Kim, Dong-Wook] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea.
[Pinilla-Ibarz, Javier] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Le Coutre, Philipp] Charite, D-13353 Berlin, Germany.
[Paquette, Ronald] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Chuah, Charles] Singapore Gen Hosp, Singapore, Singapore.
[Chuah, Charles] Duke Natl Univ Singapore Grad Med Sch, Singapore, Singapore.
[Nicolini, Franck E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France.
[Apperley, Jane F.] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England.
[Khoury, H. Jean] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[DiPersio, John F.] Washington Univ Sch Med, Div Oncol, St Louis, MO USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Abruzzese, Elisabetta] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy.
[Rea, Delphine] Hop St Louis, Paris, France.
[Baccarani, Michele] S Orsola Malpighi Univ Hosp, Bologna, Italy.
[Mueller, Martin C.] Univ Med Mannheim, Mannheim, Germany.
[Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Azienda Osped San Gerardo, Monza, Italy.
[Lustgarten, Stephanie; Rivera, Victor M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA.
[Guilhot, Francois] Univ Hosp, Poitiers, France.
[Deininger, Michael W.] Univ Utah Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA.
[Hochhaus, Andreas] Jena Univ Hosp, Jena, Germany.
[Hughes, Timothy P.] Inst Med & Vet Sci, Adelaide, SA 5000, Australia.
[Shah, Neil P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 5
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804111
ER
PT J
AU Cottini, F
Hideshima, T
Buhrlage, S
Gray, NS
Richardson, PG
Tonon, G
Anderson, KC
AF Cottini, Francesca
Hideshima, Teru
Buhrlage, Sara
Gray, Nathanael S.
Richardson, Paul G.
Tonon, Giovanni
Anderson, Kenneth C.
TI Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Cottini, Francesca; Hideshima, Teru; Buhrlage, Sara; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gray, Nathanael S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Tonon, Giovanni] Ist Sci San Raffaele, I-20132 Milan, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803025
ER
PT J
AU Coutre, S
O'Brien, S
Byrd, JC
Hillmen, P
Brown, JR
Dyer, MJS
Mato, AR
Miklos, DB
Keating, M
Zhou, C
Fardis, M
Styles, L
Jaglowski, S
AF Coutre, Steven
O'Brien, Susan
Byrd, John C.
Hillmen, Peter
Brown, Jennifer R.
Dyer, Martin J. S.
Mato, Anthony R.
Miklos, David B.
Keating, Michael
Zhou, Cathy
Fardis, Maria
Styles, Lori
Jaglowski, Samantha
TI Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have
Undergone Prior Allogeneic Stem Cell Transplant
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Coutre, Steven; Miklos, David B.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[O'Brien, Susan; Keating, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Byrd, John C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Hillmen, Peter] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
[Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dyer, Martin J. S.] Univ Leicester, Leicester, Leics, England.
[Mato, Anthony R.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Zhou, Cathy; Fardis, Maria; Styles, Lori] Pharmacyclics Inc, Sunnyvale, CA USA.
[Jaglowski, Samantha] Ohio State Univ, Columbus, OH 43210 USA.
RI Jaglowski, Samantha/E-3304-2011
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504209
ER
PT J
AU Cutler, CS
Shoemaker, D
Westervelt, P
Couriel, DR
Vasu, S
Isola, LM
Karanes, C
Newell, L
Rezner, B
Guerrettaz, L
Robbins, D
Medcalf, A
Wolchko, S
Ferraro, J
Multani, PS
AF Cutler, Corey S.
Shoemaker, Daniel
Westervelt, Peter
Couriel, Daniel R.
Vasu, Sumithra
Isola, Luis M.
Karanes, Chatchada
Newell, Laura
Rezner, Betsy
Guerrettaz, Lisa
Robbins, David
Medcalf, Amanda
Wolchko, Scott
Ferraro, John
Multani, Pratik S.
TI Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate
Engraftment of Human Umbilical Cord Blood
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shoemaker, Daniel; Rezner, Betsy; Guerrettaz, Lisa; Robbins, David; Medcalf, Amanda; Wolchko, Scott; Ferraro, John; Multani, Pratik S.] Fate Therapeut Inc, San Diego, CA USA.
[Westervelt, Peter] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA.
[Couriel, Daniel R.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Vasu, Sumithra] Ohio State Univ, Columbus, OH 43210 USA.
[Isola, Luis M.] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Karanes, Chatchada] City Hope Natl Med Ctr, Duarte, CA USA.
[Newell, Laura] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500128
ER
PT J
AU Das, DS
Ravillah, D
Ray, A
Song, Y
Richardson, PG
Trikha, M
Chauhan, D
Anderson, KC
AF Das, Deepika Sharma
Ravillah, Durgadevi
Ray, Arghya
Song, Yan
Richardson, Paul G.
Trikha, Mohit
Chauhan, Dharminder
Anderson, Kenneth C.
TI Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib
and IMiD (R) Immunomodulatory Drug Pomalidomide
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Das, Deepika Sharma; Ravillah, Durgadevi; Ray, Arghya; Song, Yan; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Das, Deepika Sharma; Ravillah, Durgadevi; Ray, Arghya; Song, Yan; Richardson, Paul G.; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Trikha, Mohit] Triphase Accelerator, San Diego, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243507200
ER
PT J
AU Devaraj, SGT
Fiskus, W
Shah, B
Sharma, S
Qi, J
Sun, BH
Saha, S
Iyer, SP
Zu, YL
Bradner, J
Bhalla, KN
AF Devaraj, Santhana G. T.
Fiskus, Warren
Shah, Bhavin
Sharma, Sunil
Qi, Jun
Sun, Baohua
Saha, Saikat
Iyer, Swaminathan Padmanabhan
Zu, Youli
Bradner, James
Bhalla, Kapil N.
TI Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth
Inhibition, Differentiation and in Vivo Lethal Activity Against Human
AML Blast Progenitor Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Devaraj, Santhana G. T.; Fiskus, Warren; Shah, Bhavin; Sun, Baohua; Saha, Saikat; Bhalla, Kapil N.] Houston Methodist Res Inst, Houston, TX USA.
[Sharma, Sunil] Huntsman Canc Inst, Salt Lake City, UT USA.
[Qi, Jun; Bradner, James] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Iyer, Swaminathan Padmanabhan] Methodist Canc Ctr, Houston, TX USA.
[Zu, Youli] Methodist Hosp, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502114
ER
PT J
AU El-Jawahri, A
Traeger, L
Kuzmuk, K
Eusebio, J
Vandusen, H
Shin, J
Gallagher, E
Greer, J
Pirl, W
Jackson, V
Ballen, KK
Spitzer, TR
Graubert, TA
McAfee, SL
Dey, BR
Chen, YB
Temel, JS
AF El-Jawahri, Areej
Traeger, Lara
Kuzmuk, Kailyn
Eusebio, Justin
Vandusen, Harry
Shin, Jennifer
Gallagher, Emily
Greer, Joseph
Pirl, William
Jackson, Vicki
Ballen, Karen K.
Spitzer, Thomas R.
Graubert, Timothy A.
McAfee, Steven L.
Dey, Bimalangshu R.
Chen, Yi-Bin
Temel, Jennifer S.
TI Prognostic Understanding, Quality of Life, and Mood in Patients
Undergoing Hematopoietic Stem Cell Transplantation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [El-Jawahri, Areej] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Traeger, Lara; Kuzmuk, Kailyn; Eusebio, Justin; Vandusen, Harry; Shin, Jennifer; Gallagher, Emily; Greer, Joseph; Pirl, William; Jackson, Vicki; Spitzer, Thomas R.; Dey, Bimalangshu R.; Temel, Jennifer S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ballen, Karen K.; Graubert, Timothy A.; McAfee, Steven L.; Chen, Yi-Bin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500036
ER
PT J
AU Emerson, RO
Nikiforow, S
Milano, F
Sherwood, AM
Papermaster, A
Guthrie, KA
Carlson, CS
Warren, EH
Ritz, J
Robins, H
Cutler, CS
Delaney, C
AF Emerson, Ryan O.
Nikiforow, Sarah
Milano, Filippo
Sherwood, Anna M.
Papermaster, Adrienne
Guthrie, Katherine A.
Carlson, Christopher S.
Warren, Edus H.
Ritz, Jerome
Robins, Harlan
Cutler, Corey S.
Delaney, Colleen
TI TCR Repertoire Diversity Assessed with Immunosequencing Is Associated
with Patient Mortality Following Cord Blood Transplant
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Emerson, Ryan O.; Sherwood, Anna M.; Carlson, Christopher S.; Robins, Harlan] Adapt Biotechnol Corp, Seattle, WA USA.
[Nikiforow, Sarah] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Milano, Filippo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Papermaster, Adrienne; Guthrie, Katherine A.; Carlson, Christopher S.; Warren, Edus H.; Robins, Harlan; Delaney, Colleen] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Warren, Edus H.] Univ Washington, Seattle, WA 98195 USA.
[Ritz, Jerome; Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804036
ER
PT J
AU Etchin, J
Le, BT
Kentsis, A
Mansour, MR
Berezovskaya, A
Stone, RM
Galinsky, I
DeAngelo, DJ
McCauley, D
Kauffman, M
Shacham, S
Wang, JCY
Kung, AL
Look, AT
AF Etchin, Julia
Bonnie Thi Le
Kentsis, Alex
Mansour, Marc R.
Berezovskaya, Alla
Stone, Richard M.
Galinsky, Ilene
DeAngelo, Daniel J.
McCauley, Dilara
Kauffman, Michael
Shacham, Sharon
Wang, Jean C. Y.
Kung, Andrew L.
Look, A. Thomas
TI Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows
Remarkable Activity Against AML Leukemia-Initiating Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Etchin, Julia; Bonnie Thi Le; Mansour, Marc R.; Berezovskaya, Alla; Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Childrens Hosp Boston, Boston, MA 02115 USA.
[Kentsis, Alex] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Stone, Richard M.; Galinsky, Ilene] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McCauley, Dilara; Kauffman, Michael; Shacham, Sharon] Karyopharm Therapeut Inc, Newton, MA USA.
[Wang, Jean C. Y.] Univ Hlth Network, Toronto, ON, Canada.
[Kung, Andrew L.] Columbia Univ, Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807014
ER
PT J
AU Fan, FJ
Vallet, S
Sattler, M
Tonon, G
Bashari, MH
Bakiri, L
Goldschmidt, H
Wagner, EF
Jaeger, D
Podar, K
AF Fan, Fengjuan
Vallet, Sonia
Sattler, Martin
Tonon, Giovanni
Bashari, Muhammad Hasan
Bakiri, Latifa
Goldschmidt, Hartmut
Wagner, Erwin F.
Jaeger, Dirk
Podar, Klaus
TI The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell
Proliferation, Survival and Drug Resistance in the Bone Marrow
Microenvironment
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Fan, Fengjuan; Vallet, Sonia; Bashari, Muhammad Hasan; Goldschmidt, Hartmut; Jaeger, Dirk; Podar, Klaus] Heidelberg Univ, Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
[Sattler, Martin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tonon, Giovanni] Ist Sci San Raffaele, I-20132 Milan, Italy.
[Bakiri, Latifa; Wagner, Erwin F.] Spanish Natl Canc Res Ctr, Madrid, Spain.
RI Bashari, Muhammad Hasan/H-7079-2016
OI Bashari, Muhammad Hasan/0000-0001-7298-0317
NR 0
TC 0
Z9 0
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501133
ER
PT J
AU Fathi, AT
DeAngelo, DJ
Stevenson, KE
Kolitz, JE
Asch, JD
Amrein, PC
Attar, EC
Steensma, DP
Wadleigh, M
Connolly, C
Galinsky, I
Stone, RM
Neuberg, DS
Ballen, KK
AF Fathi, Amir T.
DeAngelo, Daniel J.
Stevenson, Kristen E.
Kolitz, Jonathan E.
Asch, Julie D.
Amrein, Philip C.
Attar, Eyal C.
Steensma, David P.
Wadleigh, Martha
Connolly, Christine
Galinsky, Ilene
Stone, Richard M.
Neuberg, Donna S.
Ballen, Karen K.
TI Intensified Chemotherapy for Older Patients with Acute Lymphoblastic
Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute
(DFCI) ALL Consortium
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Fathi, Amir T.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[DeAngelo, Daniel J.; Stevenson, Kristen E.; Steensma, David P.; Wadleigh, Martha; Galinsky, Ilene; Stone, Richard M.; Neuberg, Donna S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kolitz, Jonathan E.] North Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA.
[Asch, Julie D.] Intermt Blood & Marrow Transplant Acute Leukemia, Salt Lake City, UT USA.
[Amrein, Philip C.; Attar, Eyal C.; Ballen, Karen K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Connolly, Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505127
ER
PT J
AU Fathi, AT
Wander, SA
Blonquist, TM
Ballen, KK
Attar, EC
McAfee, SL
Chen, YB
Graubert, TA
Brunner, AM
Joseph, C
Perry, AM
Burke, M
Silver, R
Ramos, AY
Connolly, C
Neuberg, DS
Amrein, PC
AF Fathi, Amir T.
Wander, Seth A.
Blonquist, Traci M.
Ballen, Karen K.
Attar, Eyal C.
McAfee, Steven L.
Chen, Yi-Bin
Graubert, Timothy A.
Brunner, Andrew M.
Joseph, Christelle
Perry, Ashley M.
Burke, Meghan
Silver, Regina
Ramos, Aura Y.
Connolly, Christine
Neuberg, Donna S.
Amrein, Philip C.
TI A Phase I Study of the Aurora a Kinase Inhibitor Alisertib in
Combination with 7+3 Induction Chemotherapy in Patients with Acute
Myeloid Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Fathi, Amir T.; Brunner, Andrew M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Wander, Seth A.; Ballen, Karen K.; Attar, Eyal C.; McAfee, Steven L.; Chen, Yi-Bin; Graubert, Timothy A.; Amrein, Philip C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Blonquist, Traci M.; Neuberg, Donna S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Joseph, Christelle; Perry, Ashley M.; Burke, Meghan; Silver, Regina; Ramos, Aura Y.; Connolly, Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805016
ER
PT J
AU Flinn, I
Bartlett, NL
Blum, KA
Ardeshna, KM
LaCasce, A
Flowers, CR
Shustov, AR
Thress, K
Zheng, F
Skolnik, J
Friedberg, JW
AF Flinn, Ian
Bartlett, Nancy L.
Blum, Kristie A.
Ardeshna, Kirit M.
LaCasce, Ann
Flowers, Christopher R.
Shustov, Andrei R.
Thress, Kenneth
Zheng, Fred
Skolnik, Jeffery
Friedberg, Jonathan W.
TI A Phase ll Trial to Evaluate the Efficacy of Fostamatinib in Patients
with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Flinn, Ian] Sarah Cannon Res Inst, Nashville, TN USA.
[Flinn, Ian] Tennessee Oncol PLLC, Nashville, TN USA.
[Bartlett, Nancy L.] Washington Univ, St Louis, MO USA.
[Blum, Kristie A.] Ohio State Univ, Columbus, OH 43210 USA.
[Ardeshna, Kirit M.] Univ Coll London Hosp, London, England.
[Ardeshna, Kirit M.] Sarah Cannon Res Inst UK, London, England.
[LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Flowers, Christopher R.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Shustov, Andrei R.] Univ Washington, Med Ctr, Seattle, WA 98195 USA.
[Thress, Kenneth] Astra Zeneca, Waltham, MA USA.
[Zheng, Fred; Skolnik, Jeffery] GlaxoSmithKline, Philadelphia, PA USA.
[Friedberg, Jonathan W.] Univ Rochester, Rochester, NY USA.
RI Flowers, Christopher/F-1953-2010
OI Flowers, Christopher/0000-0002-9524-3990
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233800220
ER
PT J
AU Flynn, RP
Goodman, K
Qi, J
Jing, D
Panoskaltsis-Mortari, A
Yi, Z
Dong, C
Liu, XD
MacDonald, KPA
Hill, GR
Serody, JS
Murphy, WJ
Luznik, L
Maillard, I
Koreth, J
Cutler, CS
Soiffer, RJ
Antin, JH
Ritz, J
Melnick, AM
Bradner, JE
Blazar, BR
AF Flynn, Ryan P.
Goodman, Katelyn
Qi, Jun
Jing, Du
Panoskaltsis-Mortari, Angela
Yi, Zhang
Dong, Chen
Liu, Xindong
MacDonald, Kelli P. A.
Hill, Geoffrey R.
Serody, Jonathan S.
Murphy, William J.
Luznik, Leo
Maillard, Ivan
Koreth, John
Cutler, Corey S.
Soiffer, Robert J.
Antin, Joseph H.
Ritz, Jerome
Melnick, Ari M.
Bradner, James E.
Blazar, Bruce R.
TI Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host
Disease (cGVHD) Using Direct and Epigenomic Therapies
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Flynn, Ryan P.; Goodman, Katelyn; Jing, Du; Panoskaltsis-Mortari, Angela; Blazar, Bruce R.] Univ Minnesota, Minneapolis, MN USA.
[Qi, Jun] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yi, Zhang] Univ Michigan, Ann Arbor, MI 48109 USA.
[Dong, Chen; Liu, Xindong] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[MacDonald, Kelli P. A.; Hill, Geoffrey R.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Serody, Jonathan S.] Univ N Carolina, Chapel Hill, NC USA.
[Murphy, William J.] Univ Calif Davis, Sacramento, CA 95817 USA.
[Luznik, Leo] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Maillard, Ivan] Ctr Stem Cell Biol, Ann Arbor, MI USA.
[Koreth, John; Cutler, Corey S.; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome; Bradner, James E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Melnick, Ari M.] Weill Cornell Med Coll, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500221
ER
PT J
AU Friedrich, P
Guerra-Garcia, P
Stetson, AE
Duncan, C
Lehmann, LE
AF Friedrich, Paola
Guerra-Garcia, Pilar
Stetson, Alyssa E.
Duncan, Christine
Lehmann, Leslie E.
TI Young Female Donors Do Not Confer an Increased Risk of Graft-Versus-Host
Disease in Pediatric Hematopoietic Stem Cell Transplant
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Friedrich, Paola; Stetson, Alyssa E.; Duncan, Christine; Lehmann, Leslie E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Guerra-Garcia, Pilar] Univ Hosp 12 Octubre, Madrid, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808062
ER
PT J
AU Ganzel, C
Sun, ZX
Gonen, M
Patel, JP
Abdel-Wahab, O
Fernandez, HF
Rowe, JM
Tallman, MS
Levine, RL
Paietta, EM
AF Ganzel, Chezi
Sun, Zhuoxin
Gonen, Mithat
Patel, Jay P.
Abdel-Wahab, Omar
Fernandez, Hugo F.
Rowe, Jacob M.
Tallman, Martin S.
Levine, Ross L.
Paietta, Elisabeth M.
TI Minimal Residual Disease Assessment By Flow Cytometry in AML Is an
Independant Prognostic Factor Even after Adjusting for
Cytogenetic/Molecular Abnormalities
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ganzel, Chezi] Mem Sloan Kettering, New York, NY USA.
[Ganzel, Chezi; Rowe, Jacob M.] Shaare Zedek Med Ctr, Jerusalem, Israel.
[Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gonen, Mithat; Patel, Jay P.; Abdel-Wahab, Omar; Tallman, Martin S.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Fernandez, Hugo F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Rowe, Jacob M.] Rambam Hlth Care Campus, Haifa, Israel.
[Paietta, Elisabeth M.] Montefiore Med Ctr, Bronx, NY 10467 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807123
ER
PT J
AU Geiselhart, A
Walter, D
Lier, A
Thalheimer, FB
Huntscha, S
Brocks, D
Bayindir, I
Kaschutnig, P
Mudder, K
Sobotta, M
Dick, T
Holland-Letz, T
Schmezer, P
Schroder, T
Lane, SW
Essers, M
Rieger, MA
Williams, DA
Trumpp, A
Milsom, MD
AF Geiselhart, Anja
Walter, Dagmar
Lier, Amelie
Thalheimer, Frederic B.
Huntscha, Sina
Brocks, David
Bayindir, Irem
Kaschutnig, Paul
Muedder, Katja
Sobotta, Mirko
Dick, Tobias
Holland-Letz, Tim
Schmezer, Peter
Schroeder, Timm
Lane, Steven W.
Essers, Marieke
Rieger, Michael A.
Williams, David A.
Trumpp, Andreas
Milsom, Michael D.
TI Altered HSC Metabolism in Response to Stress Leads to De Novo dna Damage
and Cellular Attrition
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Geiselhart, Anja; Brocks, David; Bayindir, Irem; Kaschutnig, Paul; Muedder, Katja; Sobotta, Mirko; Dick, Tobias; Holland-Letz, Tim; Schmezer, Peter; Essers, Marieke; Trumpp, Andreas; Milsom, Michael D.] German Canc Res Ctr, Heidelberg, Germany.
[Walter, Dagmar; Lier, Amelie; Huntscha, Sina; Trumpp, Andreas; Milsom, Michael D.] Heidelberg Inst Stem Cell Technol & Expt Med HI S, Heidelberg, Germany.
[Thalheimer, Frederic B.; Rieger, Michael A.] Goethe Univ Hosp, Dept Hematol Oncol, Frankfurt, Germany.
[Schroeder, Timm] Swiss Fed Inst Technol, Basel, Switzerland.
[Lane, Steven W.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
[Williams, David A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233800190
ER
PT J
AU Gerds, AT
Dennison, B
Latsko, J
Houk, A
Chisolm, S
Huber, JM
Stone, RM
Maciejewski, JP
Komrokji, RS
Garcia-Manero, G
Steensma, DP
Sekeres, MA
AF Gerds, Aaron T.
Dennison, Betsy
Latsko, Joan
Houk, Alice
Chisolm, Stephanie
Huber, John M.
Stone, Richard M.
Maciejewski, Jaroslaw P.
Komrokji, Rami S.
Garcia-Manero, Guillermo
Steensma, David P.
Sekeres, Mikkael A.
TI Doctor-Patient Communication and Perception of Treatment Discontinuation
in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease
Progression
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Gerds, Aaron T.; Maciejewski, Jaroslaw P.; Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Dennison, Betsy] Clar Commun, Pompton Lakes, NJ USA.
[Latsko, Joan; Houk, Alice; Chisolm, Stephanie; Huber, John M.] Aplast Anemia & MDS Int Fdn, Rockville, MD USA.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Steensma, David P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500151
ER
PT J
AU Gerds, AT
Dennison, B
Latsko, J
Houk, A
Chisolm, S
Huber, JM
Stone, RM
Maciejewski, JP
Komrokji, RS
Garcia-Manero, G
Steensma, DP
Sekeres, MA
AF Gerds, Aaron T.
Dennison, Betsy
Latsko, Joan
Houk, Alice
Chisolm, Stephanie
Huber, John M.
Stone, Richard M.
Maciejewski, Jaroslaw P.
Komrokji, Rami S.
Garcia-Manero, Guillermo
Steensma, David P.
Sekeres, Mikkael A.
TI Knowledge That the Myelodysplastic Syndromes (MDS) Are a Type of Cancer
Does Not Influence Patient Perception of Treatment Discontinuation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Gerds, Aaron T.; Maciejewski, Jaroslaw P.; Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Dennison, Betsy] Clar Commun, Pompton Lakes, NJ USA.
[Latsko, Joan; Chisolm, Stephanie; Huber, John M.] Aplast Anemia & MDS Int Fdn, Rockville, MD USA.
[Houk, Alice] AA&MDSIF, Rockville, MD USA.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Steensma, David P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806096
ER
PT J
AU Ghamari, A
Jaensch, E
Giadone, R
Akie, TE
Xu, J
Bauer, D
Orkin, SH
Cantor, AB
AF Ghamari, Alireza
Jaensch, Elizabeth
Giadone, Richard
Akie, Thomas E.
Xu, Jian
Bauer, Daniel
Orkin, Stuart H.
Cantor, Alan B.
TI An SCF-FBXW7 Ubiquitin Ligase Mediated Feedback Loop Facilitates GATA
Factor Switching and Reinforces Commitment to Terminal Erythroid
Maturation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ghamari, Alireza; Jaensch, Elizabeth; Giadone, Richard; Akie, Thomas E.; Xu, Jian; Bauer, Daniel; Orkin, Stuart H.; Cantor, Alan B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805150
ER
PT J
AU Ghobrial, IM
Redd, RA
Matous, J
Armand, P
Boswell, EN
Chuma, S
Noonan, K
MacNabb, MH
Banwait, R
Hanlon, C
Leblebjian, H
Warren, D
Castillo, JJ
Laubach, JP
Paba-Prada, CE
Anderson, KC
Richardson, PG
Weller, EA
Treon, SP
AF Ghobrial, Irene M.
Redd, Robert Allyn
Matous, Jeffrey
Armand, Philippe
Boswell, Erica N.
Chuma, Stacey
Noonan, Kimberly
MacNabb, Megan H.
Banwait, Ranjit
Hanlon, Courtney
Leblebjian, Houry
Warren, Diane
Castillo, Jorge J.
Laubach, Jacob P.
Paba-Prada, Claudia E.
Anderson, Kenneth C.
Richardson, Paul G.
Weller, Edie A.
Treon, Steven P.
TI Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus
(RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed
or Refractory Waldenstrom Macroglobulinemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ghobrial, Irene M.; Chuma, Stacey; Noonan, Kimberly; MacNabb, Megan H.; Hanlon, Courtney; Warren, Diane; Laubach, Jacob P.; Paba-Prada, Claudia E.; Weller, Edie A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Redd, Robert Allyn; Armand, Philippe; Banwait, Ranjit; Leblebjian, Houry; Treon, Steven P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Matous, Jeffrey] Rocky Mt Canc Ctr, Denver, CO USA.
[Boswell, Erica N.; Anderson, Kenneth C.; Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Anderson, Kenneth C.; Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505151
ER
PT J
AU Ghobrial, IM
Perez, R
Baz, R
Richardson, PG
Anderson, KC
Sabbatini, P
Dilea, C
Cardarelli, PM
Wade, M
Xing, G
Gutierrez, A
Cohen, L
Becker, PS
AF Ghobrial, Irene M.
Perez, Raymond
Baz, Rachid
Richardson, Paul G.
Anderson, Kenneth C.
Sabbatini, Peter
Dilea, Clifford
Cardarelli, Pina M.
Wade, Mark
Xing, Guan
Gutierrez, Andres
Cohen, Lewis
Becker, Pamela S.
TI Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564)
in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with
Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory
Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Perez, Raymond] Univ Kansas, Fairway, KS USA.
[Baz, Rachid] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Richardson, Paul G.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
[Richardson, Paul G.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Sabbatini, Peter; Cardarelli, Pina M.] Bristol Myers Squibb Co, Sunnyvale, CA USA.
[Dilea, Clifford; Wade, Mark; Xing, Guan; Gutierrez, Andres] Bristol Myers Squibb Co, Princeton, NJ USA.
[Cohen, Lewis] Bristol Myers Squibb Co, Lawrenceville, NJ USA.
[Becker, Pamela S.] Univ Washington, Seattle, WA 98195 USA.
RI Perez, Raymond/R-6159-2016
OI Perez, Raymond/0000-0002-7432-2411
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233802095
ER
PT J
AU Gkotzamanidou, M
Fulciniti, M
Sanchez, JM
Samur, MK
Parmigiani, G
Anderson, KC
Munshi, NC
AF Gkotzamanidou, Maria
Fulciniti, Mariateresa
Martin Sanchez, Jesus
Samur, Mehmet Kemal
Parmigiani, Giovanni
Anderson, Kenneth C.
Munshi, Nikhil C.
TI LSD1 Impairs the Epithelial-Mesenchymal Transition (EMT) and
Osteoclastogenesis Potency in Multiple Myeloma and Synergistically
Induces Cytotoxicity with HDAC Inhibitors
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Gkotzamanidou, Maria; Fulciniti, Mariateresa; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Gkotzamanidou, Maria; Fulciniti, Mariateresa; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Martin Sanchez, Jesus] Univ Seville, CSIC, Inst Biomed Sevilla IBIS, Hosp Univ Virgen del Rocio, Seville, Spain.
[Samur, Mehmet Kemal] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Parmigiani, Giovanni] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503017
ER
PT J
AU Gkotzamanidou, M
Shammas, M
Souliotis, VL
Song, WH
Pal, J
Nanjappa, P
Rashid, N
Anderson, KC
Dimopoulos, MA
Bradner, J
Munshi, NC
AF Gkotzamanidou, Maria
Shammas, Masood
Souliotis, Vassilis L.
Song, Weihua
Pal, Jagannath
Nanjappa, Puru
Rashid, Naim
Anderson, Kenneth C.
Dimopoulos, Meletios A.
Bradner, James
Munshi, Nikhil C.
TI Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in
Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Gkotzamanidou, Maria; Song, Weihua; Pal, Jagannath; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Gkotzamanidou, Maria; Song, Weihua; Pal, Jagannath; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Shammas, Masood; Nanjappa, Puru; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Shammas, Masood; Nanjappa, Puru; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Souliotis, Vassilis L.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Athens, Greece.
[Rashid, Naim; Bradner, James] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dimopoulos, Meletios A.] Univ Athens, Sch Med, GR-11527 Athens, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806098
ER
PT J
AU Glavey, S
Reagan, M
Manier, S
Moschetta, M
Kawano, Y
Sacco, A
Roccaro, AM
Robbins, M
Ghobrial, IM
AF Glavey, Siobhan
Reagan, Michaela
Manier, Salomon
Moschetta, Michele
Kawano, Yawara
Sacco, Antonio
Roccaro, Aldo M.
Robbins, Michael
Ghobrial, Irene M.
TI Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting
Antibody Elotuzumab in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Glavey, Siobhan; Reagan, Michaela; Manier, Salomon; Moschetta, Michele; Kawano, Yawara; Sacco, Antonio; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Robbins, Michael] Bristol Myers Squibb Co, Princeton, NJ USA.
RI Reagan, Michaela/E-3549-2017
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233801152
ER
PT J
AU Haddad, A
Kantar, R
Tamim, H
Jamali, FR
Taher, A
AF Haddad, Anthony
Kantar, Rami
Tamim, Hani
Jamali, Faek R.
Taher, Ali
TI Venous Thromboembolism and Preoperative Steroid Use, a Retrospective
Cohort Study from the ACS-NSQIP Database: Are Surgical Patients at Risk?
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Haddad, Anthony; Tamim, Hani] Amer Univ Beirut, Dept Internal Med, Med Ctr, Beirut, Lebanon.
[Kantar, Rami] Massachusetts Gen Hosp, Expt Therapeut & Mol Imaging Lab, Boston, MA 02114 USA.
[Jamali, Faek R.] Amer Univ Beirut, Dept Surg, Med Ctr, Beirut, Lebanon.
[Taher, Ali] Amer Univ Beirut, Med Ctr, Beirut, Lebanon.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804162
ER
PT J
AU Hansen, E
Quivoron, C
Straley, K
Lemieux, RM
Popovici-Muller, J
Sadrzadeh, H
Fathi, AT
Gliser, C
David, M
Saada, V
Micol, JB
Bernard, O
Dorsch, M
Yang, H
Su, M
Agresta, S
de Botton, S
Penard-Lacronique, V
Yen, K
AF Hansen, Erica
Quivoron, Cyril
Straley, Kim
Lemieux, Rene M.
Popovici-Muller, Janeta
Sadrzadeh, Hossein
Fathi, Amir T.
Gliser, Camelia
David, Muriel
Saada, Veronique
Micol, Jean-Baptiste
Bernard, Olivier
Dorsch, Marion
Yang, Hua
Su, Michael
Agresta, Sam
de Botton, Stephane
Penard-Lacronique, Virginie
Yen, Katharine
TI AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant
IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in
TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples
Treated Ex Vivo
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Hansen, Erica; Straley, Kim; Lemieux, Rene M.; Popovici-Muller, Janeta; Gliser, Camelia; Dorsch, Marion; Yang, Hua; Su, Michael; Agresta, Sam; Yen, Katharine] Agios Pharmaceut, Cambridge, MA USA.
[Quivoron, Cyril; David, Muriel; Saada, Veronique; Micol, Jean-Baptiste; Bernard, Olivier; de Botton, Stephane; Penard-Lacronique, Virginie] INSERM, Villejuif, France.
[Quivoron, Cyril; David, Muriel; Saada, Veronique; Bernard, Olivier; de Botton, Stephane; Penard-Lacronique, Virginie] Inst Rech Integree Cancerol Villejuif Gustave Rou, Villejuif, France.
[Quivoron, Cyril; David, Muriel; Saada, Veronique; Bernard, Olivier; de Botton, Stephane; Penard-Lacronique, Virginie] Univ Paris 11, Orsay, France.
[Sadrzadeh, Hossein; Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
[Micol, Jean-Baptiste; Penard-Lacronique, Virginie] Gustave Roussy, Serv Hematol Clin, Villejuif, France.
RI David, Muriel/F-9592-2012
OI David, Muriel/0000-0003-1392-2701
NR 0
TC 2
Z9 2
U1 0
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500090
ER
PT J
AU Hari, PN
Shain, KH
Voorhees, PM
Gabrail, N
Abidi, MH
Zonder, J
Boccia, RV
Richardson, PG
Neuman, LL
Dixon, SJ
Prada, CP
AF Hari, Parameswaran N.
Shain, Kenneth H.
Voorhees, Peter M.
Gabrail, Nashat
Abidi, Muneer H.
Zonder, Jeffrey
Boccia, Ralph V.
Richardson, Paul G.
Neuman, Linda L.
Dixon, Sandra J.
Prada, Claudia Paba
TI Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory
Multiple Myeloma: Initial Results from the Dose Escalation Portion of a
Phase 1b/2, Multicenter, Open-Label Study
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Hari, Parameswaran N.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Shain, Kenneth H.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Voorhees, Peter M.] Univ N Carolina, Chapel Hill, NC USA.
[Gabrail, Nashat] Gabrail Canc Ctr, Canton, OH USA.
[Abidi, Muneer H.; Zonder, Jeffrey] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA.
[Boccia, Ralph V.] Ctr Canc & Blood Disorders, Bethesda, MD USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Neuman, Linda L.] Onyx Pharmaceut Inc, Redwood City, CA USA.
[Dixon, Sandra J.] Onyx Pharmaceut Inc, San Francisco, CA USA.
[Prada, Claudia Paba] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503200
ER
PT J
AU Harris, M
Neuberg, DS
Zheng, JB
Faham, M
Sallan, SE
Silverman, LB
AF Harris, Marian
Neuberg, Donna S.
Zheng, Jianbiao
Faham, Malek
Sallan, Stephen E.
Silverman, Lewis B.
TI Minimal Residual Disease Detection Using High-Throughput Sequencing
Predicts Clinical Outcome in Patients with Pediatric B-Lineage Acute
Lymphoblastic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Harris, Marian; Sallan, Stephen E.; Silverman, Lewis B.] Boston Childrens Hosp, Boston, MA USA.
[Neuberg, Donna S.; Sallan, Stephen E.; Silverman, Lewis B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zheng, Jianbiao; Faham, Malek] Sequenta Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505046
ER
PT J
AU Herrera, AF
Kim, HT
Faham, M
Sun, H
Sohani, AR
Alyea, EP
Chen, YB
Cutler, CS
Ho, VT
Koreth, J
Nikiforow, S
Ritz, J
Rodig, SJ
Soiffer, RJ
Antin, JH
Armand, P
AF Herrera, Alex F.
Kim, Haesook T.
Faham, Malek
Sun, Heather
Sohani, Aliyah R.
Alyea, Edwin P.
Chen, Yi-Bin
Cutler, Corey S.
Ho, Vincent T.
Koreth, John
Nikiforow, Sarah
Ritz, Jerome
Rodig, Scott J.
Soiffer, Robert J.
Antin, Joseph H.
Armand, Philippe
TI Sequencing-Based Detection of Minimal Residual Disease Is Associated
with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
in Patients with Lymphoid Malignancies
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Herrera, Alex F.; Kim, Haesook T.; Alyea, Edwin P.; Cutler, Corey S.; Ho, Vincent T.; Nikiforow, Sarah; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Faham, Malek] Sequenta Inc, San Francisco, CA USA.
[Sun, Heather] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Sohani, Aliyah R.] Maasachusetts Gen Hosp, Boston, MA USA.
[Chen, Yi-Bin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Koreth, John; Ritz, Jerome; Soiffer, Robert J.; Armand, Philippe] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505177
ER
PT J
AU Hosoba, S
Flowers, CR
Wu, CJ
Wrammert, JR
Waller, EK
AF Hosoba, Sakura
Flowers, Christopher R.
Wu, Catherine J.
Wrammert, Jens R.
Waller, Edmund K.
TI Rituximab Administration before Allogeneic HSCT Is Associated with
Accelerated T Cell Reconstitution after Transplantation: Kinetic
Evidence for a Graft-Versus-Leukemia Effect
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Hosoba, Sakura; Flowers, Christopher R.; Wrammert, Jens R.; Waller, Edmund K.] Emory Univ, Atlanta, GA 30322 USA.
[Hosoba, Sakura] Shiga Univ Med Sci, Otsu, Shiga 52021, Japan.
[Wu, Catherine J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Flowers, Christopher/F-1953-2010
OI Flowers, Christopher/0000-0002-9524-3990
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504177
ER
PT J
AU Huang, XG
Di Liberto, M
Chiron, D
Niesvizky, R
Schinzel, AC
Hahn, WC
Chen-Kiang, S
AF Huang, Xiangao
Di Liberto, Maurizio
Chiron, David
Niesvizky, Ruben
Schinzel, Anna C.
Hahn, William C.
Chen-Kiang, Selina
TI Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based
Combination Therapy in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Huang, Xiangao; Di Liberto, Maurizio; Chiron, David; Chen-Kiang, Selina] Weill Cornell Med Coll, New York, NY USA.
[Niesvizky, Ruben] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, New York, NY 10021 USA.
[Schinzel, Anna C.; Hahn, William C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501085
ER
PT J
AU Inamoto, Y
Martin, PJ
Flowers, ME
Urbano-Ispizua, A
Wang, T
Hemmer, MT
Cutler, CS
Couriel, DR
Alousi, AM
Arora, M
Spellman, SR
AF Inamoto, Yoshihiro
Martin, Paul J.
Flowers, Mary E.
Urbano-Ispizua, Alvaro
Wang, Tao
Hemmer, Michael T.
Cutler, Corey S.
Couriel, Daniel R.
Alousi, Amin M.
Arora, Mukta
Spellman, Stephen R.
TI Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for
Immunosuppression after Allogeneic Hematopoietic Cell Transplantation
for Severe Aplastic Anemia: A CIBMTR Analysis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Inamoto, Yoshihiro] Natl Canc Ctr, Tokyo, Japan.
[Inamoto, Yoshihiro; Martin, Paul J.; Flowers, Mary E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Urbano-Ispizua, Alvaro] Hosp Clin Barcelona, Barcelona, Spain.
[Wang, Tao; Hemmer, Michael T.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Couriel, Daniel R.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Alousi, Amin M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Arora, Mukta] Univ Minnesota, Minneapolis, MN USA.
[Spellman, Stephen R.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503166
ER
PT J
AU Jabbour, E
Sasaki, K
Sekeres, MA
Komrokji, RS
Steensma, DP
DeZern, AE
Gail, RJ
Daver, NG
Pemmaraju, N
Kadia, T
DiNardo, CD
Wang, XM
Nogueras-Gonzalez, G
Borthakur, G
Estrov, Z
Kantarjian, HM
Garcia-Manero, G
AF Jabbour, Elias
Sasaki, Koji
Sekeres, Mikkael A.
Komrokji, Rami S.
Steensma, David P.
DeZern, Amy E.
Gail, Roboz J.
Daver, Naval G.
Pemmaraju, Naveen
Kadia, Tapan
DiNardo, Courtney D.
Wang, Xuemei
Nogueras-Gonzalez, Graciela
Borthakur, Gautam
Estrov, Zeev
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
TI Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS)
Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS
Clinical Research Consortium
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Jabbour, Elias; Sasaki, Koji; Daver, Naval G.; Pemmaraju, Naveen; Kadia, Tapan; DiNardo, Courtney D.; Wang, Xuemei; Nogueras-Gonzalez, Graciela; Borthakur, Gautam; Estrov, Zeev; Kantarjian, Hagop M.; Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[DeZern, Amy E.] Johns Hopkins Univ, Baltimore, MD USA.
[Gail, Roboz J.] Weill Cornell Phys, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505034
ER
PT J
AU Jakubikova, J
Kastritis, E
Cholujova, D
Hideshima, T
Flores, LM
Leiba, M
Laubach, JP
Munshi, NC
Richardson, P
Dorfman, DM
Anderson, KC
AF Jakubikova, Jana
Kastritis, Efstathios
Cholujova, Danka
Hideshima, Teru
Flores, Ludmila M.
Leiba, Merav
Laubach, Jacob P.
Munshi, Nikhil C.
Richardson, Paul
Dorfman, David M.
Anderson, Kenneth C.
TI Evaluation of Immune Profile in Patients with Multiple Myeloma Using
Cytof Technology
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Jakubikova, Jana; Hideshima, Teru; Flores, Ludmila M.; Laubach, Jacob P.; Munshi, Nikhil C.; Richardson, Paul; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kastritis, Efstathios] Univ Athens, Sch Med, Athens 11528, Greece.
[Cholujova, Danka] Slovak Acad Sci, Canc Res Inst, Bratislava, Slovakia.
[Leiba, Merav] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.
[Dorfman, David M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807206
ER
PT J
AU Jakubikova, J
Cholujova, D
Hideshima, T
Laubach, JP
Munshi, NC
Treon, SP
Richardson, P
Kastritis, E
Dorfman, DM
Anderson, KC
AF Jakubikova, Jana
Cholujova, Danka
Hideshima, Teru
Laubach, Jacob P.
Munshi, Nikhil C.
Treon, Steven P.
Richardson, Paul
Kastritis, Efstathios
Dorfman, David M.
Anderson, Kenneth C.
TI Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom
Macroglobulinemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Jakubikova, Jana; Hideshima, Teru; Laubach, Jacob P.; Munshi, Nikhil C.; Treon, Steven P.; Richardson, Paul; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cholujova, Danka] Slovak Acad Sci, Canc Res Inst, Bratislava, Slovakia.
[Kastritis, Efstathios] Univ Athens, Sch Med, Athens 11528, Greece.
[Dorfman, David M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805099
ER
PT J
AU Jakubikova, J
Cholujova, D
Groen, RW
Joo, J
Kong, SY
Hideshima, T
Suzuki, R
Sedlak, J
Mitsiades, CS
Dorfman, DM
Laubach, JP
Munshi, NC
Richardson, PG
Anderson, K
AF Jakubikova, Jana
Cholujova, Danka
Groen, Richard W.
Joo, Jungnam
Kong, Sun-Young
Hideshima, Teru
Suzuki, Rikio
Sedlak, Jan
Mitsiades, Constantine S.
Dorfman, David M.
Laubach, Jacob P.
Munshi, Nikhil C.
Richardson, Paul G.
Anderson, Kenneth
TI Mimicking Myeloma Niche Ex Vivo
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Jakubikova, Jana; Groen, Richard W.; Hideshima, Teru; Suzuki, Rikio; Mitsiades, Constantine S.; Laubach, Jacob P.; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cholujova, Danka; Sedlak, Jan] Slovak Acad Sci, Canc Res Inst, Bratislava, Slovakia.
[Joo, Jungnam; Kong, Sun-Young] Natl Canc Ctr, Goyang, South Korea.
[Dorfman, David M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233802151
ER
PT J
AU Jazieh, KA
Stetson, AE
Duncan, C
Lehmann, LE
AF Jazieh, Khalid Abdulrahman
Stetson, Alyssa E.
Duncan, Christine
Lehmann, Leslie E.
TI No Effect of Birth Order on Relapse, Graft-Versus-Host Disease or
Transplant Related Mortality in Matched Sibling Donor Bone Marrow
Transplant in Pediatric Patients with Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Jazieh, Khalid Abdulrahman] Alfaisal Univ, Riyadh, Saudi Arabia.
[Stetson, Alyssa E.; Duncan, Christine; Lehmann, Leslie E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lehmann, Leslie E.] Boston Childrens Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503195
ER
PT J
AU Jiang, H
An, G
Acharya, C
Zhong, MY
Cai, T
Song, ZL
Yang, G
Adrian, F
Munshi, NC
Tai, YT
Anderson, KC
AF Jiang, Hua
An, Gang
Acharya, Chirag
Zhong, Mike Y.
Cai, Ti
Song, Zhili
Yang, Guang
Adrian, Francisco
Munshi, Nikhil C.
Tai, Yu-Tzu
Anderson, Kenneth C.
TI SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple
Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced
By Pomalidomide, More Potently Than Lenalidomide
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Jiang, Hua; An, Gang; Zhong, Mike Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Acharya, Chirag; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Acharya, Chirag; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Tai, Yu-Tzu] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506087
ER
PT J
AU Kaelin, WG
AF Kaelin, William G.
TI IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kaelin, William G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805200
ER
PT J
AU Karreth, F
Reschke, M
Chapuy, B
Shipp, MA
Chiarle, R
Pandolfi, PP
AF Karreth, Florian
Reschke, Markus
Chapuy, Bjoern
Shipp, Margaret A.
Chiarle, Roberto
Pandolfi, Pier Paolo
TI The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Karreth, Florian] Weill Cornell Med Coll, New York, NY USA.
[Karreth, Florian; Reschke, Markus; Pandolfi, Pier Paolo] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Chapuy, Bjoern; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chiarle, Roberto] Childrens Hosp Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501127
ER
PT J
AU Kasar, S
Tiao, G
Improgo, R
Kiezun, A
Sougnez, C
Bahl, S
Fernandes, SM
Vartanov, AR
Hoang, K
Gabriel, S
Landau, DA
Wu, CJ
Lander, E
Kim, HT
Getz, G
Brown, JR
AF Kasar, Siddha
Tiao, Grace
Improgo, Reina
Kiezun, Adam
Sougnez, Carrie
Bahl, Samira
Fernandes, Stacey M.
Vartanov, Alexander R.
Hoang, Kevin
Gabriel, Stacey
Landau, Dan A.
Wu, Catherine J.
Lander, Eric
Kim, Haesook T.
Getz, Gad
Brown, Jennifer R.
TI Whole Genome Sequencing of Indolent CLL Reveals Novel Structural
Rearrangements
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kasar, Siddha; Improgo, Reina; Fernandes, Stacey M.; Vartanov, Alexander R.; Hoang, Kevin; Landau, Dan A.; Wu, Catherine J.; Kim, Haesook T.; Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kasar, Siddha; Improgo, Reina; Wu, Catherine J.; Brown, Jennifer R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Tiao, Grace; Kiezun, Adam; Sougnez, Carrie; Bahl, Samira; Gabriel, Stacey; Landau, Dan A.; Lander, Eric; Getz, Gad] Broad Inst Harvard & MIT, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233802181
ER
PT J
AU Kawano, Y
Sahin, I
Moschetta, M
Wang, JH
Manier, S
Glavey, S
Mishima, Y
Kokubun, K
Tsukamoto, S
Sacco, A
Anderson, KC
Roccaro, AM
Gray, NS
Ghobrial, IM
AF Kawano, Yawara
Sahin, Ilyas
Moschetta, Michele
Wang, Jinhua
Manier, Salomon
Glavey, Siobhan
Mishima, Yuji
Kokubun, Katsutoshi
Tsukamoto, Shokichi
Sacco, Antonio
Anderson, Kenneth C.
Roccaro, Aldo M.
Gray, Nathanael S.
Ghobrial, Irene M.
TI Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel
Therapeutic Target in Multiple Myeloma Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kawano, Yawara; Sahin, Ilyas; Moschetta, Michele; Manier, Salomon; Glavey, Siobhan; Mishima, Yuji; Tsukamoto, Shokichi; Sacco, Antonio; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wang, Jinhua; Kokubun, Katsutoshi; Gray, Nathanael S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804210
ER
PT J
AU Kekre, N
Kim, HT
Thanarajasingam, G
Armand, P
Antin, JH
Cutler, CS
Nikiforow, S
Ho, VT
Alyea, EP
Koreth, J
Soiffer, RJ
AF Kekre, Natasha
Kim, Haesook T.
Thanarajasingam, Gita
Armand, Philippe
Antin, Joseph H.
Cutler, Corey S.
Nikiforow, Sarah
Ho, Vincent T.
Alyea, Edwin P.
Koreth, John
Soiffer, Robert J.
TI Immunosuppression Taper to Induce Graft-Verus-Tumor Activity As the Sole
Therapy for Early Relapse after Reduced Intensity Allogeneic
Hematopoietic Cell Transplantation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kekre, Natasha; Armand, Philippe; Antin, Joseph H.; Cutler, Corey S.; Nikiforow, Sarah; Ho, Vincent T.; Alyea, Edwin P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kim, Haesook T.; Koreth, John; Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Thanarajasingam, Gita] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506033
ER
PT J
AU Kim, E
Werner, L
Keating, MJ
Wierda, WG
Ferrajoli, A
Estrov, Z
Zacharian, G
Kipps, TJ
Kantarjian, HM
Neuberg, D
O'Brien, S
Burger, JA
AF Kim, Ekaterina
Werner, Lillian
Keating, Michael J.
Wierda, William G.
Ferrajoli, Alessandra
Estrov, Zeev
Zacharian, Gracy
Kipps, Thomas J.
Kantarjian, Hagop M.
Neuberg, Donna
O'Brien, Susan
Burger, Jan A.
TI Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and
Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients
with Relapsed Chronic Lymphocytic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kim, Ekaterina; Keating, Michael J.; Wierda, William G.; Ferrajoli, Alessandra; Estrov, Zeev; Zacharian, Gracy; Kantarjian, Hagop M.; O'Brien, Susan; Burger, Jan A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Werner, Lillian; Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kipps, Thomas J.] Univ Calif San Diego, La Jolla, CA 92093 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505201
ER
PT J
AU Kim, HT
Armand, P
Frederick, D
Andler, E
Cutler, CS
Koreth, J
Alyea, EP
Antin, JH
Soiffer, RJ
Ritz, J
Ho, VT
AF Kim, Haesook T.
Armand, Philippe
Frederick, David
Andler, Emily
Cutler, Corey S.
Koreth, John
Alyea, Edwin P.
Antin, Joseph H.
Soiffer, Robert J.
Ritz, Jerome
Ho, Vincent T.
TI Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem
Cell Transplantation Predicts Clinical Outcome
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kim, Haesook T.; Armand, Philippe; Frederick, David; Andler, Emily; Cutler, Corey S.; Koreth, John; Alyea, Edwin P.; Antin, Joseph H.; Ritz, Jerome; Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233800182
ER
PT J
AU Klitgaard, JL
Magori-Cohen, R
Improgo, R
Fernandes, SM
Tesar, B
Hoang, K
Kim, HT
Brown, JR
AF Klitgaard, Josephine L.
Magori-Cohen, Reuma
Improgo, Reina
Fernandes, Stacey M.
Tesar, Bethany
Hoang, Kevin
Kim, Haesook T.
Brown, Jennifer R.
TI Inhibition of the Notch1 Pathway in Chronic Lymphocytic Leukemia
Promotes Apoptosis and Inhibits Proliferation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Klitgaard, Josephine L.; Magori-Cohen, Reuma; Improgo, Reina; Fernandes, Stacey M.; Tesar, Bethany; Hoang, Kevin; Kim, Haesook T.; Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Klitgaard, Josephine L.; Improgo, Reina; Tesar, Bethany; Brown, Jennifer R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Magori-Cohen, Reuma] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805062
ER
PT J
AU Konopleva, M
Pollyea, DA
Potluri, J
Chyla, BJ
Busman, T
McKeegan, E
Salem, A
Zhu, M
Ricker, JL
Blum, W
DiNardo, CD
Dunbar, M
Kirby, R
Falotico, N
Leverson, JD
Humerickhouse, RA
Mabry, M
Stone, RM
Kantarjian, HM
Letai, AG
AF Konopleva, Marina
Pollyea, Daniel A.
Potluri, Jalaja
Chyla, Brenda J.
Busman, Todd
McKeegan, Evelyn
Salem, Ahmed
Zhu, Ming
Ricker, Justin L.
Blum, William
DiNardo, Courtney D.
Dunbar, Martin
Kirby, Rachel
Falotico, Nancy
Leverson, Joel D.
Humerickhouse, Rod A.
Mabry, Mack
Stone, Richard M.
Kantarjian, Hagop M.
Letai, Anthony G.
TI A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous
Leukemia (AML)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Konopleva, Marina; DiNardo, Courtney D.; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Pollyea, Daniel A.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Potluri, Jalaja; Chyla, Brenda J.; Busman, Todd; McKeegan, Evelyn; Salem, Ahmed; Zhu, Ming; Ricker, Justin L.; Dunbar, Martin; Kirby, Rachel; Falotico, Nancy; Leverson, Joel D.; Humerickhouse, Rod A.; Mabry, Mack] AbbVie Inc, N Chicago, IL USA.
[Blum, William] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Stone, Richard M.; Letai, Anthony G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 15
Z9 15
U1 1
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807006
ER
PT J
AU Kopp, N
Tschuri, S
Haebe, S
van Bodegom, D
Bird, L
Christie, AL
Saur, A
Christodoulou, AN
Tivey, T
Kung, AL
Weigert, O
Weinstock, D
AF Kopp, Nadja
Tschuri, Sebastian
Haebe, Sarah
van Bodegom, Diederik
Bird, Liat
Christie, Amanda L.
Saur, Amy
Christodoulou, Alexandra N.
Tivey, Trevor
Kung, Andrew L.
Weigert, Oliver
Weinstock, David
TI Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and
Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in
Vivo
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kopp, Nadja; van Bodegom, Diederik; Bird, Liat; Christie, Amanda L.; Saur, Amy; Christodoulou, Alexandra N.; Tivey, Trevor; Weinstock, David] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tschuri, Sebastian; Haebe, Sarah; Weigert, Oliver] Univ Hosp Munich, LMU, Munich, Germany.
[Kung, Andrew L.] Columbia Univ Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502011
ER
PT J
AU Kostadinov, R
Scharpf, R
Sabunciyan, S
Magoon, D
Irizarry, R
Brown, P
AF Kostadinov, Rumen
Scharpf, Robert
Sabunciyan, Sarven
Magoon, Daniel
Irizarry, Rafael
Brown, Patrick
TI Identifying Methylation Changes Driving Evolution of Relapse in
MLL-Rearranged Acute Lymphoblastic Leukemias
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kostadinov, Rumen] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Scharpf, Robert] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Sabunciyan, Sarven] Johns Hopkins Sch Med, Baltimore, MD USA.
[Magoon, Daniel] Johns Hopkins, Baltimore, MD USA.
[Irizarry, Rafael] Dana Farber Canc Ctr, Boston, MA USA.
[Brown, Patrick] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501102
ER
PT J
AU Kotini, A
Delrow, JJ
Graubert, TA
Nimer, S
Papapetrou, EP
AF Kotini, Andriana
Delrow, Jeffrey J.
Graubert, Timothy A.
Nimer, Stephen
Papapetrou, Eirini P.
TI Functional Dissection of Chromosome 7q Loss and Haploinsufficient Gene
Discovery Using iPSC Models of MDS
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kotini, Andriana; Papapetrou, Eirini P.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
[Delrow, Jeffrey J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Graubert, Timothy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Nimer, Stephen] Univ Miami, Miami, FL USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806082
ER
PT J
AU Kretz, CA
Novakovic, VA
Kiseleva, A
Cleuren, ACA
Khoriaty, R
Adams, E
Ginsburg, D
Gilbert, GE
AF Kretz, Colin A.
Novakovic, Valerie A.
Kiseleva, Anna
Cleuren, Audrey C. A.
Khoriaty, Rami
Adams, Elizabeth
Ginsburg, David
Gilbert, Gary E.
TI TMEM16F Deficiency Causes a Strain-Dependent Lethality in Mice and
Reduced Phosphatidylserine Exposure on Heterozygous As Well As
Homozygous Deficient Mouse Platelets
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kretz, Colin A.; Khoriaty, Rami; Ginsburg, David] Univ Michigan, Ann Arbor, MI 48109 USA.
[Novakovic, Valerie A.; Gilbert, Gary E.] VA Boston Healthcare Syst, Boston, MA USA.
[Kiseleva, Anna; Cleuren, Audrey C. A.; Adams, Elizabeth] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.
[Ginsburg, David] Howard Hughes Med Inst, Ann Arbor, MI USA.
[Gilbert, Gary E.] Harvard Univ, Sch Med, West Roxbury, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506046
ER
PT J
AU Kritharis, A
Kanakry, JA
Sehn, LH
Feldman, T
Kroll, A
Gascoyne, RD
Petrich, AM
Abramson, JS
Hernandez-Ilizaliturri, F
Al-Mansour, Z
Adeimy, C
Hemminger, J
Bartlett, NL
Mato, AR
Caimi, P
Advani, R
Klein, AK
Lossos, IS
Press, OW
Smith, SM
Fabregas, JC
Nabhan, C
Fenske, TS
Friedberg, JW
Vose, JM
Blum, KA
Evens, AM
AF Kritharis, Athena
Kanakry, Jennifer A.
Sehn, Laurie H.
Feldman, Tatyana
Kroll, Aimee
Gascoyne, Randy D.
Petrich, Adam M.
Abramson, Jeremy S.
Hernandez-Ilizaliturri, Francisco
Al-Mansour, Zeina
Adeimy, Camille
Hemminger, Jessica
Bartlett, Nancy L.
Mato, Anthony R.
Caimi, Paolo
Advani, Ranjana
Klein, Andreas K.
Lossos, Izidore S.
Press, Oliver W.
Smith, Sonali M.
Fabregas, Jesus C.
Nabhan, Chadi
Fenske, Timothy S.
Friedberg, Jonathan W.
Vose, Julie M.
Blum, Kristie A.
Evens, Andrew M.
TI Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical
Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL):
Analysis of Tumor Immunophenotype (IP) and Critical Examination of
Therapy with Associated Impact on Outcome
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kritharis, Athena; Evens, Andrew M.] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA.
[Kanakry, Jennifer A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Sehn, Laurie H.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
[Feldman, Tatyana; Mato, Anthony R.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[Kroll, Aimee] Univ Massachusetts, Worcester, MA 01605 USA.
[Gascoyne, Randy D.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
[Petrich, Adam M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Hernandez-Ilizaliturri, Francisco] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Al-Mansour, Zeina] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Adeimy, Camille] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
[Hemminger, Jessica; Blum, Kristie A.] Ohio State Univ, Columbus, OH 43210 USA.
[Bartlett, Nancy L.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA.
[Mato, Anthony R.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Caimi, Paolo] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Advani, Ranjana] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA.
[Klein, Andreas K.] Tufts Med Ctr, Boston, MA USA.
[Lossos, Izidore S.] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA.
[Press, Oliver W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Smith, Sonali M.] Univ Chicago, Chicago, IL 60637 USA.
[Fabregas, Jesus C.] Univ Miami, Div Hematol Oncol, Miami, FL USA.
[Nabhan, Chadi] Oncol Specialists SC, Park Ridge, IL USA.
[Fenske, Timothy S.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Friedberg, Jonathan W.] Univ Rochester, Rochester, NY USA.
[Vose, Julie M.] Univ Nebraska Med Ctr, Omaha, NE USA.
NR 0
TC 6
Z9 6
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505124
ER
PT J
AU Kumar, S
Berdeja, JG
Niesvizky, R
Lonial, S
Laubach, JP
Hamadani, M
Stewart, K
Hari, PN
Roy, V
Vescio, R
Kaufman, JL
Berg, D
Liao, E
Hui, AM
Rajkumar, SV
Richardson, PG
AF Kumar, Shaji
Berdeja, Jesus G.
Niesvizky, Ruben
Lonial, Sagar
Laubach, Jacob P.
Hamadani, Mehdi
Stewart, Keith
Hari, Parameswaran N.
Roy, Vivek
Vescio, Robert
Kaufman, Jonathan L.
Berg, Deborah
Liao, Eileen
Hui, Ai-Min
Rajkumar, S. Vincent
Richardson, Paul G.
TI Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of
Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in
Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2
Study Results
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kumar, Shaji; Rajkumar, S. Vincent] Mayo Clin, Rochester, MN USA.
[Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA.
[Niesvizky, Ruben] Weill Cornell Med Coll, New York, NY USA.
[Lonial, Sagar; Kaufman, Jonathan L.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Laubach, Jacob P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hamadani, Mehdi] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA.
[Stewart, Keith] Mayo Clin, Scottsdale, AZ USA.
[Hari, Parameswaran N.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Roy, Vivek] Mayo Clin, Jacksonville, FL 32224 USA.
[Vescio, Robert] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA.
[Berg, Deborah; Liao, Eileen; Hui, Ai-Min] Takeda Pharmaceut Int Co, Cambridge, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233801066
ER
PT J
AU Kuruvilla, J
Byrd, JC
Flynn, JM
Garzon, R
Porcu, P
Wagner-Johnston, N
Savoie, ML
Stone, RM
Jacobsen, ED
Mau-Sorensen, M
Brown, PD
Baz, R
Shal, B
Flinn, I
Gabrail, N
Kukreti, V
Tiedemann, RE
Landesman, Y
Klebanov, B
Shacham, E
Saint-Martin, JR
Marshall, T
McCartney, J
McCauley, D
Carlson, R
Norori, S
Savona, MR
Rashal, T
Mirza, MR
Kauffman, M
Shacham, S
AF Kuruvilla, John
Byrd, John C.
Flynn, Joseph M.
Garzon, Ramiro
Porcu, Pierluigi
Wagner-Johnston, Nina
Savoie, Mary Lynn
Stone, Richard M.
Jacobsen, Eric D.
Mau-Sorensen, Morten
Brown, Peter de Nully
Baz, Rachid
Shal, Bijal
Flinn, Ian
Gabrail, Nashat
Kukreti, Vishal
Tiedemann, Rodger E.
Landesman, Yosef
Klebanov, Boris
Shacham, Eran
Saint-Martin, Jean-Richard
Marshall, Tracey
McCartney, John
McCauley, Dilara
Carlson, Robert
Norori, Sasha
Savona, Michael R.
Rashal, Tami
Mirza, Mansoor R.
Kauffman, Michael
Shacham, Sharon
TI The Oral Selective Inhibitor of Nuclear Export ( SINE) Selinexor
(KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed /
Refractory Non Hodgkin's Lymphoma (NHL)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kuruvilla, John] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Byrd, John C.; Porcu, Pierluigi] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Flynn, Joseph M.; Garzon, Ramiro] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Wagner-Johnston, Nina] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA.
[Savoie, Mary Lynn] Alberta Hlth Serv, Calgary, AB, Canada.
[Stone, Richard M.; Jacobsen, Eric D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mau-Sorensen, Morten] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark.
[Brown, Peter de Nully] Rigshosp, DK-2100 Copenhagen, Denmark.
[Baz, Rachid; Shal, Bijal] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Flinn, Ian] Sarah Cannon Res Inst, Nashville, TN USA.
[Gabrail, Nashat] Gabrail Canc Ctr, Canton, OH USA.
[Kukreti, Vishal; Tiedemann, Rodger E.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Landesman, Yosef; Klebanov, Boris; Shacham, Eran; Saint-Martin, Jean-Richard; Marshall, Tracey; McCartney, John; McCauley, Dilara; Carlson, Robert; Savona, Michael R.; Rashal, Tami; Mirza, Mansoor R.; Kauffman, Michael; Shacham, Sharon] Karyopharm Therapeut Inc, Newton, MA USA.
[Norori, Sasha] Ozmosis Res Inc, Toronto, ON, Canada.
RI Garzon, Ramiro/E-3104-2011
NR 0
TC 0
Z9 0
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243508066
ER
PT J
AU Landau, DA
Stewart, C
Reiter, JG
Lawrence, M
Sougnez, C
Brown, JR
Lopez-Guillermo, A
Gabriel, S
Lander, E
Neuberg, DS
Lopez-Otin, C
Campo, E
Getz, G
Wu, CJ
AF Landau, Dan A.
Stewart, Chip
Reiter, Johannes G.
Lawrence, Michael
Sougnez, Carrie
Brown, Jennifer R.
Lopez-Guillermo, Armando
Gabriel, Stacey
Lander, Eric
Neuberg, Donna S.
Lopez-Otin, Carlos
Campo, Elias
Getz, Gad
Wu, Catherine J.
TI Novel Putative Driver Gene Mutations in Chronic Lymphocytic Leukemia
(CLL): Results from a Combined Analysis of Whole-Exome Sequencing of 262
Primary CLL Samples
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Landau, Dan A.; Reiter, Johannes G.; Brown, Jennifer R.; Neuberg, Donna S.; Wu, Catherine J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Landau, Dan A.; Lawrence, Michael; Sougnez, Carrie; Gabriel, Stacey; Lander, Eric; Getz, Gad; Wu, Catherine J.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Stewart, Chip] Broad Inst, Cambridge, MA USA.
[Reiter, Johannes G.] IST Austria, Klosterneuburg, Austria.
[Lopez-Guillermo, Armando; Campo, Elias] IDIBAPS, Hosp Clin, Barcelona, Spain.
[Lopez-Otin, Carlos] Univ Oviedo, Oviedo, Spain.
RI Lopez-Otin, Carlos/C-6657-2013
OI Lopez-Otin, Carlos/0000-0001-6964-1904
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506068
ER
PT J
AU Landau, DA
Tausch, E
Taylor-Weiner, AN
Bottcher, S
Bahlo, J
Stewart, C
Edelmann, J
Kluth, S
Mertens, D
Kneba, M
Kless, S
Sougnez, C
Fischer, K
Ritgen, M
Gabriel, S
Lander, E
Dohner, H
Hallek, M
Getz, G
Neuberg, D
Stilgenbauer, S
Wu, CJ
AF Landau, Dan A.
Tausch, Eugen
Taylor-Weiner, Amaro N.
Bottcher, Sebastian
Bahlo, Jasmin
Stewart, Chip
Edelmann, Jennifer
Kluth, Sandra
Mertens, Daniel
Kneba, Michael
Kless, Sabrina
Sougnez, Carrie
Fischer, Kirsten
Ritgen, Matthias
Gabriel, Stacey
Lander, Eric
Dohner, Hartmut
Hallek, Michael
Getz, Gad
Neuberg, Donna
Stilgenbauer, Stephan
Wu, Catherine J.
TI Subclonal Driver Mutations Predict Shorter Progression Free Survival in
Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno) Therapy:
Results from the CLL8 Trial
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Landau, Dan A.; Taylor-Weiner, Amaro N.; Sougnez, Carrie; Gabriel, Stacey; Lander, Eric; Getz, Gad; Wu, Catherine J.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Landau, Dan A.; Neuberg, Donna; Wu, Catherine J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tausch, Eugen; Edelmann, Jennifer; Mertens, Daniel; Kless, Sabrina; Stilgenbauer, Stephan] Univ Ulm, D-89069 Ulm, Germany.
[Bottcher, Sebastian; Kneba, Michael; Ritgen, Matthias] Univ Hosp Schleswig Holstein, Kiel, Germany.
[Bahlo, Jasmin; Fischer, Kirsten; Hallek, Michael] Univ Cologne, D-50931 Cologne, Germany.
[Stewart, Chip] Broad Inst, Cambridge, MA USA.
[Kluth, Sandra] Univ Hosp, Cologne, Germany.
[Mertens, Daniel] German Canc Res Ctr, Heidelberg, Germany.
[Dohner, Hartmut] Univ Hosp Ulm, Ulm, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505050
ER
PT J
AU Laubach, JP
Raje, NS
Yee, AJ
Armand, P
Schlossman, RL
Rosenblatt, J
Matous, J
Hedlund, J
Martin, MG
Reynolds, C
Shain, KH
Zackon, I
Stampleman, LV
Boswell, EN
Chuma, S
Liguori, R
Mar, S
Handisides, D
Kroll, S
Anderson, KC
Richardson, PG
Ghobrial, IM
AF Laubach, Jacob P.
Raje, Noopur S.
Yee, Andrew J.
Armand, Philippe
Schlossman, Robert L.
Rosenblatt, Jacalyn
Matous, Jeffrey
Hedlund, Jacquelyn
Martin, Michael G.
Reynolds, Craig
Shain, Kenneth H.
Zackon, Ira
Stampleman, Laura V.
Boswell, Erica N.
Chuma, Stacey
Liguori, Rebecca
Mar, Stephanie
Handisides, Damian
Kroll, Stew
Anderson, Kenneth C.
Richardson, Paul G.
Ghobrial, Irene M.
TI A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib
(TBorD) in Patients with Relapsed/Refractory Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Laubach, Jacob P.; Armand, Philippe; Schlossman, Robert L.; Boswell, Erica N.; Chuma, Stacey; Anderson, Kenneth C.; Richardson, Paul G.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Laubach, Jacob P.; Armand, Philippe; Schlossman, Robert L.; Rosenblatt, Jacalyn; Matous, Jeffrey; Hedlund, Jacquelyn; Martin, Michael G.; Reynolds, Craig; Zackon, Ira; Stampleman, Laura V.; Boswell, Erica N.; Chuma, Stacey; Liguori, Rebecca; Anderson, Kenneth C.; Richardson, Paul G.; Ghobrial, Irene M.] Blood Canc Res Partnership, Boston, MA USA.
[Raje, Noopur S.; Yee, Andrew J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rosenblatt, Jacalyn] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Matous, Jeffrey] Colorado Blood Canc Inst, Denver, CO USA.
[Hedlund, Jacquelyn] New England Canc Specialisits, Scarborough, ME USA.
[Martin, Michael G.] Univ Tennessee, Ctr Hlth Sci, West Clin, Memphis, TN 38163 USA.
[Reynolds, Craig] Ocala Oncol Ctr, Ocala, FL USA.
[Shain, Kenneth H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Zackon, Ira] New York Oncol Hematol, Albany, NY USA.
[Stampleman, Laura V.] Pacific Care Ctr, Salinas, CA USA.
[Liguori, Rebecca] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mar, Stephanie; Handisides, Damian; Kroll, Stew] Threshold Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502092
ER
PT J
AU Lehmann, LE
Williams, DA
London, WB
Agarwal, S
AF Lehmann, Leslie E.
Williams, David A.
London, Wendy B.
Agarwal, Suneet
TI Full Donor Myeloid Engraftment with Minimal Toxicity in Dyskeratosis
Congenita Patients Undergoing Allogeneic Bone Marrow Transplantation
without Radiation or Alkylating Agents
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Lehmann, Leslie E.; Williams, David A.; London, Wendy B.; Agarwal, Suneet] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lehmann, Leslie E.; Williams, David A.; London, Wendy B.; Agarwal, Suneet] Boston Childrens Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503181
ER
PT J
AU Li, A
Bendapudi, PK
Hamdan, A
Makar, RS
AF Li, Ang
Bendapudi, Pavan K.
Hamdan, Ayad
Makar, Robert S.
TI Moderate Deficiency of ADAMTS13 in Thrombotic Microangiopathy Is
Associated with Poor Survival Regardless of Plasma Exchange
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Li, Ang] Massachussetts Gen Hosp, Boston, MA USA.
[Bendapudi, Pavan K.; Makar, Robert S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hamdan, Ayad] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807069
ER
PT J
AU Lindner, JR
Widlansky, M
Wu, MD
Dargatz, J
Harmann, LM
Belcik, T
Neuberg, DS
Nathan, DG
Linden, J
Field, JJ
AF Lindner, Jonathan R.
Widlansky, Michael
Wu, Melinda D.
Dargatz, Jillian
Harmann, Leanne M.
Belcik, Todd
Neuberg, Donna S.
Nathan, David G.
Linden, Joel
Field, Joshua J.
TI Contrast-Enhanced Ultrasound Detects Differences in Microvascular Blood
Flow in Adults with Sickle Cell Disease Administered Regadenoson
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Lindner, Jonathan R.; Wu, Melinda D.; Belcik, Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Widlansky, Michael; Harmann, Leanne M.; Field, Joshua J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Dargatz, Jillian; Field, Joshua J.] BloodCtr Wisconsin, Milwaukee, WI USA.
[Neuberg, Donna S.; Nathan, David G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Linden, Joel] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807035
ER
PT J
AU Lindsley, RC
Mar, BG
Mazzola, E
Grauman, P
Shareef, S
DeAngelo, DJ
Neuberg, DS
Stone, RM
Ebert, BL
AF Lindsley, R. Coleman
Mar, Brenton G.
Mazzola, Emanuele
Grauman, Peter
Shareef, Sarah
DeAngelo, Daniel J.
Neuberg, Donna S.
Stone, Richard M.
Ebert, Benjamin L.
TI Ontogeny-Specific Patterns of Genetic Alterations in Acute Myeloid
Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Lindsley, R. Coleman; Mar, Brenton G.; Mazzola, Emanuele; DeAngelo, Daniel J.; Neuberg, Donna S.; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Grauman, Peter; Ebert, Benjamin L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Shareef, Sarah] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500158
ER
PT J
AU Litzow, MR
Wang, XV
Carroll, MP
Karp, JE
Ketterling, R
Kaufmann, SH
Lazarus, HM
Luger, SM
Paietta, EM
Rowe, JM
Altman, JK
Pratz, KW
Broun, ER
Tallman, MS
AF Litzow, Mark R.
Wang, Xin Victoria
Carroll, Martin P.
Karp, Judith E.
Ketterling, Rhett
Kaufmann, Scott H.
Lazarus, Hillard M.
Luger, Selina M.
Paietta, Elisabeth M.
Rowe, Jacob M.
Altman, Jessica K.
Pratz, Keith W.
Broun, E. Randolph
Tallman, Martin S.
TI A Randomized Phase II Trial of Three Novel Regimens for
Relapsed/Refractory Acute Myeloid Leukemia (AML) Demonstrates
Encouraging Results with a Flavopiridol-Based Regimen: Results of
Eastern Cooperative Oncology Group (ECOG) Trial E1906
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Litzow, Mark R.; Ketterling, Rhett; Kaufmann, Scott H.] Mayo Clin, Rochester, MN USA.
[Wang, Xin Victoria] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Carroll, Martin P.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Karp, Judith E.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Lazarus, Hillard M.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
[Luger, Selina M.] Univ Penn, Philadelphia, PA 19104 USA.
[Paietta, Elisabeth M.] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Rowe, Jacob M.] Shaare Zedek Med Ctr, Jerusalem, Israel.
[Altman, Jessica K.] Northwestern Univ, Chicago, IL 60611 USA.
[Pratz, Keith W.] Johns Hopkins, Baltimore, MD USA.
[Broun, E. Randolph] Oncol Hematol Care Inc, Cincinnati, OH USA.
[Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505025
ER
PT J
AU Liu, SY
Kharbanda, S
Stone, RM
AF Liu, Suiyang
Kharbanda, Surender
Stone, Richard M.
TI OncoHist (R), an rh Histone 1.3, Is Cytotoxic to Acute Myeloid Leukemia
Cells and Results in Altered Downstream Signaling
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Liu, Suiyang; Kharbanda, Surender; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243507150
ER
PT J
AU Lobbardi, R
Pinder, J
Martinez-Pastor, B
Blackburn, JS
Abdelfattah, N
Toiber, D
De Waard, M
Asara, JM
Mostoslavsky, R
Dellaire, G
Langenau, DM
AF Lobbardi, Riadh
Pinder, Jordan
Martinez-Pastor, Barbara
Blackburn, Jessica S.
Abdelfattah, Nouran
Toiber, Deborah
De Waard, Manon
Asara, John M.
Mostoslavsky, Raul
Dellaire, Graham
Langenau, David M.
TI Thymocyte Selection-Associated High-Mobility Group Box Protein (TOX)
Induces Genomic Instability in T-Cell Acute Lymphoblastic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Lobbardi, Riadh; Martinez-Pastor, Barbara; Blackburn, Jessica S.; Abdelfattah, Nouran; Mostoslavsky, Raul; Langenau, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lobbardi, Riadh; Blackburn, Jessica S.; Abdelfattah, Nouran; Langenau, David M.] Harvard Stem Cell Inst, Cambridge, MA USA.
[Pinder, Jordan; Dellaire, Graham] Dalhousie Univ, Halifax, NS, Canada.
[Toiber, Deborah] Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel.
[De Waard, Manon] Leiden Univ, Leiden, Netherlands.
[Asara, John M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501020
ER
PT J
AU Loukogeorgakis, SP
Li, HY
Tang, L
Kim, AG
Vrecenak, JD
Nissim, I
Conner, MA
Nissim, I
De Coppi, P
Peranteau, W
Irvine, DJ
Flake, AW
AF Loukogeorgakis, Stavros P.
Li, Haiying
Tang, Li
Kim, Aimee G.
Vrecenak, Jesse D.
Nissim, Ilana
Conner, Michael A.
Nissim, Izhtak
De Coppi, Paolo
Peranteau, William
Irvine, Darrell J.
Flake, Alan W.
TI Cell Engineering with Glycogen Synthase Kinase-3 Beta Inhibitor-Loaded
Synthetic Nanoparticles Enhances Hematopoietic Engraftment of Bone
Marrow Mononuclear Cells Following in Utero Transplantation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Loukogeorgakis, Stavros P.; Li, Haiying; Kim, Aimee G.; Vrecenak, Jesse D.; Nissim, Ilana; Conner, Michael A.; Nissim, Izhtak; Peranteau, William; Flake, Alan W.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Loukogeorgakis, Stavros P.; De Coppi, Paolo] UCL, London, England.
[Tang, Li; Irvine, Darrell J.] MIT, Boston, MA USA.
[Nissim, Izhtak] Univ Penn, Philadelphia, PA 19104 USA.
[Irvine, Darrell J.] Massachusetts Gen Hosp, MIT, Boston, MA 02114 USA.
[Irvine, Darrell J.] Harvard Univ, Boston, MA 02115 USA.
[Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504067
ER
PT J
AU Luskin, MR
Lee, JW
Fernandez, HF
Lazarus, HM
Rowe, JM
Tallman, MS
Paietta, EM
Litzow, M
Abdel-Wahab, O
Patel, JP
Levine, RL
Sun, ZX
Luger, SM
AF Luskin, Marlise R.
Lee, Ju-Whei
Fernandez, Hugo F.
Lazarus, Hillard M.
Rowe, Jacob M.
Tallman, Martin S.
Paietta, Elisabeth M.
Litzow, Mark
Abdel-Wahab, Omar
Patel, Jay P.
Levine, Ross L.
Sun, Zhuoxin
Luger, Selina M.
TI High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All
Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic
Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative
Oncology Trial E1900
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Luskin, Marlise R.; Luger, Selina M.] Univ Penn, Philadelphia, PA 19104 USA.
[Lee, Ju-Whei; Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fernandez, Hugo F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Lazarus, Hillard M.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
[Rowe, Jacob M.] Shaare Zedek Med Ctr, Jerusalem, Israel.
[Tallman, Martin S.; Abdel-Wahab, Omar; Patel, Jay P.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Paietta, Elisabeth M.] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Litzow, Mark] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505099
ER
PT J
AU Manier, S
Avet-Loiseau, H
Campigotto, F
Glavey, S
Salem, K
Huynh, D
Boswell, EN
Sacco, A
Mishima, Y
Moschetta, M
Reagan, MR
Kawano, Y
Anderson, KC
Roccaro, AM
Moreau, P
Facon, T
Leleu, X
Weller, EA
Ghobrial, IM
AF Manier, Salomon
Avet-Loiseau, Herve
Campigotto, Federico
Glavey, Siobhan
Salem, Karma
Huynh, Daisy
Boswell, Erica N.
Sacco, Antonio
Mishima, Yuji
Moschetta, Michele
Reagan, Michaela R.
Kawano, Yawara
Anderson, Kenneth C.
Roccaro, Aldo M.
Moreau, Philippe
Facon, Thierry
Leleu, Xavier
Weller, Edie A.
Ghobrial, Irene M.
TI Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with
Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Manier, Salomon; Campigotto, Federico; Glavey, Siobhan; Salem, Karma; Huynh, Daisy; Boswell, Erica N.; Sacco, Antonio; Mishima, Yuji; Moschetta, Michele; Reagan, Michaela R.; Kawano, Yawara; Anderson, Kenneth C.; Roccaro, Aldo M.; Weller, Edie A.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Avet-Loiseau, Herve] Univ Hosp Toulouse, Toulouse, France.
[Moreau, Philippe] Univ Hosp Nantes, Nantes, France.
[Facon, Thierry; Leleu, Xavier] CHRU Lille, Hop Claude Huriez, F-59037 Lille, France.
RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015; Reagan,
Michaela/E-3549-2017
OI FACON, THIERRY/0000-0001-7705-8460;
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501167
ER
PT J
AU Mantha, S
Goldman, D
Devlin, SM
Lee, JW
Zannino, D
Douer, D
Iland, HJ
Litzow, MR
Stein, EM
Appelbaum, F
Larson, RA
Rowe, JM
Tallman, MS
AF Mantha, Simon
Goldman, Debra
Devlin, Sean M.
Lee, Ju-Whei
Zannino, Diana
Douer, Dan
Iland, Harry J.
Litzow, Mark R.
Stein, Eytan M.
Appelbaum, Frederick
Larson, Richard A.
Rowe, Jacob M.
Tallman, Martin S.
TI Determinants of Fatal Bleeding during Induction Therapy for Acute
Promyelocytic Leukemia in the ATRA Era
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Mantha, Simon; Goldman, Debra; Devlin, Sean M.; Stein, Eytan M.; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Lee, Ju-Whei] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zannino, Diana] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Douer, Dan] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Iland, Harry J.] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia.
[Litzow, Mark R.] Mayo Clin, Rochester, MN USA.
[Appelbaum, Frederick] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA.
[Rowe, Jacob M.] Rambam Med Ctr, Haifa, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233800134
ER
PT J
AU Marcucci, G
Geyer, S
Zhao, WQ
Caroll, AJ
Bucci, D
Uy, GL
Blum, W
Pardee, T
Wetzler, M
Stock, W
Kolitz, JE
Eisfeld, AK
Bloomfield, CD
Stone, RM
Larson, RA
AF Marcucci, Guido
Geyer, Susan
Zhao, Weiqiang
Caroll, Andrew J.
Bucci, Donna
Uy, Geoffrey L.
Blum, William
Pardee, Timothy
Wetzler, Meir
Stock, Wendy
Kolitz, Jonathan E.
Eisfeld, Ann-Kathrin
Bloomfield, Clara D.
Stone, Richard M.
Larson, Richard A.
TI Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the
Negative Impact of KIT Mutation/over-Expression in Core Binding Factor
(CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Marcucci, Guido] Ohio State Univ, Columbus, OH 43210 USA.
[Geyer, Susan] Alliance Clin Trials Oncol Stat & Data Ctr, Rochester, MN USA.
[Zhao, Weiqiang; Bucci, Donna; Blum, William; Eisfeld, Ann-Kathrin; Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Caroll, Andrew J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Uy, Geoffrey L.] Washington Univ, Sch Med, St Louis, MO USA.
[Pardee, Timothy] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA.
[Wetzler, Meir] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Stock, Wendy] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Kolitz, Jonathan E.] Monter Canc Ctr, Lake Success, NY USA.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807159
ER
PT J
AU Marcucci, G
Geyer, S
Zhao, W
Caroll, AJ
Bucci, D
Uy, GL
Blum, W
Pardee, T
Wetzler, M
Stock, W
Kolitz, JE
Eisfeld, AK
Bloomfield, CD
Stone, RM
Larson, RA
AF Marcucci, Guido
Geyer, Susan
Zhao, Weiqiang
Caroll, Andrew J.
Bucci, Donna
Uy, Geoffrey L.
Blum, William
Pardee, Timothy
Wetzler, Meir
Stock, Wendy
Kolitz, Jonathan E.
Eisfeld, Ann-Kathrin
Bloomfield, Clara D.
Stone, Richard M.
Larson, Richard A.
TI Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the
Negative Impact of KIT Mutation/over-Expression in Core Binding Factor
(CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 ( Alliance)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Marcucci, Guido] Ohio State Univ, Columbus, OH 43210 USA.
[Geyer, Susan] Alliance Clin Trials Oncol Stat & Data Ctr, Rochester, MN USA.
[Zhao, Weiqiang; Bucci, Donna; Blum, William; Eisfeld, Ann-Kathrin; Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Caroll, Andrew J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Uy, Geoffrey L.] Washington Univ, Sch Med, St Louis, MO USA.
[Pardee, Timothy] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA.
[Wetzler, Meir] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Stock, Wendy] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Kolitz, Jonathan E.] Monter Canc Ctr, Lake Success, NY USA.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 1
Z9 1
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233802034
ER
PT J
AU Marshall, AL
Goodarzi, K
Kuter, DJ
AF Marshall, Ariela L.
Goodarzi, Katayoon
Kuter, David J.
TI Romiplostim in Management of the Thrombocytopenic Surgical Patient
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Marshall, Ariela L.; Goodarzi, Katayoon; Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Marshall, Ariela L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808141
ER
PT J
AU Mattano, LA
Devidas, M
Friedmann, AM
Raetz, EA
Loh, M
Buckley, P
Borowitz, MJ
Carroll, AJ
Gastier-Foster, J
Heerema, NA
Kadan-Lottick, N
Matloub, Y
Marshall, DT
Stork, LC
Wood, BL
Winick, NJ
Hunger, S
Carroll, WL
Maloney, K
AF Mattano, Leonard A.
Devidas, Meenakshi
Friedmann, Alison M.
Raetz, Elizabeth A.
Loh, Mignon
Buckley, Patrick
Borowitz, Michael J.
Carroll, Andrew J.
Gastier-Foster, Julie
Heerema, Nyla A.
Kadan-Lottick, Nina
Matloub, Yousif
Marshall, David T.
Stork, Linda C.
Wood, Brent L.
Winick, Naomi J.
Hunger, Stephen
Carroll, William L.
Maloney, Kelly
TI Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute
Lymphoblastic Leukemia (ALL) and No Benefit to Intensified
Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children's Oncology
Group (COG) Study AALL0331
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Mattano, Leonard A.] Bronson Methodist Hosp, Kalamazoo, MI USA.
[Devidas, Meenakshi] Univ Florida, Gainesville, FL USA.
[Friedmann, Alison M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Raetz, Elizabeth A.] Primary Childrens Med Ctr, Salt Lake City, UT USA.
[Loh, Mignon] Dept Pediat Hematol Oncol, San Francisco, CA USA.
[Buckley, Patrick] Duke Univ, Med Ctr, Durham, NC USA.
[Borowitz, Michael J.] Johns Hopkins Univ, Baltimore, MD USA.
[Carroll, Andrew J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Gastier-Foster, Julie] Nationwide Childrens Hosp, Columbus, OH USA.
[Heerema, Nyla A.] Ohio State Univ, Columbus, OH 43210 USA.
[Kadan-Lottick, Nina] Yale Univ, Sch Med, New Haven, CT USA.
[Matloub, Yousif] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA.
[Marshall, David T.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Stork, Linda C.] OR Hlth Sci Univ, Portland, OR USA.
[Wood, Brent L.] Seattle Canc Care Alliance, Seattle, WA USA.
[Winick, Naomi J.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Hunger, Stephen] Univ Colorado, Sch Med, Aurora, CO USA.
[Hunger, Stephen] Childrens Hosp, Aurora, CO USA.
[Carroll, William L.] NYU, Langone Med Ctr, New York, NY USA.
[Maloney, Kelly] Childrens Hosp Colorado, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505162
ER
PT J
AU Maxson, JE
Melissa, AL
Wang, JH
Deng, XM
Luty, SB
Sun, HH
Gorenstein, J
Middleton, R
Gray, NS
Druker, BJ
Tyner, JW
AF Maxson, Julia Elizabeth
Melissa, Abel L.
Wang, Jinhua
Deng, Xianming
Luty, Samuel B.
Sun, Huahang
Gorenstein, Julie
Middleton, Richard
Gray, Nathanael S.
Druker, Brian J.
Tyner, Jeffrey W.
TI Development and Repurposing of Small-Molecule Kinase Inhibitors to
Target Novel Leukemogenic TNK2 Mutations
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Maxson, Julia Elizabeth] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Maxson, Julia Elizabeth; Melissa, Abel L.; Luty, Samuel B.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Wang, Jinhua; Deng, Xianming; Sun, Huahang; Gorenstein, Julie; Middleton, Richard; Gray, Nathanael S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501148
ER
PT J
AU McEachern, KA
Tron, AE
O'Connor, G
DuPont, R
Gibbons, FD
Pablo, L
Vishwanathan, K
McCoon, P
Cortes, JE
DeAngelo, DJ
Minden, MD
Uy, GL
Neumann, F
Keating, K
Huszar, D
Pease, JE
Brown, J
Barrett, JC
AF McEachern, Kristen A.
Tron, Adriana E.
O'Connor, Greg
DuPont, Rachel
Gibbons, Francis D.
Pablo, Lourdes
Vishwanathan, Karthick
McCoon, Patricia
Cortes, Jorge E.
DeAngelo, Daniel J.
Minden, Mark D.
Uy, Geoffrey L.
Neumann, Frank
Keating, Karen
Huszar, Dennis
Pease, J. Elizabeth
Brown, Jeffrey
Barrett, J. Carl
TI Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By
AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency
for Bad and 4EBP1 Phosphorylation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [McEachern, Kristen A.; Tron, Adriana E.; O'Connor, Greg; DuPont, Rachel; Gibbons, Francis D.; Pablo, Lourdes; Vishwanathan, Karthick; McCoon, Patricia; Neumann, Frank; Keating, Karen; Huszar, Dennis; Pease, J. Elizabeth; Brown, Jeffrey; Barrett, J. Carl] AstraZeneca, Waltham, MA USA.
[Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Minden, Mark D.] Univ Hlth Network, Toronto, ON, Canada.
[Uy, Geoffrey L.] Washington Univ, Sch Med, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504005
ER
PT J
AU Melchardt, T
Hufnagl, C
Weigert, O
Weinstock, DM
Kopp, N
Weiss, L
Neureiter, D
Trankenschuh, W
Hackl, H
Greil, R
Egle, A
AF Melchardt, Thomas
Hufnagl, Clemens
Weigert, Oliver
Weinstock, David M.
Kopp, Nadja
Weiss, Lukas
Neureiter, Daniel
Traenkenschuh, Wolfgang
Hackl, Hubert
Greil, Richard
Egle, Alexander
TI Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Melchardt, Thomas; Hufnagl, Clemens; Neureiter, Daniel; Traenkenschuh, Wolfgang; Greil, Richard] Paracelsus Med Univ, Salzburg, Austria.
[Weigert, Oliver] Univ Hosp Grosshadern LMU, Dept Med 3, Munich, Germany.
[Weinstock, David M.; Kopp, Nadja] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Weiss, Lukas; Egle, Alexander] Paracelsus Med Univ, Dept Internal Med 3, Salzburg, Austria.
[Hackl, Hubert] Med Univ Innsbruck, A-6020 Innsbruck, Austria.
RI Greil, Richard/C-7673-2017
OI Greil, Richard/0000-0002-4462-3694
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500033
ER
PT J
AU Mercier, F
Shi, JT
Sykes, D
Kfoury, YS
Yusuf, RZ
Miller, E
Vasic, R
Zhu, A
Michor, F
Hide, W
Scadden, DT
AF Mercier, Francois
Shi, Jiantao
Sykes, David
Kfoury, Youmna Sami
Yusuf, Rushdia Z.
Miller, Elizabeth
Vasic, Radovan
Zhu, Alex
Michor, Franziska
Hide, Winston
Scadden, David T.
TI Identification of a Gene Expression Signature Characterizing Clonal
Fitness and Dominance in Vivo in a Murine Model of MLL-AF9 Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Mercier, Francois; Sykes, David; Kfoury, Youmna Sami; Yusuf, Rushdia Z.; Zhu, Alex; Scadden, David T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mercier, Francois; Hide, Winston; Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA USA.
[Shi, Jiantao] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Yusuf, Rushdia Z.; Scadden, David T.] Harvard Univ, Cambridge, MA 02138 USA.
[Miller, Elizabeth] Harvard Univ, Boston, MA 02115 USA.
[Vasic, Radovan] Yale Univ, New Haven, CT USA.
[Michor, Franziska] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hide, Winston] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806028
ER
PT J
AU Mishima, Y
Moschetta, M
Shi, JT
Mercier, F
Manier, S
Glavey, S
Reagan, MR
Kawano, Y
Munshi, NC
Anderson, KC
Roccaro, AM
Hide, W
Scadden, DT
Ghobrial, IM
AF Mishima, Yuji
Moschetta, Michele
Shi, Jiantao
Mercier, Francois
Manier, Salomon
Glavey, Siobhan
Reagan, Michaela R.
Kawano, Yawara
Munshi, Nikhil C.
Anderson, Kenneth C.
Roccaro, Aldo M.
Hide, Winston
Scadden, David T.
Ghobrial, Irene M.
TI Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple
Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Mishima, Yuji; Moschetta, Michele; Manier, Salomon; Glavey, Siobhan; Reagan, Michaela R.; Kawano, Yawara; Anderson, Kenneth C.; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mishima, Yuji] Japanese Fdn Canc Res, Tokyo, Japan.
[Shi, Jiantao] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Mercier, Francois] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Hide, Winston] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Scadden, David T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
RI Reagan, Michaela/E-3549-2017
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806156
ER
PT J
AU Moschetta, M
Mishima, Y
Kawano, Y
Aljawai, Y
Paiva, B
Palomera, L
Calcinotto, A
Christine, UL
Sahin, I
Sacco, A
Glavey, S
Reagan, MR
Manier, S
Bergsagel, PL
Chesi, M
Bellone, M
Roccaro, AM
Ghobrial, IM
AF Moschetta, Michele
Mishima, Yuji
Kawano, Yawara
Aljawai, Yosra
Paiva, Bruno
Palomera, Luis
Calcinotto, Arianna
Christine, Unitt L.
Sahin, Ilyas
Sacco, Antonio
Glavey, Siobhan
Reagan, Michaela R.
Manier, Salomon
Bergsagel, Peter Leif
Chesi, Marta
Bellone, Matteo
Roccaro, Aldo M.
Ghobrial, Irene M.
TI Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells
Promotes Multiple Myeloma Progression
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Moschetta, Michele; Mishima, Yuji; Kawano, Yawara; Aljawai, Yosra; Sahin, Ilyas; Sacco, Antonio; Glavey, Siobhan; Reagan, Michaela R.; Manier, Salomon; Roccaro, Aldo M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Paiva, Bruno] Univ Navarra Clin, Pamplona, Spain.
[Palomera, Luis] Hosp Univ Lozano Bielsa, Zaragoza, Spain.
[Calcinotto, Arianna; Bellone, Matteo] Ist Sci San Raffaele, Milan, Italy.
[Christine, Unitt L.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
[Bergsagel, Peter Leif] Mayo Clin, Scottsdale, AZ USA.
[Chesi, Marta] Mayo Clin Scottsdale, Scottsdale, AZ USA.
[Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
RI Reagan, Michaela/E-3549-2017
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806167
ER
PT J
AU Moskowitz, CH
Ribrag, V
Michot, JM
Martinelli, G
Zinzani, PL
Gutierrez, M
De Maeyer, G
Jacob, AG
Giallella, K
Anderson, JW
Derosier, M
Wang, J
Yang, ZJ
Rubin, E
Rose, S
Shipp, MA
Armand, P
AF Moskowitz, Craig H.
Ribrag, Vincent
Michot, Jean-Marie
Martinelli, Giovanni
Zinzani, Pier Luigi
Gutierrez, Martin
De Maeyer, Guadalupe
Jacob, Alexandra G.
Giallella, Karen
Anderson, Jennifer Weimer
Derosier, Martha
Wang, Joy
Yang, Zijiang
Rubin, Eric
Rose, Shelonitda
Shipp, Margaret A.
Armand, Philippe
TI PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in
Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin
Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Moskowitz, Craig H.; Jacob, Alexandra G.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Ribrag, Vincent] Inst Gustave Roussy, Villejuif, France.
[Michot, Jean-Marie] Gustave Roussy Canc Ctr, Villejuif, France.
[Martinelli, Giovanni] Univ Bologna, Sch Med, Bologna, Italy.
[Zinzani, Pier Luigi] Inst Hematol & Med Oncol, Bologna, Italy.
[Gutierrez, Martin] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[De Maeyer, Guadalupe; Shipp, Margaret A.; Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Giallella, Karen; Anderson, Jennifer Weimer; Derosier, Martha; Rose, Shelonitda] Merck & Co Inc, Rahway, NJ 07065 USA.
[Wang, Joy] Accenture, Philadelphia, PA USA.
[Yang, Zijiang; Rubin, Eric] Merck & Co Inc, N Wales, PA USA.
RI Zinzani, Pier Luigi/J-9182-2016
OI Zinzani, Pier Luigi/0000-0002-2112-2651
NR 0
TC 6
Z9 8
U1 2
U2 14
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808074
ER
PT J
AU Murase, K
Kim, HT
Hirakawa, M
Matos, TR
Kawano, Y
Ryan, J
Matsuoka, KI
Koreth, J
Soiffer, RJ
Letai, AG
Kato, J
Ritz, J
AF Murase, Kazuyuki
Kim, Haesook T.
Hirakawa, Masahiro
Matos, Tiago Reis
Kawano, Yutaka
Ryan, Jeremy
Matsuoka, Ken-Ichi
Koreth, John
Soiffer, Robert J.
Letai, Anthony G.
Kato, Junji
Ritz, Jerome
TI Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2
Expression in CD4 Memory Regulatory T Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Murase, Kazuyuki; Kim, Haesook T.; Hirakawa, Masahiro; Matos, Tiago Reis; Ryan, Jeremy; Letai, Anthony G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Murase, Kazuyuki; Kawano, Yutaka; Kato, Junji] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan.
[Matsuoka, Ken-Ichi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008530, Japan.
[Koreth, John; Soiffer, Robert J.; Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806055
ER
PT J
AU Natoni, A
Moschetta, M
Glavey, S
Wu, P
Morgan, GJ
Joshi, L
Magnani, JL
Ghobrial, IM
O'Dwyer, ME
AF Natoni, Alessandro
Moschetta, Michele
Glavey, Siobhan
Wu, Ping
Morgan, Gareth J.
Joshi, Lokesh
Magnani, John L.
Ghobrial, Irene M.
O'Dwyer, Michael E.
TI Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can
be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of
Survival in a Murine Transplant Model
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Natoni, Alessandro; Glavey, Siobhan; Joshi, Lokesh; O'Dwyer, Michael E.] Natl Univ Ireland Galway, Galway, Ireland.
[Moschetta, Michele; Glavey, Siobhan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wu, Ping] Inst Canc Res, London SW3 6JB, England.
[Morgan, Gareth J.] Royal Marsden Hosp, London SW3 6JJ, England.
[Magnani, John L.] GlycoMimetics Inc, Gaithersburg, MD USA.
[Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504045
ER
PT J
AU Nazha, A
Komrokji, RS
Garcia-Manero, G
Barnard, J
Zimmerman, C
Najla, AA
Roboz, GJ
Steensma, DP
DeZern, AE
Jabbour, E
Lee, S
Greenberg, MD
List, AF
Kantarjian, HM
Maciejewski, JP
Sekeres, MA
AF Nazha, Aziz
Komrokji, Rami S.
Garcia-Manero, Guillermo
Barnard, John
Zimmerman, Cassie
Najla, Al Ali
Roboz, Gail J.
Steensma, David P.
DeZern, Amy E.
Jabbour, Elias
Lee, Sangmin
Greenberg, Molly D.
List, Alan F.
Kantarjian, Hagop M.
Maciejewski, Jaroslaw P.
Sekeres, Mikkael A.
TI The Efficacy of Current Prognostic Models in Predicting Outcome of
Patients with Myelodysplastic Syndromes (MDS) at the Time of
Hypomethylating Agent Failure
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Nazha, Aziz; Barnard, John; Zimmerman, Cassie; Maciejewski, Jaroslaw P.; Sekeres, Mikkael A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Garcia-Manero, Guillermo; Jabbour, Elias; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Najla, Al Ali; List, Alan F.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Roboz, Gail J.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Steensma, David P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[DeZern, Amy E.] Johns Hopkins Univ, Baltimore, MD USA.
[Lee, Sangmin] Weill Cornell New York Presbyterian Hosp, New York, NY USA.
[Greenberg, Molly D.] Weill Cornell Med Coll, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501114
ER
PT J
AU Nazha, A
Sekeres, MA
Garcia-Manero, G
Barnard, J
Al Ali, NH
Roboz, GJ
Steensma, DP
DeZern, AE
Zimmerman, C
Jabbour, E
Greenberg, MD
Lee, S
List, AF
Kantarjian, HM
Maciejewski, JP
Komrokji, RS
AF Nazha, Aziz
Sekeres, Mikkael A.
Garcia-Manero, Guillermo
Barnard, John
Al Ali, Najla H.
Roboz, Gail J.
Steensma, David P.
DeZern, Amy E.
Zimmerman, Cassie
Jabbour, Elias
Greenberg, Molly D.
Lee, Sangmin
List, Alan F.
Kantarjian, Hagop M.
Maciejewski, Jaroslaw P.
Komrokji, Rami S.
TI Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve
Stable Disease after Treatment with Hypomethylating Agents (HMA)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Nazha, Aziz; Sekeres, Mikkael A.; Barnard, John; Zimmerman, Cassie; Maciejewski, Jaroslaw P.] Cleveland Clin, Cleveland, OH 44106 USA.
[Garcia-Manero, Guillermo; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Al Ali, Najla H.; List, Alan F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Roboz, Gail J.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Steensma, David P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[DeZern, Amy E.] Johns Hopkins Univ, Baltimore, MD USA.
[Greenberg, Molly D.] Weill Cornell Med Coll, New York, NY USA.
[Lee, Sangmin] Weill Cornell New York Presbyterian Hosp, New York, NY USA.
[Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804071
ER
PT J
AU Nonami, A
Zhao, C
Liu, QS
Cowens, K
Christie, AL
Chen, YF
Sattler, M
Wang, KK
Gray, NS
Griffin, JD
Weisberg, EL
AF Nonami, Atsushi
Zhao, Chen
Liu Qingsong
Cowens, Kristen
Christie, Amanda L.
Chen, Yongfei
Sattler, Martin
Wang, Kwok-Kin
Gray, Nathanael S.
Griffin, James D.
Weisberg, Ellen L.
TI Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for
Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Nonami, Atsushi; Zhao, Chen; Cowens, Kristen; Christie, Amanda L.; Sattler, Martin; Wang, Kwok-Kin; Gray, Nathanael S.; Griffin, James D.; Weisberg, Ellen L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Liu Qingsong; Chen, Yongfei] Chinese Acad Sci, Hefei, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808081
ER
PT J
AU O'Brien, S
Jones, JA
Coutre, S
Mato, AR
Hillmen, P
Tam, C
Osterborg, A
Siddiqi, T
Thirman, MJ
Furman, RR
Ilhan, O
Keating, M
Call, TG
Brown, JR
Stevens-Brogan, M
Li, YF
Fardis, M
Clow, F
James, DF
Chu, AD
Hallek, M
Stilgenbauer, S
AF O'Brien, Susan
Jones, Jeffrey A.
Coutre, Steven
Mato, Anthony R.
Hillmen, Peter
Tam, Constantine
Osterborg, Anders
Siddiqi, Tanya
Thirman, Michael J.
Furman, Richard R.
Ilhan, Osman
Keating, Michael
Call, Timothy G.
Brown, Jennifer R.
Stevens-Brogan, Michelle
Li, Yunfeng
Fardis, Maria
Clow, Fong
James, Danelle F.
Chu, Alvina D.
Hallek, Michael
Stilgenbauer, Stephan
TI Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory
Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p
Deletion: Results from the Phase II RESONATE (TM)-17 Trial
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [O'Brien, Susan; Keating, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Jones, Jeffrey A.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Coutre, Steven] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Mato, Anthony R.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Hillmen, Peter] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
[Tam, Constantine] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Tam, Constantine] St Vincents Hosp, Melbourne, Vic, Australia.
[Osterborg, Anders] Karolinska Univ Hosp, Solna, Sweden.
[Siddiqi, Tanya] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Thirman, Michael J.] Univ Chicago Med, Chicago, IL USA.
[Furman, Richard R.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Ilhan, Osman] Ankara Univ, Fac Med, TR-06100 Ankara, Turkey.
[Call, Timothy G.] Mayo Clin, Rochester, MN USA.
[Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Stevens-Brogan, Michelle; Li, Yunfeng; Fardis, Maria; Clow, Fong; James, Danelle F.; Chu, Alvina D.] Pharmacyclics Inc, Sunnyvale, CA USA.
[Hallek, Michael] Univ Cologne, D-50931 Cologne, Germany.
[Stilgenbauer, Stephan] Univ Ulm, D-89069 Ulm, Germany.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805131
ER
PT J
AU O'Donnell, E
Laubach, JP
Yee, AJ
Huff, CA
Basile, F
Wade, PM
Paba-Prada, CE
Ghobrial, IM
Schlossman, RL
Couture, N
Doherty, L
Lyons, H
English, C
Munshi, N
Anderson, KC
Richardson, PG
Raje, N
AF O'Donnell, Elizabeth
Laubach, Jacob P.
Yee, Andrew J.
Huff, Carol Ann
Basile, Frank
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Couture, Nicole
Doherty, Lauren
Lyons, Hannah
English, Caroline
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur
TI A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone
(RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed
Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [O'Donnell, Elizabeth; Couture, Nicole; Doherty, Lauren; Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Laubach, Jacob P.; Schlossman, Robert L.; Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yee, Andrew J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
[Huff, Carol Ann; English, Caroline] Johns Hopkins Univ, Baltimore, MD USA.
[Basile, Frank] Cape Cod Healthcare, Hyannis, MA USA.
[Wade, Philip M.] Cape Cod Hosp, Hyannis, MA USA.
[Paba-Prada, Claudia E.; Munshi, Nikhil; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Schlossman, Robert L.] Harvard Univ, Boston, MA 02115 USA.
[Lyons, Hannah] North Shore Med Ctr, Danvers, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500085
ER
PT J
AU Odejide, OO
Cronin, AM
LaCasce, A
Abel, GA
AF Odejide, Oreofe O.
Cronin, Angel M.
LaCasce, Ann
Abel, Gregory A.
TI Predictors of Hospice Utilization Among Patients with Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Odejide, Oreofe O.; Cronin, Angel M.; LaCasce, Ann; Abel, Gregory A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233800069
ER
PT J
AU Ostro, J
Kopolovic, I
Lin, YL
Dzik, WH
Cserti, C
Tsubota, H
Keir, A
Messner, HA
DenHollander, N
Callum, J
AF Ostro, Jackie
Kopolovic, Ilana
Lin, Yulia
Dzik, Walter H.
Cserti, Christine
Tsubota, Hideki
Keir, Amy
Messner, Hans A.
DenHollander, Neal
Callum, Jeannie
TI Systematic Review of Cases of Transfusion Associated
Graft-Versus-Host-Disease (TA-GVHD): Analysis of Patient Characteristics
and Outcomes
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ostro, Jackie; Kopolovic, Ilana] Univ Toronto, Toronto, ON, Canada.
[Lin, Yulia; Tsubota, Hideki; Callum, Jeannie] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
[Dzik, Walter H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cserti, Christine; DenHollander, Neal] Univ Hlth Network, Toronto, ON, Canada.
[Keir, Amy] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Messner, Hans A.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806107
ER
PT J
AU Ott, CJ
Lu, G
Reyes, J
Lin, CY
Kaelin, WG
Bradner, JE
AF Ott, Christopher J.
Lu, Gang
Reyes, Jaime
Lin, Charles Y.
Kaelin, William G.
Bradner, James E.
TI Disruption of the Ikaros-Mediated Gene Expression Program in Multiple
Myeloma with Immunomodulatory Agents
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ott, Christopher J.; Lu, Gang; Reyes, Jaime; Lin, Charles Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kaelin, William G.; Bradner, James E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806074
ER
PT J
AU Paba-Prada, C
Palumbo, A
Mellqvist, UH
Voorhees, PM
Plesner, T
Sonneveld, P
Byrne, C
Harmenberg, J
Nordstrom, E
Richardson, PG
AF Paba-Prada, Claudia
Palumbo, Antonio
Mellqvist, Ulf-Henrik
Voorhees, Peter M.
Plesner, Torben
Sonneveld, Pieter
Byrne, Catriona
Harmenberg, Johan
Nordstrom, Eva
Richardson, Paul G.
TI Determination of the MTD and Encouraging Results in an Ongoing
Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and
Dexamethasone in Combination for Patients with Relapsed and
Relapsed-Refractory Multiple Myeloma (RRMM)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Paba-Prada, Claudia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Palumbo, Antonio] AOU San Giovanni Battista, Turin, Italy.
[Mellqvist, Ulf-Henrik] Sahlgrens Univ Hosp, Gothenburg, Sweden.
[Voorhees, Peter M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Plesner, Torben] Vejle Hosp, Vejle, Denmark.
[Sonneveld, Pieter] Erasmus MC, Dept Hematol, Rotterdam, Netherlands.
[Byrne, Catriona; Harmenberg, Johan; Nordstrom, Eva] Oncopeptides AB, Stockholm, Sweden.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 2
Z9 2
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503128
ER
PT J
AU Pal, J
Shammas, M
Kumar, S
Gkotzamanidou, M
Nanjappa, P
Buon, L
Munshi, NC
AF Pal, Jagannath
Shammas, Masood
Kumar, Subodh
Gkotzamanidou, Maria
Nanjappa, Puru
Buon, Leutz
Munshi, Nikhil C.
TI Telomerase-Mediated Repair of Induced DNA Breaks Leads to Increased
Genomic Instability in Multiple Myeloma Cells: Possible Mechanism and
Translational Significance
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Pal, Jagannath; Shammas, Masood; Kumar, Subodh; Nanjappa, Puru; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Pal, Jagannath; Shammas, Masood; Kumar, Subodh; Nanjappa, Puru; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Buon, Leutz] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503029
ER
PT J
AU Park, JH
Chung, SS
Chung, YR
Won, H
Kim, E
Saven, A
Wadleigh, M
Stone, RM
Barrientos, JC
Rai, KR
Grever, MR
Altman, JK
Lacouture, ME
Rosen, N
Berger, M
Levine, RL
Abdel-Wahab, O
Tallman, MS
AF Park, Jae H.
Chung, Stephen S.
Chung, Young Rock
Won, Helen
Kim, Eunhee
Saven, Alan
Wadleigh, Martha
Stone, Richard M.
Barrientos, Jacqueline C.
Rai, Kanti R.
Grever, Michael R.
Altman, Jessica K.
Lacouture, Mario E.
Rosen, Neal
Berger, Michael
Levine, Ross L.
Abdel-Wahab, Omar
Tallman, Martin S.
TI Vemurafenib Has Potent Antitumor Activity in Patients with
Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Park, Jae H.; Chung, Stephen S.; Chung, Young Rock; Won, Helen; Kim, Eunhee; Lacouture, Mario E.; Rosen, Neal; Berger, Michael; Levine, Ross L.; Abdel-Wahab, Omar; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Saven, Alan] Scripps Hlth, La Jolla, CA USA.
[Wadleigh, Martha; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Barrientos, Jacqueline C.] North Shore LIJ Canc Inst, Lake Success, NY USA.
[Rai, Kanti R.] Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA.
[Grever, Michael R.] Ohio State Univ, Columbus, OH 43210 USA.
[Altman, Jessica K.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803022
ER
PT J
AU Prabhala, RH
Hideshima, T
Fulciniti, M
Adamia, S
Bandi, RL
Nanjappa, P
Anderson, KC
Munshi, NC
AF Prabhala, Rao H.
Hideshima, Teru
Fulciniti, Mariateresa
Adamia, Sophia
Bandi, Rajya Lakshmi
Nanjappa, Puru
Anderson, Kenneth C.
Munshi, Nikhil C.
TI IL-17A-Mediated Notch Signaling in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Prabhala, Rao H.; Anderson, Kenneth C.; Munshi, Nikhil C.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Prabhala, Rao H.; Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA.
[Prabhala, Rao H.; Hideshima, Teru; Fulciniti, Mariateresa; Adamia, Sophia; Bandi, Rajya Lakshmi; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Nanjappa, Puru] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806036
ER
PT J
AU Praditsuktavorn, P
Pera, B
Kwiatkowski, N
Yang, SN
Zhang, TH
Gray, N
Cerchietti, L
AF Praditsuktavorn, Pannee
Pera, Benet
Kwiatkowski, Nicholas
Yang, ShaoNing
Zhang, Tinghu
Gray, Nathanael
Cerchietti, Leandro
TI Transcription Regulation Targeting in Peripheral T Cell Lymphomas
Induces Apoptosis and Sensitization to BCL2 Inhibitors
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Praditsuktavorn, Pannee; Pera, Benet; Yang, ShaoNing; Zhang, Tinghu; Gray, Nathanael; Cerchietti, Leandro] Weill Cornell Med Coll, New York, NY USA.
[Kwiatkowski, Nicholas] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805022
ER
PT J
AU Pyzer, AR
Stroopinsky, D
Rosenblatt, J
Palmer, KA
Coll, MD
Bar-Natan, M
Rajabi, H
Somaiya, P
Luptakova, K
Jain, S
McMasters, M
Levine, JD
Arnason, J
Kufe, D
Avigan, D
AF Pyzer, Athalia Rachel
Stroopinsky, Dina
Rosenblatt, Jacalyn
Palmer, Kristen Anna
Coll, Maxwell Douglas
Bar-Natan, Michal
Rajabi, Hasan
Somaiya, Poorvi
Luptakova, Katarina
Jain, Salvia
McMasters, Malgorzata
Levine, James D.
Arnason, Jon
Kufe, Donald
Avigan, David
TI Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and
Are Dependent on MUC1 Expression
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Pyzer, Athalia Rachel; Stroopinsky, Dina; Rosenblatt, Jacalyn; Palmer, Kristen Anna; Coll, Maxwell Douglas; Bar-Natan, Michal; Somaiya, Poorvi; Luptakova, Katarina; Jain, Salvia; McMasters, Malgorzata; Levine, James D.; Arnason, Jon; Avigan, David] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Rajabi, Hasan; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804105
ER
PT J
AU Rajabi, H
Coll, MD
Rosenblatt, J
Yin, L
Stroopinsky, D
Luptakova, K
Vasir, B
Pyzer, AR
Palmer, K
Bar-Natan, M
Jain, S
Somaiya, P
Arnason, J
Kufe, D
Avigan, D
AF Rajabi, Hasan
Coll, Maxwell Douglas
Rosenblatt, Jacalyn
Yin, Li
Stroopinsky, Dina
Luptakova, Katarina
Vasir, Baldev
Pyzer, Athalia Rachel
Palmer, Kristen
Bar-Natan, Michal
Jain, Salvia
Somaiya, Poorvi
Arnason, Jon
Kufe, Donald
Avigan, David
TI Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1
Responses By Down Regulating the Expression of Mir-200c and
up-Regulating the PDL1 Expression
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Rajabi, Hasan; Yin, Li; Vasir, Baldev; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Coll, Maxwell Douglas; Rosenblatt, Jacalyn; Luptakova, Katarina; Pyzer, Athalia Rachel; Palmer, Kristen; Jain, Salvia; Somaiya, Poorvi; Arnason, Jon; Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Stroopinsky, Dina] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Bar-Natan, Michal] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506100
ER
PT J
AU Ray, A
Das, DS
Ravillah, D
Song, Y
Macri, V
Brooks, C
Rowinsky, E
Richardson, PG
Chauhan, D
Anderson, KC
AF Ray, Arghya
Das, Deepika Sharma
Ravillah, Durgadevi
Song, Yan
Macri, Vincent
Brooks, Christopher
Rowinsky, Eric
Richardson, Paul G.
Chauhan, Dharminder
Anderson, Kenneth C.
TI SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor
(IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell
Growth and Prevents Osteoclastogenesis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ray, Arghya; Das, Deepika Sharma; Ravillah, Durgadevi; Song, Yan; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Ray, Arghya; Das, Deepika Sharma; Ravillah, Durgadevi; Song, Yan; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Macri, Vincent; Brooks, Christopher; Rowinsky, Eric] Stemline Therapeut Inc, New York, NY USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503129
ER
PT J
AU Ray, A
Ravillah, D
Das, DS
Song, Y
Nordstrom, E
Lindberg, J
Richardson, PG
Chauhan, D
Anderson, KC
AF Ray, Arghya
Ravillah, Durgadevi
Das, Deepika Sharma
Song, Yan
Nordstrom, Eva
Lindberg, Jakob
Richardson, Paul G.
Chauhan, Dharminder
Anderson, Kenneth C.
TI A Novel Alkylating Agent Melphalan Flufenamide Ethyl Ester Induces an
Irreversible DNA Damage in Multiple Myeloma Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ray, Arghya; Ravillah, Durgadevi; Das, Deepika Sharma; Song, Yan; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Ray, Arghya; Ravillah, Durgadevi; Das, Deepika Sharma; Song, Yan; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Nordstrom, Eva; Lindberg, Jakob] Oncopeptides AB, Stockholm, Sweden.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807064
ER
PT J
AU Richardson, PG
Jagannath, S
Moreau, P
Jakubowiak, A
Raab, MS
Facon, T
Vij, R
White, D
Reece, DE
Benboubker, L
Zonder, J
Tsao, LC
Anderson, KC
Bleickardt, E
Singhal, AK
Lonial, S
AF Richardson, Paul G.
Jagannath, Sundar
Moreau, Philippe
Jakubowiak, Andrzej
Raab, Marc S.
Facon, Thierry
Vij, Ravi
White, Darrell
Reece, Donna E.
Benboubker, Lotfi
Zonder, Jeffrey
Tsao, L. Claire
Anderson, Kenneth C.
Bleickardt, Eric
Singhal, Anil K.
Lonial, Sagar
TI Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination
with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory
Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Richardson, Paul G.; Jagannath, Sundar; Jakubowiak, Andrzej; Vij, Ravi; Zonder, Jeffrey; Anderson, Kenneth C.; Lonial, Sagar] Multiple Myeloma Res Consortium, Norwalk, CT USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Moreau, Philippe] Univ Hosp Nantes, Nantes, France.
[Jakubowiak, Andrzej] Univ Chicago Med, Chicago, IL USA.
[Raab, Marc S.] Univ Klinikum Heidelberg, Heidelberg, Germany.
[Facon, Thierry] Hosp Claude Huriez, Lille, France.
[Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA.
[White, Darrell] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
[Reece, Donna E.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
[Benboubker, Lotfi] CHU Tours Hop Bretonneau, Tours, France.
[Zonder, Jeffrey] Karmanos Canc Inst, Detroit, MI USA.
[Tsao, L. Claire; Singhal, Anil K.] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bleickardt, Eric] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
[Lonial, Sagar] Emory Univ, Sch Med, Atlanta, GA USA.
RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015
OI FACON, THIERRY/0000-0001-7705-8460;
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505133
ER
PT J
AU Richardson, PG
Kernan, NA
Grupp, SA
Martin, PL
Soiffer, RJ
Martin, R
Hannah, AL
Villa, KF
AF Richardson, Paul G.
Kernan, Nancy A.
Grupp, Stephan A.
Martin, Paul L.
Soiffer, Robert J.
Martin, Richard
Hannah, Alison L.
Villa, Kathleen F.
TI Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease:
An Analysis of Clinical Benefit As Determined By Number Needed to Treat
(NNT) to Achieve Complete Response and to Improve Survival
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Martin, Paul L.] Duke Univ, Med Ctr, Durham, NC USA.
[Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Martin, Richard] EUSA Pharma, Oxford, England.
[Hannah, Alison L.; Villa, Kathleen F.] Jazz Pharmaceut Inc, Palo Alto, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504189
ER
PT J
AU Richardson, PG
Hungria, VTM
Yoon, SS
Beksac, M
Dimopoulos, MA
Elghandour, A
Jedrzejczak, WW
Guenther, A
Nakorn, TN
Siritanaratkul, N
Schlossman, RL
Hou, J
Moreau, P
Lonial, S
Lee, JH
Einsele, H
Salwender, H
Sopala, M
Panneerselvam, A
Redhu, S
Corrado, C
Binlich, F
San Miguel, JF
AF Richardson, Paul G.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw Wiktor
Guenther, Andreas
Thanyaphong Na Nakorn
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae Hoon
Einsele, Hermann
Salwender, Hans
Sopala, Monika
Panneerselvam, Ashok
Redhu, Suman
Corrado, Claudia
Binlich, Florence
San Miguel, Jesus F.
TI Characterization of the Incidence and Management of Gastrointestinal
Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib
and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in
Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Richardson, Paul G.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.; Schlossman, Robert L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Hungria, Vania T. M.] Fac Ciencias Med Santa Casa Miserordia Sao Paulo, Disciplina Hematol & Oncol, Sao Paulo, Brazil.
[Yoon, Sung-Soo] Seoul Natl Univ, Coll Med, Seoul, South Korea.
[Beksac, Meral] Ankara Univ, Sch Med, TR-06100 Ankara, Turkey.
[Dimopoulos, Meletios A.] Univ Athens, Sch Med, GR-11527 Athens, Greece.
[Elghandour, Ashraf] Univ Alexandria, Alexandria, Egypt.
[Jedrzejczak, Wieslaw Wiktor] Med Univ Warsaw, Warsaw, Poland.
[Guenther, Andreas] Univ Hosp Kiel, Kiel, Germany.
[Thanyaphong Na Nakorn] King Chulalongkorn Mem Hosp, Bangkok, Thailand.
[Thanyaphong Na Nakorn] Chulalongkorn Univ, Bangkok, Thailand.
[Siritanaratkul, Noppadol] Mahidol Univ, Siriraj Hosp, Bangkok 10700, Thailand.
[Hou, Jian] Shanghai Changzheng Hosp, Shanghai, Peoples R China.
[Moreau, Philippe] CHU Nantes, F-44035 Nantes 01, France.
[Lonial, Sagar] Emory Univ, Sch Med, Atlanta, GA USA.
[Lee, Jae Hoon] Gachon Univ, Gil Med Ctr, Inchon, South Korea.
[Einsele, Hermann] Univ Klinikum, Med Klin 2, Wurzburg, Germany.
[Salwender, Hans] Asklepios Klin Altona, Hamburg, Germany.
[Sopala, Monika; Corrado, Claudia] Novartis Pharma AG, Basel, Switzerland.
[Panneerselvam, Ashok; Redhu, Suman] Novartis Pharmaceut, E Hanover, NJ USA.
[Binlich, Florence] Novartis Pharma SAS, Rueil Malmaison, France.
[San Miguel, Jesus F.] Univ Navarra Clin, Pamplona, Spain.
RI richard, chrystelle/K-8595-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501188
ER
PT J
AU Richardson, PG
Smith, AR
Triplett, BM
Kernan, NA
Grupp, SA
Arai, S
Antin, JH
Lehmann, LE
Bandiera, V
Hume, RL
Hannah, AL
Nejadnik, B
Soiffer, RJ
AF Richardson, Paul G.
Smith, Angela R.
Triplett, Brandon M.
Kernan, Nancy A.
Grupp, Stephan A.
Arai, Sally
Antin, Joseph H.
Lehmann, Leslie E.
Bandiera, Valeria
Hume, Robin L.
Hannah, Alison L.
Nejadnik, Bijan
Soiffer, Robert J.
CA Defibrotide Study Grp
TI Updated Results from a Large, Ongoing, Treatment IND Study Using
Defibrotide for Patients with Hepatic Veno-Occlusive Disease
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Richardson, Paul G.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Smith, Angela R.] Univ Minnesota, Minneapolis, MN USA.
[Triplett, Brandon M.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
[Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Arai, Sally] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Antin, Joseph H.; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lehmann, Leslie E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bandiera, Valeria; Defibrotide Study Grp] Gentium SpA, Villa Guardia, Italy.
[Hume, Robin L.; Hannah, Alison L.; Nejadnik, Bijan] Jazz Pharmaceut Inc, Palo Alto, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804028
ER
PT J
AU Richardson, PG
Lee, JH
Majer, I
Krishna, A
Woodman, RC
AF Richardson, Paul G.
Lee, Jae Hoon
Majer, Istvan
Krishna, Arun
Woodman, Richard C.
TI Efficacy of Treatments in Relapsed or Relapsed and Refractory Multiple
Myeloma: An Indirect Treatment Comparison
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Richardson, Paul G.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Lee, Jae Hoon] Gachon Univ, Gil Med Ctr, Inchon, South Korea.
[Majer, Istvan] Pharmerit, Rotterdam, Netherlands.
[Krishna, Arun; Woodman, Richard C.] Novartis Pharmaceut, E Hanover, NJ USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233800165
ER
PT J
AU Roberts, AW
Ma, S
Brander, DM
Kipps, TJ
Barrientos, JC
Davids, MS
Anderson, MA
Tam, C
Mason-Bright, T
Rudersdorf, NK
Gressick, L
Yang, JN
Munasinghe, W
Zhu, M
Cerri, E
Enschede, SH
Humerickhouse, RA
Seymour, JF
AF Roberts, Andrew W.
Ma, Shuo
Brander, Danielle M.
Kipps, Thomas J.
Barrientos, Jacqueline C.
Davids, Matthew S.
Anderson, Mary Ann
Tam, Constantine
Mason-Bright, Tanita
Rudersdorf, Nikita K.
Gressick, Lori
Yang, Jianning
Munasinghe, Wijith
Zhu, Ming
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Seymour, John F.
TI Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined
with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic
Lymphocytic Leukemia (CLL)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Roberts, Andrew W.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.
[Roberts, Andrew W.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
[Ma, Shuo] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Brander, Danielle M.] Duke Univ, Med Ctr, Durham, NC USA.
[Kipps, Thomas J.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Barrientos, Jacqueline C.] Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA.
[Davids, Matthew S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Anderson, Mary Ann] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
[Tam, Constantine; Seymour, John F.] Peter MacCallum Canc Ctr, East Melbourne, Australia.
[Mason-Bright, Tanita; Rudersdorf, Nikita K.; Gressick, Lori; Yang, Jianning; Munasinghe, Wijith; Zhu, Ming; Cerri, Elisa; Enschede, Sari H.; Humerickhouse, Rod A.] AbbVie Inc, N Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503159
ER
PT J
AU Roberts, DA
Wadleigh, M
McDonnell, A
DeAngelo, DJ
Stone, RM
Steensma, DP
AF Roberts, Daniel A.
Wadleigh, Martha
McDonnell, Anne
DeAngelo, Daniel J.
Stone, Richard M.
Steensma, David P.
TI Low Efficacy and High Mortality Associated with Clofarabine Treatment of
Patients with Acute Myeloid Leukemia and Higher-Risk Myelodysplastic
Syndromes
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Roberts, Daniel A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Wadleigh, Martha; DeAngelo, Daniel J.; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McDonnell, Anne; Steensma, David P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500061
ER
PT J
AU Roccaro, AM
Sacco, A
Moschetta, M
Mishima, Y
Maiso, P
Huynh, D
Chiarini, M
Cardarelli, PM
Cohen, L
Kuhne, M
Ghobrial, IM
AF Roccaro, Aldo M.
Sacco, Antonio
Moschetta, Michele
Mishima, Yuji
Maiso, Patricia
Huynh, Daisy
Chiarini, Marco
Cardarelli, Pina M.
Cohen, Lewis
Kuhne, Michelle
Ghobrial, Irene M.
TI Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone
Dissemination
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Roccaro, Aldo M.; Sacco, Antonio; Moschetta, Michele; Mishima, Yuji; Maiso, Patricia; Huynh, Daisy; Chiarini, Marco] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chiarini, Marco] Spedali Civil Brescia, I-25125 Brescia, Italy.
[Cardarelli, Pina M.; Kuhne, Michelle] Bristol Myers Squibb Co, Sunnyvale, CA USA.
[Cohen, Lewis] Bristol Myers Squibb Co, Lawrenceville, NJ USA.
[Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807119
ER
PT J
AU Rowe, RG
Wang, LD
Coma, S
Ross, S
Nguyen, P
Pearson, D
Wagers, AJ
Daley, GQ
AF Rowe, Robert G.
Wang, Leo D.
Coma, Silvia
Ross, Samantha
Nguyen, Phi
Pearson, Daniel
Wagers, Amy J.
Daley, George Q.
TI Inhibition of Let-7 Maturation By Lin28b Controls Timing of Embryonic
and Adult Myeloid Progenitor Phenotypes during Development
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Rowe, Robert G.; Wang, Leo D.; Daley, George Q.] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA.
[Wang, Leo D.; Nguyen, Phi] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Coma, Silvia; Ross, Samantha] Childrens Hosp Boston, Boston, MA USA.
[Coma, Silvia; Wagers, Amy J.; Daley, George Q.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Coma, Silvia; Pearson, Daniel; Daley, George Q.] Harvard Univ, Sch Med, Boston, MA USA.
[Wagers, Amy J.] Joslin Diabet Ctr, Harvard Stem Cell Inst, Boston, MA 02215 USA.
[Wagers, Amy J.] Harvard Univ, Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Daley, George Q.] Manton Ctr Orphan Dis Res, Boston, MA USA.
[Daley, George Q.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Daley, George Q.] Harvard Stem Cell Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500227
ER
PT J
AU Samur, MK
Rashid, N
Cleynen, A
Fulciniti, M
Sperling, A
Minvielle, S
Anderson, KC
Parmigiani, G
Avet-Loiseau, H
Munshi, NC
AF Samur, Mehmet Kemal
Rashid, Naim
Cleynen, Alice
Fulciniti, Mariateresa
Sperling, Adam
Minvielle, Stephane
Anderson, Kenneth C.
Parmigiani, Giovanni
Avet-Loiseau, Herve
Munshi, Nikhil C.
TI Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical
Outcome in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Samur, Mehmet Kemal; Rashid, Naim; Fulciniti, Mariateresa; Sperling, Adam] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cleynen, Alice; Parmigiani, Giovanni] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cleynen, Alice] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Minvielle, Stephane] CNRS 6299, Ctr Rech Cancerol Nantes Angers, UMR Inserm 892, Nantes, France.
[Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Avet-Loiseau, Herve] Univ Hosp Nantes, Nantes, France.
[Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
RI Minvielle, Stephane/K-8251-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233800210
ER
PT J
AU San Miguel, J
Hungria, VTM
Yoon, SS
Beksac, M
Dimopoulos, MA
Elghandour, A
Jedrzejczak, WW
Guenther, A
Nakorn, TN
Siritanaratkul, N
Schlossman, RL
Hou, J
Moreau, P
Lonial, S
Lee, JH
Einsele, H
Salwender, H
Sopala, M
Redhu, S
Paul, S
Corrado, C
Binlich, F
Richardson, PG
AF San Miguel, Jesus
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw Wiktor
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae-Hoon
Einsele, Hermann
Salwender, Hans
Sopala, Monika
Redhu, Suman
Paul, Sofia
Corrado, Claudia
Binlich, Florence
Richardson, Paul G.
TI Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus
Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and
Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [San Miguel, Jesus] Univ Navarra, E-31080 Pamplona, Spain.
[Hungria, Vania T. M.] Santa Case Misericordia Sao Paulo Hosp, Sao Paulo, Brazil.
[Yoon, Sung-Soo] Seoul Natl Univ Hosp, Seoul 110744, South Korea.
[Beksac, Meral] Ankara Univ, Sch Med, TR-06100 Ankara, Turkey.
[Dimopoulos, Meletios A.] Univ Athens, Sch Med, Athens 11528, Greece.
[Elghandour, Ashraf] Univ Alexandria, Alexandria, Egypt.
[Jedrzejczak, Wieslaw Wiktor] Med Univ Warsaw, Warsaw, Poland.
[Guenther, Andreas] Univ Hosp Kiel, Kiel, Germany.
[Nakorn, Thanyaphong Na] King Chulalongkorn Mem Hosp, Bangkok, Thailand.
[Nakorn, Thanyaphong Na] Chulalongkorn Univ, Bangkok, Thailand.
[Siritanaratkul, Noppadol] Mahidol Univ, Siriraj Hosp, Bangkok 10700, Thailand.
[Schlossman, Robert L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Hou, Jian] Shanghai Changzheng Hosp, Shanghai, Peoples R China.
[Moreau, Philippe] Univ Hosp Nantes, Nantes, France.
[Lonial, Sagar] Emory Univ, Atlanta, GA 30322 USA.
[Lee, Jae-Hoon] Gachon Univ, Gil Hosp, Inchon, South Korea.
[Einsele, Hermann] Med Klin & Poliklin 2, Wurzburg, Germany.
[Salwender, Hans] Asklepios Klin Altona, Hamburg, Germany.
[Sopala, Monika; Corrado, Claudia] Novartis Pharma AG, Basel, Switzerland.
[Redhu, Suman; Paul, Sofia] Novartis Pharmaceut, E Hanover, NJ USA.
[Binlich, Florence] Novartis Pharma SAS, Rueil Malmaison, France.
[Richardson, Paul G.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
RI richard, chrystelle/K-8595-2015
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506142
ER
PT J
AU Sanchez, G
Li, A
Yellapragada, SV
Mims, MP
Frolov, A
Rahman, E
Rivero, GA
AF Sanchez, Gabriela
Li, Ang
Yellapragada, Sarvari Venkata
Mims, Martha P.
Frolov, Anna
Rahman, Effie
Rivero, Gustavo A.
TI Survival Improvement in Myelodysplastic Syndrome with Refractory Anemia
after Treatment with Selective-Serotonin-Reuptake-Inhibitors
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Sanchez, Gabriela] St Luke Episcopal Hosp, Houston, TX USA.
[Li, Ang] Massachussetts Gen Hosp, Boston, MA USA.
[Yellapragada, Sarvari Venkata; Mims, Martha P.; Frolov, Anna; Rahman, Effie] Baylor Coll Med, Houston, TX 77030 USA.
[Yellapragada, Sarvari Venkata] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
[Rivero, Gustavo A.] Michael E DeBakey VAMC, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806152
ER
PT J
AU Sanchez-Guerrero, SA
Treon, SP
Guevara-Arnal, L
Darwich, A
Cardenas-Ortega, A
Castillo, JJ
AF Sanchez-Guerrero, Sergio A.
Treon, Steven P.
Guevara-Arnal, Luis
Darwich, Akram
Cardenas-Ortega, Andrea
Castillo, Jorge J.
TI Bing-Neel Syndrome: A Rare Complication of Waldenstrom's
Macroglobulinemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Sanchez-Guerrero, Sergio A.; Guevara-Arnal, Luis; Darwich, Akram; Cardenas-Ortega, Andrea] Med Sur, Mexico City, DF, Mexico.
[Treon, Steven P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Castillo, Jorge J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506217
ER
PT J
AU Santo, L
Ramachandran, J
Cirstea, DD
Eda, H
Nemani, N
Hideshima, T
Dharminder, C
Huszar, D
Anderson, KC
Raje, N
AF Santo, Loredana
Ramachandran, Janani
Cirstea, Diana D.
Eda, Homare
Nemani, Neeharika
Hideshima, Teru
Dharminder, Chauhan
Huszar, Dennis
Anderson, Kenneth C.
Raje, Noopur
TI Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in
Combination with Bortezomib in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Santo, Loredana; Ramachandran, Janani; Cirstea, Diana D.; Eda, Homare; Nemani, Neeharika; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Hideshima, Teru; Dharminder, Chauhan; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Huszar, Dennis] AstraZeneca, Waltham, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807029
ER
PT J
AU Sousa, PSE
Lomas, C
Shorrock, H
Conlan, T
Means, TK
Plagnol, V
Bennett, CL
Chakraverty, R
AF Santos e Sousa, Pedro
Lomas, Cara
Shorrock, Hannah
Conlan, Thomas
Means, Terry K.
Plagnol, Vincent
Bennett, Clare L.
Chakraverty, Ronjon
TI A Systems Immunology Approach to Graft-Versus-Host Disease
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Santos e Sousa, Pedro; Lomas, Cara; Shorrock, Hannah; Conlan, Thomas; Plagnol, Vincent; Bennett, Clare L.; Chakraverty, Ronjon] UCL, London, England.
[Means, Terry K.] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501146
ER
PT J
AU Seftel, MD
Neuberg, D
Zhang, MJ
Wang, HL
Bergeron, J
Couban, S
DeAngelo, DJ
de Lima, MJ
Devine, SM
Eapen, M
Horowitz, MM
Pasquini, MC
Rizzo, JD
Saber, W
Sallan, SE
Sandmaier, BM
Weisdorf, DJ
AF Seftel, Matthew D.
Neuberg, Donna
Zhang, Mei-Jie
Wang, Hai-Lin
Bergeron, Julie
Couban, Stephen
DeAngelo, Daniel J.
de Lima, Marcos J.
Devine, Steven M.
Eapen, Mary
Horowitz, Mary M.
Pasquini, Marcelo C.
Rizzo, J. Douglas
Saber, Wael
Sallan, Stephen E.
Sandmaier, Brenda M.
Weisdorf, Daniel J.
TI Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell
Transplantation for Philadelphia Chromosome Negative Adult ALL in First
Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium
and CIBMTR Cohorts
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Seftel, Matthew D.] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Seftel, Matthew D.] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
[Neuberg, Donna; DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zhang, Mei-Jie; Wang, Hai-Lin; Eapen, Mary; Horowitz, Mary M.; Pasquini, Marcelo C.; Rizzo, J. Douglas; Saber, Wael] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Bergeron, Julie] Univ Monteal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada.
[Couban, Stephen] Dalhousie Univ, Halifax, NS, Canada.
[de Lima, Marcos J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Devine, Steven M.] Ohio State Univ, Columbus, OH 43210 USA.
[Sallan, Stephen E.] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503178
ER
PT J
AU Seymour, JF
Dohner, H
Butrym, A
Wierzbowska, A
Selleslag, D
Jang, JH
Cavenagh, JD
Kumar, R
Schuh, AC
Candoni, A
Recher, C
Sandhu, I
del Castillo, TB
Al-Ali, HK
Martinelli, G
Falantes, J
Stone, RM
Minden, MD
McIntyre, H
Songer, S
Lucy, LM
Beach, CL
Dombret, H
AF Seymour, John F.
Doehner, Hartmut
Butrym, Aleksandra
Wierzbowska, Agnieszka
Selleslag, Dominik
Jang, Jun Ho
Cavenagh, James D.
Kumar, Rajat
Schuh, Andre C.
Candoni, Anna
Recher, Christian
Sandhu, Irwindeep
Bernal del Castillo, Teresa
Al-Ali, Haifa Kathrin
Martinelli, Giovanni
Falantes, Jose
Stone, Richard M.
Minden, Mark D.
McIntyre, Heidi
Songer, Stephen
Lucy, Lela M.
Beach, C. L.
Dombret, Herve
TI Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older
Patients with Newly Diagnosed Acute Myeloid Leukemia (> 30% Bone Marrow
Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the
AZA-AML-001 Trial
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Seymour, John F.] Peter MacCallum Canc Ctr, East Melbourne, Australia.
[Doehner, Hartmut] Univ Ulm Klinikum, Ulm, Germany.
[Butrym, Aleksandra] Wroclaw Med Univ, Wroclaw, Poland.
[Wierzbowska, Agnieszka] Med Univ Lodz, Lodz, Poland.
[Selleslag, Dominik] AZ Sint Jan Brugge Oostende, Brugge, Belgium.
[Jang, Jun Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Cavenagh, James D.] St Bartholomews Hosp, London, England.
[Kumar, Rajat] Canc Care Manitoba, Winnipeg, MB, Canada.
[Schuh, Andre C.; Minden, Mark D.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Candoni, Anna] Azienda Osped Univ S Maria della Misericordia Udi, Udine, Italy.
[Recher, Christian] Inst Univ Canc Toulouse Oncopole, Toulouse, France.
[Sandhu, Irwindeep] Univ Alberta, Edmonton, AB, Canada.
[Bernal del Castillo, Teresa] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain.
[Al-Ali, Haifa Kathrin] Univ Hosp Leipzig, Leipzig, Germany.
[Martinelli, Giovanni] Inst Hematol & Med Oncol LeA Seragnoli, Bologna, Italy.
[Falantes, Jose] Hosp Univ Virgen del Rocio, Inst BioMed Sevilla, Seville, Spain.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McIntyre, Heidi; Songer, Stephen; Lucy, Lela M.; Beach, C. L.] Celgene Corp, Summit, NJ USA.
[Dombret, Herve] Hop St Louis, Paris 10, France.
RI Wierzbowska, Agnieszka/S-9449-2016
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506214
ER
PT J
AU Seymour, JF
Dohner, H
Butrym, A
Wierzbowska, A
Selleslag, D
Jang, JH
Cavenagh, JD
Kumar, R
Schuh, AC
Candoni, A
Recher, C
Sandhu, I
del Castillo, TB
Al-Ali, HK
Martinelli, G
Falantes, J
Stone, RM
Minden, MD
McIntyre, H
Songer, S
Lucy, LM
Beach, CL
Dombret, H
AF Seymour, John F.
Doehner, Hartmut
Butrym, Aleksandra
Wierzbowska, Agnieszka
Selleslag, Dominik
Jang, Jun Ho
Cavenagh, James D.
Kumar, Rajat
Schuh, Andre C.
Candoni, Anna
Recher, Christian
Sandhu, Irwindeep
del Castillo, Teresa Bernal
Al-Ali, Haifa Kathrin
Martinelli, Giovanni
Falantes, Jose
Stone, Richard M.
Minden, Mark D.
McIntyre, Heidi
Songer, Stephen
Lucy, Lela M.
Beach, C. L.
Dombret, Herve
TI Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older
Patients with Newly Diagnosed Acute Myeloid Leukemia (> 30% Bone Marrow
Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the
AZA-AML-001 Trial
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Seymour, John F.] Peter MacCallum Canc Ctr, East Melbourne, Australia.
[Doehner, Hartmut] Univ Ulm Klinikum, Ulm, Germany.
[Butrym, Aleksandra] Wroclaw Med Univ, Wroclaw, Poland.
[Wierzbowska, Agnieszka] Med Univ Lodz, Lodz, Poland.
[Selleslag, Dominik] AZ Sint Jan Brugge Oostende, Brugge, Belgium.
[Jang, Jun Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Cavenagh, James D.] St Bartholomews Hosp, London, England.
[Kumar, Rajat] Canc Care Manitoba, Winnipeg, MB, Canada.
[Schuh, Andre C.; Minden, Mark D.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Candoni, Anna] Azienda Osped Univ S Maria della Misericordia Udi, Udine, Italy.
[Recher, Christian] Inst Univ Canc Toulouse Oncopole, Toulouse, France.
[Sandhu, Irwindeep] Univ Alberta, Edmonton, AB, Canada.
[del Castillo, Teresa Bernal] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain.
[Al-Ali, Haifa Kathrin] Univ Hosp Leipzig, Leipzig, Germany.
[Martinelli, Giovanni] Inst Hematol & Med Oncol LeA Seragnoli, Bologna, Italy.
[Falantes, Jose] Hosp Univ Virgen del Rocio, Inst BioMed Sevilla, Seville, Spain.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McIntyre, Heidi; Songer, Stephen; Lucy, Lela M.; Beach, C. L.] Celgene Corp, Summit, NJ USA.
[Dombret, Herve] Hop St Louis, Paris 10, France.
RI Wierzbowska, Agnieszka/S-9449-2016
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506215
ER
PT J
AU Shank, KR
Koppikar, P
Bhagwat, N
Keller, MD
Michor, F
Levine, RL
Roditi, LD
AF Shank, Kaitlyn R.
Koppikar, Priya
Bhagwat, Neha
Keller, Matthew D.
Michor, Franziska
Levine, Ross L.
Roditi, Laura De Vargas
TI Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN
Patients
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Shank, Kaitlyn R.; Koppikar, Priya; Bhagwat, Neha; Keller, Matthew D.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Michor, Franziska] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Roditi, Laura De Vargas] Eldgenoss Tech Hsch Zurich, Zurich, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803062
ER
PT J
AU Sharma, D
Ravillah, D
Ray, A
Song, Y
Munshi, NC
Richardson, PG
Chauhan, D
Anderson, KC
AF Sharma, Deepika
Ravillah, Durgadevi
Ray, Arghya
Song, Yan
Munshi, Nikhil C.
Richardson, Paul G.
Chauhan, Dharminder
Anderson, Kenneth C.
TI Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Sharma, Deepika; Ravillah, Durgadevi; Ray, Arghya; Song, Yan; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
[Sharma, Deepika; Ravillah, Durgadevi; Ray, Arghya; Song, Yan; Richardson, Paul G.; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500225
ER
PT J
AU Shastri, A
Schinke, C
Yanovsky, AV
Bhagat, TD
Giricz, O
Barreyro, L
Boultwood, J
Pellagati, A
Yu, YT
Brown, JR
Frank, DA
Das, B
Kambhampati, S
Will, B
Steidl, U
Verma, A
AF Shastri, Aditi
Schinke, Carolina
Yanovsky, Asya Varshavsky
Bhagat, Tushar D.
Giricz, Orsolya
Barreyro, Laura
Boultwood, Jacqueline
Pellagati, Andrea
Yu, Yiting
Brown, Jennifer R.
Frank, David A.
Das, Bhaskar
Kambhampati, Suman
Will, Britta
Steidl, Ulrich
Verma, Amit
TI Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By
Pyrimethamine
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Shastri, Aditi; Yanovsky, Asya Varshavsky; Bhagat, Tushar D.; Giricz, Orsolya; Barreyro, Laura; Will, Britta] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Schinke, Carolina] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
[Boultwood, Jacqueline; Pellagati, Andrea] Univ Oxford, Oxford, England.
[Yu, Yiting; Verma, Amit] Albert Einstein Coll Med, Montefiore Med Ctr, Bronx, NY USA.
[Brown, Jennifer R.; Frank, David A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Das, Bhaskar] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Kambhampati, Suman] Univ Kansas, Ctr Canc, Kansas City, KS USA.
[Steidl, Ulrich] Albert Einstein Coll Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502072
ER
PT J
AU Shi, C
Han, LN
Tabe, Y
Mu, H
Wu, SC
Zhou, J
Zeng, ZH
Fruman, DA
Tasian, SK
Weinstock, DM
Konopleva, M
AF Shi, Ce
Han, Lina
Tabe, Yoko
Mu, Hong
Wu, Shuo-Chieh
Zhou, Jin
Zeng, Zhihong
Fruman, David A.
Tasian, Sarah K.
Weinstock, David M.
Konopleva, Marina
TI Dual Targeting of JAK2 Signaling with a Type II JAK2 Inhibitor and of
mTOR with a TOR Kinase Inhibitor Induces Apoptosis in CRLF2-Rearranged
Ph-like Acute Lymphoblastic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Shi, Ce; Han, Lina; Zeng, Zhihong; Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Tabe, Yoko] Juntendo Univ, Sch Med, Tokyo 113, Japan.
[Mu, Hong] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX 77030 USA.
[Wu, Shuo-Chieh; Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zhou, Jin] Harbin Med Univ, Hosp Affiliated 1, Harbin, Peoples R China.
[Fruman, David A.] Univ Calif Irvine, Irvine, CA USA.
[Tasian, Sarah K.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
RI Han, Lina/J-5119-2015
OI Han, Lina/0000-0003-1538-1734
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503144
ER
PT J
AU Shimizu, T
Hui, HS
Kubovcakova, L
Lundberg, P
Dirnhofer, S
Orkin, SH
Grisouard, J
Shimizu, Y
Pianta, A
Szczerba, B
Nienhold, R
Skoda, RC
AF Shimizu, Takafumi
Hui Hao-Shen
Kubovcakova, Lucia
Lundberg, Pontus
Dirnhofer, Stephan
Orkin, Stuart H.
Grisouard, Jean
Shimizu, Yukiko
Pianta, Annalisa
Szczerba, Barbara
Nienhold, Ronny
Skoda, Radek C.
TI JAK2V61 7F and Loss of Ezh2 in Hematopoietic Cells Contribute
Synergistically to Myeloproliferative Neoplasm Initiation Potential, and
Accelerate Progression of Disease
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Shimizu, Takafumi; Hui Hao-Shen; Kubovcakova, Lucia; Lundberg, Pontus; Grisouard, Jean; Shimizu, Yukiko; Pianta, Annalisa; Szczerba, Barbara; Nienhold, Ronny; Skoda, Radek C.] Univ Basel Hosp, CH-4031 Basel, Switzerland.
[Dirnhofer, Stephan] Univ Spital, Basel, Switzerland.
[Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506090
ER
PT J
AU Siegel, DS
Kaufman, JL
Raje, NS
Mikhael, JR
Kapoor, P
Treon, SP
Castillo, JJ
Neuman, LL
Lee, JR
Ghobrial, I
AF Siegel, David S.
Kaufman, Jonathan L.
Raje, Noopur S.
Mikhael, Joseph R.
Kapoor, Prashant
Treon, Steven P.
Castillo, Jorge J.
Neuman, Linda L.
Lee, Ju RueyJiuan
Ghobrial, Irene
TI Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase
1b/2 Study of Single-Agent Oprozomib in Patients with Waldenstrom
Macroglobulinemia (WM)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Siegel, David S.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Kaufman, Jonathan L.] Emory Univ, Atlanta, GA 30322 USA.
[Raje, Noopur S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mikhael, Joseph R.] Mayo Clin Arizona, Scottsdale, AZ USA.
[Kapoor, Prashant] Mayo Clin, Rochester, MN USA.
[Treon, Steven P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Castillo, Jorge J.; Ghobrial, Irene] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Neuman, Linda L.] Onyx Pharmaceut Inc, Redwood City, CA USA.
[Lee, Ju RueyJiuan] Onyx Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808148
ER
PT J
AU Silberstein, L
Kharchenko, P
Kfoury, Y
Mercier, F
Osawa, M
Hoggatt, J
Tate, T
Lin, C
Scadden, DT
AF Silberstein, Lev
Kharchenko, Peter
Kfoury, Youmna
Mercier, Francois
Osawa, Masatake
Hoggatt, Jonathan
Tate, Tiffany
Lin, Charles
Scadden, David T.
TI Proximity-Based Single Cell Analysis of the Bone Marrow Niche Identifies
Interleukin-18 As a Quiescence Regulator of Early Hematopoietic
Progenitors
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Silberstein, Lev; Kharchenko, Peter; Kfoury, Youmna; Mercier, Francois; Hoggatt, Jonathan; Lin, Charles; Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA USA.
[Silberstein, Lev; Kfoury, Youmna; Mercier, Francois; Hoggatt, Jonathan; Tate, Tiffany; Lin, Charles; Scadden, David T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kharchenko, Peter] Harvard Ctr Biomed Informat, Boston, MA USA.
[Osawa, Masatake] Gifu Univ, Gifu, Japan.
[Scadden, David T.] Harvard Univ, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500194
ER
PT J
AU Skert, C
Perucca, S
Imberti, L
Chiarini, M
Malagola, M
Fili, C
Bergonzi, C
Ribolla, R
Cancelli, V
Turra, A
Cattina, F
Di Palma, A
Russo, D
AF Skert, Cristina
Perucca, Simone
Imberti, Luisa
Chiarini, Marco
Malagola, Michele
Fili, Carla
Bergonzi, Cesare
Ribolla, Rossella
Cancelli, Valeria
Turra, Alessandro
Cattina, Federica
Di Palma, Andrea
Russo, Domenico
TI Patterns of Lymphocyte Subsets and Index of Bone Marrow Output (KRECs)
Correlate Differently with Graft-Versus-Host Disease and Relapse
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Skert, Cristina; Perucca, Simone; Ribolla, Rossella; Turra, Alessandro; Di Palma, Andrea; Russo, Domenico] Univ Brescia, Unit Blood Dis & Stem Cell Transplantat, Chair Hematol, Brescia, Italy.
[Imberti, Luisa; Chiarini, Marco] Spedali Civili Brescia, Brescia, Italy.
[Chiarini, Marco] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Malagola, Michele] Univ Brescia, Chair Hematol, Brescia, Italy.
[Fili, Carla; Bergonzi, Cesare; Cancelli, Valeria; Cattina, Federica] Univ Brescia, Brescia, Italy.
[Cattina, Federica] Univ Brescia, Bone Marrow Transplant Unit, Chair Hematol, Brescia, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803197
ER
PT J
AU Song, WH
Zhang, CL
Hu, YG
Gkotzamanidou, M
Shah, P
Shan, WS
Yang, G
Li, Y
Sperling, A
Rashid, N
Samur, MK
Amin, SB
Tai, YT
Hideshima, T
Parmigiani, G
Magrangeas, F
Minvielle, S
Avet-Loiseau, H
Anderson, KC
Li, C
Munshi, NC
AF Song, Weihua
Zhang, Chaolin
Hu, Yiguo
Gkotzamanidou, Maria
Shah, Parantu
Shan, Weisong
Yang, Guang
Li, Yi
Sperling, Adam
Rashid, Naim
Samur, Mehmet Kemal
Amin, Samir B.
Tai, Yu-Tzu
Hideshima, Teru
Parmigiani, Giovanni
Magrangeas, Florence
Minvielle, Stephane
Avet-Loiseau, Herve
Anderson, Kenneth C.
Li, Cheng
Munshi, Nikhil C.
TI Bone Marrow Microenvironment Regulates Alternative Splicing Events in
Myeloma Cells through Downregulation of RNA Binding Protein Fox2
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Song, Weihua; Hu, Yiguo; Shah, Parantu; Yang, Guang; Li, Yi; Sperling, Adam; Samur, Mehmet Kemal; Amin, Samir B.; Tai, Yu-Tzu; Hideshima, Teru; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zhang, Chaolin] Rockefeller Univ, New Yorki City, NY USA.
[Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Shan, Weisong] McGill Univ, Montreal, PQ, Canada.
[Rashid, Naim; Parmigiani, Giovanni; Li, Cheng] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Magrangeas, Florence; Minvielle, Stephane] CHU Nantes, F-44035 Nantes 01, France.
[Avet-Loiseau, Herve] Univ Hosp Nantes, Nantes, France.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233808057
ER
PT J
AU Sperling, A
Rashid, N
Bolli, N
Wedge, D
Van Loo, P
Tai, YT
Shammas, M
Fulciniti, M
Samur, MK
Richardson, PG
Magrangeas, F
Minvielle, S
Futreal, PA
Anderson, KC
Avet-Ioiseau, H
Campbell, PJ
Parmigiani, G
Munshi, N
AF Sperling, Adam
Rashid, Naim
Bolli, Niccolo
Wedge, David
Van Loo, Peter
Tai, Yu-Tzu
Shammas, Masood
Fulciniti, Mariateresa
Samur, Mehmet Kemal
Richardson, Paul G.
Magrangeas, Florence
Minvielle, Stephane
Futreal, P. Andrew
Anderson, Kenneth C.
Avet-Ioiseau, Herve
Campbell, Peter J.
Parmigiani, Giovanni
Munshi, Nikhil
TI Differential and Limited Expression of Mutant Alleles in Multiple
Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Sperling, Adam; Tai, Yu-Tzu; Fulciniti, Mariateresa; Samur, Mehmet Kemal; Anderson, Kenneth C.; Munshi, Nikhil] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rashid, Naim] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bolli, Niccolo; Campbell, Peter J.] Univ Cambridge, Cambridge, England.
[Wedge, David; Van Loo, Peter] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
[Shammas, Masood; Parmigiani, Giovanni] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Magrangeas, Florence; Minvielle, Stephane] CNRS 6299, UMR Inserm 892, Ctr Rech Cancerol Nantes Angers, Nantes, France.
[Futreal, P. Andrew] Wellcome Trust Sanger Inst, Cambridge, England.
[Avet-Ioiseau, Herve] Inst Univ Canc, Toulouse, France.
[Avet-Ioiseau, Herve] Univ Hosp, Toulouse, France.
RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804125
ER
PT J
AU Stathis, A
Freedman, AS
Flinn, IW
Maddocks, KJ
Weitman, S
Berdeja, JG
Mejia, AV
Zucca, E
Green, R
Romanelli, A
Zildjian, SH
Ruiz-Soto, R
Palomba, L
AF Stathis, Anastasios
Freedman, Arnold S.
Flinn, Ian W.
Maddocks, Kami J.
Weitman, Steven
Berdeja, Jesus G.
Mejia, Alex V.
Zucca, Emanuele
Green, Rebecca
Romanelli, Angela
Zildjian, Sybil H.
Ruiz-Soto, Rodrigo
Palomba, Lia
TI A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting
CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin's
Lymphoma (NHL)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Stathis, Anastasios; Zucca, Emanuele] Oncol Inst Southern Switzerland, Bellinzona, Switzerland.
[Freedman, Arnold S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Flinn, Ian W.; Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA.
[Maddocks, Kami J.] Ohio State Univ, Columbus, OH 43210 USA.
[Weitman, Steven; Mejia, Alex V.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Weitman, Steven; Mejia, Alex V.] CTRC Inst Drug Dev, San Antonio, TX USA.
[Green, Rebecca; Palomba, Lia] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Romanelli, Angela; Zildjian, Sybil H.; Ruiz-Soto, Rodrigo] ImmunoGen Inc, Waltham, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506191
ER
PT J
AU Stein, EM
Altman, JK
Collins, R
DeAngelo, DJ
Fathi, AT
Flinn, I
Frankel, A
Levine, RL
Medeiros, BC
Patel, M
Pollyea, DA
Roboz, GJ
Stone, RM
Swords, RT
Tallman, MS
Agresta, S
Fan, B
Yang, H
Yen, K
de Botton, S
AF Stein, Eytan M.
Altman, Jessica K.
Collins, Robert
DeAngelo, Daniel J.
Fathi, Amir T.
Flinn, Ian
Frankel, Arthur
Levine, Ross L.
Medeiros, Bruno C.
Patel, Manish
Pollyea, Daniel A.
Roboz, Gail J.
Stone, Richard M.
Swords, Ronan T.
Tallman, Martin S.
Agresta, Sam
Fan, Bin
Yang, Hua
Yen, Katharine
de Botton, Stephane
TI AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2
Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study
in Patients with IDH2 Mutation Positive Advanced Hematologic
Malignancies
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Stein, Eytan M.; Levine, Ross L.; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Altman, Jessica K.] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA.
[Collins, Robert; Frankel, Arthur] Univ Texas Southwestern, Dallas, TX USA.
[DeAngelo, Daniel J.; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Flinn, Ian] Sarah Cannon Res Inst, Nashville, TN USA.
[Medeiros, Bruno C.] Stanford Univ, Stanford, CA 94305 USA.
[Patel, Manish] Florida Canc Specialists, Sarasota, FL USA.
[Pollyea, Daniel A.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Roboz, Gail J.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Swords, Ronan T.] Univ Miami Hosp, Sylvester Comprehens Canc Ctr, Miami, FL USA.
[Agresta, Sam; Fan, Bin; Yang, Hua; Yen, Katharine] Agios Pharmaceut, Cambridge, MA USA.
[de Botton, Stephane] Inst Gustave Roussy, Villejuif, France.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806164
ER
PT J
AU Stein, EM
Stein, A
Walter, RB
Fathi, AT
Lancet, JE
Kovacsovics, TJ
Advani, AS
DeAngelo, DJ
O'Meara, MM
Zhao, BT
Kennedy, DA
Erba, HP
AF Stein, Eytan M.
Stein, Anthony
Walter, Roland B.
Fathi, Amir T.
Lancet, Jeffrey E.
Kovacsovics, Tibor J.
Advani, Anjali S.
DeAngelo, Daniel J.
O'Meara, Megan M.
Zhao, Baiteng
Kennedy, Dana A.
Erba, Harry P.
TI Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with
CD33-Positive Acute Myeloid Leukemia (AML)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Stein, Eytan M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Stein, Anthony] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Walter, Roland B.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Fathi, Amir T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lancet, Jeffrey E.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Kovacsovics, Tibor J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Advani, Anjali S.] Cleveland Clin, Cleveland, OH 44106 USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[O'Meara, Megan M.; Zhao, Baiteng; Kennedy, Dana A.] Seattle Genet Inc, Bothell, WA USA.
[Erba, Harry P.] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805178
ER
PT J
AU Stock, W
Luger, SM
Advani, AS
Geyer, S
Harvey, RC
Mullighan, CG
Willman, CL
Malnassy, G
Parker, E
Laumann, KM
Sanford, B
Marcucci, G
Paietta, EM
Liedtke, M
Claxton, DF
Foster, MC
Appelbaum, FR
Erba, H
Litzow, MR
Tallman, MS
Stone, RM
Larson, RA
AF Stock, Wendy
Luger, Selina M.
Advani, Anjali S.
Geyer, Susan
Harvey, Richard C.
Mullighan, Charles G.
Willman, Cheryl L.
Malnassy, Greg
Parker, Edy
Laumann, Kristina M.
Sanford, Ben
Marcucci, Guido
Paietta, Elisabeth M.
Liedtke, Michaela
Claxton, David F.
Foster, Matthew C.
Appelbaum, Frederick R.
Erba, Harry
Litzow, Mark R.
Tallman, Martin S.
Stone, Richard M.
Larson, Richard A.
TI Favorable Outcomes for Older Adolescents and Young Adults (AYA) with
Acute Lymphoblastic Leukemia (ALL): Early Results of US Intergroup Trial
C10403
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Stock, Wendy] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Luger, Selina M.] Univ Penn, Philadelphia, PA 19104 USA.
[Advani, Anjali S.] Cleveland Clin, Cleveland, OH 44106 USA.
[Geyer, Susan; Marcucci, Guido] Ohio State Univ, Columbus, OH 43210 USA.
[Geyer, Susan] Alliance Clin Trials Oncol, Stat & Data Ctr, Rochester, MN USA.
[Harvey, Richard C.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
[Mullighan, Charles G.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
[Willman, Cheryl L.] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA.
[Malnassy, Greg; Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA.
[Parker, Edy; Stone, Richard M.] ALLIANCE, Boston, MA USA.
[Laumann, Kristina M.; Litzow, Mark R.] Mayo Clin, Rochester, MN USA.
[Sanford, Ben] Duke Univ, Med Ctr, Alliance Clin Trials Oncol, Stat & Data Ctr, Durham, NC USA.
[Paietta, Elisabeth M.] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Liedtke, Michaela] Stanford Canc Inst, Stanford, CA USA.
[Claxton, David F.] Penn State Coll Med, Penn State Hershey Canc Inst, Dept Med Hematol Oncol, Hershey, PA USA.
[Foster, Matthew C.] Univ N Carolina, Chapel Hill, NC USA.
[Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Erba, Harry] Univ Alabama Birmingham, Birmingham, AL USA.
[Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Larson, Richard A.] Alliance Clin Trials Oncol, Boston, MA USA.
NR 0
TC 6
Z9 6
U1 2
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803088
ER
PT J
AU Stroopinsky, D
Pyzer, AR
Palmer, KA
Coll, MD
Bar-Natan, M
Rajabi, H
Somaiya, P
Luptakova, K
Jain, S
McMasters, M
Levine, JD
Arnason, J
Taverna, P
Kufe, D
Avigan, D
Rosenblatt, J
AF Stroopinsky, Dina
Pyzer, Athalia Rachel
Palmer, Kristen A.
Coll, Maxwell D.
Bar-Natan, Michal
Rajabi, Hasan
Somaiya, Poorvi
Luptakova, Katarina
Jain, Salvia
McMasters, Malgorzata
Levine, James D.
Arnason, Jon
Taverna, Pietro
Kufe, Donald
Avigan, David
Rosenblatt, Jacalyn
TI Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in
Acute Myeloid Leukemia (AML)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Stroopinsky, Dina; Pyzer, Athalia Rachel; Palmer, Kristen A.; Coll, Maxwell D.; Bar-Natan, Michal; Somaiya, Poorvi; Luptakova, Katarina; Jain, Salvia; McMasters, Malgorzata; Levine, James D.; Arnason, Jon; Avigan, David; Rosenblatt, Jacalyn] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Rajabi, Hasan; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Taverna, Pietro] Astex Pharmaceut Inc, Dublin, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233805189
ER
PT J
AU Sujobert, P
Paubelle, E
Grenier, A
Zylbersztejn, F
Lambert, M
Poulain, L
Townsend, E
Brusq, JM
Nicodeme, E
Decrooqc, J
Nepstad, I
Green, A
Hospital, MA
Jacque, N
Hermine, O
Foretz, M
Viollet, B
Lacombe, C
Weinstock, DM
Mayeux, P
Moura, IC
Bouscary, D
Tamburini, J
AF Sujobert, Pierre
Paubelle, Etienne
Grenier, Adrien
Zylbersztejn, Florence
Lambert, Mireille
Poulain, Laury
Townsend, Elizabeth
Brusq, Jean-Marie
Nicodeme, Edwige
Decrooqc, Justine
Nepstad, Ina
Green, Alexa
Hospital, Marie-Anne
Jacque, Nathalie
Hermine, Olivier
Foretz, Marc
Viollet, Benoit
Lacombe, Catherine
Weinstock, David M.
Mayeux, Patrick
Moura, Ivan C.
Bouscary, Didier
Tamburini, Jerome
TI Co-Activation of AMPK and mTORC1 Is Synthetically Lethal in Acute
Myeloid Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Sujobert, Pierre; Grenier, Adrien; Poulain, Laury; Decrooqc, Justine; Jacque, Nathalie; Foretz, Marc; Moura, Ivan C.] Paris Descartes Sorbonne Paris Cite Univ, Paris, France.
[Paubelle, Etienne; Hermine, Olivier] Hop Necker Enfants Malad, Paris, France.
[Paubelle, Etienne] Univ Paris 05, ICNRS, UMR 8147, Paris, France.
[Zylbersztejn, Florence] INSERM, U699, Paris, France.
[Lambert, Mireille; Hospital, Marie-Anne] Cochin Hosp, Paris, France.
[Townsend, Elizabeth] Harvard Univ, Boston, MA 02115 USA.
[Brusq, Jean-Marie; Nicodeme, Edwige] GlaxoSmithKline Res Ctr, Les Ulis, France.
[Nepstad, Ina] Univ Bergen, Bergen, Norway.
[Green, Alexa; Viollet, Benoit] INSERM, U1016, Paris, France.
[Hermine, Olivier] Univ Paris 05, Paris, France.
[Lacombe, Catherine] Inst Cochin Genet Mol, F-75014 Paris, France.
[Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mayeux, Patrick] Inst Cochin Genet Mol, Dept Hematol, F-75014 Paris, France.
[Bouscary, Didier] Hop Cochin, APHP, F-75674 Paris, France.
[Tamburini, Jerome] Univ Paris 05, Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233801168
ER
PT J
AU Sun, BH
Fiskus, W
Shah, B
Qi, J
Devaraj, SGT
Iyer, SP
Sharma, S
Bradner, J
Zu, YL
Bhalla, KN
AF Sun, Baohua
Fiskus, Warren
Shah, Bhavin
Qi, Jun
Devaraj, Santhana G. T.
Iyer, Swaminathan Padmanabhan
Sharma, Sunil
Bradner, James
Zu, Youli
Bhalla, Kapil N.
TI Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal)
Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib
Against Human Mantle Cell Lymphoma (MCL) Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Sun, Baohua; Fiskus, Warren; Shah, Bhavin; Devaraj, Santhana G. T.; Bhalla, Kapil N.] Houston Methodist Res Inst, Houston, TX USA.
[Qi, Jun; Bradner, James] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Iyer, Swaminathan Padmanabhan] Methodist Canc Ctr, Houston, TX USA.
[Sharma, Sunil] Huntsman Canc Inst, Salt Lake City, UT USA.
[Zu, Youli] Methodist Hosp, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506010
ER
PT J
AU Sun, WL
Gaynon, PS
Sposto, R
Bittencourt, H
Place, AE
Messinger, YH
Fraser, C
Dalla-Pozza, L
van der Giessen, J
Eckroth, E
Yang, XJ
Liang, GN
Jones, PA
Wayne, AS
Cooper, T
AF Sun, Weili
Gaynon, Paul S.
Sposto, Richard
Bittencourt, Henrique
Place, Andrew E.
Messinger, Yoav H.
Fraser, Chris
Dalla-Pozza, Luciano
van der Giessen, Jeannette
Eckroth, Elena
Yang, Xiaojing
Liang, Gangning
Jones, Peter A.
Wayne, Alan S.
Cooper, Todd
TI A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and
Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic
Advances in Childhood Leukemia & Lymphoma (TACL) Study
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Sun, Weili; Wayne, Alan S.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA.
[Gaynon, Paul S.; Sposto, Richard; van der Giessen, Jeannette; Eckroth, Elena] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Bittencourt, Henrique] Univ Montreal, St Justine Univ Hosp, Montreal, PQ, Canada.
[Place, Andrew E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Messinger, Yoav H.] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA.
[Fraser, Chris] Royal Childrens Hosp, Brisbane, Qld, Australia.
[Dalla-Pozza, Luciano] Childrens Hosp Westmead, Sydney, NSW, Austria.
[Yang, Xiaojing; Liang, Gangning; Jones, Peter A.] Univ So Calif, Los Angeles, CA USA.
[Jones, Peter A.] Van Andel Res Inst, Grand Rapids, MI USA.
[Cooper, Todd] Emory Univ, Aflac Canc Ctr, Atlanta, GA 30322 USA.
[Cooper, Todd] Emory Univ, Blood Disorders Serv, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243503202
ER
PT J
AU Usmani, SZ
Sexton, R
Ailawadhi, S
Shah, JJ
Callander, NS
Zimmerman, T
Valent, J
Rosenzweig, M
Lipe, BC
Zonder, J
Fredette, S
Durie, BGM
Hoering, A
Rajkumar, SV
Richardson, PG
Orlowski, RZ
AF Usmani, Saad Z.
Sexton, Rachael
Ailawadhi, Sikander
Shah, Jatin J.
Callander, Natalie S.
Zimmerman, Todd
Valent, Jason
Rosenzweig, Michael
Lipe, Brea C.
Zonder, Jeffrey
Fredette, Sandi
Durie, Brian G. M.
Hoering, Antje
Rajkumar, S. Vincent
Richardson, Paul G.
Orlowski, Robert Z.
TI SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY
Diagnosed High Risk Multiple Myeloma (HRMM)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Usmani, Saad Z.] Levine Canc Inst, Charlotte, NC USA.
[Sexton, Rachael; Hoering, Antje] Canc Res & Biostat, Seattle, WA USA.
[Ailawadhi, Sikander] Mayo Clin, Jacksonville, FL 32224 USA.
[Shah, Jatin J.; Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Callander, Natalie S.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Callander, Natalie S.] Univ Wisconsin, Madison, WI USA.
[Zimmerman, Todd] Univ Chicago Med, Chicago, IL USA.
[Valent, Jason] Cleveland Clin, Cleveland, OH 44106 USA.
[Rosenzweig, Michael] City Hope Natl Med Ctr, Duarte, CA USA.
[Lipe, Brea C.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Zonder, Jeffrey] Karmanos Canc Inst, Detroit, MI USA.
[Fredette, Sandi] SWOG Operat, San Antonio, TX USA.
[Durie, Brian G. M.] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA.
[Rajkumar, S. Vincent] Mayo Clin, Rochester, MN USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804025
ER
PT J
AU van der Hulle, T
den Exter, PL
Meyer, G
Planquette, B
Soler, S
Monreal, M
Jimenez, D
Portillo, AK
O'Connell, C
Liebman, H
Shteinberg, M
Adir, Y
Tiseo, M
Bersanelli, M
Abdel-Razeq, HN
Mansour, AH
Donnelly, OG
Radhakrishna, G
Ramasamy, S
Bozas, G
Maraveyas, A
Shinagare, AB
Hatabu, H
Nishino, M
Huisman, MV
Klok, FA
AF van der Hulle, T.
den Exter, P. L.
Meyer, G.
Planquette, B.
Soler, S.
Monreal, M.
Jimenez, D.
Portillo, A. K.
O'Connell, C.
Liebman, H.
Shteinberg, M.
Adir, Y.
Tiseo, M.
Bersanelli, M.
Abdel-Razeq, H. N.
Mansour, A. H.
Donnelly, O. G.
Radhakrishna, G.
Ramasamy, S.
Bozas, G.
Maraveyas, A.
Shinagare, A. B.
Hatabu, H.
Nishino, M.
Huisman, M. V.
Klok, F. A.
TI Risk of Recurrent Venous Thromboembolism and Major Bleeding in
Cancer-Associated Incidental Pulmonary Embolism Amongst Treated and
Untreated Patients: A Pooled Analysis of 926 Patients
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [van der Hulle, T.; den Exter, P. L.; Huisman, M. V.; Klok, F. A.] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Meyer, G.; Planquette, B.] Univ Paris 05, Hop Europeen Georges Pompidou, Paris, France.
[Soler, S.] Hosp St Jaume, Olot, Gerona, Spain.
[Monreal, M.] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain.
[Jimenez, D.; Portillo, A. K.] IRYCIS, Ramon & Cajal Hosp, Madrid, Spain.
[Jimenez, D.; Portillo, A. K.] Univ Alcala de Henares, Madrid, Spain.
[O'Connell, C.; Liebman, H.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Shteinberg, M.; Adir, Y.] Technion Israel Inst Technol, Fac Med, Carmel Med Ctr, Haifa, Israel.
[Tiseo, M.; Bersanelli, M.] Univ Hosp Parma, Parma, Italy.
[Abdel-Razeq, H. N.; Mansour, A. H.] King Hussein Canc Ctr, Amman, Jordan.
[Donnelly, O. G.] Univ Leeds, Leeds, W Yorkshire, England.
[Donnelly, O. G.; Radhakrishna, G.; Ramasamy, S.] St James Inst Oncol, Leeds, W Yorkshire, England.
[Bozas, G.; Maraveyas, A.] Hull & East Yorkshire Hosp NHS Trust, Castle Hill Hosp, Cottingham, Yorks, England.
[Maraveyas, A.] Hull York Med Sch, Cottingham, Yorks, England.
[Shinagare, A. B.; Hatabu, H.; Nishino, M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Shinagare, A. B.; Hatabu, H.; Nishino, M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804063
ER
PT J
AU Varga, C
Laubach, JP
Ghobrial, IM
Weinstock, M
Paba-Prada, CE
Schlossman, RL
Munshi, N
Xie, W
Weller, EA
Anderson, KC
Mitsiades, CS
Richardson, PG
AF Varga, Cindy
Laubach, Jacob P.
Ghobrial, Irene M.
Weinstock, Matthew
Paba-Prada, Claudia E.
Schlossman, Robert L.
Munshi, Nikhil
Xie, Wanling
Weller, Edie A.
Anderson, Kenneth C.
Mitsiades, Constantine S.
Richardson, Paul G.
TI Time to Development of Treatment-Emergent Extramedullary and Osseous
Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront
Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Varga, Cindy; Paba-Prada, Claudia E.; Schlossman, Robert L.; Munshi, Nikhil; Weller, Edie A.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Laubach, Jacob P.; Xie, Wanling] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Weinstock, Matthew] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233802019
ER
PT J
AU Verstovsek, S
Mesa, RA
Foltz, LM
Gupta, V
Mascarenhas, JO
Ritchie, EK
Hoffman, R
Silver, RT
Kremyanskaya, M
Pozdnyakova, O
Hasserjian, RP
Trehu, E
Kantarjian, HM
Gotlib, JR
AF Verstovsek, Srdan
Mesa, Ruben A.
Foltz, Lynda M.
Gupta, Vikas
Mascarenhas, John O.
Ritchie, Ellen K.
Hoffman, Ronald
Silver, Richard T.
Kremyanskaya, Marina
Pozdnyakova, Olga
Hasserjian, Robert P.
Trehu, Elizabeth
Kantarjian, Hagop M.
Gotlib, Jason R.
TI Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with
Myelofibrosis: Stage 1 Results
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Verstovsek, Srdan; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Mesa, Ruben A.] Mayo Clin Canc Ctr, Scottsdale, AZ USA.
[Foltz, Lynda M.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada.
[Foltz, Lynda M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Gupta, Vikas] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Mascarenhas, John O.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Ritchie, Ellen K.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Hoffman, Ronald] Ichan Sch Med Mt Sinai, Div Hematol Oncol, Tisch Canc Inst, Dept Med,Myeloproliferat Disorders Res Consortium, New York, NY USA.
[Silver, Richard T.] Weill Cornell New York Presbyterian Hosp, New York, NY USA.
[Kremyanskaya, Marina] Icahn Schoool Med Mt Sinai, New York, NY USA.
[Pozdnyakova, Olga] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Hasserjian, Robert P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Trehu, Elizabeth] Promedior Inc, Lexington, MA USA.
[Gotlib, Jason R.] Stanford Canc Inst, Stanford, CA USA.
[Gotlib, Jason R.] Stanford Univ Sch Med, Stanford, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233804115
ER
PT J
AU Viel, KR
Kim, B
Tejero, ME
Cole, SS
Howard, TE
Ortiz, AS
AF Viel, Kevin R.
Kim, Benjamin
Elizabeth Tejero, Maria
Cole, Shelley S.
Howard, Tom E.
Santamaria Ortiz, Amparo
TI The Spectrum of Amino Acid Substitutions Resulting from Single
Nucleotide Substitutions in the Coagulation Biosystem: Impact on
Identification By Mass Spectrometry
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Viel, Kevin R.] Histonis Inc, Atlanta, GA USA.
[Kim, Benjamin] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Elizabeth Tejero, Maria] Inst Nacl Med Genom, Mexico City, DF, Mexico.
[Cole, Shelley S.] Texas Biomed Res Inst, San Antonio, TX USA.
[Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Santamaria Ortiz, Amparo] Hosp Valle De Hebron, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502119
ER
PT J
AU Vij, R
Huff, CA
Bensinger, WI
Siegel, DS
Jagannath, S
Berdeja, J
Lendvai, N
Lebovic, D
Anderson, LD
Costello, CL
Stockerl-Goldstein, KE
Laubach, JP
Elias, L
Clow, F
Fardis, M
Graef, T
Bilotti, E
Richardson, PG
AF Vij, Ravi
Huff, Carol Ann
Bensinger, William I.
Siegel, David S.
Jagannath, Sundar
Berdeja, Jesus
Lendvai, Nikoletta
Lebovic, Daniel
Anderson, Larry D.
Costello, Caitlin L.
Stockerl-Goldstein, Keith E.
Laubach, Jacob P.
Elias, Laurence
Clow, Fong
Fardis, Maria
Graef, Thorsten
Bilotti, Elizabeth
Richardson, Paul G.
TI Ibrutinib, Single Agent or in Combination with Dexamethasone, in
Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM):
Preliminary Phase 2 Results
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Vij, Ravi; Stockerl-Goldstein, Keith E.] Washington Univ, Sch Med, St Louis, MO USA.
[Huff, Carol Ann] Johns Hopkins Univ, Baltimore, MD USA.
[Bensinger, William I.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Siegel, David S.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Berdeja, Jesus] Sarah Cannon Res Inst, Nashville, TN USA.
[Lendvai, Nikoletta] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Lendvai, Nikoletta] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
[Lebovic, Daniel] Univ Michigan, Ann Arbor, MI 48109 USA.
[Anderson, Larry D.] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Dallas, TX USA.
[Costello, Caitlin L.] Moores UCSD Canc Ctr, La Jolla, CA USA.
[Laubach, Jacob P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Elias, Laurence; Clow, Fong; Fardis, Maria; Graef, Thorsten; Bilotti, Elizabeth] Pharmacyclics Inc, Sunnyvale, CA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506005
ER
PT J
AU Vij, R
Savona, M
Siegel, DS
Kaufman, JL
Badros, A
Ghobrial, IM
Paner, A
Jagannath, S
Jakubowiak, A
Mikhael, JR
Kapoor, P
Neuman, LL
Lee, JR
Berdeja, JG
AF Vij, Ravi
Savona, Michael
Siegel, David S.
Kaufman, Jonathan L.
Badros, Ashraf
Ghobrial, Irene M.
Paner, Agne
Jagannath, Sundar
Jakubowiak, Andrzej
Mikhael, Joseph R.
Kapoor, Prashant
Neuman, Linda L.
Lee, Ju RueyJiuan
Berdeja, Jesus G.
TI Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with
Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label,
Dose Escalation Phase 1b/2 Study
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA.
[Savona, Michael] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
[Siegel, David S.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Kaufman, Jonathan L.] Emory Univ, Atlanta, GA 30322 USA.
[Badros, Ashraf] Univ Maryland, Baltimore, MD 21201 USA.
[Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Paner, Agne] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Jagannath, Sundar] Mt Sinai Hosp, New York, NY 10029 USA.
[Jakubowiak, Andrzej] Univ Chicago Med, Chicago, IL USA.
[Mikhael, Joseph R.] Mayo Clin Arizona, Scottsdale, AZ USA.
[Kapoor, Prashant] Mayo Clin, Rochester, MN USA.
[Neuman, Linda L.] Onyx Pharmaceut Inc, Redwood City, CA USA.
[Lee, Ju RueyJiuan] Onyx Pharmaceut Inc, San Francisco, CA USA.
[Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504031
ER
PT J
AU Vij, R
Hars, V
Blum, W
Shore, TB
Rapoport, AP
Shea, TC
Hoke, E
Stone, RM
Friedman, P
Owzar, K
Devine, SM
AF Vij, Ravi
Hars, Vera
Blum, William
Shore, Tsiporah B.
Rapoport, Aaron P.
Shea, Thomas C.
Hoke, Eva
Stone, Richard M.
Friedman, Paula
Owzar, Kouros
Devine, Steven M.
TI CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group
Study of the Addition of Azacitidine (AZA) to Reduced-Intensity
Conditioning (RIC) Allogeneic Transplantation for High Risk
Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia
(AML): Results of a "test dose" Strategy to Target Busulfan Exposure
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA.
[Hars, Vera] Duke Univ, Med Ctr, Durham, NC USA.
[Blum, William; Devine, Steven M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Shore, Tsiporah B.] New York Hosp, New York, NY 10021 USA.
[Rapoport, Aaron P.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Shea, Thomas C.] Univ N Carolina, Chapel Hill, NC USA.
[Hoke, Eva] Duke Univ, Med Ctr, Alliance Clin Trials Oncol Stat & Data Ctr, Durham, NC USA.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Friedman, Paula] Univ Chicago, Chicago, IL 60637 USA.
[Owzar, Kouros] Canc & Leukemia Grp B, Boston, MA USA.
NR 0
TC 2
Z9 2
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806177
ER
PT J
AU Vogl, DT
Raje, N
Hari, P
Jones, SS
Supko, JG
Leone, G
Wheeler, C
Orlowski, RZ
Richardson, PG
Lonial, S
Tamang, D
Jagannath, S
AF Vogl, Dan T.
Raje, Noopur
Hari, Parameswaran
Jones, Simon S.
Supko, Jeffrey G.
Leone, Gina
Wheeler, Catherine
Orlowski, Robert Z.
Richardson, Paul G.
Lonial, Sagar
Tamang, David
Jagannath, Sundar
TI Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with
Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and
Refractory Multiple Myeloma (MM)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Vogl, Dan T.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Raje, Noopur; Supko, Jeffrey G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hari, Parameswaran] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Jones, Simon S.; Leone, Gina; Wheeler, Catherine; Tamang, David] Acetylon Pharmaceut Inc, Boston, MA USA.
[Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Lonial, Sagar] Emory Univ, Sch Med, Atlanta, GA USA.
[Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505209
ER
PT J
AU Voorhees, PM
Schlossman, RL
Gasparetto, CJ
Berdeja, JG
Morris, J
Jacobstein, DA
Anderson, KC
Mitsiades, CS
Laubach, JP
Richardson, PG
AF Voorhees, Peter M.
Schlossman, Robert L.
Gasparetto, Cristina J.
Berdeja, Jesus G.
Morris, John
Jacobstein, Douglas A.
Anderson, Kenneth C.
Mitsiades, Constantine S.
Laubach, Jacob P.
Richardson, Paul G.
TI An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX
93936, an Agent Synthetically Active Against the Activated Ras Pathway,
in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Voorhees, Peter M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Schlossman, Robert L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gasparetto, Cristina J.] Duke Univ, Med Ctr, Durham, NC USA.
[Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA.
[Morris, John] Univ Cincinnati, Inst Canc, Cincinnati, OH USA.
[Jacobstein, Douglas A.] Prolexys Pharmaceut Inc, Columbia, MD USA.
[Anderson, Kenneth C.; Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Anderson, Kenneth C.; Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Mitsiades, Constantine S.; Laubach, Jacob P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500015
ER
PT J
AU Wagers, AJ
AF Wagers, Amy J.
TI Stem Cell Rejuvenation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wagers, Amy J.] Harvard Stem Cell Inst, Joslin Diabet Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243501074
ER
PT J
AU Wagner, DD
AF Wagner, Denisa D.
TI Neutrophil Extracellular Traps and von Willebrand Factor in Thrombosis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wagner, Denisa D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233802013
ER
PT J
AU Walter, RB
Othus, M
Paietta, EM
Racevskis, J
Fernandez, HF
Lee, JW
Sun, ZX
Tallman, MS
Patel, JP
Gonen, M
Abdel-Wahab, O
Levine, RL
Estey, EH
AF Walter, Roland B.
Othus, Megan
Paietta, Elisabeth M.
Racevskis, Janis
Fernandez, Hugo F.
Lee, Ju-Whei
Sun, Zhuoxin
Tallman, Martin S.
Patel, Jay P.
Goenen, Mithat
Abdel-Wahab, Omar
Levine, Ross L.
Estey, Elihu H.
TI Effect of Genetic Profiling on Prediction of Therapeutic Resistance and
Survival in Adult Acute Myeloid Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Walter, Roland B.; Estey, Elihu H.] Univ Washington, Seattle, WA 98195 USA.
[Walter, Roland B.; Othus, Megan; Estey, Elihu H.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Paietta, Elisabeth M.; Racevskis, Janis] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Fernandez, Hugo F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Lee, Ju-Whei; Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tallman, Martin S.; Patel, Jay P.; Goenen, Mithat; Abdel-Wahab, Omar; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233807082
ER
PT J
AU Wang, HF
Yashiro-Ohtani, Y
Zang, CZ
Wong, YJ
Bailis, W
Knoechel, B
Bernstein, B
Blacklow, S
Liu, XS
Pear, WS
Aster, JC
AF Wang, Hongfang
Yashiro-Ohtani, Yumi
Zang, Chongzhi
Wong, Yinling Joey
Bailis, Will
Knoechel, Birgit
Bernstein, Bradley
Blacklow, Steve
Liu, X. Shirley
Pear, Warren S.
Aster, Jon C.
TI Alternative Super-Enhancer States Determine MYC Sensitivity to Notch and
Brd4 Inhibitors in T Lymphoblastic Leukemia/Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wang, Hongfang; Wong, Yinling Joey; Aster, Jon C.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yashiro-Ohtani, Yumi; Bailis, Will; Pear, Warren S.] Univ Penn, Philadelphia, PA 19104 USA.
[Zang, Chongzhi; Liu, X. Shirley] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zang, Chongzhi; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Knoechel, Birgit] Boston Childrens Hosp, Boston, MA USA.
[Bernstein, Bradley] Massachusetts Gen Hosp, Broad Inst, Boston, MA 02114 USA.
[Blacklow, Steve] Harvard Univ, Sch Med, Boston, MA USA.
RI Zang, Chongzhi/D-1445-2011
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803096
ER
PT J
AU Wang, LD
Nguyen, P
Ficarro, SB
Hutchinson, J
Hofmann, O
Marto, JA
Wagers, AJ
AF Wang, Leo D.
Phi Nguyen
Ficarro, Scott B.
Hutchinson, John
Hofmann, Oliver
Marto, Jarrod A.
Wagers, Amy J.
TI Small-Scale Mass Spectrometry-Based Phosphoproteomic Analysis of Primary
Hematopoietic Stem and Progenitor Cells to Identify Critical Regulators
of HSPC Mobilization and Leukemogenesis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wang, Leo D.; Phi Nguyen] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Wang, Leo D.] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA.
[Wang, Leo D.; Phi Nguyen; Hutchinson, John; Hofmann, Oliver] Harvard Stem Cell Inst, Cambridge, MA USA.
[Ficarro, Scott B.; Marto, Jarrod A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hutchinson, John; Hofmann, Oliver] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Wagers, Amy J.] Harvard Stem Cell Inst, Joslin Diabet Ctr, Boston, MA USA.
[Wagers, Amy J.] Harvard Univ, Harvard Stem Cell Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243504093
ER
PT J
AU Wang, LD
Nguyen, P
Rowe, RG
Rao, TN
Daley, GQ
Wagers, AJ
AF Wang, Leo D.
Phi Nguyen
Rowe, Robert G.
Rao, Tata Nageswara
Daley, George Q.
Wagers, Amy J.
TI Ectopic Expression of Lin28 Biases Myeloid Differentiation to Promote an
Immature Mast Cell State and Is Implicated in Aggressive Mastocytosis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wang, Leo D.; Rowe, Robert G.; Daley, George Q.] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA.
[Wang, Leo D.; Phi Nguyen; Rao, Tata Nageswara] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Wagers, Amy J.] Harvard Stem Cell Inst, Joslin Diabet Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500114
ER
PT J
AU Wang, LL
Kotliar, D
Fan, J
Li, SQ
Grimsby, J
Landau, DA
Brown, JR
Lennon, N
Neuberg, D
Livak, KJ
Wu, CJ
AF Wang, Lili
Kotliar, Dylan
Fan, Jean
Li, Shuqiang
Grimsby, Jonna
Landau, Dan A.
Brown, Jennifer R.
Lennon, Niall
Neuberg, Donna
Livak, Kenneth J.
Wu, Catherine J.
TI Integrated Single-Cell Detection of Genotype and Phenotype in
SF3B1-Mutated Chronic Lymphocytic Leukemia Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wang, Lili; Landau, Dan A.; Brown, Jennifer R.; Neuberg, Donna; Wu, Catherine J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wang, Lili; Kotliar, Dylan; Fan, Jean; Landau, Dan A.; Wu, Catherine J.] Harvard Univ, Sch Med, Boston, MA USA.
[Li, Shuqiang; Livak, Kenneth J.] Fluidigm Co, San Francisco, CA USA.
[Grimsby, Jonna; Lennon, Niall] Broad Inst, Cambridge, MA USA.
[Landau, Dan A.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Brown, Jennifer R.; Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803145
ER
PT J
AU Weinacht, KG
AF Weinacht, Katja G.
TI Linking Oxidative Stress to Cell Fate-Ipsc-Based Disease Modeling
Identifies New Therapeutic Target in Reticular Dysgenesis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Weinacht, Katja G.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 2
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233800093
ER
PT J
AU Weinstock, M
Aljawai, Y
Ghobrial, IM
Morgan, EA
Laubach, JP
Roccaro, AM
Varga, C
Gannon, M
Paba-Prada, CE
Schlossman, RL
Munshi, N
Anderson, KC
Richardson, PG
Mitsiades, CS
AF Weinstock, Matthew
Aljawai, Yosra
Ghobrial, Irene M.
Morgan, Elizabeth A.
Laubach, Jacob P.
Roccaro, Aldo M.
Varga, Cindy
Gannon, Muriel
Paba-Prada, Claudia E.
Schlossman, Robert L.
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Mitsiades, Constantine S.
TI Incidence and Clinical Features of Extramedullary Multiple Myeloma in
Patients Who Underwent Stem Cell Transplantation
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Weinstock, Matthew] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Aljawai, Yosra; Roccaro, Aldo M.; Varga, Cindy; Paba-Prada, Claudia E.; Munshi, Nikhil; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ghobrial, Irene M.; Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Morgan, Elizabeth A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Laubach, Jacob P.; Gannon, Muriel] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schlossman, Robert L.] Harvard Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233803129
ER
PT J
AU Whitlock, J
Pozza, LD
Goldberg, JM
Silverman, LB
Ziegler, DS
Attarbaschi, A
Brown, P
Gardner, RA
Gaynon, PS
Hutchinson, RJ
Marcus, LJ
Messinger, YH
Schultz, KR
Vandergiessen, J
Eckroth, E
Locatelli, F
Zwaan, CM
Wood, BL
Sposto, R
Gore, L
AF Whitlock, James
Pozza, Luciano dalla
Goldberg, John M.
Silverman, Lewis B.
Ziegler, David S.
Attarbaschi, Andishe
Brown, Patrick
Gardner, Rebecca A.
Gaynon, Paul S.
Hutchinson, Raymond J.
Marcus, Leigh J.
Messinger, Yoav H.
Schultz, Kirk R.
Vandergiessen, Jeannette
Eckroth, Elena
Locatelli, Franco
Zwaan, C. Michel
Wood, Brent L.
Sposto, Richard
Gore, Lia
TI Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active
in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and
T-Lymphoblastic Lymphoma (T-LL)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Whitlock, James] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Pozza, Luciano dalla] Childrens Hosp Westmead, Sydney, NSW, Australia.
[Goldberg, John M.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Goldberg, John M.] Sylvester Comprehens Canc Ctr, Miami, FL USA.
[Silverman, Lewis B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ziegler, David S.] Sydney Childrens Hosp, Sydney, NSW, Australia.
[Attarbaschi, Andishe] St Anna Childrens Hosp, A-1090 Vienna, Austria.
[Brown, Patrick] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Gardner, Rebecca A.] Seattle Childrens Hosp, Seattle, WA USA.
[Gaynon, Paul S.; Vandergiessen, Jeannette; Eckroth, Elena] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Hutchinson, Raymond J.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Marcus, Leigh J.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Messinger, Yoav H.] Childrens Hosp & Clin, St Paul, MN USA.
[Schultz, Kirk R.] Univ British Columbia, BC Childrens Hosp, Vancouver, BC V5Z 1M9, Canada.
[Locatelli, Franco] Univ Pavia, IRCCS Bambino Gesu Childrens Hosp Rome, Rome, Italy.
[Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands.
[Wood, Brent L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Sposto, Richard] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA.
[Gore, Lia] Univ Colorado, Ctr Canc, Aurora, CO USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243502167
ER
PT J
AU Xu, J
Shao, Z
Li, D
Xie, HF
Kim, W
Huang, JL
Pinello, L
Glass, K
Yuan, GC
Orkin, SH
AF Xu, Jian
Shao, Zhen
Li, Dan
Xie, Huafeng
Kim, Woojin
Huang, Jialiang
Pinello, Luca
Glass, Kimberly
Yuan, Guo-Cheng
Orkin, Stuart H.
TI Developmental Control of Polycomb Subunit Composition Mediates a Switch
to Non-Canonical Functions during Hematopoiesis
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Xu, Jian; Shao, Zhen; Xie, Huafeng; Kim, Woojin; Huang, Jialiang; Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Xu, Jian] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Shao, Zhen] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai, Peoples R China.
[Li, Dan] Harvard Univ, Boston, MA USA.
[Pinello, Luca; Glass, Kimberly; Yuan, Guo-Cheng] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233801222
ER
PT J
AU Yee, AJ
Voorhees, PM
Bensinger, W
Berdeja, JG
Supko, JG
Richardson, PG
Tamang, D
Jones, SS
Patrick, G
Wheeler, C
Raje, N
AF Yee, Andrew J.
Voorhees, Peter M.
Bensinger, William
Berdeja, Jesus G.
Supko, Jeffrey G.
Richardson, Paul G.
Tamang, David
Jones, Simon S.
Patrick, Gretchen
Wheeler, Catherine
Raje, Noopur
TI Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination
with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in
Relapsed and Relapsed Refractory Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yee, Andrew J.; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Voorhees, Peter M.] Univ N Carolina, Chapel Hill, NC USA.
[Bensinger, William] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA.
[Supko, Jeffrey G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Tamang, David; Jones, Simon S.; Patrick, Gretchen; Wheeler, Catherine] Acetylon Pharmaceut Inc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505057
ER
PT J
AU Zeidan, AM
Sekeres, MA
Garcia-Manero, G
Barnard, J
Al Ali, NH
Zimmerman, C
Roboz, GJ
Steensma, DP
DeZern, AE
Jabbour, E
Kantarjian, H
Zell, K
Wang, QQ
Gore, SD
Nazha, A
Maciejewski, JP
List, AF
Komrokji, RS
AF Zeidan, Amer M.
Sekeres, Mikkael A.
Garcia-Manero, Guillermo
Barnard, John
Al Ali, Najla H.
Zimmerman, Cassie
Roboz, Gail J.
Steensma, David P.
DeZern, Amy E.
Jabbour, Elias
Kantarjian, Hagop
Zell, Katrina
Wang, Quiqing
Gore, Steven D.
Nazha, Aziz
Maciejewski, Jaroslaw P.
List, Alan F.
Komrokji, Rami S.
TI The Prognostic Utility of the Current Risk Models in Predicting Outcomes
of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Treated with Hypomethylating Agents (HMA)
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Zeidan, Amer M.; Gore, Steven D.] Yale Univ, Yale Canc Ctr, New Haven, CT USA.
[Sekeres, Mikkael A.; Barnard, John; Zimmerman, Cassie; Zell, Katrina; Wang, Quiqing; Nazha, Aziz; Maciejewski, Jaroslaw P.] Cleveland Clin, Cleveland, OH 44106 USA.
[Garcia-Manero, Guillermo; Jabbour, Elias; Kantarjian, Hagop] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Al Ali, Najla H.; List, Alan F.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Roboz, Gail J.] Weill Cornell Med Coll, New York, NY USA.
[Steensma, David P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[DeZern, Amy E.] Johns Hopkins Univ, Baltimore, MD USA.
[Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 4
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243505131
ER
PT J
AU Zhang, HJ
Kozono, D
O'Connor, K
Vidal-Cardenas, S
Hamilton, A
Gaudiano, E
Greenberger, JS
Grompe, M
Parmar, K
D'Andrea, AD
AF Zhang, Haojian
Kozono, David
O'Connor, Kevin
Vidal-Cardenas, Sofia
Hamilton, Abigail
Gaudiano, Emily
Greenberger, Joel S.
Grompe, Markus
Parmar, Kalindi
D'Andrea, Alan D.
TI Bone Marrow Failure in Fanconi Anemia from Hyperactive TGF-beta
Signaling
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Zhang, Haojian; Kozono, David; O'Connor, Kevin; Vidal-Cardenas, Sofia; Hamilton, Abigail; Gaudiano, Emily; Parmar, Kalindi; D'Andrea, Alan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Greenberger, Joel S.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Grompe, Markus] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506220
ER
PT J
AU Zhang, QS
Benedetti, E
Deater, M
Schubert, K
Major, A
Pelz, C
Impey, S
Marquez-Loza, L
Rathbun, K
Kato, S
Bagby, GC
Grompe, M
AF Zhang, Qingshuo
Benedetti, Eric
Deater, Matthew
Schubert, Kathryn
Major, Angela
Pelz, Carl
Impey, Soren
Marquez-Loza, Laura
Rathbun, Keaney
Kato, Shigeaki
Bagby, Grover C.
Grompe, Markus
TI Oxymetholone Therapy of Fanconi Anemia Induces Hematopoietic Stem Cell
Cycling By Suppressing Osteopontin Transcription
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Zhang, Qingshuo; Benedetti, Eric; Deater, Matthew; Schubert, Kathryn; Pelz, Carl; Impey, Soren; Marquez-Loza, Laura; Grompe, Markus] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Major, Angela] Texas Childrens Hosp, Houston, TX 77030 USA.
[Rathbun, Keaney; Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA.
[Kato, Shigeaki] Univ Tokyo, Tokyo, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233806030
ER
PT J
AU Zhou, Z
Rademaker, AW
Gordon, LI
LaCasce, AS
Crosby-Thompson, A
Vanderplas, A
Abel, GA
Rodriguez, MA
Nademanee, A
Kaminski, M
Czuczman, MS
Millenson, MM
Niland, J
Zelenetz, AD
Friedberg, JW
Winter, JN
AF Zhou, Zheng
Rademaker, Alfred W.
Gordon, Leo I.
LaCasce, Ann S.
Crosby-Thompson, Allison
Vanderplas, Ann
Abel, Gregory A.
Rodriguez, Maria A.
Nademanee, Auayporn
Kaminski, Mark
Czuczman, Myron S.
Millenson, Michael M.
Niland, Joyce
Zelenetz, Andrew D.
Friedberg, Jonathan W.
Winter, Jane N.
TI High Body Mass Index (BMI) in North American Elderly Diffuse Large
B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP
Compensates for Negative Impact of Male Gender
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Zhou, Zheng] Northwestern Univ, NW Mem Hosp, Feinberg Sch Med, Chicago, IL 60611 USA.
[Rademaker, Alfred W.; Gordon, Leo I.; Winter, Jane N.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[LaCasce, Ann S.; Crosby-Thompson, Allison; Abel, Gregory A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Vanderplas, Ann; Niland, Joyce] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Rodriguez, Maria A.] UT MD Anderson Canc Ctr, Houston, TX USA.
[Nademanee, Auayporn] City Hope Natl Med Ctr, Duarte, CA USA.
[Kaminski, Mark] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Millenson, Michael M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Friedberg, Jonathan W.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243506118
ER
PT J
AU Zweidler-McKay, PA
DeAngelo, DJ
Douer, D
Dombret, H
Ottmann, OG
Vey, N
Thomas, DA
Zhu, LL
Huang, F
Bajaj, G
Fischer, BS
AF Zweidler-McKay, Patrick A.
DeAngelo, Daniel J.
Douer, Dan
Dombret, Herve
Ottmann, Oliver G.
Vey, Norbert
Thomas, Deborah A.
Zhu, Lili
Huang, Fei
Bajaj, Gaurav
Fischer, Bruce S.
TI The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI)
with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute
Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Zweidler-McKay, Patrick A.; Thomas, Deborah A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Douer, Dan] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, New York, NY 10021 USA.
[Dombret, Herve] Hop St Louis, AP HP, Paris, France.
[Ottmann, Oliver G.] Goethe Univ Hosp, Frankfurt, Germany.
[Vey, Norbert] Inst J Paoli I Calmettes, F-13009 Marseille, France.
[Zhu, Lili; Huang, Fei; Bajaj, Gaurav; Fischer, Bruce S.] Bristol Myers Squibb Co, Princeton, NJ USA.
RI Ottmann, Oliver/D-5007-2016
OI Ottmann, Oliver/0000-0001-9559-1330
NR 0
TC 5
Z9 5
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9KX
UT WOS:000349243500196
ER
PT J
AU Kling, S
Akca, IB
Chang, EW
Scarcelli, G
Bekesi, N
Yun, SH
Marcos, S
AF Kling, Sabine
Akca, Imran B.
Chang, Ernest W.
Scarcelli, Giuliano
Bekesi, Nandor
Yun, Seok-Hyun
Marcos, Susana
TI Numerical model of optical coherence tomographic vibrography imaging to
estimate corneal biomechanical properties
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE non-contact; corneal biomechanical properties; vibrography; corneal
natural frequencies
ID CROSS-LINKING; AIR-PUFF; TONOMETRY; DEFORMATION; MICROSCOPY; THICKNESS
AB Most techniques measuring corneal biomechanics in vivo are biased by side factors. We demonstrate the ability of optical coherence tomographic (OCT) vibrography to determine corneal material parameters, while reducing current prevalent restrictions of other techniques (such as intraocular pressure (IOP) and thickness dependency). Modal analysis was performed in a finite-element (FE) model to study the oscillation response in isolated thin corneal flaps/eye globes and to analyse the dependency of the frequency response function on: corneal elasticity, viscoelasticity, geometry (thickness and curvature), IOP and density. The model was verified experimentally in flaps from three bovine corneas and in two enucleated porcine eyes using sound excitation (100-110 dB) together with a phase-sensitive OCT to measure the frequency response function (range 50-510 Hz). Simulations showed that corneal vibration in flaps is sensitive to both, geometrical and biomechanical parameters, whereas in whole globes it is primarily sensitive to corneal biomechanical parameters only. Calculations based on the natural frequency shift revealed that flaps of the posterior cornea were 0.8 times less stiff than flaps from the anterior cornea and cross-linked corneas were 1.6 times stiffer than virgin corneas. Sensitivity analysis showed that natural vibration frequencies of whole globes were nearly independent from corneal thickness and IOP within the physiological range. OCT vibrography is a promising non-invasive technique to measure corneal elasticity without biases from corneal thickness and IOP.
C1 [Kling, Sabine; Bekesi, Nandor; Marcos, Susana] CSIC, Inst Opt, E-28006 Madrid, Spain.
[Akca, Imran B.; Chang, Ernest W.; Scarcelli, Giuliano; Yun, Seok-Hyun] Wellman Ctr Photomed, Boston, MA USA.
[Akca, Imran B.; Chang, Ernest W.; Scarcelli, Giuliano; Yun, Seok-Hyun] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Kling, S (reprint author), CSIC, Inst Opt, Serrano 121, E-28006 Madrid, Spain.
EM kling.sabine@gmail.com; susana@io.cfmac.csic.es
RI Bekesi, Nandor/A-6812-2010
OI Bekesi, Nandor/0000-0001-7532-9589
FU European Research Council under the European Union [294099]; Spanish
Government, MINECO [FIS2011-25637, FPI-BES-2009-024560]; Harvard
Clinical and Translational Science Center [NIH UL1-RR025758]; NIH
[P41-EB015903]; NSF [CBET-1264356]; Comunidad de Madrid; EU
[FP7/2007-2013/REA 291820]
FX The research leading to these results has received funding from the
European Research Council under the European Union's Seventh Framework
Program (FP7/2007-2013)/ERC grant agreement no. 294099 and furthermore
from the Spanish Government, MINECO, FIS2011-25637, FPI-BES-2009-024560,
Harvard Clinical and Translational Science Center (NIH UL1-RR025758),
NIH grant no. P41-EB015903, NSF grant no. CBET-1264356; Comunidad de
Madrid and EU (FP7/2007-2013/REA 291820).
NR 28
TC 9
Z9 9
U1 1
U2 10
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742-5689
EI 1742-5662
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD DEC 6
PY 2014
VL 11
IS 101
AR UNSP 20140920
DI 10.1098/rsif.2014.0920
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR6DF
UT WOS:000343672800016
PM 25320067
ER
PT J
AU Li, W
Long, JA
Watts, LT
Jiang, Z
Shen, Q
Li, YX
Duong, TQ
AF Li, Wei
Long, Justin Alexander
Watts, Lora Talley
Jiang, Zhao
Shen, Qiang
Li, Yunxia
Duong, Timothy Q.
TI A Quantitative MRI Method for Imaging Blood-Brain Barrier Leakage in
Experimental Traumatic Brain Injury
SO PLOS ONE
LA English
DT Article
ID REPERFUSION INJURY; MODEL SELECTION; PATLAK PLOTS; RAT MODEL; GD-DTPA;
PERMEABILITY; STROKE; PARAMETERS; DIFFUSION; BREAKDOWN
AB Blood-brain barrier (BBB) disruption is common following traumatic brain injury (TBI). Dynamic contrast enhanced (DCE) MRI can longitudinally measure the transport coefficient K-trans which reflects BBB permeability. K-trans measurements however are not widely used in TBI research because it is generally considered to be noisy and possesses low spatial resolution. We improved spatiotemporal resolution and signal sensitivity of K-trans MRI in rats by using a high-sensitivity surface transceiver coil. To overcome the signal drop off profile of the surface coil, a pre-scan module was used to map the flip angle (B-1 field) and magnetization (M-0) distributions. A series of T-1-weighted gradient echo images were acquired and fitted to the extended Kety model with reversible or irreversible leakage, and the best model was selected using F-statistics. We applied this method to study the rat brain one hour following controlled cortical impact (mild to moderate TBI), and observed clear depiction of the BBB damage around the impact regions, which matched that outlined by Evans Blue extravasation. Unlike the relatively uniform T-2 contrast showing cerebral edema, K-trans shows a pronounced heterogeneous spatial profile in and around the impact regions, displaying a nonlinear relationship with T-2. This improved K-trans MRI method is also compatible with the use of high-sensitivity surface coil and the high-contrast two-coil arterial spin-labeling method for cerebral blood flow measurement, enabling more comprehensive investigation of the pathophysiology in TBI.
C1 [Li, Wei; Long, Justin Alexander; Watts, Lora Talley; Jiang, Zhao; Shen, Qiang; Li, Yunxia; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Li, Wei; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
RP Li, W (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
EM liw5@uthscsa.edu; duongt@uthscsa.edu
RI Shen, Qiang/B-8784-2008
OI Shen, Qiang/0000-0002-4287-3403
FU NIH/NINDS [R01 NS45879, UL1 TR001119, TL1TR001119, KL2 TR001118];
NIH/NINDS via the Clinical Translational Science Awards (CTSA)
[TL1TR001119, UL1TR001119, 8UL1TR000149]
FX The study was supported in part by grants from NIH/NINDS R01 NS45879
(TQD), UL1 TR001119 (WL), TL1TR001119 (JAL), and KL2 TR001118 (LTW) via
the Clinical Translational Science Awards (CTSA, parent grant
UL1TR001119, 8UL1TR000149, and TL1TR001119). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 26
TC 7
Z9 9
U1 2
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2014
VL 9
IS 12
AR e114173
DI 10.1371/journal.pone.0114173
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX4MS
UT WOS:000346907200050
PM 25478693
ER
PT J
AU Lahav, A
Skoe, E
AF Lahav, Amir
Skoe, Erika
TI An acoustic gap between the NICU and womb: a potential risk for
compromised neuroplasticity of compromised neuroplasticity of the
auditory system in preterm infants
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE auditory development; NICU; preterm infants; noise exposure; high
frequency
ID NEONATAL INTENSIVE-CARE; BRAIN-STEM; HEARING-LOSS; TRAINING INFLUENCES;
SOUND ENVIRONMENT; CRITICAL PERIOD; NOISE EXPOSURE; FETAL HEARING;
SPEECH SOUNDS; HUMAN COCHLEA
AB The intrauterine environment allows the fetus to begin hearing low-frequency sounds in a protected fashion, ensuring intial optimal development of the peripheral and central auditory system. However, the auditory nursery provided by the womb vanishes once the preterm newborn enters the high-frequency (HF) noisy environment of the neonatal intensive care unit (NICU). The present article draws a concerning line between auditory system development and HF noise in the NICU, which we argue is not necessarily conductive to fostering this development. Overexposure to HF noise during critical periods disrupts the functional organization of auditory cortical cicuits. As a result, we theorize that the ability to tune out noise and extract acoustic information in a noisy environment may be impaired, leading to increased risks for a variety of auditory, language, and attention disorders. Additionally, HF noise in the NICU often masks human speech sounds, further limitting quality exposure to linguistic stimuli. Understanding the impact of the sound environment on the developing auditory system is an important first step in meeting the development demands of preterm newborns undergoing intensive care.
C1 [Lahav, Amir] Brigham & Womens Hosp, Dept Pediat & Newborn Med, Boston, MA 02115 USA.
[Lahav, Amir] Harvard Univ, Sch Med, Dept Pediat, MassGen Hosp Children, Boston, MA 02115 USA.
[Skoe, Erika] Univ Connecticut, Dept Speech Language & Hearing Sci, Dept Psychol Affiliate, Cognit Sci Program Affiliate, Storrs, CT USA.
RP Lahav, A (reprint author), Brigham & Womens Hosp, Dept Pediat & Newborn Med, 75 Francis St, Boston, MA 02115 USA.
EM amir_lahav@hms.harvard.edu
FU Charles H. Hood Foundation; Peter and Elizabeth C. Tower Foundation;
Gerber Foundation; Little Giraffe Foundation; Hailey's Hope Foundation;
Jackson L. Graves Foundation; TripAdvisor Fund
FX We gratefully thank Linda Malie for assisting with graphic design of
Figure 1 and Parker Tichko for comments on the manuscript. We are also
grateful for the generous support Amir Lahav received from the Charles
H. Hood Foundation, Peter and Elizabeth C. Tower Foundation, Gerber
Foundation, Little Giraffe Foundation, Hailey's Hope Foundation, Jackson
L. Graves Foundation, and TripAdvisor Fund.
NR 108
TC 7
Z9 8
U1 3
U2 15
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD DEC 5
PY 2014
VL 8
AR 381
DI 10.3389/fnins.2014.00381
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA AW9DA
UT WOS:000346556600001
PM 25538543
ER
PT J
AU Wang, Y
AF Wang, Yu
TI RING Finger Protein 4 (RNF4) Derepresses Gene Expression from DNA
Methylation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE DNA Methylation; Protein Turnover; RING Finger Protein 4 (RNF4);
Transcription; Ubiquitylation (Ubiquitination); Methyl CpG-binding
Protein 2 (MeCP2)
ID MAMMALIAN DNA; TET PROTEINS; 5-METHYLCYTOSINE; DEMETHYLATION;
5-HYDROXYMETHYLCYTOSINE; 5-CARBOXYLCYTOSINE; IDENTIFICATION;
TRANSCRIPTION; COREGULATOR; CONVERSION
AB Background: RNF4 is a transcription activator, yet the mechanism is unknown. Results: RNF4 mediates ubiquitination and turnover of MeCP2 and thus derepresses transcription from DNA methylation. Conclusion: RNF4 regulates transcription by creating a permissive epigenetic environment. Significance: This study lays the basis for better understanding the role of RNF4 in epigenetics and transcription.
RNF4 is an E3 ubiquitin ligase originally identified as a transcription co-activator. The mechanism by which RNF4 promotes transcription remains unclear. In this study, I found that RNF4 antagonizes transcriptional repression mediated by DNA methylation. RNF4 does not promote DNA demethylation, but mediates the ubiquitination of MeCP2, a methyl-CpG-binding domain (MBD) protein. Removal of MeCP2 from gene promoters activates transcription. This study thus not only uncovers how RNF4 functions as a transcription activator, but also reveals the mechanism by which MeCP2 protein stability is regulated.
C1 [Wang, Yu] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Wang, Yu] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Wang, Y (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, WAB 164,200 Longwood Ave, Boston, MA 02115 USA.
EM yu.wang@childrens.harvard.edu
FU American Heart Association
FX Supported by a postdoctoral fellowship from American Heart Association.
To whom correspondence should be addressed: Program in Cellular and
Molecular Medicine, Boston Children's Hospital, Harvard Medical School,
WAB-164, 200 Longwood Ave., Boston, MA 02115. E-mail:
yu.wang@childrens.harvard.edu.
NR 21
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 5
PY 2014
VL 289
IS 49
BP 33808
EP 33813
DI 10.1074/jbc.C114.611558
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AW1UZ
UT WOS:000346077600008
PM 25355316
ER
PT J
AU Woody, G
Bruce, D
Korthuis, PT
Chhatre, S
Hillhouse, M
Jacobs, P
Sorensen, J
Saxon, AJ
Poole, S
Metzger, D
Ling, W
AF Woody, George
Bruce, Douglas
Korthuis, P. Todd
Chhatre, Sumedha
Hillhouse, Maureen
Jacobs, Petra
Sorensen, James
Saxon, Andrew J.
Poole, Sabrina
Metzger, David
Ling, Walter
TI Authors' Reply: "Risk Reduction With Buprenorphine-Naloxone and
Methadone: Patient's Choice"
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
C1 [Woody, George; Chhatre, Sumedha; Poole, Sabrina; Metzger, David] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Woody, George; Chhatre, Sumedha; Jacobs, Petra; Metzger, David] Treatment Res Inst, Philadelphia, PA USA.
[Bruce, Douglas] Yale Univ, Sch Med, New Haven, CT USA.
[Korthuis, P. Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Hillhouse, Maureen; Ling, Walter] Univ Calif Los Angeles, Los Angeles, CA USA.
[Sorensen, James] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Woody, G (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RI Metzger, David/D-9499-2012
FU NIAID NIH HHS [P30 AI045008]; NIDA NIH HHS [K05 DA-17009, K05 DA017009,
U10 DA-13043, U10 DA013043, U10 DA013714, U10-DA013714, UG1 DA013714];
NIMH NIH HHS [P30 MH097488]
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 5
PY 2014
VL 67
IS 5
BP E142
EP E143
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AT2NW
UT WOS:000344772300003
PM 25243431
ER
PT J
AU Kapoor, R
Saint, S
Kapoor, JR
Johnson, RA
Dhaliwal, G
AF Kapoor, Roger
Saint, Sanjay
Kapoor, John R.
Johnson, Richard A.
Dhaliwal, Gurpreet
TI D Is for Delay
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PELLAGRA; SKIN
C1 [Kapoor, Roger] Beloit Hlth Syst, Dept Med, Beloit, WI 53511 USA.
[Kapoor, Roger] Univ Illinois, Coll Med, Rockford, IL 61107 USA.
[Kapoor, John R.] Chicago Med Sch, Dept Med, Chicago, IL USA.
[Saint, Sanjay] Ann Arbor Vet Affairs VA Med Ctr, Ann Arbor, MI USA.
[Saint, Sanjay] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Johnson, Richard A.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
RP Kapoor, R (reprint author), Beloit Hlth Syst, Dept Med, 1969 W Hart Rd, Beloit, WI 53511 USA.
EM rogerkapoor@gmail.com
FU Doximity; Jvion
FX Dr. Saint reports receiving fees for board membership from Doximity and
Jvion. No other potential conflict of interest relevant to this article
was reported.
NR 13
TC 3
Z9 3
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 4
PY 2014
VL 371
IS 23
BP 2218
EP 2223
DI 10.1056/NEJMcps1212211
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW0IY
UT WOS:000345976700012
PM 25470698
ER
PT J
AU Sahay, T
Ananthakrishnan, AN
AF Sahay, Tanya
Ananthakrishnan, Ashwin N.
TI Vitamin D deficiency is associated with community-acquired clostridium
difficile infection: a case-control study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE C difficile; Vitamin D; Community-acquired; Infection; Cathelicidin
ID INFLAMMATORY-BOWEL-DISEASE; BINDING PROTEIN; REDUCED RISK; CATHELICIDIN;
PLASMA; REPRODUCIBILITY; EPIDEMIOLOGY; HOSPITALS; DIARRHEA; BURDEN
AB Background: Clostridium difficile infection (CDI) is increasingly recognized as an important community acquired pathogen causing disease (CA-CDI). Vitamin D [25(OH)D] has immune modulatory effects and plays an important role in intestinal immunity. The role of vitamin D in CA-CDI has not been examined previously.
Methods: This was a single referral center case-control study. Cases comprised of all patients with CA-CDI who had a serum 25(OH)D measured within 12 months prior to infection. Controls were drawn from patients who had 25(OH)D checked and matched based on age, gender, race and health status. Serum 25(OH)D was stratified as < 15 ng/ mL, 15-30 ng/ mL or > 30 ng/ mL. Regression models adjusting for potential confounders were used to define independent association between vitamin D and CA-CDI.
Results: We identified 58 matched case-control pairs (66% women; 85% Caucasian). The mean age was 62 years. The mean serum 25(OH)D level was significantly lower in CA-CDI cases compared to controls (28.5 ng/ mL vs. 33.8 ng/ mL, p = 0.046). Cases had higher rate of antibiotic exposure and more comorbidity. Serum 25(OH) D < 15 ng/ mL was associated with an increased risk of CA-CDI on univariate (Odds ratio (OR) 5.10, 95% confidence interval (CI) 1.51 - 17.24) and multivariate analysis (OR 3.84, 95% CI 1.10 - 13.42). Vitamin D levels between 15-30 ng/ mL did not modify disease risk.
Conclusions: Low serum 25(OH)D < 15 ng/mL was associated with increased risk of CA-CDI. This suggests vitamin D may have a role in determining susceptibility to CA-CDI.
C1 [Sahay, Tanya] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
[Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Ananthakrishnan, Ashwin N.] MGH Crohns & Colitis Ctr, Boston, MA 02114 USA.
RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
EM aananthakrishnan@mgh.harvard.edu
FU National Institutes of Health [DK097142]
FX Dr. Ananthakrishnan is supported by a grant from the National Institutes
of Health (DK097142).
NR 45
TC 3
Z9 4
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 4
PY 2014
VL 14
AR 661
DI 10.1186/s12879-014-0661-6
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA AX6CR
UT WOS:000347011600001
PM 25471926
ER
PT J
AU Batista, PJ
Molinie, B
Wang, JK
Qu, K
Zhang, JJ
Li, LJ
Bouley, DM
Lujan, E
Haddad, B
Daneshvar, K
Carter, AC
Flynn, RA
Zhou, C
Lim, KS
Dedon, P
Wernig, M
Mullen, AC
Xing, Y
Giallourakis, CC
Chang, HY
AF Batista, Pedro J.
Molinie, Benoit
Wang, Jinkai
Qu, Kun
Zhang, Jiajing
Li, Lingjie
Bouley, Donna M.
Lujan, Ernesto
Haddad, Bahareh
Daneshvar, Kaveh
Carter, Ava C.
Flynn, Ryan A.
Zhou, Chan
Lim, Kok-Seong
Dedon, Peter
Wernig, Marius
Mullen, Alan C.
Xing, Yi
Giallourakis, Cosmas C.
Chang, Howard Y.
TI m(6)A RNA Modification Controls Cell Fate Transition in Mammalian
Embryonic Stem Cells
SO CELL STEM CELL
LA English
DT Article
ID LONG NONCODING RNA; MESSENGER-RNA; LINEAGE SPECIFIERS;
SACCHAROMYCES-CEREVISIAE; POSTNATAL-DEVELOPMENT; NUCLEAR-RNA;
PLURIPOTENCY; MOUSE; METHYLATION; REVEALS
AB N6-methyl-adenosine (m(6)A) is the most abundant modification on messenger RNAs and is linked to human diseases, but its functions in mammalian development are poorly understood. Here we reveal the evolutionary conservation and function of m(6)A by mapping the m(6)A methylome in mouse and human embryonic stem cells. Thousands of messenger and long noncoding RNAs show conserved m(6)A modification, including transcripts encoding core pluripotency transcription factors. m(6)A is enriched over 30 untranslated regions at defined sequence motifs and marks unstable transcripts, including transcripts turned over upon differentiation. Genetic inactivation or depletion of mouse and human Mettl3, one of the m(6)A methylases, led to m(6)A erasure on select target genes, prolonged Nanog expression upon differentiation, and impaired ESC exit from self-renewal toward differentiation into several lineages in vitro and in vivo. Thus, m(6)A is a mark of transcriptome flexibility required for stem cells to differentiate to specific lineages.
C1 [Batista, Pedro J.; Qu, Kun; Zhang, Jiajing; Li, Lingjie; Carter, Ava C.; Flynn, Ryan A.; Chang, Howard Y.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.
[Batista, Pedro J.; Qu, Kun; Zhang, Jiajing; Li, Lingjie; Carter, Ava C.; Flynn, Ryan A.; Chang, Howard Y.] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA.
[Molinie, Benoit; Daneshvar, Kaveh; Zhou, Chan; Mullen, Alan C.; Giallourakis, Cosmas C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA.
[Zhang, Jiajing; Xing, Yi] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
[Bouley, Donna M.] Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA.
[Lujan, Ernesto; Haddad, Bahareh; Wernig, Marius] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.
[Lujan, Ernesto; Haddad, Bahareh; Wernig, Marius] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.
[Lujan, Ernesto] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.
[Lim, Kok-Seong; Dedon, Peter] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Mullen, Alan C.; Giallourakis, Cosmas C.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Xing, Y (reprint author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
EM yxing@ucla.edu; cgiallourakis@mgh.harvard.edu; howchang@stanford.edu
RI Qu, Kun/G-3359-2012; Wang, Jinkai/H-1750-2015; Fang,
Fengqin/F-4387-2016; ZHOU, Chan/A-7110-2009;
OI ZHOU, Chan/0000-0002-0351-6235; Daneshvar, Kaveh/0000-0002-7863-0489;
Flynn, Ryan/0000-0001-5013-0442
FU California Institute for Regenerative Medicine; NIH [R01-CA118750,
DK090122]; MGH Start-Up Funds; MGH ECOR [2013A051178]; Eli and Edythe
Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
Research Award
FX We thank C. He, C. Mason, S. Schwartz, A. Regev, J.M. Claycomb, N. Van
Wittenberghe, B.D. Howard, and members of the Chang and Giallourakis
labs for discussions and assistance. We thank H.E. Arda and S.K. Kim for
help with FACS analysis and A. Memmelaar for his expertise in graphic
arts. This work was supported by the California Institute for
Regenerative Medicine and NIH R01-CA118750 (H.Y.C.), the MGH Start-Up
Funds and MGH ECOR grant 2013A051178 (C.C.G.), NIH grant DK090122
(A.C.M.), and the Eli and Edythe Broad Center of Regenerative Medicine
and Stem Cell Research at UCLA Research Award (Y.X.). P.J.B. is the
Kenneth G. and Elaine A. Langone Fellow of the Damon Runyon Cancer
Research Foundation. Y.X. is an Alfred Sloan Foundation Research Fellow.
H.Y.C. is an Early Career Scientist of the Howard Hughes Medical
Institute.
NR 44
TC 76
Z9 82
U1 5
U2 38
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD DEC 4
PY 2014
VL 15
IS 6
BP 707
EP 719
DI 10.1016/j.stem.2014.09.019
PG 13
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA AX8QS
UT WOS:000347174300010
PM 25456834
ER
PT J
AU Cuiffo, BG
Campagne, A
Bell, GW
Lembo, A
Orso, F
Lien, EC
Bhasin, MK
Raimo, M
Hanson, SE
Marusyk, A
El-Ashry, D
Hematti, P
Polyak, K
Mechta-Grigoriou, F
Mariani, O
Volinia, S
Vincent-Salomon, A
Taverna, D
Kamoub, AE
AF Cuiffo, Benjamin G.
Campagne, Antoine
Bell, George W.
Lembo, Antonio
Orso, Francesca
Lien, Evan C.
Bhasin, Manoj K.
Raimo, Monica
Hanson, Summer E.
Marusyk, Andriy
El-Ashry, Dorraya
Hematti, Peiman
Polyak, Kornelia
Mechta-Grigoriou, Fatima
Mariani, Odette
Volinia, Stefano
Vincent-Salomon, Anne
Taverna, Daniela
Kamoub, Antoine E.
TI MSC-Regulated MicroRNAs Converge on the Transcription Factor FOXP2 and
Promote Breast Cancer Metastasis
SO CELL STEM CELL
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; HUMAN OVARIAN-CANCER; EXPRESSION SIGNATURE;
TUMOR PROGRESSION; EMERGING ROLES; SURVIVAL; GROWTH; CARCINOGENESIS;
TUMORIGENESIS; TRANSITION
AB Mesenchymal stem/stromal cells (MSCs) are progenitor cells shown to participate in breast tumor stroma formation and to promote metastasis. Despite expanding knowledge of their contributions to breast malignancy, the underlying molecular responses of breast cancer cells (BCCs) to MSC influences remain incompletely understood. Here, we show that MSCs cause aberrant expression of microRNAs, which, led by microRNA-199a, provide BCCs with enhanced cancer stem cell (CSC) properties. We demonstrate that such MSC-deregulated microRNAs constitute a network that converges on and represses the expression of FOXP2, a forkhead transcription factor tightly associated with speech and language development. FOXP2 knockdown in BCCs was sufficient in promoting CSC propagation, tumor initiation, and metastasis. Importantly, elevated microRNA-199a and depressed FOXP2 expression levels are prominent features of malignant clinical breast cancer and are associated significantly with poor survival. Our results identify molecular determinants of cancer progression of potential utility in the prognosis and therapy of breast cancer.
C1 [Cuiffo, Benjamin G.; Campagne, Antoine; Lien, Evan C.; Kamoub, Antoine E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
[Campagne, Antoine; Mechta-Grigoriou, Fatima; Mariani, Odette; Vincent-Salomon, Anne] Inst Curie, F-75248 Paris 05, France.
[Bell, George W.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Lembo, Antonio; Orso, Francesca; Raimo, Monica; Taverna, Daniela] Univ Turin, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy.
[Lembo, Antonio; Orso, Francesca; Raimo, Monica; Taverna, Daniela] MBC, I-10126 Turin, Italy.
[Bhasin, Manoj K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.
[Hanson, Summer E.; Hematti, Peiman] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Madison, WI 53792 USA.
[Marusyk, Andriy; Polyak, Kornelia] Harvard Univ, Dana Farber Canc Inst, Sch Med, Dept Med Oncol, Boston, MA 02215 USA.
[Marusyk, Andriy; Polyak, Kornelia] Harvard Univ, Dept Med, Sch Med, Boston, MA 02215 USA.
[El-Ashry, Dorraya] Univ Miami, Miller Sch Med, Dept Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
[Volinia, Stefano] Univ Ferrara, Human Anat Branch, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy.
[Kamoub, Antoine E.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Kamoub, Antoine E.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
RP Kamoub, AE (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
EM akarnoub@bidmc.harvard.edu
RI taverna, daniela/J-8358-2016; Orso, Francesca/B-1985-2014;
MECHTA-GRIGORIOU, Fatima/C-5253-2017;
OI taverna, daniela/0000-0002-6365-527X; MECHTA-GRIGORIOU,
Fatima/0000-0002-3751-6989; Lien, Evan/0000-0001-7866-4761; Volinia,
Stefano/0000-0003-0910-3893
FU BIDMC; Sidney Kimmel Cancer Research Foundation; Susan G. Komen For The
Cure; AIRC [IG14201]; Compagnia di San Paolo [2008.1054]; Progetto
Ricerca Ateneo Torino; BIDMC Prostate and Breast Cancer Research Program
FX We thank J. Love, J.-A. Kwon, and S. Gupta for miRNA profiling data
analysis; A. Contreras for assistance in animal studies; K. Groglio and
M. Fahlberg for FACS sorting assistance; D. Louvard for assistance in
clinical specimen procurement; and P. Pandolfi and P. Provero for
helpful discussions. This work was supported by start-up funds from
BIDMC (A.E.K.), the Sidney Kimmel Cancer Research Foundation (A.E.K.),
the Susan G. Komen For The Cure (A.E.K.), AIRC IG14201 (D.T.), Compagnia
di San Paolo, 2008.1054 (D.T.), and Progetto Ricerca Ateneo Torino
(D.T.). Human BM-MSCs were provided by the Texas A&M Health Science
Center (CMI for Regenerative Medicine at Scott & White) through NIH
P40RR017447. B.G.C. is a 2012 American Cancer Society Postdoctoral
Fellow. F.O. is a recipient of FIRB giovani 2008 (RBFR08F2FS-276 002).
A.E.K. is a 2010 Kimmel Scholar, a recipient of a Career Development
Award from the BIDMC Prostate and Breast Cancer Research Program, and a
recipient of a 2012 Career Catalyst Research Award from Susan G. Komen
For The Cure.
NR 65
TC 25
Z9 26
U1 0
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD DEC 4
PY 2014
VL 15
IS 6
BP 762
EP 774
DI 10.1016/j.stem.2014.10.001
PG 13
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA AX8QS
UT WOS:000347174300014
PM 25515522
ER
PT J
AU Bruedigam, C
Bagger, FO
Heidel, FH
Kuhn, CP
Guignes, S
Song, A
Austin, R
Vu, T
Lee, E
Riyat, S
Moore, AS
Lock, RB
Bullinger, L
Hill, GR
Armstrong, SA
Williams, DA
Lane, SW
AF Bruedigam, Claudia
Bagger, Frederik O.
Heidel, Florian H.
Kuhn, Catherine Paine
Guignes, Solene
Song, Axia
Austin, Rebecca
Vu, Therese
Lee, Erwin
Riyat, Sarbjit
Moore, Andrew S.
Lock, Richard B.
Bullinger, Lars
Hill, Geoffrey R.
Armstrong, Scott A.
Williams, David A.
Lane, Steven W.
TI Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells
and Delays Relapse following Chemotherapy
SO CELL STEM CELL
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; SELF-RENEWAL; COMMITTED PROGENITOR;
GENE-EXPRESSION; DNA-DAMAGE; LIFE-SPAN; MICE; TRANSFORMATION; MUTATIONS;
HIERARCHY
AB Acute myeloid leukemia (AML) is an aggressive and lethal blood cancer maintained by rare populations of leukemia stem cells (LSCs). Selective targeting of LSCs is a promising approach for treating AML and preventing relapse following chemotherapy, and developing such therapeutic modalities is a key priority. Here, we show that targeting telomerase activity eradicates AML LSCs. Genetic deletion of the telomerase subunit Terc in a retroviral mouse AML model induces cell-cycle arrest and apoptosis of LSCs, and depletion of telomerase-deficient LSCs is partially rescued by p53 knockdown. Murine Terc(-/-) LSCs express a specific gene expression signature that can be identified in human AML patient cohorts and is positively correlated with patient survival following chemotherapy. In xenografts of primary human AML, genetic or pharmacological inhibition of telomerase targets LSCs, impairs leukemia progression, and delays relapse following chemotherapy. Altogether, these results establish telomerase inhibition as an effective strategy for eliminating AML LSCs.
C1 [Bruedigam, Claudia; Kuhn, Catherine Paine; Guignes, Solene; Song, Axia; Austin, Rebecca; Vu, Therese; Hill, Geoffrey R.; Lane, Steven W.] QIMR Berghofer Med Res Inst, Div Immunol, Brisbane, Qld 4006, Australia.
[Bagger, Frederik O.] Univ Copenhagen, Finsen Lab, Bioinformat Ctr, Dept Biol, DK-1165 Copenhagen, Denmark.
[Bagger, Frederik O.] Univ Copenhagen, BRIC, DK-1165 Copenhagen, Denmark.
[Heidel, Florian H.] Otto Von Guericke Univ, Univ Hosp, Dept Hematol & Oncol, D-39120 Magdeburg, Germany.
[Lee, Erwin; Lock, Richard B.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Sydney, NSW 2052, Australia.
[Riyat, Sarbjit; Hill, Geoffrey R.; Lane, Steven W.] Royal Brisbane & Womens Hosp, Dept Haematol, Brisbane, Qld 4006, Australia.
[Moore, Andrew S.] Queensland Childrens Med Res Inst, Brisbane, Qld 4029, Australia.
[Moore, Andrew S.; Hill, Geoffrey R.; Lane, Steven W.] Univ Queensland, Brisbane, Qld 4072, Australia.
[Bullinger, Lars] Univ Hosp Ulm, Dept Hematol & Oncol, D-89081 Ulm, Germany.
[Armstrong, Scott A.] Mem Sloan Kettering Leukemia Ctr, Dept Pediat, New York, NY 10065 USA.
[Williams, David A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol & Oncol, Cambridge, MA 02138 USA.
[Williams, David A.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Lane, SW (reprint author), QIMR Berghofer Med Res Inst, Div Immunol, Brisbane, Qld 4006, Australia.
EM steven.lane@qimrberghofer.edu.au
RI Lock, Richard/G-4253-2013; Moore, Andrew/I-6275-2012; Hill,
Geoffrey/O-2630-2016;
OI Moore, Andrew/0000-0001-8062-1779; Hill, Geoffrey/0000-0003-2994-0429;
Otzen Bagger, Frederik/0000-0003-0636-8845
FU Leukaemia Foundation of Queensland; National Health and Medical Research
Council; In Vitro Technologies; Pfizer Cancer Research Grant; Rio Tinto
Ride to Conquer Cancer; NIH [CA66996, CA140575]
FX We acknowledge the generous contribution of imetelstat, provided by
Geron Corporation. We gratefully acknowledge the technical assistance of
Amity Roberts, Glen Boyle, Grace Chojnowski, and Paula Hall (flow
cytometry) and the members of the QIMR-Berghofer Animal House. We thank
Stephen Sykes, Mark Smyth, Kelli MacDonald, and members of their
laboratories for their helpful discussion. S.W.L. and G.R.H. have
received funding from the Leukaemia Foundation of Queensland and the
National Health and Medical Research Council. S.W.L. is the recipient of
the Rhys Pengelly Fellowship in Leukaemia Research from In Vitro
Technologies and Pfizer Cancer Research Grant. C.B., G.R.H., and S.W.L.
have received funding from the Rio Tinto Ride to Conquer Cancer. S. A.
A. acknowledges funding from the NIH (CA66996 and CA140575).
NR 47
TC 17
Z9 20
U1 1
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD DEC 4
PY 2014
VL 15
IS 6
BP 775
EP 790
DI 10.1016/j.stem.2014.11.010
PG 16
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA AX8QS
UT WOS:000347174300015
PM 25479751
ER
PT J
AU Kumar, RM
Cahan, P
Shalek, AK
Satija, R
DaleyKeyser, A
Li, H
Zhang, J
Pardee, K
Gennert, D
Trombetta, JJ
Ferrante, TC
Regev, A
Daley, GQ
Collins, JJ
AF Kumar, Roshan M.
Cahan, Patrick
Shalek, Alex K.
Satija, Rahul
DaleyKeyser, Ajay
Li, Hu
Zhang, Jin
Pardee, Keith
Gennert, David
Trombetta, John J.
Ferrante, Thomas C.
Regev, Aviv
Daley, George Q.
Collins, James J.
TI Deconstructing transcriptional heterogeneity in pluripotent stem cells
SO NATURE
LA English
DT Article
ID SELF-RENEWAL; RNA-SEQ; GENE-EXPRESSION; GROUND-STATE; MICRORNA; NOISE;
GENERATION; NANOG; BIOLOGY; DIFFERENTIATION
AB Pluripotent stem cells (PSCs) are capable of dynamic interconversion between distinct substates; however, the regulatory circuits specifying these states and enabling transitions between them are not well understood. Here we set out to characterize transcriptional heterogeneity in mouse PSCs by single-cell expression profiling under different chemical and genetic perturbations. Signalling factors and developmental regulators show highly variable expression, with expression states for some variable genes heritable through multiple cell divisions. Expression variability and population heterogeneity can be influenced by perturbation of signalling pathways and chromatin regulators. Notably, either removal of mature microRNAs or pharmacological blockage of signalling pathways drives PSCs into a low-noise ground state characterized by a reconfigured pluripotency network, enhanced self-renewal and a distinct chromatin state, an effect mediated by opposing microRNA families acting on the Myc/Lin28/let-7 axis. These data provide insight into the nature of transcriptional heterogeneity in PSCs.
C1 [Kumar, Roshan M.; DaleyKeyser, Ajay; Pardee, Keith; Ferrante, Thomas C.; Collins, James J.] Harvard Univ, Wyss lnst Biologically Inspired Engn, Boston, MA 02115 USA.
[Kumar, Roshan M.; Pardee, Keith; Collins, James J.] Boston Univ, Ctr Synthet Biol, Dept Biomed Engn, Howard Hughes Inst, Boston, MA 02215 USA.
[Cahan, Patrick; Zhang, Jin; Daley, George Q.] Boston Childrens Hosp, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA 02115 USA.
[Cahan, Patrick; Daley, George Q.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Dana Farber Canc Inst,Dept Biol Chem & Mol Pharma, Boston, MA 02115 USA.
[Shalek, Alex K.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Shalek, Alex K.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.
[Satija, Rahul; Gennert, David; Trombetta, John J.; Regev, Aviv] Harvard Univ, MIT, Broad Inst, Cambridge Ctr 7, Cambridge, MA 02142 USA.
[Li, Hu] Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Ctr Individualized Med, Rochester, MN 55905 USA.
[Regev, Aviv] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02140 USA.
RP Daley, GQ (reprint author), Harvard Univ, Sch Med,Manton Ctr Orphan Dis Res, Harvard Stem Cell Inst,Howard Hughes Med Inst, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA 02115 USA.
EM george.daley@childrens.harvard.edu; jcollins@bu.edu
OI Shalek, Alex K./0000-0001-5670-8778; Cahan, Patrick/0000-0003-3652-2540
FU NIH [R24DK092760, R01GM107536, P50HG005550]; HHMI; Broad Institute;
Klarman Cell Observatory at the Broad Institute; NIH CEGS
[1P50HG006193-01]; NIH Pioneer Award [DP1OD003958-01]; Wyss Institute;
NIDDK [K01DK096013]; NHLBI [T32HL066987, T32HL007623]; Manton Center for
Orphan Disease Research; NIH Postdoctoral Fellowship [1F32HD075541-01];
Mayo Clinic Center for Individualized Medicine; [NIH-P30-HD18655]
FX We thank members of the Collins and Daley laboratories for discussions.
J.J.C. is supported by NIH grant R24DK092760 and the HHMI. G.Q.D. is
supported by grants from the NIH (R01GM107536, R24DK092760, P50HG005550)
and is an affiliate member of the Broad Institute and an investigator of
the Manton Center for Orphan Disease Research and the Howard Hughes
Medical Institute. A.R. is supported by the Broad Institute, the Klarman
Cell Observatory at the Broad Institute, an NIH CEGS (1P50HG006193-01),
an NIH Pioneer Award (DP1OD003958-01) and the HHMI. R.M.K. is supported
by the Wyss Institute. P.C. is supported by NIDDK (K01DK096013) and
received support from NHLBI (T32HL066987 and T32HL007623) and the Manton
Center for Orphan Disease Research. R.S. was supported by an NIH
Postdoctoral Fellowship (1F32HD075541-01). H.L. is supported by the Mayo
Clinic Center for Individualized Medicine. Sequencing was performed by
the Broad Institute Genomics Platform. Flow cytometry was performed in
the Hematologic Neoplasia Flow Cytometry Facility at the Dana-Farber
Cancer Institute and the BCH IDDRC Stem Cell Core Facility at Boston
Children's Hospital supported by NIH-P30-HD18655. Single-cell qPCR
experiments were performed at the BCH IDDRC Molecular Genetics Core
Facility at Children's Hospital Boston supported by NIH-P30-HD18655.
Fludigm C1 experiments were performed at the Broad Institute
and the Biopolymers Facility at Harvard Medical School.
NR 69
TC 86
Z9 86
U1 5
U2 53
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 4
PY 2014
VL 516
IS 7529
BP 56
EP U112
DI 10.1038/nature13920
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW5JD
UT WOS:000346310800037
PM 25471879
ER
PT J
AU Duan, JB
Shi, JX
Fiorentino, A
Leites, C
Chen, XN
Moy, W
Chen, JC
Alexandrov, BS
Usheva, A
He, DL
Freda, J
O'Brien, NL
McQuillin, A
Sanders, AR
Gershon, ES
DeLisi, LE
Bishop, AR
Gurling, HMD
Pato, MT
Levinson, DF
Kendler, KS
Pato, CN
Gejman, PV
AF Duan, Jubao
Shi, Jianxin
Fiorentino, Alessia
Leites, Catherine
Chen, Xiangning
Moy, Winton
Chen, Jingchun
Alexandrov, Boian S.
Usheva, Anny
He, Deli
Freda, Jessica
O'Brien, Niamh L.
McQuillin, Andrew
Sanders, Alan R.
Gershon, Elliot S.
DeLisi, Lynn E.
Bishop, Alan R.
Gurling, Hugh M. D.
Pato, Michele T.
Levinson, Douglas F.
Kendler, Kenneth S.
Pato, Carlos N.
Gejman, Pablo V.
CA MGS
GPC
TI A Rare Functional Noncoding Variant at the GWAS-Implicated
MIR137/MIR2682 Locus Might Confer Risk to Schizophrenia and Bipolar
Disorder
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; MACULAR
DEGENERATION; COMMON VARIANTS; PSYCHIATRIC-DISORDERS; TRANSCRIPTION
FACTOR; REGULATORY ELEMENTS; LOW-FREQUENCY; STEM-CELLS; MIR137
AB Schizophrenia (SZ) genome-wide association studies (GWASs) have identified common risk variants in >100 susceptibility loci; however, the contribution of rare variants at these loci remains largely unexplored. One of the strongly associated loci spans MIR137 (miR137) and M1R2682 (miR2682), two microRNA genes important for neuronal function. We sequenced -6.9 kb MIR137/MIR2682 and upstream regulatory sequences in 2,610 SZ cases and 2,611 controls of European ancestry. We identified 133 rare variants with minor allele frequency (MAF) <0.5%. The rare variant burden in promoters and enhancers, but not insulators, was associated with SZ (p = 0.021 for MAF < 0.5%, p = 0.003 for MAF < 0.1%). A rare enhancer SNP, 1:g.98515539A>T, presented exclusively in 11 SZ cases (nominal p = 4.8 x 10(-4) ). We further identified its risk allele Tin 2 of 2,434 additional SZ cases, 11 of 4,339 bipolar (BP) cases, and 3 of 3,572 SZ/BP study controls and 1,688 population controls; yielding combined p values of 0.0007, 0.0013, and 0.0001 for SZ, BP, and SZ/BP, respectively. The risk allele T of 1:g.98515539A>T reduced enhancer activity of its flanking sequence by >50% in human neuroblastoma cells, predicting lower expression of MIR137/MIR2682. Both empirical and computational analyses showed weaker transcription factor (YY1) binding by the risk allele. Chromatin conformation capture (3C) assay further indicated that 1:g.98515539A>T influenced MIR137/MIR2682, but not the nearby DPYD or LOC729987. Our results suggest that rare noncoding risk variants are associated with SZ and BP at MIR137/MIR2682 locus, with risk alleles decreasing MIR137/MIR2682 expression.
C1 [Duan, Jubao; Leites, Catherine; Moy, Winton; He, Deli; Freda, Jessica; Sanders, Alan R.; Gejman, Pablo V.] NorthShore Univ HealthSyst, Dept Psychiat & Behav Sci, Ctr Psychiat Genet, Evanston, IL 60201 USA.
[Duan, Jubao; Sanders, Alan R.; Gershon, Elliot S.; Gejman, Pablo V.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
[Shi, Jianxin] NCI, Biostat Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Fiorentino, Alessia; O'Brien, Niamh L.; McQuillin, Andrew; Gurling, Hugh M. D.] UCL, Mol Psychiat Lab, Div Psychiat, London WC1E 6JJ, England.
[Chen, Xiangning; Chen, Jingchun; Kendler, Kenneth S.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23298 USA.
[Alexandrov, Boian S.; Usheva, Anny] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Alexandrov, Boian S.; Bishop, Alan R.] Los Alamos Natl Lab, Los Alamos, NM 87544 USA.
[DeLisi, Lynn E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Brockton, MA 02301 USA.
[Pato, Michele T.; Pato, Carlos N.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.
[Levinson, Douglas F.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94305 USA.
RP Duan, JB (reprint author), NorthShore Univ HealthSyst, Dept Psychiat & Behav Sci, Ctr Psychiat Genet, Evanston, IL 60201 USA.
EM jduan@uchicago.edu
RI Macciardi, Fabio/N-3768-2014; McQuillin, Andrew/C-1623-2008;
OI Macciardi, Fabio/0000-0003-0537-4266; McQuillin,
Andrew/0000-0003-1567-2240; Nicolini, Humberto/0000-0003-2494-0067;
Alexandrov, Boian/0000-0001-8636-4603
FU Wellcome Trust [WT091310]; NIH [R01MH067257, R01MH059588, R01MH059565,
R01MH059587, R01MH060870, R01MH059566, R01MH059586, R01MH061675,
R01MH060879, U01MH046276, U01MH079470]; MRC [G1000708]; National Nuclear
Security Administration of the US Department of Energy; LANL, LDRD
[20110516ECR]; National Institutes of Health (NIH) [R21MH102685];
NorthShore University HealthSystem Research Career Development Award;
[R01MH059571]; [R01MH081800]; [U01MH079469]; [MH085548]; [MH085542]
FX We thank the study participants of MGS, CNG, ICCSS, ISHDSF, UCL, GPC,
NIME-BP collections. This study also makes use of whole-genome
sequencing data (TwinsUK) generated by the UK10K Consortium. A full list
of the investigators who contributed to the generation of the data is
available from UK10K Project homepage. Wellcome Trust award WT091310
provided funding for UK10K. We also thank K. Fang and N. Park (Illinois
Mathematics and Science Academy) for their technical help with the 3C
experiment. This work was primarily supported by R01MH059571,
R01MH081800, and U01MH079469 (to P.V.G.) and other NIH grants for MGS
(R01MH067257 to N.G.B., R01MH059588 to B.J.M., R01MH059565 to R.F.,
R01MH059587 to F.A., R01MH060870 to W.F.B., R01MH059566 to D.W.B.,
R01MH059586 to J.M.S., R01MH061675 to D.F.L., R01MH060879 to C.R.C.,
U01MH046276 to C.R.C., and U01MH079470 to D.F.L). GPC was supported by
MH085548 and MH085542 (to C.N.P and M.T.P). UCL genotyping was supported
by MRC grant G1000708 (to H.M.D.G. and A.M.). The computational modeling
of transcription factor binding at Los Alamos National Laboratory was
carried out under the auspices of the National Nuclear Security
Administration of the US Department of Energy and was supported by the
LANL, LDRD, 20110516ECR grant (to B.S.A.). This work was also partially
supported by National Institutes of Health (NIH) grant R21MH102685 and
NorthShore University HealthSystem Research Career Development Award (to
J.D.).
NR 76
TC 17
Z9 17
U1 1
U2 21
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD DEC 4
PY 2014
VL 95
IS 6
BP 744
EP 753
DI 10.1016/j.ajhg.2014.11.001
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA AX0DH
UT WOS:000346623100011
PM 25434007
ER
PT J
AU Duan, B
Cheng, LZ
Bourane, S
Britz, O
Padilla, C
Garcia-Campmany, L
Krashes, M
Knowlton, W
Velasquez, T
Ren, XY
Ross, SE
Lowell, BB
Wang, Y
Goulding, M
Ma, QF
AF Duan, Bo
Cheng, Longzhen
Bourane, Steeve
Britz, Olivier
Padilla, Christopher
Garcia-Campmany, Lidia
Krashes, Michael
Knowlton, Wendy
Velasquez, Tomoko
Ren, Xiangyu
Ross, Sarah E.
Lowell, Bradford B.
Wang, Yun
Goulding, Martyn
Ma, Qiufu
TI Identification of Spinal Circuits Transmitting and Gating Mechanical
Pain
SO CELL
LA English
DT Article
ID SUBSTANTIA-GELATINOSA NEURONS; SUPERFICIAL DORSAL-HORN; NEUROPATHIC
PAIN; MARGINAL ZONE; SOMATIC SENSATIONS; GABAERGIC NEURONS; THERMAL
STIMULI; SENSORY NEURONS; CELLULAR BASIS; NERVE INJURY
AB Pain information processing in the spinal cord has been postulated to rely on nociceptive transmission (T) neurons receiving inputs from nociceptors and A beta mechanoreceptors, with A beta inputs gated through feed-forward activation of spinal inhibitory neurons (INs). Here, we used intersectional genetic manipulations to identify these critical components of pain transduction. Marking and ablating six populations of spinal excitatory and inhibitory neurons, coupled with behavioral and electrophysiological analysis, showed that excitatory neurons expressing somatostatin (SOM) include T-type cells, whose ablation causes loss of mechanical pain. Inhibitory neurons marked by the expression of dynorphin (Dyn) represent INs, which are necessary to gate A beta fibers from activating SOM+ neurons to evoke pain. Therefore, peripheral mechanical nociceptors and A beta mechanoreceptors, together with spinal SOM+ excitatory and Dyn(+) inhibitory neurons, form a microcircuit that transmits and gates mechanical pain.
C1 [Duan, Bo; Cheng, Longzhen; Knowlton, Wendy; Ma, Qiufu] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Duan, Bo; Cheng, Longzhen; Knowlton, Wendy; Ma, Qiufu] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
[Bourane, Steeve; Britz, Olivier; Padilla, Christopher; Garcia-Campmany, Lidia; Velasquez, Tomoko; Goulding, Martyn] Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.
[Garcia-Campmany, Lidia; Krashes, Michael; Lowell, Bradford B.] Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA.
[Garcia-Campmany, Lidia; Krashes, Michael; Lowell, Bradford B.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Ross, Sarah E.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA.
[Ross, Sarah E.] Univ Pittsburgh, Pain Ctr, Pittsburgh, PA 15213 USA.
[Cheng, Longzhen; Wang, Yun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.
[Cheng, Longzhen; Wang, Yun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
RP Goulding, M (reprint author), Salk Inst Biol Studies, Mol Neurobiol Lab, 10010 North Torrey Pines Rd, La Jolla, CA 92037 USA.
EM goulding@salk.edu; Qiufu_Ma@dfci.harvard.edu
FU NIH [R01NS086372, NS047710, P01 NS072040, R01 NS 080586, P01 NS072031,
R01 AR063772, R21 AR064445, R01 DK075632, R37 DK053477, R01 DK071051,
R01 DK089044, R01 DK096010, P30 DK057521, P30 DK046200, F32 DK089710];
National Natural Science Foundation of China [81171224, 81100815]
FX We thank Dr. Z. Josh Huang and the Jackson laboratory for the
SOM-IRES-Cre and Calb2-IRES-Cre mice, GENSAT and MMRRC at University of
California, Davis, for the NPY-Cre mice, the Allen Brain Institute, and
the Jackson Laboratory for the Rosa26LSL-tdTomato mice, and
Dr. Susan Dymecki for the ROSA26CAG-FRT-STOP-FRT-GFP mice. We
thank Drs. Yan Lu, Clifford Woolf, and Fu-Chia Yang for critical
comments on the manuscript; Dr Yan Lu for his advice on spinal cord
slice recording; and Dr. Enrique Jose Cobos for providing the scoring
system in measuring dynamic allodynia. The Ma lab was supported by NIH
grants (R01NS086372, NS047710, and P01 NS072040), the Goulding lab is
supported by NIH grants (R01NS086372, R01 NS 080586, and P01 NS072031),
the Ross lab is supported by NIH grants (R01 AR063772 and R21 AR064445),
and the Lowell lab was supported by NIH grants (R01 DK075632, R37
DK053477, R01 DK071051, R01 DK089044, R01 DK096010, P30 DK057521, and
P30 DK046200). M.K. was supported by F32 DK089710. L.C. and Y.W. were
supported by grants from the National Natural Science Foundation of
China (81171224 and 81100815).
NR 69
TC 58
Z9 58
U1 10
U2 48
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD DEC 4
PY 2014
VL 159
IS 6
BP 1417
EP 1432
DI 10.1016/j.cell.2014.11.003
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AX0PA
UT WOS:000346652900019
PM 25467445
ER
PT J
AU Sulahian, R
Casey, F
Shen, J
Qian, ZR
Shin, H
Ogino, S
Weir, BA
Vazquez, F
Liu, XS
Hahn, WC
Bass, AJ
Chan, V
Shivdasani, RA
AF Sulahian, R.
Casey, F.
Shen, J.
Qian, Z. R.
Shin, H.
Ogino, S.
Weir, B. A.
Vazquez, F.
Liu, X. S.
Hahn, W. C.
Bass, A. J.
Chan, V.
Shivdasani, R. A.
TI An integrative analysis reveals functional targets of GATA6
transcriptional regulation in gastric cancer
SO ONCOGENE
LA English
DT Article
DE transcriptional control of cancer; synexpression groups; somatic copy
number alterations; ChIP-seq; GATA transcription factors
ID LINEAGE-SURVIVAL ONCOGENE; GENE-EXPRESSION; STEM-CELLS; DIFFERENTIATION;
ADENOCARCINOMA; PATTERNS; STOMACH; GENOME; AMPLIFICATION; INTESTINE
AB Lineage-restricted transcription factors (TFs) are frequently mutated or overexpressed in cancer and contribute toward malignant behaviors; however, the molecular bases of their oncogenic properties are largely unknown. As TF activities are difficult to inhibit directly with small molecules, the genes and pathways they regulate might represent more tractable targets for drug therapy. We studied GATA6, a TF gene that is frequently amplified or overexpressed in gastric, esophageal and pancreatic adenocarcinomas. GATA6-overexpressing gastric cancer cell lines cluster in gene expression space, separate from non-overexpressing lines. This expression clustering signifies a shared pathogenic group of genes that GATA6 may regulate through direct cis-element binding. We used chromatin immunoprecipitation and sequencing (ChIP-seq) to identify GATA6-bound genes and considered TF occupancy in relation to genes that respond to GATA6 depletion in cell lines and track with GATA6 mRNA (synexpression groups) in primary gastric cancers. Among other cellular functions, GATA6-occupied genes control apoptosis and govern the M-phase of the cell cycle. Depletion of GATA6 reduced the levels of the latter transcripts and arrested cells in G2 and M phases of the cell cycle. Synexpression in human tumor samples identified likely direct transcriptional targets substantially better than consideration only of transcripts that respond to GATA6 loss in cultured cells. Candidate target genes responded to the loss of GATA6 or its homolog GATA4 and even more to the depletion of both proteins. Many GATA6-dependent genes lacked nearby binding sites but several strongly dependent, synexpressed and GATA6-bound genes encode TFs such as MYC, HES1, RARB and CDX2. Thus, many downstream effects occur indirectly through other TFs and GATA6 activity in gastric cancer is partially redundant with GATA4. This integrative analysis of locus occupancy, gene dependency and synexpression provides a functional signature of GATA6-overexpressing gastric cancers, revealing both limits and new therapeutic directions for a challenging and frequently fatal disease.
C1 [Sulahian, R.; Qian, Z. R.; Ogino, S.; Weir, B. A.; Vazquez, F.; Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Sulahian, R.; Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Casey, F.; Shen, J.; Chan, V.] Novartis Inst Biomed Res, Emeryville, CA USA.
[Qian, Z. R.; Ogino, S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA.
[Qian, Z. R.; Ogino, S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Shin, H.; Liu, X. S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Shivdasani, RA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM ramesh_shivdasani@dfci.harvard.edu
FU Dana-Farber Cancer Institute-Novartis Drug Discovery Program; National
Institutes of Health [R01CA151993, R01HG4069, K08CA134931]; SPORE
program in GI cancers [P50 CA127003]
FX This study was supported by the Dana-Farber Cancer Institute-Novartis
Drug Discovery Program and National Institutes of Health awards
R01CA151993 (SO), R01HG4069 (XSL), K08CA134931 (AJB) and the SPORE
program in GI cancers P50 CA127003. Data associated with this study are
available in the GEO, GSE51936.
NR 49
TC 13
Z9 13
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD DEC 4
PY 2014
VL 33
IS 49
BP 5637
EP 5648
DI 10.1038/onc.2013.517
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA AW1ZW
UT WOS:000346088700008
PM 24317510
ER
PT J
AU Sequist, TD
Taveras, EM
AF Sequist, Thomas D.
Taveras, Elsie M.
TI Clinic-Community Linkages for High-Value Care
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Sequist, Thomas D.] Harvard Univ, Brigham & Womens Hosp, Partners HealthCare Syst, Dept Hlth Care Policy,Med Sch,Div Gen Med, Boston, MA 02115 USA.
[Taveras, Elsie M.] Massachusetts Gen Hosp, Div Gen Pediat, Boston, MA 02114 USA.
RP Sequist, TD (reprint author), Harvard Univ, Brigham & Womens Hosp, Partners HealthCare Syst, Dept Hlth Care Policy,Med Sch,Div Gen Med, Boston, MA 02115 USA.
NR 4
TC 8
Z9 8
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 4
PY 2014
VL 371
IS 23
BP 2148
EP 2150
DI 10.1056/NEJMp1408457
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW0IY
UT WOS:000345976700002
PM 25470692
ER
PT J
AU Mauri, L
Kereiakes, DJ
Yeh, RW
Driscoll-Shempp, P
Cutlip, DE
Steg, PG
Normand, SLT
Braunwald, E
Wiviott, SD
Cohen, DJ
Holmes, DR
Krucoff, MW
Hermiller, J
Dauerman, HL
Simon, DI
Kandzari, DE
Garratt, KN
Lee, DP
Pow, TK
Lee, PV
Rinaldi, MJ
Massaro, JM
AF Mauri, Laura
Kereiakes, Dean J.
Yeh, Robert W.
Driscoll-Shempp, Priscilla
Cutlip, Donald E.
Steg, P. Gabriel
Normand, Sharon-Lise T.
Braunwald, Eugene
Wiviott, Stephen D.
Cohen, David J.
Holmes, David R., Jr.
Krucoff, Mitchell W.
Hermiller, James
Dauerman, Harold L.
Simon, Daniel I.
Kandzari, David E.
Garratt, Kirk N.
Lee, David P.
Pow, Thomas K.
Lee, Peter Ver
Rinaldi, Michael J.
Massaro, Joseph M.
CA DAPT Study Investigators
TI Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting
Stents
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION;
CLINICAL-OUTCOMES; RANDOMIZED-TRIAL; HEART-ASSOCIATION; CLOPIDOGREL;
ASPIRIN; EVENTS; IMPLANTATION; DEFINITIONS
AB BACKGROUND
Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain.
METHODS
Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding.
RESULTS
A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P = 0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P = 0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment.
CONCLUSIONS
Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding.
C1 [Mauri, Laura; Yeh, Robert W.; Driscoll-Shempp, Priscilla; Cutlip, Donald E.; Massaro, Joseph M.] Harvard Clin Res Inst, Boston, MA USA.
[Mauri, Laura; Braunwald, Eugene; Wiviott, Stephen D.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Mauri, Laura; Yeh, Robert W.; Cutlip, Donald E.; Normand, Sharon-Lise T.; Braunwald, Eugene; Wiviott, Stephen D.] Harvard Univ, Sch Med, Boston, MA USA.
[Yeh, Robert W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Kereiakes, Dean J.] Christ Hosp, Heart & Vasc Ctr, Cincinnati, OH 45219 USA.
[Kereiakes, Dean J.] Lindner Ctr Res & Educ, Cincinnati, OH USA.
[Steg, P. Gabriel] Hop Bichat Claude Bernard, AP HP, Dept Hosp Univ Fibrosis, INSERM,U1148, F-75877 Paris, France.
[Steg, P. Gabriel] Univ Paris Diderot, Paris, France.
[Steg, P. Gabriel] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, Inst Cardiovasc Med & Sci, London, England.
[Cohen, David J.] Univ Missouri, Sch Med, St Lukes Mid Amer Heart Inst, Kansas City, MO 64108 USA.
[Holmes, David R., Jr.] Mayo Clin, Rochester, MN USA.
[Krucoff, Mitchell W.] Duke Univ, Med Ctr, Durham, NC USA.
[Rinaldi, Michael J.] Carolinas HealthCare Syst, Sanger Heart & Vasc Inst, Charlotte, NC USA.
[Hermiller, James] St Vincent Heart Ctr, Indianapolis, IN USA.
[Dauerman, Harold L.] Univ Vermont, Burlington, VT USA.
[Simon, Daniel I.] Univ Hosp Case Med Ctr, Cleveland, OH USA.
[Kandzari, David E.] Piedmont Heart Inst, Atlanta, GA USA.
[Garratt, Kirk N.] Lenox Hill Hosp, New York, NY 10021 USA.
[Lee, David P.] Stanford Univ, Stanford, CA 94305 USA.
[Pow, Thomas K.] Great Lakes Heart & Vasc Inst, St Joseph, MI USA.
[Lee, Peter Ver] Eastern Maine Med Ctr, Bangor, ME USA.
RP Mauri, L (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
EM lmauri1@partners.org
FU Abbott; Boston Scientific; Cordis; Medtronic; Bristol-Myers
Squibb-Sanofi Pharmaceuticals; Eli Lilly; Daiichi Sankyo; Department of
Health and Human Services [1RO1FD003870-01]
FX Supported by Abbott, Boston Scientific, Cordis, and Medtronic,
Bristol-Myers Squibb-Sanofi Pharmaceuticals Partnership, Eli Lilly, and
Daiichi Sankyo, and by a grant (1RO1FD003870-01) from the Department of
Health and Human Services.
NR 35
TC 435
Z9 447
U1 5
U2 35
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 4
PY 2014
VL 371
IS 23
BP 2155
EP 2166
DI 10.1056/NEJMoa1409312
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW0IY
UT WOS:000345976700004
PM 25399658
ER
PT J
AU Smith, PK
Puskas, JD
Ascheim, DD
Voisine, P
Gelijns, AC
Moskowitz, AJ
Hung, JW
Parides, MK
Ailawadi, G
Perrault, LP
Acker, MA
Argenziano, M
Thourani, V
Gammie, JS
Miller, MA
Page, P
Overbey, JR
Bagiella, E
Dagenais, F
Blackstone, EH
Kron, IL
Rose, EA
Moquete, EG
Jeffries, N
Gardner, TJ
O'Gara, PT
Alexander, JH
Michler, RE
AF Smith, P. K.
Puskas, J. D.
Ascheim, D. D.
Voisine, P.
Gelijns, A. C.
Moskowitz, A. J.
Hung, J. W.
Parides, M. K.
Ailawadi, G.
Perrault, L. P.
Acker, M. A.
Argenziano, M.
Thourani, V.
Gammie, J. S.
Miller, M. A.
Page, P.
Overbey, J. R.
Bagiella, E.
Dagenais, F.
Blackstone, E. H.
Kron, I. L.
Rose, E. A.
Moquete, E. G.
Jeffries, N.
Gardner, T. J.
O'Gara, P. T.
Alexander, J. H.
Michler, R. E.
CA Cardiothoracic Surg Trials Network
TI Surgical Treatment of Moderate Ischemic Mitral Regurgitation
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID MYOCARDIAL-INFARCTION; HEART-FAILURE; THORACIC SURGEONS;
CLINICAL-TRIALS; SURVIVAL; REVASCULARIZATION; ECHOCARDIOGRAPHY;
ASSOCIATION; DETERMINANT; MECHANISM
AB BACKGROUND
Ischemic mitral regurgitation is associated with increased mortality and morbidity. For surgical patients with moderate regurgitation, the benefits of adding mitralvalve repair to coronary-artery bypass grafting (CABG) are uncertain.
METHODS
We randomly assigned 301 patients with moderate ischemic mitral regurgitation to CABG alone or CABG plus mitral-valve repair (combined procedure). The primary end point was the left ventricular end-systolic volume index (LVESVI), a measure of left ventricular remodeling, at 1 year. This end point was assessed with the use of a Wilcoxon rank-sum test in which deaths were categorized as the lowest LVESVI rank.
RESULTS
At 1 year, the mean LVESVI among surviving patients was 46.1+/-22.4 ml per square meter of body-surface area in the CABG-alone group and 49.6+/-31.5 ml per square meter in the combined-procedure group (mean change from baseline, -9.4 and -9.3 ml per square meter, respectively). The rate of death was 6.7% in the combined-procedure group and 7.3% in the CABG-alone group (hazard ratio with mitral-valve repair, 0.90; 95% confidence interval, 0.38 to 2.12; P = 0.81). The rank-based assessment of LVESVI at 1 year (incorporating deaths) showed no significant between-group difference (z score, 0.50; P = 0.61). The addition of mitral-valve repair was associated with a longer bypass time (P<0.001), a longer hospital stay after surgery (P = 0.002), and more neurologic events (P = 0.03). Moderate or severe mitral regurgitation was less common in the combined-procedure group than in the CABG-alone group (11.2% vs. 31.0%, P<0.001). There were no significant between-group differences in major adverse cardiac or cerebrovascular events, deaths, readmissions, functional status, or quality of life at 1 year.
CONCLUSIONS
In patients with moderate ischemic mitral regurgitation, the addition of mitral-valve repair to CABG did not result in a higher degree of left ventricular reverse remodeling. Mitral-valve repair was associated with a reduced prevalence of moderate or severe mitral regurgitation but an increased number of untoward events. Thus, at 1 year, this trial did not show a clinically meaningful advantage of adding mitral-valve repair to CABG. Longer-term follow-up may determine whether the lower prevalence of mitral regurgitation translates into a net clinical benefit.
C1 [Smith, P. K.] Duke Univ, Med Ctr, Dept Surg, Div Cardiovasc & Thorac Surg, Durham, NC 27710 USA.
[Alexander, J. H.] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.
[Puskas, J. D.; Rose, E. A.] Icahn Sch Med Mt Sinai, Mt Sinai Hlth Syst, Dept Cardiac Surg, New York, NY 10029 USA.
[Ascheim, D. D.; Gelijns, A. C.; Moskowitz, A. J.; Parides, M. K.; Overbey, J. R.; Bagiella, E.; Moquete, E. G.] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, Int Ctr Hlth Outcomes & Innovat Res, New York, NY 10029 USA.
[Argenziano, M.] Columbia Univ, Coll Phys & Surg, Dept Surg, Dept Cardiothorac Surg, New York, NY USA.
[Michler, R. E.] Albert Einstein Coll Med, Monash Med Ctr, Dept Cardiothorac & Vasc Surg, New York, NY USA.
[Voisine, P.; Dagenais, F.] Hop Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.
[Perrault, L. P.] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
[Page, P.] Hop Sacre Coeur, Dept Surg, Montreal, PQ H4J 1C5, Canada.
[Hung, J. W.] Massachusetts Gen Hosp, Echocardiog Core Lab, Boston, MA 02114 USA.
[O'Gara, P. T.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Ailawadi, G.; Kron, I. L.] Univ Virginia, Sch Med, Div Thorac & Cardiovasc Surg, Charlottesville, VA 22908 USA.
[Acker, M. A.] Univ Penn, Sch Med, Dept Surg, Div Cardiovasc Surg, Philadelphia, PA 19104 USA.
[Thourani, V.] Emory Univ, Sch Med, Div Cardiothorac Surg, Clin Res Unit, Atlanta, GA 30322 USA.
[Gammie, J. S.] Univ Maryland, Baltimore, MD 21201 USA.
[Miller, M. A.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Jeffries, N.] NHLBI, Off Biostat Res, Bethesda, MD 20892 USA.
[Blackstone, E. H.] Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH USA.
[Gardner, T. J.] Christiana Care Hlth Syst, Ctr Heart & Vasc Hlth, Newark, DE USA.
RP Gelijns, AC (reprint author), Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, 1 Gustave L Levy Pl,Box 1077, New York, NY 10029 USA.
EM annetine.gelijns@mssm.edu
RI Stevens, Louis-Mathieu/E-6453-2016;
OI Stevens, Louis-Mathieu/0000-0003-3372-3419; Moskowitz,
Alan/0000-0002-4412-9450; Browndyke, Jeffrey/0000-0002-8573-7073
FU National Heart, Lung, and Blood Institute [U01 HL088942]; National
Institute of Neurological Disorders and Stroke; Canadian Institutes of
Health Research; Thoratec and HeartWare; Edwards Lifesciences; St. Jude
Medical; Sorin Medical
FX Supported by a cooperative agreement (U01 HL088942) with the National
Heart, Lung, and Blood Institute, including funding by the National
Institute of Neurological Disorders and Stroke and the Canadian
Institutes of Health Research.; Dr. Acker reports receiving consulting
fees from Thoratec and HeartWare. Dr. Gelijns reports holding equity in
MERS International. Dr. Thourani reports receiving grant support from
Edwards Lifesciences, St. Jude Medical, and Sorin Medical. No other
potential conflict of interest relevant to this article was reported.
NR 42
TC 93
Z9 96
U1 0
U2 11
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 4
PY 2014
VL 371
IS 23
BP 2178
EP 2188
DI 10.1056/NEJMoa1410490
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW0IY
UT WOS:000345976700006
PM 25405390
ER
PT J
AU Sundt, TM
AF Sundt, Thoralf M.
TI Surgery for Ischemic Mitral Regurgitation
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID VALVE; REVASCULARIZATION; SURVIVAL; REPAIR
C1 Massachusetts Gen Hosp, Dept Surg, Div Cardiac Surg, Boston, MA 02114 USA.
RP Sundt, TM (reprint author), Massachusetts Gen Hosp, Dept Surg, Div Cardiac Surg, Boston, MA 02114 USA.
NR 10
TC 6
Z9 7
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 4
PY 2014
VL 371
IS 23
BP 2228
EP 2229
DI 10.1056/NEJMe1412045
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AW0IY
UT WOS:000345976700015
PM 25405391
ER
PT J
AU Pan, H
He, MH
Liu, RX
Brecha, NC
Yu, ACH
Pu, ML
AF Pan, Hong
He, Meihua
Liu, Ruixing
Brecha, Nicholas C.
Yu, Albert Cheung Hoi
Pu, Mingliang
TI Sulforaphane Protects Rodent Retinas against Ischemia-Reperfusion Injury
through the Activation of the Nrf2/HO-1 Antioxidant Pathway
SO PLOS ONE
LA English
DT Article
ID NRF2-DEPENDENT PHASE-2 ENZYME; OXIDATIVE STRESS; HEME OXYGENASE-1;
ISCHEMIA/REPERFUSION INJURY; PHARMACOLOGICAL INDUCTION; CALCIUM
DOBESILATE; RESPONSE ELEMENT; KAPPA-B; CELLS; GENE
AB Retinal ischemia-reperfusion (I/R) injury induces oxidative stress, leukocyte infiltration, and neuronal cell death. Sulforaphane (SF), which can be obtained in cruciferous vegetables such as broccoli, exerts protective effects in response to oxidative stress in various tissues. These effects can be initiated through nuclear factor E2-related factor 2 (Nrf2)-mediated induction of heme oxygenase-1 (HO-1). This investigation was designed to elucidate the neural protective mechanisms of SF in the retinal I/R rat model. Animals were intraperitoneally (i.p.) injected with SF (12.5 mg/kg) or vehicle (corn oil) once a day for 7 consecutive days. Then, retinal I/R was made by elevating the intraocular pressure (IOP) to 130 mmHg for 1 h. To determine if HO-1 was involved in the Nrf2 antioxidant pathway, rats were subjected to protoporphyrin IX zinc (II) (ZnPP, 30 mg/kg, i.p.) treatments at 24 h before retinal ischemia. The neuroprotective effects of SF were assessed by determining the morphology of the retina, counting the infiltrating inflammatory cells and the surviving retinal ganglion cells (RGCs) and amacrine cells, and measuring apoptosis in the retinal layers. The expression of Nrf2 and HO-1 was studied by immunofluorescence analysis and western blotting. I/R induced a marked increase of ROS generation, caused pronounced inflammation, increased the apoptosis of RGCs and amacrine cells and caused the thinning of the inner retinal layer (IRL), and these effects were diminished or abolished by SF pretreatment. Meanwhile, SF pretreatment significantly elevated the nuclear accumulation of Nrf2 and the level of HO-1 expression in the I/R retinas; however, ZnPP reversed the protective effects of SF on I/R retinas. Together, we offer direct evidence that SF had protective effects on I/R retinas, which could be attributed, at least in part, to the activation of the Nrf2/HO-1 antioxidant pathway.
C1 [Pan, Hong; Yu, Albert Cheung Hoi] Peking Univ, Neurosci Res Inst, Dept Neurobiol, Sch Basic Med Sci, Beijing 100871, Peoples R China.
[Pan, Hong; He, Meihua; Liu, Ruixing; Pu, Mingliang] Peking Univ, Dept Anat Embryol, Sch Basic Med Sci, Beijing 100871, Peoples R China.
[Pan, Hong] Binzhou Med Coll, Dept Phys, Yantai, Shandong, Peoples R China.
[Pan, Hong; He, Meihua; Liu, Ruixing; Pu, Mingliang] Peking Univ, Key Lab Machine Percept, Minist Educ, Beijing 100871, Peoples R China.
[Pan, Hong; He, Meihua; Liu, Ruixing; Pu, Mingliang] Peking Univ, Key Lab Visual Impairment & Restorat, Minist Educ, Beijing 100871, Peoples R China.
[Brecha, Nicholas C.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med Los Angeles, Jules Stein Eye Inst,CURE Digest Dis Res Ctr,Dept, Los Angeles, CA 90024 USA.
[Brecha, Nicholas C.] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA USA.
RP Pu, ML (reprint author), Peking Univ, Dept Anat Embryol, Sch Basic Med Sci, Beijing 100871, Peoples R China.
EM mpu@hsc.pku.edu.cn
RI He, Meihua/D-4312-2017
FU National Basic Research Program of China (973 Program) [2011CB510206];
National Science Foundation of China [30831160516, 81200691]; Ministry
of Education of China [20090001120075]; Azalea Endowment Fund;
Fundamental Research Fund for the Central Universities [21609101]; NIH
[EY04067]; VA Merit Review
FX This study was supported by grants obtained from the National Basic
Research Program of China (973 Program, 2011CB510206 [MP]), the National
Science Foundation of China (30831160516 [MP] and 81200691 [MH]), the
Ministry of Education of China (20090001120075 [MH]), Azalea (1972)
Endowment Fund (KS & RC), and the Fundamental Research Fund for the
Central Universities (21609101, KS), NIH EY04067 (NCB) and VA Merit
Review (NB). NCB is a VA Career Research Scientist. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 60
TC 14
Z9 16
U1 3
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 3
PY 2014
VL 9
IS 12
AR e114186
DI 10.1371/journal.pone.0114186
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA7WS
UT WOS:000349128700082
PM 25470382
ER
PT J
AU de Lima-Pardini, AC
Coelho, DB
Silva, MB
Azzi, NM
Martinelli, AR
Horak, FB
Teixeira, LA
AF de Lima-Pardini, Andrea Cristina
Coelho, Daniel Boari
Silva, Marina Brito
Azzi, Nametala Maia
Martinelli, Alessandra Rezende
Horak, Fay Bahling
Teixeira, Luis Augusto
TI Aging increases flexibility of postural reactive responses based on
constraints imposed by a manual task
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE postural control; manual constraint; dual task; elderly; postural
adaptation; balance control
ID AGE-RELATED-CHANGES; PARKINSONIAN SUBJECTS; FALLS PREVENTION; BALANCE
CONTROL; GRIP FORCE; LIFE-SPAN; COORDINATION; MOVEMENT; SET; ATTENTION
AB This study compared the effect of stability constraints imposed by a manual task on the adaptation of postural responses between 16 healthy elderly (7.38) and 16 healthy young (mean age = 22.94 years, SD = 4.82) individuals. Postural stability was perturbed through unexpected release of a load attached to the participant's trunk while performing two versions of a voluntary task: holding a tray with a cylinder placed with its flat side down (low constraint) or with its rolling round side down (high constraint). Low and high constraint tasks were performed in alternate blocks of trials. Results showed that young participants adapted muscular activation and kinematics of postural responses in association with previous experience with the first block of manual task constraint, whereas the elderly modulated postural responses based on the current manual constraint. This study provides evidence for flexibility of postural strategies in the elderly to deal with constraints imposed by a manual task.
C1 [de Lima-Pardini, Andrea Cristina] Univ Sao Paulo, Fac Med, Inst Radiol, Lab Med Invest LIM44, BR-05403900 Sao Paulo, Brazil.
[Coelho, Daniel Boari; Silva, Marina Brito; Azzi, Nametala Maia; Martinelli, Alessandra Rezende; Teixeira, Luis Augusto] Univ Sao Paulo, Sch Phys Educ & Sport, Dept Human Movement Biodynam, Human Motor Syst Lab, BR-05403900 Sao Paulo, Brazil.
[Horak, Fay Bahling] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
[Horak, Fay Bahling] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Balance Disorders Lab, Portland, OR 97201 USA.
RP de Lima-Pardini, AC (reprint author), Univ Sao Paulo, Fac Med, Inst Radiol, Lab Med Invest LIM44, Av Dr Eneas de Carvalho Aguiar,S-N Rua1, BR-05403900 Sao Paulo, Brazil.
EM aclfisio@yahoo.com.br
RI Coelho, Daniel/I-9369-2012;
OI Coelho, Daniel/0000-0001-8758-6507; Teixeira, Luis/0000-0003-4132-0484
FU Coordination for the Improvement of Higher Level Personnel (CAPES,
Brazil); Foundation for Research Advancement of the State of Sao Paulo
(FAPESP, Brazil) [2009/11319-2]; Brazilian Council for Scientific and
Technological Development (CNPq, Brazil) [200321/2010-2]
FX We thank Coordination for the Improvement of Higher Level Personnel
(CAPES, Brazil) for a studentship granted to the first author, the
Foundation for Research Advancement of the State of Sao Paulo (FAPESP,
Brazil), process number 2009/11319-2, and the Brazilian Council for
Scientific and Technological Development (CNPq, Brazil), process number
200321/2010-2, for funding this research. We are also thankful to the
great contribution in the review process given by the professor Kim
Barrett from the University of California San Diego, USA, and to the
participants of this study.
NR 48
TC 2
Z9 2
U1 1
U2 6
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD DEC 3
PY 2014
VL 6
AR 327
DI 10.3389/fnagi.2014.00327
PG 9
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA AY9RN
UT WOS:000347888100001
PM 25520656
ER
PT J
AU Dilisio, MF
Miller, LR
Warner, JJP
Higgins, LD
AF Dilisio, Matthew F.
Miller, Lindsay R.
Warner, Jon J. P.
Higgins, Laurence D.
TI Arthroscopic Tissue Culture for the Evaluation of Periprosthetic
Shoulder Infection
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Article
ID POSITIVE INTRAOPERATIVE CULTURES; PROPIONIBACTERIUM-ACNES; ARTHROPLASTY;
REVISION; PROSTHESIS; MANAGEMENT; SERIES
AB Background: Periprosthetic shoulder infections can be difficult to diagnose. The purpose of this study was to investigate the utility of arthroscopic tissue culture for the diagnosis of infection following shoulder arthroplasty. Our hypothesis was that culture of arthroscopic biopsy tissue is a more reliable method than fluoroscopically guided shoulder aspiration for diagnosing such infection.
Methods: A retrospective review identified patients who had undergone culture of arthroscopic biopsy tissue during the evaluation of a possible chronic periprosthetic shoulder infection. The culture results of the arthroscopic biopsies were compared with those of fluoroscopically guided glenohumeral aspiration and open tissue biopsy samples obtained at the time of revision surgery.
Results: Nineteen patients had undergone arthroscopic biopsy to evaluate a painful shoulder arthroplasty for infection. All subsequently underwent revision surgery, and 41% of those with culture results at that time had a positive result, which included Propionibacterium acnes in each case. All arthroscopic biopsy culture results were consistent with the culture results obtained during the revision surgery, yielding 100% sensitivity, specificity, positive predictive value, and negative predictive value. In contrast, fluoroscopically guided glenohumeral aspiration yielded a sensitivity of 16.7%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 58.3%.
Conclusions: Arthroscopic tissue biopsy is a reliable method for diagnosing periprosthetic shoulder infection and identifying the causative organism.
C1 [Dilisio, Matthew F.; Miller, Lindsay R.; Warner, Jon J. P.; Higgins, Laurence D.] Harvard Univ, Sch Med, Boston Shoulder Inst, Brigham & Womens Hosp,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Dilisio, MF (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Orthopaed, 75 Francis St, Boston, MA 02115 USA.
EM ldhiggins@partners.org
NR 29
TC 8
Z9 8
U1 0
U2 3
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0021-9355
EI 1535-1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD DEC 3
PY 2014
VL 96A
IS 23
BP 1952
EP 1958
DI 10.2106/JBJS.M.01512
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA AW7WC
UT WOS:000346471300009
PM 25471909
ER
PT J
AU Bharadwaj, R
Peter, CJ
Jiang, Y
Roussos, P
Vogel-Ciernia, A
Shen, EY
Mitchell, AC
Mao, WJ
Whittle, C
Dincer, A
Jakovcevski, M
Pothula, V
Rasmussen, TP
Giakoumaki, SG
Bitsios, P
Sherif, A
Gardner, PD
Ernst, P
Ghose, S
Sklar, P
Haroutunian, V
Tamminga, C
Myers, RH
Futai, K
Wood, MA
Akbarian, S
AF Bharadwaj, Rahul
Peter, Cyril J.
Jiang, Yan
Roussos, Panos
Vogel-Ciernia, Annie
Shen, Erica Y.
Mitchell, Amanda C.
Mao, Wenjie
Whittle, Catheryne
Dincer, Aslihan
Jakovcevski, Mira
Pothula, Venu
Rasmussen, Theodore P.
Giakoumaki, Stella G.
Bitsios, Panos
Sherif, Ajfar
Gardner, Paul D.
Ernst, Patricia
Ghose, Subroto
Sklar, Pamela
Haroutunian, Vahram
Tamminga, Carol
Myers, Richard H.
Futai, Kensuke
Wood, Marcelo A.
Akbarian, Schahram
TI Conserved Higher-Order Chromatin Regulates NMDA Receptor Gene Expression
and Cognition
SO NEURON
LA English
DT Article
ID DE-NOVO MUTATIONS; GENOME-WIDE; SYNAPTIC-TRANSMISSION; SCHIZOPHRENIA
RISK; PREFRONTAL CORTEX; ENERGY-METABOLISM; MAMMALIAN GENOMES; ENHANCER
FUNCTION; SUBUNIT GENES; CYTOCHROME-C
AB Three-dimensional chromosomal conformations regulate transcription by moving enhancers and regulatory elements into spatial proximity with target genes. Here we describe activity-regulated long-range loopings bypassing up to 0.5 Mb of linear genome to modulate NMDA glutamate receptor GRIN2B expression in human and mouse prefrontal cortex. Distal intronic and 3' intergenic loop formations competed with repressor elements to access promoter-proximal sequences, and facilitated expression via a "cargo'' of AP-1 and NRF-1 transcription factors and TALE-based transcriptional activators. Neuronal deletion or overexpression of Kmt2a/Mll1 H3K4-and Kmt1e/Setdb1 H3K9-methyl-transferase was associated with higher-order chromatin changes at distal regulatory Grin2b sequences and impairments in working memory. Genetic polymorphisms and isogenic deletions of loop-bound sequences conferred liability for cognitive performance and decreased GRIN2B expression. Dynamic regulation of chromosomal conformations emerges as a novel layer for transcriptional mechanisms impacting neuronal signaling and cognition.
C1 [Bharadwaj, Rahul; Peter, Cyril J.; Jiang, Yan; Roussos, Panos; Shen, Erica Y.; Mitchell, Amanda C.; Dincer, Aslihan; Pothula, Venu; Sherif, Ajfar; Sklar, Pamela; Haroutunian, Vahram; Akbarian, Schahram] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
[Bharadwaj, Rahul; Peter, Cyril J.; Jiang, Yan; Roussos, Panos; Shen, Erica Y.; Mitchell, Amanda C.; Dincer, Aslihan; Pothula, Venu; Sherif, Ajfar; Sklar, Pamela; Haroutunian, Vahram; Akbarian, Schahram] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Roussos, Panos; Sklar, Pamela] Icahn Sch Med Mt Sinai, Inst Multiscale Biol, New York, NY 10029 USA.
[Roussos, Panos; Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Mao, Wenjie; Whittle, Catheryne; Gardner, Paul D.; Futai, Kensuke] Univ Massachusetts, Sch Med, Brudnick Neuropsychiat Res Inst, Worcester, MA 01604 USA.
[Bitsios, Panos] Fdn Res & Technol Hellas, Inst Comp Sci, Computat Med Lab, Iraklion 71003, Greece.
[Rasmussen, Theodore P.] Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA.
[Rasmussen, Theodore P.] Univ Connecticut, Univ Conn Stem Cell Inst, Storrs, CT 06269 USA.
[Jakovcevski, Mira] Max Planck Inst Psychiat, D-80804 Munich, Germany.
[Giakoumaki, Stella G.; Bitsios, Panos] Univ Crete, Dept Psychiat, Iraklion 71003, Greece.
[Giakoumaki, Stella G.] Univ Crete, Dept Psychol, Iraklion 71003, Greece.
[Ernst, Patricia] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Genet, Hanover, NH 03755 USA.
[Ernst, Patricia] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Microbiol & Immunol, Hanover, NH 03755 USA.
[Ghose, Subroto; Tamminga, Carol] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Myers, Richard H.] Boston Univ, Dept Neurol, Boston, MA 02118 USA.
[Vogel-Ciernia, Annie; Wood, Marcelo A.] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA.
RP Akbarian, S (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
EM schahram.akbarian@mssm.edu
RI Dincer, Aslihan/N-4435-2015; Ghose, Subroto/J-6732-2016; Roussos,
Panos/J-7090-2013;
OI Dincer, Aslihan/0000-0002-4971-1597; Roussos, Panos/0000-0002-4640-6239;
Peter, Cyril/0000-0001-9190-8724
FU National Institute of Mental Health [R01 MH086509, P50 MH096890];
National Institute of Neurological Disorders and Stroke [R01
NS073947-04]; National Institute of Drug Abuse [R01 DA036984]; NIH Brain
and Tissue Repository grant [HHSN271201300031C]; VA; Veterans Affairs
Merit grant [BX002395]; BBRF; APA-Merck & Co. Early Academic Career
Research Award; Connecticut State Stem Cell Research Program
[09-SCB-UCON-18]; Whitehall Foundation; University of Crete Research
Funds Account [E.L.K.E. 1348]
FX This work was supported by National Institute of Mental Health grants
R01 MH086509 and P50 MH096890 (S.A.); National Institute of Neurological
Disorders and Stroke grant R01 NS073947-04 (R.H.M.); National Institute
of Drug Abuse grant R01 DA036984 (M.A.W. and S.A.); NIH Brain and Tissue
Repository grant HHSN271201300031C and the VA, and Veterans Affairs
Merit grant BX002395, BBRF, the APA-Merck & Co. Early Academic Career
Research Award (P.R.); the Connecticut State Stem Cell Research Program
(09-SCB-UCON-18) (T.P.R.); the Whitehall Foundation (K.F.); and the
University of Crete Research Funds Account (E.L.K.E. 1348). The authors
thank the participants and the personnel of the Military Training Camp
of Candidate, Supply Army officers (SEAP) in Heraklion, Crete, for their
help with the LOGOS study.
NR 74
TC 13
Z9 13
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD DEC 3
PY 2014
VL 84
IS 5
BP 997
EP 1008
DI 10.1016/j.neuron.2014.10.032
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA AW9JW
UT WOS:000346574300012
PM 25467983
ER
PT J
AU Albertsson, AM
Zhang, XL
Leavenworth, J
Bi, D
Nair, S
Qiao, LL
Hagberg, H
Mallard, C
Cantor, H
Wang, XY
AF Albertsson, Anna-Maj
Zhang, Xiaoli
Leavenworth, Jianmei
Bi, Dan
Nair, Syam
Qiao, Lili
Hagberg, Henrik
Mallard, Carina
Cantor, Harvey
Wang, Xiaoyang
TI The effect of osteopontin and osteopontin-derived peptides on preterm
brain injury
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Preterm; Brain injury; Osteopontin; Hypoxia; Ischemia
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LATE OLIGODENDROCYTE
PROGENITORS; NEONATAL ISCHEMIC BRAIN; DEVELOPING MOUSE-BRAIN;
CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER INJURY; HYPOXIA-ISCHEMIA; DENDRITIC
CELLS; INTRANASAL DELIVERY; MULTIPLE-SCLEROSIS
AB Background: Osteopontin (OPN) is a highly phosphorylated sialoprotein and a soluble cytokine that is widely expressed in a variety of tissues, including the brain. OPN and OPN-derived peptides have been suggested to have potential neuroprotective effects against ischemic brain injury, but their role in preterm brain injury is unknown.
Methods: We used a hypoxia-ischemia (HI)-induced preterm brain injury model in postnatal day 5 mice. OPN and OPN-derived peptides were given intracerebroventricularly and intranasally before HI. Brain injury was evaluated at 7 days after the insults.
Results: There was a significant increase in endogenous OPN mRNA and OPN protein in the mouse brain after the induction of HI at postnatal day 5. Administration of full-length OPN protein and thrombin-cleaved OPN did not affect preterm brain injury. This was demonstrated with both intracerebroventricular and intranasal administration of OPN as well as in OPN-deficient mice. Interestingly, both N134-153 and C154-198 OPN-derived peptides increased the severity of brain injury in this HI-induced preterm brain injury model.
Conclusions: The neuroprotective effects of OPN are age-dependent, and, in contrast to the more mature brain, OPN-derived peptides potentiate injury in postnatal day 5 mice. Intranasal administration is an efficient way of delivering drugs to the central nervous system (CNS) in neonatal mice and is likely to be an easy and noninvasive method of drug delivery to the CNS in preterm infants.
C1 [Albertsson, Anna-Maj; Zhang, Xiaoli; Bi, Dan; Nair, Syam; Qiao, Lili; Hagberg, Henrik; Wang, Xiaoyang] Univ Gothenburg, Sahlgrenska Acad, Dept Neurosci & Physiol, Perinatal Ctr, SE-40530 Gothenburg, Sweden.
[Zhang, Xiaoli; Bi, Dan; Wang, Xiaoyang] Zhengzhou Univ, Affiliated Hosp 3, Dept Pediat, Zhengzhou 450052, Peoples R China.
[Leavenworth, Jianmei; Cantor, Harvey] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Leavenworth, Jianmei; Cantor, Harvey] Harvard Univ, Sch Med, Div Immunol, Dept Microbiol & Immunol, Boston, MA 02115 USA.
[Qiao, Lili] Song Jiang Cent Hosp, Dept Pediat, Shanghai 201600, Peoples R China.
[Hagberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Obstet & Gynecol, Perinatal Ctr, S-41685 Gothenburg, Sweden.
[Hagberg, Henrik] St Thomas Hosp, Kings Hlth Partners, Div Imaging Sci & Biomed Engn, Kings Coll London,Dept Perinatal Imaging & Hlth, London SE1 7EH, England.
RP Wang, XY (reprint author), Univ Gothenburg, Sahlgrenska Acad, Dept Neurosci & Physiol, Perinatal Ctr, Box 432, SE-40530 Gothenburg, Sweden.
EM xiaoyang.wang@fysiologi.gu.se
RI Albertsson, Ann-Christine /Q-6107-2016;
OI Albertsson, Ann-Christine /0000-0001-8696-9143; Hagberg,
Henrik/0000-0003-3962-1448
NR 65
TC 6
Z9 7
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD DEC 3
PY 2014
VL 11
AR 197
DI 10.1186/s12974-014-0197-0
PG 13
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA AW6LM
UT WOS:000346381000001
PM 25465048
ER
PT J
AU Deo, RC
Musso, G
Tasan, M
Tang, P
Poon, A
Yuan, C
Felix, JF
Vasan, RS
Beroukhim, R
De Marco, T
Kwok, PY
MacRae, CA
Roth, FP
AF Deo, Rahul C.
Musso, Gabriel
Tasan, Murat
Tang, Paul
Poon, Annie
Yuan, Christiana
Felix, Janine F.
Vasan, Ramachandran S.
Beroukhim, Rameen
De Marco, Teresa
Kwok, Pui-Yan
MacRae, Calum A.
Roth, Frederick P.
TI Prioritizing causal disease genes using unbiased genomic features
SO GENOME BIOLOGY
LA English
DT Article
AB Background: Cardiovascular disease (CVD) is the leading cause of death in the developed world. Human genetic studies, including genome-wide sequencing and SNP-array approaches, promise to reveal disease genes and mechanisms representing new therapeutic targets. In practice, however, identification of the actual genes contributing to disease pathogenesis has lagged behind identification of associated loci, thus limiting the clinical benefits.
Results: To aid in localizing causal genes, we develop a machine learning approach, Objective Prioritization for Enhanced Novelty (OPEN), which quantitatively prioritizes gene-disease associations based on a diverse group of genomic features. This approach uses only unbiased predictive features and thus is not hampered by a preference towards previously well-characterized genes. We demonstrate success in identifying genetic determinants for CVD-related traits, including cholesterol levels, blood pressure, and conduction system and cardiomyopathy phenotypes. Using OPEN, we prioritize genes, including FLNC, for association with increased left ventricular diameter, which is a defining feature of a prevalent cardiovascular disorder, dilated cardiomyopathy or DCM. Using a zebrafish model, we experimentally validate FLNC and identify a novel FLNC splice-site mutation in a patient with severe DCM.
Conclusion: Our approach stands to assist interpretation of large-scale genetic studies without compromising their fundamentally unbiased nature.
C1 [Deo, Rahul C.; Yuan, Christiana; Kwok, Pui-Yan] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.
[Deo, Rahul C.; De Marco, Teresa] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Deo, Rahul C.; Tang, Paul; Poon, Annie; Kwok, Pui-Yan] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94158 USA.
[Deo, Rahul C.] Calif Inst Quantitat Biosci, San Francisco, CA 94143 USA.
[Deo, Rahul C.; Musso, Gabriel; Tasan, Murat; MacRae, Calum A.; Roth, Frederick P.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Musso, Gabriel; Beroukhim, Rameen] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Tasan, Murat; Roth, Frederick P.] Univ Toronto, Donnelly Ctr, Toronto, ON M5G 1X5, Canada.
[Tasan, Murat; Roth, Frederick P.] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X5, Canada.
[Tasan, Murat; Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON M5G 1X5, Canada.
[Tasan, Murat; Roth, Frederick P.] Mt Sinai Hosp, Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Felix, Janine F.] Erasmus Univ, Med Ctr, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Prevent Med Sect, Boston, MA 02118 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Framingham Heart Study, Framingham, MA 01702 USA.
[Beroukhim, Rameen] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA.
[Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Roth, Frederick P.] Dana Farber Canc Inst, CCSB, Boston, MA 02215 USA.
[Roth, Frederick P.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Roth, Frederick P.] Canadian Inst Adv Res, Toronto, ON M5G 1Z8, Canada.
RP Deo, RC (reprint author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.; Deo, RC (reprint author), Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM rahul.deo@ucsf.edu; fritz.roth@utoronto.ca
OI Roth, Frederick/0000-0002-6628-649X
FU NIH awards [K08 HL098361, DP2 OD017483, U01 HL107440-03]; NIH/NHGRI
Center of Excellence in Genomic Science (CEGS) grant [P50 HG004233];
NIH/NHGRI grant [HG001715]; Ontario Research Fund Research Excellence
Award; Krembil Foundation; Avon Foundation; Canada Excellence Research
Chairs Program
FX The work was funded by NIH awards K08 HL098361 (RCD), DP2 OD017483
(RCD), U01 HL107440-03 (RCD and FPR), and by an NIH/NHGRI Center of
Excellence in Genomic Science (CEGS) grant (P50 HG004233) (FPR). FPR was
also supported by NIH/NHGRI grant HG001715, an Ontario Research Fund
Research Excellence Award, the Krembil Foundation, the Avon Foundation
and by the Canada Excellence Research Chairs Program.
NR 76
TC 6
Z9 6
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PD DEC 3
PY 2014
VL 15
AR 534
DI 10.1186/s13059-014-0534-8
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA V45YL
UT WOS:000209851800001
PM 25633252
ER
PT J
AU Knights, D
Silverberg, MS
Weersma, RK
Gevers, D
Dijkstra, G
Huang, HL
Tyler, AD
van Sommeren, S
Imhann, F
Stempak, JM
Huang, H
Vangay, P
Al-Ghalith, GA
Russell, C
Sauk, J
Knight, J
Daly, MJ
Huttenhower, C
Xavier, RJ
AF Knights, Dan
Silverberg, Mark S.
Weersma, Rinse K.
Gevers, Dirk
Dijkstra, Gerard
Huang, Hailiang
Tyler, Andrea D.
van Sommeren, Suzanne
Imhann, Floris
Stempak, Joanne M.
Huang, Hu
Vangay, Pajau
Al-Ghalith, Gabriel A.
Russell, Caitlin
Sauk, Jenny
Knight, Jo
Daly, Mark J.
Huttenhower, Curtis
Xavier, Ramnik J.
TI Complex host genetics influence the microbiome in inflammatory bowel
disease
SO GENOME MEDICINE
LA English
DT Article
ID POUCH-ANAL ANASTOMOSIS; CROHNS-DISEASE; PHENOTYPE; DIVERSITY; CORRELATE;
ECOLOGY; GENOME; ALTERS
AB Background: Human genetics and host-associated microbial communities have been associated independently with a wide range of chronic diseases. One of the strongest associations in each case is inflammatory bowel disease (IBD), but disease risk cannot be explained fully by either factor individually. Recent findings point to interactions between host genetics and microbial exposures as important contributors to disease risk in IBD. These include evidence of the partial heritability of the gut microbiota and the conferral of gut mucosal inflammation by microbiome transplant even when the dysbiosis was initially genetically derived. Although there have been several tests for association of individual genetic loci with bacterial taxa, there has been no direct comparison of complex genome-microbiome associations in large cohorts of patients with an immunity-related disease.
Methods: We obtained 16S ribosomal RNA (rRNA) gene sequences from intestinal biopsies as well as host genotype via Immunochip in three independent cohorts totaling 474 individuals. We tested for correlation between relative abundance of bacterial taxa and number of minor alleles at known IBD risk loci, including fine mapping of multiple risk alleles in the Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene exon. We identified host polymorphisms whose associations with bacterial taxa were conserved across two or more cohorts, and we tested related genes for enrichment of host functional pathways.
Results: We identified and confirmed in two cohorts a significant association between NOD2 risk allele count and increased relative abundance of Enterobacteriaceae, with directionality of the effect conserved in the third cohort. Forty-eight additional IBD-related SNPs have directionality of their associations with bacterial taxa significantly conserved across two or three cohorts, implicating genes enriched for regulation of innate immune response, the JAK-STAT cascade, and other immunity-related pathways.
Conclusions: These results suggest complex interactions between genetically altered host functional pathways and the structure of the microbiome. Our findings demonstrate the ability to uncover novel associations from paired genome-microbiome data, and they suggest a complex link between host genetics and microbial dysbiosis in subjects with IBD across independent cohorts.
C1 [Knights, Dan] Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA.
[Knights, Dan; Gevers, Dirk; Daly, Mark J.; Huttenhower, Curtis; Xavier, Ramnik J.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Knights, Dan; Russell, Caitlin; Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Knights, Dan; Russell, Caitlin; Sauk, Jenny; Daly, Mark J.; Xavier, Ramnik J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Knights, Dan] Univ Minnesota, Inst Biotechnol, St Paul, MN 55108 USA.
[Silverberg, Mark S.; Tyler, Andrea D.; Stempak, Joanne M.] Univ Toronto, Zane Cohen Ctr Digest Dis, Mt Sinai Hosp, IBD Grp, Toronto, ON M5G 1X5, Canada.
[Weersma, Rinse K.; Dijkstra, Gerard; van Sommeren, Suzanne; Imhann, Floris] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, NL-9700 RB Groningen, Netherlands.
[Huang, Hailiang] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[van Sommeren, Suzanne; Imhann, Floris] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands.
[Huang, Hu; Vangay, Pajau; Al-Ghalith, Gabriel A.] Univ Minnesota, Minneapolis, MN 55455 USA.
[Russell, Caitlin; Sauk, Jenny; Xavier, Ramnik J.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Knight, Jo] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada.
[Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Huttenhower, Curtis] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Knights, D (reprint author), Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA.
EM dknights@umn.edu; xavier@molbio.mgh.harvard.edu
RI Silverberg, Mark/B-4183-2008;
OI Huang, Hailiang/0000-0003-1461-5762; Knight, Joanne/0000-0002-7148-1660
FU VIDI grant from the Netherlands Organization for Scientific Research
(NWO); Dutch Digestive Foundation [WO 11-72]; NIH [R01HG005969]; NSF
[DBI-1053486]; ARO [W911NF-11-1-0473]; Gale and Graham Wright Research
Chair in Digestive Disease; Crohn's and Colitis Foundation of Canada;
Crohn's and Colitis Foundation of America, NIH [U54 DE023798, R01
DK092405]
FX We thank the patients who donated samples for this study, and the health
professionals who collected them. We thank Tjasso Blokzijl for technical
assistance and Levi Waldron for power analysis code. We thank Aylwin Ng
and Moran Yassour for critical review of the manuscript. We thank
Timothy Tickle and Tonya Ward for helpful discussions regarding methods.
RKW is supported by a VIDI grant from the Netherlands Organization for
Scientific Research (NWO) and the Dutch Digestive Foundation (WO 11-72).
CH is partially supported by NIH R01HG005969, NSF DBI-1053486, and ARO
W911NF-11-1-0473. MSS is partially supported by the Gale and Graham
Wright Research Chair in Digestive Disease. Partial funding for sample
collection for Toronto samples provided by the Crohn's and Colitis
Foundation of Canada. Work was supported by grants from the Crohn's and
Colitis Foundation of America, NIH grants U54 DE023798, and R01 DK092405
(RJX, CH, DG). JK is the Joanne Murphy Professor in Behavioural Science.
NR 42
TC 53
Z9 54
U1 4
U2 29
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD DEC 2
PY 2014
VL 6
AR 107
DI 10.1186/s13073-014-0107-1
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA AZ3ZD
UT WOS:000348161400001
PM 25587358
ER
EF